Sequence,Sequence_Length,Origin,Type,Hemolytic_Activity,Cytotoxicity,Binding_Target,Affinity,Mechanism,Nature,Classification,Helicity,Linear_Cyclic,Disulfide_Bond,N-terminal_Modification,C-terminal_Modification,Other_Modification,Other_Information,VEGF,Secuence
RGLRRLGRKIAHGVKKYGPTVLRIIRIA,28,Ovis aries,Native peptide,Human erythrocytes (4% Hemolysis=4 µM; 19% Hemolysis=20 µM; 67% Hemolysis=80 µM; 50% Hemolysis=86 µM; 10% Hemolysis=6.0 µm) ; Sheep erythrocytes (3% Hemolysis=80 µM),NIH 3T3: IC50=16 µM,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide##Membrane-targeted,,Linear,,Free,Amidation,,,0,RGLRRLGRKIAHGVKKYGPTVLRIIRIA
KWKLFKKIGIGKFLHSAKKF,20,Ceropin-Magainin hybrid peptides,Synthetic peptide,Human erythrocytes (Hemolysis 0% =100 μM),NIH-3T3 fibroblast: IC50>100 μM,,,,Anticancer; Antibacterial,Tumor active peptide##Membrane-targeted,,Linear,,Free,Amidation,,,0,KWKLFKKIGIGKFLHSAKKF
KWKLFKKIGPGKFLHSAKKF,20,Ceropin-Magainin hybrid peptides,Synthetic peptide,Human erythrocytes: Hemolysis 0% (100 μM),NIH-3T3 fibroblast: IC50>100 μM,,,,Anticancer; Antibacterial,Tumor active peptide##Membrane-targeted,,Linear,,Free,Amidation,,,0,KWKLFKKIGPGKFLHSAKKF
KWKLFKKIKFLHSAKKF,17,Ceropin-Magainin hybrid peptides,Synthetic peptide,Human erythrocytes: Hemolysis 0% (100 μM),NIH-3T3 fibroblast: IC50>100 μM,,,,Anticancer; Antibacterial,Tumor active peptide##Membrane-targeted,,Linear,,Free,Amidation,,,0,KWKLFKKIKFLHSAKKF
KWKLFKKIPKFLHSAKKF,18,Ceropin-Magainin hybrid peptides,Synthetic peptide,Human erythrocytes: Hemolysis 0% (100 μM),NIH-3T3 fibroblast: IC50>100 μM,,,,Anticancer; Antibacterial,Tumor active peptide##Membrane-targeted,,Linear,,Free,Amidation,,,0,KWKLFKKIPKFLHSAKKF
GLFDIAKKVIGVIGSL,16,Southern bell frog,Native peptide,,,,,Anticancer activity is due to penetration and disruption of the membranes of the cancer cells,Anticancer; Antimicrobial,Tumor active peptide##Membrane-targeted,,Linear,,Free,Amidation,,,0,GLFDIAKKVIGVIGSL
GLFDIIKKIAESF,13,Southern bell frog,Native peptide,,,,,Anticancer activity is due to penetration and disruption of the membranes of the cancer cells,Anticancer; Antimicrobial,Tumor active peptide##Membrane-targeted,,Linear,,Free,Amidation,,,0,GLFDIIKKIAESF
GLFDIVKKIAGHIAGSI,17,Southern bell frog,Native peptide,,,,,Anticancer activity is due to penetration and disruption of the membranes of the cancer cells,Anticancer; Antimicrobial,Tumor active peptide##Membrane-targeted,,Linear,,Free,Amidation,,,0,GLFDIVKKIAGHIAGSI
GLFDIVKKIAGHIASSI,17,Southern bell frog,Native peptide,,,,,Anticancer activity is due to penetration and disruption of the membranes of the cancer cells,Anticancer; Antimicrobial,Tumor active peptide##Membrane-targeted,,Linear,,Free,Amidation,,,0,GLFDIVKKIAGHIASSI
GLFDIVKKIAGHIVSSI,17,Southern bell frog,Native peptide,,,,,Anticancer activity is due to penetration and disruption of the membranes of the cancer cells,Anticancer; Antimicrobial,Tumor active peptide##Membrane-targeted,,Linear,,Free,Amidation,,,0,GLFDIVKKIAGHIVSSI
GLFDIVKKVVGAFGSL,16,Southern bell frog,Native peptide,,,,,Anticancer activity is due to penetration and disruption of the membranes of the cancer cells,Anticancer; Antimicrobial,Tumor active peptide##Membrane-targeted,,Linear,,Free,Amidation,,,0,GLFDIVKKVVGAFGSL
ISRLAGLLRKGGEKIGEKLKKIGQKIKNFFQKLVPQPE,38,Mus musculus,Native peptide,Human erythrocytes: 2% Hemolysis=100 µM,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide##Membrane-targeted,,Linear,,Free,Free,,,0,ISRLAGLLRKGGEKIGEKLKKIGQKIKNFFQKLVPQPE
DTHFPICIFCCGCCHRSKCGMCCKT,25,Homo sapiens; Pan troglodytes; Pongo pygmaeus; Gorilla gorilla;  Nomascus concolor; Hylobates lar,Native peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide##Membrane-targeted,,Cyclic,Cys7<--->Cys23; Cys10<--->Cys13; Cys11<--->Cys19; Cys14<--->Cys22,Free,Free,,,0,DTHFPICIFCCGCCHRSKCGMCCKT
ICIFCCGCCHRSKCGMCCKT,20,Homo sapiens; Pan troglodytes; Pongo pygmaeus; Gorilla gorilla;  Nomascus concolor; Hylobates lar,Native peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide##Membrane-targeted,,Cyclic,Cys2<--->Cys18; Cys5<--->Cys8; Cys6<--->Cys14; Cys9<--->Cys17,Free,Free,,,0,ICIFCCGCCHRSKCGMCCKT
GIGTKILGGVKTALKGALKELASTYAN,27,Bombina maxima,Native peptide,Had little hemolytic activity to red blood cells even with the concentration of the peptides up to 50 μg/ml,,,,,Anticancer; Antimicrobial,Tumor active peptide,,Linear,,Free,Amidation,,,0,GIGTKILGGVKTALKGALKELASTYAN
GIGGKILSGLKTALKGAAKELASTYLH,27,Bombina maxima,Native peptide,Had little hemolytic activity to red blood cells even with the concentration of the peptides up to 50 μg/ml,,,,,Anticancer; Antimicrobial,Tumor active peptide,,Linear,,Free,Free,,,0,GIGGKILSGLKTALKGAAKELASTYLH
GIGGVLLSAGKAALKGLAKVLAEKYAN,27,Bombina maxima,Native peptide,Had little hemolytic activity to red blood cells even with the concentration of the peptides up to 50 μg/ml,,,,,Anticancer; Antimicrobial; Antiviral,Tumor active peptide,,Linear,,Free,Amidation,,,0,GIGGVLLSAGKAALKGLAKVLAEKYAN
SIGAKILGGVKTFFKGALKELASTYLQ,27,Bombina maxima,Native peptide,Had little hemolytic activity to red blood cells even with the concentration of the peptides up to 50 μg/ml,,,,,Anticancer; Antimicrobial,Tumor active peptide,,Linear,,Free,Free,,,0,SIGAKILGGVKTFFKGALKELASTYLQ
KNLRRIIRKGIHIIKKYG,18,Synthetic,Synthetic peptide,Human erythrocytes: 3% Hemolysis=80 µg/ml,,,,,Anticancer; Antibacterial,Tumor active peptide##Membrane-targeted,,Linear,,Free,Free,,,0,KNLRRIIRKGIHIIKKYG
KNLRRIIRKIIHIIKKYG,18,Synthetic,Synthetic peptide,Human erythrocytes: 70% Hemolysis=80 µg/ml ,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide##Membrane-targeted,,Linear,,Free,Free,,,0,KNLRRIIRKIIHIIKKYG
KNLRRITRKIIHIIKKYG,18,Synthetic,Synthetic peptide,Human erythrocytes: 10% Hemolysis=80 µg/ml,,,,,Anticancer; Antibacterial,Tumor active peptide##Membrane-targeted,,Linear,,Free,Free,,,0,KNLRRITRKIIHIIKKYG
ACYCRIPACIAGERRYGTCIYQGRLWAFCC,30,Human alpha-defensins,Native peptide,,,,,,Anticancer,Tumor active peptide##Membrane-targeted,,Cyclic,Cys2<--->Cys30; Cys4<--->Cys19; Cys9<--->Cys29,Free,Free,,,0,ACYCRIPACIAGERRYGTCIYQGRLWAFCC
CYCRIPACIAGERRYGTCIYQGRLWAFCC,29,Human alpha-defensins,Native peptide,,,,,,Anticancer,Tumor active peptide##Membrane-targeted,,Cyclic,Cys1<--->Cys29; Cys9<--->Cys18; Cys8<--->Cys28,Free,Free,,,0,CYCRIPACIAGERRYGTCIYQGRLWAFCC
DCYCRIPACIAGERRYGTCIYQGRLWAFCC,30,Human alpha-defensins,Native peptide,,,,,,Anticancer,Tumor active peptide##Membrane-targeted,,Cyclic,Cys2<--->Cys30; Cys4<--->Cys19; Cys9<--->Cys29,Free,Free,,,0,DCYCRIPACIAGERRYGTCIYQGRLWAFCC
KWKFKKIPKFLHLAKKF,17,Ceropin A,Synthetic peptide,Human erythrocytes: hemolysis: 0%=100 µM; hemolysis: 0%=50 µM; hemolysis: 0%=25.0 µM; hemolysis: 0%=12.5 µM; hemolysis: 0%=6.25 µM; hemolysis: 0%=3.125 µM; hemolysis: 0%=1.56 µM; hemolysis: 0%=0.78 µM,NIH 3T3: IC50=75 µM,,,,Anticancer; Antibacterial,Tumor active peptide##Membrane-targeted,,Linear,,Free,Amidation,,,0,KWKFKKIPKFLHLAKKF
KWKLFKKILKFLHLAKKF,18,Ceropin A,Synthetic peptide,Human erythrocytes: hemolysis: 88.6%=100 µM; hemolysis: 77.8%=50 µM; hemolysis: 66.3%=25.0 µM; hemolysis: 40.8%=12.5 µM; hemolysis: 31.6%=6.25 µM; hemolysis: 27.3%=3.125 µM; hemolysis: 4.6%=1.56 µM; hemolysis: 1.1%=0.78 µM,NIH 3T3: IC50=70 µM,,,,Anticancer; Antibacterial,Tumor active peptide##Membrane-targeted,,Linear,,Free,Amidation,,,0,KWKLFKKILKFLHLAKKF
KWKLFKKISKFLHLAKKF,18,Ceropin A,Synthetic peptide,Human erythrocytes: hemolysis: 50.4%=100 µM; hemolysis: 22%=50 µM; hemolysis: 11.1%=25.0 µM; hemolysis: 5.1%=12.5 µM; hemolysis: 1.8%=6.25 µM; hemolysis: 0.4%=3.125 µM; hemolysis: 0%=1.56 µM; hemolysis: 0%=0.78 µM,NIH 3T3: IC50=50 µM,,,,Anticancer; Antibacterial,Tumor active peptide##Membrane-targeted,,Linear,,Free,Amidation,,,0,KWKLFKKISKFLHLAKKF
WKLFKKIPKFLHLAKKF,17,Ceropin A,Synthetic peptide,Human erythrocytes: hemolysis: 10.1%=100 µM; hemolysis: 3%=50 µM; hemolysis: 0.7%=25.0 µM; hemolysis: 0%=12.5 µM; hemolysis: 0%=6.25 µM; hemolysis: 0%=3.125 µM; hemolysis: 0%=1.56 µM; hemolysis: 0%=0.78 µM,NIH 3T3: IC50=75 µM,,,,Anticancer; Antibacterial,Tumor active peptide##Membrane-targeted,,Linear,,Free,Amidation,,,0,WKLFKKIPKFLHLAKKF
FKLFKKIPKFLHLAKKF,17,Ceropin A,Synthetic peptide,Human erythrocytes: hemolysis: 0.6%=100 µM; hemolysis: 0%=50 µM; hemolysis: 0%=25.0 µM; hemolysis: 0%=12.5 µM; hemolysis: 0%=6.25 µM; hemolysis: 0%=3.125 µM; hemolysis: 0%=1.56 µM; hemolysis: 0%=0.78 µM,NIH 3T3: IC50=70 µM,,,,Anticancer; Antibacterial,Tumor active peptide##Membrane-targeted,,Linear,,Free,Amidation,,,0,FKLFKKIPKFLHLAKKF
KWFKKIPKFLHLAKKF,16,Ceropin A,Synthetic peptide,Human erythrocytes: hemolysis: 1.8%=100 µM; hemolysis: 0.7%=50 µM; hemolysis: 0%=25.0 µM; hemolysis: 0%=12.5 µM; hemolysis: 0%=6.25 µM; hemolysis: 0%=3.125 µM; hemolysis: 0%=1.56 µM; hemolysis: 0%=0.78 µM,NIH 3T3: IC50=50 µM,,,,Anticancer; Antibacterial,Tumor active peptide##Membrane-targeted,,Linear,,Free,Amidation,,,0,KWFKKIPKFLHLAKKF
WFKKIPKFLHLAKKF,15,Ceropin A,Synthetic peptide,Human erythrocytes: hemolysis: 1.5%=100 µM; hemolysis: 0.3%=50 µM; hemolysis: 0%=25.0 µM; hemolysis: 0%=12.5 µM; hemolysis: 0%=6.25 µM; hemolysis: 0%=3.125 µM; hemolysis: 0%=1.56 µM; hemolysis: 0%=0.78 µM,NIH 3T3: IC50=100 µM,,,,Anticancer; Antibacterial,Tumor active peptide##Membrane-targeted,,Linear,,Free,Amidation,,,0,WFKKIPKFLHLAKKF
WKKIPKFLHLAKKF,14,Ceropin A,Synthetic peptide,Human erythrocytes: hemolysis: 0%=100 µM; hemolysis: 0%=50 µM; hemolysis: 0%=25.0 µM; hemolysis: 0%=12.5 µM; hemolysis: 0%=6.25 µM; hemolysis: 0%=3.125 µM; hemolysis: 0%=1.56 µM; hemolysis: 0%=0.78 µM,NIH 3T3: IC50=100.0< µM,,,,Anticancer; Antibacterial,Tumor active peptide##Membrane-targeted,,Linear,,Free,Amidation,,,0,WKKIPKFLHLAKKF
KWFKKIPKFLHLLKKF,16,Ceropin A,Synthetic peptide,Human erythrocytes: hemolysis: 27.3%=100 µM; hemolysis: 10.7%=50 µM; hemolysis: 3%=25.0 µM; hemolysis: 1.7%=12.5 µM; hemolysis: 0.6%=6.25 µM; hemolysis: 0%=3.125 µM; hemolysis: 0%=1.56 µM; hemolysis: 0%=0.78 µM,NIH 3T3: IC50=50 µM,,,,Anticancer; Antibacterial,Tumor active peptide##Membrane-targeted,,Linear,,Free,Amidation,,,0,KWFKKIPKFLHLLKKF
WFKKIPKFLHLLKKF,14,Ceropin A,Synthetic peptide,Human erythrocytes: hemolysis: 28.8%=100 µM; hemolysis: 8.1%=50 µM; hemolysis: 4.3%=25.0 µM; hemolysis: 0.8%=12.5 µM; hemolysis: 0%=6.25 µM; hemolysis: 0%=3.125 µM; hemolysis: 0%=1.56 µM; hemolysis: 0%=0.78 µM,NIH 3T3: IC50=50 µM,,,,Anticancer; Antibacterial,Tumor active peptide##Membrane-targeted,,Linear,,Free,Amidation,,,0,WFKKIPKFLHLLKKF
WKKIPKFLHLLKKF,14,Ceropin A,Synthetic peptide,Human erythrocytes: hemolysis: 9.4%=100 µM; hemolysis: 2.6%=50 µM; hemolysis: 0.2%=25.0 µM; hemolysis: 0%=12.5 µM; hemolysis: 0%=6.25 µM; hemolysis: 0%=3.125 µM; hemolysis: 0%=1.56 µM; hemolysis: 0%=0.78 µM,NIH 3T3: IC50=50 µM,,,,Anticancer; Antibacterial,Tumor active peptide##Membrane-targeted,,Linear,,Free,Amidation,,,0,WKKIPKFLHLLKKF
KWKLFKKIPFLHLAKKF,17,Ceropin A,Synthetic peptide,Human erythrocytes: hemolysis: 30.3%=100 µM; hemolysis: 10.2%=50 µM; hemolysis: 5.1%=25.0 µM; hemolysis: 1%=12.5 µM; hemolysis: 0%=6.25 µM; hemolysis: 0%=3.125 µM; hemolysis: 0%=1.56 µM; hemolysis: 0%=0.78 µM,NIH 3T3: IC50=100 µM,,,,Anticancer; Antibacterial,Tumor active peptide##Membrane-targeted,,Linear,,Free,Amidation,,,0,KWKLFKKIPFLHLAKKF
KWKLFKKIPKFLHLAKK,17,Ceropin A,Synthetic peptide,Human erythrocytes: hemolysis: 19.8%=100 µM; hemolysis: 4.9%=50 µM; hemolysis: 1.2%=25.0 µM; hemolysis: 0%=12.5 µM; hemolysis: 0%=6.25 µM; hemolysis: 0%=3.125 µM; hemolysis: 0%=1.56 µM; hemolysis: 0%=0.78 µM,NIH 3T3: IC50=100 µM,,,,Anticancer; Antibacterial,Tumor active peptide##Membrane-targeted,,Linear,,Free,Amidation,,,0,KWKLFKKIPKFLHLAKK
KWKLFKKIPLHLAKKF,16,Ceropin A,Synthetic peptide,Human erythrocytes: hemolysis: 4.7%=100 µM; hemolysis: 1.2%=50 µM; hemolysis: 0%=25.0 µM; hemolysis: 0%=12.5 µM; hemolysis: 0%=6.25 µM; hemolysis: 0%=3.125 µM; hemolysis: 0%=1.56 µM; hemolysis: 0%=0.78 µM,NIH 3T3: IC50=100.0< µM,,,,Anticancer; Antibacterial,Tumor active peptide##Membrane-targeted,,Linear,,Free,Amidation,,,0,KWKLFKKIPLHLAKKF
KWKLFKKIPKFLHLAK,16,Ceropin A,Synthetic peptide,Human erythrocytes: hemolysis: 0%=100 µM; hemolysis: 0%=50 µM; hemolysis: 0%=25.0 µM; hemolysis: 0%=12.5 µM; hemolysis: 0%=6.25 µM; hemolysis: 0%=3.125 µM; hemolysis: 0%=1.56 µM; hemolysis: 0%=0.78 µM,NIH 3T3: IC50=100 µM,,,,Anticancer; Antibacterial,Tumor active peptide##Membrane-targeted,,Linear,,Free,Amidation,,,0,KWKLFKKIPKFLHLAK
KWKLFKKIPHLAKKF,15,Ceropin A,Synthetic peptide,Human erythrocytes: hemolysis: 0%=100 µM; hemolysis: 0%=50 µM; hemolysis: 0%=25.0 µM; hemolysis: 0%=12.5 µM; hemolysis: 0%=6.25 µM; hemolysis: 0%=3.125 µM; hemolysis: 0%=1.56 µM; hemolysis: 0%=0.78 µM,NIH 3T3: IC50=100.0< µM,,,,Anticancer; Antibacterial,Tumor active peptide##Membrane-targeted,,Linear,,Free,Amidation,,,0,KWKLFKKIPHLAKKF
KWKLFKKIPKFLHLA,15,Ceropin A,Synthetic peptide,Human erythrocytes: hemolysis: 6.7%=100 µM; hemolysis: 3.4%=50 µM; hemolysis: 0.6%=25.0 µM; hemolysis: 0%=12.5 µM; hemolysis: 0%=6.25 µM; hemolysis: 0%=3.125 µM; hemolysis: 0%=1.56 µM; hemolysis: 0%=0.78 µM,NIH 3T3: IC50=100 µM,,,,Anticancer; Antibacterial,Tumor active peptide##Membrane-targeted,,Linear,,Free,Amidation,,,0,KWKLFKKIPKFLHLA
KWKLFKKIPLAKKF,14,Ceropin A,Synthetic peptide,Human erythrocytes: hemolysis: 0%=100 µM; hemolysis: 0%=50 µM; hemolysis: 0%=25.0 µM; hemolysis: 0%=12.5 µM; hemolysis: 0%=6.25 µM; hemolysis: 0%=3.125 µM; hemolysis: 0%=1.56 µM; hemolysis: 0%=0.78 µM,NIH 3T3: IC50=100.0< µM,,,,Anticancer; Antibacterial,Tumor active peptide##Membrane-targeted,,Linear,,Free,Amidation,,,0,KWKLFKKIPLAKKF
KWKLFKKIPKFLHL,14,Ceropin A,Synthetic peptide,Human erythrocytes: hemolysis: 0%=100 µM; hemolysis: 0%=50 µM; hemolysis: 0%=25.0 µM; hemolysis: 0%=12.5 µM; hemolysis: 0%=6.25 µM; hemolysis: 0%=3.125 µM; hemolysis: 0%=1.56 µM; hemolysis: 0%=0.78 µM,NIH 3T3: IC50=100.0< µM,,,,Anticancer; Antibacterial,Tumor active peptide##Membrane-targeted,,Linear,,Free,Amidation,,,0,KWKLFKKIPKFLHL
KWKLFKKIPLKKF,13,Ceropin A,Synthetic peptide,Human erythrocytes: hemolysis: 6.2%=100 µM; hemolysis: 2.9%=50 µM; hemolysis: 0.3%=25.0 µM; hemolysis: 0%=12.5 µM; hemolysis: 0%=6.25 µM; hemolysis: 0%=3.125 µM; hemolysis: 0%=1.56 µM; hemolysis: 0%=0.78 µM,NIH 3T3: IC50=100.0< µM,,,,Anticancer; Antibacterial,Tumor active peptide##Membrane-targeted,,Linear,,Free,Amidation,,,0,KWKLFKKIPLKKF
KWKLFKKIPKFLH,13,Ceropin A,Synthetic peptide,Human erythrocytes: hemolysis: 7.6%=100 µM; hemolysis: 3.6%=50 µM; hemolysis: 0.5%=25.0 µM; hemolysis: 0%=12.5 µM; hemolysis: 0%=6.25 µM; hemolysis: 0%=3.125 µM; hemolysis: 0%=1.56 µM; hemolysis: 0%=0.78 µM,NIH 3T3: IC50=100.0< µM,,,,Anticancer; Antibacterial,Tumor active peptide##Membrane-targeted,,Linear,,Free,Amidation,,,0,KWKLFKKIPKFLH
KSCCPSTTARNIYNTCRLTGASRSVCASLSGCKIISGSTCDSGWNH,46,Phoradendron liga,Native peptide,,,,,,Anticancer,Tumor active peptide##Membrane-targeted,,Cyclic,Cys3<--->Cys40; Cys4<--->Cys32; Cys16<---Cys26,Free,Free,,,0,KSCCPSTTARNIYNTCRLTGASRSVCASLSGCKIISGSTCDSGWNH
FVQWFSKFLGRIL,13,Rana temporaria,Native peptide,Human erythrocytes: 94% Hemolysis=24 µM; 92% Hemolysis=12 µM; 48% Hemolysis=6 µM;  13% Hemolysis=3 µM; 3% Hemolysis=1.5 µM; 100% Hemolysis=40 µM,NIH 3T3: 100% Killing=40 µM,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide##Membrane-targeted,,Linear,,Free,Amidation,,,0,FVQWFSKFLGRIL
EWYNQTKDLQQKFYEIIMDIEQNNVQGKKGIQQLQ,35,Synthetic,Synthetic peptide,Human erythrocytes: Not active up to 1025 µg/ml,,,,,Anticancer; Antiviral,Tumor active peptide##Membrane-targeted,,Linear,,Acetylation,Amidation,,,0,EWYNQTKDLQQKFYEIIMDIEQNNVQGKKGIQQLQ
GEWYNQTKDLQQKFYEIIMDIEQNNVQGKKGIQQL,35,Synthetic,Synthetic peptide,Human erythrocytes: Not active up to 1024 µg/ml,,,,,Anticancer; Antiviral,Tumor active peptide##Membrane-targeted,,Linear,,Acetylation,Amidation,,,0,GEWYNQTKDLQQKFYEIIMDIEQNNVQGKKGIQQL
GVSGHGQHGVHG,12,the blow fly Calliphora vicina (Diptera),Native peptide,,,,,"(i) stimulates natural cytotoxicity of human peripheral blood lymphocytes, (ii) induces IFN synthesis in mouse and human models, and (iii) enhances antiviral and antitumor resistance in mice.",Anticancer; Antitumor; Antiviral,Tumor active peptide##Immune system stimulating peptides,,Linear,,Free,Free,,,0,GVSGHGQHGVHG
HGVSGHGQHGVHG,13,the blow fly Calliphora vicina (Diptera),Native peptide,,,,,"(i) stimulates natural cytotoxicity of human peripheral blood lymphocytes, (ii) induces IFN synthesis in mouse and human models, and (iii) enhances antiviral and antitumor resistance in mice.",Anticancer; Antitumor; Antiviral,Tumor active peptide##Immune system stimulating peptides,,Linear,,Free,Free,,,0,HGVSGHGQHGVHG
PEWFKCRRWQWRMKKLGA,18,Bovine Lactoferrin,Native peptide,Human red blood cells: EC50>404 µM,Fibroblas: IC50>404 µM,,,,Anticancer; Antimicrobial,Tumor active peptide##Membrane-targeted,,Linear,,Free,Free,,,0,PEWFKCRRWQWRMKKLGA
PAWFKARRWAWRMKKLAA,18,Synthetic,Synthetic peptide,Human red blood cells: EC50>440 µM,Fibroblas: IC50>440 µM,,,,Anticancer; Antimicrobial,Tumor active peptide##Membrane-targeted,,Linear,,Free,Free,,,0,PAWFKARRWAWRMKKLAA
PAWRKAFRWAWRMKKLAA,18,Synthetic,Synthetic peptide,Human red blood cells: EC50>440 µM,Fibroblas: IC50=163 µM,,,,Anticancer; Antimicrobial,Tumor active peptide##Membrane-targeted,,Linear,,Free,Free,,,0,PAWRKAFRWAWRMKKLAA
PAWFKARRWAWRMLKKAA,18,Synthetic,Synthetic peptide,Human red blood cells: EC50>440 µM,Fibroblas: IC50=299 µM,,,,Anticancer; Antimicrobial,Tumor active peptide##Membrane-targeted,,Linear,,Free,Free,,,0,PAWFKARRWAWRMLKKAA
PAWRKAFRWAWRMLKKAA,18,Synthetic,Synthetic peptide,Human red blood cells: EC50=33 µM,Fibroblas: IC50=17 µM; CHO: IC50=5 ± 1 μM(pH=7.4); IC50=5 ± 1 μM(pH=5.5),,,,Anticancer; Antimicrobial,Tumor active peptide##Membrane lysis,,Linear,,Free,Free,,,0,PAWRKAFRWAWRMLKKAA
PAWRKAFRWAARMLKKAA,18,Synthetic,Synthetic peptide,Human red blood cells: EC50=278 µM,Fibroblas: IC50=46 µM,,,,Anticancer; Antimicrobial,Tumor active peptide##Membrane-targeted,,Linear,,Free,Free,,,0,PAWRKAFRWAARMLKKAA
PAWRKAFRAAWRMLKKAA,18,Synthetic,Synthetic peptide,Human red blood cells: EC50=382 µM,Fibroblas: IC50=46 µM,,,,Anticancer; Antimicrobial,Tumor active peptide##Membrane-targeted,,Linear,,Free,Free,,,0,PAWRKAFRAAWRMLKKAA
PAWAKAFRAAARMKLKAA,18,Synthetic,Synthetic peptide,Human red blood cells: EC50>489 µM,Fibroblas: IC50>489 µM,,,,Anticancer; Antimicrobial,Tumor active peptide##Membrane-targeted,,Linear,,Free,Free,,,0,PAWAKAFRAAARMKLKAA
PAWRKAARWAWRMLKKAA,18,Synthetic,Synthetic peptide,Human red blood cells: EC50>455 µM,Fibroblas: IC50=289 µM,,,,Anticancer; Antimicrobial,Tumor active peptide##Membrane-targeted,,Linear,,Free,Free,,,0,PAWRKAARWAWRMLKKAA
PAARKAFRWAWRMLKKAA,18,Synthetic,Synthetic peptide,Human red blood cells: EC50>463 µM,Fibroblas: IC50=190 µM,,,,Anticancer; Antimicrobial,Tumor active peptide##Membrane-targeted,,Linear,,Free,Free,,,0,PAARKAFRWAWRMLKKAA
PAARKAARWAWRMLKKGA,18,Synthetic,Synthetic peptide,Human red blood cells: EC50>480 µM,Fibroblas: IC50>480 µM,,,,Anticancer; Antimicrobial,Tumor active peptide##Membrane-targeted,,Linear,,Free,Free,,,0,PAARKAARWAWRMLKKGA
PAWRKAFRWAKRMLKKAA,18,Synthetic,Synthetic peptide,Human red blood cells: EC50>451 µM,Fibroblas: IC50=31 µM,,,,Anticancer; Antimicrobial,Tumor active peptide##Membrane-targeted,,Linear,,Free,Free,,,0,PAWRKAFRWAKRMLKKAA
PAWRKAFRKAWRMLKKAA,18,Synthetic,Synthetic peptide,Human red blood cells: EC50>451 µM,Fibroblas: IC50=59 µM,,,,Anticancer; Antimicrobial,Tumor active peptide##Membrane-targeted,,Linear,,Free,Free,,,0,PAWRKAFRKAWRMLKKAA
PAWRKARRWAWRMKKLAA,18,Synthetic,Synthetic peptide,Human red blood cells: EC50>438 µM,Fibroblas: IC50>438 µM,,,,Anticancer; Antimicrobial,Tumor active peptide##Membrane-targeted,,Linear,,Free,Free,,,0,PAWRKARRWAWRMKKLAA
PAWRKARRWARRMKKLAA,18,Synthetic,Synthetic peptide,Human red blood cells: EC50>444 µM,Fibroblas: IC50>444 µM,,,,Anticancer; Antimicrobial,Tumor active peptide##Membrane-targeted,,Linear,,Free,Free,,,0,PAWRKARRWARRMKKLAA
GIGKFLHSAKKWGKAFVGQIMNC,23,Synthetic,Synthetic peptide,,,,,,Anticancer; Antimicrobial,Tumor active peptide##Membrane-targeted,,Linear,,Free,Amidation,,,0,GIGKFLHSAKKWGKAFVGQIMNC
TRSSRAGLQWPVGRVHRLLRKGGC,24,Synthetic,Synthetic peptide,,,,,,Anticancer; Antimicrobial,Transducing peptide##Cell-penetrating peptides,,Linear,,Free,Amidation,,,0,TRSSRAGLQWPVGRVHRLLRKGGC
YGRKKRRQRRR,11,Synthetic,Synthetic peptide,,,,,,Anticancer; Antimicrobial,Transducing peptide##Cell-penetrating peptides,,Linear,,Free,Free,,,0,YGRKKRRQRRR
GLPVCGETCVGGTCNTPGCSCSWPVCTRN,29,Viola arvensis (European field pansy) (Field violet),Native peptide,,PBMC: IC50=12.13 µM ,,,,Anticancer,Tumor active peptide##Membrane-targeted,,Cyclic,Cys5<--->Cys19; Cys9<--->Cys21; Cys14<--->Cys26; NCB: Gly1<--->Asn29,Free,Free,,,0,GLPVCGETCVGGTCNTPGCSCSWPVCTRN
GVPICGETCTLGTCYTAGCSCSWPVCTRN,29,Viola arvensis (European field pansy) (Field violet),Native peptide,HRBCs: HD50=33.04 µM,,,,,Anticancer,Tumor active peptide##Membrane-targeted,,Cyclic,Cys5<--->Cys19; Cys9<--->Cys21; Cys14<--->Cys26; NCB: Gly1<--->Asn29,Free,Free,,,0,GVPICGETCTLGTCYTAGCSCSWPVCTRN
GIPCGESCVWIPCISSAIGCSCKSKVCYRN,30,Viola odorata,Native peptide,HRBCs: HC50=25.60 ± 1.93 µM,PBMC: IC50=0.87 µM; HUVEC: CC50=0.80 ± 0.03 µM,,,,Anticancer,Tumor active peptide##Membrane-targeted,,Cyclic,Cys4<--->Cys20; Cys8<--->Cys22; Cys13<--->Cys27; NCB: Gly1<--->Asn30,Free,Free,,,0,GIPCGESCVWIPCISSAIGCSCKSKVCYRN
GLPVCGETCFGGTCNTPGCSCETWPVCSRN,30,Viola arvensis (European field pansy) (Field violet),Native peptide,HRBCs: HD50=7.52 µM,,,,,Anticancer,Tumor active peptide##Membrane-targeted,,Cyclic,Cys5<--->Cys19; Cys9<--->Cys21; Cys14<--->Cys27; NCB: Gly1<--->Asn30,Free,Free,,,0,GLPVCGETCFGGTCNTPGCSCETWPVCSRN
GLPICGETCVGGSCNTPGCSCSWPVCTRN,29,Viola arvensis (European field pansy) (Field violet),Native peptide,,,,,,Anticancer,Tumor active peptide##Membrane-targeted,,Cyclic,Cys5<--->Cys19; Cys9<--->Cys21; Cys14<--->Cys26; NCB: Gly1<--->Asn29,Free,Free,,,0,GLPICGETCVGGSCNTPGCSCSWPVCTRN
GLPICGETCVGGTCNTPGCSCSWPVCTRN,29,Viola arvensis (European field pansy) (Field violet),Native peptide,HRBCs: HD50=6.96 µM,,,,,Anticancer,Tumor active peptide##Membrane-targeted,,Cyclic,Cys5<--->Cys19; Cys9<--->Cys21; Cys14<--->Cys26; NCB: Gly1<--->Asn29,Free,Free,,,0,GLPICGETCVGGTCNTPGCSCSWPVCTRN
GLFDVIKKVASVIGGL,16,Amphibian skin secretions,Native peptide,,,,,,Anticancer; Antimicrobial,Tumor active peptide##Membrane-targeted,,Linear,,Free,Amidation,,,0,GLFDVIKKVASVIGGL
glfdvikkvasviggl,16,Amphibian skin secretions,Synthetic peptide,,,,,,Anticancer; Antimicrobial,Tumor active peptide##Membrane-targeted,,Linear,,Free,Amidation,,,0,GLFDVIKKVASVIGGL
GLFAVIKKVASVIGGL,16,Amphibian skin secretions,Synthetic peptide,,CHO: IC50=19 ± 2 μM(pH=7.4); IC50=21 ± 1 μM(pH=5.5),,,,Anticancer; Antimicrobial,Tumor active peptide##Membrane lysis,,Linear,,Free,Amidation,,,0,GLFAVIKKVASVIGGL
GLFDVIKAVASVIGGL,16,Amphibian skin secretions,Synthetic peptide,,,,,,Anticancer; Antimicrobial,Tumor active peptide##Membrane-targeted,,Linear,,Free,Amidation,,,0,GLFDVIKAVASVIGGL
GLFDVIKKVAAVIGGL,16,Amphibian skin secretions,Synthetic peptide,,,,,,Anticancer; Antimicrobial,Tumor active peptide##Membrane-targeted,,Linear,,Free,Amidation,,,0,GLFDVIKKVAAVIGGL
GLFDVIKKVASVIKGL,16,Amphibian skin secretions,Synthetic peptide,,,,,,Anticancer; Antimicrobial,Tumor active peptide##Membrane-targeted,,Linear,,Free,Amidation,,,0,GLFDVIKKVASVIKGL
GLFDVIKKVASVIKKL,16,Amphibian skin secretions,Synthetic peptide,,,,,,Anticancer; Antimicrobial,Tumor active peptide##Membrane-targeted,,Linear,,Free,Amidation,,,0,GLFDVIKKVASVIKKL
GLFDVIAKVASVIKKL,16,Amphibian skin secretions,Synthetic peptide,,,,,,Anticancer; Antimicrobial,Tumor active peptide##Membrane-targeted,,Linear,,Free,Amidation,,,0,GLFDVIAKVASVIKKL
GLFAVIKKVASVIKGL,16,Amphibian skin secretions,Synthetic peptide,,,,,,Anticancer; Antimicrobial,Tumor active peptide##Membrane-targeted,,Linear,,Free,Amidation,,,0,GLFAVIKKVASVIKGL
GLFAVIKKVASVIKKL,16,Amphibian skin secretions,Synthetic peptide,,,,,,Anticancer; Antimicrobial,Tumor active peptide##Membrane-targeted,,Linear,,Free,Amidation,,,0,GLFAVIKKVASVIKKL
GLFAVIKKVAAVIKKL,16,Amphibian skin secretions,Synthetic peptide,,,,,,Anticancer; Antimicrobial,Tumor active peptide##Membrane-targeted,,Linear,,Free,Amidation,,,0,GLFAVIKKVAAVIKKL
GLFAVIKKVAAVIRRL,16,Amphibian skin secretions,Synthetic peptide,,,,,,Anticancer; Antimicrobial,Tumor active peptide##Membrane-targeted,,Linear,,Free,Amidation,,,0,GLFAVIKKVAAVIRRL
GLFAVIKKVAKVIKKL,16,Amphibian skin secretions,Synthetic peptide,,,,,,Anticancer; Antimicrobial,Tumor active peptide##Membrane-targeted,,Linear,,Free,Amidation,,,0,GLFAVIKKVAKVIKKL
GLFKVIKKVASVIGGL,16,Amphibian skin secretions,Synthetic peptide,,,,,,Anticancer; Antimicrobial,Tumor active peptide##Membrane-targeted,,Linear,,Free,Amidation,,,0,GLFKVIKKVASVIGGL
GLFKVIKKVAKVIKKL,16,Amphibian skin secretions,Synthetic peptide,,,,,,Anticancer; Antimicrobial,Tumor active peptide##Membrane-targeted,,Linear,,Free,Amidation,,,0,GLFKVIKKVAKVIKKL
LGGIVSAVKKIVDFLG,16,Amphibian skin secretions,Synthetic peptide,,,,,,Anticancer; Antimicrobial,Tumor active peptide##Membrane-targeted,,Linear,,Free,Amidation,,,0,LGGIVSAVKKIVDFLG
KLllKLKlKlLK,12,Diastereomeric peptide,Synthetic peptide,Human erythrocyte: Hemolysis% at 50 μm peptide LC50=0 µM,NIH-3T3: LC50>100 µM,,,,Anticancer; Antibacterial,Tumor active peptide##Membrane-targeted,,Linear,,Free,Free,l=D-Leucine; k=D-Lysine,,0,KLLLKLKLKLLK
KLlRLLkkLlRLlLK,15,Diastereomeric peptide,Synthetic peptide,Human erythrocyte: Hemolysis% at 50 μm peptide LC50=0 µM,NIH-3T3: LC50=40 µM,,,,Anticancer; Antibacterial,Tumor active peptide##Membrane-targeted,,Linear,,Free,Free,l=D-Leucine; k=D-Lysine,,0,KLLRLLKKLLRLLLK
AIGSILGALAKGLPTLISWIKNR,23,Rana tagoi,Native peptide,Human erythrocytes: HC50=8 μM,L929: LC50=20 μM,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide##Membrane-targeted,,Linear,,Free,Amidation,,,0,AIGSILGALAKGLPTLISWIKNR
AIGKFLHSAKKFGKAFVGEIMNS,23,African clawed frog Xenopus laevis skin,Native peptide,Detectable but low hemolytic activity,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide##Membrane-targeted,,Linear,,Beta-alanine,Amidation,,,0,AIGKFLHSAKKFGKAFVGEIMNS
GIGKFLHSAKKFAKAFVAEIMNS,23,African clawed frog Xenopus laevis skin,Native peptide,Magainin G  showed <1% hemolytic activity at 200 μg /ml (65.7μM),Magainin G did not exhibit cytotoxic effects on normal human peripheral blood lymphocytes at concentrations of up to 100-200 μg/ml (32.9-65.7 μM),,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide##Membrane-targeted,,Linear,,Beta-alanine,Amidation,,,0,GIGKFLHSAKKFAKAFVAEIMNS
FLPLLAGLAANFLPTIICKISYKC,24,Skin secretions of Rana rugosa,Native peptide,Human RBCs: less than 6% hemolysis at 100 μg/ml,HEK293: IC50=5.62±1.50 µg/ml,,,,Anticancer; Antimicrobial,Tumor active peptide##Induce apoptosis,,Cyclic,Cys18<--->Cys24,Free,Amidation,,,0,FLPLLAGLAANFLPTIICKISYKC
LLAGLAANFLPTIICKISYKC,21,Synthetic,Synthetic peptide,Human RBCs: less than 6% hemolysis at 100 μg/ml,HEK293: IC50>100 µg/ml,,,,Anticancer; Antimicrobial,Tumor active peptide##Induce apoptosis,,Cyclic,Cys15<--->Cys21,Free,Amidation,,,0,LLAGLAANFLPTIICKISYKC
FAGLAANFLPTIICKISYKC,20,Synthetic,Synthetic peptide,Human RBCs: less than 6% hemolysis at 100 μg/ml,HEK293: IC50>100 µg/ml,,,,Anticancer; Antimicrobial,Tumor active peptide##Induce apoptosis,,Cyclic,Cys14<--->Cys20,Free,Amidation,,,0,FAGLAANFLPTIICKISYKC
FLKLLKKLAAKFLPTIICKISYKC,24,Synthetic,Synthetic peptide,Human RBCs: 45.17% hemolysis at 100 μg/ml,HEK293: IC50=26.15 ± 6.23 µg/ml,,,,Anticancer; Antimicrobial,Tumor active peptide##Induce apoptosis,,Linear,,Free,Amidation,,,0,FLKLLKKLAAKFLPTIICKISYKC
FLKLLKKLAAKLF,13,Synthetic,Synthetic peptide,Human RBCs: less than 6% hemolysis at 100 μg/ml,HEK293: IC50=15.11±0.85 µg/ml,,,,Anticancer; Antimicrobial,Tumor active peptide##Induce apoptosis,,Linear,,Free,Amidation,,,0,FLKLLKKLAAKLF
FLKLLKKLAAKFL,13,Synthetic,Synthetic peptide,Human RBCs: less than 6% hemolysis at 100 μg/ml,HEK293: IC50=14.00 ± 1.46 µg/ml,,,,Anticancer; Antimicrobial,Tumor active peptide##Induce apoptosis,,Linear,,Free,Amidation,,,0,FLKLLKKLAAKFL
FLGALFKALSKLL,13,Synthetic,Synthetic peptide,Human RBCs: less than 6% hemolysis at 100 μg/ml,HEK293: IC50=6.71 ± 0.47 µg/ml; MCF-10A: IC50=8 μM,,,Induce cell death via apoptosis,Anticancer; Antimicrobial,Tumor active peptide##Membrane lysis##Induce apoptosis,,Linear,,Free,Amidation,,,0,FLGALFKALSKLL
FLKLLAGLLKNFA,13,Synthetic,Synthetic peptide,Human RBCs: less than 6% hemolysis at 100 μg/ml,HEK293: IC50=26.80 ± 5.52 µg/ml,,,,Anticancer; Antimicrobial,Tumor active peptide##Induce apoptosis,,Linear,,Free,Amidation,,,0,FLKLLAGLLKNFA
KTCENLADDY,10,Gymnocladus chinensis,Native peptide,,,,,,Anticancer; Antifungal; Antiviral,Tumor active peptide##Affect cell cycle,,Linear,,Free,Free,,,0,KTCENLADDY
KIFGSLAFL,9,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide##Immune system stimulating peptides,,Linear,,Free,Free,,,0,KIFGSLAFL
VMAGVGSPYV,10,Synthetic,Synthetic peptide,,,,,"The low-avidity T cell repertoire for a self tumor antigen is functional, can be activated and expanded with the help of costimulation",Anticancer,Tumor active peptide##Immune system stimulating peptides,,Linear,,Free,Free,,,0,VMAGVGSPYV
DNGEAGRAAR,10,Pleurotus sajor-caju,Native peptide,,Mouse splenocytes: IC50=0.065 µM,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide##Affect cell cycle,,Linear,,Free,Free,,,0,DNGEAGRAAR
FRKSKEKIGKEFKRIVQRIKDFLRNLV,27,hCAP18 Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide##Induce apoptosis,,Linear,,Free,Free,,,0,FRKSKEKIGKEFKRIVQRIKDFLRNLV
HHPHGHHPHGHHPHGHHPHG,20,Synthetic,Synthetic peptide,,,Tropomyosin,,Bind to Tropomyosin and Have Antiangiogenic and Antitumor Activities,Anticancer,Tumor active peptide##Cancer targeted peptides##Antiangiogenic,,Linear,,Acetylation,Amidation,,,0,HHPHGHHPHGHHPHGHHPHG
CVKVKVKVGSGVKVKVKVC,19,Synthetic,Synthetic peptide,Human erythrocytes: 50% Hemolysis=880 µM,,,,,Anticancer; Antibacterial,Tumor active peptide##Membrane-targeted,,Cyclic,Cys1<--->Cys19,Acetylization,Amidation,,,0,CVKVKVKVGSGVKVKVKVC
CVKVSVKVGSGVKVSVKVC,19,Synthetic,Synthetic peptide,Human erythrocytes: 50% Hemolysis=589 µM,,,,,Anticancer; Antibacterial,Tumor active peptide##Membrane-targeted,,Cyclic,Cys1<--->Cys19,Acetylization,Amidation,,,0,CVKVSVKVGSGVKVSVKVC
CVKVRVKVGSGVKVRVKVC,19,Synthetic,Synthetic peptide,Human erythrocytes: 50% Hemolysis=590 µM,,,,,Anticancer; Antibacterial,Tumor active peptide##Membrane-targeted,,Cyclic,Cys1<--->Cys19,Acetylization,Amidation,,,0,CVKVRVKVGSGVKVRVKVC
CVKVQVKVGSGVKVQVKVC,19,Synthetic,Synthetic peptide,Human erythrocytes: 50% Hemolysis=3226 µM,,,,,Anticancer; Antibacterial,Tumor active peptide##Membrane-targeted,,Cyclic,Cys1<--->Cys19,Acetylization,Amidation,,,0,CVKVQVKVGSGVKVQVKVC
CAKAKAKAGSGAKAKAKAC,19,Synthetic,Synthetic peptide,Human erythrocytes: 50% Hemolysis=1055 µM,,,,,Anticancer; Antibacterial,Tumor active peptide##Membrane-targeted,,Cyclic,Cys1<--->Cys19,Acetylization,Amidation,,,0,CAKAKAKAGSGAKAKAKAC
CFKFKFKFGSGFKFKFKFC,19,Synthetic,Synthetic peptide,Human erythrocytes: 50% Hemolysis=35 µM,,,,,Anticancer; Antibacterial,Tumor active peptide##Membrane-targeted,,Cyclic,Cys1<--->Cys19,Acetylization,Amidation,,,0,CFKFKFKFGSGFKFKFKFC
CWKWKWKWGSGWKWKWKWC,19,Synthetic,Synthetic peptide,Human erythrocytes: 50% Hemolysis=45 µM,,,,,Anticancer; Antibacterial,Tumor active peptide##Membrane-targeted,,Cyclic,Cys1<--->Cys19,Acetylization,Amidation,,,0,CWKWKWKWGSGWKWKWKWC
CWMSPRHLGTCGRKKRRQRRRPPQ,24,Synthetic,Synthetic peptide,,,,,"CIGB-300 is a cyclic synthetic peptide that induces apoptosis in malignant cells, elicits antitumor activity in cancer animal models",Anticancer; Antitumor,Transducing peptide##Cell-penetrating peptides,,Cyclic,Cys1<--->Cys11,Free,Free,,,0,CWMSPRHLGTCGRKKRRQRRRPPQ
GRKKRRQRRRGGWMWVTNLRTD,22,RasGAP-derived peptides,Native peptide,,,,,Enhances genotoxin-induced cytotoxicity in tumor cells,Anticancer,Transducing peptide##Cell-penetrating peptides,,Linear,,Free,Free,,,0,GRKKRRQRRRGGWMWVTNLRTD
KQTENLADTY,10,Phaseolus coccineus,Native peptide,,,,,,Anticancer; Antifungal; Antiviral,Tumor active peptide,,Linear,,Free,Free,,,0,KQTENLADTY
ANDPQCLYGNVAAKF,15,Agrocybe cylindracea,Native peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Free,,,0,ANDPQCLYGNVAAKF
ERRP,4,EGFR-related peptide,Native peptide,,,,,ERRP inhibits the growth of prostate cancer cells by attenuating EGFR signaling processes,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,ERRP
LRVRLASHLRKLRKRLLRDADDLQKRLAVY,30,Apoprotein E,Synthetic peptide,Human red blood cells: ApoE does not lyse erythrocytes,,,,"ApoE has anti-tumor activity, probably through perturbation and formation of ionpermeable ""pores"" in membranes",Anticancer; Antimicrobial,Tumor active peptide,,Linear,,Free,Free,,,0,LRVRLASHLRKLRKRLLRDADDLQKRLAVY
LW,2,Anthranilic acid,Native peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,LW
HSHRDFQPVLHLVALNSPLSGGMRG,25,Human endostatin peptides,Native peptide,,,"α5β1 integrin, metalloproteinases",,"Inhibition of endothelial cell proliferation, migration, and tube formation",Anticancer; Antiangiogenesis,Tumor active peptide##Cancer targeted peptides,,Linear,,Free,Free,,,0,HSHRDFQPVLHLVALNSPLSGGMRG
MRGIRGADFQAFQQARAVGLAGTFR,25,Human endostatin peptides,Native peptide,,,"α5β1 integrin, metalloproteinases",,"Inhibition of endothelial cell proliferation, migration, and tube formation",Anticancer; Antiangiogenesis,Tumor active peptide##Cancer targeted peptides,,Linear,,Free,Free,,,0,MRGIRGADFQAFQQARAVGLAGTFR
TFRAFLSSRLQDLYSIVRRADRAAV,25,Human endostatin peptides,Native peptide,,,"α5β1 integrin, metalloproteinases",,"Inhibition of endothelial cell proliferation, migration, and tube formation",Anticancer; Antiangiogenesis,Tumor active peptide##Cancer targeted peptides,,Linear,,Free,Free,,,0,TFRAFLSSRLQDLYSIVRRADRAAV
AAVPIVNLKDELLFPSWEALFSGSE,25,Human endostatin peptides,Native peptide,,,"α5β1 integrin, metalloproteinases",,"Inhibition of endothelial cell proliferation, migration, and tube formation",Anticancer; Antiangiogenesis,Tumor active peptide##Cancer targeted peptides,,Linear,,Free,Free,,,0,AAVPIVNLKDELLFPSWEALFSGSE
GSEGPLKPGARIFSFDGKDVLRHPT,25,Human endostatin peptides,Native peptide,,,"α5β1 integrin, metalloproteinases",,"Inhibition of endothelial cell proliferation, migration, and tube formation",Anticancer; Antiangiogenesis,Tumor active peptide##Cancer targeted peptides,,Linear,,Free,Free,,,0,GSEGPLKPGARIFSFDGKDVLRHPT
HPTWPQKSVWHGSDPNGRRLTESY,24,Human endostatin peptides,Native peptide,,,"α5β1 integrin, metalloproteinases",,"Inhibition of endothelial cell proliferation, migration, and tube formation",Anticancer; Antiangiogenesis,Tumor active peptide##Cancer targeted peptides,,Linear,,Free,Free,,,0,HPTWPQKSVWHGSDPNGRRLTESY
ETWRTEAPSATGQASSLLGGRLLGQ,25,Human endostatin peptides,Native peptide,,,"α5β1 integrin, metalloproteinases",,"Inhibition of endothelial cell proliferation, migration, and tube formation",Anticancer; Antiangiogenesis,Tumor active peptide##Cancer targeted peptides,,Linear,,Free,Free,,,0,ETWRTEAPSATGQASSLLGGRLLGQ
LGQSAASAHHAYIVLAIENSFMTASKKK,28,Human endostatin peptides,Native peptide,,,"α5β1 integrin, metalloproteinases",,"Inhibition of endothelial cell proliferation, migration, and tube formation",Anticancer; Antiangiogenesis,Tumor active peptide##Cancer targeted peptides,,Linear,,Free,Free,,,0,LGQSAASAHHAYIVLAIENSFMTASKKK
AXQNXXXPLXXVX,13,Terrestrial blue-green alga Anabaena laxa or the marine cyanobacterium Lyngbya Majuscula,Native peptide,,,,,,Anticancer; Antifungal,Tumor active peptide,,Cyclic,X1<--->X13,,,X(2/13)=Leu(3-OH); X(5)=N(Me)xiIle; X(6)=Asn(3-OH); X(7/10)=xiThr; X(11)=Unk,,0,AXQNXXXPLXXVX
XXXFLXXLGXX,11,Terrestrial blue-green alga Anabaena laxa or the marine cyanobacterium Lyngbya Majuscula,Native peptide,,,,,,Anticancer; Antifungal,Tumor active peptide,,Cyclic,X1<--->X11,,,"X(1)=Abu(2,3-dehydro); X(2)=xiHyp; X(3/11)=Hse; X(6/7)=xiIle; X(10)=Unk",,0,XXXFLXXLGXX
KTCENLADTY,10,Ground beans,Native peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,KTCENLADTY
MWKWFHNVLSSWQLLADKRPARDYNRK,27,S. pneumoniae,Synthetic peptide,"Human RBCs(0% hemolysis at 0.19 μM, 0.39 μM, 0.78 μM, 1.56 μM, 3.12 μM, 6.25 μM, 12.5 μM)",,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,MWKWFHNVLSSWQLLADKRPARDYNRK
MWKWFHNVLSWWWLLADKRPARDYNRK,27,S. pneumoniae,Synthetic peptide,"Human RBCs(18% hemolysis at  12.5 μM), Human RBCs(0% hemolysis at 0.19 μM, 0.39 μM, 0.78 μM, 1.56 μM, 3.12 μM, 6.25 μM)",,,,"Pep27anal2 can penetrate the plasma membrane, and then induce apoptosis in both caspase-and cytochrome c-independent manner",Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,MWKWFHNVLSWWWLLADKRPARDYNRK
MRKWFHNVLSSGQLLADKWPAWDYNRK,27,S. pneumoniae,Synthetic peptide,"Human RBCs(0% hemolysis at 0.19 μM, 0.39 μM, 0.78 μM, 1.56 μM, 3.12 μM, 6.25 μM, 12.5 μM)",,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,MRKWFHNVLSSGQLLADKWPAWDYNRK
MWKEFHNVLSSGQLLADKRWARWYNRW,27,S. pneumoniae,Synthetic peptide,"Human RBCs(0% hemolysis at 0.19 μM, 0.39 μM, 0.78 μM, 1.56 μM, 3.12 μM, 6.25 μM, 12.5 μM)",,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,MWKEFHNVLSSGQLLADKRWARWYNRW
MWKWFHNVLSSGQLLADKWWAWWYNWW,27,S. pneumoniae,Native peptide,"Human RBCs(0% hemolysis at 0.19 μM, 0.39 μM, 0.78 μM, 1.56 μM, 3.12 μM, 6.25 μM, 12.5 μM)",,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,MWKWFHNVLSSGQLLADKWWAWWYNWW
MRKEFHNVLSSGQLLADKRPARDYNRK,27,S. pneumoniae,Native peptide,"Human RBCs(0% hemolysis at 0.19 μM, 0.39 μM, 0.78 μM, 1.56 μM, 3.12 μM, 6.25 μM, 12.5 μM)",,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,MRKEFHNVLSSGQLLADKRPARDYNRK
SNDIYFNFQR,10,Phaseolus vulgaris,Native peptide,,Mouse splenocytes: NA,,,,Anticancer; Antifungal; Antiviral,Tumor active peptide,,Linear,,Free,Free,,,0,SNDIYFNFQR
PGLGFY,6,Annona cherimola (Custard apple) (Cherimoya),Native peptide,,,,,,Anticancer,Tumor active peptide,,Cyclic,NCB: Pro1<--->Tyr6,Free,Free,,,0,PGLGFY
YSL,3,Synthetic,Synthetic peptide,,,,,"Enhances the antitumor effects of macrophages and stimulates macrophage secretion of IL-1β, TNF-α, and NO in vitro",Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,YSL
IDWKKLLDAAKQIL,14,Polybia paulista,Native peptide,Human erythrocytes: Not active up to 64 µM; 3.2% Hemolysis=25 µM;  <1% Hemolysis=12.5 µM,Rat mast cells: 62% degranulation=100 µM; NIH 3T3: 50% Cell death>60 µM,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Free,,,0,IDWKKLLDAAKQIL
KILRGVCKKIMRTFLRRISKDILTGKK,27,Sus scrofa (Pig),Native peptide,Human erythrocytes: 45% Hemolysis=100 µg/ml,Non-toxic to a human keratinocyte cell line,,,,Anticancer; Antibacterial,Tumor active peptide##Membrane lysis,,Linear,,Free,Amidation,,,0,KILRGVCKKIMRTFLRRISKDILTGKK
KTCENLADTFRGPCFATSNC,20,Phaseolus lunatus,Native peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,KTCENLADTFRGPCFATSNC
FLSLALAALPKLFCLIFKKC,20,Rana dybowskii; Rana pirica; Rana amurensis,Native peptide,Human erythrocytes: 50% Hemolysis<5 µM; 50% Hemolysis=125 µM; 50% Hemolysis=7 µM; Horse erythrocytes: 50% Hemolysis=4.7 µM,HMEC-1: IC50=25.2 µM,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Cyclic,Cys14<--->Cys20,Free,Free,,,0,FLSLALAALPKLFCLIFKKC
rrrrrrrrGNLWAAQRYGRELRRMSDEFVDSFKK,34,Synthetic,Synthetic peptide,,,,,Induce apoptosis in highly malignant NB-derived cell lines,Anticancer,Tumor active peptide,,Linear,,Free,Free,rrrrrrrr=D-isomer homopolymer of eight arginine residues,,0,RRRRRRRRGNLWAAQRYGRELRRMSDEFVDSFKK
rrrrrrrrGEDIIRNIARHLAQVGDSMDR,29,Synthetic,Synthetic peptide,,,,,Induce apoptosis in highly malignant NB-derived cell lines,Anticancer,Tumor active peptide,,Linear,,Free,Free,rrrrrrrr=D-isomer homopolymer of eight arginine residues,,0,RRRRRRRRGEDIIRNIARHLAQVGDSMDR
rrrrrrrrGEDIIRNIARHAAQVGASMDR,29,Synthetic,Synthetic peptide,,,,,Induce apoptosis in highly malignant NB-derived cell lines,Anticancer,Tumor active peptide,,Linear,,Free,Free,rrrrrrrr=D-isomer homopolymer of eight arginine residues,,0,RRRRRRRRGEDIIRNIARHAAQVGASMDR
FKCRRWQWRMKKLGAPSITCVRRAF,25,The big centipede Scolopendra subspinipes mutilans,Native peptide,,,,,LfcinB possesses a cytotoxic effect on MYCN-amplified NB cells by directly targeting and destabilizing the cytoplasmic membrane and the mitochondria.,Anticancer; Antimicrobial,Tumor active peptide,,Cyclic,Cys3 <--> Cys20,Free,Amidation,,,0,FKCRRWQWRMKKLGAPSITCVRRAF
FKRIVQRIKDFLRNLV,16,"LL-37,a series of peptide fragments",Synthetic peptide,,HBMEC: LC50=40 µM,,,,Anticancer; Antibacterial,Tumor active peptide##Induce apoptosis,,Linear,,Free,Amidation,,,0,FKRIVQRIKDFLRNLV
FKRIVQRIKDFLR,13,"LL-37,a series of peptide fragments",Synthetic peptide,Human erythrocytes: Not active up to 500 µg/ml,HBMEC: LC50=41 µM; DLF lung fibroblasts: IC50=29.3 μg/ml,,,,Anticancer; Antibacterial,Tumor active peptide##Induce apoptosis,,Linear,,Free,Amidation,,,0,FKRIVQRIKDFLR
IGKEFKRIVQRIKDFLRNLVPRTES,25,"LL-37,a series of peptide fragments",Synthetic peptide,,HBMEC: LC50=38±3 µM,,,,Anticancer; Antibacterial,Tumor active peptide##Induce apoptosis,,Linear,,Free,Amidation,,,0,IGKEFKRIVQRIKDFLRNLVPRTES
LKlLKKLlkKLLkLL,15,Host Defense lytic Peptide,Synthetic peptide,,,surface phosphatidylserine,,The exclusive selectivity of the peptide towards cancer derives from its specific binding to surface phosphatidylserine and the killing of the cancer cells via cytoplasmic membrane depolarization,Anticancer,Tumor active peptide##Cancer targeted peptides,,Linear,,Free,Amidation,l=D-Leucine; k=D-Lysine,,0,LKLLKKLLKKLLKLL
YGGFM,5,The native opioid growth factor,Native peptide,,,,,lead to apoptosis,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,YGGFM
YX,2,Synthetic,Synthetic peptide,,,,,lead to apoptosis,Anticancer,Tumor active peptide,,Linear,,Free,Free,X=Cαα -dialkylated glycine (Aaa1 ),,0,YX
YXG,3,Synthetic,Synthetic peptide,,,,,lead to apoptosis,Anticancer,Tumor active peptide,,Linear,,Free,Free,"X=Cα -dialkylated glycine (Aaa2,S )",,0,YXG
YXGFM,5,Synthetic,Synthetic peptide,,,,,lead to apoptosis,Anticancer,Tumor active peptide,,Linear,,Free,Free,X=Cαα -dialkylated glycine (Aaa1 ),,0,YXGFM
YGGFMX,6,Synthetic,Synthetic peptide,,,,,lead to apoptosis,Anticancer,Tumor active peptide,,Linear,,Free,Free,X=Cαα -dialkylated glycine (Aaa1 ),,0,YGGFMX
FLGALFKVASKVLPSVKCAITKKC,24,Rana rugosa,Synthetic peptide,Human erythrocytes: 7% Hemolysis=100 µg/ml,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,Cys18<--->Cys24,Free,Free,,,0,FLGALFKVASKVLPSVKCAITKKC
FLGALFKWASK,11,Synthetic,Synthetic peptide,Human erythrocytes: 7% Hemolysis=100 µg/ml,MCF-10a: IC50=434.79 µg/ml,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,FLGALFKWASK
FLGWLFKVASK,11,Synthetic,Synthetic peptide,Human erythrocytes: 12% Hemolysis=100 µg/ml,MCF-10a: IC50=311.38 µg/ml,,,,Anticancer; Antifungal,Tumor active peptide,,Linear,,Free,Free,,,0,FLGWLFKVASK
FLPLAVSLAANFLPKLFCKITKKC,24,Amolops loloensis; Amolops jingdongensis,Native peptide,Rabbit erythrocytes: 50% Hemolysis=5 µg/ml; 96% Hemolysis=20 µg/ml,Rat mast cells: 17% degranulation=100 µg/ml,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Cyclic,Cys18<--->Cys24,Free,Free,,,0,FLPLAVSLAANFLPKLFCKITKKC
LKCNKLVPLFYKTCPAGKNL,20,Daboia russelii (Russel's viper) (Vipera russelii),Native peptide,,,,,,Anticancer,Tumor active peptide,,,,,,,,0,LKCNKLVPLFYKTCPAGKNL
GIGKFLHAAKKFAKAFVAEIMNS,23,Xenopus laevis,Native peptide,,,,,magainin 2 and synthetic analogues can rapidly and irreversibly lyse hematopoietic tumor and solid tumor ,Anticancer; Antimicrobial,Tumor active peptide,,Linear,,Free,Amidation,,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",0,GIGKFLHAAKKFAKAFVAEIMNS
ALSKALSKALSKALSKALSKALSK,24,Xenopus laevis,Synthetic peptide,,,,,magainin 2 and synthetic analogues can rapidly and irreversibly lyse hematopoietic tumor and solid tumor ,Anticancer; Antimicrobial,Tumor active peptide,,Linear,,Free,Amidation,,,0,ALSKALSKALSKALSKALSKALSK
AKSKAKSKAKSKAKSKAKSKAKSK,24,Xenopus laevis,Native peptide,,,,,magainin 2 and synthetic analogues can rapidly and irreversibly lyse hematopoietic tumor and solid tumor ,Anticancer; Antimicrobial,Tumor active peptide,,Linear,,Free,Amidation,,,0,AKSKAKSKAKSKAKSKAKSKAKSK
GIGKFLHSAKKFGKAFVGEIMNS,23,Xenopus laevis,Native peptide,,,,,magainin 2 and synthetic analogues can rapidly and irreversibly lyse hematopoietic tumor and solid tumor ,Anticancer; Antimicrobial,Tumor active peptide,,Linear,,Free,Amidation,,,0,GIGKFLHSAKKFGKAFVGEIMNS
GVLGAVKDLLIGAGKSAAQSVLKTLSCKLSNDC,33,Odorrana grahami,Native peptide,Human erythrocytes: 0% Hemolysis=50 µg/ml; Sheep erythrocytes: <10% Hemolysis=256 µM,Human mast cells: 2.9±1.5% degranulation=50 µg/ml; HEK293T: IC50=48.7 µM,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Cyclic,Cys27<--->Cys33,Free,Free,,,0,GVLGAVKDLLIGAGKSAAQSVLKTLSCKLSNDC
KILRGVSKKIMRTFLRRILTGKK,23,Synthetic,Synthetic peptide,Human erythrocytes: 15% Hemolysis=100 µg/ml,,,,,Anticancer; Antibacterial,Tumor active peptide##Membrane lysis,,Linear,,Free,Free,,,0,KILRGVSKKIMRTFLRRILTGKK
KILRGVSKKIMRTFLRRISKDILTGKK,27,Synthetic,Synthetic peptide,Human erythrocytes: 25% Hemolysis=100 µg/ml,,,,,Anticancer; Antibacterial,Tumor active peptide##Membrane lysis,,Linear,,Free,Amidation,,,0,KILRGVSKKIMRTFLRRISKDILTGKK
KISKKIMRTFLRRISKDILTGKK,23,Synthetic,Synthetic peptide,Human erythrocytes: <5% Hemolysis=100 µg/ml,,,,,Anticancer; Antibacterial,Tumor active peptide##Membrane lysis,,Linear,,Free,Amidation,,,0,KISKKIMRTFLRRISKDILTGKK
VXLfPVXLfP,10,Bacillus brevis,Native peptide,Human erythrocytes: 100% Hemolysis=39 µg/ml; 50% Hemolysis=11 µM; Sheep erythrocytes: 50% Hemolysis=21.1±2.6 µM; 100% Hemolysis=100 µM,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide##Membrane lysis,,Cyclic,NCB: Val1<--->Pro10,Free,Free,X=Orn; f=D-Phe,,0,VXLFPVXLFP
GLWSKIKEAAKAAGKAALNAVTGLVNQGDQPS,32,skin secretions of the lemur leaf frog Hylomantis lemur (Hylidae: Phyllomedusinae),Native peptide,Human erythrocytes: LC50=40 μM,,,,Cytolytic,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Free,,,0,GLWSKIKEAAKAAGKAALNAVTGLVNQGDQPS
LLGMIPLAISAISALSKL,18,skin secretions of the lemur leaf frog Hylomantis lemur (Hylidae: Phyllomedusinae),Native peptide,Human erythrocytes: LC50=200 μM,,,,Cytolytic,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Free,,,0,LLGMIPLAISAISALSKL
RWCVYAYVRVRGVLVRYRRCW,21,Arenicola marina,Native peptide,Human erythrocytes: 0% Hemolysis=12.5 µM; 12% Hemolysis=25 µM; 35% Hemolysis=50 µM; 51% Hemolysis=100 µM; 10% Hemolysis=4.1 µM; 15% Hemolysis=10.3 µM; 50% Hemolysis=66.3 µM,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Cyclic,Cys3<--->Cys20,Free,Free,,,0,RWCVYAYVRVRGVLVRYRRCW
GTFPCGESCVFIPCLTSAIGCSCKSKVCYKN,31,V. biflora,Native peptide,,,,,,Anticancer,Tumor active peptide,,Cyclic,,Free,Free,,,0,GTFPCGESCVFIPCLTSAIGCSCKSKVCYKN
GLLPCAESCVYIPCLTTVIGCSCKSKVCYKN,31,V. biflora,Native peptide,,,,,,Anticancer,Tumor active peptide,,Cyclic,,Free,Free,,,0,GLLPCAESCVYIPCLTTVIGCSCKSKVCYKN
GIPCAESCVWIPCTVTALIGCGCSNKVCYN,30,V. biflora,Native peptide,,,,,,Anticancer,Tumor active peptide,,Cyclic,,Free,Free,,,0,GIPCAESCVWIPCTVTALIGCGCSNKVCYN
GLPVCGETCFGGRCNTPGCTCSYPICTRN,29,V. biflora,Native peptide,,,,,,Anticancer,Tumor active peptide,,Cyclic,,Free,Free,,,0,GLPVCGETCFGGRCNTPGCTCSYPICTRN
KWKLFKKIEKVGQNIRDGIIKAGPAVAVVGQATQIAK,37,Hyalophora Cecropia(silkmoth),Native peptide,,Normal murine or human fibroblasts: low cytotoxic,,,Cecropin A and B inhibit bladder cancer cell proliferation and viability in a dose-dependent fashion,Anticancer; Antimicrobial,Tumor active peptide##Membrane-targeted,,Linear,,Free,Amidation,,,0,KWKLFKKIEKVGQNIRDGIIKAGPAVAVVGQATQIAK
KWKVFKKIEKMGRNIRNGIVKAGPAIAVLGEAKAL,35,Chinese oak silk moth,Native peptide,,Normal murine or human fibroblasts: low cytotoxic,,,Cecropin A and B inhibit bladder cancer cell proliferation and viability in a dose-dependent fashion,Anticancer; Antimicrobial,Tumor active peptide##Membrane-targeted,,Linear,,Free,Amidation,,,0,KWKVFKKIEKMGRNIRNGIVKAGPAIAVLGEAKAL
FKCRRWQWRMKKLGAPSITCVR,22,Bovine lactoferrin (Lf-B),Native peptide,,,,,Pep1 may kill cancer cells by activating an apoptosis-inducing pathway,Anticancer; Antimicrobial,Tumor active peptide,,Linear,,Free,Free,,,0,FKCRRWQWRMKKLGAPSITCVR
RKAFRWAWRMLKKAAPSITCVR,22,Bovine lactoferrin (Lf-B),Synthetic peptide,,,,,mPep1 causes necrotic cell death by destroying cellular membrane structure ,Anticancer; Antimicrobial,Tumor active peptide,,Linear,,Free,Free,,,0,RKAFRWAWRMLKKAAPSITCVR
KLKNFAIGVAQSLLNKASCKLSGQC,25,Pelophylax ridibundus (Marsh frog) (Rana ridibunda),Native peptide,Sheep erythrocytes(2.5% hemolytic activity at 200 μg/ml),L929: LD50=20-25μg/ml,,,,Anticance; Antimicrobial; Antibacterial,Tumor active peptide,,Linear,,,,,,0,KLKNFAIGVAQSLLNKASCKLSGQC
RAGLQFPVGRLLRRLLRRLLR,21,Histone H2A,Native peptide,,,Gangliosides,,"After specifically targeting cancer cells through interaction with gangliosides, buforin IIb induces apoptosis in cancer cells by a mitochondria-dependent pathway",Anticancer; Antimicrobial,Tumor active peptide##Cancer targeted peptides##Antiangiogenic,,Linear,,Free,Free,,,0,RAGLQFPVGRLLRRLLRRLLR
KAQIRAMECNIL,12,Cyclin B (285-296),Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,KAQIRAMECNIL
KAQIRAMECNILGRKKRRQRRR,22,HIV-Tat (49-57),Synthetic peptide,,,HIV-Tat,,Tat-a5 could arrest cancer cells at G2/M phase and make them apoptotic; Tat-a5 would have the potential to inhibit tumor angiogenesis,Anticancer,Tumor active peptide##Cancer targeted peptides,,Linear,,Free,Free,,,0,KAQIRAMECNILGRKKRRQRRR
KKKFPWWWPFKKK,13,Derivative of tritrpticin,Native peptide,,NIH-3T3 (mouse): IC50=83 µg/ml,,,,Anticancer; Antimicrobial,Tumor active peptide,,Linear,,Free,Amidation,,,0,KKKFPWWWPFKKK
KKKFPWWWPFKKKCKKKFPWWWPFKKKC,28,Derivative of tritrpticin,Native peptide,,NIH-3T3 (mouse): IC50=20 µg/ml,,,,Anticancer; Antimicrobial,Tumor active peptide,,Linear,,Free,Amidation,,,0,KKKFPWWWPFKKKCKKKFPWWWPFKKKC
ETFSDLWKLL,10,Antennapedia,Native peptide,,,,,"PNC-28 may be effective in treating human pancreatic cancer. The penetratin sequence appears to be responsible for the fundamental change in the mechanism of action, inducing rapid necrosis initiated by membrane pore formation.",Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,ETFSDLWKLL
YKQCHKKGGKKGSG,14,Synthetic,Synthetic peptide,Human erythrocytes: 50% Hemolysis>300µM,PBMC: IC50>300µM,,,,Anticancer; Antibacterial,Tumor active peptide##Cell-penetrating peptides,,Linear,,Free,Amidation,,,0,YKQCHKKGGKKGSG
FLPAIVGAAAKFLPKIFCAISKKC,24,"North America, leopard frog, Lithobates blairi",Native peptide,Human erythrocytes: LD50=14 μM,,,,potent cytolytic activity,Anticancer; Antibacterial,Tumor active peptide##Membrane lysis,,Linear,Cys18<--->Cys24,Free,Free,,,0,FLPAIVGAAAKFLPKIFCAISKKC
FLPIIAGIAAKFLPKIFCTISKKC,24,"North America, leopard frog, Lithobates blairi",Native peptide,Human erythrocytes: LD50=9 μM,,,,potent cytolytic activity,Anticancer; Antibacterial,Tumor active peptide##Membrane lysis,,Linear,Cys18<--->Cys24,Free,Free,,,0,FLPIIAGIAAKFLPKIFCTISKKC
FLPVIAGVAANFLPKLFCAISKKC,24,"North America, leopard frog, Lithobates blairi",Native peptide,Human erythrocytes: LD50=18 μM,,,,potent cytolytic activity,Anticancer; Antibacterial,Tumor active peptide##Membrane lysis,,Linear,Cys18<--->Cys24,Free,Free,,,0,FLPVIAGVAANFLPKLFCAISKKC
FLPIIAGAAAKVVQKIFCAISKKC,24,"North America, leopard frog, Lithobates blairi",Native peptide,Human erythrocytes: LD50=16 μM,,,,potent cytolytic activity,Anticancer; Antibacterial,Tumor active peptide##Membrane lysis,,Linear,Cys18<--->Cys24,Free,Free,,,0,FLPIIAGAAAKVVQKIFCAISKKC
FLPIIAGAAAKVVEKIFCAISKKC,24,"North America, leopard frog, Lithobates blairi",Native peptide,Human erythrocytes: LD50=13 μM,,,,potent cytolytic activity,Anticancer; Antibacterial,Tumor active peptide##Membrane lysis,,Linear,Cys18<--->Cys24,Free,Free,,,0,FLPIIAGAAAKVVEKIFCAISKKC
GLMDTIKGVAKTVAASWLDKLKCKITGC,28,"North America, leopard frog, Lithobates yavapaiensis",Native peptide,Human erythrocytes: LD50>100 μM,,,,potent cytolytic activity,Anticancer; Antibacterial,Tumor active peptide##Membrane lysis,,Linear,Cys23<--->Cys28,Free,Free,,,0,GLMDTIKGVAKTVAASWLDKLKCKITGC
FLIGMTQGLICLITRKC,17,"skin of the Chinese brown frog, Rana chensinensis",Native peptide,Human erythrocytes: LD50=48 μM,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Amidation,,,0,FLIGMTQGLICLITRKC
FVDLKKIANIINSIF,15,"skin of the Chinese brown frog, Rana chensinensis",Native peptide,Human erythrocytes: LD50=230 μM,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Amidation,,,0,FVDLKKIANIINSIF
ILPILSLIGGLL,12,"skin of the Chinese brown frog, Rana chensinensis",Native peptide,Human erythrocytes: LD50=112 μM,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Amidation,,,0,ILPILSLIGGLL
SAVGRHGRRFGLRKHRKH,18,"skin of the Chinese brown frog, Rana chensinensis",Native peptide,Human erythrocytes: LD50>500 μM,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Amidation,,,0,SAVGRHGRRFGLRKHRKH
DYPKLTFTTS,10,Malania oleifera,Native peptide,,Vero: IC50=2.79±0.05nM; MDCK: IC50=3.92±0.01nM,,,,Anticancer,Tumor active peptide,,,,,,,,0,DYPKLTFTTS
DETXTDEEFN,10,Malania oleifera,Native peptide,,Vero: IC50=2.79±0.05nM; MDCK: IC50=3.92±0.01nM,,,,Anticancer,Tumor active peptide,,,,,,,,0,DETXTDEEFN
FKCRRWQWRMKK,12,Bovine lactoferrin (Lf-B),Native peptide,,,,,Peptides induce lysis of cancer cells through interactions with the plasma membrane,Anticancer; Antimicrobial,Tumor active peptide,,Linear,,Free,Free,,,0,FKCRRWQWRMKK
KAAKKAAKAAKKAAKAAKKAA,21,Bovine lactoferrin (Lf-B),Native peptide,,,,,Peptides induce lysis of cancer cells through interactions with the plasma membrane,Anticancer; Antimicrobial,Tumor active peptide,,Linear,,Free,Free,,,0,KAAKKAAKAAKKAAKAAKKAA
IDWKKLLDAAKQIX,14,Synthetic,Synthetic peptide,,NIH 3T3: 50% Cell death>60 µM,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,X=Leu-S,,0,IDWKKLLDAAKQIX
GFFGKRKEYFKKFGASFKRRFANLKKRL,28,Synthetic,Synthetic peptide,Human erythrocytes: 50% Hemolysis>36 µM,,,,,Anticancer; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,,0,GFFGKRKEYFKKFGASFKRRFANLKKRL
GKLIKKFGRKAISYAVKKARGKH,23,Synthetic,Synthetic peptide,Human erythrocytes: 50% Hemolysis>36 µM,,,,,Anticancer; Antifungal,Tumor active peptide,,Linear,,Free,Free,,,0,GKLIKKFGRKAISYAVKKARGKH
GKMKEYFKKFGASFKRRFANLKKRL,25,Synthetic,Synthetic peptide,Human erythrocytes: 50% Hemolysis>36 µM,,,,,Anticancer; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,,0,GKMKEYFKKFGASFKRRFANLKKRL
GLFGKLIKKFLRKAISYAVKKARGKH,26,Synthetic,Synthetic peptide,Human erythrocytes: 50% Hemolysis=3 µM,Human leukocytes: 50% Cell death=3 µM,,,,Anticancer; Antifungal,Tumor active peptide,,Linear,,Free,Free,,,0,GLFGKLIKKFLRKAISYAVKKARGKH
GLFGKLIKKKGRKAISYAVKKARGKH,26,Synthetic,Synthetic peptide,Human erythrocytes: 50% Hemolysis>36 µM,Human leukocytes: 50% Cell death>36 µM,,,,Anticancer; Antifungal,Tumor active peptide,,Linear,,Free,Free,,,0,GLFGKLIKKKGRKAISYAVKKARGKH
GLFGKLQKKFGRKAISYAVKKARGKH,26,Synthetic,Synthetic peptide,Human erythrocytes: 50% Hemolysis>36 µM,Human leukocytes: 50% Cell death>36 µM,,,,Anticancer; Antifungal,Tumor active peptide,,Linear,,Free,Free,,,0,GLFGKLQKKFGRKAISYAVKKARGKH
GFFGKMKEYFKKFGASFKRRFANLKKRL,28,Lachesana tarabaevi,Native peptide,Rabbit erythrocytes: 20% Hemolysis=40 µM; Human erythrocytes: 50% Hemolysis=12 µM; 27% Hemolysis=256 µg/ml,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,,0,GFFGKMKEYFKKFGASFKRRFANLKKRL
DDESSKPCCDQCACTKSNPPQCRCSDMRLNSCHSACKSCICALSYPAQCFCVDITDFCYEPCKPSEDDKEN,71,Glycine max,Native peptide,,,,,,Anticancer; Antifungal,Tumor active peptide,,Cyclic,Cys8<--->Cys62; Cys9<--->Cys24; Cys12<--->Cys58; Cys14<--->Cys22; Cys32<--->Cys39; Cys36<--->Cys51; Cys41<--->Cys49 ,Free,Free,,,0,DDESSKPCCDQCACTKSNPPQCRCSDMRLNSCHSACKSCICALSYPAQCFCVDITDFCYEPCKPSEDDKEN
KWKLFKKIPKFLHLAKKF,18,Synthetic,Synthetic peptide,,"99 ± 1.6% cell viability at 10 µM, 	98 ± 1.6% cell viability at 20 µM, 75.2 ± 5.6% cell viability at 40 µM, 70.8 ± 3.6% cell viability at 60 µM, 47.7 ± 3.1% cell viability at 80 µM",,,"Amphiphilic α-helical structure of P18 peptide, coupled with changes in ion channels and an increase in plasma membrane permeability that eventually leads to melanoma cell death",Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,KWKLFKKIPKFLHLAKKF
KWKLFKKIGAVLKVL,15,Ceropin-Melittin hybrid,Synthetic peptide,At CAMEL concentrations toxic for B16-F10 cells the peptide did not cause erythrocyte hemolysis.,"Increasing the amount of CAMEL (1–20 μM) proved toxic to all tested cell lines The LC50 values were from 2.95 to 5.2 μM for normal cells (HECa10, HEC PP, NIH3T3, Wi38)",,,specific combinations of necrosis-inducing peptide (CAMEL) and IL-12-carrying plasmid DNA can inhibit tumor growth as well as prevent tumor relapse,Anticancer; Antimicrobial,Tumor active peptide,,Linear,,Free,Free,,,0,KWKLFKKIGAVLKVL
MNFNKLFVFVALVLAVCIGQSEAGWLKKIGKKIERVGQHTRDATIQTIGVAQQAANVAATLKG,63,Musca domestica,Native peptide,,,,,"cecropin can induce apoptosis of the human hepatoma BEL-7402 cells, which might be associated with up-regulation of Fas, Fas-L, caspase-8, and caspase-3",Anticancer; Antimicrobial,Tumor active peptide,,Linear,,Free,Free,,,0,MNFNKLFVFVALVLAVCIGQSEAGWLKKIGKKIERVGQHTRDATIQTIGVAQQAANVAATLKG
ACDCRGDCFCGGGGIVRRADRAAVP,25,Endostatin derived Synthetic,Synthetic peptide,,,integrin αvβ3,,,Anticancer,Tumor active peptide##Cancer targeted peptides,,Linear,,Free,Free,,,0,ACDCRGDCFCGGGGIVRRADRAAVP
IVRRADRAAVPGGGGACDCRGDCFC,25,Endostatin derived Synthetic,Synthetic peptide,,,integrin αvβ4,,,Anticancer,Tumor active peptide##Cancer targeted peptides,,Linear,,Free,Free,,,0,IVRRADRAAVPGGGGACDCRGDCFC
GIACGESCVFLGCFIPGCSCKSKVCYFN,28,Micronesian Plant Psychotria leptothyrsa,Native peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Cyclic,,Free,Free,,,0,GIACGESCVFLGCFIPGCSCKSKVCYFN
GVIPCGESCVFIPCISSVLGCSCKNKVCYRD,31,Micronesian Plant Psychotria leptothyrsa,Native peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Cyclic,,Free,Free,,,0,GVIPCGESCVFIPCISSVLGCSCKNKVCYRD
KLCGETCFKFKCYTPGCSCSYPFCK,25,Micronesian Plant Psychotria leptothyrsa,Native peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Cyclic,,Free,Free,,,0,KLCGETCFKFKCYTPGCSCSYPFCK
LPFFPPVXPIIG,12,Callyspongia aerizusa,Native peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Cyclic,SMB: Leu1<--->X(8),Free,Amidation,X=Daa,,0,LPFFPPVXPIIG
VPVFPXPLF,9,Callyspongia aerizusa,Native peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Cyclic,SMB: Val1<--->X(6),Free,Amidation,X=Daa,,0,VPVFPXPLF
IIFPXPLXPINAI,13,Callyspongia aerizusa,Native peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Cyclic,SMB: Ile1<--->X(8),Free,Amidation,X(5)= 4-Hydroxyproline; X(8)=Daa,,0,IIFPXPLXPINAI
VPVFPPLXPI,10,Callyspongia aerizusa,Native peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Cyclic,SMB: Val1<--->X(8),Free,Amidation,X=Daa,,0,VPVFPPLXPI
LPPPPLXPFFF,11,Callyspongia aerizusa,Native peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Cyclic,SMB: Leu1<--->X(7),Free,Amidation,X=Daa,,0,LPPPPLXPFFF
CSSRTMHHC,9,Synthetic,Synthetic peptide,,,cadherin constituent at the tumor cell surface,,,Anticancer; Antitumor,Tumor active peptide##Cancer targeted peptides,,Cyclic,,Free,Free,,,0,CSSRTMHHC
KWKWKW,6,Synthetic,Synthetic peptide,rabbit red blood cell: hemolysis=1.9±0.2%,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,KWKWKW
RRRRRRR,7,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antiviral,Tumor active peptide,,Linear,,Free,Free,,,0,RRRRRRR
KWKSFAKTFKSAKKTVAHTALKAISS,26,PeptideV13K,Synthetic peptide,Human red blood cells: MHC>334.3 μmol/L,,,,Peptides killed cancer cells with a fast necrotic mechanism causing cell membrane lysis,Anticancer,Tumor active peptide##Membrane-targeted,,Linear,,Acetylation,Amidation,,,0,KWKSFAKTFKSAKKTVAHTALKAISS
KWKSFLKTFKSAKKTVAHTAAKAISS,26,PeptideV13K,Synthetic peptide,Human red blood cells: MHC>334.4 μmol/L,,,,Peptides killed cancer cells with a fast necrotic mechanism causing cell membrane lysis,Anticancer,Tumor active peptide##Membrane-targeted,,Linear,,Acetylation,Amidation,,,0,KWKSFLKTFKSAKKTVAHTAAKAISS
KWKSFLKTFKSAKKTVAHTALKAISS,26,PeptideV13K,Synthetic peptide,Human red blood cells: MHC>334.4 μmol/L,,,,Peptides killed cancer cells with a fast necrotic mechanism causing cell membrane lysis,Anticancer,Tumor active peptide##Membrane-targeted,,Linear,,Acetylation,Amidation,,,0,KWKSFLKTFKSAKKTVAHTALKAISS
KWKSFLKTFKSAKKTVLHTAAKAISS,26,PeptideV13K,Synthetic peptide,Human red blood cells: MHC>334.4 μmol/L,,,,Peptides killed cancer cells with a fast necrotic mechanism causing cell membrane lysis,Anticancer,Tumor active peptide##Membrane-targeted,,Linear,,Acetylation,Amidation,,,0,KWKSFLKTFKSAKKTVLHTAAKAISS
KWKSFAKTFKSAKKTVLHTALKAISS,26,PeptideV13K,Synthetic peptide,Human red blood cells: MHC>334.4 μmol/L,,,,Peptides killed cancer cells with a fast necrotic mechanism causing cell membrane lysis,Anticancer,Tumor active peptide##Membrane-targeted,,Linear,,Acetylation,Amidation,,,0,KWKSFAKTFKSAKKTVLHTALKAISS
KWKSFLKTFKSAKKTVLHTALKAISS,26,PeptideV13K,Synthetic peptide,Human red blood cells: MHC=167.2 ± 5.91 μmol/L,,,,Peptides killed cancer cells with a fast necrotic mechanism causing cell membrane lysis,Anticancer,Tumor active peptide##Membrane-targeted,,Linear,,Acetylation,Amidation,,,0,KWKSFLKTFKSAKKTVLHTALKAISS
KWKSFLKTFKSLKKTVLHTALKAISS,26,PeptideV13K,Synthetic peptide,Human red blood cells: MHC=41.8 ± 0.30 μmol/L,,,,Peptides killed cancer cells with a fast necrotic mechanism causing cell membrane lysis,Anticancer,Tumor active peptide##Membrane-targeted,,Linear,,Acetylation,Amidation,,,0,KWKSFLKTFKSLKKTVLHTALKAISS
KWKSFLKTFKSAKKTVLHTLLKAISS,26,PeptideV13K,Synthetic peptide,Human red blood cells: MHC=41.8 ± 0.22 μmol/L,,,,Peptides killed cancer cells with a fast necrotic mechanism causing cell membrane lysis,Anticancer,Tumor active peptide##Membrane-targeted,,Linear,,Acetylation,Amidation,,,0,KWKSFLKTFKSAKKTVLHTLLKAISS
KWKSFLKTFKSLKKTVLHTLLKAISS,26,PeptideV13K,Synthetic peptide,Human red blood cells: MHC=10.5 ± 0.25 μmol/L,,,,Peptides killed cancer cells with a fast necrotic mechanism causing cell membrane lysis,Anticancer,Tumor active peptide##Membrane-targeted,,Linear,,Acetylation,Amidation,,,0,KWKSFLKTFKSLKKTVLHTLLKAISS
KWKSFLKTFKSLKKTVLHTLLKLISS,26,PeptideV13K,Synthetic peptide,Human red blood cells: MHC=2.6 ± 0.01 μmol/L,,,,Peptides killed cancer cells with a fast necrotic mechanism causing cell membrane lysis,Anticancer,Tumor active peptide##Membrane-targeted,,Linear,,Acetylation,Amidation,,,0,KWKSFLKTFKSLKKTVLHTLLKLISS
GILSSIKGVAKGVAKNVAAQLLDTLKCKITGC,32,Rana luteiventris; Rana pretiosa,Native peptide,Human erythrocytes: 50% Hemolysis>100 µM; Sheep erythrocytes: <10% Hemolysis=256 µM,HEK293T: IC50=63.16 µM,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Cyclic,Cys27<--->Cys32,Free,Free,,,0,GILSSIKGVAKGVAKNVAAQLLDTLKCKITGC
YHWYGYTPQNVIGGGKLlLKlLKKLLKlLKKK,32,Synthetic,Synthetic peptide,,,,,,Anticancer; Antitumor,Tumor active peptide,,Linear,,Free,Free,,,0,YHWYGYTPQNVIGGGKLLLKLLKKLLKLLKKK
VDKPPYLPRPRPPRXXYNX,19,Synthetic,Synthetic peptide,Human erythrocytes: Not active up to 600 µg/ml,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,X(15)=Orn; X(16)=L-tert-leucine; X(19)=Orn,,0,VDKPPYLPRPRPPRXXYNX
VDKPPYLPRPRPXRXIYNX,19,Synthetic,Synthetic peptide,Human erythrocytes: Not active up to 600 µg/ml,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,X(13)= 4-Hydroxyproline; X(15)= 4-Hydroxyproline; X(19)=Orn,,0,VDKPPYLPRPRPXRXIYNX
VDKPPYLPRPRPXRXXYNX,19,Synthetic,Synthetic peptide,Human erythrocytes: Not active up to 600 µg/ml,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,X(13)= 4-Hydroxyproline; X(15)= 4-Hydroxyproline; X(16)=L-tert-leucine; X(19)=Orn,,0,VDKPPYLPRPRPXRXXYNX
TRSSRAGLQFPVGRVHRLLRK,21,Bufo Bufo Gargarizans,Native peptide,,,,,,Anticancer; Antimicrobial,Tumor active peptide##Antiangiogenic,,Linear,,Free,Amidation,,,0,TRSSRAGLQFPVGRVHRLLRK
AKRHHGYKRKFH,12,Amphibian skin peptide,Synthetic peptide,,,,,,Anticancer; Antimicrobial,Tumor active peptide,,Linear,,Free,Amidation,,,0,AKRHHGYKRKFH
ILRWPWWPWRRK,12,Helical peptide with a predominance of one or more amino acids tryptophane-rich,Synthetic peptide,,,,,,Anticancer; Antimicrobial,Tumor active peptide,,Linear,,Free,Amidation,,,0,ILRWPWWPWRRK
GIGKFLKKAKKFGKAFVKILKK,22,Helical peptide with a predominance of one or more amino acids tryptophane-rich,Synthetic peptide,,,,,,Anticancer; Antimicrobial,Tumor active peptide,,Linear,,Free,Amidation,,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",0,GIGKFLKKAKKFGKAFVKILKK
RGGRLCYCRRRFCVCVGR,18,Alpha helical peptide without cysteines,Synthetic peptide,,,,,,Anticancer; Antimicrobial,Tumor active peptide,,Linear,,Free,Amidation,,,0,RGGRLCYCRRRFCVCVGR
FLPLIGRVLSGIL,13,Frog Rana temporaria,Synthetic peptide,,,,,,Anticancer; Antimicrobial,Tumor active peptide,,Linear,,Free,Amidation,,,0,FLPLIGRVLSGIL
LTFEHYWAQLTS,12,E3 ubiquitin-protein ligase,Synthetic peptide,,,MDM2,,Inhibits MDM2-p53 Interaction,Anticancer; Antitumor,Tumor active peptide##Cancer targeted peptides##Affect cell cycle,,Linear,,Free,Free,,,0,LTFEHYWAQLTS
LTAEHYAAQATS,12,E3 ubiquitin-protein ligase,Synthetic peptide,,,MDM2,,Inhibits MDM2-p53 Interaction,Anticancer; Antitumor,Tumor active peptide##Cancer targeted peptides##Affect cell cycle,,Linear,,Free,Free,,,0,LTAEHYAAQATS
QETFSDLWKLLP,12,E3 ubiquitin-protein ligase,Synthetic peptide,,,MDM2,,Inhibits MDM2-p53 Interaction,Anticancer; Antitumor,Tumor active peptide##Cancer targeted peptides##Affect cell cycle,,Linear,,Free,Free,,,0,QETFSDLWKLLP
PRAWEYWLRLME,12,E3 ubiquitin-protein ligase,Synthetic peptide,,,MDM2,,Inhibits MDM2-p53 Interaction,Anticancer; Antitumor,Tumor active peptide##Cancer targeted peptides##Affect cell cycle,,Linear,,Free,Free,,,0,PRAWEYWLRLME
PRFWEAWLRLME,12,E3 ubiquitin-protein ligase,Synthetic peptide,,,MDM2,,Inhibits MDM2-p53 Interaction,Anticancer; Antitumor,Tumor active peptide##Cancer targeted peptides##Affect cell cycle,,Linear,,Free,Free,,,0,PRFWEAWLRLME
PRFWEYALRLME,12,E3 ubiquitin-protein ligase,Synthetic peptide,,,MDM2,,Inhibits MDM2-p53 Interaction,Anticancer; Antitumor,Tumor active peptide##Cancer targeted peptides##Affect cell cycle,,Linear,,Free,Free,,,0,PRFWEYALRLME
PRFWEYWLALME,12,E3 ubiquitin-protein ligase,Synthetic peptide,,,MDM2,,Inhibits MDM2-p53 Interaction,Anticancer; Antitumor,Tumor active peptide##Cancer targeted peptides##Affect cell cycle,,Linear,,Free,Free,,,0,PRFWEYWLALME
PRFWEYWLRAME,12,E3 ubiquitin-protein ligase,Synthetic peptide,,,MDM2,,Inhibits MDM2-p53 Interaction,Anticancer; Antitumor,Tumor active peptide##Cancer targeted peptides##Affect cell cycle,,Linear,,Free,Free,,,0,PRFWEYWLRAME
PRFWEYWLRLAE,12,E3 ubiquitin-protein ligase,Synthetic peptide,,,MDM2,,Inhibits MDM2-p53 Interaction,Anticancer; Antitumor,Tumor active peptide##Cancer targeted peptides##Affect cell cycle,,Linear,,Free,Free,,,0,PRFWEYWLRLAE
PRFWEYWLRLME,12,E3 ubiquitin-protein ligase,Synthetic peptide,,,MDM2,,Inhibits MDM2-p53 Interaction,Anticancer; Antitumor,Tumor active peptide##Cancer targeted peptides##Affect cell cycle,,Linear,,Free,Free,,,0,PRFWEYWLRLME
GLPVCGETCAGGTCNTPGCSCSWPICTRN,29,Viola abyssinica of the Ethiopian Highlands,Native peptide,,,,,,Anticancer,Tumor active peptide,,Cyclic,,Free,Free,,,0,GLPVCGETCAGGTCNTPGCSCSWPICTRN
GLPVCGETCFGGTCNTPGCTCDPWPVCTRN,30,Viola abyssinica of the Ethiopian Highlands,Native peptide,,,,,,Anticancer,Tumor active peptide,,Cyclic,,Free,Free,,,0,GLPVCGETCFGGTCNTPGCTCDPWPVCTRN
WKKWXKKWK,9,Synthetic,Synthetic peptide,Human red blood cells (RBC): IC50>695 μM,HUVEC: IC50=123 ± 9 μM; MRC-5: IC50=122 ± 16 µM,,,,Anticancer; Antimicrobial,Tumor active peptide##Membrane lysis,,Linear,,Free,Amidation,X=Dip (Diphenylalanine),,0,WKKWXKKWK
KKWWKKWXK,9,Synthetic,Synthetic peptide,Human red blood cells (RBC): IC50>695 μM,HUVEC: IC50=28 ± 1 μM;MRC-5: IC50=34.3 ± 2.3 µM,,,,Anticancer; Antimicrobial,Tumor active peptide##Membrane lysis,,Linear,,Free,Amidation,X=Dip (Diphenylalanine),,0,KKWWKKWXK
XXWXXXWWX,9,Synthetic,Synthetic peptide,Human red blood cells (RBC): IC50>695 μM,HUVEC: IC50> 347 μM; MRC-5: IC50=323 ± 33 µM,,,,Anticancer; Antimicrobial,Tumor active peptide##Membrane lysis,,Linear,,Free,Amidation,X(1/2/5/6/9)=ornithine; X(4)=Dip (Diphenylalanine),,0,XXWXXXWWX
GEFLKCGESCVQGECYTPGCSCDWPICKKN,30,Clitoria ternatea,Native peptide,Human red blood cells: HD50=8.0 μM,,,,,Anticancer; Antibacterial,Tumor active peptide,,Cyclic,Cys6<--->Cys20; Cys10<--->Cys22; Cys15<--->Cys27; NCB: Gly1<--->Asn30,Free,Free,,,0,GEFLKCGESCVQGECYTPGCSCDWPICKKN
GIPCGESCVFIPCITAAIGCSCKSKVCYRN,30,Clitoria ternatea,Native peptide,Human red blood cells: HD50=0.6 μM,,,,,Anticancer; Antibacterial,Tumor active peptide,,Cyclic,Cys4<--->Cys20; Cys8<--->Cys22; Cys13<--->Cys27; NCB: Gly1<--->Asn30,Free,Free,,,0,GIPCGESCVFIPCITAAIGCSCKSKVCYRN
GIPCGESCVFIPCITGAIGCSCKSKVCYRN,30,Clitoria ternatea,Native peptide,Human red blood cells: HD50=0.6 μM,,,,,Anticancer; Antibacterial,Tumor active peptide,,Cyclic,Cys4<--->Cys20; Cys8<--->Cys22; Cys13<--->Cys27; NCB: Gly1<--->Asn30,Free,Free,,,0,GIPCGESCVFIPCITGAIGCSCKSKVCYRN
GLPTCGETCTLGTCYVPDCSCSWPICMKN,29,Clitoria ternatea,Native peptide,Human red blood cells: HD50=2.0 μM,,,,,Anticancer; Antibacterial,Tumor active peptide,,Cyclic,Cys5<--->Cys21; Cys9<--->Cys21; Cys14<--->Cys26; NCB: Gly1<--->Asn29,Free,Free,,,0,GLPTCGETCTLGTCYVPDCSCSWPICMKN
GSIPCGESCVFIPCISSVIGCACKSKVCYKN,31,Viola philippica,Native peptide,,HFF-1: IC50=3.19±0.01µM,,,,Anticancer,Tumor active peptide,,Cyclic,Cys5<--->Cys21; Cys9<--->Cys23; Cys14<--->Cys28,Free,Free,,,0,GSIPCGESCVFIPCISSVIGCACKSKVCYKN
GIPCGESCVFIPCLTSAIGCSCKSKVCYRN,30,Viola philippica,Native peptide,,HFF-1: IC50=3.19±0.01µM,,,,Anticancer,Tumor active peptide,,Cyclic,Cys4<--->Cys20; Cys8<--->Cys22; Cys13<--->Cys27,Free,Free,,,0,GIPCGESCVFIPCLTSAIGCSCKSKVCYRN
GIPCGESCVFIPCISSVIGCSCSSKVCYRN,30,Viola philippica,Native peptide,,HFF-1: IC50=1.55±0.11µM,,,,Anticancer,Tumor active peptide,,Cyclic,Cys4<--->Cys20; Cys8<--->Cys22; Cys13<--->Cys27,Free,Free,,,0,GIPCGESCVFIPCISSVIGCSCSSKVCYRN
GSIPCGESCVFIPCISAVIGCSCSNKVCYKN,31,Viola philippica,Native peptide,,HFF-1: IC50=1.55±0.09µM,,,,Anticancer,Tumor active peptide,,Cyclic,Cys5<--->Cys21; Cys9<--->Cys23; Cys14<--->Cys28,Free,Free,,,0,GSIPCGESCVFIPCISAVIGCSCSNKVCYKN
GSIPCGESCVFIPCISAIIGCSCSSKVCYKN,31,Viola philippica,Native peptide,,HFF-1: IC50=1.76±0.12µM,,,,Anticancer,Tumor active peptide,,Cyclic,Cys5<--->Cys21; Cys9<--->Cys23; Cys14<--->Cys28,Free,Free,,,0,GSIPCGESCVFIPCISAIIGCSCSSKVCYKN
GSIPCGESCVFIPCISAIIGCSCSNKVCYKN,31,Viola philippica,Native peptide,,HFF-1: IC50=1.76±0.12µM,,,,Anticancer,Tumor active peptide,,Cyclic,Cys5<--->Cys21; Cys9<--->Cys23; Cys14<--->Cys28,Free,Free,,,0,GSIPCGESCVFIPCISAIIGCSCSNKVCYKN
GLPVCGETCVGGTCNTPGCGCSWPVCTRN,29,Viola philippica,Native peptide,,HFF-1: IC50=2.38±0.09µM,,,,Anticancer,Tumor active peptide,,Cyclic,Cys5<--->Cys19; Cys9<--->Cys21; Cys14<--->Cys26.,Free,Free,,,0,GLPVCGETCVGGTCNTPGCGCSWPVCTRN
GLPVCGETCVGGTCNTPGCACSWPVCTRN,29,Viola philippica,Native peptide,,HFF-1: IC50=2.38±0.09µM,,,,Anticancer,Tumor active peptide,,Cyclic,Cys5<--->Cys19; Cys9<--->Cys21; Cys14<--->Cys26.,Free,Free,,,0,GLPVCGETCVGGTCNTPGCACSWPVCTRN
GLPVCGETCVGGTCNTPGCTCSWPVCTRN,29,Oldenlandia affinis; Viola yedoensis; Viola odorata; Viola baoshanensis,Native peptide,Human erythrocytes: Human erythrocytes: 41% Hemolysis=25 µM; Human erythrocytes: 50% Hemolysis=29.1±1.1 µM,HFF-1: IC50=2.38±0.09 µM; 50% Cell death=12.0±0.5 µM; CEM-SS cells: IC50=5.7 µM; Human PBMC: 50% Cell death=11.2±0.5 µM,,,,Anticancer; Antibacterial; Antifungal; Antiviral,Tumor active peptide,,Cyclic,Cys5<--->Cys19; Cys9<--->Cys21; Cys14<--->Cys26; NCB: Gly1<--->Asn29,Free,Free,,,0,GLPVCGETCVGGTCNTPGCTCSWPVCTRN
AGWGSIFKHIFKAGKFIHGAIQAHND,26,Synthetic,Synthetic peptide,Human erythrocytes: 50% Hemolysis>256 µg/ml,"Zebrafish embryos: >10% Killing=5 µM (28, 52hpf embryo); 100% Killing=25 µM (4hpf embryo)",,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,,0,AGWGSIFKHIFKAGKFIHGAIQAHND
FFRLLFHGVHHGGGYLNAA,19,Synthetic,Synthetic peptide,Human erythrocytes: 50% Hemolysis>256 µg/ml,Zebrafish embryos: No Killing,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,,0,FFRLLFHGVHHGGGYLNAA
FFRLLFHGVHHVGKIKPRA,19,Synthetic,Synthetic peptide,Human erythrocytes: 50% Hemolysis>256 µg/ml,"Zebrafish embryos: >10% Killing=25 µg/ml (4, 28, 52hpf embryo)",,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,,0,FFRLLFHGVHHVGKIKPRA
FLGALIKGAIHGGRFIHGMIQNHH,24,Pseudopleuronectes americanus,Native peptide,Human erythrocytes: 50% Hemolysis>256 µg/ml,"Zebrafish embryos: >10% Killing=5 µg/ml(4, 52hpf embryo); 100% Killing=25 µg/ml (28hpf embryo)",,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,,0,FLGALIKGAIHGGRFIHGMIQNHH
FLGLLFHGVHHVGKWIHGLIHGHH,24,Synthetic,Synthetic peptide,Human erythrocytes: 50% Hemolysis=16 µg/ml,"Zebrafish embryos: >10% Killing=5 µg/ml (4, 28, 52hpf embryo)",,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,,0,FLGLLFHGVHHVGKWIHGLIHGHH
GFWGKLFKLGLHGIGLLHLHL,21,Synthetic,Synthetic peptide,Human erythrocytes: 50% Hemolysis=64 µg/ml,"Zebrafish embryos: >10% Killing=1 µg/ml (4hpf embryo); >10% Killing=5 µg/ml (28, 52hpf embryo)",,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,,0,GFWGKLFKLGLHGIGLLHLHL
GKGRWLERIGKAGGIIIGGALDHL,24,Synthetic,Synthetic peptide,Human erythrocytes: 50% Hemolysis>256 µg/ml,"Zebrafish embryos: 100% Killing=25 µg/ml (4, 28hpf embryo); >10% Killing=5 µg/ml (52hpf embryo)",,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,,0,GKGRWLERIGKAGGIIIGGALDHL
GRRKRKWLRRIGKGVKIIGGAALDHL,26,Synthetic,Synthetic peptide,Human erythrocytes: 50% Hemolysis>256 µg/ml,"Zebrafish embryos: 100% Killing=5 µg/ml (4hpf embryo); 100% Killing=25 µg/ml(28, 52hpf embryo); HUVEC: 50% Cell death=128 µg/ml; HUVEC: 50% Cell death=64 µg/ml",,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,,0,GRRKRKWLRRIGKGVKIIGGAALDHL
GWGSIFKHGRHAAKHIGHAAVNHYL,25,Pseudopleuronectes americanus,Native peptide,Human erythrocytes: 50% Hemolysis>256 µg/ml,"Zebrafish embryos: 100% Killing=25 µg/ml (4, 28hpf embryo); >10% Killing=5 µg/ml (52hpf embryo)",,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,,0,GWGSIFKHGRHAAKHIGHAAVNHYL
GWKKWFNRAKKVGKTVGGLAVDHYL,25,Synthetic,Synthetic peptide,Human erythrocytes: 50% Hemolysis>256 µg/ml,Zebrafish embryos: >10% Killing=5 µg/ml (4hpf embryo); >10% Killing=25 µg/ml (28hpf embryo); 100% Killing=5 µg/ml (52hpf embryo),,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,,0,GWKKWFNRAKKVGKTVGGLAVDHYL
GWKKWFTKGERLSQRHFA,18,Synthetic,Synthetic peptide,Human erythrocytes: 50% Hemolysis>256 µg/ml,Zebrafish embryos: No Killing,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Free,,,0,GWKKWFTKGERLSQRHFA
GWKKWLRKGAKHLGQAAIKGLAS,23,Synthetic,Synthetic peptide,Human erythrocytes: 50% Hemolysis>256 µg/ml,"Zebrafish embryos: 100% Killing=5 µg/ml (52hpf embryo); >10% Killing=5 µg/ml(4, 28hpf embryo)",,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Free,,,0,GWKKWLRKGAKHLGQAAIKGLAS
GWKSVFRKAKKVGKTVGGLALDHYL,25,Synthetic,Synthetic peptide,Human erythrocytes: 50% Hemolysis>256 µg/ml,"Zebrafish embryos: >10% Killing=5 µg/ml (4, 28, 52hpf embryo)",,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,,0,GWKSVFRKAKKVGKTVGGLALDHYL
GWRTLLKKAEVKTVGKLALKHYL,23,Synthetic,Synthetic peptide,Human erythrocytes: 50% Hemolysis>256 µg/ml,"Zebrafish embryos: 100% Killing=25 µg/ml(4hpf embryo); >10% Killing=25 µg/ml (28, 52hpf embryo)",,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,,0,GWRTLLKKAEVKTVGKLALKHYL
RSTEDIIKSISGGGFLNAMNA,21,Synthetic,Synthetic peptide,Human erythrocytes: 50% Hemolysis>256 µg/ml,Zebrafish embryos: No Killing; HUVEC: 50% Cell death>128 µg/ml; HMEC-1: 50% Cell death>128 µg/ml,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,,0,RSTEDIIKSISGGGFLNAMNA
KLlLKlLkkLLKlLKKK,17,Transferrin receptor (TfR),Synthetic peptide,,,Transferrin receptor,,Lytic peptide containing cationic-rich amino acids components that disintegrates the cell membrane for the cancer cell killing,Anticancer,Tumor active peptide##Cancer targeted peptides##Membrane-targeted,,Linear,,Free,Free,l=D-Leucine; k=D-Lysine,"Granted Patent Family: 19s / 19ex; Family Jurisdictions: US, JP, EP, WO, CN; Legal Status:   Active; Application No: 200913132580; Filed: Dec 3, 2009; Published: Dec 29, 2011; Earliest Priority: Dec 3, 2008; Granted: May 7, 2013",0,KLLLKLLKKLLKLLKKK
THRPPMWSPVWPGGGKLlLKlLkkLLKlLKKK,32,Transferrin receptor (TfR),Synthetic peptide,,MRC-5: IC50>20μM; HC cell: IC50>20μM; PE cell: IC50>20μM,Transferrin receptor,,Lytic peptide containing cationic-rich amino acids components that disintegrates the cell membrane for the cancer cell killing,Anticancer,Tumor active peptide##Cancer targeted peptides,,Linear,,Free,Free,l=D-Leucine; k=D-Lysine,"Granted Patent Family: 19s / 19ex; Family Jurisdictions: US, JP, EP, WO, CN; Legal Status:   Active; Application No: 200913132580; Filed: Dec 3, 2009; Published: Dec 29, 2011; Earliest Priority: Dec 3, 2008; Granted: May 7, 2013",0,THRPPMWSPVWPGGGKLLLKLLKKLLKLLKKK
GLFDVVKGVLKGVGKNVAGSLLEQLKCKLSGGC,33,Rana dybowskii; Rana nigromaculata,Native peptide,Human erythrocytes: 2% Hemolysis=100 µg/ml; 50% Hemolysis=65.2±7.6 µM,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Cyclic,Cys27<--->Cys33,Free,Free,,,0,GLFDVVKGVLKGVGKNVAGSLLEQLKCKLSGGC
AWXLFDDGV,9,Synthetic,Synthetic peptide,Human erythrocytes: 5% Hemolysis=1 mM,NIH 3T3: IC50=4 mM,DNA,,Proapoptosis,Anticancer; Antibacterial,Tumor active peptide##Cancer targeted peptides##Induce apoptosis##Proliferation inhibition,,Linear,,Acetylation,Free,X=Lys-Acetylation (Lysine with acetylation side group),,0,AWXLFDDGV
AWKLFDDGV,9,Cycas revoluta seeds,Native peptide,Human erythrocytes: 5% Hemolysis=1 mM,NIH 3T3: IC50>4 mM,DNA,,Proapoptosis,Anticancer; Antibacterial,Tumor active peptide##Cancer targeted peptides##Induce apoptosis,,Linear,,Free,Free,,,0,AWKLFDDGV
GVGSPYVSRLLGICL,15,Synthetic,Synthetic peptide,,,,,Disrupting tumor-mediated mechanisms suppressing host immunity,Anticancer; Antitumor,Tumor active peptide,,Linear,,Free,Free,,,0,GVGSPYVSRLLGICL
LIAHNQVRQV,10,Synthetic,Synthetic peptide,,,,,Disrupting tumor-mediated mechanisms suppressing host immunity,Anticancer; Antitumor,Tumor active peptide,,Linear,,Free,Free,,,0,LIAHNQVRQV
GIIKKIIIKKI,11,AMP,Synthetic peptide,"Human red blood cells: over the active concentration ranges against bacteria and cancer cells, there is little activity or toxicity against hRBCs",NIH 3T3: low toxic,,,,Anticancer; Antimicrobial,Tumor active peptide,,Linear,,Free,Amidation,,,0,GIIKKIIIKKI
GIIKKIIIKKIIIKKI,16,AMP,Synthetic peptide,"Human red blood cells: over the active concentration ranges against bacteria and cancer cells, there is little activity or toxicity against hRBCs",NIH 3T3: low toxic,,,,Anticancer; Antimicrobial,Tumor active peptide,,Linear,,Free,Amidation,,,0,GIIKKIIIKKIIIKKI
GIIKKIIIKKIIIKKIIIKKI,21,AMP,Synthetic peptide,"Human red blood cells: over the active concentration ranges against bacteria and cancer cells, there is little activity or toxicity against hRBCs",NIH 3T3: low toxic,,,,Anticancer; Antimicrobial,Tumor active peptide,,Linear,,Free,Amidation,,,0,GIIKKIIIKKIIIKKIIIKKI
RWGKWFKKATHVGKHVGKAALTAYL,25,Pleurocidin-family,Native peptide,"25 μM NRC-07: HMECs Cytotoxicity=20%, Fibroblasts  Cytotoxicity=1%, HUVECs Cytotoxicity=17%; 50 μM NRC-07: HMECs Cytotoxicity=47%, Fibroblasts  Cytotoxicity=0%, HUVECs Cytotoxicity=17%",Erythrocytes(25 μM NRC-07): Hemolysis=2%; Erythrocytes(50 μM NRC-07): Hemolysis=3%; ,Cell surface molecules,,NRC-03- and NRC-07-mediated cell death is initiated by peptide binding to negatively-charged molecules,Anticancer; Antimicrobial,Tumor active peptide##Cancer targeted peptides,,Linear,,Biotinylated,Amidation,,,0,RWGKWFKKATHVGKHVGKAALTAYL
AAKKWAKAKWAKAKKWAKAA,20,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,AAKKWAKAKWAKAKKWAKAA
AAWKWAWAKKWAKAKKWAKAA,21,Synthetic,Synthetic peptide,MRC-5: EC58=14 μM,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,AAWKWAWAKKWAKAKKWAKAA
AWKKWAKAWKWAKAKWWAKAA,21,Synthetic,Synthetic peptide,MRC-5: EC57=17 μM,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,AWKKWAKAWKWAKAKWWAKAA
KAAKKAWKAAKKAAKWWKKAA,21,Synthetic,Synthetic peptide,MRC-5: EC53=78 μM,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,KAAKKAWKAAKKAAKWWKKAA
KAAKKAWKAAKKAWKAAKKAA,21,Synthetic,Synthetic peptide,MRC-5: EC56=20 μM,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,KAAKKAWKAAKKAWKAAKKAA
KAAKKAWKAWKKAAKAAWKKAA,22,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,KAAKKAWKAWKKAAKAAWKKAA
KAAKKAWKWAKKAAKWAKKAA,21,Synthetic,Synthetic peptide,MRC-5: EC54=27 μM,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,KAAKKAWKWAKKAAKWAKKAA
KAAKKWAKAAKKAAKAWKKAA,21,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,KAAKKWAKAAKKAAKAWKKAA
KAAKKWAKAWKKAAKAWKKAA,21,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,KAAKKWAKAWKKAAKAWKKAA
KWWKKAAKAAKKAAKAAKKWA,21,Synthetic,Synthetic peptide,MRC-5: EC55=23 μM,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,KWWKKAAKAAKKAAKAAKKWA
GFFALIPKIISSPLFKTLLSAVGSALSSSGGQE,33,Red Sea Mosessole,Native peptide,,,,,pardaxin disrupted mitochondrial function and caused an accumulation of ROS that activated a caspase-dependent intrinsic apoptotic pathway,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,GFFALIPKIISSPLFKTLLSAVGSALSSSGGQE
IELLQARGGCX,11,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide##Coupling peptide,,Linear,,Free,Amidation,X(11)=Pemetrexed,,0,IELLQARGGCX
IELLQARGGCXGGRRRRRRRR,21,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide##Coupling peptide,,Linear,,Free,Amidation,X(11)=Pemetrexed,,0,IELLQARGGCXGGRRRRRRRR
RRRRRRRRGGCX,12,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide##Coupling peptide,,Linear,,Free,Amidation,X(12)=Pemetrexed,,0,RRRRRRRRGGCX
KQLIRFLKRLDRNGGGKLlLKlLkkLLKlLKKK,33,Interleukin-4 receptor a (IL-4Ra) chain,Synthetic peptide,,,Targeting Interleukin-4 Receptor α,,The IL-4Rα–lytic peptide contains a target moiety to bind to IL-4Rα and a cellular toxic lytic peptide that selectively kills cancer cells,Anticancer,Tumor active peptide##Cancer targeted peptides,,Linear,,Free,Free,l=D-Leucine; k=D-Lysine,"Granted Patent Family: 19s / 19ex; Family Jurisdictions: US, JP, EP, WO, CN; Legal Status:   Active; Application No: 200913132580; Filed: Dec 3, 2009; Published: Dec 29, 2011; Earliest Priority: Dec 3, 2008; Granted: May 7, 2013",0,KQLIRFLKRLDRNGGGKLLLKLLKKLLKLLKKK
AFGMALKLLKKVL,13,Synthetic,Synthetic peptide,Human erythrocytes: IC50>200 μM,HUVEC: IC50=30±4 μM,,,,Anticancer; Antimicrobial; Antifungal,Tumor active peptide##Membrane-targeted,,Linear,,Free,Amidation,,,0,AFGMALKLLKKVL
GFGMAXKLLKKVL,13,Synthetic,Synthetic peptide,Human erythrocytes: IC50=93 μM,HUVEC: IC50=16 μM,,,,Anticancer; Antimicrobial; Antifungal,Tumor active peptide##Membrane-targeted,,Linear,,Free,Amidation,X(6)=AC6C=cyclohexyl-1-carboxylic acid,,0,GFGMAXKLLKKVL
GFGMALKXLKKVL,13,Synthetic,Synthetic peptide,Human erythrocytes: IC50=88 μM,HUVEC: IC50=13±2 μM,,,,Anticancer; Antimicrobial; Antifungal,Tumor active peptide##Membrane-targeted,,Linear,,Free,Amidation,X(6)=AC6C=cyclohexyl-1-carboxylic acid,,0,GFGMALKXLKKVL
GFGMALKLXKKVL,13,Synthetic,Synthetic peptide,Human erythrocytes: IC50=88 μM,HUVEC: IC50=15±3 μM,,,,Anticancer; Antimicrobial; Antifungal,Tumor active peptide##Membrane-targeted,,Linear,,Free,Amidation,X(6)=AC6C=cyclohexyl-1-carboxylic acid,,0,GFGMALKLXKKVL
GFGMALKLLKKVL,13,Macropins and their analogs,Synthetic peptide,Human erythrocytes: IC50=165 μM,HUVEC: IC50=28±6 μM,,,,Anticancer; Antimicrobial; Antifungal,Tumor active peptide##Membrane-targeted,,Linear,,Free,Amidation,,,0,GFGMALKLLKKVL
gfgmalkllkkvl,13,Synthetic,Synthetic peptide,Human erythrocytes: IC50=152 μM,HUVEC: IC50=21±5 μM,,,,Anticancer; Antimicrobial; Antifungal,Tumor active peptide##Membrane-targeted,,Linear,,Free,Amidation,,,0,GFGMALKLLKKVL
GFGMALKLlKKVL,13,Synthetic,Synthetic peptide,Human erythrocytes: IC50>200 μM,HUVEC: IC50=87±3 μM,,,,Anticancer; Antimicrobial; Antifungal,Tumor active peptide##Membrane-targeted,,Linear,,Free,Amidation,l=D-Leu,,0,GFGMALKLLKKVL
GFGmALKLLKKVL,13,Synthetic,Synthetic peptide,Human erythrocytes: IC50>200 μM,HUVEC: IC50=52±15 μM,,,,Anticancer; Antimicrobial; Antifungal,Tumor active peptide##Membrane-targeted,,Linear,,Free,Amidation,m=D-Met,,0,GFGMALKLLKKVL
GFGMaLKLLKKVL,13,Synthetic,Synthetic peptide,Human erythrocytes: IC50>200 μM,HUVEC: IC50=56±2 μM,,,,Anticancer; Antimicrobial; Antifungal,Tumor active peptide##Membrane-targeted,,Linear,,Free,Amidation,a=D-Ala,,0,GFGMALKLLKKVL
GfGMALKLLKKVL,13,Synthetic,Synthetic peptide,Human erythrocytes: IC50=177 μM,HUVEC: IC50=21±5 μM,,,,Anticancer; Antimicrobial; Antifungal,Tumor active peptide##Membrane-targeted,,Linear,,Free,Amidation,f=D-Phe,,0,GFGMALKLLKKVL
GFGMALXLLXXVL,13,Synthetic,Synthetic peptide,Human erythrocytes: IC50>200 μM,HUVEC: IC50=33±3 μM,,,,Anticancer; Antimicrobial; Antifungal,Tumor active peptide##Membrane-targeted,,Linear,,Free,Amidation,X=Ornithine,,0,GFGMALXLLXXVL
GFGMALRLLRRVL,13,Synthetic,Synthetic peptide,Human erythrocytes: IC50=72 μM,HUVEC: IC50=17±2 μM,,,,Anticancer; Antimicrobial; Antifungal,Tumor active peptide##Membrane-targeted,,Linear,,Free,Amidation,,,0,GFGMALRLLRRVL
GFkMALKLLKKVL,13,Synthetic,Synthetic peptide,Human erythrocytes: IC50>200 μM,HUVEC: IC50=23 μM,,,,Anticancer; Antimicrobial; Antifungal,Tumor active peptide##Membrane-targeted,,Linear,,Free,Amidation,k=D-Lys,,0,GFKMALKLLKKVL
GFKMALKLLKKVL,13,Synthetic,Synthetic peptide,Human erythrocytes: IC50=199 μM,HUVEC: IC50=17±2 μM,,,,Anticancer; Antimicrobial; Antifungal,Tumor active peptide##Membrane-targeted,,Linear,,Free,Amidation,,,0,GFKMALKLLKKVL
GKFMSLLKHILK,12,Synthetic,Synthetic peptide,Rat erythrocytes: IC50>200 μM,HUVEC: IC50=74±10 μM,,,,Anticancer; Antimicrobial; Antifungal,Tumor active peptide##Membrane-targeted,,Linear,,Free,Amidation,,,0,GKFMSLLKHILK
GKWKKILGHLIR,12,Synthetic,Synthetic peptide,Rat erythrocytes: IC50>200 μM,HUVEC: IC50> 100 μM,,,,Anticancer; Antimicrobial; Antifungal,Tumor active peptide##Membrane-targeted,,Linear,,Free,Amidation,,,0,GKWKKILGHLIR
GKWKKILGKLIR,12,Synthetic,Synthetic peptide,Rat erythrocytes: IC50>200 μM,HUVEC: IC50> 100 μM,,,,Anticancer; Antimicrobial; Antifungal,Tumor active peptide##Membrane-targeted,,Linear,,Free,Amidation,,,0,GKWKKILGKLIR
GKWKSLLKHILK,12,Synthetic,Synthetic peptide,Rat erythrocytes: IC50>200 μM,HUVEC: IC50> 100 μM,,,,Anticancer; Antimicrobial; Antifungal,Tumor active peptide##Membrane-targeted,,Linear,,Free,Amidation,,,0,GKWKSLLKHILK
GKWLSLLKHILK,12,Synthetic,Synthetic peptide,Rat erythrocytes: IC50=65 μM,HUVEC: IC50=42±3 μM,,,,Anticancer; Antimicrobial; Antifungal,Tumor active peptide##Membrane-targeted,,Linear,,Free,Amidation,,,0,GKWLSLLKHILK
GKWMKLLKHILK,12,Synthetic,Synthetic peptide,Rat erythrocytes: IC50=87.4 μM,HUVEC: IC50=40±4 μM,,,,Anticancer; Antimicrobial; Antifungal,Tumor active peptide##Membrane-targeted,,Linear,,Free,Amidation,,,0,GKWMKLLKHILK
GMWSKLLGHLLR,12,Synthetic,Synthetic peptide,Rat erythrocytes: IC50=62 μM,HUVEC: IC50=26±6 μM,,,,Anticancer; Antimicrobial; Antifungal,Tumor active peptide##Membrane-targeted,,Linear,,Free,Amidation,,,0,GMWSKLLGHLLR
GTGLPMSERRKIMLMMR,17,Synthetic,Synthetic peptide,Human erythrocytes: IC50>200 μM,HUVEC: IC50> 100 μM,,,,Anticancer; Antimicrobial; Antifungal,Tumor active peptide##Membrane-targeted,,Linear,,Free,Amidation,,,0,GTGLPMSERRKIMLMMR
KMWSKILGHLIR,12,Synthetic,Synthetic peptide,Rat erythrocytes: IC50>200  μM,HUVEC: IC50> 100 μM,,,,Anticancer; Antimicrobial; Antifungal,Tumor active peptide##Membrane-targeted,,Linear,,Free,Amidation,,,0,KMWSKILGHLIR
KNWKKXLKKXIKXVK,15,Synthetic,Synthetic peptide,Rat erythrocytes: IC50>200 μM,HUVEC: IC50> 100 μM,,,,Anticancer; Antimicrobial; Antifungal,Tumor active peptide##Membrane-targeted,,Linear,,Free,Amidation,X=Aib=1-amino-isobutyric acid,,0,KNWKKXLKKXIKXVK
KNWKKILGKIIKVVK,15,Synthetic,Synthetic peptide,Rat erythrocytes: IC50>200 μM,HUVEC: IC50=35±11 μM,,,,Anticancer; Antimicrobial; Antifungal,Tumor active peptide##Membrane-targeted,,Linear,,Free,Amidation,,,0,KNWKKILGKIIKVVK
KNWKKILKKIIKVVK,15,Synthetic,Synthetic peptide,Rat erythrocytes: IC50>200 μM,HUVEC: IC50=22±8 μM,,,,Anticancer; Antimicrobial; Antifungal,Tumor active peptide##Membrane-targeted,,Linear,,Free,Amidation,,,0,KNWKKILKKIIKVVK
LFGMALKLLKKVL,13,Synthetic,Synthetic peptide,Human erythrocytes: IC50=53 μM,HUVEC: IC50=27±5 μM,,,,Anticancer; Antimicrobial; Antifungal,Tumor active peptide##Membrane-targeted,,Linear,,Free,Amidation,,,0,LFGMALKLLKKVL
NKWKKILGKIIKVVK,15,Synthetic,Synthetic peptide,Rat erythrocytes: IC50>200 μM,HUVEC: IC50=52±7 μM,,,,Anticancer; Antimicrobial; Antifungal,Tumor active peptide##Membrane-targeted,,Linear,,Free,Amidation,,,0,NKWKKILGKIIKVVK
NVWKKILGKIIKVVK,15,Synthetic,Synthetic peptide,Rat erythrocytes: IC50>200 μM,HUVEC: not tested,,,,Anticancer; Antimicrobial; Antifungal,Tumor active peptide##Membrane-targeted,,Linear,,Free,Amidation,,,0,NVWKKILGKIIKVVK
VNFKKLLGKLLKVVK,15,Synthetic,Synthetic peptide,Rat erythrocytes: IC50>200 μM,HUVEC: IC50=≥70 μM,,,,Anticancer; Antimicrobial; Antifungal,Tumor active peptide##Membrane-targeted,,Linear,,Free,Amidation,,,0,VNFKKLLGKLLKVVK
VNXKKLLGKLLKVVK,15,Synthetic,Synthetic peptide,Rat erythrocytes: IC50>200 μM,HUVEC: IC50=15±1 μM,,,,Anticancer; Antimicrobial; Antifungal,Tumor active peptide##Membrane-targeted,,Linear,,Free,Amidation,X=Nal=3-(1-naphthyl)alanine,,0,VNXKKLLGKLLKVVK
VNWKKXLGKXIKXVK,15,Synthetic,Synthetic peptide,Rat erythrocytes: IC50>200 μM,HUVEC: IC50=38±6 μM,,,,Anticancer; Antimicrobial; Antifungal,Tumor active peptide##Membrane-targeted,,Linear,,Free,Amidation,X=Aib=1-amino-isobutyric acid,,0,VNWKKXLGKXIKXVK
VNWKKIILGKIIKVVK,16,Synthetic,Synthetic peptide,Rat erythrocytes: IC50>200 μM,HUVEC: IC50=50± μM,,,,Anticancer; Antimicrobial; Antifungal,Tumor active peptide##Membrane-targeted,,Linear,,Free,Amidation,,,0,VNWKKIILGKIIKVVK
VNWKKILAKIIKVVK,15,Synthetic,Synthetic peptide,Rat erythrocytes: IC50>200 μM,HUVEC: IC50=10±2 μM,,,,Anticancer; Antimicrobial; Antifungal,Tumor active peptide##Membrane-targeted,,Linear,,Free,Amidation,,,0,VNWKKILAKIIKVVK
VNWKKILGKIIKVVK,15,Lasioglossin III and its analogs,Native peptide,Rat erythrocytes: IC50>200 μM,HUVEC: IC50=15±4 μM,,,,Anticancer; Antimicrobial; Antifungal,Tumor active peptide##Membrane-targeted,,Linear,,Free,Amidation,,,0,VNWKKILGKIIKVVK
vnwkkilgkiikvvk,15,Synthetic,Synthetic peptide,Rat erythrocytes: IC50>200 μM,HUVEC: IC50=17±3 μM,,,,Anticancer; Antimicrobial; Antifungal,Tumor active peptide##Membrane-targeted,,Linear,,Free,Amidation,,,0,VNWKKILGKIIKVVK
VNWKKVLAKIIKVVK,15,Synthetic,Synthetic peptide,Rat erythrocytes: IC50>200 μM,HUVEC: IC50=18±2 μM,,,,Anticancer; Antimicrobial; Antifungal,Tumor active peptide##Membrane-targeted,,Linear,,Free,Amidation,,,0,VNWKKVLAKIIKVVK
VNWKKILGKIKKVVK,15,Synthetic,Synthetic peptide,Rat erythrocytes: IC50>200 μM,HUVEC: IC50> 80 μM,,,,Anticancer; Antimicrobial; Antifungal,Tumor active peptide##Membrane-targeted,,Linear,,Free,Amidation,,,0,VNWKKILGKIKKVVK
VNWKKILKKIIKVVK,15,Synthetic,Synthetic peptide,Rat erythrocytes: IC50>200 μM,HUVEC: IC50=20±1 μM,,,,Anticancer; Antimicrobial; Antifungal,Tumor active peptide##Membrane-targeted,,Linear,,Free,Amidation,,,0,VNWKKILKKIIKVVK
VNWKKILPKIIKVVK,15,Synthetic,Synthetic peptide,Rat erythrocytes: IC50>200 μM,HUVEC: IC50> 100 μM,,,,Anticancer; Antimicrobial; Antifungal,Tumor active peptide##Membrane-targeted,,Linear,,Free,Amidation,,,0,VNWKKILPKIIKVVK
VNWKKLLGKLLKVVK,15,Synthetic,Synthetic peptide,Rat erythrocytes: IC50>200 μM,HUVEC: IC50=12±3 μM,,,,Anticancer; Antimicrobial; Antifungal,Tumor active peptide##Membrane-targeted,,Linear,,Free,Amidation,,,0,VNWKKLLGKLLKVVK
vnwkkllgkllkvvk,15,Synthetic,Synthetic peptide,Rat erythrocytes: IC50>200 μM,HUVEC: IC50=12±3 μM,,,,Anticancer; Antimicrobial; Antifungal,Tumor active peptide##Membrane-targeted,,Linear,,Free,Amidation,,,0,VNWKKLLGKLLKVVK
VNWKKVLGKVVKVVK,15,Synthetic,Synthetic peptide,Rat erythrocytes: IC50>200 μM,HUVEC: IC50> 100 μM,,,,Anticancer; Antimicrobial; Antifungal,Tumor active peptide##Membrane-targeted,,Linear,,Free,Amidation,,,0,VNWKKVLGKVVKVVK
VNWXXILGXIIXVVX,15,Synthetic,Synthetic peptide,Rat erythrocytes: IC50>200 μM,HUVEC: IC50=20±4 μM,,,,Anticancer; Antimicrobial; Antifungal,Tumor active peptide##Membrane-targeted,,Linear,,Free,Amidation,X=Ornithine,,0,VNWXXILGXIIXVVX
VNWRRILGRIIRVVR,15,Synthetic,Synthetic peptide,Rat erythrocytes: IC50>200 μM,HUVEC: IC50=11±4 μM,,,,Anticancer; Antimicrobial; Antifungal,Tumor active peptide##Membrane-targeted,,Linear,,Free,Amidation,,,0,VNWRRILGRIIRVVR
VYWKKILGKIIKVVK,15,Synthetic,Synthetic peptide,Rat erythrocytes: IC50>200 μM,HUVEC: IC50=18±1 μM,,,,Anticancer; Antimicrobial; Antifungal,Tumor active peptide##Membrane-targeted,,Linear,,Free,Amidation,,,0,VYWKKILGKIIKVVK
KVKVKVKVpPTKVKVKVK,18,Synthetic,Synthetic peptide,Human erythrocytes: 50% Hemolysis=80.8±12.8µM,,,,,Anticancer,Tumor active peptide##Membrane-targeted,,Linear,,Free,Free,p=D-Pro,,0,KVKVKVKVPPTKVKVKVK
kvkvkvkvPptkvkvkvk,18,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide##Membrane-targeted,,Linear,,Free,Free,k=D-Lys; v=D-Val; p=D-Pro; t=D-Thr,,0,KVKVKVKVPPTKVKVKVK
KVKVKVKVPPTKVKVKVK,18,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide##Membrane-targeted,,Linear,,Free,Free,,,0,KVKVKVKVPPTKVKVKVK
AIPCGESCVWIPCISTVIGCSCSNKVCYR,29,Chassalia chartacea,Native peptide,Human erythrocytes: HD50=25.5 μM,,,,,Anticancer; Antibacterial,Tumor active peptide##Membrane-targeted,,Cyclic,Cys4<--->Cys20; Cys8<--->Cys22; Cys13<--->Cys27,Free,Free,,,0,AIPCGESCVWIPCISTVIGCSCSNKVCYR
GASCGETCFTGICFTAGCSCNPWPTCTRN,29,Chassalia chartacea,Native peptide,Human erythrocytes: HD50=51.9 μM,,,,,Anticancer; Antibacterial,Tumor active peptide##Membrane-targeted,,Cyclic,Cys4<--->Cys18; Cys8<--->Cys20; Cys13<--->Cys26; NCB: Gly1<--->Asn29,Free,Free,,,0,GASCGETCFTGICFTAGCSCNPWPTCTRN
GEYCGESCYLIPCFTPGCYCVSRQCVNKN,29,Chassalia chartacea,Native peptide,Human erythrocytes: HD50>25 μM,,,,,Anticancer; Antibacterial,Tumor active peptide##Membrane-targeted,,Cyclic,Cys4<--->Cys18; Cys8<--->Cys20; Cys13<--->Cys25; NCB: Gly1<--->Asn29,Free,Free,,,0,GEYCGESCYLIPCFTPGCYCVSRQCVNKN
GIPCAESCVWIPCTITALMGCSCKNNVCYNN,31,Chassalia chartacea,Native peptide,Human erythrocytes: HD50>25 μM,,,,,Anticancer; Antibacterial,Tumor active peptide##Membrane-targeted,,Cyclic,Cys4<--->Cys21; Cys8<--->Cys23; Cys13<--->Cys28; NCB: Gly1<--->Asn31,Free,Free,,,0,GIPCAESCVWIPCTITALMGCSCKNNVCYNN
GIPCAESCVWIPCTITALXGCSCKNNVCYNN,31,Synthetic,Synthetic peptide,Human erythrocytes: HD50>25 μM,,,,,Anticancer; Antibacterial,Tumor active peptide##Membrane-targeted,,Cyclic,Cys4<--->Cys21; Cys8<--->Cys23; Cys13<--->Cys28; NCB: Gly1<--->Asn31,Free,Free,X=MetO (Methionine sulfoxide),,0,GIPCAESCVWIPCTITALXGCSCKNNVCYNN
GDACGETCFTGICFTAGCSCNPWPTCTRN,29,Chassalia chartacea,Native peptide,Human erythrocytes: HD50=51.9 μM,,,,,Anticancer; Antimicrobial,Tumor active peptide##Membrane-targeted,,Cyclic,Cys4<--->Cys18; Cys8<--->Cys20; Cys13<--->Cys26; NCB: Gly1<--->Asn29,Free,Free,,,0,GDACGETCFTGICFTAGCSCNPWPTCTRN
IPCGESCVWIPCISGMFGCSCKDKVCYS,28,Chassalia chartacea,Native peptide,Human erythrocytes: HD50=13.3 μM,,,,,Anticancer; Antibacterial,Tumor active peptide##Membrane-targeted,,Cyclic,Cys3<--->Cys19; Cys7<--->Cys21; Cys12<--->Cys26,Free,Free,,,0,IPCGESCVWIPCISGMFGCSCKDKVCYS
IPCGESCVWIPCISGXFGCSCKDKVCYS,28,Synthetic,Synthetic peptide,Human erythrocytes: HD50>25 μM,,,,,Anticancer; Antibacterial,Tumor active peptide##Membrane-targeted,,Cyclic,Cys3<--->Cys19; Cys7<--->Cys21; Cys12<--->Cys26,Free,Free,X=MetO (Methionine sulfoxide),,0,IPCGESCVWIPCISGXFGCSCKDKVCYS
IPCGESCVWIPCITAIAGCSCKNKVCYT,28,Chassalia chartacea,Native peptide,Human erythrocytes: HD50=11.6 μM,,,,,Anticancer; Antibacterial,Tumor active peptide##Membrane-targeted,,Cyclic,Cys3<--->Cys19; Cys7<--->Cys21; Cys12<--->Cys26,Free,Free,,,0,IPCGESCVWIPCITAIAGCSCKNKVCYT
PLLQATLGGGS,11,No information found in the references,Native peptide,,,Angiogenic factor FGF2,,,Anticancer; Antiproliferative; Antiangiogenic,Tumor active peptide##Cancer targeted peptides##Membrane-targeted,,Linear,,Free,Free,,,0,PLLQATLGGGS
LLRHVVKILEKYL,13,Temporins family,Synthetic peptide,Showed no hemolytic activity against rabbit erythrocytes and human erythrocytes at 250 µg/ml,"Showed little effects on the proliferation of the 293T human embryonic kidney cell line, MECs, and human lymphomonocytes at concentrations of less than 50 µg/ml",,,A membrane-disturbing action seems to be the major mechanism for cell death,Anticancer,Tumor active peptide##Membrane-targeted,,Linear,,Free,Free,,,0,LLRHVVKILEKYL
LLRHVVKILSKYL,13,Temporins family,Synthetic peptide,Showed no hemolytic activity against rabbit erythrocytes and human erythrocytes at 250 µg/ml,"Showed little effects on the proliferation of the 293T human embryonic kidney cell line, MECs, and human lymphomonocytes at concentrations of less than 50 µg/ml",,,A membrane-disturbing action seems to be the major mechanism for cell death,Anticancer,Tumor active peptide##Membrane-targeted,,Linear,,Free,Free,,,0,LLRHVVKILSKYL
RGDLLRHVVKILEKYL,16,Arg-Gly-Asp(RGD) tripeptide ana temporins,Synthetic peptide,Showed no hemolytic activity against rabbit erythrocytes and human erythrocytes at 250 µg/ml,"Showed little effects on the proliferation of the 293T human embryonic kidney cell line, MECs, and human lymphomonocytes at concentrations of less than 50 µg/ml",,,A membrane-disturbing action seems to be the major mechanism for cell death,Anticancer,Tumor active peptide##Membrane-targeted,,Linear,,Free,Free,,,0,RGDLLRHVVKILEKYL
RGDLLRHVVKILSKYL,16,Arg-Gly-Asp(RGD) tripeptide ana temporins,Synthetic peptide,Showed no hemolytic activity against rabbit erythrocytes and human erythrocytes at 250 µg/ml,"Showed little effects on the proliferation of the 293T human embryonic kidney cell line, MECs, and human lymphomonocytes at concentrations of less than 50 µg/ml",,,A membrane-disturbing action seems to be the major mechanism for cell death,Anticancer,Tumor active peptide##Membrane-targeted,,Linear,,Free,Free,,,0,RGDLLRHVVKILSKYL
FLGWLFKWAKK,11,Brevinin-1EMa,Native peptide,,,,,,Anticancer; Antimicrobial,Tumor active peptide##Membrane-targeted,,Linear,,Free,Amidation,,,0,FLGWLFKWAKK
FLGWLFKWAWK,11,Brevinin-1EMa,Native peptide,,,,,,Anticancer; Antimicrobial,Tumor active peptide##Membrane-targeted,,Linear,,Free,Amidation,,,0,FLGWLFKWAWK
FLKWLFKWAKK,11,Brevinin-1EMa,Native peptide,,,,,,Anticancer; Antimicrobial,Tumor active peptide,,Linear,,Free,Amidation,,,0,FLKWLFKWAKK
FLWWLFKWAWK,11,Brevinin-1EMa,Native peptide,,,,,,Anticancer; Antimicrobial,Tumor active peptide,,Linear,,Free,Amidation,,,0,FLWWLFKWAWK
PDEDAINDALNKVCSTGRRQRSICKQLLKK,30,Synthetic,Synthetic peptide,,,,,Lyse cancer cells,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,PDEDAINDALNKVCSTGRRQRSICKQLLKK
PDEDAINNALNKVCSTGRRQRSICKQLLKK,30,Synthetic,Synthetic peptide,,,,,Lyse cancer cells,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,PDEDAINNALNKVCSTGRRQRSICKQLLKK
KWKSFLKTFKSLKkTVLHTLLKAISS,26,Acetylation,Synthetic peptide,Human red blood cells: MHC=5.20±0.02 μmol/L,,,,,Anticancer,Tumor active peptide,,Linear,,Acetylation,Amidation,,,0,KWKSFLKTFKSLKKTVLHTLLKAISS
KWKSFLKTFKSLKkTVLHTLLkAISS,26,Acetylation,Synthetic peptide,Human red blood cells: MHC=20.81±0.06 μmol/L,,,,,Anticancer,Tumor active peptide,,Linear,,Acetylation,Amidation,,,0,KWKSFLKTFKSLKKTVLHTLLKAISS
kWkSFLkTFkSLKkTVLHTLLkAISS,26,Acetylation,Synthetic peptide,Human red blood cells: MHC> 325.20 μmol/L,,,,,Anticancer,Tumor active peptide,,Linear,,Acetylation,Amidation,,,0,KWKSFLKTFKSLKKTVLHTLLKAISS
KWKSFLKTFKSLKKTVLHTLLkAISS,26,Acetylation,Synthetic peptide,Human red blood cells: MHC=20.81±0.10 μmol/L,,,,,Anticancer,Tumor active peptide,,Linear,,Acetylation,Amidation,,,0,KWKSFLKTFKSLKKTVLHTLLKAISS
KWkSFLkTFkSLKkTVLHTLLkAISS,26,Acetylation,Synthetic peptide,Human red blood cells: MHC> 325.20 μmol/L,,,,,Anticancer,Tumor active peptide,,Linear,,Acetylation,Amidation,,,0,KWKSFLKTFKSLKKTVLHTLLKAISS
KWKSFLkTFKSLKKTVLHTLLKAISS,26,Acetylation,Synthetic peptide,Human red blood cells: MHC=10.4±0.04 μmol/L,,,,,Anticancer,Tumor active peptide,,Linear,,Acetylation,Amidation,,,0,KWKSFLKTFKSLKKTVLHTLLKAISS
KWKSFLkTFkSLKkTVLHTLLkAISS,26,Acetylation,Synthetic peptide,Human red blood cells: MHC=325.20±0.82 μmol/L,,,,,Anticancer,Tumor active peptide,,Linear,,Acetylation,Amidation,,,0,KWKSFLKTFKSLKKTVLHTLLKAISS
KWKSFLkTFKSLKkTVLHTLLKAISS,26,Acetylation,Synthetic peptide,Human red blood cells: MHC=20.81±0.15 μmol/L,,,,,Anticancer,Tumor active peptide,,Linear,,Acetylation,Amidation,,,0,KWKSFLKTFKSLKKTVLHTLLKAISS
KWKSFLKTFKSlKKTVLHTLLKAISS,26,Acetylation,Synthetic peptide,Human red blood cells: MHC=20.81±0.03 μmol/L,,,,,Anticancer,Tumor active peptide,,Linear,,Acetylation,Amidation,,,0,KWKSFLKTFKSLKKTVLHTLLKAISS
KWKSFLKTFKSlKKTVLHTlLKAISS,26,Acetylation,Synthetic peptide,Human red blood cells: MHC=81.31±.43 μmol/L,,,,,Anticancer,Tumor active peptide,,Linear,,Acetylation,Amidation,,,0,KWKSFLKTFKSLKKTVLHTLLKAISS
KWKSFLKTFKSLKKTVLHTlLKAISS,26,Acetylation,Synthetic peptide,Human red blood cells: MHC=20.81 +0.13 μmol/L,,,,,Anticancer,Tumor active peptide,,Linear,,Acetylation,Amidation,,,0,KWKSFLKTFKSLKKTVLHTLLKAISS
KWKSFlKTFKSLKKTVLHTLLKAISS,26,Acetylation,Synthetic peptide,Human red blood cells: MHC=10.40±0.08 μmol/L,,,,,Anticancer,Tumor active peptide,,Linear,,Acetylation,Amidation,,,0,KWKSFLKTFKSLKKTVLHTLLKAISS
KWKSFlKTFKSlKKTVLHTLLKAISS,26,Acetylation,Synthetic peptide,Human red blood cells: MHC=20.81±0.10 μmol/L,,,,,Anticancer,Tumor active peptide,,Linear,,Acetylation,Amidation,,,0,KWKSFLKTFKSLKKTVLHTLLKAISS
KWKSFlKTFKSlKKTVlHTlLKAISS,26,Acetylation,Synthetic peptide,Human red blood cells: MHC=81.31±1.05 μmol/L,,,,,Anticancer,Tumor active peptide,,Linear,,Acetylation,Amidation,,,0,KWKSFLKTFKSLKKTVLHTLLKAISS
KWKSFlKTFKSlKKTVlHTllKAISS,26,Acetylation,Synthetic peptide,Human red blood cells: MHC> 325.20 μmol/L,,,,,Anticancer,Tumor active peptide,,Linear,,Acetylation,Amidation,,,0,KWKSFLKTFKSLKKTVLHTLLKAISS
KWKSFlKTFKSlKKTVLHTlLKAISS,26,Acetylation,Synthetic peptide,Human red blood cells: MHC=162.61±0.19 . μmol/L,,,,,Anticancer,Tumor active peptide,,Linear,,Acetylation,Amidation,,,0,KWKSFLKTFKSLKKTVLHTLLKAISS
GLFGKLIKKFARKAISYAVKKARGKH,26,"Central Asian spider, Lachesana tarabaevi",Native peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,GLFGKLIKKFARKAISYAVKKARGKH
GLFGKLIKKFGRKAISYAVKKARGKH,26,"Central Asian spider, Lachesana tarabaevi",Native peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,GLFGKLIKKFGRKAISYAVKKARGKH
KKWXWKK,7,Synthetic,Synthetic peptide,Human red blood cells: EC50=87 μM,MRC-5: IC50=10±1 μM,,,,Anticancer,Tumor active peptide,,Cyclic,NCB: Lys1<--->Lys7,lactam,lactam,X=2-Nal-CH2-,,0,KKWXWKK
KKXWKK,6,Synthetic,Synthetic peptide,Human red blood cells: EC50=256 μM,MRC-5: IC50=1030±21 μM,,,,Anticancer,Tumor active peptide,,Cyclic,NCB: Lys1<--->Lys6,lactam,lactam,X=2-Nal-CH2-,,0,KKXWKK
KWXKK,5,Synthetic,Synthetic peptide,Human red blood cells: EC50=110 μM,MRC-5: IC50=23.5±0.7 μM,,,,Anticancer,Tumor active peptide,,Cyclic,NCB: Lys1<--->Lys5,lactam,lactam,X=2-Nal-CH2-,,0,KWXKK
KWXWKK,6,Synthetic,Synthetic peptide,Human red blood cells: EC50=31 μM,MRC-5: IC50=13±1 μM,,,,Anticancer,Tumor active peptide,,Cyclic,NCB: Lys1<--->Lys6,lactam,lactam,X=2-Nal-CH2-,,0,KWXWKK
FLGALFHALSKLL,13,Synthetic,Synthetic peptide,Human erythrocytes: 6.8% Hemolysis=30 µM,MCF-10A: IC50=32 μM,,,Induced cell tissue damage through a new cell lysis mechanism ,Anticancer; Antibacterial,Tumor active peptide##Membrane lysis,,Linear,,Free,Free,,,0,FLGALFHALSKLL
FLGALFKALSHLL,13,Synthetic,Synthetic peptide,Human erythrocytes: 8.8% Hemolysis=30 µM,MCF-10A: IC50=56 μM,,,Induced cell tissue damage through a new cell lysis mechanism ,Anticancer; Antibacterial,Tumor active peptide##Membrane lysis,,Linear,,Free,Free,,,0,FLGALFKALSHLL
RRRRRNWMWC,10,Nullomer derived anticancer peptides (NulloPs):,Native peptide,no hemolytic effect on human RBCs,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Amidation,,,0,RRRRRNWMWC
RRRRRWCMNW,10,Nullomer derived anticancer peptides (NulloPs):,Native peptide,significant hemolytic activity,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Amidation,,,0,RRRRRWCMNW
GLWSKIKEVGKEAAKAAAKAAGKAALGAVSEAV,33,South American frog Phyllomedusa bicolor,Native peptide,,,,,"Drs B2 does not act by apoptosis but possibly by necrosis,antitumor and angiostatic activities",Anticancer; Antimicrobial,Tumor active peptide,,Linear,,Free,Free,,,0,GLWSKIKEVGKEAAKAAAKAAGKAALGAVSEAV
FLGGLIKIVPAMICAVTKKC,20,Rana catesbeiana,Native peptide,Human erythrocytes: <15% Hemolysis=250 µg/ml,Monkey COS-7: IC50=14.8 µg/ml; NL20: Not active up to 62.5 µg/ml,,,,Anticancer; Antibacterial,Tumor active peptide##Membrane-targeted,,Cyclic,Cys14<--->Cys20,Free,Free,,,0,FLGGLIKIVPAMICAVTKKC
RWRWRW,6,Synthetic,Synthetic peptide,Sheep erythrocytes: 50% Hemolysis=210 µM; Human erythrocytes: 17% Hemolysis=333 µM,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,,0,RWRWRW
DDFLCAGGCL,10,Allium sativum,Native peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Free,,,0,DDFLCAGGCL
GFGALFKFLAKKVAKTVAKQAAKQGAKYVVNKQME,35,Cupiennius salei,Native peptide,Human erythrocytes: 50% Hemolysis=7.8 µg/ml; 50% Cell death=23 µg/ml,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,,,0,GFGALFKFLAKKVAKTVAKQAAKQGAKYVVNKQME
PPPEE,5,Bovine milk,Native peptide,,,,,,Anticancer; Antimicrobial; Antihypertensive; Antiviral; Antioxidant; Immunomodulant,Tumor active peptide,,Linear,,Free,Amidation,,,0,PPPEE
RYLGYL,6,Bovine milk,Native peptide,,,,,,Anticancer; Antimicrobial; Antihypertensive; Antiviral; Antioxidant; Immunomodulant,Tumor active peptide,,Linear,,Free,Amidation,,,0,RYLGYL
YPFPG,5,Bovine milk,Native peptide,,,,,,Anticancer; Antimicrobial; Antihypertensive; Antiviral; Antioxidant; Immunomodulant,Tumor active peptide,,Linear,,Free,Amidation,,,0,YPFPG
FIFHIIKGLFHAGKMI,16,Epinephelus nebulosus,Native peptide,EP-8 did not have a strong hemolytic effect at low doses,,,,,Anticancer; Antimicrobial,Tumor active peptide,,Linear,,Free,Free,,,0,FIFHIIKGLFHAGKMI
GFFALIPKIISSPLFKTLLSAVGSALS,27,Epinephelus nebulosus,Native peptide,The HL50 values of Pardaxin-6 (about 100 mg/L) were much higher than those of EP-1 and EP-9,,,,,Anticancer; Antimicrobial,Tumor active peptide,,Linear,,Free,Free,,,0,GFFALIPKIISSPLFKTLLSAVGSALS
GFIFHIIKGLFHAGKMIHGLV,21,Epinephelus nebulosus,Native peptide,EP-1  did not have a strong hemolytic effect at low doses,,,,,Anticancer; Antimicrobial,Tumor active peptide,,Linear,,Free,Free,,,0,GFIFHIIKGLFHAGKMIHGLV
FKDLKKIANIINSIFKK,17,Synthetic construct,Synthetic peptide,Human erythrocytes: LC50=1186 µM,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Amidation,,,0,FKDLKKIANIINSIFKK
FKKLKKIANIINSIFKK,17,Synthetic construct,Synthetic peptide,Human erythrocytes: LC50=4649 µM,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Amidation,,,0,FKKLKKIANIINSIFKK
FVDLKKIANIINSIFKK,17,Synthetic construct,Synthetic peptide,Human erythrocytes: LC50=95.74 µM,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Amidation,,,0,FVDLKKIANIINSIFKK
FVKLKKIANIINSIFKK,17,Synthetic construct,Synthetic peptide,Human erythrocytes: LC50=1993 µM,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Amidation,,,0,FVKLKKIANIINSIFKK
FVKLKKILNIILSIFKK,17,Synthetic construct,Synthetic peptide,Human erythrocytes: LC50=28.34 µM,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Amidation,,,0,FVKLKKILNIILSIFKK
FVKLKKILNIINSIFKK,17,Synthetic construct,Synthetic peptide,Human erythrocytes: LC50=86.99 µM,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Amidation,,,0,FVKLKKILNIINSIFKK
GFGSKPIDSFGLSWL,15,Streptomyces,Native peptide,,,,,,Anticancer,Tumor active peptide,,Cyclic,LAC: Gly1<--->Asp8,Free,Free,,,0,GFGSKPIDSFGLSWL
GWKKWLRKGAKHLGQAAIK,19,Synthetic,Synthetic peptide,Human erythrocytes: 50% Hemolysis>256 µg/ml,"HaCat: Not active up to 50 µM; Zebrafish embryos: >10% Killing=5 µM(52hpf embryos (hpf - hours postfertilization)); Zebrafish embryos: >10% Killing=25 µM(4hpf, 28hpf embryos)",,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,,0,GWKKWLRKGAKHLGQAAIK
FLGMIPGLIGGLISAFK,17,Tityus serrulatus (Brazilian yellow scorpion),Native peptide,Horse erythrocytes(possess little haemolytic activity (6.48%) at the highest concentration tested (160 μM) ),,,,,Anticance; Antimicrobial; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,,,0,FLGMIPGLIGGLISAFK
FLSLIPSLVGGSISAFK,17,Tityus serrulatus (Brazilian yellow scorpion),Native peptide,Horse erythrocytes(possess little haemolytic activity (6.48%) at the highest concentration tested (160 μM) ),,,,,Anticance; Antimicrobial; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,,,0,FLSLIPSLVGGSISAFK
GIGAVLKVLTTGLPALISWIKRKRQQ,26,Apis mellifera (Honeybee),Native peptide,high haemolytic activity,APH-R: IC50=0.9±0.1 μM,,,,Anticancer; Antimicrobial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",0,GIGAVLKVLTTGLPALISWIKRKRQQ
KKLFKKILKKL,11,Synthetic,Synthetic peptide,Human erythrocytes: 0% Hemolysis=150 µM ,NIH 3T3: IC50>200 µM,,,,Anticancer; Antimicrobial,Cell-penetrating peptides,,Linear,,Free,Amidation,,,0,KKLFKKILKKL
LKLFKKILKFL,11,Synthetic,Synthetic peptide,Human erythrocytes: 15.5 ± 0.7% Hemolysis=150 µM ,NIH 3T3: IC50=15.5 ± 0.7 µM,,,,Anticancer; Antimicrobial,Cell-penetrating peptides,,Linear,,Free,Amidation,,,0,LKLFKKILKFL
LKLFKKILKYL,11,Synthetic,Synthetic peptide,Human erythrocytes: 39.0 ± 8.5% Hemolysis=150 µM ,NIH 3T3: IC50=39.0 ± 8.5 µM,,,,Anticancer; Antimicrobial,Cell-penetrating peptides,,Linear,,Free,Amidation,,,0,LKLFKKILKYL
RRLFRRILRYL,11,Synthetic,Synthetic peptide,Human erythrocytes: 28 ± 3.2% Hemolysis=150 µM ,NIH 3T3: IC50=40.0 ± 7.1 µM,,,,Anticancer; Antimicrobial,Cell-penetrating peptides,,Linear,,Free,Amidation,,,0,RRLFRRILRYL
CLBKKLFKKILKKL,14,Synthetic,Synthetic peptide,,NIH 3T3: IC50=20.6 ± 3.3 µM,,,,Anticancer; Antimicrobial,Coupling peptide,,Linear,,Free,Amidation,,,0,CLBKKLFKKILKKL
RRWRIVVIRVRR,12,Synthetic,Synthetic peptide,Human erythrocytes: 50% Hemolysis>50 µM,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,,0,RRWRIVVIRVRR
RWRWRWX,7,Synthetic,Synthetic peptide,Human erythrocytes:16% Hemolysis=142µM; 50% Hemolysis=285µM,Human fibroblasts: IC50=31.3µM,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,X=Lysine with Octanoylated side group,,0,RWRWRWX
GKPRPYSPRPTSHPRPIRV,19,Drosophila melanogaster; Drosophila simulans,Native peptide,Mouse erythrocytes: <10% Hemolysis=100 µM; Pig erythrocytes: <10% Hemolysis=100 µM; Human erythrocytes: Not active up to 600 µg/ml,CEM-SS cells: 50% Cell death>45.5 µM; HEK293: Not active up to 600 µg/ml,,,,Anticancer; Antibacterial; Antifungal; Antiviral,Tumor active peptide,,Linear,,Free,Free,,,0,GKPRPYSPRPTSHPRPIRV
YGRKKRRQRRRREADFFWSLCTA,23,The C-terminal domain of c-FLIP,Synthetic peptide,,"No toxicity was observed in epithelial and endothelial cells (HPDE and HUVEC, respectively)",,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,YGRKKRRQRRRREADFFWSLCTA
GIIKKIIKKI,10,Alpha-helical proteins,Synthetic peptide,,,,,"In addition to rapid membrane-permeabilizing capacities, the peptides can also induce the programmed cell death of cancer cells via both mitochondrial pathway and death receptor pathway, without inducing non-specific immunogenic responses.",Anticancer,Tumor active peptide,,Linear,,Free,Amidation,,,0,GIIKKIIKKI
GIIKKIIKKIIKKI,14,Alpha-helical proteins,Synthetic peptide,Human erythrocytes: HC50>250 µM,Human keratinocytes HaCat: <5% Killing=40 µM,,,"In addition to rapid membrane-permeabilizing capacities, the peptides can also induce the programmed cell death of cancer cells via both mitochondrial pathway and death receptor pathway, without inducing non-specific immunogenic responses.",Anticancer,Tumor active peptide##Membrane-targeted,,Linear,,Free,Amidation,,,0,GIIKKIIKKIIKKI
GIIKKIIKKIIKKIIKKI,18,Alpha-helical proteins,Synthetic peptide,,,,,"In addition to rapid membrane-permeabilizing capacities, the peptides can also induce the programmed cell death of cancer cells via both mitochondrial pathway and death receptor pathway, without inducing non-specific immunogenic responses.",Anticancer,Tumor active peptide,,Linear,,Free,Amidation,,,0,GIIKKIIKKIIKKIIKKI
WKLFKKILKVL,11,Synthetic,Synthetic peptide,Human erythrocytes: 50% Hemolysis=104 µM; 56% Hemolysis=150 µM,CHO: 50% Cell death=13 µg/ml,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,,0,WKLFKKILKVL
CREKAKKLFKKILKKL,16,Synthetic,Synthetic peptide,,NIH 3T3: IC50=74.5±4.1µM,,,,Anticancer,Coupling peptide,,Linear,,Free,Amidation,,,0,CREKAKKLFKKILKKL
RRLFRRILRRL,11,Synthetic,Synthetic peptide,Human erythrocytes: 1±0.1% Hemolysis=150µM,NIH 3T3: IC50=68.0±7.6µM,,,,Anticancer,Cell-penetrating peptides,,Linear,,Free,Amidation,,,0,RRLFRRILRRL
KKLFKKILKFL,11,Synthetic,Synthetic peptide,Human erythrocytes: 50% Hemolysis=203 µM; 34 ±2.1% Hemolysis=150 µM,NIH 3T3: IC50=13.5±0.7 µM,,,,Anticancer; Antibacterial; Antiviral,Cell-penetrating peptides,,Linear,,Free,Amidation,,,0,KKLFKKILKFL
ALWDTLLKKVLKAAAKAALDAVLVGANA,28,Synthetic,Synthetic peptide,Human erythrocytes: 50% Hemolysis=5±1 µM,Vero cells: 50% Cytotoxicity =17.75 µM,,,,Anticancer; Antibacterial; Antiviral,Tumor active peptide,,Linear,,Free,Free,,,0,ALWDTLLKKVLKAAAKAALDAVLVGANA
ALWKTLLKKVLKAAAK,16,Synthetic,Synthetic peptide,Human erythrocytes: 50% Hemolysis=57±3 µM,Vero cells: 50% Cytotoxicity =30.19 µM,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,ALWKTLLKKVLKAAAK
ALWKTLLKKVLKAAAKAALKAVLVGANA,28,Synthetic,Synthetic peptide,Human erythrocytes: 50% Hemolysis=0.5±0.2 µM,Vero cells: 50% Cytotoxicity =25 µM,,,,Anticancer; Antibacterial; Antifungal; Antiviral,Tumor active peptide,,Linear,,Free,Free,,,0,ALWKTLLKKVLKAAAKAALKAVLVGANA
ALWKTLLKKVLKAAAKAALNAVLVGANA,28,Synthetic,Synthetic peptide,Human erythrocytes: 50% Hemolysis=2±0.1 µM,BHK-21 BSR: 10.5% Cytotoxicity =10 µM; Vero cells: 50% Cytotoxicity =12 µM,,,,Anticancer; Antibacterial; Antiviral,Tumor active peptide,,Linear,,Free,Free,,,0,ALWKTLLKKVLKAAAKAALNAVLVGANA
TLLKKVLKAAAKAALNAVLVGANA,24,Synthetic,Synthetic peptide,Human erythrocytes: 50% Hemolysis=16.5±0.5 µM;,Vero cells: 50% Cytotoxicity =34 µM,,,,Anticancer; Antibacterial; Antiviral,Tumor active peptide,,Linear,,Free,Free,,,0,TLLKKVLKAAAKAALNAVLVGANA
RLGDGCTR,8,somatic seedlings of sandalwood,Native peptide,,Normal fibroblast (L929) cell line: Peptide (0–1000 μg/mL) did not exhibit any cytotoxicity.,,,,Anticancer,Tumor active peptide,,Cyclic,,Free,Free,,,0,RLGDGCTR
FFGRLKSVWSAVKHGWKAAKSR,22,Trichoplax adhaerens,Native peptide,Rat erythrocytes:20% Hemolysis=800µM,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Free,,,0,FFGRLKSVWSAVKHGWKAAKSR
HGFQWPGSWTWENGKWTWKGAYQFLKGGGGSRRRRRRRRR,40,Synthetic,Synthetic peptide,,,STAT3,,"With the addition of a cell-penetrating motif, the resulting APTSTAT3-9R aptide was able to suppress the viability and proliferation of cancer cells by blocking STAT3 phosphorylation, thereby inhibiting STAT3 downstream signaling.",Anticancer; Antitumor,Tumor active peptide##Cancer targeted peptides,,Linear,,Free,Free,,,0,HGFQWPGSWTWENGKWTWKGAYQFLKGGGGSRRRRRRRRR
LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES,37,Also known human cathelicidin,Synthetic peptide,,Primary dermal fibroblast: LC50=26 at 100 µM,,,,Anticancer; Antimicrobial,Tumor active peptide,,Linear,,Free,Free,,,0,LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES
KKCKFFCKVKKKIKSIGFQIPIVSIPFK,28,Lithobates catesbeiana,Native peptide,Human erythrocytes:0% Hemolysis=100µg/ml; 3% Hemolysis=200µg/ml,L929: At 200 µg/ml induced 1.1% cell death,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Free,,,0,KKCKFFCKVKKKIKSIGFQIPIVSIPFK
KAQXQKQAW,9,Synthetic,Synthetic peptide,,,,,,Anticancer; Antimicrobial,Tumor active peptide##Immune system stimulating peptides,,Linear,,Free,Amidation,X=Dip=diphenylalanine,,0,KAQXQKQAW
FFGWLIKGAIHAGKAIHGLIHRRRH,25,Red sea bream,Native peptide,,NIH3T3: ~35%Inhibit=5 µg/mL; WS-1: ~42%Inhibit=5 µg/mL,,,,Anticancer; Antimicrobial,Tumor active peptide,,Linear,,Free,Free,,,0,FFGWLIKGAIHAGKAIHGLIHRRRH
TKPRKTKPRKTKPRKTKPR,19,Tuftsin derivative,Synthetic peptide,,,,,,Anticancer; Antitumor,Tumor active peptide,,Linear,,Free,Free,,,0,TKPRKTKPRKTKPRKTKPR
ESFSDWWKLLAE,12,MDM2,Synthetic peptide,,,MDM2,,target the p53–MDM4 interaction,Anticancer,Tumor active peptide##Cancer targeted peptides,,Linear,,Free,Free,,,0,ESFSDWWKLLAE
ETFADWWKLLAE,12,MDM2,Synthetic peptide,,,MDM2,,target the p53–MDM5 interaction,Anticancer,Tumor active peptide##Cancer targeted peptides,,Linear,,Free,Free,,,0,ETFADWWKLLAE
ETFSDWWKLLAE,12,MDM2,Synthetic peptide,,,MDM2,,target the p53–MDM2 interaction,Anticancer,Tumor active peptide##Cancer targeted peptides,,Linear,,Free,Free,,,0,ETFSDWWKLLAE
LTFSDWWKLLAE,12,MDM2,Synthetic peptide,,,MDM2,,target the p53–MDM3 interaction,Anticancer,Tumor active peptide##Cancer targeted peptides,,Linear,,Free,Free,,,0,LTFSDWWKLLAE
SMWSGMWRRKLKKLRNALKKKLKGE,25,Lachesana tarabaevi,Native peptide,Rabbit erythrocytes: 20% Hemolysis=80 µM; Human erythrocytes: 36% Hemolysis=256 µg/ml,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Free,,,0,SMWSGMWRRKLKKLRNALKKKLKGE
KILRGVAKKIMRTFLRRISKDILTGKK,27,Synthetic,Synthetic peptide,Whole blood cells: experiments revealed absent or minimal hemolysis,lymphotoxic effects in vitro,,,,Anticancer; Antimicrobial,Tumor active peptide##Membrane lysis,,Linear,,Free,Amidation,,,0,KILRGVAKKIMRTFLRRISKDILTGKK
KILRGVAKKIMRTFLRRILTGKK,23,Synthetic,Synthetic peptide,Whole blood cells: experiments revealed absent or minimal hemolysis,lymphotoxic effects in vitro,,,,Anticancer; Antimicrobial,Tumor active peptide##Membrane lysis,,Linear,,Free,Amidation,,,0,KILRGVAKKIMRTFLRRILTGKK
KILRGVAKKIMRTFLRRISKKILTGKK,27,Synthetic,Synthetic peptide,Whole blood cells: experiments revealed absent or minimal hemolysis,lymphotoxic effects in vitro,,,,Anticancer; Antimicrobial,Tumor active peptide##Membrane lysis,,Linear,,Free,Amidation,,,0,KILRGVAKKIMRTFLRRISKKILTGKK
MICYSHKTPQPSATITCEEKTCYKKSVRKLPAIVAGRGCGCPSKEMLVAIHCCRSDKCNE,60,"venom of the Eastern green mamba, Dendroaspis angusticeps (Elapidae)",Native peptide,Human erythrocytes: LC50>1000 μg/mL,HUVEC: LC50>300 μg/mL,,,,Anticancer; Antitumor; Antimicrobial,Tumor active peptide,,Linear,,Free,Free,,,0,MICYSHKTPQPSATITCEEKTCYKKSVRKLPAIVAGRGCGCPSKEMLVAIHCCRSDKCNE
RICYSHKLLQAKTTKTCEENSCYKRSLPKIPLIIIGRGCGCPLTLPFLRIKCCTSDKCN,59,"venom of the Eastern green mamba, Dendroaspis angusticeps (Elapidae)",Native peptide,Human erythrocytes: LC50>600 μg/mL,HUVEC: LC50=57±3 μg/mL,,,,Anticancer; Antitumor; Antimicrobial,Tumor active peptide,,Linear,,Free,Free,,,0,RICYSHKLLQAKTTKTCEENSCYKRSLPKIPLIIIGRGCGCPLTLPFLRIKCCTSDKCN
KKKK,4,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,3-OH-C16,Amidation,,,0,KKKK
LKLSPKTKDTLKKVLKGAIKGAIAIASMA,29,skin secretions of the frog Pseudhymenochirus merlini (Pipidae),Native peptide,Human red blood cells (RBC): LC50=162±13 μM,HUVEC: LC50=7.7±0.7 μM,,,,Anticancer; Antimicrobial,Tumor active peptide,,Linear,,Free,Amidation,,,0,LKLSPKTKDTLKKVLKGAIKGAIAIASMA
LKLSPKTKKTLKKVLKGAIKGAIAIASMA,29,skin secretions of the frog Pseudhymenochirus merlini (Pipidae),Native peptide,Human red blood cells (RBC): LC50=192±21 μM,HUVEC: LC50=6.5±0.2 μM,,,,Anticancer; Antimicrobial,Tumor active peptide,,Linear,,Free,Amidation,,,0,LKLSPKTKKTLKKVLKGAIKGAIAIASMA
LKLSPKTKkTLKKVLKGAIKGAIAIASMA,29,skin secretions of the frog Pseudhymenochirus merlini (Pipidae),Native peptide,Human red blood cells (RBC): LC50>400 μM,HUVEC: LC50=9.3±0.3 μM,,,,Anticancer; Antimicrobial,Tumor active peptide,,Linear,,Free,Amidation,k=D-Lys,,0,LKLSPKTKKTLKKVLKGAIKGAIAIASMA
INLKALAALAKKIL,14,Vespula lewisii,Native peptide,,"non-tumor cells (melan-a and HaCaT) were more resistant to mastoparan treatment, and their IC50 values were 411.5 and 428 μM",,,Mastoparan induces apoptosis in B16F10-Nex2 melanoma cells via the intrinsic mitochondrial pathway ,Anticancer,Tumor active peptide##Cell-penetrating peptides##Induce apoptosis,,Linear,,Free,Free,,,0,INLKALAALAKKIL
GIFPIFAKLLGKVIKVASSLISKGRTE,27,skin secretions of the frog Pseudhymenochirus merlini (Pipidae),Native peptide,Human erythrocytes: LC50=6.2±1.0 μM,HUVEC: LC50=68±2 μM,,,,Anticancer; Antimicrobial,Tumor active peptide,,Linear,,Free,Free,,,0,GIFPIFAKLLGKVIKVASSLISKGRTE
IKIPSFFRNILKKVGKEAVSLIAGALKQS,29,skin secretions of the frog Pseudhymenochirus merlini (Pipidae),Native peptide,Human red blood cells (RBC): LC50>403 μM,HUVEC: LC50=5.6±0.9 μM,,,,Anticancer; Antimicrobial,Tumor active peptide,,Linear,,Free,Free,,,0,IKIPSFFRNILKKVGKEAVSLIAGALKQS
VKRFKKFFRKLKKAV,15,Cathelicidin-BF15 C-terminal amidated derivative B1,Synthetic peptide,,GES-1: IC50=87.1 µM,,,,Anticancer; Antimicrobial,Tumor active peptide,,Linear,,Free,Amidation,,,0,VKRFKKFFRKLKKAV
VKRFKKFFRKLKKDV,15,Cathelicidin-BF15 C-terminal amidated derivative B3,Synthetic peptide,,GES-1: IC50=120.2 µM,,,,Anticancer; Antimicrobial,Tumor active peptide,,Linear,,Free,Amidation,,,0,VKRFKKFFRKLKKDV
VKRFKKFFRKLKKEV,15,Cathelicidin-BF15 C-terminal amidated derivative B3,Synthetic peptide,,GES-1: IC50=104.5 µM,,,,Anticancer; Antimicrobial,Tumor active peptide,,Linear,,Free,Amidation,,,0,VKRFKKFFRKLKKEV
VKRFKKFFRKLKKFV,15,Cathelicidin-BF15 C-terminal amidated derivative B1,Synthetic peptide,,GES-1: IC50=107.2 µM,,,,Anticancer; Antimicrobial,Tumor active peptide,,Linear,,Free,Amidation,,,0,VKRFKKFFRKLKKFV
VKRFKKFFRKLKKGV,15,Cathelicidin-BF15 C-terminal amidated derivative B2,Synthetic peptide,,GES-1: IC50=107.2 µM,,,,Anticancer; Antimicrobial,Tumor active peptide,,Linear,,Free,Amidation,,,0,VKRFKKFFRKLKKGV
VKRFKKFFRKLKKHV,15,Cathelicidin-BF15 C-terminal amidated derivative B3,Synthetic peptide,,GES-1: IC50=104.7 µM,,,,Anticancer; Antimicrobial,Tumor active peptide,,Linear,,Free,Amidation,,,0,VKRFKKFFRKLKKHV
VKRFKKFFRKLKKKV,15,Cathelicidin-BF15 C-terminal amidated derivative B3,Synthetic peptide,,GES-1: IC50=123.0 µM,,,,Anticancer; Antimicrobial,Tumor active peptide,,Linear,,Free,Amidation,,,0,VKRFKKFFRKLKKKV
VKRFKKFFRKLKKLV,15,Cathelicidin-BF15 C-terminal amidated derivative B1,Synthetic peptide,,GES-1: IC50=77.6 µM,,,,Anticancer; Antimicrobial,Tumor active peptide,,Linear,,Free,Amidation,,,0,VKRFKKFFRKLKKLV
VKRFKKFFRKLKKQV,15,Cathelicidin-BF15 C-terminal amidated derivative B3,Synthetic peptide,,GES-1: IC50=102.3 µM,,,,Anticancer; Antimicrobial,Tumor active peptide,,Linear,,Free,Amidation,,,0,VKRFKKFFRKLKKQV
VKRFKKFFRKLKKRV,15,Cathelicidin-BF15 C-terminal amidated derivative B3,Synthetic peptide,,GES-1: IC50=93.3 µM,,,,Anticancer; Antimicrobial,Tumor active peptide,,Linear,,Free,Amidation,,,0,VKRFKKFFRKLKKRV
VKRFKKFFRKLKKSV,15,Cathelicidin-BF15 C-terminal amidated derivative B1,Synthetic peptide,,GES-1: IC50=102.3 µM,,,,Anticancer; Antimicrobial,Tumor active peptide,,Linear,,Free,Amidation,,,0,VKRFKKFFRKLKKSV
VKRFKKFFRKLKKTV,15,Cathelicidin-BF15 C-terminal amidated derivative B3,Synthetic peptide,,GES-1: IC50=109.6 µM,,,,Anticancer; Antimicrobial,Tumor active peptide,,Linear,,Free,Amidation,,,0,VKRFKKFFRKLKKTV
VKRFKKFFRKLKKVV,15,Cathelicidin-BF15 C-terminal amidated derivative B1,Synthetic peptide,,GES-1: IC50=64.6 µM,,,,Anticancer; Antimicrobial,Tumor active peptide,,Linear,,Free,Amidation,,,0,VKRFKKFFRKLKKVV
WKX,3,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Picolinoyl,Free,X=MET-Boro,,0,WKX
IKWKRWWWR,9,Synthetic,Synthetic peptide,Human erythrocytes:<10% Hemolysis>400µg/ml,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,,,0,IKWKRWWWR
IWKRWWWKR,9,Synthetic,Synthetic peptide,Human erythrocytes:<=10% Hemolysis>400µg/ml,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,,,0,IWKRWWWKR
KKRWWWWWR,9,Synthetic,Synthetic peptide,Human erythrocytes:<=10% Hemolysis=100µg/ml,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,,,0,KKRWWWWWR
KWWKIWRWR,9,Synthetic,Synthetic peptide,Human erythrocytes:<10% Hemolysis>400µg/ml,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,,,0,KWWKIWRWR
KWWRWRRWW,9,Synthetic,Synthetic peptide,Human erythrocytes:<10% Hemolysis=100µg/ml,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,,,0,KWWRWRRWW
RIWKIWWKR,9,Synthetic,Synthetic peptide,Human erythrocytes:<10% Hemolysis>400µg/ml,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,,,0,RIWKIWWKR
RKRWWWWFR,9,Synthetic,Synthetic peptide,Human erythrocytes:<=10% Hemolysis=100µg/ml,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,,,0,RKRWWWWFR
RLWKRWWIR,9,Synthetic,Synthetic peptide,Human erythrocytes:<10% Hemolysis>400µg/ml,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,,,0,RLWKRWWIR
RWKKWWRWL,9,Synthetic,Synthetic peptide,Human erythrocytes:<=10% Hemolysis=100µg/ml,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,,,0,RWKKWWRWL
RWKRWWRWI,9,Synthetic,Synthetic peptide,Human erythrocytes:<=10% Hemolysis=128µg/ml,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,,,0,RWKRWWRWI
GLFDIWAWWRWRR,13,Synthetic,Synthetic peptide,Human erythrocytes:10% Hemolysis=114.3±26.1µg/ml; 50% Hemolysis>250µg/ml,NL20: 50% Cell death>250µg/ml,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,,,0,GLFDIWAWWRWRR
GLFDIWKKLRWRR,13,Synthetic,Synthetic peptide,Human erythrocytes:10% Hemolysis>250µg/ml;50% Hemolysis>250µg/ml,NL20: 50% Cell death=179.2±3.8µg/ml,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,,,0,GLFDIWKKLRWRR
GLFDIWKKWRWRR,13,Synthetic,Synthetic peptide,Human erythrocytes:10% Hemolysis>250µg/ml;50% Hemolysis>250µg/ml,NL20: 50% Cell death=160.2±11.8µg/ml,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,,,0,GLFDIWKKWRWRR
GLFDIWKWWRWRR,13,Synthetic,Synthetic peptide,Human erythrocytes:10% Hemolysis=52.7±5.5µg/ml; 50% Hemolysis>250µg/ml,NL20: 50% Cell death=68.5±11.0µg/ml,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,,,0,GLFDIWKWWRWRR
GLFDKWAWWRWRR,13,Synthetic,Synthetic peptide,Human erythrocytes:10% Hemolysis>250µg/ml; 50% Hemolysis>250µg/ml,NL20: 50% Cell death=221.8±7.8µg/ml,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,,,0,GLFDKWAWWRWRR
RTRCRfLRRC,10,Synthetic,Synthetic peptide,,Madin-Darby canine kidney cells: IC50=190µg/ml; Human dermal fibroblasts: IC50=164µg/ml,,,,Anticancer; Antibacterial,Tumor active peptide,,Cyclic,Cys4<---Cys10,C9,Amidation,f=D-Phe,,0,RTRCRFLRRC
RTRCXfLRXC,10,Synthetic,Synthetic peptide,,Madin-Darby canine kidney cells: IC50=472µg/ml; Human dermal fibroblasts: IC50=461µg/ml,,,,Anticancer; Antibacterial,Tumor active peptide,,Cyclic,Cys4<---Cys10,C9,Amidation,X=diaminobutyrate; f=D-Phe,,0,RTRCXFLRXC
RTXCXfLRXC,10,Synthetic,Synthetic peptide,,Madin-Darby canine kidney cells: IC50=548µg/ml; Human dermal fibroblasts: IC50=534µg/ml,,,,Anticancer; Antibacterial,Tumor active peptide,,Cyclic,Cys4<---Cys10,C9,Amidation,X=diaminobutyrate; f=D-Phe,,0,RTXCXFLRXC
GAFLKCGESCVYLPCLTTVVGCSCQNSVCYRD,32,Hedyotis diffusa,Native peptide,,,,,induce apoptosis and inhibit proliferation and migration of prostate cancer cells,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,GAFLKCGESCVYLPCLTTVVGCSCQNSVCYRD
GAVPCGETCVYLPCITPDIGCSCQNKVCYRD,31,Hedyotis diffusa,Native peptide,,,,,induce apoptosis and inhibit proliferation and migration of prostate cancer cells,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,GAVPCGETCVYLPCITPDIGCSCQNKVCYRD
GTSCGETCVLLPCLSSVLGCTCQNKRCYKD,30,Hedyotis diffusa,Native peptide,,,,,induce apoptosis and inhibit proliferation and migration of prostate cancer cells,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,GTSCGETCVLLPCLSSVLGCTCQNKRCYKD
KGIRDWLRGFNKLRKWFLRLIKGL,24,membrane disrupting antimicrobial peptide KL15,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,KGIRDWLRGFNKLRKWFLRLIKGL
KRKLYKWFAHLIKGL,15,membrane disrupting antimicrobial peptide KL15,Synthetic peptide,,"H184B5F5/M10: IC50=150 μg/ml, testing time is 24h",,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,KRKLYKWFAHLIKGL
LRLLDRWLRLFNRLLRWLRLLRGL,24,membrane disrupting antimicrobial peptide KL15,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,LRLLDRWLRLFNRLLRWLRLLRGL
LRRLDRWLRLFNRLRRWFLRLLRGL,25,membrane disrupting antimicrobial peptide KL15,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,LRRLDRWLRLFNRLRRWFLRLLRGL
RLWRLAWRLYRLWRLTL,17,membrane disrupting antimicrobial peptide KL15,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,RLWRLAWRLYRLWRLTL
RLYRLYFRLYRLWRRLTL,18,membrane disrupting antimicrobial peptide KL15,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,RLYRLYFRLYRLWRRLTL
HXLLPPVXPLFG,12,Callyspongia aerizusa,Native peptide,,MRC-5:IC50>100µM; IC90>100µM ,,,,Anticancer; Antibacterial,Tumor active peptide,,Cyclic,SMB: His1<--->X(8),Free,Amidation,X(2)= 4-Hydroxyproline; X(8)=Daa,,0,HXLLPPVXPLFG
IXIILPPLXPII,12,Callyspongia aerizusa,Native peptide,,MRC-5:IC50=2µM; IC90=6µM ,,,,Anticancer; Antibacterial,Tumor active peptide,,Cyclic,SMB: Ile1<--->X(9),Free,Amidation,X(2)= 4-Hydroxyproline; X(9)=Daa,,0,IXIILPPLXPII
IXVILPPLXPIFG,13,Callyspongia aerizusa,Native peptide,,MRC-5:IC50=20µM; IC90=40µM ,,,,Anticancer; Antibacterial,Tumor active peptide,,Cyclic,SMB: Ile1<--->X(9),Free,Amidation,X(2)= 4-Hydroxyproline; X(9)=Daa,,0,IXVILPPLXPIFG
FWQRRIRRWRRFWQRRIRRWRR,22,Human lactoferricin derived,Native peptide,,Normal Human Dermal Fibroblasts (NHDF): LC50=13.9±0.4 µM,,,Human lactoferricin derived di-peptides deploying loop structures induce apoptosis specifically in cancer cells through targeting membranous phosphatidylserin,Anticancer; Antitumor,Tumor active peptide,,Linear,,Free,Amidation,,,0,FWQRRIRRWRRFWQRRIRRWRR
PFWRIRIRR,9,Human lactoferricin derived,Native peptide,,Normal Human Dermal Fibroblasts (NHDF): LC50=65.1±0.3 µM ,,,Human lactoferricin derived di-peptides deploying loop structures induce apoptosis specifically in cancer cells through targeting membranous phosphatidylserin,Anticancer; Antitumor,Tumor active peptide,,Linear,,Free,Amidation,,,0,PFWRIRIRR
PFWRIRIRRPRRIRIRWFP,19,Human lactoferricin derived,Native peptide,,Normal Human Dermal Fibroblasts (NHDF):LC50>101 µM,,,Human lactoferricin derived di-peptides deploying loop structures induce apoptosis specifically in cancer cells through targeting membranous phosphatidylserin,Anticancer; Antitumor,Tumor active peptide,,Linear,,Free,Amidation,,,0,PFWRIRIRRPRRIRIRWFP
PFWRRRIRIRRRRIRIRRRWFP,22,Human lactoferricin derived,Native peptide,,Normal Human Dermal Fibroblasts (NHDF): LC50=22.8±0.1 µM,,,Human lactoferricin derived di-peptides deploying loop structures induce apoptosis specifically in cancer cells through targeting membranous phosphatidylserin,Anticancer; Antitumor,Tumor active peptide,,Linear,,Free,Amidation,,,0,PFWRRRIRIRRRRIRIRRRWFP
RWKRINRQWFFWQRNIRKWR,20,Human lactoferricin derived,Native peptide,,Normal Human Dermal Fibroblasts (NHDF): LC50=61.8±0.1 µM ,,,Human lactoferricin derived di-peptides deploying loop structures induce apoptosis specifically in cancer cells through targeting membranous phosphatidylserin,Anticancer; Antitumor,Tumor active peptide,,Linear,,Free,Amidation,,,0,RWKRINRQWFFWQRNIRKWR
WWRRWWRRWRRWWRRWWR,18,Human lactoferricin derived,Native peptide,,Normal Human Dermal Fibroblasts (NHDF): LC50=9.6±0.2 µM ,,,Human lactoferricin derived di-peptides deploying loop structures induce apoptosis specifically in cancer cells through targeting membranous phosphatidylserin,Anticancer; Antitumor,Tumor active peptide,,Linear,,Free,Amidation,,,0,WWRRWWRRWRRWWRRWWR
DGVKLCDVPSGTWSGHCGSSSKCSQQCKDREHFAYGGACHYQFPSVKCFCKRQC,54,Heuchera sanguinea,Native peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Cyclic,Cys6<--->Cys54; Cys17<--->Cys39; Cys23<--->Cys48; Cys27<--->Cys50,Free,Free,,,0,DGVKLCDVPSGTWSGHCGSSSKCSQQCKDREHFAYGGACHYQFPSVKCFCKRQC
GKPICGETCFKGKCYTPGCTCSYPICKKD,29,Melicytus latifolius,Native peptide,,HFF-1: CC50=5.39±0.33µM,,,,Anticancer; Antibacterial,Tumor active peptide,,Cyclic,Cys5<--->Cys19; Cys9<--->Cys21; Cys14<--->Cys26; NCB: Gly1<--->Asp29,Free,Free,,,0,GKPICGETCFKGKCYTPGCTCSYPICKKD
GKPICGETCFKGKCYTPGCTCSYPICKKN,29,Melicytus latifolius,Native peptide,,HFF-1: CC50=5.39±0.33µM,,,,Anticancer; Antibacterial,Tumor active peptide,,Cyclic,Cys5<--->Cys19; Cys9<--->Cys21; Cys14<--->Cys26; NCB: Gly1<--->Asn29,Free,Free,,,0,GKPICGETCFKGKCYTPGCTCSYPICKKN
GKPTCGETCFKGKCYTPGCTCSYPLCKKD,29,Melicytus latifolius,Native peptide,Human erythrocytes: 50% Hemolysis>64µM,HFF-1: CC50=5.86±0.38µM,,,,Anticancer; Antibacterial,Tumor active peptide,,Cyclic,Cys5<--->Cys19; Cys9<--->Cys21; Cys14<--->Cys26; NCB: Gly1<--->Asp29,Free,Free,,,0,GKPTCGETCFKGKCYTPGCTCSYPLCKKD
GKYTCGETCFKGKCYTPGCTCSYPICKKD,29,Melicytus latifolius,Native peptide,Human erythrocytes: 50% Hemolysis>64µM,HFF-1: CC50=3.07±0.15µM,,,,Anticancer; Antibacterial,Tumor active peptide,,Cyclic,Cys5<--->Cys19; Cys9<--->Cys21; Cys14<--->Cys26; NCB: Gly1<--->Asp29,Free,Free,,,0,GKYTCGETCFKGKCYTPGCTCSYPICKKD
GLPTCGETCFKGKCYTPGCSCSYPICKKD,29,Melicytus latifolius,Native peptide,Human erythrocytes: 50% Hemolysis>64µM,HFF-1: CC50=3.13±0.16µM,,,,Anticancer; Antibacterial,Tumor active peptide,,Cyclic,Cys5<--->Cys19; Cys9<--->Cys21; Cys14<--->Cys26; NCB: Gly1<--->Asp29,Free,Free,,,0,GLPTCGETCFKGKCYTPGCSCSYPICKKD
GLPTCGETCFKGKCYTPGCSCSYPICKKN,29,Melicytus latifolius,Native peptide,Human erythrocytes: 50% Hemolysis>64µM,HFF-1: CC50=3.13±0.16µM,,,,Anticancer; Antibacterial,Tumor active peptide,,Cyclic,Cys5<--->Cys19; Cys9<--->Cys21; Cys14<--->Cys26; NCB: Gly1<--->Asn29,Free,Free,,,0,GLPTCGETCFKGKCYTPGCSCSYPICKKN
GLPTCGETCTLGKCNTPKCTCNWPICYKD,29,Melicytus chathamicus,Native peptide,Human erythrocytes: 50% Hemolysis>64µM,HFF-1: CC50=12.45±0.99µM,,,,Anticancer,Tumor active peptide,,Cyclic,Cys5<--->Cys19; Cys9<--->Cys21; Cys14<--->Cys26; NCB: Gly1<--->Asp29,Free,Free,,,0,GLPTCGETCTLGKCNTPKCTCNWPICYKD
GLPTCGETCTLGKCNTPKCTCNWPICYKN,29,Melicytus chathamicus,Native peptide,Human erythrocytes: 50% Hemolysis>64µM,HFF-1: CC50=12.45±0.99µM,,,,Anticancer,Tumor active peptide,,Cyclic,Cys5<--->Cys19; Cys9<--->Cys21; Cys14<--->Cys26; NCB: Gly1<--->Asn29,Free,Free,,,0,GLPTCGETCTLGKCNTPKCTCNWPICYKN
GFGSKPLDSFGLNFF,15,Streptomyces leeuwenhoekii,Native peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,GFGSKPLDSFGLNFF
FKKLKKLFSKLWNWK,15,Synthetic,Synthetic peptide,Human RBC: MHC=64±6.80 μM,,,,,Anticancer,Tumor active peptide,,Linear,,Acetylation,Amidation,,,0,FKKLKKLFSKLWNWK
FKKLKKLFSKLWNWKRKKRRQRRR,24,Synthetic,Synthetic peptide,Human RBC: MHC>500 μM,,,,,Anticancer,Tumor active peptide,,Linear,,Acetylation,Amidation,,,0,FKKLKKLFSKLWNWKRKKRRQRRR
fkklkklfsklwnwk,15,AMP,Synthetic peptide,Human red blood cells: low toxicity,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,FKKLKKLFSKLWNWK
KKRLKKIFKKPMVIGVTIPF,20,Rattlesnake Venom Cathelicidin,Native peptide,"Human erythrocytes: nonhemolytic up to 400 μM, and their equimolar mixture at that concentration caused only 7% hemolysis",Human Splenic Fibroblasts (HSF): IC50=12.78±0.33 µg/mL; Endometrial epithelial cells(HEEC): IC50=2.66±0.34 µg/mL; HPDE6c7 Human Pancreatic Duct Epithelial Cell: IC50=3.45±0.20 µg/mL; Normal Human Hepatic Cell (Lo-2): IC50=2.91±0.07 µg/mL; NCM460: IC50=3.04±0.10 µg/mL; CCD-19Lu: IC50=4.76±0.03 µg/mL,,,,Anticancer; Antitumor; Antimicrobial,Tumor active peptide,,Linear,,Free,Amidation,,,0,KKRLKKIFKKPMVIGVTIPF
KRFKKFFKKVKKSV,14,Rattlesnake Venom Cathelicidin,Native peptide,"Human erythrocytes: nonhemolytic up to 400 μM, and their equimolar mixture at that concentration caused only 7% hemolysis",Human Splenic Fibroblasts (HSF): IC50=12.78±0.33 µg/mL; Endometrial epithelial cells(HEEC): IC50=2.66±0.34 µg/mL; HPDE6c7 Human Pancreatic Duct Epithelial Cell: IC50=3.45±0.20 µg/mL; Normal Human Hepatic Cell (Lo-2): IC50=2.91±0.07 µg/mL; NCM460: IC50=3.04±0.10 µg/mL; CCD-19Lu: IC50=4.76±0.03 µg/mL,,,,Anticancer; Antitumor; Antimicrobial,Tumor active peptide,,Linear,,Free,Amidation,,,0,KRFKKFFKKVKKSV
YGFVMPRSGLWFR,13,Spirulina (Arthrospira) platensis,Native peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,YGFVMPRSGLWFR
CTLEW,5,walnut residual protein,Native peptide,,IEC-6: IC50>4 mg/mL; spleen lymphocytes: IC50>4 mg/mL.,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,CTLEW
GIFPIFAKLLGKVIKVASSLISKGRTK,27,Synthetic,Synthetic peptide,Mouse erythrocytes:50% Hemolysis=4±1µM,HUVEC: 50% Cell death=5.0±0.4µM,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,k=D-Lys,,0,GIFPIFAKLLGKVIKVASSLISKGRTK
IKIPSFFRNILKKVGKkAVSLIAGALKQS,29,Synthetic,Synthetic peptide,Mouse erythrocytes:50% Hemolysis=19±4µM,HUVEC: 50% Cell death=5.0±0.5µM,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,k=D-Lys,,0,IKIPSFFRNILKKVGKKAVSLIAGALKQS
FFSMIPKIAGGIASLVKNL,19,Phyllomedusa baltea,Native peptide,Horse erythrocytes: 1.4% Hemolysis=8µg/ml; Human erythrocytes: 80% Hemolysis=128µg/ml,HMEC-1: IC50=36.6µM,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,,0,FFSMIPKIAGGIASLVKNL
FFSMIPKIAGGIASLVKNLG,20,Skin Secretion of the Peruvian Purple-Sided Leaf Frog (Phyllomedusa Baltea),Native peptide,"Horse red cells: Phylloseptin-PBa was associated with a relatively low cytotoxicity (1.4%) on horse erythrocytes at a concentration of 8 mg/L, but this rose to around 80% at a concentration of 128 mg/L",HMEC-1: IC50=36.6 μM,,,,Anticancer; Antitumor; Antimicrobial,Tumor active peptide,,Linear,,Free,Free,,,0,FFSMIPKIAGGIASLVKNLG
IRKLKSWKWLRWL,13,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,IRKLKSWKWLRWL
KLLKLLKKLLKLLK,14,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Amidation,,,0,KLLKLLKKLLKLLK
KLLKLLKLKKLLKL,14,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Amidation,,,0,KLLKLLKLKKLLKL
RLLRLLRLRRLLRL,14,Synthetic,Synthetic peptide,Mice red blood cells: HD50>200 μM,HLF: IC50=21.4±1.3 μM; 293T: IC50=41.6±2.7 μM; HUVEC: IC50=19±1.5 μM,,,,Anticancer,Tumor active peptide,,Linear,,Free,Amidation,,,0,RLLRLLRLRRLLRL
RLLRLLRRLLRLLR,14,Synthetic,Synthetic peptide,Mice red blood cells: HD50=2.9±0.3 μM,HLF: IC50=6.3±0.2 μM; 293T: IC50=9.6±1.4 μM; HUVEC: IC50=8.4±0.6 μM,,,,Anticancer,Tumor active peptide,,Linear,,Free,Amidation,,,0,RLLRLLRRLLRLLR
FKIGGFIKKLWRSKLA,16,Synthetic,Synthetic peptide,,HEK293T: IC50=186.7±13.1 µM; WPMY-1: IC50=283.3±19.0 µM,,," ZXR-1 could internalize into cells by endocytosis, target on mitochondria, and induce cell apoptosis",Anticancer; Antitumor,Tumor active peptide,,Linear,,Free,Free,,,0,FKIGGFIKKLWRSKLA
FKIGGFIKKLWRSLLA,16,Synthetic,Synthetic peptide,,HEK293T: IC50=6.3±0.7 µM; WPMY-1: IC50=12.4±2.0 µM,,,ZXR-2 could cause cell membrane lysis,Anticancer; Antitumor,Tumor active peptide,,Linear,,Free,Free,,,0,FKIGGFIKKLWRSLLA
XIXIXIXRPVYXPRPRPPHPRL,22,Synthetic,Synthetic peptide,Human erythrocytes:0% Hemolysis=100-600µg/ml,HEK293: 50% Cell death>600µg/ml,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,"gu=N , N , N ', N'-tetramethylguanidino)",Free,X=Orn,,0,XIXIXIXRPVYXPRPRPPHPRL
XIXIXRPVYXPRPRPPHPRL,20,Synthetic,Synthetic peptide,Human erythrocytes:0% Hemolysis=100-600µg/ml,HEK293: 50% Cell death>600µg/ml,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,"gu=N , N , N ', N'-tetramethylguanidino)",Free,X=Orn,,0,XIXIXRPVYXPRPRPPHPRL
XWXWXRPVYXPRPRPPHPRL,20,Synthetic,Synthetic peptide,Human erythrocytes:1% Hemolysis=100µg/ml; Human erythrocytes:2% Hemolysis=600µg/ml,HEK293: 50% Cell death=640±50µg/ml,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,"gu=N , N , N ', N'-tetramethylguanidino)",Free,X=Orn,,0,XWXWXRPVYXPRPRPPHPRL
XWXWXWXRPVYXPRPRPPHPRL,22,Synthetic,Synthetic peptide,Human erythrocytes:2% Hemolysis=100-600µg/ml,HEK293: 50% Cell death=280±30µg/ml,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,"gu=N , N , N ', N'-tetramethylguanidino)",Free,X=Orn,,0,XWXWXWXRPVYXPRPRPPHPRL
KWKSFLKTFKSAAKTVLHTALKAISS,26,Synthetic,Synthetic peptide,Human erythrocytes: <5% Hemolysis=16 µM,3T3-L1: 50% Cell death=6.79 µM,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Acetylation,Amidation,,,0,KWKSFLKTFKSAAKTVLHTALKAISS
KWKSFLKTFKSAEKTVLHTALKAISS,26,Synthetic,Synthetic peptide,Human erythrocytes:<5% Hemolysis=>500µM,3T3-L1:50% Cell death>125µM,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Acetylation,Amidation,,,0,KWKSFLKTFKSAEKTVLHTALKAISS
KWKSFLKTFKSALKTVLHTALKAISS,26,Synthetic,Synthetic peptide,Human erythrocytes: <5% Hemolysis=4 µM,3T3-L1: 50% Cell death=6.55 µM,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Acetylation,Amidation,,,0,KWKSFLKTFKSALKTVLHTALKAISS
ATCETPSKHFNGLCIRSSNCASVCHGEHFTDGRCQGVRRRCMCLKPC,47,Plant defensins,Native peptide,,,,,PaDef defensin from avocado (Persea americana) fruit is cytotoxic to MCF-7 cells via the induction of mitochondrial apoptosis,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,ATCETPSKHFNGLCIRSSNCASVCHGEHFTDGRCQGVRRRCMCLKPC
TSLDASIWAMMQNA,14,derived from the extracellular sequence of the human TGF-β type III receptor,Native peptide,,,Transforming Growth Factor beta,,P144 induced an upregulation of SMAD7 and downregulation of SKI through inhibition of the TGF-β pathway.,Anticancer,Tumor active peptide##Cancer targeted peptides,,Linear,,Free,Free,,,0,TSLDASIWAMMQNA
RECKTESHRFKGPCITKPPCRKACISEKFTDGHCSKILRRCLCTKPC,47,Synthetic,Synthetic peptide,,,,,,Anticancer; Antifungal,Tumor active peptide,,Cyclic,Cys23<--->Cys47; Cys14<---Cys34; Cys20<--->Cys41; Cys24<--->Cys43,Free,Free,,,0,RECKTESHRFKGPCITKPPCRKACISEKFTDGHCSKILRRCLCTKPC
RECKTESNTFPGICITKPPCRKACISEKFSGGDCSKILRRCLCTKPC,47,Synthetic,Synthetic peptide,,,,,,Anticancer; Antifungal,Tumor active peptide,,Cyclic,Cys23<--->Cys47; Cys14<---Cys34; Cys20<--->Cys41; Cys24<--->Cys43,Free,Free,,,0,RECKTESNTFPGICITKPPCRKACISEKFSGGDCSKILRRCLCTKPC
RECKTESNTFPGICITKPPCRKACISEKFTDGHCRGFRRRCLCTKPC,47,Synthetic,Synthetic peptide,,,,,,Anticancer; Antifungal,Tumor active peptide,,Cyclic,Cys23<--->Cys47; Cys14<---Cys34; Cys20<--->Cys41; Cys24<--->Cys43,Free,Free,,,0,RECKTESNTFPGICITKPPCRKACISEKFTDGHCRGFRRRCLCTKPC
RECKTESNTFPGICITKPPCRKACISEKFTDGHCSKILRRCFCTRPC,47,Synthetic,Synthetic peptide,,,,,,Anticancer; Antifungal,Tumor active peptide,,Cyclic,Cys23<--->Cys47; Cys14<---Cys34; Cys20<--->Cys41; Cys24<--->Cys43,Free,Free,,,0,RECKTESNTFPGICITKPPCRKACISEKFTDGHCSKILRRCFCTRPC
RECKTESNTFPGICITKPPCRKACLTEGFTDGHCSKILRRCLCTKPC,47,Synthetic,Synthetic peptide,,,,,,Anticancer; Antifungal,Tumor active peptide,,Cyclic,Cys23<--->Cys47; Cys14<---Cys34; Cys20<--->Cys41; Cys24<--->Cys43,Free,Free,,,0,RECKTESNTFPGICITKPPCRKACLTEGFTDGHCSKILRRCLCTKPC
RTCESQSHRFKGPCARDSNCATVCLTEGFSGGDCRGFRRRCFCTRPC,47,Synthetic,Synthetic peptide,,,,,,Anticancer; Antifungal,Tumor active peptide,,Cyclic,Cys23<--->Cys47; Cys14<---Cys34; Cys20<--->Cys41; Cys24<--->Cys43,Free,Free,,,0,RTCESQSHRFKGPCARDSNCATVCLTEGFSGGDCRGFRRRCFCTRPC
RTCESQSNTFPGICITKPPCRKACISEKFTDGHCSKILRRCLCTKPC,47,Synthetic,Synthetic peptide,,,,,,Anticancer; Antifungal,Tumor active peptide,,Cyclic,Cys23<--->Cys47; Cys14<---Cys34; Cys20<--->Cys41; Cys24<--->Cys43,Free,Free,,,0,RTCESQSNTFPGICITKPPCRKACISEKFTDGHCSKILRRCLCTKPC
RECKTESNTFPGICITKPPCRKACISEKFTDGHCSKILRRCLCTKPC,47,Nicotiana alata,Native peptide,Human erythrocytes: 1.5% Hemolysis=50 µM,Human dermal fibroblasts: 100% Killing=25 µM,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Cyclic,Cys3<--->Cys47; Cys14<--->Cys34; Cys20<--->Cys41; Cys24<--->Cys43,Free,Free,,,0,RECKTESNTFPGICITKPPCRKACISEKFTDGHCSKILRRCLCTKPC
MQFITDLIKKAVDFFKGLFDNK,22,Synthetic,Synthetic peptide,Human erythrocytes:10% Hemolysis=12.36µM,,,,,Anticancer; Antibacterial,Tumor active peptide##Membrane lysis,,Linear,,Free,Free,,,0,MQFITDLIKKAVDFFKGLFDNK
MQFITDLIKKAVDVFKGLFGNK,22,Synthetic,Synthetic peptide,Human erythrocytes:10% Hemolysis=12.5µM,,,,,Anticancer; Antibacterial,Tumor active peptide##Membrane lysis,,Linear,,Free,Free,,,0,MQFITDLIKKAVDVFKGLFGNK
RWKIFKKIEKMGRNIRDGIVKAGPAIEVLGSAKAIGK,37,Bombyx mori,Native peptide,Human erythrocytes: 5% Hemolysis=134.6µg/ml,NIH 3T3: Not active up to 20 µM,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,,,0,RWKIFKKIEKMGRNIRDGIVKAGPAIEVLGSAKAIGK
GIKHILFMAKTKLPRATCTAEIKENCDRKK,30,Sarcophilus harrisii,Native peptide,Human erythrocytes:5% Hemolysis=1-500µg/ml,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Free,,,0,GIKHILFMAKTKLPRATCTAEIKENCDRKK
KREDFLDQIIRDFRNFIYQKYRRLRDEFRKLRDILSG,37,Sarcophilus harrisii,Native peptide,Human erythrocytes:5% Hemolysis=1-500µg/ml,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Free,,,0,KREDFLDQIIRDFRNFIYQKYRRLRDEFRKLRDILSG
KRIGLIRLIGKILRGLRRLG,20,Sarcophilus harrisii,Native peptide,Human erythrocytes:5% Hemolysis=1-31.25µg/ml; 7% Hemolysis=62.5µg/ml; 12% Hemolysis=125µg/ml; 30% Hemolysis=250µg/ml,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Free,,,0,KRIGLIRLIGKILRGLRRLG
KRIRFFERIRDRLRDLGNRIKNRIRDFFS,29,Sarcophilus harrisii,Native peptide,Human erythrocytes:8% Hemolysis=31.25µg/ml; Human erythrocytes:10% Hemolysis=62.5µg/ml; Human erythrocytes:12% Hemolysis=125µg/ml,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Free,,,0,KRIRFFERIRDRLRDLGNRIKNRIRDFFS
KRMGIFHLFWAGLRKLGNLIKNKIQQGIENFLG,33,Sarcophilus harrisii,Native peptide,Human erythrocytes:5% Hemolysis=1-500µg/ml,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Free,,,0,KRMGIFHLFWAGLRKLGNLIKNKIQQGIENFLG
TFKRKNGSRKNGHRPGGYSLIALGNKKVLKAPYMESI,37,Sarcophilus harrisii,Native peptide,Human erythrocytes:5% Hemolysis=1-500µg/ml,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Free,,,0,TFKRKNGSRKNGHRPGGYSLIALGNKKVLKAPYMESI
CGRRKRRRGCRRDSDCPGACICRYwKVCGSGSDGGV,36,Synthetic,Synthetic peptide,Human red blood cells:  no hemolytic activity(as show in Fig.4),HUVEC: IC50=10.83±0.09 μM,pigment epithelium-derived factor; somatostatin,,,Anticancer; Antitumor,Tumor active peptide##Cancer targeted peptides,,Cyclic,,Free,Free,w=D-Tryptophane,,0,CGRRKRRRGCRRDSDCPGACICRYWKVCGSGSDGGV
CPKILKKCRRDSDCPGACICRGNGYCGRRKRRRG,34,Synthetic,Synthetic peptide,Human red blood cells:  no hemolytic activity(as show in Fig.4),HUVEC: IC50=34.95±0.03 μM,pigment epithelium-derived factor; somatostatin,,,Anticancer; Antitumor,Tumor active peptide##Cancer targeted peptides,,Cyclic,,Free,Free,,,0,CPKILKKCRRDSDCPGACICRGNGYCGRRKRRRG
CPKILKKCRRDSDCPGACICRGNGYCGSGSDGGV,34,Synthetic,Synthetic peptide,Human red blood cells:  no hemolytic activity(as show in Fig.4),HUVEC: IC50>100 μM,pigment epithelium-derived factor; somatostatin,,,Anticancer; Antitumor,Tumor active peptide##Cancer targeted peptides##Induce apoptosis,,Cyclic,,Free,Free,,,0,CPKILKKCRRDSDCPGACICRGNGYCGSGSDGGV
CPKILKKCRRDSDCPGACICRGNGYCRFwKTW,32,Synthetic,Synthetic peptide,Human red blood cells:  no hemolytic activity(as show in Fig.4),HUVEC: IC50>100 μM,pigment epithelium-derived factor; somatostatin,,,Anticancer; Antitumor,Tumor active peptide##Cancer targeted peptides,,Cyclic,,Free,Free,w=D-Tryptophane,,0,CPKILKKCRRDSDCPGACICRGNGYCRFWKTW
CPKILKKCRRDSDCPGACICRGNGYCYHLNQPF,33,Synthetic,Synthetic peptide,Human red blood cells:  no hemolytic activity(as show in Fig.4),HUVEC: IC50=50.16±0.15 μM,pigment epithelium-derived factor; somatostatin,,,Anticancer; Antitumor,Tumor active peptide##Cancer targeted peptides,,Cyclic,,Free,Free,,,0,CPKILKKCRRDSDCPGACICRGNGYCYHLNQPF
CPKILKKCRRDSDCPGACICRYwKVCGSGSDGGV,34,Synthetic,Synthetic peptide,Human red blood cells:  no hemolytic activity(as show in Fig.4),HUVEC: IC50=17.12±0.05 μM,pigment epithelium-derived factor; somatostatin,,,Anticancer; Antitumor,Tumor active peptide##Cancer targeted peptides,,Cyclic,,Free,Free,w=D-Tryptophane,,0,CPKILKKCRRDSDCPGACICRYWKVCGSGSDGGV
CPKILKKCRRDSDCPGACICRYwKVCGYHLNQPFG,35,Synthetic,Synthetic peptide,Human red blood cells:  no hemolytic activity(as show in Fig.4),HUVEC: IC50=27.06±0.06 μM,pigment epithelium-derived factor; somatostatin,,,Anticancer; Antitumor,Tumor active peptide##Cancer targeted peptides,,Cyclic,,Free,Free,w=D-Tryptophane,,0,CPKILKKCRRDSDCPGACICRYWKVCGYHLNQPFG
CRRKRRRCRRDSDCPGACICRGNGYCGSGSDGGV,34,Synthetic,Synthetic peptide,Human red blood cells:  no hemolytic activity(as show in Fig.4),HUVEC: IC50>100 μM,pigment epithelium-derived factor; somatostatin,,,Anticancer; Antitumor,Tumor active peptide##Cancer targeted peptides,,Cyclic,,Free,Free,,,0,CRRKRRRCRRDSDCPGACICRGNGYCGSGSDGGV
CRRKRRRICFPDGR,14,Synthetic,Synthetic peptide,Human red blood cells:  no hemolytic activity(as show in Fig.4),HUVEC: IC50>100 μM,pigment epithelium-derived factor; somatostatin,,,Anticancer; Antitumor,Tumor active peptide##Cancer targeted peptides,,Cyclic,,Free,Free,,,0,CRRKRRRICFPDGR
CTKSIPPICFPDGR,14,Synthetic,Synthetic peptide,Human red blood cells:  no hemolytic activity(as show in Fig.4),HUVEC: IC50>100 μM,pigment epithelium-derived factor; somatostatin,,,Anticancer; Antitumor,Tumor active peptide##Cancer targeted peptides,,Cyclic,,Free,Free,,,0,CTKSIPPICFPDGR
CTKSIPPICRFwKTW,15,Synthetic,Synthetic peptide,Human red blood cells:  no hemolytic activity(as show in Fig.4),HUVEC: IC50>100 μM,pigment epithelium-derived factor; somatostatin,,,Anticancer; Antitumor,Tumor active peptide##Cancer targeted peptides,,Cyclic,,Free,Free,w=D-Tryptophane,,0,CTKSIPPICRFWKTW
CTKSIPPICRRKRRR,15,Synthetic,Synthetic peptide,Human red blood cells:  no hemolytic activity(as show in Fig.4),HUVEC: IC50>100 μM,pigment epithelium-derived factor; somatostatin,,,Anticancer; Antitumor,Tumor active peptide##Cancer targeted peptides,,Cyclic,,Free,Free,,,0,CTKSIPPICRRKRRR
CTKSIPPICYHLNQPF,16,Synthetic,Synthetic peptide,Human red blood cells:  no hemolytic activity(as show in Fig.4),HUVEC: IC50=27.89±0.11 μM,pigment epithelium-derived factor; somatostatin,,,Anticancer; Antitumor,Tumor active peptide##Cancer targeted peptides,,Cyclic,,Free,Free,,,0,CTKSIPPICYHLNQPF
CTKSIPPICYwKV,13,Synthetic,Synthetic peptide,Human red blood cells:  no hemolytic activity(as show in Fig.4),HUVEC: IC50=18.32±0.05 μM,pigment epithelium-derived factor; somatostatin,,,Anticancer; Antitumor,Tumor active peptide##Cancer targeted peptides,,Cyclic,,Free,Free,w=D-Tryptophane,,0,CTKSIPPICYWKV
RFwKTW,6,Synthetic,Synthetic peptide,Human red blood cells:  no hemolytic activity(as show in Fig.4),HUVEC: IC50>100 μM,pigment epithelium-derived factor; somatostatin,,,Anticancer; Antitumor,Tumor active peptide##Cancer targeted peptides,,Linear,,Free,Free,w=D-Tryptophane,,0,RFWKTW
RRKRRR,6,Synthetic,Synthetic peptide,Human red blood cells:  no hemolytic activity(as show in Fig.4),HUVEC: IC50=44.64±0.03 μM,pigment epithelium-derived factor; somatostatin,,,Anticancer; Antitumor,Tumor active peptide##Cancer targeted peptides,,Linear,,Free,Free,,,0,RRKRRR
YHLNQPF,7,Synthetic,Synthetic peptide,Human red blood cells:  no hemolytic activity(as show in Fig.4),HUVEC: IC50=19.40±0.08 μM,pigment epithelium-derived factor; somatostatin,,,Anticancer; Antitumor,Tumor active peptide##Cancer targeted peptides,,Linear,,Free,Free,,,0,YHLNQPF
YwKV,4,Synthetic,Synthetic peptide,Human red blood cells:  no hemolytic activity(as show in Fig.4),HUVEC: IC50=57.54±0.04 μM,pigment epithelium-derived factor; somatostatin,,,Anticancer; Antitumor,Tumor active peptide##Cancer targeted peptides,,Linear,,Free,Free,w=D-Tryptophane,,0,YWKV
FKAGGFIKKLWRSLLA,16,Synthetic,Synthetic peptide,,HEK293T: IC50=24.1±3.2 μM; WPMY-1: IC50=43.2±4.9 μM,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,FKAGGFIKKLWRSLLA
FKIGGFAKKLWRSLLA,16,Synthetic,Synthetic peptide,,HEK293T: IC50=40.0±5.5 μM; WPMY-1: IC50=19.4±5.3 μM,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,FKIGGFAKKLWRSLLA
FKIGGFIKKAWRSLLA,16,Synthetic,Synthetic peptide,,HEK293T: IC50=48.5±4.9 μM; WPMY-1: IC50=40.1±6.9 μM,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,FKIGGFIKKAWRSLLA
FKIGGFIKKLWRSALA,16,Synthetic,Synthetic peptide,,HEK293T: IC50=36.1±4.7 μM; WPMY-1: IC50=19.9±6.3 μM,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,FKIGGFIKKLWRSALA
FKIGGFIKKLWRSLAA,16,Synthetic,Synthetic peptide,,HEK293T: IC50=27.6±2.7 μM; WPMY-1: IC50=12.7±3.1 μM,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,FKIGGFIKKLWRSLAA
FIGAIARLLSK,11,Scorpion venom,Native peptide,,,,,BmKn-2 exerts selective cytotoxic effects on human oral cancer cells by inducting apoptosis via a p53-dependent intrinsic apoptotic pathway. BmKn-2 peptide originally derived from a natural source shows great promise as a candidate treatment for oral cancer,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,FIGAIARLLSK
FIGAIARLLSKIF,13,Scorpion venom,Native peptide,,,,,BmKn-2 exerts selective cytotoxic effects on human oral cancer cells by inducting apoptosis via a p53-dependent intrinsic apoptotic pathway. BmKn-2 peptide originally derived from a natural source shows great promise as a candidate treatment for oral cancer,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,FIGAIARLLSKIF
KRIVQRIKDFLR,12,Synthetic,Synthetic peptide,Human erythrocytes: 50% Hemolysis>800µM; 10.6% Hemolysis=100µM; <5% Hemolysis=256µg/ml; Rabbit erythrocytes: 73% Hemolysis=125µg/ml,NIH 3T3: EC50=0.8µg/ml; HaCat: IC50=74.6µg/ml,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,,,0,KRIVQRIKDFLR
WWWLKKIW,8,Synthetic,Synthetic peptide,Human erythrocytes:50% Hemolysis=40µM; Pig erythrocytes:50% Hemolysis=55µM; Chicken erythrocytes:50% Hemolysis=50µM,HEK293:50% Cell death=50µM; HaCat:50% Cell death=50µM,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Free,,,0,WWWLKKIW
WWWLKRIW,8,Synthetic,Synthetic peptide,Human erythrocytes:50% Hemolysis=30µM; Pig erythrocytes:50% Hemolysis=50µM; Chicken erythrocytes:50% Hemolysis=35µM,HEK293:50% Cell death=55µM; HaCat:50% Cell death=60µM,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Free,,,0,WWWLKRIW
WWWLRKIW,8,Synthetic,Synthetic peptide,Human erythrocytes:50% Hemolysis=30µM; Pig erythrocytes:50% Hemolysis=40µM; Chicken erythrocytes:50% Hemolysis=35µM,HEK293:50% Cell death=60µM; HaCat:50% Cell death=60µM,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Free,,,0,WWWLRKIW
WWWLRRIW,8,Synthetic,Synthetic peptide,Human erythrocytes:50% Hemolysis=20µM; Pig erythrocytes:50% Hemolysis=40µM; Chicken erythrocytes:50% Hemolysis=55µM,HEK293:50% Cell death=70µM; HaCat:50% Cell death=70µM,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Free,,,0,WWWLRRIW
WGEAFSAGVHRLANGGNG,18,Synthetic,Synthetic peptide,Human erythrocytes:10% Hemolysis>71.15µM,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,,0,WGEAFSAGVHRLANGGNG
WGRAFRRGVRRLARGGRR,18,Synthetic,Synthetic peptide,Human erythrocytes:10% Hemolysis>58.64µM,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,,0,WGRAFRRGVRRLARGGRR
WGRAFRRLVRRLARGLRR,18,Synthetic,Synthetic peptide,Human erythrocytes:10% Hemolysis>55.78µM,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,,0,WGRAFRRLVRRLARGLRR
WGRAFSAGVHRLANGGNG,18,Synthetic,Synthetic peptide,Human erythrocytes:10% Hemolysis>70.09µM,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,,0,WGRAFSAGVHRLANGGNG
WGRAFSAGVHRLARGGRG,18,Synthetic,Synthetic peptide,Human erythrocytes:10% Hemolysis>67.01µM,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,,0,WGRAFSAGVHRLARGGRG
WGRAFSRGVRRLARGGRG,18,Synthetic,Synthetic peptide,Human erythrocytes:10% Hemolysis>63.54µM,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,,0,WGRAFSRGVRRLARGGRG
WLRAFRRLVRRLARGLRR,18,Synthetic,Synthetic peptide,Human erythrocytes:10% Hemolysis=27.22µM,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,,0,WLRAFRRLVRRLARGLRR
WLRAFRRLVRRLARLLRR,18,Synthetic,Synthetic peptide,Human erythrocytes:10% Hemolysis=53.18µM,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,,0,WLRAFRRLVRRLARLLRR
RYRRKKKMKKALQYIKLLKE,20,Synthetic,Synthetic peptide,Human erythrocytes: 14% Hemolysis=350µM,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,RYRRKKKMKKALQYIKLLKE
FFPGIIKVAGAILPTAICAITKRC,24,Synthetic,Synthetic peptide,Human erythrocytes: 60% Hemolysis=50µM; 85% Hemolysis=100µM,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,FFPGIIKVAGAILPTAICAITKRC
FFPGIIKVASAILPTAICAITKRC,24,Hydrophylax bahuvistara,Native peptide,Human erythrocytes:60% Hemolysis=50µM; 80% Hemolysis=100µM,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,FFPGIIKVASAILPTAICAITKRC
GLFKKLRRKIKKGFKKIFKRL,21,Synthetic,Synthetic peptide,Sheep erythrocytes(Not active up to 300 µg/ml,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,GLFKKLRRKIKKGFKKIFKRL
GLFKKLRRKIKKGFKKIFKRLPPIGVGVSIPLAGKR,36,Alligator mississippiensis,Native peptide,Sheep erythrocytes(Not active up to 300 µg/ml,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,GLFKKLRRKIKKGFKKIFKRLPPIGVGVSIPLAGKR
KIKKGFKKIFKRLPPIGVGVSIPLAGKR,28,Synthetic,Synthetic peptide,Sheep erythrocytes(Not active up to 300 µg/ml,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,KIKKGFKKIFKRLPPIGVGVSIPLAGKR
XXXVXAaXXXX,11,Tolypocladium inflatum,Native peptide,,"Vero E6: <10% Killing=5µM, 25% Killing=17µM; Fcwf-4: 0% Killing=4µM, 40% Killing=12µM",,,,Anticancer; Antiviral,Tumor active peptide,,Cyclic,NCB: X(1)<--->X(11),Free,Free,X(1)=alpha-Aminobutyrate; X(2)=Sarcosine; X(3)=METH-Leu; X(5)=METH-Leu; X(7)=D-Ala; X(8)=METH-Leu; X(9)=METH-Leu; X(10)=METH-Val; X(11)=N-methyl-(4R)-4-[(E)-but-2-enyl]-4-methyl-L-threonyl,,0,XXXVXAAXXXX
ASVVNKLTGGVAGLLK,16,Bacillus subtilis,Native peptide,Mouse erythrocytes: <10% Hemolysis=160µM; 10% Hemolysis=320µM,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,ASVVNKLTGGVAGLLK
FASGIAGMAGKLF,13,Synthetic,Synthetic peptide,Rat erythrocytes: 50% Hemolysis>200µM; Human erythrocytes: 50% Hemolysis	>100µM,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,,0,FASGIAGMAGKLF
RWKIFKKIERVGQNVRDGIIKAGKAIQVLGTAKALGK,37,ABP-dHC-Cecropin A and its analog,Synthetic peptide,Human red blood cells (hRBCs): only 3% hemolysis was observed at the concentration of 800 µM,"HEK-293, PBMCs: no cytotoxicity toward HEK-293 cells or PBMCs, even at the highest concentration of 640 µM.",,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,RWKIFKKIERVGQNVRDGIIKAGKAIQVLGTAKALGK
RWKIFKKIERVGQNVRDGIIKAGPAIQVLGTAKALGK,37,ABP-dHC-Cecropin A and its analog,Synthetic peptide,Human red blood cells (hRBCs): only 3% hemolysis was observed at the concentration of 800 µM,"HEK-293, PBMCs: no cytotoxicity toward HEK-293 cells or PBMCs, even at the highest concentration of 640 µM.",,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,RWKIFKKIERVGQNVRDGIIKAGPAIQVLGTAKALGK
ALlVNx,6,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Cyclic,NCB: Ala1<--->x(6),Free,Free,l=D-Leu; x(6)=D-Orn,,0,ALLVNX
lLWVNx,6,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Cyclic,NCB: Ile1<--->x(6),Free,Free,l=D-Leu; x(6)=D-Orn,,0,LLWVNX
WAlVNx,6,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Cyclic,NCB: Trp1<--->x(6),Free,Free,l=D-Leu; x(6)=D-Orn,,0,WALVNX
WIlVNx,6,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Cyclic,NCB: Trp1<--->x(6),Free,Free,l=D-Leu; x(6)=D-Orn,,0,WILVNX
WLaVNx,6,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Cyclic,NCB: Trp1<--->x(6),Free,Free,l=D-Leu; x(6)=D-Orn,,0,WLAVNX
WLIVNx,6,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Cyclic,NCB: Trp1<--->x(6),Free,Free,x(6)=D-Orn,,0,WLIVNX
WLlANx,6,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Cyclic,NCB: Trp1<--->x(6),Free,Free,l=D-Leu; x(6)=D-Orn,,0,WLLANX
WLlIIx,6,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Cyclic,NCB: Trp1<--->x(6),Free,Free,l=D-Leu; x(6)=D-Orn,,0,WLLIIX
WLlINx,6,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Cyclic,NCB: Trp1<--->x(6),Free,Free,l=D-Leu; x(6)=D-Orn,,0,WLLINX
WLlISx,6,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Cyclic,NCB: Trp1<--->x(6),Free,Free,l=D-Leu; x(6)=D-Orn,,0,WLLISX
WLlIXx,6,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Cyclic,NCB: Trp1<--->x(6),Free,Free,l=D-Leu; x(6)=D-Orn,,0,WLLIXX
WLlVAx,6,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Cyclic,NCB: Trp1<--->x(6),Free,Free,l=D-Leu; x(6)=D-Orn,,0,WLLVAX
WLlVxx,6,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Cyclic,NCB: Trp1<--->x(6),Free,Free,l=D-Leu; x(5)=D-Orn; x(6)=D-Orn,,0,WLLVXX
WLxIxx,6,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Cyclic,NCB: Trp1<--->x(6),Free,Free,x(3)=D-4-Cl-Phe; x(5)=D-Orn; x(6)=D-Orn,,0,WLXIXX
WLxVNx,6,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Cyclic,NCB: Trp1<--->x(6),Free,Free,x(3)=D-4-Cl-Phe; x(6)=D-Orn,,0,WLXVNX
WLxVXx,6,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Cyclic,NCB: Trp1<--->x(6),Free,Free,x(3)=METH-Leu; x(5)=METH-Asn; x(6)=D-Orn,,0,WLXVXX
WxlVNx,6,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Cyclic,NCB: Trp1<--->x(6),Free,Free,x(2)=D-4-Cl-Phe; l=D-Leu; x(6)=D-Orn,,0,WXLVNX
WXlVXx,6,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Cyclic,NCB: Trp1<--->x(6),Free,Free,x(2)=METH-Leu; l=D-Leu; x(5)=METH-Asn; x(6)=D-Orn,,0,WXLVXX
WXlXNx,6,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Cyclic,NCB: Trp1<--->x(6),Free,Free,x(2)=METH-Leu; l=D-Leu; x(5)=METH-Val; x(6)=D-Orn,,0,WXLXNX
xLlVNx,6,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Cyclic,NCB: x(1)<--->x(6),Free,Free,x(1)=D-4-Cl-Phe; l=D-Leu; x(6)=D-Orn,,0,XLLVNX
FLPIVGLLKSLLK,13,Synthetic,Synthetic peptide,Horse erythrocytes: <10% Hemolysis=48µM,PBMC: IC50=52µM,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,,0,FLPIVGLLKSLLK
LLPIVGNLLKSLL,13,Rana temporaria,Native peptide,Human erythrocytes: 5% Hemolysis=32 µM,Human PBMC: 10% Killing=96 µM; Vero cells: 50% Cytotoxicity=90.4 µg/ml; HEK293: 50% Cytotoxicity=84 µg/ml,,,,Anticancer; Antibacterial; Antifungal; Antiviral,Tumor active peptide,,Linear,,Free,Amidation,,,0,LLPIVGNLLKSLL
KKLFKKILKAL,11,Synthetic,Synthetic peptide,Rabbit erythrocytes: 4% Hemolysis=160µM,GES-1: IC50=77.3±7.4µM,,,,Anticancer,Tumor active peptide,,Linear,,Free,Amidation,,,0,KKLFKKILKAL
KKLFKKILKDL,11,Synthetic,Synthetic peptide,Rabbit erythrocytes: 11% Hemolysis=160µM,GES-1: IC50>100µM,,,,Anticancer,Tumor active peptide,,Linear,,Free,Amidation,,,0,KKLFKKILKDL
KKLFKKILKEL,11,Synthetic,Synthetic peptide,Rabbit erythrocytes: 6.5% Hemolysis=160µM,GES-1: IC50>100µM,,,,Anticancer,Tumor active peptide,,Linear,,Free,Amidation,,,0,KKLFKKILKEL
KKLFKKILKGL,11,Synthetic,Synthetic peptide,Rabbit erythrocytes: 11% Hemolysis=160µM,GES-1: IC50>100µM,,,,Anticancer,Tumor active peptide,,Linear,,Free,Amidation,,,0,KKLFKKILKGL
KKLFKKILKHL,11,Synthetic,Synthetic peptide,Rabbit erythrocytes: 4% Hemolysis=160µM,GES-1: IC50=72.3±7.4µM,,,,Anticancer,Tumor active peptide,,Linear,,Free,Amidation,,,0,KKLFKKILKHL
KKLFKKILKIL,11,Synthetic,Synthetic peptide,Rabbit erythrocytes: 7.5% Hemolysis=160µM,GES-1: IC50=76.9±6.7µM,,,,Anticancer,Tumor active peptide,,Linear,,Free,Amidation,,,0,KKLFKKILKIL
KKLFKKILKLL,11,Synthetic,Synthetic peptide,Rabbit erythrocytes: 5% Hemolysis=160µM,GES-1: IC50=67.4±8.3µM,,,,Anticancer,Tumor active peptide,,Linear,,Free,Amidation,,,0,KKLFKKILKLL
KKLFKKILKQL,11,Synthetic,Synthetic peptide,Rabbit erythrocytes: 6.5% Hemolysis=160µM,GES-1: IC50=77.9±5.6µM,,,,Anticancer,Tumor active peptide,,Linear,,Free,Amidation,,,0,KKLFKKILKQL
KKLFKKILKRL,11,Synthetic,Synthetic peptide,Rabbit erythrocytes: 5% Hemolysis=160µM,GES-1: IC50>100µM,,,,Anticancer,Tumor active peptide,,Linear,,Free,Amidation,,,0,KKLFKKILKRL
KKLFKKILKTL,11,Synthetic,Synthetic peptide,Rabbit erythrocytes: 5% Hemolysis=160µM,GES-1: IC50=82.8±9.2µM,,,,Anticancer,Tumor active peptide,,Linear,,Free,Amidation,,,0,KKLFKKILKTL
FRRFFKWFRRFFKFF,15,AMP,Synthetic peptide,,,,,,Anticancer; Antimicrobial,Tumor active peptide,,Linear,,Free,Free,,,0,FRRFFKWFRRFFKFF
FRRFFKWFRRPFKFF,15,AMP,Synthetic peptide,,,,,,Anticancer; Antimicrobial,Tumor active peptide,,Linear,,Free,Free,,,0,FRRFFKWFRRPFKFF
FRRFFKWPRRFFKFF,15,AMP,Synthetic peptide,,,,,,Anticancer; Antimicrobial,Tumor active peptide,,Linear,,Free,Free,,,0,FRRFFKWPRRFFKFF
FRRFFKWPRRPFKFF,15,AMP,Synthetic peptide,,,,,,Anticancer; Antimicrobial,Tumor active peptide,,Linear,,Free,Free,,,0,FRRFFKWPRRPFKFF
FRRPFKWFRRFFKFF,15,AMP,Synthetic peptide,,,,,,Anticancer; Antimicrobial,Tumor active peptide,,Linear,,Free,Free,,,0,FRRPFKWFRRFFKFF
FRRPFKWPRRFFKFF,15,AMP,Synthetic peptide,,,,,,Anticancer; Antimicrobial,Tumor active peptide,,Linear,,Free,Free,,,0,FRRPFKWPRRFFKFF
KKLFKKILKY,10,antimicrobial peptides,Synthetic peptide,Rabbit red blood cells: very low hemolytic activity even at the concentration of 160 μm(as show in fig.3),GES-1: IC50>100 μM,,,"disrupt the cell membrane, trigger the cytochrome C release into cytoplasm, and ultimately lead to apoptosis",Anticancer; Antitumor; Antimicrobial,Tumor active peptide,,Linear,,Free,Free,,,0,KKLFKKILKY
KKLFKKILKYL,11,antimicrobial peptides,Synthetic peptide,Human erythrocytes: 22 ± 2.8% Hemolysis=150µM,GES-1: IC50=57.9±5.2 µM; NIH 3T3: IC50=62.5 ± 6.4 µM,,,"disrupt the cell membrane, trigger the cytochrome C release into cytoplasm, and ultimately lead to apoptosis",Anticancer; Antitumor; Antimicrobial,Cell-penetrating peptides,,Linear,,Free,Amidation,,,0,KKLFKKILKYL
KKLFKKILKYLK,12,antimicrobial peptides,Synthetic peptide,Rabbit red blood cells: very low hemolytic activity even at the concentration of 160 μm(as show in fig.3),GES-1: IC50=52.3±4.5 μM,,,"disrupt the cell membrane, trigger the cytochrome C release into cytoplasm, and ultimately lead to apoptosis",Anticancer; Antitumor; Antimicrobial,Tumor active peptide,,Linear,,Free,Free,,,0,KKLFKKILKYLK
KKLFKKILKYLKK,13,antimicrobial peptides,Synthetic peptide,Rabbit red blood cells: very low hemolytic activity even at the concentration of 160 μm(as show in fig.3),GES-1: IC50=89.6±7.2 μM,,,"disrupt the cell membrane, trigger the cytochrome C release into cytoplasm, and ultimately lead to apoptosis",Anticancer; Antitumor; Antimicrobial,Tumor active peptide,,Linear,,Free,Free,,,0,KKLFKKILKYLKK
KKLFKKILKYLKKL,14,antimicrobial peptides,Synthetic peptide,Rabbit red blood cells: very low hemolytic activity even at the concentration of 160 μm(as show in fig.3),GES-1: IC50>100 μM,,,"disrupt the cell membrane, trigger the cytochrome C release into cytoplasm, and ultimately lead to apoptosis",Anticancer; Antitumor; Antimicrobial,Tumor active peptide,,Linear,,Free,Free,,,0,KKLFKKILKYLKKL
KLKKLFKKILKY,12,antimicrobial peptides,Synthetic peptide,Rabbit red blood cells: very low hemolytic activity even at the concentration of 160 μm(as show in fig.3),GES-1: IC50=76.7±6.2 μM,,,"disrupt the cell membrane, trigger the cytochrome C release into cytoplasm, and ultimately lead to apoptosis",Anticancer; Antitumor; Antimicrobial,Tumor active peptide,,Linear,,Free,Free,,,0,KLKKLFKKILKY
LKKLFKKILKY,11,antimicrobial peptides,Synthetic peptide,Rabbit red blood cells: very low hemolytic activity even at the concentration of 160 μm(as show in fig.3),GES-1: IC50=64.2±5.6 μM,,,"disrupt the cell membrane, trigger the cytochrome C release into cytoplasm, and ultimately lead to apoptosis",Anticancer; Antitumor; Antimicrobial,Tumor active peptide,,Linear,,Free,Free,,,0,LKKLFKKILKY
LKKLFKKILKYL,12,antimicrobial peptides,Synthetic peptide,Rabbit red blood cells: very low hemolytic activity even at the concentration of 160 μm(as show in fig.3),GES-1: IC50=73.7±4.5 μM,,,"disrupt the cell membrane, trigger the cytochrome C release into cytoplasm, and ultimately lead to apoptosis",Anticancer; Antitumor; Antimicrobial,Tumor active peptide,,Linear,,Free,Free,,,0,LKKLFKKILKYL
LKKLFKKILKYLK,13,antimicrobial peptides,Synthetic peptide,Rabbit red blood cells: very low hemolytic activity even at the concentration of 160 μm(as show in fig.3),GES-1: IC50=63.6±4.7 μM,,,"disrupt the cell membrane, trigger the cytochrome C release into cytoplasm, and ultimately lead to apoptosis",Anticancer; Antitumor; Antimicrobial,Tumor active peptide,,Linear,,Free,Free,,,0,LKKLFKKILKYLK
LKKLFKKILKYLKK,14,antimicrobial peptides,Synthetic peptide,Rabbit red blood cells: very low hemolytic activity even at the concentration of 160 μm(as show in fig.3),GES-1: IC50=77.9±5.2 μM,,,"disrupt the cell membrane, trigger the cytochrome C release into cytoplasm, and ultimately lead to apoptosis",Anticancer; Antitumor; Antimicrobial,Tumor active peptide,,Linear,,Free,Free,,,0,LKKLFKKILKYLKK
KAKAKAVSRSARAGLQFPVGRIHRHLK,27,Synthetic,Synthetic peptide,Crab haemocytes: Not active up to 100 µg/ml,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Free,,,0,KAKAKAVSRSARAGLQFPVGRIHRHLK
GIGGALLSAGKSALKGLAKGLAEHFAN,27,"skin secretion of Oriental fire-bellied toad, Bombina orientalis",Synthetic peptide,"Human erythrocytes: BLP-7 exhibited rather low cytotoxicity on human erythrocytes at concentration of 50.2 μm (128 mg/ml), and almost no haemolytic activity was detected around its range of MIC values.",,,,,Anticancer,Tumor active peptide,,Linear,,Free,Amidation,,,0,GIGGALLSAGKSALKGLAKGLAEHFAN
IIGPVLGLIGKALGGLL,17,"skin secretion of Oriental fire-bellied toad, Bombina orientalis",Synthetic peptide,"Human erythrocytes: Bombinin H-BO was found to lyse 38% of erythrocytes at concentration of 80.0 μm (128 mg/ml), and up to 85% at the concentration of 159.7 μm (256 mg/ml).",,,,,Anticancer,Tumor active peptide,,Linear,,Free,Amidation,,,0,IIGPVLGLIGKALGGLL
kwfrvyrGiyrrr,13,Synthetic,Synthetic peptide,Sheep erythrocytes: <1% Hemolysis=67µM,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,k=D-Lys; w=D-Trp; f=D-Phe; r=D-Arg; v=D-Val; y=D-Tyr; i=D-Ile,,0,KWFRVYRGIYRRR
KWFRVYRGIYRRR,13,Synthetic,Synthetic peptide,Sheep erythrocytes: <1% Hemolysis=67µM,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,,,0,KWFRVYRGIYRRR
rrryiGryvrfwk,13,Synthetic,Synthetic peptide,Sheep erythrocytes: <1% Hemolysis=8.4µM,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,k=D-Lys; w=D-Trp; f=D-Phe; r=D-Arg; v=D-Val; y=D-Tyr; i=D-Ile,,0,RRRYIGRYVRFWK
RRRYIGRYVRFWK,13,Synthetic,Synthetic peptide,Sheep erythrocytes: <1% Hemolysis=540µM,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,,,0,RRRYIGRYVRFWK
LVKRFKKFFRKLKKSVLL,18,cationic host defense peptides,Synthetic peptide,Rabbit red blood cells: modest hemolytic activity(as show in Fig.2),HUVEC: IC50=80.84±3.9 μM,,,,Anticancer; Antitumor,Tumor active peptide,,Linear,,Free,Amidation,,,0,LVKRFKKFFRKLKKSVLL
LVRRFRRFFRRLRRSVLL,18,cationic host defense peptides,Synthetic peptide,Rabbit red blood cells: modest hemolytic activity(as show in Fig.2),HUVEC: IC50=85.24±3.4 μM,,,,Anticancer; Antitumor,Tumor active peptide,,Linear,,Free,Amidation,,,0,LVRRFRRFFRRLRRSVLL
VKRFKKFFLKLKSV,14,cationic host defense peptides,Synthetic peptide,Rabbit red blood cells: modest hemolytic activity(as show in Fig.2),HUVEC: IC50=74.58±5.9 μM,,,,Anticancer; Antitumor,Tumor active peptide,,Linear,,Free,Amidation,,,0,VKRFKKFFLKLKSV
VKRFKKFFRKLKKSVL,16,cationic host defense peptides,Synthetic peptide,Rabbit red blood cells: modest hemolytic activity(as show in Fig.2),HUVEC: IC50=50.62±6.1 μM,,,,Anticancer; Antitumor,Tumor active peptide,,Linear,,Free,Amidation,,,0,VKRFKKFFRKLKKSVL
VKRFKKFFRKLKKSVLL,17,cationic host defense peptides,Synthetic peptide,Rabbit red blood cells: modest hemolytic activity(as show in Fig.2),HUVEC: IC50=64.15±3.7 μM,,,,Anticancer; Antitumor,Tumor active peptide,,Linear,,Free,Amidation,,,0,VKRFKKFFRKLKKSVLL
VKRFKLFFRKLKSV,14,cationic host defense peptides,Synthetic peptide,Rabbit red blood cells: modest hemolytic activity(as show in Fig.2),HUVEC: IC50=72.37±2.7 μM,,,,Anticancer; Antitumor,Tumor active peptide,,Linear,,Free,Amidation,,,0,VKRFKLFFRKLKSV
VRRFRLFFRRLRRSV,15,cationic host defense peptides,Synthetic peptide,Rabbit red blood cells: modest hemolytic activity(as show in Fig.2),HUVEC: IC50=70.73±3.5 μM,,,,Anticancer; Antitumor,Tumor active peptide,,Linear,,Free,Amidation,,,0,VRRFRLFFRRLRRSV
VRRFRRFFLRLRRSV,15,cationic host defense peptides,Synthetic peptide,Rabbit red blood cells: modest hemolytic activity(as show in Fig.2),HUVEC: IC50=70.07±2.1 μM,,,,Anticancer; Antitumor,Tumor active peptide,,Linear,,Free,Amidation,,,0,VRRFRRFFLRLRRSV
VRRFRRFFRRLRRSV,15,cationic host defense peptides,Synthetic peptide,Rabbit red blood cells: modest hemolytic activity(as show in Fig.2),HUVEC: IC50=69.74±2.9 μM,,,,Anticancer; Antitumor,Tumor active peptide,,Linear,,Free,Amidation,,,0,VRRFRRFFRRLRRSV
VRRFRRFFRRLRRSVL,16,cationic host defense peptides,Synthetic peptide,Rabbit red blood cells: modest hemolytic activity(as show in Fig.2),HUVEC: IC50=75.84±6.8 μM,,,,Anticancer; Antitumor,Tumor active peptide,,Linear,,Free,Amidation,,,0,VRRFRRFFRRLRRSVL
VRRFRRFFRRLRRSVLL,17,cationic host defense peptides,Synthetic peptide,Rabbit red blood cells: modest hemolytic activity(as show in Fig.2),HUVEC: IC50=82.37±4.4 μM,,,,Anticancer; Antitumor,Tumor active peptide,,Linear,,Free,Amidation,,,0,VRRFRRFFRRLRRSVLL
GGTIFDCGESCFLGTCYTKGCSCGEWKLCYGTN,33,Viola odorata,Native peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Cyclic,Cys7<--->Cys21; Cys11<--->Cys23; Cys16<--->Cys29; NCB: Gly1<--->Asn33,Free,Free,,,0,GGTIFDCGESCFLGTCYTKGCSCGEWKLCYGTN
GGVCPKILKKCRRDSDCPGACICRGNGYCGSGSD,34,Momordica cochinchinensis,Native peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Cyclic,Cys4<--->Cys21; Cys11<--->Cys23; Cys17<--->Cys29; NCB: Gly1<--->Asp34,Free,Free,,,0,GGVCPKILKKCRRDSDCPGACICRGNGYCGSGSD
GGVCPKILQRCRRDSDCPGACICRGNGYCGSGSD,34,Momordica cochinchinensis,Native peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Cyclic,Cys4<--->Cys21; Cys11<--->Cys23; Cys17<--->Cys29; NCB: Gly1<--->Asp34,Free,Free,,,0,GGVCPKILQRCRRDSDCPGACICRGNGYCGSGSD
GIPCAESCVWIPCTVTALLGCSCKDKVCYLD,31,Clitoria ternatea ,Native peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Cyclic,Cys4<--->Cys21; Cys5<--->Cys23; Cys13<--->Cys28; NCB: Gly1<--->Asp31,Free,Free,,,0,GIPCAESCVWIPCTVTALLGCSCKDKVCYLD
GIPCGESCVWIPCLTSAIGCSCKSKVCYRN,30,Viola odorata,Native peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Cyclic,Cys4<--->Cys20; Cys8<--->Cys22; Cys13<--->Cys27; NCB: Gly1<--->Asn30,Free,Free,,,0,GIPCGESCVWIPCLTSAIGCSCKSKVCYRN
GLPCGESCVFIPCITTVVGCSCKNKVCYNN,30,Clitoria ternatea ,Native peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Cyclic,Cys4<--->Cys20; Cys8<--->Cys22; Cys13<--->Cys27; NCB: Gly1<--->Asn30,Free,Free,,,0,GLPCGESCVFIPCITTVVGCSCKNKVCYNN
GLPVCGETCFGGTCNTPGCACDPWPVCTRD,30,Oldenlandia affinis,Native peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Cyclic,Cys5<--->Cys19; Cys9<--->Cys21; Cys14<--->Cys27; NCB: Gly1<--->Asp30,Free,Free,,,0,GLPVCGETCFGGTCNTPGCACDPWPVCTRD
GLPVCGETCTLGTCSTQGCTCSWPICKRN,29,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Cyclic,Cys5<--->Cys19; Cys9<--->Cys21; Cys14<--->Cys26; NCB: Gly1<--->Asn29,Free,Free,,,0,GLPVCGETCTLGTCSTQGCTCSWPICKRN
GTLPCGESCVWIPCISSVVGCSCKSKVCYKD,31,Viola odorata,Native peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Cyclic,Cys5<--->Cys21; Cys9<--->Cys23; Cys14<--->Cys28; NCB: Gly1<--->Asp31,Free,Free,,,0,GTLPCGESCVWIPCISSVVGCSCKSKVCYKD
FpFw,4,Synthetic,Synthetic peptide,,,,,,Anticancer; Antitumor; Antimicrobial,Tumor active peptide,,Cyclic,,Lactam,Lactam,p=D-Proline; w=D-Tryptophane,,0,FPFW
FpFW,4,Synthetic,Synthetic peptide,,,,,,Anticancer; Antitumor; Antimicrobial,Tumor active peptide,,Cyclic,,Lactam,,p=D-Proline,,0,FPFW
FLGAIAQALTSLLGKL,16,skin secretions of the Italian stream frog Rana italica (Ranidae),Native peptide,mouse erythrocytes: LC50=22 μM,,,,,Anticancer; Antitumor; Antimicrobial,Tumor active peptide,,Linear,,Free,α-amidated residue at the C-terminus,α-amidated residue at the C-terminus,,0,FLGAIAQALTSLLGKL
IVPFLLGMVPKLVCLITKKC,20,skin secretions of the Italian stream frog Rana italica (Ranidae),Native peptide,mouse erythrocytes: LC50=7 μM,,,,,Anticancer; Antitumor; Antimicrobial,Tumor active peptide,,Linear,,Free,Free,,,0,IVPFLLGMVPKLVCLITKKC
GCRALCYKQRCVTYCRGA,18,Redesigned Spider Peptide,Synthetic peptide,Human red blood cells (hRBCs): hemolysis(%)=39.3±9.3 with 64 μM of peptide,"PBMCs:CC50=30.8±2.5 µM, testing time is 18-24h; HFF-1: CC50=51.2 ± 4.0 µM",,,,Anticancer; Antimicrobial,Tumor active peptide,,Cyclic,Cys2<--->Cys15; Cys6<--->Cys11,Free,Amidation,,,0,GCRALCYKQRCVTYCRGA
GCRRLCWKQRCVTYCRGR,18,Redesigned Spider Peptide,Synthetic peptide,Human red blood cells (hRBCs): hemolysis(%)=45.3±10.2 with 64 μM of peptide,HFF-1: CC50=39.7 ± 3.8 µM,,,,Anticancer; Antimicrobial,Tumor active peptide,,Cyclic,Cys2<--->Cys15; Cys6<--->Cys11,Free,Amidation,,,0,GCRRLCWKQRCVTYCRGR
GCRRLCWRQRCVTWCRGR,18,Redesigned Spider Peptide,Synthetic peptide,Human red blood cells (hRBCs): hemolysis(%)=45.9±3.9 with 64 μM of peptide,HFF-1: CC50=31.3 ± 2.6 µM,,,,Anticancer; Antimicrobial,Tumor active peptide,,Cyclic,Cys2<--->Cys15; Cys6<--->Cys11,Free,Amidation,,,0,GCRRLCWRQRCVTWCRGR
GCRRLCYKQRCVTWCRGR,18,Redesigned Spider Peptide,Synthetic peptide,Human red blood cells (hRBCs): hemolysis(%)=50.8±4.7 with 64 μM of peptide,HFF-1: CC50=68.4 ± 9.6 µM,,,,Anticancer; Antimicrobial,Tumor active peptide,,Cyclic,Cys2<--->Cys15; Cys6<--->Cys11,Free,Amidation,,,0,GCRRLCYKQRCVTWCRGR
GCRRLCYKQRCVTYCRGpPR,20,Redesigned Spider Peptide,Synthetic peptide,Human red blood cells (hRBCs): hemolysis(%)=43.2±1.7 with 64 μM of peptide,"PBMCs:CC50=14.1±0.9 µM, testing time is 18-24h; HFF-1: CC50=14.9 ± 0.8 µM",,,,Anticancer; Antimicrobial,Tumor active peptide,,Cyclic,Cys2<--->Cys15; Cys6<--->Cys11,Free,Amidation,p=D-Proline,,0,GCRRLCYKQRCVTYCRGPPR
GCRRLCYKQRCVTYCRGR,18,Redesigned Spider Peptide,Synthetic peptide,Human red blood cells (hRBCs): hemolysis(%)=45.9±9.4 with 64 μM of peptide,"PBMCs:CC50=10.8±0.8 µM, testing time is 18-24h",,,,Anticancer; Antimicrobial,Tumor active peptide,,Cyclic,Cys2<--->Cys15; Cys6<--->Cys11,Free,Amidation,,,0,GCRRLCYKQRCVTYCRGR
GCRRLCYRQRCVTYCRGR,18,Redesigned Spider Peptide,Synthetic peptide,Human red blood cells (hRBCs): hemolysis(%)=44.8±10.0 with 64 μM of peptide,HFF-1: CC50=34.5 ± 3.6 µM,,,,Anticancer; Antimicrobial,Tumor active peptide,,Cyclic,Cys2<--->Cys15; Cys6<--->Cys11,Free,Amidation,,,0,GCRRLCYRQRCVTYCRGR
GCRRWCYKQRCVTYCRGR,18,Redesigned Spider Peptide,Synthetic peptide,Human red blood cells (hRBCs): hemolysis(%)=40.1±3.3 with 64 μM of peptide,HFF-1: CC50=25.0 ± 2.9 µM,,,,Anticancer; Antimicrobial,Tumor active peptide,,Cyclic,Cys2<--->Cys15; Cys6<--->Cys11,Free,Amidation,,,0,GCRRWCYKQRCVTYCRGR
GURRLUYKQRUVTYURGR,18,Redesigned Spider Peptide,Synthetic peptide,Human red blood cells (hRBCs): hemolysis(%)=32.8±0.5 with 64 μM of peptide,"PBMCs:CC50=15.5±0.8 µM, testing time is 18-24h; HFF-1: CC50=51.0 ± 4.6 µM",,,,Anticancer; Antimicrobial,Tumor active peptide,,Cyclic,SelenoCys2<--->SelenoCys; SelenoCys<--->SelenoCys11,Free,Amidation,U=SelenoCys,,0,GURRLUYKQRUVTYURGR
GXRRLXYKQRXVTYXRGR,18,Synthetic,Synthetic peptide,Human erythrocytes: 32.8±0.5% Hemolysis=64µM,HFF-1: CC50=15.6±3.6µM; PBMC: CC50=15.5±0.8µM,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Cyclic,Cys2<--->Cys15; Cys6<--->Cys11; NCB: Gly1<--->Arg18,Free,Free,X=Se-Cys,,0,GXRRLXYKQRXVTYXRGR
KCRRLCYRQRCVTYCRGR,18,Redesigned Spider Peptide,Synthetic peptide,Human red blood cells (hRBCs): hemolysis(%)=45.1±11.8 with 64 μM of peptide,"PBMCs:CC50=5.1±0.3 µM , testing time is 18-24h; HFF-1: CC50=9.0 ± 0.5 µM",,,,Anticancer; Antimicrobial,Tumor active peptide,,Cyclic,Cys2<--->Cys15; Cys6<--->Cys11,Free,Amidation,,,0,KCRRLCYRQRCVTYCRGR
KCRRYCYRQRCVTYCRGR,18,Redesigned Spider Peptide,Synthetic peptide,Human red blood cells (hRBCs): hemolysis(%)=26.3±5.7 with 64 μM of peptide,"PBMCs:CC50=10.4±1.0µM, testing time is 18-24h; HFF-1: CC50=14.7 ± 1.5 µM",,,,Anticancer; Antimicrobial,Tumor active peptide,,Cyclic,Cys2<--->Cys15; Cys6<--->Cys11,Free,Amidation,,,0,KCRRYCYRQRCVTYCRGR
KURRYUYRQRUVTYURGR,18,Redesigned Spider Peptide,Synthetic peptide,Human red blood cells (hRBCs): hemolysis(%)=20.9±3.1 with 64 μM of peptide,"PBMCs:CC50=9.5±0.5 µM, testing time is 18-24h; HFF-1: CC50=30.8 ± 2.0 µM",,,,Anticancer; Antimicrobial,Tumor active peptide,,Cyclic,SelenoCys2<--->SelenoCys15; SelenoCys6<--->SelenoCys11,Free,Amidation,U=SelenoCys,,0,KURRYUYRQRUVTYURGR
KXRRYXYRQRXVTYXRGR,18,Synthetic,Synthetic peptide,Human erythrocytes: 20.9±3.1% Hemolysis=64µM,HFF-1: CC50=30.8±2.0µM; PBMC: CC50=9.5±0.5µM,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Cyclic,Cys2<--->Cys15; Cys6<--->Cys11; NCB: Gly1<--->Arg18,Free,Free,X=Se-Cys,,0,KXRRYXYRQRXVTYXRGR
XCRRLCYKQRCVTYCRGR,18,Redesigned Spider Peptide,Synthetic peptide,Human red blood cells (hRBCs): hemolysis(%)=30.7±8.1 with 64 μM of peptide,"PBMCs: CC50=13.4±1.8 µM, testing time is 18-24h; HFF-1: CC50=49.9 ± 16.6 µM, testing time is 18-24h",,,,Anticancer; Antimicrobial,Tumor active peptide,,Cyclic,Cys2<--->Cys15; Cys6<--->Cys11,Free,Amidation,X=N-terminal pyroglutamic acid,,0,XCRRLCYKQRCVTYCRGR
RRGLFKKLRRKIKKGFKKIFKRLPPVGVGVSIPLAGRR,38,Alligator sinensis,Native peptide,Human erythrocytes: 4±0.5% Hemolysis=200µg/ml,CHO: 55±2.5% Cell death=200µg/ml,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Free,,,0,RRGLFKKLRRKIKKGFKKIFKRLPPVGVGVSIPLAGRR
WDPYFAGVKKLTKAILAVRA,20,Synthetic,Synthetic peptide,,HDME: Not active up to 100 µM,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,,,0,WDPYFAGVKKLTKAILAVRA
WGKFFAGVKKLTKAILAVRA,20,Synthetic,Synthetic peptide,,HDME: Not active up to 100 µM,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,,,0,WGKFFAGVKKLTKAILAVRA
WDPYFAGVKKLTKAILGEIA,20,Synthetic,Synthetic peptide,,HDME: Not active up to 100 µM,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,,,0,WDPYFAGVKKLTKAILGEIA
WGKFFAGVKKLTKAILGEIA,20,Synthetic,Synthetic peptide,,HDME: Not active up to 100 µM,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,,,0,WGKFFAGVKKLTKAILGEIA
IKKILSKIKKLLK,13,some cationic antimicrobial peptides,Synthetic peptide,Rabbit red blood cells: modest hemolytic activity(as show in Fig.2),HUVEC: IC50=65.88±4.5 μM,,,,Anticancer; Antitumor,Tumor active peptide,,Linear,,Free,Free,,,0,IKKILSKIKKLLK
FLSLIPAAISAVSALANHF,19,Pithecopus hypochondrialis,Native peptide,Horse erythrocytes: 10% Hemolysis=76.5µM; 50% Hemolysis=109.5µM; 50% Hemolysis=52.17µM,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,,0,FLSLIPAAISAVSALANHF
FLSLIPKIAGGIAALAKHL,19,Phyllomedusa baltea,Native peptide,Horse erythrocytes: 10% Hemolysis=7.79µM; 50% Hemolysis=22.8µM,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,,0,FLSLIPKIAGGIAALAKHL
XXLXAXX,7,Streptomyces atratus SCSIO ZH16,Native peptide,,HL-7702 (L02): IC50>50µM; HUVEC: IC50>50µM,,,,Anticancer; Antibacterial,Tumor active peptide,,Cyclic,NCB: X1<--->X7,Free,Free,X(1)=Pre-Trp; X(2)=(2S)-2-Aminohex-4-enoic acid; X(4)=METH-Leu; X(6)=N-Tyr; X(7)=METH-Leu,,0,XXLXAXX
FTVAXFI,7,Bacillus subtilis URID 12.1,Native peptide,Human erythrocytes: <5% Hemolysis=128µg/ml; 30% Hemolysis=256µg/ml,,,,,Anticancer; Antibacterial,Tumor active peptide,,Cyclic,LCB: X(5)<--->Ile7,Acetylation,Free,X=dehydrobutyrine,,0,FTVAXFI
NPEKALEKLIAIQKAIKGMLNGWFTGVGFRRKR,33,Synthetic,Synthetic peptide,Human erythrocytes: 1.97% Hemolysis=4µM; <10% Hemolysis=256µM,HaCat: Not active up to 200 µM,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,NPEKALEKLIAIQKAIKGMLNGWFTGVGFRRKR
FKARRWQWRMKKLGAFKARRWQWRMKKLGAKX,32,Bovine Lactoferricin,Native peptide,,,,,,Anticancer; Antitumor; Antimicrobial,Tumor active peptide,,Linear,,Free,Free,X=Ahx,,0,FKARRWQWRMKKLGAFKARRWQWRMKKLGAKX
FKARRWQWRMKKLGAFKARRWQWRMKKLGAKXC,33,Bovine Lactoferricin,Native peptide,,,,,,Anticancer; Antitumor; Antimicrobial,Tumor active peptide,,Tetrameric,,Free,Free,X=Ahx,,0,FKARRWQWRMKKLGAFKARRWQWRMKKLGAKXC
RRWQWRRRWQWRKX,14,Bovine Lactoferricin,Native peptide,,,,,,Anticancer; Antitumor; Antimicrobial,Tumor active peptide,,Linear,,Free,Free,X=Ahx,,0,RRWQWRRRWQWRKX
RRWQWRRRWQWRKXC,15,Bovine Lactoferricin,Native peptide,,,,,,Anticancer; Antitumor; Antimicrobial,Tumor active peptide,,Tetrameric,,Free,Free,X=Ahx,,0,RRWQWRRRWQWRKXC
RWQWRMKKLGRWQWRMKKLGKX,22,Bovine Lactoferricin,Native peptide,,,,,,Anticancer; Antitumor; Antimicrobial,Tumor active peptide,,Linear,,Free,Free,X=Ahx,,0,RWQWRMKKLGRWQWRMKKLGKX
RWQWRMKKLGRWQWRMKKLGKXC,23,Bovine Lactoferricin,Native peptide,,,,,,Anticancer; Antitumor; Antimicrobial,Tumor active peptide,,Tetrameric,,Free,Free,X=Ahx,,0,RWQWRMKKLGRWQWRMKKLGKXC
FKARRWQWRMKKLGA,15,Bovine Lactoferricin,Native peptide,,,,,,Anticancer; Antitumor; Antimicrobial,Tumor active peptide,,Linear,,Free,Free,,,0,FKARRWQWRMKKLGA
CFKARRWQWRMKKLGAXC,18,Bovine Lactoferricin,Native peptide,,,,,,Anticancer; Antitumor; Antimicrobial,Tumor active peptide,,Linear,Cys1<--->Cys18,Free,Free,X=Ahx,,0,CFKARRWQWRMKKLGAXC
RRWQWR,6,Bovine Lactoferricin,Native peptide,,,,,,Anticancer; Antitumor; Antimicrobial,Tumor active peptide,,Linear,,Free,Free,,,0,RRWQWR
CRRWQWRXC,9,Bovine Lactoferricin,Native peptide,,,,,,Anticancer; Antitumor; Antimicrobial,Tumor active peptide,,Cyclic,Cys1<--->Cys10,Free,Free,X=Ahx,,0,CRRWQWRXC
RWQWRMKKLG,10,Bovine Lactoferricin,Native peptide,,,,,,Anticancer; Antitumor; Antimicrobial,Tumor active peptide,,Linear,,Free,Free,,,0,RWQWRMKKLG
CRWQWRMKKLGXC,13,Bovine Lactoferricin,Native peptide,,,,,,Anticancer; Antitumor; Antimicrobial,Tumor active peptide,,Linear,Cys1<--->Cys13,Free,Free,X=Ahx,,0,CRWQWRMKKLGXC
GFGCPFNARRCHRHCRSIRRRAGYCAGRLRLTCTCVR,37,Synthetic,Synthetic peptide,Human erythrocytes: <5% Hemolysis=10µM; 18% Hemolysis=20µM; 60% Hemolysis=50µM,HEK293T: Not active up to 20 µM,,,,Anticancer; Antibacterial; Antifungal,Undefined,,Cyclic,Cys4<--->Cys25; Cys11<--->Cys33; Cys15<--->Cys35,Free,Free,,,0,GFGCPFNARRCHRHCRSIRRRAGYCAGRLRLTCTCVR
GFGCPLNQGACHRHCRSIRRRGGYCSGIIKQTCTCY,36,Synthetic,Synthetic peptide,Human erythrocytes: <5% Hemolysis=50µM,HEK293T: Not active up to 20 µM,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Cyclic,Cys4<--->Cys25; Cys11<--->Cys33; Cys15<--->Cys35,Free,Free,,,0,GFGCPLNQGACHRHCRSIRRRGGYCSGIIKQTCTCY
ALWKEVLKNAGKAALNEINNLVQ,23,Phyllomedusa hypochondrialis,Native peptide,Horse erythrocytes: 1% Hemolysis=16µM; 3% Hemolysis=64µM; 10% Hemolysis=128µM; 45% Hemolysis=256µM; 100% Hemolysis=512µM,HMEC-1: IC50=4.85µM,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,,0,ALWKEVLKNAGKAALNEINNLVQ
GIGSAILSAGKSIIKGLAKGLAEHF,25,Bombina orientalis,Native peptide,Human erythrocytes: 2.89% Hemolysis=26.3µM; Human erythrocytes=38.05% Hemolysis=52.5µM,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,,0,GIGSAILSAGKSIIKGLAKGLAEHF
GIGSAILSAGKSIIKGLAKGLA,22,"skin secretion of Oriental fire-bellied toad, Bombina orientalis",Native peptide,Human Red cells: only 2.89% hemolysis of the red cells at a concentration of 26.3 μM and 38.05% hemolysis at 52.5 μM,,,,,Anticancer; Antitumor; Antimicrobial,Tumor active peptide,,Linear,,Free,Amidation,,,0,GIGSAILSAGKSIIKGLAKGLA
IIGPVLGLVGKALGGLL,17,"skin secretion of Oriental fire-bellied toad, Bombina orientalis",Native peptide,Human Red cells: caused 42.03% hemolysis of the red cells at a concentration of 40.3 μM while reaching 100% hemolysis at 161.1 μM,,,,,Anticancer; Antitumor; Antimicrobial,Tumor active peptide,,Linear,,Free,Amidation,,,0,IIGPVLGLVGKALGGLL
FLSLIPKIATGIAALAKHL,19,Phyllomedusa camba,Native peptide,Horse erythrocytes: 100% Hemolysis=64µM; Horse erythrocytes=50% Hemolysis=23µM,HMEC-1: IC50=51.83µM,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,,0,FLSLIPKIATGIAALAKHL
ATCYCRTGRCATRESLSGVCEISGRLYRLCCR,32,Homo sapiens,Native peptide,Human erythrocytes: NA; Mouse erythrocytes: 20% Hemolysis=25 µg/ml;  33% Hemolysis=50 µg/ml; 40% Hemolysis=100 µg/ml,HaCat: 10% Killing=150 µg/ml; ARPE-19: 50% Cytotoxicity=24 µM; CaSki: Not active up to 50 µg/ml,,,,Anticancer; Antibacterial; Antifungal; Antiviral,Tumor active peptide##Membrane-targeted,,Linear,,Free,Free,,,0,ATCYCRTGRCATRESLSGVCEISGRLYRLCCR
FLPIVAKLLSGLL,13,Pelophylax kl.esculentus(Europe edible frog),Native peptide,Horse erythrocytes(HD50=39.64μM),HMEC-1: IC50=58.62µM,,,,Anticancer; Antimicrobial; Antibacterial; Anitifungal,Tumor active peptide##Membrane-targeted,,Linear,,,,,,0,FLPIVAKLLSGLL
FLPIVAKLLSGLLGRKKRRQRRR,23,Synthetic,Synthetic peptide,Horse erythrocytes: 50% Hemolysis=44.65µM,HMEC-1: IC50=9.976µM,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide##Membrane-targeted,,Linear,,Free,Amidation,,,0,FLPIVAKLLSGLLGRKKRRQRRR
FLYIVAKLLSGLL,13,Synthetic,Synthetic peptide,Horse erythrocytes: 50% Hemolysis=526.5µM,HMEC-1: IC50=40.30µM,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide##Membrane-targeted,,Linear,,Free,Amidation,,,0,FLYIVAKLLSGLL
HLRRINKLLTRIGLYRHAFG,20,Synthetic,Synthetic peptide,Human erythrocytes: 20% Hemolysis=500µg/ml; Sheep erythrocytes: 25% Hemolysis=500µg/ml,HUVEC: Not active up to 128 µg/ml,,,,Anticancer; Antibacterial,Tumor active peptide##Membrane-targeted,,Linear,,Free,Free,,,0,HLRRINKLLTRIGLYRHAFG
LPRRNRWSKIWKKVVTVFS,19,Synthetic,Synthetic peptide,Human erythrocytes: 20% Hemolysis=500µg/ml; Sheep erythrocytes: 10% Hemolysis=500µg/ml; Horse erythrocytes:0% Hemolysis=536µg/ml,HUVEC: LC50=98.1µg/ml,,,,Anticancer; Antibacterial,Tumor active peptide##Membrane-targeted,,Linear,,Free,Free,,,0,LPRRNRWSKIWKKVVTVFS
NRFTARFRRTPWRLCLQFRQ,20,Synthetic,Synthetic peptide,Human erythrocytes: 45% Hemolysis=500µg/ml; Sheep erythrocytes: 0% Hemolysis=500µg/ml,HUVEC: LC50>128µg/ml,,,,Anticancer; Antibacterial,Tumor active peptide##Membrane-targeted,,Linear,,Free,Free,,,0,NRFTARFRRTPWRLCLQFRQ
FLSLALAALPKFLCLVFKKC,20,Rana dybowskii; Rana huanrenensis; Rana amurensis,Native peptide,Human erythrocytes: 50% Hemolysis<5 µM; Horse erythrocytes: 50% Hemolysis=17.0 µM,HMEC-1: IC50=35.9 µM,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide##Membrane-targeted,,Cyclic,Cys14<--->Cys20,Free,Free,,,0,FLSLALAALPKFLCLVFKKC
CLNLKALLAVAKKILC,16,wasp venom,Native peptide,Horse erythrocytes: HC50=40.11 μM,HMEC-1: IC50=57.15 μM,,,,Anticancer; Antitumor; Antimicrobial,Tumor active peptide##Membrane-targeted,,Linear,,Free,Amidation,,,0,CLNLKALLAVAKKILC
LNLKALLAVAKKIL,14,wasp venom,Native peptide,Horse erythrocytes: HC50=40.11 μM,HMEC-1: IC50=57.15 μM,,,,Anticancer; Antitumor; Antimicrobial,Tumor active peptide##Membrane-targeted,,Linear,,Free,Amidation,,,0,LNLKALLAVAKKIL
RKKRRQRRRLNLKALLAVAKKIL,23,wasp venom,Native peptide,Horse erythrocytes: HC50=77.94 μM,HMEC-1: IC50=9.18 μM,,,,Anticancer; Antitumor; Antimicrobial,Tumor active peptide##Membrane-targeted,,Linear,,Free,Amidation,,,0,RKKRRQRRRLNLKALLAVAKKIL
RLLSLIRKLIT,11,Synthetic,Synthetic peptide (Derived from Decoralin),Human red blood cells: MHC=25.00 μmol/L,,,,,Anticancer; Antitumor,Tumor active peptide##Membrane lysis,,Linear,,Free,Amidation,,,0,RLLSLIRKLIT
SFLSLIRKLIT,11,Synthetic,Synthetic peptide (Derived from Decoralin),Human red blood cells: MHC=3.12 μmol/L,,,,,Anticancer; Antitumor,Tumor active peptide##Membrane lysis,,Linear,,Free,Amidation,,,0,SFLSLIRKLIT
SLLPLIRKLIT,11,Synthetic,Synthetic peptide (Derived from Decoralin),Human red blood cells: MHC=12.50 μmol/L,,,,,Anticancer; Antitumor,Tumor active peptide##Membrane lysis,,Linear,,Free,Amidation,,,0,SLLPLIRKLIT
SLLSLFRKLI,10,Synthetic,Synthetic peptide (Derived from Decoralin),Human red blood cells: MHC=12.50 μmol/L,,,,,Anticancer; Antitumor,Tumor active peptide##Membrane lysis,,Linear,,Free,Amidation,,,0,SLLSLFRKLI
SLLSLFRKLIT,11,Synthetic,Synthetic peptide (Derived from Decoralin),Human red blood cells: MHC=3.12 μmol/L,,,,,Anticancer; Antitumor,Tumor active peptide##Membrane lysis,,Linear,,Free,Amidation,,,0,SLLSLFRKLIT
SLLSLIRKLIT,11,Oreumenes decoratus,Native peptide,Human red blood cells: MHC=1.56 μmol/L,,,,,Anticancer; Antitumor,Tumor active peptide##Membrane lysis##Cell-penetrating peptides,,Linear,,Free,Amidation,,,0,SLLSLIRKLIT
SLLSLIRKLIW,11,Synthetic,Synthetic peptide (Derived from Decoralin),Human red blood cells: MHC=1.56 μmol/L,,,,,Anticancer; Antitumor,Tumor active peptide##Membrane lysis,,Linear,,Free,Amidation,,,0,SLLSLIRKLIW
SLLSLIRKLLT,11,Synthetic,Synthetic peptide (Derived from Decoralin),Human red blood cells: MHC=25.00 μmol/L,,,,,Anticancer; Antitumor,Tumor active peptide##Membrane lysis,,Linear,,Free,Amidation,,,0,SLLSLIRKLLT
SLLSLIRLLIT,11,Synthetic,Synthetic peptide (Derived from Decoralin),Human red blood cells: MHC=50.00 μmol/L,,,,,Anticancer; Antitumor,Tumor active peptide##Membrane lysis,,Linear,,Free,Amidation,,,0,SLLSLIRLLIT
FIFHIIKGLFHAGKMIHGLVTRRRHGVEELQDLDQRAFEREKAFA,45,Epinephelus coioides; Epinephelus malabaricus,Native peptide,Fish erythrocytes:25% Hemolysis=20µM; Rabbit erythrocytes:47% Hemolysis=20µM,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,FIFHIIKGLFHAGKMIHGLVTRRRHGVEELQDLDQRAFEREKAFA
ALWKDILKNAGKAALNEINQIVQ,23,skin secretion of Phyllomedusa sauvagii,Native peptide,Horse blood cells: HC50=138.1 μM,HMEC-1: IC50=132.10 μM,,,,Anticancer; Antitumor; Antimicrobial,Tumor active peptide,,Linear,,Free,Free,,,0,ALWKDILKNAGKAALNEINQIVQ
ALWKDILKNLLKAALNEINQIVQ,23,skin secretion of Phyllomedusa sauvagii,Native peptide,Horse blood cells: HC50=3.44 μM,HMEC-1: IC50=8.76 μM,,,,Anticancer; Antitumor; Antimicrobial,Tumor active peptide,,Linear,,Free,Free,,,0,ALWKDILKNLLKAALNEINQIVQ
ALWKKILKNAGKAALNKINQIVQ,23,skin secretion of Phyllomedusa sauvagii,Native peptide,Horse blood cells: HC50=14.98 μM,HMEC-1: IC50=123.00 μM,,,,Anticancer; Antitumor; Antimicrobial,Tumor active peptide,,Linear,,Free,Free,,,0,ALWKKILKNAGKAALNKINQIVQ
IEELIKKSEEQQKKNEEELKKLEX,24,Synthetic,Synthetic peptide,,HEK293T: 50% Cytotoxicity=140.43±10.7 µM; PBMC: 50% Cytotoxicity=46.43±2.6 µM,,,,Anticancer; Antiviral,Tumor active peptide,,Linear,,Acetylation,Amidation,X(24)= Lysine with palmitoylated side group,,0,IEELIKKSEEQQKKNEEELKKLEX
IEELLKKAEEQQKKNEEELKKLEX,24,Synthetic,Synthetic peptide,,HEK293T: 50% Cytotoxicity=208.43±22.9 µM; PBMC: 50% Cytotoxicity=49.95±2.97 µM,,,,Anticancer; Antiviral,Tumor active peptide##Induce apoptosis,,Linear,,Acetylation,Amidation,X(24)= Lysine with palmitoylated side group,,0,IEELLKKAEEQQKKNEEELKKLEX
LEANIEELLKKAEEQQKKNEEELKKLEX,28,Synthetic,Synthetic peptide,,HEK293T cells: 50% Cytotoxicity=130.07±15.27 µM; PBMC: 50% Cytotoxicity=46.83±4.65 µM,,,,Anticancer; Antiviral,Tumor active peptide,,Linear,,Acetylation,Amidation,X(28)= Lysine with palmitoylated side group,,0,LEANIEELLKKAEEQQKKNEEELKKLEX
WEQKIEELLKKAEEQQKKNEEELKKLEX,28,Synthetic,Synthetic peptide,,HEK293T cells: 50% Cytotoxicity=88.86±6.68 µM; PBMC: 50% Cytotoxicity=114.8±12.68 µM,,,,Anticancer; Antiviral,Tumor active peptide,,Linear,,Acetylation,Amidation,X(28)=Lysine with palmitoylated side group,,0,WEQKIEELLKKAEEQQKKNEEELKKLEX
YTSLIEELIKKSEEQQKKNEEELKKLEX,28,Synthetic,Synthetic peptide,,HEK293T cells: 50% Cytotoxicity=408±40.1 µM; PBMC: 50% Cytotoxicity=212.6±25.71 µM,,,,Anticancer; Antiviral,Tumor active peptide,,Linear,,Acetylation,Amidation,X(28)= Lysine with palmitoylated side group,,0,YTSLIEELIKKSEEQQKKNEEELKKLEX
YTSLIHSLIEESQNQQEKNEQELLELDX,28,Synthetic,Synthetic peptide,,HEK293T cells: 50% Cytotoxicity=408±40.1 µM; PBMC: 50% Cytotoxicity=212.6±25.71 µM,,,,Anticancer; Antiviral,Tumor active peptide,,Linear,,Acetylation,Amidation,X(28)=	Lysine with palmitoylated side group,,0,YTSLIHSLIEESQNQQEKNEQELLELDX
CIKPHQGQHICNDE,14,Synthetic,Native peptide,,,,,,Anticancer; Antitumor,Tumor active peptide,,Cyclic,Cys1<--->Cys11,Free,Free,,,0,CIKPHQGQHICNDE
GALKGCWTKSIPPKPCK,17,skin secretion of Pelophylax esculentus (PE) named PE-BBI,Native peptide,,HKE3: IC50=50.2 μM,,,,Anticancer,Tumor active peptide,,Linear,,Free,Amidation,,,0,GALKGCWTKSIPPKPCK
GIMDTVKNAAKNLAGQLLDKLKCSITAC,28,skin secretions of the pickerel frog (Rana palustris),Native peptide,Horse erythrocytes: Low haemolytic activity,HMEC-1: IC50=1185.00 μM,,,,Anticancer; Antimicrobial,Tumor active peptide,,Linear,,Free,Free,,,0,GIMDTVKNAAKNLAGQLLDKLKCSITAC
GCRLYGFKFHGCG,13,Synthetic,Synthetic peptide,,,Protein kinase CK2,,,Anticancer; Antitumor; Antimicrobial,Tumor active peptide##Cancer targeted peptides,,Cyclic,Cys2<--->Cys12,Free,Free,,,0,GCRLYGFKFHGCG
GCRLYGFKIFGCG,13,Synthetic,Synthetic peptide,,,Protein kinase CK2,,,Anticancer; Antitumor; Antimicrobial,Tumor active peptide##Cancer targeted peptides,,Cyclic,Cys2<--->Cys12,Free,Free,,,0,GCRLYGFKIFGCG
GCRLYGFKIHGCG,13,Synthetic,Synthetic peptide,,,Protein kinase CK2,,,Anticancer; Antitumor; Antimicrobial,Tumor active peptide##Cancer targeted peptides,,Cyclic,Cys2<--->Cys12,Free,Free,,,0,GCRLYGFKIHGCG
GCRLYGFKIWGG,12,Synthetic,Synthetic peptide,,,Protein kinase CK2,,,Anticancer; Antitumor; Antimicrobial,Tumor active peptide##Cancer targeted peptides,,Cyclic,Cys2<--->Cys12,Free,Free,,,0,GCRLYGFKIWGG
GCRLYGFKWHGCG,13,Synthetic,Synthetic peptide,,,Protein kinase CK2,,,Anticancer; Antitumor; Antimicrobial,Tumor active peptide##Cancer targeted peptides,,Cyclic,Cys2<--->Cys12,Free,Free,,,0,GCRLYGFKWHGCG
GCRVYGFKIHGCG,13,Synthetic,Synthetic peptide,,,Protein kinase CK2,,,Anticancer; Antitumor; Antimicrobial,Tumor active peptide##Cancer targeted peptides,,Cyclic,Cys2<--->Cys12,Free,Free,,,0,GCRVYGFKIHGCG
PMKKLKLALRLAAKIAPVW,19,Synthetic,Synthetic peptide,Human erythrocytes: Not active up to 100 µM,3T3-L1: Not active up to 100 µM; HUVEC: Not active up to 100 µM,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,PMKKLKLALRLAAKIAPVW
IWLTALKFLGKNLGKLAKQQLAKL,24,Lycosa erythrognatha spider venom,Native peptide,hRBC(human blood red cells): IC50=155±13.04 μM (testing time is 48 h),Vero(African green monkey kidney): IC50≥100 μM (testing time is 48 h); PBMC(Peripheral Blood Mononuclear Cells): IC50=4.16±1.94 μM (testing time is 48 h); GM00637: IC50 ≥ 100 μM ,,,,Anticancer; Antitumor,Tumor active peptide,,Linear,,Free,Free,,,0,IWLTALKFLGKNLGKLAKQQLAKL
HSDGIFTDSYSRYRKQMAVKKYLAAVLGRRYRQRFRNK,38,Synthetic,Synthetic peptide,"Human red blood cells: PACAP was not hemolytic for human erythrocytes at concentrations below 75 μM (0% hemolysis). At concentration between 75 μM and 150 μM the hemolytic activity was less than 3%; Fish red blood cells:PACAP was not hemolytic for fish red blood cells at concentrations below 18.75 μM (0% hemolysis). At concentration between 18.75 μM and 150 μM, the hemolytic activity was less than 20%",,,,,Anticancer; Antimicrobial,Tumor active peptide,,Linear,,Free,Free,,,0,HSDGIFTDSYSRYRKQMAVKKYLAAVLGRRYRQRFRNK
KWCFRVCYRGICYRKCR,17,horseshoe crab Limulus polyphemus,Native peptide,"Human red blood cells (hBRC): TP I lysed 20%, at a maximal concentration of 100 µM",HEK 293T: IC50=19.7±1.9 μM; HEF:IC50=14.1±1.2 μM; NHA: IC50=14.1±1.2 μM,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,KWCFRVCYRGICYRKCR
KWCFRVCYRGICYRRCR,17,horseshoe crab Limulus polyphemus,Native peptide,"Human red blood cells (hBRC): TP I lysed 38%, at a maximal concentration of 100 µM",HEK 293T: IC50=23.5±1.2 μM; HEF: IC50=13.0±1.5 μM; NHA: IC50=24.7±1.8 μM,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,KWCFRVCYRGICYRRCR
RRGCFRVCYRGFCFQRCR,18,horseshoe crab Limulus polyphemus,Native peptide,Human red blood cells (hBRC): HC50=46 µM,HEK 293T: IC50=7.3±0.4 μM; HEF: IC50=7.0±0.4 μM; NHA: IC50=7.5±0.5 μM,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,RRGCFRVCYRGFCFQRCR
RRWCFRVCYKGFCYRKCR,18,horseshoe crab Limulus polyphemus,Native peptide,"Human red blood cells (hBRC): only ~30%, even at the maximal concentration of 100 µM",HEK 293T: IC50=11.3±1.6 μM; HEF: IC50=9.7±0.2 μM; NHA: IC50=18.3±1.4 μM,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,RRWCFRVCYKGFCYRKCR
RRWCFRVCYRGFCYRKCR,18,horseshoe crab Limulus polyphemus,Native peptide,"Human red blood cells (hBRC): only ~45%, even at the maximal concentration of 100 µM",HEK 293T: IC50=9.4±1.5 μM; HEF: IC50=8.3±0.7 μM; NHA: IC50=14.5±1.6 μM,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,RRWCFRVCYRGFCYRKCR
RWCFRVCYRGICYRKCR,17,horseshoe crab Limulus polyphemus,Native peptide,"Human red blood cells (hBRC): TP I lysed 33%, at a maximal concentration of 100 µM",HEK 293T: IC50=24.6±1.7 μM; HEF: IC50=17.7±1.2 μM; NHA: IC50=29.4±1.7 μM,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,RWCFRVCYRGICYRKCR
FKKLKKLFSKLWNWKCRGDKGPDC,24,Synthetic,Synthetic peptide,"Human red blood cells: MHC=125 μM, MHC: the minimum hemolytic concentration is the concentration of peptide that results in 10% hemolysis of human red blood cells (hRBCs).",HUVEC: IC50=26.5 μM,,,,Anticancer; Antitumor,Tumor active peptide,,Linear,,Free,Free,,,0,FKKLKKLFSKLWNWKCRGDKGPDC
FKKLKKLFSKLWNWKGGCRGDKGPDC,26,Synthetic,Synthetic peptide,"Human red blood cells: MHC=125 μM, MHC: the minimum hemolytic concentration is the concentration of peptide that results in 10% hemolysis of human red blood cells (hRBCs).",HUVEC: IC50=31.6 μM,,,,Anticancer; Antitumor,Tumor active peptide,,Linear,,Free,Free,,,0,FKKLKKLFSKLWNWKGGCRGDKGPDC
FKKLKKLFSKLWNWKGGRGD,20,Synthetic,Synthetic peptide,"Human red blood cells: MHC=125 μM, MHC: the minimum hemolytic concentration is the concentration of peptide that results in 10% hemolysis of human red blood cells (hRBCs).",HUVEC: IC50=29.1 μM,,,,Anticancer; Antitumor,Tumor active peptide,,Linear,,Free,Free,,,0,FKKLKKLFSKLWNWKGGRGD
FKKLKKLFSKLWNWKRGD,18,Synthetic,Synthetic peptide,"Human red blood cells: MHC=125 μM, MHC: the minimum hemolytic concentration is the concentration of peptide that results in 10% hemolysis of human red blood cells (hRBCs).",HUVEC: IC50=31.6 μM,,,,Anticancer; Antitumor,Tumor active peptide,,Linear,,Free,Free,,,0,FKKLKKLFSKLWNWKRGD
GRFKRFRKKLKRLWHKVGPFVGPILHY,27,Goat Antimicrobial,Native peptide,Human erythrocytes: ChMAP-28 has a low hemolytic activity (hemolysis less than 10%) at a concentration range up to 10 μM.,HEK293T: IC50=5.09±0.40 μM; HEF: IC50=8.95±2.68 μM,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,GRFKRFRKKLKRLWHKVGPFVGPILHY
WEQKIEELLKKAEEQQKKNEEELKKLEK,28,Synthetic,Synthetic peptide,,PBMC: 50% Cytotoxicity=80.45 µM; HEK293T cells: 50% Cytotoxicity=78.52 µM,,,,Anticancer; Antiviral,Tumor active peptide,,Linear,,Acetylation,Amidation,,,0,WEQKIEELLKKAEEQQKKNEEELKKLEK
RQCKAESNTFTGICIAKPPCRKACIREKFTDGHCSKVLRRCLCTKRC,47,Nicotiana occidentalis,Native peptide,Human red blood cells: with ∼12% lysis at the very high concentration (100 µM),HUVEC: IC50=6.20±0.07 μM; AHDF: IC50=6.49±0.13 μM,,,,Anticancer; Antitumor; Antimicrobial,Tumor active peptide,,Linear,,Free,Free,,,0,RQCKAESNTFTGICIAKPPCRKACIREKFTDGHCSKVLRRCLCTKRC
RQCKAESNTFTGICIAKPPCRQACIREKFTDGHCSKVLRRCLCTKRC,47,Nicotiana occidentalis,Native peptide,Human red blood cells: with ∼12% lysis at the very high concentration (100 µM),HUVEC: IC50=12.31±0.08 μM; AHDF: IC50=10.17±0.29 μM,,,,Anticancer; Antitumor; Antimicrobial,Tumor active peptide,,Linear,,Free,Free,,,0,RQCKAESNTFTGICIAKPPCRQACIREKFTDGHCSKVLRRCLCTKRC
RQCKRESNTFTGICIAKPPCRQACIREKFTDGHCSKVLRRCLCTKRC,47,Nicotiana occidentalis,Native peptide,,HUVEC: IC50=25.15±0.14 μM,,,,Anticancer; Antitumor; Antimicrobial,Tumor active peptide,,Linear,,Free,Free,,,0,RQCKRESNTFTGICIAKPPCRQACIREKFTDGHCSKVLRRCLCTKRC
WEQKIEELLKKAEEQQKKNEEELKKLEKC,29,Synthetic,Synthetic peptide,,PBMC: 50% Cytotoxicity=40.27 µM; HEK293T cells: 50% Cytotoxicity=25.31 µM,,,,Anticancer; Antiviral,Tumor active peptide,,Linear,,Acetylation,Chol-NH2,,,0,WEQKIEELLKKAEEQQKKNEEELKKLEKC
NGVQPKYKWWKWWKKWW,17,AMP,Synthetic peptide,,,,,"KT2 interacts with the plasma membrane and is then internalized into cells. Moreover, the KT2 peptide increases membrane permeability and induces cytotoxicity against cancer cells through DNA condensation, the increase of apoptotic factor protein levels, and autophagy suppression.",Anticancer,Tumor active peptide,,Linear,Cys2<--->Gly11,Free,Amidation,,,0,NGVQPKYKWWKWWKKWW
GRFKRFRKKFKKLFKKLS,18,Synthetic,Synthetic peptide,Human erythrocytes: 10% Hemolysis<400 µM; 50% Hemolysis>200 µM,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,,0,GRFKRFRKKFKKLFKKLS
KWCVYAYVKVKGVLVKYKKCW,21,Synthetic,Synthetic peptide,Human erythrocytes: 15% Hemolysis=10.1 µM; 50% Hemolysis=63 µM,,,,,Anticancer; Antibacterial,Tumor active peptide,,Cyclic,Cys3<--->Cys20,Free,Free,,,0,KWCVYAYVKVKGVLVKYKKCW
INLKKLAARIKKKI,14,Synthetic,Synthetic peptide,Human erythrocytes: 8% Hemolysis=100 µM,3T3-L1: 50% Cell death>100 µM	; HUVEC: 50% Cell death>100 µM,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,,,0,INLKKLAARIKKKI
KILKRLAAKIKKIL,14,Synthetic,Synthetic peptide,Human erythrocytes: 3% Hemolysis=100 µM,3T3-L1: 50% Cell death>100 µM	; HUVEC: 50% Cell death>100 µM,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,,,0,KILKRLAAKIKKIL
LP,2,marine natural metabolite,Native peptide,Human red blood cells (RBC): LC50>401 μM,MCF-12A: IC50>100 μM,,,,Anticancer; Antimicrobial,Tumor active peptide,,Cyclic,,Lactam,Lactam,Lactam,,0,LP
RFRPPIRRPPIRPPFWP,17,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,RFRPPIRRPPIRPPFWP
RFRPPIRRPPIRPPFYR,17,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,RFRPPIRRPPIRPPFYR
RFRPPIRRPPIRPPFYW,17,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,RFRPPIRRPPIRPPFYW
RFRRPIRRPPIRPPFYR,17,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,RFRRPIRRPPIRPPFYR
RFRRPIRRPPIRPPWYP,17,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,RFRRPIRRPPIRPPWYP
RFRRPIRRRPIRPPFWR,17,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,RFRRPIRRRPIRPPFWR
RFRRPIRRRPIRPPFYP,17,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,RFRRPIRRRPIRPPFYP
RFRRPIRRRPIRPPFYR,17,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,RFRRPIRRRPIRPPFYR
RFRRPIRRRPIRPPWYR,17,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,RFRRPIRRRPIRPPWYR
RFRWPIRRPPIRPPFYR,17,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,RFRWPIRRPPIRPPFYR
RFRWPIRRPPIRPPWYP,17,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,RFRWPIRRPPIRPPWYP
RFRWPIRRRPIRPPFWR,17,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,RFRWPIRRRPIRPPFWR
RFRWPIRRRPIRPPFYP,17,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,RFRWPIRRRPIRPPFYP
RFRWPIRRRPIRPPFYR,17,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,RFRWPIRRRPIRPPFYR
RFRWPIRRRPIRPPFYW,17,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,RFRWPIRRRPIRPPFYW
RFRWPIRRRPIRPPWYR,17,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,RFRWPIRRRPIRPPWYR
RRRRPIRRRPIRPPFYR,17,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,RRRRPIRRRPIRPPFYR
RRRRPIRRRPIRPPWYP,17,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,RRRRPIRRRPIRPPWYP
RRRRPIRRRPIRPPWYR,17,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,RRRRPIRRRPIRPPWYR
RRRRPWRRRPIRPPFYW,17,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,RRRRPWRRRPIRPPFYW
RWRPPIRRPPIRPPWYP,17,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,RWRPPIRRPPIRPPWYP
RWRRPIRRPPIRPPFYP,17,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,RWRRPIRRPPIRPPFYP
RWRRPIRRPPIRPPFYR,17,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,RWRRPIRRPPIRPPFYR
RWRRPIRRPPIRPPWYP,17,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,RWRRPIRRPPIRPPWYP
RWRRPIRRRPIRPPFWR,17,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,RWRRPIRRRPIRPPFWR
RWRRPIRRRPIRPPFYP,17,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,RWRRPIRRRPIRPPFYP
RWRRPIRRRPIRPPFYR,17,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,RWRRPIRRRPIRPPFYR
RWRRPIRRRPIRPPFYW,17,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,RWRRPIRRRPIRPPFYW
RWRRPIRRRPIRPPWYP,17,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,RWRRPIRRRPIRPPWYP
RWRRPIRRRPIRPPWYR,17,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,RWRRPIRRRPIRPPWYR
RWRRPWRRRPIRPPFYR,17,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,RWRRPWRRRPIRPPFYR
RWRWPIRRPPIRPPFYP,17,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,RWRWPIRRPPIRPPFYP
RWRWPIRRPPIRPPFYR,17,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,RWRWPIRRPPIRPPFYR
RWRWPIRRPPIRPPWYP,17,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,RWRWPIRRPPIRPPWYP
RWRWPIRRRPIRPPFWR,17,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,RWRWPIRRRPIRPPFWR
RWRWPIRRRPIRPPWYR,17,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,RWRWPIRRRPIRPPWYR
KSCFRVCYRGICYRRCRG,18,host defense peptide from the horseshoe crab Tachypleus tridentatus,Synthetic peptide,Human RBCs: CC50>32 µM ,HaCaT: CC50=41.4±2.6 µM ,,,,Anticancer; Antitumor,Tumor active peptide,,Cyclic,Cys3<--->Cys16; Cys7<--->Cys12,Free,Free,,,0,KSCFRVCYRGICYRRCRG
KWCFKVCYKGICYKKCKG,18,host defense peptide from the horseshoe crab Tachypleus tridentatus,Synthetic peptide,Human RBCs: CC50>32 µM ,HaCaT: CC50=31.1±2.1 µM ,,,,Anticancer; Antitumor,Tumor active peptide,,Cyclic,Cys3<--->Cys16; Cys7<--->Cys12,Free,Free,,,0,KWCFKVCYKGICYKKCKG
KWCFRVCSRGSCYRRCRG,18,host defense peptide from the horseshoe crab Tachypleus tridentatus,Synthetic peptide,Human RBCs: CC50>32 µM ,HaCaT: CC50>64 µM ,,,,Anticancer; Antitumor,Tumor active peptide,,Cyclic,Cys3<--->Cys16; Cys7<--->Cys12,Free,Free,,,0,KWCFRVCSRGSCYRRCRG
KWCFRVCYRGFCYRRCRK,18,host defense peptide from the horseshoe crab Tachypleus tridentatus,Synthetic peptide,Human RBCs: CC50=8.4±1.2 µM,HaCaT: CC50=4.1±0.1 µM,,,,Anticancer; Antitumor,Tumor active peptide,,Cyclic,Cys3<--->Cys16; Cys7<--->Cys12,Free,Free,,,0,KWCFRVCYRGFCYRRCRK
KWCFRVCYRGICYRRCRG,18,host defense peptide from the horseshoe crab Tachypleus tridentatus,Synthetic peptide,Human RBCs: CC50=107±21 µM ,HaCaT: CC50=7.9±0.5 µM ,,,,Anticancer; Antitumor,Tumor active peptide,,Cyclic,Cys3<--->Cys16; Cys7<--->Cys12,Free,Free,,,0,KWCFRVCYRGICYRRCRG
KWCFRVCYRGICYRRCRK,18,host defense peptide from the horseshoe crab Tachypleus tridentatus,Synthetic peptide,Human RBCs: CC50=6.9±0.3 µM ,HaCaT: CC50>64 µM ,,,,Anticancer; Antitumor,Tumor active peptide,,Cyclic,Cys3<--->Cys16; Cys7<--->Cys12,Free,Free,,,0,KWCFRVCYRGICYRRCRK
KWCFRVCYRGICYRRCSG,18,host defense peptide from the horseshoe crab Tachypleus tridentatus,Synthetic peptide,Human RBCs: CC50=10.3±0.4 µM ,HaCaT: CC50>64 µM ,,,,Anticancer; Antitumor,Tumor active peptide,,Cyclic,Cys3<--->Cys16; Cys7<--->Cys12,Free,Free,,,0,KWCFRVCYRGICYRRCSG
KWCFRVCYRGICYSRCRG,18,host defense peptide from the horseshoe crab Tachypleus tridentatus,Synthetic peptide,Human RBCs: CC50=5.3±0.3 µM ,HaCaT: CC50>64 µM ,,,,Anticancer; Antitumor,Tumor active peptide,,Cyclic,Cys3<--->Cys16; Cys7<--->Cys12,Free,Free,,,0,KWCFRVCYRGICYSRCRG
KWCFRVCYSGICYRRCRG,18,host defense peptide from the horseshoe crab Tachypleus tridentatus,Synthetic peptide,Human RBCs: CC50>64 µM ,,,,,Anticancer; Antitumor,Tumor active peptide,,Cyclic,Cys3<--->Cys16; Cys7<--->Cys12,Free,Free,,,0,KWCFRVCYSGICYRRCRG
KWCFRVCYSGICYSRCSG,18,host defense peptide from the horseshoe crab Tachypleus tridentatus,Synthetic peptide,Human RBCs: CC50=15.3±1.4 µM,,,,,Anticancer; Antitumor,Tumor active peptide,,Cyclic,Cys3<--->Cys16; Cys7<--->Cys12,Free,Free,,,0,KWCFRVCYSGICYSRCSG
KWCSRVCYRGICSRRCRG,18,host defense peptide from the horseshoe crab Tachypleus tridentatus,Synthetic peptide,Human RBCs: CC50>64 µM ,HaCaT: CC50>64 µM ,,,,Anticancer; Antitumor,Tumor active peptide,,Cyclic,Cys3<--->Cys16; Cys7<--->Cys12,Free,Free,,,0,KWCSRVCYRGICSRRCRG
SRSCLIVCQRLF,12,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Cyclic,Cys4<--->Cys8,Free,Amidation,,,0,SRSCLIVCQRLF
AWWRRTVAKVRK,12,Synthetic,Synthetic peptide,Human erythrocytes:0% Hemolysis=25 µM; 1.6% Hemolysis=200 µM,MRC-5: IC50>100 µM,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,,0,AWWRRTVAKVRK
GAWRRTVAKVRK,12,Synthetic,Synthetic peptide,Human erythrocytes:0% Hemolysis=25-200 µM,MRC-5: IC50>200 µM,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,,0,GAWRRTVAKVRK
GWARRTVAKVRK,12,Synthetic,Synthetic peptide,Human erythrocytes:0% Hemolysis=25-200 µM,MRC-5: IC50>200 µM,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,,0,GWARRTVAKVRK
GWWARTVAKVRK,12,Synthetic,Synthetic peptide,Human erythrocytes:0% Hemolysis=25 µM; 3.6% Hemolysis=200 µM,MRC-5: IC50>200 µM,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,,0,GWWARTVAKVRK
GWWRATVAKVRK,12,Synthetic,Synthetic peptide,Human erythrocytes:0% Hemolysis=25-200 µM,MRC-5: IC50>200 µM,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,,0,GWWRATVAKVRK
GWWRRTAAKVRK,12,Synthetic,Synthetic peptide,Human erythrocytes:0% Hemolysis=25-200 µM,MRC-5: IC50>200 µM,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,,0,GWWRRTAAKVRK
GWWRRTVAAVRK,12,Synthetic,Synthetic peptide,Human erythrocytes:0% Hemolysis=25 µM; 5.1% Hemolysis=200 µM,MRC-5: IC50>200 µM,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,,0,GWWRRTVAAVRK
GWWRRTVAKVAK,12,Synthetic,Synthetic peptide,Human erythrocytes:0% Hemolysis=25-200 µM,MRC-5: IC50>200 µM,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Free,,,0,GWWRRTVAKVAK
GWWRRTVAKVRK,12,Synthetic,Synthetic peptide,Human erythrocytes:2.4% Hemolysis=25 µM; 25.1% Hemolysis=200 µM,MRC-5: IC50>200 µM,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,,0,GWWRRTVAKVRK
GWWRRTVAKVRNAGRK,16,Synthetic,Synthetic peptide,Human erythrocytes: 0% Hemolysis=25 µM; 5% Hemolysis=200 µM,MRC-5: IC50>200 µM,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,,0,GWWRRTVAKVRNAGRK
GWWRRTVDKVRNAGRK,16,Synthetic,Synthetic peptide,Human erythrocytes: 0% Hemolysis=25-200 µM,MRC-5: IC50>200 µM,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Free,,,0,GWWRRTVDKVRNAGRK
SNGYRPAYRPAYRPSYRP,18,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,,,0,SNGYRPAYRPAYRPSYRP
SNVYRPPPYRPVYRPLRRPGYRP,23,Procambarus clarkii; Procambarus clarkii,Native peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,,,0,SNVYRPPPYRPVYRPLRRPGYRP
FYPRPYRPPYLPDPRPFPRPLPAFGHEFRRH,31,Procambarus clarkii,Native peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,FYPRPYRPPYLPDPRPFPRPLPAFGHEFRRH
GIKEMLCNMACAQTVCKKSGGPLCDTCQAACKALG,35,Synoicum turgens,Native peptide,,MRC-5: IC50=7.5 µM,,,,Anticancer; Antibacterial,Tumor active peptide,,Cyclic,Cys7<--->Cys31; Cys11<--->Cys27; Cys16<--->Cys24,Free,Amidation,,,0,GIKEMLCNMACAQTVCKKSGGPLCDTCQAACKALG
GIKEXLCNMACAQTVCKKSGGPLCDTCQAACKALG,35,Synoicum turgens,Native peptide,,MRC-5: IC50> 50 µM,,,,Anticancer; Antibacterial,Tumor active peptide,,Cyclic,Cys7<--->Cys31; Cys11<--->Cys27; Cys16<--->Cys24,Free,Amidation,X=MET-OXD,,0,GIKEXLCNMACAQTVCKKSGGPLCDTCQAACKALG
GIKEXLCNXACAQTVCKKSGGPLCDTCQAACKALG,35,Synoicum turgens,Native peptide,,MRC-5: IC50> 50 µM,,,,Anticancer; Antibacterial,Tumor active peptide,,Cyclic,Cys7<--->Cys31; Cys11<--->Cys27; Cys16<--->Cys24,Free,Amidation,X=MET-OXD,,0,GIKEXLCNXACAQTVCKKSGGPLCDTCQAACKALG
GPKTKAACKXACKLATCGKKPGGWKCKLCELGCDAV,36,Synoicum turgens,Native peptide,,MRC-5: IC50=4.8 µM,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Cyclic,Cys8<--->Cys33; Cys12<--->Cys29; Cys17<--->Cys26,Free,Amidation,X=MET-OXD,,0,GPKTKAACKXACKLATCGKKPGGWKCKLCELGCDAV
ILPWKWPWWPWKK,13,porcine cathelicidin peptide,Synthetic peptide,RBC: IC50 ≥ 65 µM,PBMC: IC50=26.4 µM,,,,Anticancer,Tumor active peptide,,Linear,,Free,Amidation,,,0,ILPWKWPWWPWKK
ILPWKWPWWPWRR,13,porcine cathelicidin peptide,Synthetic peptide,RBC: IC50 ≥ 65 µM,PBMC: IC50=26.8 µM,,,,Anticancer,Tumor active peptide,,Linear,,Free,Amidation,,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",0,ILPWKWPWWPWRR
KETWWETWWTEWSQPKKKRKV,21,porcine cathelicidin peptide,Synthetic peptide,RBC: IC50 ≥ 65 µM,PBMC: IC50 ≥ 65 µM,,,,Anticancer,Tumor active peptide,,Linear,,Free,Cysteamidation,,,0,KETWWETWWTEWSQPKKKRKV
RAWVAWR,7,porcine cathelicidin peptide,Synthetic peptide,RBC: IC50 ≥ 65 µM,PBMC: IC50 ≥ 65 µM,,,,Anticancer,Tumor active peptide,,Linear,,Free,Amidation,,,0,RAWVAWR
RRWWRF,6,porcine cathelicidin peptide,Synthetic peptide,RBC: IC50 ≥ 65 µM,PBMC: IC50 ≥ 65 µM,,,,Anticancer,Tumor active peptide,,Linear,,Free,Amidation,,,0,RRWWRF
CLBCREKAKKLFKKILKKL,19,Synthetic,Synthetic peptide,,NIH 3T3: IC50=33.7 ± 1.9 µM,,,,Anticancer; Antibacterial,Coupling peptide,,Linear,,Free,Amidation,,,0,CLBCREKAKKLFKKILKKL
VXXFPWWWPFLXX,13,porcine cathelicidin peptide,Synthetic peptide,RBC: IC50=34.6 µM,PBMC: IC50=9.3 µM,,,,Anticancer,Tumor active peptide,,Linear,,Free,Amidation,X=Agb=(S)-2-amino-4 guanidinobutyric acid,,0,VXXFPWWWPFLXX
VKKFAWWWAFLKK,13,porcine cathelicidin peptide,Synthetic peptide,RBC: IC50 ≥ 65 µM,PBMC: IC50=27.6 µM,,,,Anticancer,Tumor active peptide,,Linear,,Free,Amidation,,,0,VKKFAWWWAFLKK
VKKFAWWWPFLKK,13,porcine cathelicidin peptide,Synthetic peptide,RBC: IC50 ≥ 65 µM,PBMC: IC50=27.6 µM,,,,Anticancer,Tumor active peptide,,Linear,,Free,Amidation,,,0,VKKFAWWWPFLKK
VKKFPWWWAFLKK,13,porcine cathelicidin peptide,Synthetic peptide,RBC: IC50 ≥ 65 µM,PBMC: IC50=22.5 µM,,,,Anticancer,Tumor active peptide,,Linear,,Free,Amidation,,,0,VKKFPWWWAFLKK
VKKFPWWWPFLKK,13,porcine cathelicidin peptide,Synthetic peptide,RBC: IC50 ≥ 65 µM,PBMC: IC50=41.0 µM,,,,Anticancer,Tumor active peptide,,Linear,,Free,Amidation,,,0,VKKFPWWWPFLKK
VRRFAWWWAFLRR,13,porcine cathelicidin peptide,Synthetic peptide,RBC: IC50=52.5 µM,PBMC: IC50=20.7 µM,,,,Anticancer,Tumor active peptide,,Linear,,Free,Amidation,,,0,VRRFAWWWAFLRR
VRRFAWWWPFLRR,13,porcine cathelicidin peptide,Synthetic peptide,RBC: IC50 ≥ 65 µM,PBMC: IC50=26.4 µM,,,,Anticancer,Tumor active peptide,,Linear,,Free,Amidation,,,0,VRRFAWWWPFLRR
VRRFPXXXPFLRR,13,porcine cathelicidin peptide,Synthetic peptide,RBC: IC50=12.2 µM,PBMC: IC50=16.5 µM,,,,Anticancer,Tumor active peptide,,Linear,,Free,Amidation,X=bTA=β-3-benzothienyl-1-Ala,,0,VRRFPXXXPFLRR
VRRFPXWWPFLRR,13,porcine cathelicidin peptide,Synthetic peptide,RBC: IC50 ≥ 65 µM,PBMC: IC50=39.8 µM,,,,Anticancer,Tumor active peptide,,Linear,,Free,Amidation,X=HTrp=5-hydroxytryptophan; bTA,,0,VRRFPXWWPFLRR
VRRFPAAAPFLRR,13,porcine cathelicidin peptide,Synthetic peptide,RBC: IC50 ≥ 65 µM,PBMC: IC50 ≥ 65 µM,,,,Anticancer,Tumor active peptide,,Linear,,Free,Amidation,,,0,VRRFPAAAPFLRR
VRRFPAAWPFLRR,13,porcine cathelicidin peptide,Synthetic peptide,RBC: IC50 ≥ 65 µM,PBMC: IC50 ≥ 65 µM,,,,Anticancer,Tumor active peptide,,Linear,,Free,Amidation,,,0,VRRFPAAWPFLRR
VRRFPAWAPFLRR,13,porcine cathelicidin peptide,Synthetic peptide,RBC: IC50 ≥ 65 µM,PBMC: IC50 ≥ 65 µM,,,,Anticancer,Tumor active peptide,,Linear,,Free,Amidation,,,0,VRRFPAWAPFLRR
VRRFPAWWPFLRR,13,porcine cathelicidin peptide,Synthetic peptide,RBC: IC50 ≥ 65 µM,PBMC: IC50 ≥ 65 µM,,,,Anticancer,Tumor active peptide,,Linear,,Free,Amidation,,,0,VRRFPAWWPFLRR
VRRFPFFFPFLRR,13,porcine cathelicidin peptide,Synthetic peptide,RBC: IC50 ≥ 65 µM,PBMC: IC50 ≥ 65 µM,,,,Anticancer,Tumor active peptide,,Linear,,Free,Amidation,,,0,VRRFPFFFPFLRR
VRRFPWXWPFLRR,13,porcine cathelicidin peptide,Synthetic peptide,RBC: IC50 ≥ 65 µM,PBMC: IC50=24.3 µM,,,,Anticancer,Tumor active peptide,,Linear,,Free,Amidation,X=HTrp=5-hydroxytryptophan; bTA,,0,VRRFPWXWPFLRR
VRRFPWAAPFLRR,13,porcine cathelicidin peptide,Synthetic peptide,RBC: IC50 ≥ 65 µM,PBMC: IC50 ≥ 65 µM,,,,Anticancer,Tumor active peptide,,Linear,,Free,Amidation,,,0,VRRFPWAAPFLRR
VRRFPWAWPFLRR,13,porcine cathelicidin peptide,Synthetic peptide,RBC: IC50 ≥ 65 µM,PBMC: IC50 ≥ 65 µM,,,,Anticancer,Tumor active peptide,,Linear,,Free,Amidation,,,0,VRRFPWAWPFLRR
VRRFPWWXPFLRR,13,porcine cathelicidin peptide,Synthetic peptide,RBC: IC50 ≥ 65 µM,PBMC: IC50=23.9 µM,,,,Anticancer,Tumor active peptide,,Linear,,Free,Amidation,X=HTrp=5-hydroxytryptophan; bTA,,0,VRRFPWWXPFLRR
VRRFPWWAPFLRR,13,porcine cathelicidin peptide,Synthetic peptide,RBC: IC50 ≥ 65 µM,PBMC: IC50=52.1 µM,,,,Anticancer,Tumor active peptide,,Linear,,Free,Amidation,,,0,VRRFPWWAPFLRR
VRRFPWWWAFLRR,13,porcine cathelicidin peptide,Synthetic peptide,RBC: IC50=29.3 µM,PBMC: IC50=12.8 µM,,,,Anticancer,Tumor active peptide,,Linear,,Free,Amidation,,,0,VRRFPWWWAFLRR
VRRFPWWWPFLRR,13,porcine cathelicidin peptide,Synthetic peptide,RBC: IC50=62.2 µM,PBMC: IC50=18.4 µM,,,,Anticancer,Tumor active peptide,,Linear,,Free,Amidation,,,0,VRRFPWWWPFLRR
VRRFPWWYPFLRR,13,porcine cathelicidin peptide,Synthetic peptide,RBC: IC50 ≥ 65 µM,PBMC: IC50=21.6 µM,,,,Anticancer,Tumor active peptide,,Linear,,Free,Amidation,,,0,VRRFPWWYPFLRR
VRRFPWYWPFLRR,13,porcine cathelicidin peptide,Synthetic peptide,RBC: IC50 ≥ 65 µM,PBMC: IC50=26.4 µM,,,,Anticancer,Tumor active peptide,,Linear,,Free,Amidation,,,0,VRRFPWYWPFLRR
VRRFPWYYPFLRR,13,porcine cathelicidin peptide,Synthetic peptide,RBC: IC50 ≥ 65 µM,PBMC: IC50 ≥ 65 µM,,,,Anticancer,Tumor active peptide,,Linear,,Free,Amidation,,,0,VRRFPWYYPFLRR
VRRFPYWWPFLRR,13,porcine cathelicidin peptide,Synthetic peptide,RBC: IC50 ≥ 65 µM,PBMC: IC50=34.5 µM,,,,Anticancer,Tumor active peptide,,Linear,,Free,Amidation,,,0,VRRFPYWWPFLRR
VRRFPYWYPFLRR,13,porcine cathelicidin peptide,Synthetic peptide,RBC: IC50 ≥ 65 µM,PBMC: IC50 ≥ 65 µM,,,,Anticancer,Tumor active peptide,,Linear,,Free,Amidation,,,0,VRRFPYWYPFLRR
VRRFPYYWPFLRR,13,porcine cathelicidin peptide,Synthetic peptide,RBC: IC50 ≥ 65 µM,PBMC: IC50 ≥ 65 µM,,,,Anticancer,Tumor active peptide,,Linear,,Free,Amidation,,,0,VRRFPYYWPFLRR
VRRFPYYYPFLRR,13,porcine cathelicidin peptide,Synthetic peptide,RBC: IC50 ≥ 65 µM,PBMC: IC50 ≥ 65 µM,,,,Anticancer,Tumor active peptide,,Linear,,Free,Amidation,,,0,VRRFPYYYPFLRR
KTMMQSGGTFGTFMAIGMGIR,21,Synthetic,Synthetic peptide,Mouse erythrocytes: 20% Hemolysis=256µg/ml,HEK293: 20% Hemolysis=256µg/ml; HUVEC: 20% Hemolysis=256µg/ml,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,KTMMQSGGTFGTFMAIGMGIR
RWKLFKKIEKVGRNVRDGLIKAGPAIAVIGQAKSLGK,37,Bombyx mori,Native peptide,,HEK293T: 40% Killing=100µM,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,RWKLFKKIEKVGRNVRDGLIKAGPAIAVIGQAKSLGK
GFLKKIGKKLEGAVQRTRDATIQTIAVAQAAANVAATAKQ,40,Synthetic,Synthetic peptide,Human erythrocytes: Not active up to 1024 µg/ml,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,,0,GFLKKIGKKLEGAVQRTRDATIQTIAVAQAAANVAATAKQ
GFLKKVGKKLEGASDLTRDATIQTIAVAQAAANVAATAKQ,40,Synthetic,Synthetic peptide,Human erythrocytes: Not active up to 1024 µg/ml,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,,0,GFLKKVGKKLEGASDLTRDATIQTIAVAQAAANVAATAKQ
GWLRDFGKRIERTGQNIRDATIQTIGIAQEAANVAATLK,39,Synthetic,Synthetic peptide,Human erythrocytes: Not active up to 512 µg/ml,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,,0,GWLRDFGKRIERTGQNIRDATIQTIGIAQEAANVAATLK
QFNMQGGGSPRQGFDVNANARFPIWQSQNARNSVHGTASYAQHLGGPYGNSRPNFGGGLQFT,62,Synthetic,Synthetic peptide,Human erythrocytes: Not active up to 1024 µg/ml,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Free,,,0,QFNMQGGGSPRQGFDVNANARFPIWQSQNARNSVHGTASYAQHLGGPYGNSRPNFGGGLQFT
GFPCGESCVYIPCFTAAIGCSCKSKVCYKN,30,medicinal herb Hybanthus enneaspermus,Native peptide,Human red blood cells (hRBCs): HC50=24.56±2.16 µM ,"HUVEC:CC50=0.62±0.01 µM, testing time is 24h",,,,Anticancer,Tumor active peptide,,Cyclic,Cys4<--->Cys20; Cys8<--->Cys22; Cys13<--->Cys27,Free,Free,,,0,GFPCGESCVYIPCFTAAIGCSCKSKVCYKN
GIPCAESCVYIPCTVTALLGCSCSDKVCYN,30,medicinal herb Hybanthus enneaspermus,Native peptide,Human red blood cells (hRBCs): HC50>50 µM ,"HUVEC: CC50=2.06±0.08 µM , testing time is 24h",,,,Anticancer,Tumor active peptide,,Cyclic,Cys4<--->Cys20; Cys8<--->Cys22; Cys13<--->Cys27,Free,Free,,,0,GIPCAESCVYIPCTVTALLGCSCSDKVCYN
GTHPCQETCVTSTRCSTQGCHCNWPICFKN,30,medicinal herb Hybanthus enneaspermus,Native peptide,,,,,,Anticancer,Tumor active peptide,,Cyclic,Cys5<--->Cys15; Cys9<--->Cys20; Cys22<--->Cys27,Free,Free,,,0,GTHPCQETCVTSTRCSTQGCHCNWPICFKN
GVPCGESCVYIPCFTGIINCSCRDKVCYNN,30,medicinal herb Hybanthus enneaspermus,Native peptide,Human red blood cells (hRBCs): HC50>50 µM ,"HUVEC: CC50=2.06±0.08 µM , testing time is 24h",,,,Anticancer,Tumor active peptide,,Cyclic,Cys4<--->Cys20; Cys8<--->Cys22; Cys13<--->Cys27,Free,Free,,,0,GVPCGESCVYIPCFTGIINCSCRDKVCYNN
SIPCAESCVWIPCTVTALLGCSCSDKVCYN,30,medicinal herb Hybanthus enneaspermus,Native peptide,Human red blood cells (hRBCs): HC50>50 µM ,"HUVEC: CC50=1.38±0.03 µM, testing time is 24h",,,,Anticancer,Tumor active peptide,,Cyclic,Cys4<--->Cys20; Cys8<--->Cys22; Cys13<--->Cys27,Free,Free,,,0,SIPCAESCVWIPCTVTALLGCSCSDKVCYN
FLGAILKIGHALAKTVLPMVTNAFKPKQ,28,Boana raniceps,Native peptide,Human erythrocytes: 9% Hemolysis=16µM; 23% Hemolysis=32µM; 50% Hemolysis=48.9µM,,,,,Anticancer; Antibacterial; Antifungal; Antiviral,Tumor active peptide,,Linear,,Free,Free,,,0,FLGAILKIGHALAKTVLPMVTNAFKPKQ
ALWKDMLKGIGKLAGKAALGAVKTLV,26,Phyllomedusa palliata Skin Secretions,Native peptide,Horse erythrocytes: Dermaseptin-PP exhibited only a moderate hemolytic effect (<20% at 16 μM with a calculated HC50 of 38.77 μM),,,,,Anticancer; Antitumor; Antimicrobial,Tumor active peptide##Membrane-targeted,,Linear,,Free,Free,,,0,ALWKDMLKGIGKLAGKAALGAVKTLV
FIQHLIPLIPHAIQGIKDIF,20,"Skin Secretion of the African Frog, Kassina senegalensis",Native peptide,Human RBCs: Kassinatuerin-3 produced no detectable hemolysis activity up to a concentration of 160 μM,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Amidation,,,0,FIQHLIPLIPHAIQGIKDIF
GLLKRIKXLL,10,Synthetic,Synthetic peptide,Horse erythrocytes : 0% Hemolysis=256µM,HEK293T: 17% Hemolysis=256µM,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,X(8)=Beta-Ala,,0,GLLKRIKXLL
XLLKRIKTLL,10,Synthetic,Synthetic peptide,Horse erythrocytes : <5% Hemolysis=256µM,HEK293T: 15% Hemolysis=256µM,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,X(1)=Beta-Ala,,0,XLLKRIKTLL
XXGXGXXXA,9,Lyngbya majuscula,Native peptide,,,,,,Anticancer,Tumor active peptide,,Cyclic,NCB: X(1)<--->Ala9,Free,Free,"X(1)=3-amino-2-methylpentanoic acid; X(2)=2-hydroxy-3-methylpentanoate; X(4)=METH-Ile; X(6)=METH-Val; X(7)=METH-Phe; X(8)=4-amino-2,2-dimethyl-3-oxo-pentanoate",,0,XXGXGXXXA
RKIKRYLRRMI,11,Synthetic,Synthetic peptide,Mouse erythrocytes: 10% Hemolysis=1660µg/ml,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Free,,,0,RKIKRYLRRMI
RKIKVYLPRMK,11,Synthetic,Synthetic peptide,Mouse erythrocytes: 10% Hemolysis>1660µg/ml,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Free,,,0,RKIKVYLPRMK
GIFSKLAGKKIKNLLISGLKG,21,Synthetic,Synthetic peptide,Sheep erythrocytes: 10% Hemolysis=64 µM,HaCat: 20% Killing=64 µM,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,,0,GIFSKLAGKKIKNLLISGLKG
GIFSKLAGKKIKNlLIsGLKG,21,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,l=D-Leu; s=D-Ser,,0,GIFSKLAGKKIKNLLISGLKG
GIFSKLAGKKLKNLLISG,18,Synthetic,Synthetic peptide,Sheep erythrocytes: 10% Hemolysis=64 µM,HaCat: 20% Killing=64 µM,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,,,0,GIFSKLAGKKLKNLLISG
FIFLPIFRRPVS,12,Glandirana susurra,Native peptide,,COS-7: 	88.5% Killing=32µg/ml; CPAE: 99.2% Killing=32µg/ml,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Free,,,0,FIFLPIFRRPVS
GLISTIWNTASNVAGTLTDSVKCKFKKC,28,Glandirana susurra,Native peptide,,COS-7: 	88.5% Killing=32µg/ml; CPAE: 99.2% Killing=32µg/ml,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Free,,,0,GLISTIWNTASNVAGTLTDSVKCKFKKC
SLFSLIKAGAKFLGKNMLKQGPQYPACKVSKDSENVNWKS,40,Glandirana susurra,Native peptide,,COS-7: 	88.5% Killing=32µg/ml; CPAE: 99.2% Killing=32µg/ml,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Free,,,0,SLFSLIKAGAKFLGKNMLKQGPQYPACKVSKDSENVNWKS
FALGAVTKVLPKLFCLITRKC,21,skin secretion of Amolops hainanensis ,Native peptide,,Horse blood cells: HC50=53.12 µM,,,,Anticancer; Antitumor; Antimicrobial,Tumor active peptide,,Linear,,Free,Free,,,0,FALGAVTKVLPKLFCLITRKC
FALGAVTCLIRTKCKVLPKLF,21,skin secretion of Amolops hainanensis ,Native peptide,,Horse blood cells: only over 20% at a concentration of 128 µM,,,,Anticancer; Antitumor; Antimicrobial,Tumor active peptide,,Linear,,Free,Free,,,0,FALGAVTCLIRTKCKVLPKLF
FALGAVTKVLYKLFCLITRKC,21,skin secretion of Amolops hainanensis ,Native peptide,,Horse blood cells: The haemolysis at the MIC of Brevinin-1HY (28.48%) was more than threefold at the MIC for the parent peptide,,,,Anticancer; Antitumor; Antimicrobial,Tumor active peptide,,Linear,,Free,Free,,,0,FALGAVTKVLYKLFCLITRKC
GFQKVKAQAATCNHTVMA,18,Synthetic,Synthetic peptide,,IC50 on PBMCs was = 92.0 ± 39.6 μM,,,"may induce cell death through processes involving membrane surface blebs, loss of membrane integrity, PI internalization, LDH release and PS externalization, coupled with coordinated regulation of Src•Erk1/2 signaling and mitochondrial events.",Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,GFQKVKAQAATCNHTVMA
GFQKAKAKALACLAKALA,18,Synthetic,Synthetic peptide,,IC50 on PBMCs was = 92.0 ± 39.6 μM,,,"may induce cell death through processes involving membrane surface blebs, loss of membrane integrity, PI internalization, LDH release and PS externalization, coupled with coordinated regulation of Src•Erk1/18 signaling and mitochondrial events.",Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,GFQKAKAKALACLAKALA
GFQKVKAQALTCLHTVMA,18,Synthetic,Synthetic peptide,,IC50 on PBMCs was = 92.0 ± 39.6 μM,,,"may induce cell death through processes involving membrane surface blebs, loss of membrane integrity, PI internalization, LDH release and PS externalization, coupled with coordinated regulation of Src•Erk1/10 signaling and mitochondrial events.",Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,GFQKVKAQALTCLHTVMA
GIGKAIAKAIACIAKAIA,18,Synthetic,Synthetic peptide,,IC50 on PBMCs was = 92.0 ± 39.6 μM,,,"may induce cell death through processes involving membrane surface blebs, loss of membrane integrity, PI internalization, LDH release and PS externalization, coupled with coordinated regulation of Src•Erk1/34 signaling and mitochondrial events.",Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,GIGKAIAKAIACIAKAIA
GLGKALAKALACLAKALA,18,Synthetic,Synthetic peptide,"Human red blood cells: EC 50=21.2±3.2 μM, testing time is 24 h",IC50 on PBMCs was = 92.0 ± 39.6 μM,,,"may induce cell death through processes involving membrane surface blebs, loss of membrane integrity, PI internalization, LDH release and PS externalization, coupled with coordinated regulation of Src•Erk1/26 signaling and mitochondrial events.",Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,GLGKALAKALACLAKALA
FLPALAGIAGLLGKIF,16,Pelophylax saharicus,Native peptide,Human erythrocytes: 22% Hemolysis=12.5µM; 84% Hemolysis=25µM,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,,0,FLPALAGIAGLLGKIF
FIGTLIPLALGALTKLFK,18,B. raniceps skin secretion,Native peptide,Human red blood cells: HC50 =10 µM (0.019 g/L) (testing time is 24 h),NIH 3T3: IC50=13 µM (0.025 g/L) (testing time is 24 h),,,,Anticancer; Antimicrobial,Tumor active peptide,,Linear,,Free,Free,,,0,FIGTLIPLALGALTKLFK
CKKKC,5,Synthetic,Synthetic peptide,Human erythrocytes:HC50=43.9±3.5µg/ml,HaCat: IC50=23.6±6µg/ml,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide##Lipopeptides##Membrane lysis,,Cyclic,Cys1<--->Cys5,"CH3(CH2)14CO, Palmitic acid",Amidation,,,0,CKKKC
CKKKRC,6,Synthetic,Synthetic peptide,Human erythrocytes:HC50=71±6.4µg/ml,HaCat: IC50=45.7±13.5µg/ml,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide##Lipopeptides##Membrane lysis,,Cyclic,Cys1<--->Cys6,"CH3(CH2)14CO, Palmitic acid",Amidation,,,0,CKKKRC
CKKRKC,6,Synthetic,Synthetic peptide,Human erythrocytes:HC50=97±15.4µg/ml,HaCat: IC50=12.9±4.6µg/ml,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide##Lipopeptides##Membrane lysis,,Cyclic,Cys1<--->Cys6,"CH3(CH2)14CO, Palmitic acid",Amidation,,,0,CKKRKC
CRKKKC,6,Synthetic,Synthetic peptide,Human erythrocytes:HC50=66.5±14.8µg/ml,HaCat: IC50=36.8±2.7µg/ml,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide##Lipopeptides##Membrane lysis,,Cyclic,Cys1<--->Cys6,"CH3(CH2)14CO, Palmitic acid",Amidation,,,0,CRKKKC
KKKR,4,Synthetic,Synthetic peptide,Human erythrocytes:HC50=89.7±2.4µg/ml,HaCat: IC50=7.5±0.8µg/ml,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide##Lipopeptides##Membrane lysis,,Linear,,"CH3(CH2)14CO, Palmitic acid",Amidation,,,0,KKKR
KKRK,4,Synthetic,Synthetic peptide,Human erythrocytes:HC50=96.7±1.4µg/ml,HaCat: IC50=2.4±0.4µg/ml,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide##Lipopeptides##Membrane lysis,,Linear,,"CH3(CH2)14CO, Palmitic acid",Amidation,,,0,KKRK
RKKK,4,Synthetic,Synthetic peptide,Human erythrocytes:HC50=79.1±6.1µg/ml,HaCat: IC50=23.6±3.4µg/ml,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide##Lipopeptides##Membrane lysis,,Linear,,"CH3(CH2)14CO, Palmitic acid",Amidation,,,0,RKKK
WRRRYRRWRRRRRWRRRPRR,20,Synthetic,Synthetic peptide,Human erythrocytes: 50% Hemolysis>200µM,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,,,0,WRRRYRRWRRRRRWRRRPRR
RRIPFWPIPLRWQWPPPWFPPSFPIPRISRKR,32,Synthetic,Synthetic peptide,Human erythrocytes:25% Hemolysis=32µM,HaCat: 	10% Killing=32µM,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Free,,,0,RRIPFWPIPLRWQWPPPWFPPSFPIPRISRKR
RRIPFWPPNLPGPRRPPWFLPDFRIPRIPRKR,32,Synthetic,Synthetic peptide,Human erythrocytes:0% Hemolysis=32µM,HaCat: 	15% Killing=32µM,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Free,,,0,RRIPFWPPNLPGPRRPPWFLPDFRIPRIPRKR
RRIRFPFPPFPWQWPPAGFPTFHIPRIPRKQ,31,Synthetic,Synthetic peptide,Human erythrocytes:0% Hemolysis=32µM,HaCat: 	12% Killing=32µM,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Free,,,0,RRIRFPFPPFPWQWPPAGFPTFHIPRIPRKQ
RRIRFRPPRLPRPRPRPWIPPRFPFPRIPGKR,32,Synthetic,Synthetic peptide,Human erythrocytes:0% Hemolysis=32µM,HaCat: 	0% Killing=32µM,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Free,,,0,RRIRFRPPRLPRPRPRPWIPPRFPFPRIPGKR
RRIRIRPPRLPRPRPRPWFPPRFPIPRIPGKR,32,Synthetic,Synthetic peptide,Human erythrocytes:0% Hemolysis=32µM,HaCat: 	10% Killing=32µM,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Free,,,0,RRIRIRPPRLPRPRPRPWFPPRFPIPRIPGKR
KCAGSIAWAIGSGLFGGAKLIKIKKYIAELGGLQ,34,Synthetic,Synthetic peptide,,Vero E6: 50% Cytotoxicity=438 µM,,,,Anticancer; Antibacterial; Antifungal; Antiviral,Tumor active peptide,,Linear,,Free,Free,,,0,KCAGSIAWAIGSGLFGGAKLIKIKKYIAELGGLQ
KRWHWWRRHWVVW,13,Synthetic,Synthetic peptide,,HUVEC: IC50>100 μM; NL20: IC50=76.9 μM,,,,Anticancer; Antitumor; Antimicrobial,Tumor active peptide,,Linear,,Free,Amidation,,,0,KRWHWWRRHWVVW
KRWWKWWRR,9,Synthetic,Synthetic peptide,,,,,,Anticancer; Antitumor; Antimicrobial,Tumor active peptide,,Linear,,Free,Amidation,,,0,KRWWKWWRR
LWKRWVGVWRKWL,13,Synthetic,Synthetic peptide,,HUVEC: IC50=19.5 μM; NL20: IC50=19.0 μM,,,,Anticancer; Antitumor; Antimicrobial,Tumor active peptide,,Linear,,Free,Amidation,,,0,LWKRWVGVWRKWL
RWGKWFKKNSHLS,13,Synthetic,Synthetic peptide,,HUVEC: IC50>100 μM; NL20: IC50>100 μM,,,,Anticancer; Antitumor; Antimicrobial,Tumor active peptide,,Linear,,Free,Amidation,,,0,RWGKWFKKNSHLS
WKWLKKWIK,9,Synthetic,Synthetic peptide,,,,,,Anticancer; Antitumor; Antimicrobial,Tumor active peptide,,Linear,,Free,Amidation,,,0,WKWLKKWIK
FPVTWRWWKWWKG,13,Synthetic,Synthetic peptide,Sheep erythrocytes: No hemolysis up tp 500 µg/ml,NIH 3T3: IC50>250 µg/ml,,,"Dual mechanism, with the disruption of the membrane integrity possibly being the main cause of cell death, but only after peptide translocation and binding to intracellular targets.",Anticancer; Antibacterial; Antifungal,Tumor active peptide##Membrane lysis##Binding intracellular targets,,Cyclic,NCB: Phe1<--->Gly13,Free,Amidation,,,0,FPVTWRWWKWWKG
CGAISLAKLQINES,14,Synthetic,Synthetic peptide,,,programmed cell death protein 1,,,Anticancer; Antitumor,Tumor active peptide##Cancer targeted peptides,,Linear,,Free,Free,,,0,CGAISLAKLQINES
CGAISLAPKAQIKES,15,Synthetic,Synthetic peptide,,,programmed cell death protein 1,,,Anticancer; Antitumor,Tumor active peptide##Cancer targeted peptides,,Linear,,Free,Free,,,0,CGAISLAPKAQIKES
CGAISLAPKLQIKES,15,Synthetic,Synthetic peptide,,,programmed cell death protein 1,,,Anticancer; Antitumor,Tumor active peptide##Cancer targeted peptides,,Linear,,Free,Free,,,0,CGAISLAPKLQIKES
GAISAPKLQIND,12,Synthetic,Synthetic peptide,,,programmed cell death protein 1,,,Anticancer; Antitumor,Tumor active peptide##Cancer targeted peptides,,Linear,,Free,Free,,,0,GAISAPKLQIND
GAISLAKLQINeG,13,Synthetic,Synthetic peptide,,,programmed cell death protein 1,,,Anticancer; Antitumor,Tumor active peptide##Cancer targeted peptides,,Cyclic,,Acetylization,Amidation,"C,N-terminal lactam peptide; e=D-Glutamic acid",,0,GAISLAKLQINEG
GAISLAPKLQINE,13,Synthetic,Synthetic peptide,,,programmed cell death protein 1,,,Anticancer; Antitumor,Tumor active peptide##Cancer targeted peptides,,Linear,,Free,Free,,,0,GAISLAPKLQINE
GAISLAPKLQINe,13,Synthetic,Synthetic peptide,,,programmed cell death protein 1,,,Anticancer; Antitumor,Tumor active peptide##Cancer targeted peptides,,Linear,,Free,Free,e=D-Glutamic acid,,0,GAISLAPKLQINE
FFPVIGRILNGIL,13,Rana temporaria,Native peptide,,,,,,Anticancer; Antibacterial; Antiviral,Tumor active peptide,,Linear,,Free,Free,,,0,FFPVIGRILNGIL
VKLRSLLCS,9,garlic,Native peptide,,PBMC: IC50>2.0 mM,groove of the BH3 domain on target proteins,,"VS-9 could induce apoptosis and upregulate mRNA levels of caspase 3, caspase 8, caspase 9, and Bax while downregulating Bcl-2, Bcl-xL, and Bcl-w.",Anticancer,Tumor active peptide##Cancer targeted peptides,,Linear,,Free,Free,,,0,VKLRSLLCS
DVNFLLHKIYGNIRY,15,Litopenaeus vannamei,Native peptide,,THLE-3: 30.83% decrease=50μg/mL,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,DVNFLLHKIYGNIRY
ALWMTLLKKVLKAAAKAALNAVLVGANA,28,Phyllomedusa sauvagii,Native peptide,Human erythrocytes: 68.5±10.83% Hemolysis=256 µg/ml,,,,,Anticancer; Antibacterial; Antiviral,Tumor active peptide,,Linear,,Free,Amidation,,,0,ALWMTLLKKVLKAAAKAALNAVLVGANA
FFPLIAGLAARFLPKIFCSITKRC,24,Frog Skin Secretion,Native peptide,Human erythrocytes: Moderate Hemolysis,NCM460: IC50=16.84±0.56 µM; BEAS-2B: IC50=16.57±0.29 µM; HaCaT: IC50=28.67±0.36 µM ,,,,Anticancer; Antitumor; Antimicrobial,Tumor active peptide,,Linear,,Free,Free,,,0,FFPLIAGLAARFLPKIFCSITKRC
GIINTLQKYYCRVRGGRCAVLSCLPKEEQIGKCSTRGRKCCRRKK,45,Homo sapiens,Native peptide,Human erythrocytes: 0% Hemolysis=40 µg/ml,Vero cells: 20% Killing=40 µg/ml,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Cyclic,Cys11<---Cys40; Cys18<--->Cys33; Cys23<---Cys41,Free,Free,,,0,GIINTLQKYYCRVRGGRCAVLSCLPKEEQIGKCSTRGRKCCRRKK
GLFDVVKGVLKGAGKNVAGSLLEQLKCKLSGGC,33,Rana dybowskii,Native peptide,Sheep erythrocytes: <10% Hemolysis=256 µM,HEK293T cells: IC50=50.66 µM,,,,Anticancer; Antibacterial,Tumor active peptide,,Cyclic,Cys27<--->Cys33,Free,Free,,,0,GLFDVVKGVLKGAGKNVAGSLLEQLKCKLSGGC
GLFLDTLKGAAKDVAGKLEGLKCKITGCKLP,31,Rana catesbeiana,Native peptide,Human erythrocytes: 0% Hemolysis=20 µg/ml; Sheep erythrocytes: <10% Hemolysis=256 µM,HEK293T cells: IC50>128 µM,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Cyclic,Cys23<--->Cys28,Free,Free,,,0,GLFLDTLKGAAKDVAGKLEGLKCKITGCKLP
ILGTILGLLKGL,12,venom glands of three different wasps,Native peptide,hRBC(human blood red cells): CC50>>500 µM,MCF-10A : CC50=96.8±3.5 µM  (testing time is 24 h),lipids,,,Anticancer,Tumor active peptide##Cancer targeted peptides,,Linear,,Free,Amidation,,,0,ILGTILGLLKGL
CIIKKIIKKIIKK,13,AMP,Synthetic peptide,,HDF: IC50>100 µM,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,CIIKKIIKKIIKK
CIIKKIIKKIIKKII,15,AMP,Synthetic peptide,,HDF: IC50=83±5 µM,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,CIIKKIIKKIIKKII
CIIRRIIRRIIRR,13,AMP,Synthetic peptide,,HDF: IC50=22±3 µM,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,CIIRRIIRRIIRR
CLLKKLLKKLLKK,13,AMP,Synthetic peptide,,HDF: IC50>100 µM,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,CLLKKLLKKLLKK
CLLRRLLRRLLRR,13,AMP,Synthetic peptide,,HDF: IC50=24±5 µM,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,CLLRRLLRRLLRR
KKRKKKAFALKFVVDLI,17,insect-derived peptide,Native peptide,,HaCaT: not induce toxicity ,,,"PCC-1 induces cell proliferation inhibition, apoptosis, and cell cycle arrest by downregulating Sp1 expression in the melanoma cell lines SK-MEL-28 and G361.",Anticancer,Tumor active peptide,,Linear,,Free,Amidation,,,0,KKRKKKAFALKFVVDLI
VTFVLIAAK,9,Cordyceps militaris,Native peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,VTFVLIAAK
IKIKIKIKIKIK,12,cationic amphiphilic peptides,Synthetic peptide,,HDF: IC50=4.4±0.3 µM,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,IKIKIKIKIKIK
IKIRIKIRIKIR,12,cationic amphiphilic peptides,Synthetic peptide,,HDF: IC50=38.6±0.2 µM,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,IKIRIKIRIKIR
IRIKIRIKIRIK,12,cationic amphiphilic peptides,Synthetic peptide,,HDF: IC50=34.5±0.9 µM,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,IRIKIRIKIRIK
LKLKLKLKLKLK,12,cationic amphiphilic peptides,Synthetic peptide,,HDF: IC50>40 µM,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,LKLKLKLKLKLK
LKLRLKLRLKLR,12,cationic amphiphilic peptides,Synthetic peptide,,HDF: IC50=22.5±1.4 µM,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,LKLRLKLRLKLR
LRLKLRLKLRLK,12,cationic amphiphilic peptides,Synthetic peptide,,HDF: IC50=24.1±0.7 µM,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,LRLKLRLKLRLK
LRLRLRLRLRLR,12,cationic amphiphilic peptides,Synthetic peptide,,HDF: IC50=22.7±2.4 µM,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,LRLRLRLRLRLR
FLPLLISALTSLFPKLGK,18,Skin Secretion of Indosylvirana aurantiaca,Native peptide,Human red blood cell: SSTP1-induced hemolysis at 5 μM was only-0.25%,"HEK293: IC50=21.72 μM, lower cytotoxicity",IL6/IL6Rα/gp130 complex,,"In IL6Rα-overexpressing cancer cells, SSTP1 induces apoptosis at low concentration through JNK pathway, without causing significant membrane disruption.",Anticancer; Antitumor,Tumor active peptide##Cancer targeted peptides,,Linear,,Free,Free,,,0,FLPLLISALTSLFPKLGK
GYFCESCRKIIQKLEDMVGPQPNEDTVTQAASQVCDKLKILRGLCKKIMRSFLRRISWDILTGKKPQAICVDIKICKE,78,Sus scrofa,Native peptide,Sheep erythrocytes: 0% Hemolysis=170 µM,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Cyclic,Cys4<--->Cys76; Cys7<--->Cys70; Cys35<--->Cys45,Free,Free,,,0,GYFCESCRKIIQKLEDMVGPQPNEDTVTQAASQVCDKLKILRGLCKKIMRSFLRRISWDILTGKKPQAICVDIKICKE
MPRWRLFRRIDRVGKQIKQGILRAGPAIALVGDARAVG,38,Magainin,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,,,0,MPRWRLFRRIDRVGKQIKQGILRAGPAIALVGDARAVG
SWLSKTAKKLENSAKKRISEGIAIAIQGGPR,31,Small Intestine of Pig,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,,,0,SWLSKTAKKLENSAKKRISEGIAIAIQGGPR
GEILCNLCTGLINTLENLLTTKGADKVKDYISSLCNKASGFIATLCTKVLDFGIDKLIQLIEDKVDANAICAKIHAC,77,Entamoeba histolytica,Native peptide,Human erythrocytes: 10% Hemolysis=10 µm,,,,,Anticancer; Antibacterial,Tumor active peptide,,Cyclic,Cys5<--->Cys77; Cys8<--->Cys71; Cys35<--->Cys46,Free,Free,,,0,GEILCNLCTGLINTLENLLTTKGADKVKDYISSLCNKASGFIATLCTKVLDFGIDKLIQLIEDKVDANAICAKIHAC
GEILCNLCTGLINTLENLLTTKRKRQQ,27,Synthetic,Synthetic peptide,Human erythrocytes: 50% Hemolysis=10 µM,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,,,0,GEILCNLCTGLINTLENLLTTKRKRQQ
GFIATLCTKVLDFGIDKLIQLIEDK,25,Synthetic,Synthetic peptide,Human erythrocytes: 10% Hemolysis=10 µm,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,GFIATLCTKVLDFGIDKLIQLIEDK
GIGKFLKKAKKFAKAFVKIINN,22,African clawed frog Xenopus laevis skin,Synthetic peptide,,,,,A mechanism which appears to be related to short duration non-receptor-driven contact with target cell membranes.,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,,,0,GIGKFLKKAKKFAKAFVKIINN
gigkflkkakkfakafvkiinn,22,African clawed frog Xenopus laevis skin,Synthetic peptide,,,,,A mechanism which appears to be related to short duration non-receptor-driven contact with target cell membranes.,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,,,0,GIGKFLKKAKKFAKAFVKIINN
KWKLFKKIGIGAVLKVLTTG,20,Ceropin A-Magainin 2,Synthetic peptide,Human red blood cells: hemolysis 4.2%(50 μg/mL); hemolysis 14.1%(100 μg/mL),,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,,,0,KWKLFKKIGIGAVLKVLTTG
KWKLFKKIGIGAVLKVLKKG,20,Ceropin A-Magainin 2,Synthetic peptide,Human red blood cells: hemolysis 0.3%(50 μg/mL); hemolysis 1%(100 μg/mL),,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,,,0,KWKLFKKIGIGAVLKVLKKG
KWKLFKKIGIGKFLHSATTF,20,Ceropin A-Magainin 2,Synthetic peptide,Human red blood cells: hemolysis 0.2%(50 μg/mL); hemolysis 1%(100 μg/mL),,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,,,0,KWKLFKKIGIGKFLHSATTF
KWKLFKKIGIGAFLHSAKKF,20,Ceropin A-Magainin 2,Synthetic peptide,Human red blood cells: hemolysis 0.1%(50 μg/mL); hemolysis 0.2%(100 μg/mL),,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,,,0,KWKLFKKIGIGAFLHSAKKF
KWKLFKKIGIGKFLHLAKKF,20,Ceropin A-Magainin 2,Synthetic peptide,Human red blood cells: hemolysis 0.2%(50 μg/mL); hemolysis 0.7%(100 μg/mL),,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,,,0,KWKLFKKIGIGKFLHLAKKF
KWKLFKKIGIGAFLHLAKKF,20,Ceropin A-Magainin 2,Synthetic peptide,Human red blood cells: hemolysis 1.5%(50 μg/mL); hemolysis 8%(100 μg/mL),,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,,,0,KWKLFKKIGIGAFLHLAKKF
KWKLFKKIGIGKFKLAKKF,19,Ceropin A-Magainin 2,Synthetic peptide,Human red blood cells: hemolysis 0.2%(50 μg/mL); hemolysis 1.2%(100 μg/mL),,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,,,0,KWKLFKKIGIGKFKLAKKF
KWKLFAKIGIGKFLHLAKKF,20,Ceropin A-Magainin 2,Synthetic peptide,Human red blood cells: hemolysis 0.4%(50 μg/mL); hemolysis 2.4%(100 μg/mL),,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,,,0,KWKLFAKIGIGKFLHLAKKF
KWKKFLKIGIGKFLHLAKKF,20,Ceropin A-Magainin 2,Synthetic peptide,Human red blood cells: hemolysis 2.4%(50 μg/mL); hemolysis 13.7%(100 μg/mL),,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,,,0,KWKKFLKIGIGKFLHLAKKF
ALWKDILKNVGKAAGKAVLNTVTDMVNQ,28,Dermaseptins B,Native peptide,,,,,,Anticancer; Antimicrobial,Tumor active peptide,,Linear,,Free,Amidation,,,0,ALWKDILKNVGKAAGKAVLNTVTDMVNQ
ALWKNMLKGIGKLAGQAALGAVKTLVGA,28,Dermaseptins B,Native peptide,,,,,,Anticancer; Antimicrobial,Tumor active peptide,,Linear,,Free,Free,,,0,ALWKNMLKGIGKLAGQAALGAVKTLVGA
ALWKTMLKKLGTMALHAGKAALGAAADTISQGTQ,34,Dermaseptins B,Native peptide,,,,,,Anticancer; Antimicrobial,Tumor active peptide,,Linear,,Free,Free,,,0,ALWKTMLKKLGTMALHAGKAALGAAADTISQGTQ
FLPIVGKLLSGLSGLL,16,Amolops loloensis; Amolops jingdongensis; Amolops mantzorum,Native peptide,Human erythrocytes: 25% Hemolysis=61.46 µM,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,FLPIVGKLLSGLSGLL
RQSHFANAQP,10,Chickpea (Cicer arietinum L.),Native peptide,,,p53 protein,,"the bioactive peptide combined the DNA binding domain of p53 protein by hydrogen bonds, induced the expression of p53 protein and facilitated its stability so that it inhibited the cell proliferation.",Anticancer,Tumor active peptide##Cancer targeted peptides,,Linear,,Free,Free,,,0,RQSHFANAQP
WPP,3,hydrolysate of blood clam (Tegillarca granosa) muscle,Native peptide,,NIH 3T3: Has hardly any cytotoxicity on normal cells.,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,WPP
SLPQNIPPLTQTPVVVPPF,19,Synbiotic yoghurt,Native peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,SLPQNIPPLTQTPVVVPPF
YQEPVLGPVRGPFPIIV,17,Synbiotic yoghurt,Native peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,YQEPVLGPVRGPFPIIV
XXMXIVVKVLKYLX,14,Brevibacillus laterosporus,Native peptide,,Human Splenic Fibroblasts (HSF): IC50=12.78±0.33 µg/mL; Endometrial epithelial cells(HEEC): IC50=2.66±0.34 µg/mL; HPDE6c7 Human Pancreatic Duct Epithelial Cell: IC50=3.45±0.20 µg/mL; Normal Human Hepatic Cell (Lo-2): IC50=2.91±0.07 µg/mL; NCM460: IC50=3.04±0.10 µg/mL; CCD-19Lu: IC50=4.76±0.03 µg/mL; Human Intrahepatic Biliary Epithelial Cells (HIBEpiC): IC50=2.37±0.38 µg/; HEK293: IC50=4.78±0.32 µg/mL; IOSE80: IC50=1.12±0.04 µg/mL; RWPE-1: IC50=1.07±0.34 µg/mL; GES-1: IC50=10.62±0.73 µg/mL; MCF-10A: IC50=1.58±0.33 µg/mL;,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,X(1)=Hmp=2-hydroxy-3-methylpentanoic acid; X(2)=Aba=2-amino-2-butenoic acid; X(4)=Ornithine; X(14)=valinol,,0,XXMXIVVKVLKYLX
INKKI,5,β-Casein,Native peptide,,Fibroblast FN-1 (human): no effect (testing time is 24 h); Endothelial CRL 1730 (human) : no effect (testing time is 24 h),,,By apoptosis via  mitochondrial pathway in a caspase-independent manner,Anticancer; Antitumor,Tumor active peptide,,Linear,,Free,Free,,,0,INKKI
GIKCRFCCGCCTPGICGVCCRF,22,"Skin Secretion of the African Frog, Kassina senegalensis",Native peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,GIKCRFCCGCCTPGICGVCCRF
GLFDIVKGIKSLF,13,Synthetic,Synthetic peptide,,Vero: IC50=48.67±1.76 µg/mL; THLE-3: IC50=58.83±0.83 µg/mL,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,GLFDIVKGIKSLF
GLFDIVKKIKSLF,13,Synthetic,Synthetic peptide,,Vero: IC50=45.17±2.46 µg/mL; THLE-3: IC50=52.83±0.60 µg/mL,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,GLFDIVKKIKSLF
GLFDIVKKLKSLF,13,Synthetic,Synthetic peptide,,Vero: IC50=43.83±1.33 µg/mL; THLE-3: IC50=39.17±2.17 µg/mL,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,GLFDIVKKLKSLF
GLFDIVKKLVSDF,13,Synthetic,Synthetic peptide,,Vero: IC50=188.00±2.18 µg/mL; THLE-3: IC50=204.67±3.42 µg/mL,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,GLFDIVKKLVSDF
GLFDIWKGIKSLF,13,Synthetic,Synthetic peptide,,Vero: IC50=22.67±0.44 µg/mL; THLE-3: IC50=34.33±0.73 µg/mL,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,GLFDIWKGIKSLF
GLFDRVKKRKSLF,13,Synthetic,Synthetic peptide,,Vero: IC50>256 µg/mL; THLE-3: IC50>256 µg/mL,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,GLFDRVKKRKSLF
ILGKIVKKLVSDF,13,Synthetic,Synthetic peptide,,Vero: IC50>256 µg/mL; THLE-3: IC50>256 µg/mL,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,ILGKIVKKLVSDF
ILGKIWKGIKSLF,13,Synthetic,Synthetic peptide,,Vero: IC50=20.50±1.26 µg/mL ; THLE-3: IC50=31.50±1.76 µg/mL,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,ILGKIWKGIKSLF
ILGKIWKGIVSDF,13,Synthetic,Synthetic peptide,,Vero: IC50>256 µg/mL; THLE-3: IC50>256 µg/mL,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,ILGKIWKGIVSDF
ILGKIWKGLVSDF,13,Synthetic,Synthetic peptide,,Vero: IC50>256 µg/mL; THLE-3: IC50>256 µg/mL,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,ILGKIWKGLVSDF
ILGKIWKKLVSDF,13,Synthetic,Synthetic peptide,,Vero: IC50=156.33±4.33 µg/mL; THLE-3: IC50=105.33±4.42 µg/mL,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,ILGKIWKKLVSDF
ILGKRWKGRVSDF,13,Synthetic,Synthetic peptide,,Vero: IC50>256 µg/mL; THLE-3: IC50>256 µg/mL,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,ILGKRWKGRVSDF
YALPAG,6,Heated products of peptic hydrolysates of half-fin anchovy (Setipinna taty),Native peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,YALPAG
YALPAR,6,Heated products of peptic hydrolysates of half-fin anchovy (Setipinna taty),Native peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,YALPAR
YALRAH,6,Heated products of peptic hydrolysates of half-fin anchovy (Setipinna taty),Native peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,YALRAH
VWLSALKFIGKHLAKHQLSKL,21,Synthetic,Synthetic peptide,,IC50 on PBMCs was = 92.0 ± 39.6 μM,,,Lycosin-II Suppresses the Growth of Tumor Cells and Kills them Through Membrane Disruption and Apoptosis Induction,Anticancer; Antitumor,Tumor active peptide,,Linear,,Free,Free,,,0,VWLSALKFIGKHLAKHQLSKL
AAGIGILTV,9,Homo sapiens,Native peptide,,,,,,Antitumor,Tumor active peptide,,,,,,,"Granted Patent Family: 10s / 10ex; Family Jurisdictions:  CA, AU, FR, WO, US, EP, JP; Legal Status:   Discontinued; Application No: 50633405; Filed:May 25, 2005; Published: Jun 8, 2006; Earliest Priority: Mar 4, 2002",0,AAGIGILTV
VKDGYIVDDKNCAYFCGRNAYCDDECEKNGAESGYCQWAGVYGNACWCYKLPDKVPIRVPGRCNG,65,Scorpion,Native peptide,,,,,,Anticancer; Antitumor,Tumor active peptide,,Linear,,Free,Free,,"Granted Patent; Family: 2s/2ex; Family Jurisdictions: CN; Legal Status: Active; Application No: 201110069002; Filed: Mar 22, 2011; Published: Oct 29, 2014; Earliest Priority: Mar 22, 2011; Granted: Oct 29, 2014",0,VKDGYIVDDKNCAYFCGRNAYCDDECEKNGAESGYCQWAGVYGNACWCYKLPDKVPIRVPGRCNG
YALPAH,6,Yellow crucian carp protein,Native peptide,,,,,Inhibit cell proliferation and inducing apoptosis,Anticancer,Tumor active peptide,,Linear,,Free,Free,,"Granted Patent; Family: 2s / 2ex; Family Jurisdictions: CN; Legal Status:  Active; Application No: 201310460838; Filed: Sep 29, 2013; Published: Apr 6, 2016; Earliest Priority: Sep 29, 2013; Granted: Apr 6, 2016",0,YALPAH
GNKKWEQKQVQIKTLEGEFSVTMWSS,26,YY1 protein,Native peptide,,Is nontoxic to normal breast cell,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,"Granted Patent; Family: 2s / 2ex; Family Jurisdictions: CN; Legal Status:  Active; Application No: 201610018929 Filed: Jan 12, 2016 Published: Jun 7, 2019 Earliest Priority: Jan 12, 2016; Granted: Jun 7, 2019",0,GNKKWEQKQVQIKTLEGEFSVTMWSS
KFKKFFKFMVKKKKF,15,,Synthetic peptide,"Human red blood cells: no hemolytic activity at 12.5 μM, 25 μM, 50 μM, 100 μM",Less toxic than CDDP on human normal MCF10A and 293FT,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,"Granted Patent; Family: 2s / 2ex; Family Jurisdictions: CN; Legal Status:  Active; Application No: 201611198223; Filed: Dec 22, 2016; Published: Nov 10, 2020; Earliest Priority: Dec 22, 2016; Granted: Nov 10, 2020",0,KFKKFFKFMVKKKKF
KKFFKKMKKFVKKFF,15,,Synthetic peptide,"Human red blood cells: no hemolytic activity at 12.5 μM, 25 μM, 50 μM, 100 μM",Less toxic than CDDP on human normal MCF10A and 293FT,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,"Granted Patent; Family: 2s / 2ex; Family Jurisdictions: CN; Legal Status:  Active; Application No: 201611198223; Filed: Dec 22, 2016; Published: Nov 10, 2020; Earliest Priority: Dec 22, 2016; Granted: Nov 10, 2020",0,KKFFKKMKKFVKKFF
KKFFKKMKKFVKKFL,15,,Synthetic peptide,"Human red blood cells: no hemolytic activity at 12.5 μM, 25 μM, 50 μM, 100 μM",Less toxic than CDDP on human normal MCF10A and 293FT,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,"Granted Patent; Family: 2s / 2ex; Family Jurisdictions: CN; Legal Status:  Active; Application No: 201611198223; Filed: Dec 22, 2016; Published: Nov 10, 2020; Earliest Priority: Dec 22, 2016; Granted: Nov 10, 2020",0,KKFFKKMKKFVKKFL
KKFFKKMKKLVKKFF,15,,Synthetic peptide,"Human red blood cells: no hemolytic activity at 12.5 μM, 25 μM, 50 μM, 100 μM",Less toxic than CDDP on human normal MCF10A and 293FT,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,"Granted Patent; Family: 2s / 2ex; Family Jurisdictions: CN; Legal Status:  Active; Application No: 201611198223; Filed: Dec 22, 2016; Published: Nov 10, 2020; Earliest Priority: Dec 22, 2016; Granted: Nov 10, 2020",0,KKFFKKMKKLVKKFF
KKFFKKMKSFFKKFF,15,,Synthetic peptide,"Human red blood cells: no hemolytic activity at 12.5 μM, 25 μM, 50 μM, 100 μM",Less toxic than CDDP on human normal MCF10A and 293FT,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,"Granted Patent; Family: 2s / 2ex; Family Jurisdictions: CN; Legal Status:  Active; Application No: 201611198223; Filed: Dec 22, 2016; Published: Nov 10, 2020; Earliest Priority: Dec 22, 2016; Granted: Nov 10, 2020",0,KKFFKKMKSFFKKFF
KKFFKKMSFFFFKKK,15,,Synthetic peptide,"Human red blood cells: no hemolytic activity at 12.5 μM, 25 μM, 50 μM, 100 μM",Less toxic than CDDP on human normal MCF10A and 293FT,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,"Granted Patent; Family: 2s / 2ex; Family Jurisdictions: CN; Legal Status:  Active; Application No: 201611198223; Filed: Dec 22, 2016; Published: Nov 10, 2020; Earliest Priority: Dec 22, 2016; Granted: Nov 10, 2020",0,KKFFKKMSFFFFKKK
KKFFKLVKKKMKKFF,15,,Synthetic peptide,"Human red blood cells: no hemolytic activity at 12.5 μM, 25 μM, 50 μM, 100 μM",Less toxic than CDDP on human normal MCF10A and 293FT,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,"Granted Patent; Family: 2s / 2ex; Family Jurisdictions: CN; Legal Status:  Active; Application No: 201611198223; Filed: Dec 22, 2016; Published: Nov 10, 2020; Earliest Priority: Dec 22, 2016; Granted: Nov 10, 2020",0,KKFFKLVKKKMKKFF
KKFFSKMKSFFKKFF,15,,Synthetic peptide,"Human red blood cells: no hemolytic activity at 12.5 μM, 25 μM, 50 μM, 100 μM",Less toxic than CDDP on human normal MCF10A and 293FT,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,"Granted Patent; Family: 2s / 2ex; Family Jurisdictions: CN; Legal Status:  Active; Application No: 201611198223; Filed: Dec 22, 2016; Published: Nov 10, 2020; Earliest Priority: Dec 22, 2016; Granted: Nov 10, 2020",0,KKFFSKMKSFFKKFF
KKFFSKSMKSFFFFKK,16,,Synthetic peptide,"Human red blood cells: no hemolytic activity at 12.5 μM, 25 μM, 50 μM, 100 μM",Less toxic than CDDP on human normal MCF10A and 293FT,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,"Granted Patent; Family: 2s / 2ex; Family Jurisdictions: CN; Legal Status:  Active; Application No: 201611198223; Filed: Dec 22, 2016; Published: Nov 10, 2020; Earliest Priority: Dec 22, 2016; Granted: Nov 10, 2020",0,KKFFSKSMKSFFFFKK
KKKKFFMFVFFKKKK,15,,Synthetic peptide,"Human red blood cells: no hemolytic activity at 12.5 μM, 25 μM, 50 μM, 100 μM",Less toxic than CDDP on human normal MCF10A and 293FT,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,"Granted Patent; Family: 2s / 2ex; Family Jurisdictions: CN; Legal Status:  Active; Application No: 201611198223; Filed: Dec 22, 2016; Published: Nov 10, 2020; Earliest Priority: Dec 22, 2016; Granted: Nov 10, 2020",0,KKKKFFMFVFFKKKK
KKKKFFMLVKKKKFF,15,,Synthetic peptide,"Human red blood cells: no hemolytic activity at 12.5 μM, 25 μM, 50 μM, 100 μM",Less toxic than CDDP on human normal MCF10A and 293FT,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,"Granted Patent; Family: 2s / 2ex; Family Jurisdictions: CN; Legal Status:  Active; Application No: 201611198223; Filed: Dec 22, 2016; Published: Nov 10, 2020; Earliest Priority: Dec 22, 2016; Granted: Nov 10, 2020",0,KKKKFFMLVKKKKFF
KKKKFFMSFFFKKKF,15,,Synthetic peptide,"Human red blood cells: no hemolytic activity at 12.5 μM, 25 μM, 50 μM, 100 μM",Less toxic than CDDP on human normal MCF10A and 293FT,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,"Granted Patent; Family: 2s / 2ex; Family Jurisdictions: CN; Legal Status:  Active; Application No: 201611198223; Filed: Dec 22, 2016; Published: Nov 10, 2020; Earliest Priority: Dec 22, 2016; Granted: Nov 10, 2020",0,KKKKFFMSFFFKKKF
KKKKFFSMSFFKKFF,15,,Synthetic peptide,"Human red blood cells: no hemolytic activity at 12.5 μM, 25 μM, 50 μM, 100 μM",Less toxic than CDDP on human normal MCF10A and 293FT,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,"Granted Patent; Family: 2s / 2ex; Family Jurisdictions: CN; Legal Status:  Active; Application No: 201611198223; Filed: Dec 22, 2016; Published: Nov 10, 2020; Earliest Priority: Dec 22, 2016; Granted: Nov 10, 2020",0,KKKKFFSMSFFKKFF
KWKVFKKIEKKWKVFKKIEKAGPKWKVFKKIEK,33,,Synthetic peptide,Human erythrocytes: 18% Hemolysis=200 µM,RPMI-7666: IC50>100 µM; NIH 3T3: IC50>50 µM; WI-38: IC50>100 µM,,,,Anticancer,Tumor active peptide,,Linear,,Free,Amidation,,"Patent Application; Family: 2s / 2ex; Family Jurisdictions: CN; Legal Status:  Active; Application No: 201810184631; Filed: Mar 7, 2018; Published: Sep 18, 2018; Earliest Priority: Mar 7, 2018; Granted: Oct 26, 2021",0,KWKVFKKIEKKWKVFKKIEKAGPKWKVFKKIEK
MADIKQEHDTELDQNYSLGSNTDPKNMQELTQYVQTLLQSVQDKFQTMSDQILNRIDEMGSRIDDLEKNISDLMTQAGVEGPDK,84,Antlion,Native peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,"Patent Application; Family: 2s / 2ex; Family Jurisdictions: CN; Legal Status:  Active; Application No: 201811252747; Filed: Oct 25, 2018; Published: Mar 19, 2019; Earliest Priority: Oct 25, 2018; Granted: Jul 20, 2021",0,MADIKQEHDTELDQNYSLGSNTDPKNMQELTQYVQTLLQSVQDKFQTMSDQILNRIDEMGSRIDDLEKNISDLMTQAGVEGPDK
ADGAPRPGAPLA,12,Screen of phage display peptide library,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,"Search Report;  Family: 16s / 16ex; Family Jurisdictions: EP, CA, ES, JP, CY, DK, US, DE, WO, AT, PT; Legal Status: Discontinued; Application No: 06021030; Filed: Oct 15, 1999; Published: Jul 11, 2007; Earliest Priority: Oct 16, 1998",0,ADGAPRPGAPLA
APRPG,5,Screen of phage display peptide library,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,"Search Report;  Family: 16s / 16ex; Family Jurisdictions: EP, CA, ES, JP, CY, DK, US, DE, WO, AT, PT; Legal Status: Discontinued; Application No: 06021030; Filed: Oct 15, 1999; Published: Jul 11, 2007; Earliest Priority: Oct 16, 1998",0,APRPG
ASSSYPLIHWRPWAR,15,Screen of phage display peptide library,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,"Search Report;  Family: 16s / 16ex; Family Jurisdictions: EP, CA, ES, JP, CY, DK, US, DE, WO, AT, PT; Legal Status: Discontinued; Application No: 06021030; Filed: Oct 15, 1999; Published: Jul 11, 2007; Earliest Priority: Oct 16, 1998",0,ASSSYPLIHWRPWAR
DRWRPALP,8,Screen of phage display peptide library,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,"Search Report;  Family: 16s / 16ex; Family Jurisdictions: EP, CA, ES, JP, CY, DK, US, DE, WO, AT, PT; Legal Status: Discontinued; Application No: 06021030; Filed: Oct 15, 1999; Published: Jul 11, 2007; Earliest Priority: Oct 16, 1998",0,DRWRPALP
DRWRPALPVVLFPLH,15,Screen of phage display peptide library,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,"Search Report;  Family: 16s / 16ex; Family Jurisdictions: EP, CA, ES, JP, CY, DK, US, DE, WO, AT, PT; Legal Status: Discontinued; Application No: 06021030; Filed: Oct 15, 1999; Published: Jul 11, 2007; Earliest Priority: Oct 16, 1998",0,DRWRPALPVVLFPLH
HARPW,5,Screen of phage display peptide library,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,"Search Report;  Family: 16s / 16ex; Family Jurisdictions: EP, CA, ES, JP, CY, DK, US, DE, WO, AT, PT; Legal Status: Discontinued; Application No: 06021030; Filed: Oct 15, 1999; Published: Jul 11, 2007; Earliest Priority: Oct 16, 1998",0,HARPW
HWAPW,5,Screen of phage display peptide library,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,"Search Report;  Family: 16s / 16ex; Family Jurisdictions: EP, CA, ES, JP, CY, DK, US, DE, WO, AT, PT; Legal Status: Discontinued; Application No: 06021030; Filed: Oct 15, 1999; Published: Jul 11, 2007; Earliest Priority: Oct 16, 1998",0,HWAPW
HWRAW,5,Screen of phage display peptide library,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,"Search Report;  Family: 16s / 16ex; Family Jurisdictions: EP, CA, ES, JP, CY, DK, US, DE, WO, AT, PT; Legal Status: Discontinued; Application No: 06021030; Filed: Oct 15, 1999; Published: Jul 11, 2007; Earliest Priority: Oct 16, 1998",0,HWRAW
HWRP,4,Screen of phage display peptide library,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,"Search Report;  Family: 16s / 16ex; Family Jurisdictions: EP, CA, ES, JP, CY, DK, US, DE, WO, AT, PT; Legal Status: Discontinued; Application No: 06021030; Filed: Oct 15, 1999; Published: Jul 11, 2007; Earliest Priority: Oct 16, 1998",0,HWRP
HWRPW,5,Screen of phage display peptide library,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,"Search Report;  Family: 16s / 16ex; Family Jurisdictions: EP, CA, ES, JP, CY, DK, US, DE, WO, AT, PT; Legal Status: Discontinued; Application No: 06021030; Filed: Oct 15, 1999; Published: Jul 11, 2007; Earliest Priority: Oct 16, 1998",0,HWRPW
IHWRPWAR,8,Screen of phage display peptide library,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,"Search Report;  Family: 16s / 16ex; Family Jurisdictions: EP, CA, ES, JP, CY, DK, US, DE, WO, AT, PT; Legal Status: Discontinued; Application No: 06021030; Filed: Oct 15, 1999; Published: Jul 11, 2007; Earliest Priority: Oct 16, 1998",0,IHWRPWAR
LFPLH,5,Screen of phage display peptide library,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,"Search Report;  Family: 16s / 16ex; Family Jurisdictions: EP, CA, ES, JP, CY, DK, US, DE, WO, AT, PT; Legal Status: Discontinued; Application No: 06021030; Filed: Oct 15, 1999; Published: Jul 11, 2007; Earliest Priority: Oct 16, 1998",0,LFPLH
PVVLFLH,7,Screen of phage display peptide library,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,"Search Report;  Family: 16s / 16ex; Family Jurisdictions: EP, CA, ES, JP, CY, DK, US, DE, WO, AT, PT; Legal Status: Discontinued; Application No: 06021030; Filed: Oct 15, 1999; Published: Jul 11, 2007; Earliest Priority: Oct 16, 1998",0,PVVLFLH
RWRP,4,Screen of phage display peptide library,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,"Search Report;  Family: 16s / 16ex; Family Jurisdictions: EP, CA, ES, JP, CY, DK, US, DE, WO, AT, PT; Legal Status: Discontinued; Application No: 06021030; Filed: Oct 15, 1999; Published: Jul 11, 2007; Earliest Priority: Oct 16, 1998",0,RWRP
WRP,3,Screen of phage display peptide library,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,"Search Report;  Family: 16s / 16ex; Family Jurisdictions: EP, CA, ES, JP, CY, DK, US, DE, WO, AT, PT; Legal Status: Discontinued; Application No: 06021030; Filed: Oct 15, 1999; Published: Jul 11, 2007; Earliest Priority: Oct 16, 1998",0,WRP
WRPA,4,Screen of phage display peptide library,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,"Search Report;  Family: 16s / 16ex; Family Jurisdictions: EP, CA, ES, JP, CY, DK, US, DE, WO, AT, PT; Legal Status: Discontinued; Application No: 06021030; Filed: Oct 15, 1999; Published: Jul 11, 2007; Earliest Priority: Oct 16, 1998",0,WRPA
WRPW,4,Screen of phage display peptide library,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,"Search Report;  Family: 16s / 16ex; Family Jurisdictions: EP, CA, ES, JP, CY, DK, US, DE, WO, AT, PT; Legal Status: Discontinued; Application No: 06021030; Filed: Oct 15, 1999; Published: Jul 11, 2007; Earliest Priority: Oct 16, 1998",0,WRPW
LNQEDARKSE,10,Screen of phage display peptide library,Native peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,"Granted Patent; Family: 7s / 7ex; Family Jurisdictions: EP, KR, WO; Legal Status:  Active; Application No: 10843287; Filed: Dec 27, 2010; Published: Mar 9, 2016; Earliest Priority: Jan 12, 2010; Granted: Mar 9, 2016",0,LNQEDARKSE
LNQEEARKSE,10,Screen of phage display peptide library,Native peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,"Granted Patent; Family: 7s / 7ex; Family Jurisdictions: EP, KR, WO; Legal Status:  Active; Application No: 10843287; Filed: Dec 27, 2010; Published: Mar 9, 2016; Earliest Priority: Jan 12, 2010; Granted: Mar 9, 2016",0,LNQEEARKSE
LNQESARKSE,10,Screen of phage display peptide library,Native peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,"Granted Patent; Family: 7s / 7ex; Family Jurisdictions: EP, KR, WO; Legal Status:  Active; Application No: 10843287; Filed: Dec 27, 2010; Published: Mar 9, 2016; Earliest Priority: Jan 12, 2010; Granted: Mar 9, 2016",0,LNQESARKSE
TeATITGLEPGTEYTITVIAL,21,,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,e=D-Glutamic acid,"Granted Patent; Family: 8s / 8ex; Family Jurisdictions: JP, WO, US, EP; Legal Status:  Active; Application No: 12758028; Filed: Mar 9, 2012; Published: Sep 27, 2017; Earliest Priority: Mar 11, 2011; Granted: Sep 27, 2017",0,TEATITGLEPGTEYTITVIAL
TEATITGLEPGTEYTITVIAL,21,,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,"Granted Patent; Family: 8s / 8ex; Family Jurisdictions: JP, WO, US, EP; Legal Status:  Active; Application No: 12758028; Filed: Mar 9, 2012; Published: Sep 27, 2017; Earliest Priority: Mar 11, 2011; Granted: Sep 27, 2017",0,TEATITGLEPGTEYTITVIAL
GKCSTRGRKCCRRKK,15,,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,"Granted Patent; Family: 9s / 9ex; Family Jurisdictions: KR, US, WO, ES, EP; Legal Status:  Active; Application No: 16736753; Filed: Mar 3, 2016; Published: Dec 11, 2019; Earliest Priority: Mar 26, 2015; Granted: Dec 11, 2019",0,GKCSTRGRKCCRRKK
GKCSTRGRKCMRRKK,15,,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,"Granted Patent; Family: 9s / 9ex; Family Jurisdictions: KR, US, WO, ES, EP; Legal Status:  Active; Application No: 16736753; Filed: Mar 3, 2016; Published: Dec 11, 2019; Earliest Priority: Mar 26, 2015; Granted: Dec 11, 2019",0,GKCSTRGRKCMRRKK
GKCSTRGRKMCRRKK,15,,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,"Granted Patent; Family: 9s / 9ex; Family Jurisdictions: KR, US, WO, ES, EP; Legal Status:  Active; Application No: 16736753; Filed: Mar 3, 2016; Published: Dec 11, 2019; Earliest Priority: Mar 26, 2015; Granted: Dec 11, 2019",0,GKCSTRGRKMCRRKK
CLQKTPKQC,9,,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,"Patent Application; Family: 5s / 6ex; Family Jurisdictions: EP, KR, US; Legal Status:  Pending; Application No: 18888477; Filed: Dec 17, 2018; Published: Oct 21, 2020; Earliest Priority: Dec 15, 2017",0,CLQKTPKQC
CVRARTR,7,,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,"Patent Application; Family: 5s / 6ex; Family Jurisdictions: EP, KR, US; Legal Status:  Pending; Application No: 18888477; Filed: Dec 17, 2018; Published: Oct 21, 2020; Earliest Priority: Dec 15, 2017",0,CVRARTR
CNEWQLKSC,9,Screen of phage display peptide library,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,"Patent Application; Family: 6s / 7ex; Family Jurisdictions: EP, KR, US; Legal Status:  Pending; Application No: 18889460; Filed: Dec 17, 2018; Published: Nov 4, 2020; Earliest Priority: Dec 15, 2017",0,CNEWQLKSC
CNLNTIDTC,9,Screen of phage display peptide library,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,"Patent Application; Family: 6s / 7ex; Family Jurisdictions: EP, KR, US; Legal Status:  Pending; Application No: 18889460; Filed: Dec 17, 2018; Published: Nov 4, 2020; Earliest Priority: Dec 15, 2017",0,CNLNTIDTC
WLWKAIWKLLK,11,,Synthetic peptide,,"In the concentration of 50 μg/ml, the normal cell (HUVEC)  the viability  was 47.9%",,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,"Granted Patent; Family: 4s / 4ex; Family Jurisdictions: KR, JP; Legal Status:  Active; Application No: 20150145265; Filed: Oct 19, 2015; Published: Jun 21, 2017; Earliest Priority: Oct 19, 2015; Granted: Jun 21, 2017",0,WLWKAIWKLLK
WLWKAIWKLLT,11,,Synthetic peptide,,"In the concentration of 50 μg/ml, the normal cell (HUVEC)  the viability  was 32.8%",,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,"Granted Patent; Family: 4s / 4ex; Family Jurisdictions: KR, JP; Legal Status:  Active; Application No: 20150145265; Filed: Oct 19, 2015; Published: Jun 21, 2017; Earliest Priority: Oct 19, 2015; Granted: Jun 21, 2017",0,WLWKAIWKLLT
FWPGLILKGLGAL,13,,Synthetic peptide,Human red blood cell: show very low hemolytic activity,,,,,Anticancer; Antitumor,Tumor active peptide,,Linear,,Free,Free,,"Granted Patent; Family: 2s / 2ex; Family Jurisdictions: KR; Legal Status:  Active; Application No: 20170037330; Filed: Mar 24, 2017; Published: Jun 19, 2019; Earliest Priority: Mar 24, 2017; Granted: Jun 19, 2019",0,FWPGLILKGLGAL
GRPPGFSPFRSG,12,,Synthetic peptide,Human red blood cell: show very low hemolytic activity,,,,,Anticancer; Antitumor,Tumor active peptide,,Linear,,Free,Free,,"Granted Patent; Family: 2s / 2ex; Family Jurisdictions: KR; Legal Status:  Active; Application No: 20170037330; Filed: Mar 24, 2017; Published: Jun 19, 2019; Earliest Priority: Mar 24, 2017; Granted: Jun 19, 2019",0,GRPPGFSPFRSG
AEQAA,5,p57 protein,Native peptide,,,mdm2 (mouse double minute 2),,,Anticancer,Tumor active peptide##Cancer targeted peptides,,Linear,,Free,Free,,"Patent Application; Family: 5s / 5ex; Family Jurisdictions: KR, US, WO; Legal Status:  Inactive; Application No: 20050000931; Filed: Jan 5, 2005; Published: Oct 12, 2005; Earliest Priority: Apr 6, 2004; Granted: Dec 27, 2007",0,AEQAA
IEQWF,5,p53 protein,Native peptide,,,mdm2 (mouse double minute 2),,,Anticancer,Tumor active peptide##Cancer targeted peptides,,Linear,,Free,Free,,"Patent Application; Family: 5s / 5ex; Family Jurisdictions: KR, US, WO; Legal Status:  Inactive; Application No: 20050000931; Filed: Jan 5, 2005; Published: Oct 12, 2005; Earliest Priority: Apr 6, 2004; Granted: Dec 27, 2007",0,IEQWF
WEQWW,5,p61 protein,Native peptide,,,mdm2 (mouse double minute 2),,,Anticancer,Tumor active peptide##Cancer targeted peptides,,Linear,,Free,Free,,"Patent Application; Family: 5s / 5ex; Family Jurisdictions: KR, US, WO; Legal Status:  Inactive; Application No: 20050000931; Filed: Jan 5, 2005; Published: Oct 12, 2005; Earliest Priority: Apr 6, 2004; Granted: Dec 27, 2007",0,WEQWW
IKWKAILDAVKKVL,14,,Synthetic peptide,,,,,,Anticancer; Antitumor; Antimicrobial; Antifungal,Tumor active peptide,,Linear,,Free,Free,,"Patent Application; Family: 2s / 2ex; Family Jurisdictions: KR; Legal Status:  Active; Application No: 20150048678; Filed: Apr 6, 2015; Published: Oct 17, 2016; Earliest Priority: Apr 6, 2015; Granted: Dec 26, 2017",0,IKWKAILDAVKKVL
NYPQRPCRGDKGPDC,15,,Synthetic peptide,,"MSC and BEAS-2B: GI50<lg1000 μM, HEK293T :GI50<lg5 μM, as show in fig1",,,,Anticancer; Antitumor,Tumor active peptide,,Linear,,Free,Free,,"Patent Application; Family: 2s / 4ex; Family Jurisdictions: KR; Legal Status:  Active; Application No: 20190085790; Filed: Jul 16, 2019; Published: Oct 12, 2020; Earliest Priority: Apr 1, 2019; Granted: Jun 8, 2021",0,NYPQRPCRGDKGPDC
XPAXXFXPAXXLXXLXXLX,19,Peptaibols,Native peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Acetylation,Aminoethanol,X(1/4/5/16/17)=Aib=1-amino-isobutyric acid; X(7/13)=Iva=Isovaline; X(10)=AHMA=3-amino-2-hydroxy-3-methylbutanoic acid; X(11/14/19)(β)A=β-Alanine,,0,XPAXXFXPAXXLXXLXXLX
GAVPCGESCVYLPCLTTVVGCSCQNSVCYHN,31,Hedyotis biflora,Native peptide,,,,,,Anticancer,Tumor active peptide,,Cyclic,,Free,Free,,,0,GAVPCGESCVYLPCLTTVVGCSCQNSVCYHN
GAVPCGETCVYLPCITAAIGCSCQNKVCYRD,31,Hedyotis biflora,Native peptide,,,,,,Anticancer,Tumor active peptide,,Cyclic,,Free,Free,,,0,GAVPCGETCVYLPCITAAIGCSCQNKVCYRD
GIPCGESCAFLPCLTSLLGCTCQNKVCYRD,30,Hedyotis biflora,Native peptide,,,,,,Anticancer,Tumor active peptide,,Cyclic,,Free,Free,,,0,GIPCGESCAFLPCLTSLLGCTCQNKVCYRD
GISCAETCVLLPCLSSVIGCTCQNKRCYKN,30,Hedyotis biflora,Native peptide,,,,,,Anticancer,Tumor active peptide,,Cyclic,,Free,Free,,,0,GISCAETCVLLPCLSSVIGCTCQNKRCYKN
GNPCGESCVYLPCITTVVGCSCQNSVCYHN,30,Hedyotis biflora,Native peptide,,,,,,Anticancer,Tumor active peptide,,Cyclic,,Free,Free,,,0,GNPCGESCVYLPCITTVVGCSCQNSVCYHN
AIMSSLMKKLAAHIAK,16,AMP,Synthetic peptide,,Human Splenic Fibroblasts (HSF): IC50=12.78±0.33 µg/mL; Endometrial epithelial cells(HEEC): IC50=2.66±0.34 µg/mL; HPDE6c7 Human Pancreatic Duct Epithelial Cell: IC50=3.45±0.20 µg/mL; Normal Human Hepatic Cell (Lo-2): IC50=2.91±0.07 µg/mL; NCM460: IC50=3.04±0.10 µg/mL; CCD-19Lu: IC50=4.76±0.03 µg/mL,,,,Anticancer; Antitumor; Antimicrobial,Tumor active peptide,,Linear,,Free,Amidation,,,0,AIMSSLMKKLAAHIAK
GAMSSLMKKLAAHIAK,16,AMP,Synthetic peptide,,Human Splenic Fibroblasts (HSF): IC50=12.78±0.33 µg/mL; Endometrial epithelial cells(HEEC): IC50=2.66±0.34 µg/mL; HPDE6c7 Human Pancreatic Duct Epithelial Cell: IC50=3.45±0.20 µg/mL; Normal Human Hepatic Cell (Lo-2): IC50=2.91±0.07 µg/mL; NCM460: IC50=3.04±0.10 µg/mL; CCD-19Lu: IC50=4.76±0.03 µg/mL,,,,Anticancer; Antitumor; Antimicrobial,Tumor active peptide,,Linear,,Free,Amidation,,,0,GAMSSLMKKLAAHIAK
GIASSLMKKLAAHIAK,16,AMP,Synthetic peptide,,Human Splenic Fibroblasts (HSF): IC50=12.78±0.33 µg/mL; Endometrial epithelial cells(HEEC): IC50=2.66±0.34 µg/mL; HPDE6c7 Human Pancreatic Duct Epithelial Cell: IC50=3.45±0.20 µg/mL; Normal Human Hepatic Cell (Lo-2): IC50=2.91±0.07 µg/mL; NCM460: IC50=3.04±0.10 µg/mL; CCD-19Lu: IC50=4.76±0.03 µg/mL,,,,Anticancer; Antitumor; Antimicrobial,Tumor active peptide,,Linear,,Free,Amidation,,,0,GIASSLMKKLAAHIAK
GIMASLMKKLAAHIAK,16,AMP,Synthetic peptide,,Human Splenic Fibroblasts (HSF): IC50=12.78±0.33 µg/mL; Endometrial epithelial cells(HEEC): IC50=2.66±0.34 µg/mL; HPDE6c7 Human Pancreatic Duct Epithelial Cell: IC50=3.45±0.20 µg/mL; Normal Human Hepatic Cell (Lo-2): IC50=2.91±0.07 µg/mL; NCM460: IC50=3.04±0.10 µg/mL; CCD-19Lu: IC50=4.76±0.03 µg/mL,,,,Anticancer; Antitumor; Antimicrobial,Tumor active peptide,,Linear,,Free,Amidation,,,0,GIMASLMKKLAAHIAK
GIMSALMKKLAAHIAK,16,AMP,Synthetic peptide,,Human Splenic Fibroblasts (HSF): IC50=12.78±0.33 µg/mL; Endometrial epithelial cells(HEEC): IC50=2.66±0.34 µg/mL; HPDE6c7 Human Pancreatic Duct Epithelial Cell: IC50=3.45±0.20 µg/mL; Normal Human Hepatic Cell (Lo-2): IC50=2.91±0.07 µg/mL; NCM460: IC50=3.04±0.10 µg/mL; CCD-19Lu: IC50=4.76±0.03 µg/mL,,,,Anticancer; Antitumor; Antimicrobial,Tumor active peptide,,Linear,,Free,Amidation,,,0,GIMSALMKKLAAHIAK
GIMSSAMKKLAAHIAK,16,AMP,Synthetic peptide,,Human Splenic Fibroblasts (HSF): IC50=12.78±0.33 µg/mL; Endometrial epithelial cells(HEEC): IC50=2.66±0.34 µg/mL; HPDE6c7 Human Pancreatic Duct Epithelial Cell: IC50=3.45±0.20 µg/mL; Normal Human Hepatic Cell (Lo-2): IC50=2.91±0.07 µg/mL; NCM460: IC50=3.04±0.10 µg/mL; CCD-19Lu: IC50=4.76±0.03 µg/mL,,,,Anticancer; Antitumor; Antimicrobial,Tumor active peptide,,Linear,,Free,Amidation,,,0,GIMSSAMKKLAAHIAK
GIMSSLAKKLAAHIAK,16,AMP,Synthetic peptide,,Human Splenic Fibroblasts (HSF): IC50=12.78±0.33 µg/mL; Endometrial epithelial cells(HEEC): IC50=2.66±0.34 µg/mL; HPDE6c7 Human Pancreatic Duct Epithelial Cell: IC50=3.45±0.20 µg/mL; Normal Human Hepatic Cell (Lo-2): IC50=2.91±0.07 µg/mL; NCM460: IC50=3.04±0.10 µg/mL; CCD-19Lu: IC50=4.76±0.03 µg/mL,,,,Anticancer; Antitumor; Antimicrobial,Tumor active peptide,,Linear,,Free,Amidation,,,0,GIMSSLAKKLAAHIAK
GIMSSLMAKLAAHIAK,16,AMP,Synthetic peptide,,Human Splenic Fibroblasts (HSF): IC50=12.78±0.33 µg/mL; Endometrial epithelial cells(HEEC): IC50=2.66±0.34 µg/mL; HPDE6c7 Human Pancreatic Duct Epithelial Cell: IC50=3.45±0.20 µg/mL; Normal Human Hepatic Cell (Lo-2): IC50=2.91±0.07 µg/mL; NCM460: IC50=3.04±0.10 µg/mL; CCD-19Lu: IC50=4.76±0.03 µg/mL,,,,Anticancer; Antitumor; Antimicrobial,Tumor active peptide,,Linear,,Free,Amidation,,,0,GIMSSLMAKLAAHIAK
GIMSSLMKALAAHIAK,16,AMP,Synthetic peptide,,Human Splenic Fibroblasts (HSF): IC50=12.78±0.33 µg/mL; Endometrial epithelial cells(HEEC): IC50=2.66±0.34 µg/mL; HPDE6c7 Human Pancreatic Duct Epithelial Cell: IC50=3.45±0.20 µg/mL; Normal Human Hepatic Cell (Lo-2): IC50=2.91±0.07 µg/mL; NCM460: IC50=3.04±0.10 µg/mL; CCD-19Lu: IC50=4.76±0.03 µg/mL,,,,Anticancer; Antitumor; Antimicrobial,Tumor active peptide,,Linear,,Free,Amidation,,,0,GIMSSLMKALAAHIAK
GIMSSLMKKAAAHIAK,16,AMP,Synthetic peptide,,Human Splenic Fibroblasts (HSF): IC50=12.78±0.33 µg/mL; Endometrial epithelial cells(HEEC): IC50=2.66±0.34 µg/mL; HPDE6c7 Human Pancreatic Duct Epithelial Cell: IC50=3.45±0.20 µg/mL; Normal Human Hepatic Cell (Lo-2): IC50=2.91±0.07 µg/mL; NCM460: IC50=3.04±0.10 µg/mL; CCD-19Lu: IC50=4.76±0.03 µg/mL,,,,Anticancer; Antitumor; Antimicrobial,Tumor active peptide,,Linear,,Free,Amidation,,,0,GIMSSLMKKAAAHIAK
GIMSSLMKKLAAAIAK,16,AMP,Synthetic peptide,,Human Splenic Fibroblasts (HSF): IC50=12.78±0.33 µg/mL; Endometrial epithelial cells(HEEC): IC50=2.66±0.34 µg/mL; HPDE6c7 Human Pancreatic Duct Epithelial Cell: IC50=3.45±0.20 µg/mL; Normal Human Hepatic Cell (Lo-2): IC50=2.91±0.07 µg/mL; NCM460: IC50=3.04±0.10 µg/mL; CCD-19Lu: IC50=4.76±0.03 µg/mL,,,,Anticancer; Antitumor; Antimicrobial,Tumor active peptide,,Linear,,Free,Amidation,,,0,GIMSSLMKKLAAAIAK
GIMSSLMKKLAAHAAK,16,AMP,Synthetic peptide,,Human Splenic Fibroblasts (HSF): IC50=12.78±0.33 µg/mL; Endometrial epithelial cells(HEEC): IC50=2.66±0.34 µg/mL; HPDE6c7 Human Pancreatic Duct Epithelial Cell: IC50=3.45±0.20 µg/mL; Normal Human Hepatic Cell (Lo-2): IC50=2.91±0.07 µg/mL; NCM460: IC50=3.04±0.10 µg/mL; CCD-19Lu: IC50=4.76±0.03 µg/mL,,,,Anticancer; Antitumor; Antimicrobial,Tumor active peptide,,Linear,,Free,Amidation,,,0,GIMSSLMKKLAAHAAK
GIMSSLMKKLAAHIAA,16,AMP,Synthetic peptide,,Human Splenic Fibroblasts (HSF): IC50=12.78±0.33 µg/mL; Endometrial epithelial cells(HEEC): IC50=2.66±0.34 µg/mL; HPDE6c7 Human Pancreatic Duct Epithelial Cell: IC50=3.45±0.20 µg/mL; Normal Human Hepatic Cell (Lo-2): IC50=2.91±0.07 µg/mL; NCM460: IC50=3.04±0.10 µg/mL; CCD-19Lu: IC50=4.76±0.03 µg/mL,,,,Anticancer; Antitumor; Antimicrobial,Tumor active peptide,,Linear,,Free,Amidation,,,0,GIMSSLMKKLAAHIAA
GIMSSLMKKLAAHIAK,16,AMP,Synthetic peptide,,Human Splenic Fibroblasts (HSF): IC50=12.78±0.33 µg/mL; Endometrial epithelial cells(HEEC): IC50=2.66±0.34 µg/mL; HPDE6c7 Human Pancreatic Duct Epithelial Cell: IC50=3.45±0.20 µg/mL; Normal Human Hepatic Cell (Lo-2): IC50=2.91±0.07 µg/mL; NCM460: IC50=3.04±0.10 µg/mL; CCD-19Lu: IC50=4.76±0.03 µg/mL,,,,Anticancer; Antitumor; Antimicrobial,Tumor active peptide,,Linear,,Free,Amidation,,,0,GIMSSLMKKLAAHIAK
GANAAKKFATIAKKFINYLW,20,Synthetic,Synthetic peptide,,NIH 3T3: As show in fig.3,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,"Granted Patent; Family: 2s / 2ex; Family Jurisdictions: TW; Legal Status:  Active; Application No: 99121957; Filed: Jul 5, 2010; Published: Aug 11, 2014; Earliest Priority: Jul 5, 2010; Granted: Aug 11, 2014",0,GANAAKKFATIAKKFINYLW
GANLAKKFYTYINKFINYAW,20,Synthetic,Synthetic peptide,,NIH 3T3: As show in fig.3,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,"Granted Patent; Family: 2s / 2ex; Family Jurisdictions: TW; Legal Status:  Active; Application No: 99121957; Filed: Jul 5, 2010; Published: Aug 11, 2014; Earliest Priority: Jul 5, 2010; Granted: Aug 11, 2014",0,GANLAKKFYTYINKFINYAW
GATYAKKIIKTITKIATTAW,20,Synthetic,Synthetic peptide,,NIH 3T3: As show in fig.3,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,"Granted Patent; Family: 2s / 2ex; Family Jurisdictions: TW; Legal Status:  Active; Application No: 99121957; Filed: Jul 5, 2010; Published: Aug 11, 2014; Earliest Priority: Jul 5, 2010; Granted: Aug 11, 2014",0,GATYAKKIIKTITKIATTAW
GIGKFLHSAKKWGKAFVGEIMNS,23,Xenopus laevis,Native peptide,,NIH 3T3: As show in fig.3,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,"Granted Patent; Family: 2s / 2ex; Family Jurisdictions: TW; Legal Status:  Active; Application No: 99121957; Filed: Jul 5, 2010; Published: Aug 11, 2014; Earliest Priority: Jul 5, 2010; Granted: Aug 11, 2014",0,GIGKFLHSAKKWGKAFVGEIMNS
GIKIAKKAITIAKKIAKIYW,20,Synthetic,Synthetic peptide,,NIH 3T3: As show in fig.3,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,"Granted Patent; Family: 2s / 2ex; Family Jurisdictions: TW; Legal Status:  Active; Application No: 99121957; Filed: Jul 5, 2010; Published: Aug 11, 2014; Earliest Priority: Jul 5, 2010; Granted: Aug 11, 2014",0,GIKIAKKAITIAKKIAKIYW
GWGSFFKKAAHVGKHVGKAALTHYL,25,Pseudopleuronectes americanus,Native peptide,,"HEK293: IC50=87.5 ± 11.1 µg/ml; Zebrafish embryos: >10% Killing=5 µg/ml (4, 28, 52hpf embryo)",,,,Anticancer,Tumor active peptide,,Linear,,Free,Amidation,,,0,GWGSFFKKAAHVGKHVGKAALTHYL
GYNYAKKLANLAKKFANALW,20,Synthetic,Synthetic peptide,,NIH 3T3: IC50=243 μM,,,"GW-H1 treatment induced both apoptosis and autophagy of AGS cell line in the early stage, while caspase-dependent apoptosis was further enhanced by inhibition of autophagy at the final stage.",Anticancer; Antimicrobial,Tumor active peptide##Induce apoptosis,,Linear,,Free,Free,,"Granted Patent; Family: 2s / 2ex; Family Jurisdictions: TW; Legal Status:  Active; Application No: 99121957; Filed: Jul 5, 2010; Published: Aug 11, 2014; Earliest Priority: Jul 5, 2010; Granted: Aug 11, 2014",0,GYNYAKKLANLAKKFANALW
ADPRVVVDLRFFGKSDIVEENRVTFGPNPK,30,Synthetic construct,Native peptide,,,,,,Antitumor,Tumor active peptide,,Linear,,,,,"Granted Patent Family: 3s / 5ex; Family Jurisdictions: US; Legal Status:   Expired; Application No: 91196901; Filed:Jul 24, 2001; Published: Sep 26, 2002; Earliest Priority: Feb 13, 1997; Granted: Jul 13, 2004",0,ADPRVVVDLRFFGKSDIVEENRVTFGPNPK
ETLQQTLDASRGVTTLPLGVERRTDNPIYVTWTGADTVLGDVPKSPRFALVTETRVTK,58,Synthetic construct,Native peptide,,,,,,Antitumor,Tumor active peptide,,Linear,,,,,"Granted Patent Family: 3s / 5ex; Family Jurisdictions: US; Legal Status:   Expired; Application No: 91196901; Filed:Jul 24, 2001; Published: Sep 26, 2002; Earliest Priority: Feb 13, 1997; Granted: Jul 13, 2004",0,ETLQQTLDASRGVTTLPLGVERRTDNPIYVTWTGADTVLGDVPKSPRFALVTETRVTK
FVNIINGALQPISISPSDTYQPTLAVAAWAPPIDPAEGQLVIMGHNPNQEAGLNLPGSAVT,61,Synthetic construct,Native peptide,,,,,,Antitumor,Tumor active peptide,,Linear,,,,,"Granted Patent Family: 3s / 5ex; Family Jurisdictions: US; Legal Status:   Expired; Application No: 91196901; Filed:Jul 24, 2001; Published: Sep 26, 2002; Earliest Priority: Feb 13, 1997; Granted: Jul 13, 2004",0,FVNIINGALQPISISPSDTYQPTLAVAAWAPPIDPAEGQLVIMGHNPNQEAGLNLPGSAVT
GAEAVVNYLGVS,12,Synthetic construct,Native peptide,,,,,,Antitumor,Tumor active peptide,,Linear,,,,,"Granted Patent Family: 3s / 5ex; Family Jurisdictions: US; Legal Status:   Expired; Application No: 91196901; Filed:Jul 24, 2001; Published: Sep 26, 2002; Earliest Priority: Feb 13, 1997; Granted: Jul 13, 2004",0,GAEAVVNYLGVS
GSYPQFMAPGLVLHITGTTRIGTDDQTSVADPTSK,35,Synthetic construct,Native peptide,,,,,,Antitumor,Tumor active peptide,,Linear,,,,,"Granted Patent Family: 3s / 5ex; Family Jurisdictions: US; Legal Status:   Expired; Application No: 91196901; Filed:Jul 24, 2001; Published: Sep 26, 2002; Earliest Priority: Feb 13, 1997; Granted: Jul 13, 2004",0,GSYPQFMAPGLVLHITGTTRIGTDDQTSVADPTSK
LIVSETNPTQVVAALLRNLNTSNDELVVAK,30,Synthetic construct,Native peptide,,,,,,Antitumor,Tumor active peptide,,Linear,,,,,"Granted Patent Family: 3s / 5ex; Family Jurisdictions: US; Legal Status:   Expired; Application No: 91196901; Filed:Jul 24, 2001; Published: Sep 26, 2002; Earliest Priority: Feb 13, 1997; Granted: Jul 13, 2004",0,LIVSETNPTQVVAALLRNLNTSNDELVVAK
LREWEAGVTDTYGMPQPTFHVKRTNADGDRDQRMMNDMTNVANMLGGYLP,50,Synthetic construct,Native peptide,,,,,,Antitumor,Tumor active peptide,,Linear,,,,,"Granted Patent Family: 3s / 5ex; Family Jurisdictions: US; Legal Status:   Expired; Application No: 91196901; Filed:Jul 24, 2001; Published: Sep 26, 2002; Earliest Priority: Feb 13, 1997; Granted: Jul 13, 2004",0,LREWEAGVTDTYGMPQPTFHVKRTNADGDRDQRMMNDMTNVANMLGGYLP
NSIKFQKDIDKFVNIINGALQP,22,Synthetic construct,Native peptide,,,,,,Antitumor,Tumor active peptide,,Linear,,,,,"Granted Patent Family: 3s / 5ex; Family Jurisdictions: US; Legal Status:   Expired; Application No: 91196901; Filed:Jul 24, 2001; Published: Sep 26, 2002; Earliest Priority: Feb 13, 1997; Granted: Jul 13, 2004",0,NSIKFQKDIDKFVNIINGALQP
PIRLSKEKINDLLQRSQGDLTSSQHEIVH,29,Synthetic construct,Native peptide,,,,,,Antitumor,Tumor active peptide,,Linear,,,,,"Granted Patent Family: 3s / 5ex; Family Jurisdictions: US; Legal Status:   Expired; Application No: 91196901; Filed:Jul 24, 2001; Published: Sep 26, 2002; Earliest Priority: Feb 13, 1997; Granted: Jul 13, 2004",0,PIRLSKEKINDLLQRSQGDLTSSQHEIVH
PIRLSKEKINDLLQRSQGDLTSSQHEIVHFTDVFIAGSGPISCTYARHIIDNTSTTK,57,Synthetic construct,Native peptide,,,,,,Antitumor,Tumor active peptide,,Linear,,,,,"Granted Patent Family: 3s / 5ex; Family Jurisdictions: US; Legal Status:   Expired; Application No: 91196901; Filed:Jul 24, 2001; Published: Sep 26, 2002; Earliest Priority: Feb 13, 1997; Granted: Jul 13, 2004",0,PIRLSKEKINDLLQRSQGDLTSSQHEIVHFTDVFIAGSGPISCTYARHIIDNTSTTK
QEFDALLERAKTLLNVHSDQYDDSIRQIVVK,31,Synthetic construct,Native peptide,,,,,,Antitumor,Tumor active peptide,,Linear,,,,,"Granted Patent Family: 3s / 5ex; Family Jurisdictions: US; Legal Status:   Expired; Application No: 91196901; Filed:Jul 24, 2001; Published: Sep 26, 2002; Earliest Priority: Feb 13, 1997; Granted: Jul 13, 2004",0,QEFDALLERAKTLLNVHSDQYDDSIRQIVVK
RTVGGMATHWTCACPTPHDEERVNNPVDK,29,Synthetic construct,Native peptide,,,,,,Antitumor,Tumor active peptide,,Linear,,,,,"Granted Patent Family: 3s / 5ex; Family Jurisdictions: US; Legal Status:   Expired; Application No: 91196901; Filed:Jul 24, 2001; Published: Sep 26, 2002; Earliest Priority: Feb 13, 1997; Granted: Jul 13, 2004",0,RTVGGMATHWTCACPTPHDEERVNNPVDK
SFVIACGAVCTPQILWNSNIRPYALGRYLSEQSMTFCQIVLKRGIVDAIATDPRFAAK,58,Synthetic construct,Native peptide,,,,,,Antitumor,Tumor active peptide,,Linear,,,,,"Granted Patent Family: 3s / 5ex; Family Jurisdictions: US; Legal Status:   Expired; Application No: 91196901; Filed:Jul 24, 2001; Published: Sep 26, 2002; Earliest Priority: Feb 13, 1997; Granted: Jul 13, 2004",0,SFVIACGAVCTPQILWNSNIRPYALGRYLSEQSMTFCQIVLKRGIVDAIATDPRFAAK
VEAHKKKHPDDVLPIPFHEPEPQVMIPYTSDFPWHVQVHRDAFSYGDVGPK,51,Synthetic construct,Native peptide,,,,,,Antitumor,Tumor active peptide,,Linear,,,,,"Granted Patent Family: 3s / 5ex; Family Jurisdictions: US; Legal Status:   Expired; Application No: 91196901; Filed:Jul 24, 2001; Published: Sep 26, 2002; Earliest Priority: Feb 13, 1997; Granted: Jul 13, 2004",0,VEAHKKKHPDDVLPIPFHEPEPQVMIPYTSDFPWHVQVHRDAFSYGDVGPK
VHNFNNLWVGGNGCIPDATACNPTRTSVAYALK,33,Synthetic construct,Native peptide,,,,,,Antitumor,Tumor active peptide,,Linear,,,,,"Granted Patent Family: 3s / 5ex; Family Jurisdictions: US; Legal Status:   Expired; Application No: 91196901; Filed:Jul 24, 2001; Published: Sep 26, 2002; Earliest Priority: Feb 13, 1997; Granted: Jul 13, 2004",0,VHNFNNLWVGGNGCIPDATACNPTRTSVAYALK
VYMAEIGSQDNPVIGAHHK,19,Synthetic construct,Native peptide,,,,,,Antitumor,Tumor active peptide,,Linear,,,,,"Granted Patent Family: 3s / 5ex; Family Jurisdictions: US; Legal Status:   Expired; Application No: 91196901; Filed:Jul 24, 2001; Published: Sep 26, 2002; Earliest Priority: Feb 13, 1997; Granted: Jul 13, 2004",0,VYMAEIGSQDNPVIGAHHK
AAVALLPAVLLALLAP,16,Human,Native peptide,,,,,,Antitumor,Tumor active peptide,,,,,,,"Granted Patent Family: 6s / 6ex; Family Jurisdictions: CN, WO, AU, US; Legal Status:   Discontinued; Application No: 7755502; Filed:Feb 15, 2002; Published: Apr 24, 2003; Earliest Priority:  Feb 15, 2001",0,AAVALLPAVLLALLAP
AAVLLPVLLAAP,12,Synthetic construct,Synthetic peptide,,,,,,Antitumor,Tumor active peptide,,,,,,,"Granted Patent Family: 6s / 6ex; Family Jurisdictions: CN, WO, AU, US; Legal Status:   Discontinued; Application No: 7755502; Filed:Feb 15, 2002; Published: Apr 24, 2003; Earliest Priority:  Feb 15, 2001",0,AAVLLPVLLAAP
DAATATRGRSAASRPTERPRAPARSASRPRRPVE,34,Herpes simplex virus 1,Native peptide,,,,,,Antitumor,Tumor active peptide,,,,,,,"Granted Patent Family: 6s / 6ex; Family Jurisdictions: CN, WO, AU, US; Legal Status:   Discontinued; Application No: 7755502; Filed:Feb 15, 2002; Published: Apr 24, 2003; Earliest Priority:  Feb 15, 2001",0,DAATATRGRSAASRPTERPRAPARSASRPRRPVE
GALFLGWLGAAGSTMGAWSQPKKKRKV,27,Synthetic construct,Synthetic peptide,,,,,,Antitumor,Tumor active peptide,,,,,,,"Granted Patent Family: 6s / 6ex; Family Jurisdictions: CN, WO, AU, US; Legal Status:   Discontinued; Application No: 7755502; Filed:Feb 15, 2002; Published: Apr 24, 2003; Earliest Priority:  Feb 15, 2001",0,GALFLGWLGAAGSTMGAWSQPKKKRKV
GWTLNSAGYLLKINLKALAALAKKIL,26,Synthetic construct,Synthetic peptide,,,,,,Antitumor,Tumor active peptide,,,,,,,"Granted Patent Family: 6s / 6ex; Family Jurisdictions: CN, WO, AU, US; Legal Status:   Discontinued; Application No: 7755502; Filed:Feb 15, 2002; Published: Apr 24, 2003; Earliest Priority:  Feb 15, 2001",0,GWTLNSAGYLLKINLKALAALAKKIL
KKKKKKGGFLGFWRGENGRKTRSAYERMCNILKGK,35,Synthetic construct,Synthetic peptide,,,,,,Antitumor,Tumor active peptide,,,,,,,"Granted Patent Family: 6s / 6ex; Family Jurisdictions: CN, WO, AU, US; Legal Status:   Discontinued; Application No: 7755502; Filed:Feb 15, 2002; Published: Apr 24, 2003; Earliest Priority:  Feb 15, 2001",0,KKKKKKGGFLGFWRGENGRKTRSAYERMCNILKGK
PLSSIFSRIGDP,12,Hepatitis B virus,Native peptide,,,,,,Antitumor,Tumor active peptide,,,,,,,"Granted Patent Family: 6s / 6ex; Family Jurisdictions: CN, WO, AU, US; Legal Status:   Discontinued; Application No: 7755502; Filed:Feb 15, 2002; Published: Apr 24, 2003; Earliest Priority:  Feb 15, 2001",0,PLSSIFSRIGDP
RQIKIWFQNRRMKWKK,16,Antennapedia homeodomain,Native peptide,Human erythrocytes: HD50>128 μM,,,,,Anticancer; Antibacterial; Antifungal,Cell-penetrating peptides,,Linear,,Free,Amidation,,"Granted Patent Family: 6s / 6ex; Family Jurisdictions: CN, WO, AU, US; Legal Status:   Discontinued; Application No: 7755502; Filed:Feb 15, 2002; Published: Apr 24, 2003; Earliest Priority:  Feb 15, 2001",0,RQIKIWFQNRRMKWKK
SVYDFFVWL,9,Human,Native peptide,,,,,,Antitumor,Tumor active peptide,,,,,,,"Granted Patent Family: 6s / 6ex; Family Jurisdictions: CN, WO, AU, US; Legal Status:   Discontinued; Application No: 7755502; Filed:Feb 15, 2002; Published: Apr 24, 2003; Earliest Priority:  Feb 15, 2001",0,SVYDFFVWL
YARAAARQARA,11,Synthetic construct,Synthetic peptide,,,,,,Antitumor,Tumor active peptide,,,,,,,"Granted Patent Family: 6s / 6ex; Family Jurisdictions: CN, WO, AU, US; Legal Status:   Discontinued; Application No: 7755502; Filed:Feb 15, 2002; Published: Apr 24, 2003; Earliest Priority:  Feb 15, 2001",0,YARAAARQARA
YARAARRAARR,11,Synthetic construct,Synthetic peptide,,,,,,Antitumor,Tumor active peptide,,,,,,,"Granted Patent Family: 6s / 6ex; Family Jurisdictions: CN, WO, AU, US; Legal Status:   Discontinued; Application No: 7755502; Filed:Feb 15, 2002; Published: Apr 24, 2003; Earliest Priority:  Feb 15, 2001",0,YARAARRAARR
CVHAFRA,7,Sos scrofus (Pig),Native peptide,,,,,,Anticancer; Antimicrobial; Antiviral,Tumor active peptide,,,,,,,"Granted Patent Family: 11s / 14ex; Family Jurisdictions: EP, IL, AU, US, AT, DE; Legal Status:   Expired; Application No: 67049003; Filed:Sep 25, 2003; Published: Mar 4, 2004; Earliest Priority: Jul 2, 1998; Granted: Jan 13, 2009",0,CVHAFRA
CVHAFRS,7,Sos scrofus (Pig),Native peptide,,,,,,Anticancer; Antimicrobial; Antiviral,Tumor active peptide,,,,,,,"Granted Patent Family: 11s / 14ex; Family Jurisdictions: EP, IL, AU, US, AT, DE; Legal Status:   Expired; Application No: 67049003; Filed:Sep 25, 2003; Published: Mar 4, 2004; Earliest Priority: Jul 2, 1998; Granted: Jan 13, 2009",0,CVHAFRS
CVHAYRA,7,Sos scrofus (Pig),Native peptide,,,,,,Anticancer; Antimicrobial; Antiviral,Tumor active peptide,,,,,,,"Granted Patent Family: 11s / 14ex; Family Jurisdictions: EP, IL, AU, US, AT, DE; Legal Status:   Expired; Application No: 67049003; Filed:Sep 25, 2003; Published: Mar 4, 2004; Earliest Priority: Jul 2, 1998; Granted: Jan 13, 2009",0,CVHAYRA
CVHAYRS,7,Sos scrofus (Pig),Native peptide,,,,,,Anticancer; Antimicrobial; Antiviral,Tumor active peptide,,,,,,,"Granted Patent Family: 11s / 14ex; Family Jurisdictions: EP, IL, AU, US, AT, DE; Legal Status:   Expired; Application No: 67049003; Filed:Sep 25, 2003; Published: Mar 4, 2004; Earliest Priority: Jul 2, 1998; Granted: Jan 13, 2009",0,CVHAYRS
CVHSFRA,7,Sos scrofus (Pig),Native peptide,,,,,,Anticancer; Antimicrobial; Antiviral,Tumor active peptide,,,,,,,"Granted Patent Family: 11s / 14ex; Family Jurisdictions: EP, IL, AU, US, AT, DE; Legal Status:   Expired; Application No: 67049003; Filed:Sep 25, 2003; Published: Mar 4, 2004; Earliest Priority: Jul 2, 1998; Granted: Jan 13, 2009",0,CVHSFRA
CVHSFRS,7,Sos scrofus (Pig),Native peptide,,,,,,Anticancer; Antimicrobial; Antiviral,Tumor active peptide,,,,,,,"Granted Patent Family: 11s / 14ex; Family Jurisdictions: EP, IL, AU, US, AT, DE; Legal Status:   Expired; Application No: 67049003; Filed:Sep 25, 2003; Published: Mar 4, 2004; Earliest Priority: Jul 2, 1998; Granted: Jan 13, 2009",0,CVHSFRS
CVHSYRA,7,Sos scrofus (Pig),Native peptide,,,,,,Anticancer; Antimicrobial; Antiviral,Tumor active peptide,,,,,,,"Granted Patent Family: 11s / 14ex; Family Jurisdictions: EP, IL, AU, US, AT, DE; Legal Status:   Expired; Application No: 67049003; Filed:Sep 25, 2003; Published: Mar 4, 2004; Earliest Priority: Jul 2, 1998; Granted: Jan 13, 2009",0,CVHSYRA
CVHSYRS,7,Sos scrofus (Pig),Native peptide,,,,,,Anticancer; Antimicrobial; Antiviral,Tumor active peptide,,,,,,,"Granted Patent Family: 11s / 14ex; Family Jurisdictions: EP, IL, AU, US, AT, DE; Legal Status:   Expired; Application No: 67049003; Filed:Sep 25, 2003; Published: Mar 4, 2004; Earliest Priority: Jul 2, 1998; Granted: Jan 13, 2009",0,CVHSYRS
CVHTFRA,7,Sos scrofus (Pig),Native peptide,,,,,,Anticancer; Antimicrobial; Antiviral,Tumor active peptide,,,,,,,"Granted Patent Family: 11s / 14ex; Family Jurisdictions: EP, IL, AU, US, AT, DE; Legal Status:   Expired; Application No: 67049003; Filed:Sep 25, 2003; Published: Mar 4, 2004; Earliest Priority: Jul 2, 1998; Granted: Jan 13, 2009",0,CVHTFRA
CVHTFRS,7,Sos scrofus (Pig),Native peptide,,,,,,Anticancer; Antimicrobial; Antiviral,Tumor active peptide,,,,,,,"Granted Patent Family: 11s / 14ex; Family Jurisdictions: EP, IL, AU, US, AT, DE; Legal Status:   Expired; Application No: 67049003; Filed:Sep 25, 2003; Published: Mar 4, 2004; Earliest Priority: Jul 2, 1998; Granted: Jan 13, 2009",0,CVHTFRS
CVHTYRA,7,Sos scrofus (Pig),Native peptide,,,,,,Anticancer; Antimicrobial; Antiviral,Tumor active peptide,,,,,,,"Granted Patent Family: 11s / 14ex; Family Jurisdictions: EP, IL, AU, US, AT, DE; Legal Status:   Expired; Application No: 67049003; Filed:Sep 25, 2003; Published: Mar 4, 2004; Earliest Priority: Jul 2, 1998; Granted: Jan 13, 2009",0,CVHTYRA
CVHTYRS,7,Sos scrofus (Pig),Native peptide,,,,,,Anticancer; Antimicrobial; Antiviral,Tumor active peptide,,,,,,,"Granted Patent Family: 11s / 14ex; Family Jurisdictions: EP, IL, AU, US, AT, DE; Legal Status:   Expired; Application No: 67049003; Filed:Sep 25, 2003; Published: Mar 4, 2004; Earliest Priority: Jul 2, 1998; Granted: Jan 13, 2009",0,CVHTYRS
ELKCYTCKEPMTSAACRTIT,20,Synthetic construct,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,,,,,"Granted Patent Family: 3s / 3ex; Family Jurisdictions: US, WO; Legal Status:    Inactive; Application No: 97762904; Filed:Oct 29, 2004; Published: Oct 27, 2005; Earliest Priority: Oct 29, 2003; Granted: Feb 5, 2008",0,ELKCYTCKEPMTSAACRTIT
ELKCYTCKEPMTSASCRTIT,20,Synthetic construct,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,,,,,"Granted Patent Family: 3s / 3ex; Family Jurisdictions: US, WO; Legal Status:    Inactive; Application No: 97762904; Filed:Oct 29, 2004; Published: Oct 27, 2005; Earliest Priority: Oct 29, 2003; Granted: Feb 5, 2008",0,ELKCYTCKEPMTSASCRTIT
EAAGIGILT,9,Homo sapiens,Native peptide,,,,,,Antitumor,Tumor active peptide,,,,,,,"Granted Patent Family: 10s / 10ex; Family Jurisdictions:  CA, AU, FR, WO, US, EP, JP; Legal Status:   Discontinued; Application No: 50633405; Filed:May 25, 2005; Published: Jun 8, 2006; Earliest Priority: Mar 4, 2002",0,EAAGIGILT
EAAGIGILTV,10,Homo sapiens,Native peptide,,,,,,Antitumor,Tumor active peptide,,,,,,,"Granted Patent Family: 10s / 10ex; Family Jurisdictions:  CA, AU, FR, WO, US, EP, JP; Legal Status:   Discontinued; Application No: 50633405; Filed:May 25, 2005; Published: Jun 8, 2006; Earliest Priority: Mar 4, 2002",0,EAAGIGILTV
EAAGIGILTVIL,12,Homo sapiens,Native peptide,,,,,,Antitumor,Tumor active peptide,,,,,,,"Granted Patent Family: 10s / 10ex; Family Jurisdictions:  CA, AU, FR, WO, US, EP, JP; Legal Status:   Discontinued; Application No: 50633405; Filed:May 25, 2005; Published: Jun 8, 2006; Earliest Priority: Mar 4, 2002",0,EAAGIGILTVIL
EAAGIGILTY,10,Synthetic construct,Synthetic peptide,,,,,,Antitumor,Tumor active peptide,,,,,,,"Granted Patent Family: 10s / 10ex; Family Jurisdictions:  CA, AU, FR, WO, US, EP, JP; Legal Status:   Discontinued; Application No: 50633405; Filed:May 25, 2005; Published: Jun 8, 2006; Earliest Priority: Mar 4, 2002",0,EAAGIGILTY
EAAGIGILY,9,Synthetic construct,Synthetic peptide,,,,,,Antitumor,Tumor active peptide,,,,,,,"Granted Patent Family: 10s / 10ex; Family Jurisdictions:  CA, AU, FR, WO, US, EP, JP; Legal Status:   Discontinued; Application No: 50633405; Filed:May 25, 2005; Published: Jun 8, 2006; Earliest Priority: Mar 4, 2002",0,EAAGIGILY
EPAGIGILTV,10,Synthetic construct,Synthetic peptide,,,,,,Antitumor,Tumor active peptide,,,,,,,"Granted Patent Family: 10s / 10ex; Family Jurisdictions:  CA, AU, FR, WO, US, EP, JP; Legal Status:   Discontinued; Application No: 50633405; Filed:May 25, 2005; Published: Jun 8, 2006; Earliest Priority: Mar 4, 2002",0,EPAGIGILTV
EPAGIGILTY,10,Synthetic construct,Synthetic peptide,,,,,,Antitumor,Tumor active peptide,,,,,,,"Granted Patent Family: 10s / 10ex; Family Jurisdictions:  CA, AU, FR, WO, US, EP, JP; Legal Status:   Discontinued; Application No: 50633405; Filed:May 25, 2005; Published: Jun 8, 2006; Earliest Priority: Mar 4, 2002",0,EPAGIGILTY
EPAGIGILY,9,Synthetic construct,Synthetic peptide,,,,,,Antitumor,Tumor active peptide,,,,,,,"Granted Patent Family: 10s / 10ex; Family Jurisdictions:  CA, AU, FR, WO, US, EP, JP; Legal Status:   Discontinued; Application No: 50633405; Filed:May 25, 2005; Published: Jun 8, 2006; Earliest Priority: Mar 4, 2002",0,EPAGIGILY
EVDPIGHLY,9,Homo sapiens,Native peptide,,,,,,Antitumor,Tumor active peptide,,,,,,,"Granted Patent Family: 10s / 10ex; Family Jurisdictions:  CA, AU, FR, WO, US, EP, JP; Legal Status:   Discontinued; Application No: 50633405; Filed:May 25, 2005; Published: Jun 8, 2006; Earliest Priority: Mar 4, 2002",0,EVDPIGHLY
EVDPIGHVY,9,Homo sapiens,Native peptide,,,,,,Antitumor,Tumor active peptide,,,,,,,"Granted Patent Family: 10s / 10ex; Family Jurisdictions:  CA, AU, FR, WO, US, EP, JP; Legal Status:   Discontinued; Application No: 50633405; Filed:May 25, 2005; Published: Jun 8, 2006; Earliest Priority: Mar 4, 2002",0,EVDPIGHVY
EXAGIGILX,9,Synthetic construct,Synthetic peptide,,,,,,Antitumor,Tumor active peptide,,,,,,X(2)=A or P; X(9)=T or Y,"Granted Patent Family: 10s / 10ex; Family Jurisdictions:  CA, AU, FR, WO, US, EP, JP; Legal Status:   Discontinued; Application No: 50633405; Filed:May 25, 2005; Published: Jun 8, 2006; Earliest Priority: Mar 4, 2002",0,EXAGIGILX
FATPMEAEL,9,Homo sapiens,Native peptide,,,,,,Antitumor,Tumor active peptide,,,,,,,"Granted Patent Family: 10s / 10ex; Family Jurisdictions:  CA, AU, FR, WO, US, EP, JP; Legal Status:   Discontinued; Application No: 50633405; Filed:May 25, 2005; Published: Jun 8, 2006; Earliest Priority: Mar 4, 2002",0,FATPMEAEL
ILDTAGQEEY,10,Homo sapiens,Native peptide,,,,,,Antitumor,Tumor active peptide,,,,,,,"Granted Patent Family: 10s / 10ex; Family Jurisdictions:  CA, AU, FR, WO, US, EP, JP; Legal Status:   Discontinued; Application No: 50633405; Filed:May 25, 2005; Published: Jun 8, 2006; Earliest Priority: Mar 4, 2002",0,ILDTAGQEEY
ILDTAGREEY,10,Homo sapiens,Native peptide,,,,,,Antitumor,Tumor active peptide,,,,,,,"Granted Patent Family: 10s / 10ex; Family Jurisdictions:  CA, AU, FR, WO, US, EP, JP; Legal Status:   Discontinued; Application No: 50633405; Filed:May 25, 2005; Published: Jun 8, 2006; Earliest Priority: Mar 4, 2002",0,ILDTAGREEY
LAMPFATPM,9,Homo sapiens,Native peptide,,,,,,Antitumor,Tumor active peptide,,,,,,,"Granted Patent Family: 10s / 10ex; Family Jurisdictions:  CA, AU, FR, WO, US, EP, JP; Legal Status:   Discontinued; Application No: 50633405; Filed:May 25, 2005; Published: Jun 8, 2006; Earliest Priority: Mar 4, 2002",0,LAMPFATPM
LAMPFATPMEAE,12,Homo sapiens,Native peptide,,,,,,Antitumor,Tumor active peptide,,,,,,,"Granted Patent Family: 10s / 10ex; Family Jurisdictions:  CA, AU, FR, WO, US, EP, JP; Legal Status:   Discontinued; Application No: 50633405; Filed:May 25, 2005; Published: Jun 8, 2006; Earliest Priority: Mar 4, 2002",0,LAMPFATPMEAE
LAMPFATPMEAEL,13,Homo sapiens,Native peptide,,,,,,Antitumor,Tumor active peptide,,,,,,,"Granted Patent Family: 10s / 10ex; Family Jurisdictions:  CA, AU, FR, WO, US, EP, JP; Legal Status:   Discontinued; Application No: 50633405; Filed:May 25, 2005; Published: Jun 8, 2006; Earliest Priority: Mar 4, 2002",0,LAMPFATPMEAEL
LPSSADVEF,9,Homo sapiens,Native peptide,,,,,,Antitumor,Tumor active peptide,,,,,,,"Granted Patent Family: 10s / 10ex; Family Jurisdictions:  CA, AU, FR, WO, US, EP, JP; Legal Status:   Discontinued; Application No: 50633405; Filed:May 25, 2005; Published: Jun 8, 2006; Earliest Priority: Mar 4, 2002",0,LPSSADVEF
LPSSADVEFC,10,Homo sapiens,Native peptide,,,,,,Antitumor,Tumor active peptide,,,,,,,"Granted Patent Family: 10s / 10ex; Family Jurisdictions:  CA, AU, FR, WO, US, EP, JP; Legal Status:   Discontinued; Application No: 50633405; Filed:May 25, 2005; Published: Jun 8, 2006; Earliest Priority: Mar 4, 2002",0,LPSSADVEFC
MPFATPMEA,9,Homo sapiens,Native peptide,,,,,,Antitumor,Tumor active peptide,,,,,,,"Granted Patent Family: 10s / 10ex; Family Jurisdictions:  CA, AU, FR, WO, US, EP, JP; Legal Status:   Discontinued; Application No: 50633405; Filed:May 25, 2005; Published: Jun 8, 2006; Earliest Priority: Mar 4, 2002",0,MPFATPMEA
MPFATPMEAE,10,Homo sapiens,Native peptide,,,,,,Antitumor,Tumor active peptide,,,,,,,"Granted Patent Family: 10s / 10ex; Family Jurisdictions:  CA, AU, FR, WO, US, EP, JP; Legal Status:   Discontinued; Application No: 50633405; Filed:May 25, 2005; Published: Jun 8, 2006; Earliest Priority: Mar 4, 2002",0,MPFATPMEAE
MPFATPMEAEL,11,Homo sapiens,Native peptide,,,,,,Antitumor,Tumor active peptide,,,,,,,"Granted Patent Family: 10s / 10ex; Family Jurisdictions:  CA, AU, FR, WO, US, EP, JP; Legal Status:   Discontinued; Application No: 50633405; Filed:May 25, 2005; Published: Jun 8, 2006; Earliest Priority: Mar 4, 2002",0,MPFATPMEAEL
PLDCVLYRY,9,Homo sapiens,Native peptide,,,,,,Antitumor,Tumor active peptide,,,,,,,"Granted Patent Family: 10s / 10ex; Family Jurisdictions:  CA, AU, FR, WO, US, EP, JP; Legal Status:   Discontinued; Application No: 50633405; Filed:May 25, 2005; Published: Jun 8, 2006; Earliest Priority: Mar 4, 2002",0,PLDCVLYRY
PRLPSSADVEFCL,13,Homo sapiens,Native peptide,,,,,,Antitumor,Tumor active peptide,,,,,,,"Granted Patent Family: 10s / 10ex; Family Jurisdictions:  CA, AU, FR, WO, US, EP, JP; Legal Status:   Discontinued; Application No: 50633405; Filed:May 25, 2005; Published: Jun 8, 2006; Earliest Priority: Mar 4, 2002",0,PRLPSSADVEFCL
QVPLDCVLYR,10,Homo sapiens,Native peptide,,,,,,Antitumor,Tumor active peptide,,,,,,,"Granted Patent Family: 10s / 10ex; Family Jurisdictions:  CA, AU, FR, WO, US, EP, JP; Legal Status:   Discontinued; Application No: 50633405; Filed:May 25, 2005; Published: Jun 8, 2006; Earliest Priority: Mar 4, 2002",0,QVPLDCVLYR
TAEEAAGIGILTV,13,Homo sapiens,Native peptide,,,,,,Antitumor,Tumor active peptide,,,,,,,"Granted Patent Family: 10s / 10ex; Family Jurisdictions:  CA, AU, FR, WO, US, EP, JP; Legal Status:   Discontinued; Application No: 50633405; Filed:May 25, 2005; Published: Jun 8, 2006; Earliest Priority: Mar 4, 2002",0,TAEEAAGIGILTV
TPRLPSSADV,10,Homo sapiens,Native peptide,,,,,,Antitumor,Tumor active peptide,,,,,,,"Granted Patent Family: 10s / 10ex; Family Jurisdictions:  CA, AU, FR, WO, US, EP, JP; Legal Status:   Discontinued; Application No: 50633405; Filed:May 25, 2005; Published: Jun 8, 2006; Earliest Priority: Mar 4, 2002",0,TPRLPSSADV
TPRLPSSADVE,11,Homo sapiens,Native peptide,,,,,,Antitumor,Tumor active peptide,,,,,,,"Granted Patent Family: 10s / 10ex; Family Jurisdictions:  CA, AU, FR, WO, US, EP, JP; Legal Status:   Discontinued; Application No: 50633405; Filed:May 25, 2005; Published: Jun 8, 2006; Earliest Priority: Mar 4, 2002",0,TPRLPSSADVE
TPRLPSSADVEF,12,Homo sapiens,Native peptide,,,,,,Antitumor,Tumor active peptide,,,,,,,"Granted Patent Family: 10s / 10ex; Family Jurisdictions:  CA, AU, FR, WO, US, EP, JP; Legal Status:   Discontinued; Application No: 50633405; Filed:May 25, 2005; Published: Jun 8, 2006; Earliest Priority: Mar 4, 2002",0,TPRLPSSADVEF
TPRLPSSADVEFC,13,Homo sapiens,Native peptide,,,,,,Antitumor,Tumor active peptide,,,,,,,"Granted Patent Family: 10s / 10ex; Family Jurisdictions:  CA, AU, FR, WO, US, EP, JP; Legal Status:   Discontinued; Application No: 50633405; Filed:May 25, 2005; Published: Jun 8, 2006; Earliest Priority: Mar 4, 2002",0,TPRLPSSADVEFC
TPRLPSSADVEFCL,14,Homo sapiens,Native peptide,,,,,,Antitumor,Tumor active peptide,,,,,,,"Granted Patent Family: 10s / 10ex; Family Jurisdictions:  CA, AU, FR, WO, US, EP, JP; Legal Status:   Discontinued; Application No: 50633405; Filed:May 25, 2005; Published: Jun 8, 2006; Earliest Priority: Mar 4, 2002",0,TPRLPSSADVEFCL
TTAEEAAGIGIL,12,Homo sapiens,Native peptide,,,,,,Antitumor,Tumor active peptide,,,,,,,"Granted Patent Family: 10s / 10ex; Family Jurisdictions:  CA, AU, FR, WO, US, EP, JP; Legal Status:   Discontinued; Application No: 50633405; Filed:May 25, 2005; Published: Jun 8, 2006; Earliest Priority: Mar 4, 2002",0,TTAEEAAGIGIL
VPLDCVLYR,9,Homo sapiens,Native peptide,,,,,,Antitumor,Tumor active peptide,,,,,,,"Granted Patent Family: 10s / 10ex; Family Jurisdictions:  CA, AU, FR, WO, US, EP, JP; Legal Status:   Discontinued; Application No: 50633405; Filed:May 25, 2005; Published: Jun 8, 2006; Earliest Priority: Mar 4, 2002",0,VPLDCVLYR
VPLDCVLYRY,10,Homo sapiens,Native peptide,,,,,,Antitumor,Tumor active peptide,,,,,,,"Granted Patent Family: 10s / 10ex; Family Jurisdictions:  CA, AU, FR, WO, US, EP, JP; Legal Status:   Discontinued; Application No: 50633405; Filed:May 25, 2005; Published: Jun 8, 2006; Earliest Priority: Mar 4, 2002",0,VPLDCVLYRY
MGSSHHHHHHSSGLVPGSHMVRDGYIADDKNCAYFCGRNAYCDDECKKNGAESGYCQWAGVYGNACWCYKLPDKVPIRVPGKCNGG,86,Scorpion,Native peptide,,,,,,Antitumor,Tumor active peptide,,,,,,,"Granted Patent Family: 10s / 10ex; Family Jurisdictions: US, DE, AT, CN, EP, WO; Legal Status:   Active; Application No: 49107704; Filed:Dec 13, 2004; Published: Nov 9, 2006; Earliest Priority: Sep 30, 2001; Granted: Sep 22, 2009",0,MGSSHHHHHHSSGLVPGSHMVRDGYIADDKNCAYFCGRNAYCDDECKKNGAESGYCQWAGVYGNACWCYKLPDKVPIRVPGKCNGG
MVRDGYIADDKNCAYFCGRNAYCDDECKKNGAESGYCQWAGVYGNACWCYKLPDKVPIRVPGKCNGGLEHHHHHH,75,Scorpion,Native peptide,,,,,,Antitumor,Tumor active peptide,,,,,,,"Granted Patent Family: 10s / 10ex; Family Jurisdictions: US, DE, AT, CN, EP, WO; Legal Status:   Active; Application No: 49107704; Filed:Dec 13, 2004; Published: Nov 9, 2006; Earliest Priority: Sep 30, 2001; Granted: Sep 22, 2009",0,MVRDGYIADDKNCAYFCGRNAYCDDECKKNGAESGYCQWAGVYGNACWCYKLPDKVPIRVPGKCNGGLEHHHHHH
VRDGYIADDKNCAYFCGRNAYCDDECKKNGAESGYCQWAGVYGNACWCYKLPDKVPIRVPGKCNGG,66,Scorpion,Native peptide,,,,,,Antitumor,Tumor active peptide,,,,,,,"Granted Patent Family: 10s / 10ex; Family Jurisdictions: US, DE, AT, CN, EP, WO; Legal Status:   Active; Application No: 49107704; Filed:Dec 13, 2004; Published: Nov 9, 2006; Earliest Priority: Sep 30, 2001; Granted: Sep 22, 2009",0,VRDGYIADDKNCAYFCGRNAYCDDECKKNGAESGYCQWAGVYGNACWCYKLPDKVPIRVPGKCNGG
GLPPDVQR,8,Homo sapiens,Native peptide,,,,,,Antitumor,Tumor active peptide,,,,,,,"Granted Patent Family: 8s / 8ex; Family Jurisdictions: US, CA, EP, JP, FR, WO; Legal Status:   Inactive; Application No: 56195104; Filed:Jun 24, 2004; Published: Nov 15, 2007; Earliest Priority: Jun 25, 2003; Granted: Dec 8, 2009",0,GLPPDVQR
GLPPDVQRV,9,Homo sapiens,Native peptide,,,,,,Antitumor,Tumor active peptide,,,,,,,"Granted Patent Family: 8s / 8ex; Family Jurisdictions: US, CA, EP, JP, FR, WO; Legal Status:   Inactive; Application No: 56195104; Filed:Jun 24, 2004; Published: Nov 15, 2007; Earliest Priority: Jun 25, 2003; Granted: Dec 8, 2009",0,GLPPDVQRV
LGLPPDVQRV,10,Homo sapiens,Native peptide,,,,,,Antitumor,Tumor active peptide,,,,,,,"Granted Patent Family: 8s / 8ex; Family Jurisdictions: US, CA, EP, JP, FR, WO; Legal Status:   Inactive; Application No: 56195104; Filed:Jun 24, 2004; Published: Nov 15, 2007; Earliest Priority: Jun 25, 2003; Granted: Dec 8, 2009",0,LGLPPDVQRV
LPPDVQRV,8,Homo sapiens,Native peptide,,,,,,Antitumor,Tumor active peptide,,,,,,,"Granted Patent Family: 8s / 8ex; Family Jurisdictions: US, CA, EP, JP, FR, WO; Legal Status:   Inactive; Application No: 56195104; Filed:Jun 24, 2004; Published: Nov 15, 2007; Earliest Priority: Jun 25, 2003; Granted: Dec 8, 2009",0,LPPDVQRV
GGGGWGQGGTHG,12,Tragelaphus strepsiceros,Native peptide,,,,,,"Antimicrobial, Antitumor, Antiviral",Tumor active peptide,,,,,,,"Granted Patent Family: 10s / 10ex; Family Jurisdictions: EP, RU, AU, ZA, US, WO; Legal Status:   Active; Application No: 58571504 ; Filed:Dec 30, 2004; Published: Dec 20, 2007; Earliest Priority: Jan 15, 2004; Granted: Feb 12, 2013",0,GGGGWGQGGTHG
GGGWGQPHGGG,11,Bos taurus,Native peptide,,,,,,"Antimicrobial, Antitumor, Antiviral",Tumor active peptide,,,,,,,"Granted Patent Family: 10s / 10ex; Family Jurisdictions: EP, RU, AU, ZA, US, WO; Legal Status:   Active; Application No: 58571504 ; Filed:Dec 30, 2004; Published: Dec 20, 2007; Earliest Priority: Jan 15, 2004; Granted: Feb 12, 2013",0,GGGWGQPHGGG
GGGWGQPHVGG,11,Tragelaphus strepsiceros,Native peptide,,,,,,"Antimicrobial, Antitumor, Antiviral",Tumor active peptide,,,,,,,"Granted Patent Family: 10s / 10ex; Family Jurisdictions: EP, RU, AU, ZA, US, WO; Legal Status:   Active; Application No: 58571504 ; Filed:Dec 30, 2004; Published: Dec 20, 2007; Earliest Priority: Jan 15, 2004; Granted: Feb 12, 2013",0,GGGWGQPHVGG
HGGGWGQGGGTHS,13,Homo sapiens,Native peptide,,,,,,"Antimicrobial, Antitumor, Antiviral",Tumor active peptide,,,,,,,"Granted Patent Family: 10s / 10ex; Family Jurisdictions: EP, RU, AU, ZA, US, WO; Legal Status:   Active; Application No: 58571504 ; Filed:Dec 30, 2004; Published: Dec 20, 2007; Earliest Priority: Jan 15, 2004; Granted: Feb 12, 2013",0,HGGGWGQGGGTHS
HGGGWGQPHGGG,12,Tragelaphus strepsiceros,Native peptide,,,,,,"Antimicrobial, Antitumor, Antiviral",Tumor active peptide,,,,,,,"Granted Patent Family: 10s / 10ex; Family Jurisdictions: EP, RU, AU, ZA, US, WO; Legal Status:   Active; Application No: 58571504 ; Filed:Dec 30, 2004; Published: Dec 20, 2007; Earliest Priority: Jan 15, 2004; Granted: Feb 12, 2013",0,HGGGWGQPHGGG
HGGGWGQPHGGGWG,14,Homo sapiens,Native peptide,,,,,,"Antimicrobial, Antitumor, Antiviral",Tumor active peptide,,,,,,,"Granted Patent Family: 10s / 10ex; Family Jurisdictions: EP, RU, AU, ZA, US, WO; Legal Status:   Active; Application No: 58571504 ; Filed:Dec 30, 2004; Published: Dec 20, 2007; Earliest Priority: Jan 15, 2004; Granted: Feb 12, 2013",0,HGGGWGQPHGGGWG
HGVSGWGQHGTHG,13,Synthetic construct,Synthetic peptide,,,,,,"Antimicrobial, Antitumor, Antiviral",Tumor active peptide,,,,,,,"Granted Patent Family: 10s / 10ex; Family Jurisdictions: EP, RU, AU, ZA, US, WO; Legal Status:   Active; Application No: 58571504 ; Filed:Dec 30, 2004; Published: Dec 20, 2007; Earliest Priority: Jan 15, 2004; Granted: Feb 12, 2013",0,HGVSGWGQHGTHG
QGGGGWGQPHGGGWG,15,Homo sapiens,Native peptide,,,,,,"Antimicrobial, Antitumor, Antiviral",Tumor active peptide,,,,,,,"Granted Patent Family: 10s / 10ex; Family Jurisdictions: EP, RU, AU, ZA, US, WO; Legal Status:   Active; Application No: 58571504 ; Filed:Dec 30, 2004; Published: Dec 20, 2007; Earliest Priority: Jan 15, 2004; Granted: Feb 12, 2013",0,QGGGGWGQPHGGGWG
VGGWGQPHGGG,11,Tragelaphus strepsiceros,Native peptide,,,,,,"Antimicrobial, Antitumor, Antiviral",Tumor active peptide,,,,,,,"Granted Patent Family: 10s / 10ex; Family Jurisdictions: EP, RU, AU, ZA, US, WO; Legal Status:   Active; Application No: 58571504 ; Filed:Dec 30, 2004; Published: Dec 20, 2007; Earliest Priority: Jan 15, 2004; Granted: Feb 12, 2013",0,VGGWGQPHGGG
AGYLLGKINLKALAALAKKIL,21,Synthetic construct,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,,,,,"Granted Patent Family: 7s / 7ex; Family Jurisdictions: DE, EP, WO, AT, US; Legal Status:   Discontinued; Application No: 22536707; Filed:Mar 20, 2007; Published: Nov 4, 2010; Earliest Priority: Mar 20, 2006;",0,AGYLLGKINLKALAALAKKIL
CPGPEGAGC,9,Synthetic construct,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Cyclic,Cys1<--->Cys13,,,,"Granted Patent Family: 7s / 7ex; Family Jurisdictions: DE, EP, WO, AT, US; Legal Status:   Discontinued; Application No: 22536707; Filed:Mar 20, 2007; Published: Nov 4, 2010; Earliest Priority: Mar 20, 2006;",0,CPGPEGAGC
CREKA,5,Synthetic construct,Synthetic peptide,,NIH 3T3: IC50>200 µM,,,,Anticancer,Tumor-homing peptides,,,,,,,"Granted Patent Family: 7s / 7ex; Family Jurisdictions: DE, EP, WO, AT, US; Legal Status:   Discontinued; Application No: 22536707; Filed:Mar 20, 2007; Published: Nov 4, 2010; Earliest Priority: Mar 20, 2006;",0,CREKA
DAATATRGRSAASRPTERPRAPARSASRPRRVD,33,Herpes simplex virus type,Native peptide,,,,,,Anticancer,Tumor active peptide,,,,,,,"Granted Patent Family: 7s / 7ex; Family Jurisdictions: DE, EP, WO, AT, US; Legal Status:   Discontinued; Application No: 22536707; Filed:Mar 20, 2007; Published: Nov 4, 2010; Earliest Priority: Mar 20, 2006;",0,DAATATRGRSAASRPTERPRAPARSASRPRRVD
GALFLGWLGAAGSTMGAPKKKRKV,24,Synthetic construct,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,,,,,"Granted Patent Family: 7s / 7ex; Family Jurisdictions: DE, EP, WO, AT, US; Legal Status:   Discontinued; Application No: 22536707; Filed:Mar 20, 2007; Published: Nov 4, 2010; Earliest Priority: Mar 20, 2006;",0,GALFLGWLGAAGSTMGAPKKKRKV
GLFKALLKLLKSLWKLLLKA,20,Synthetic construct,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,,,,,"Granted Patent Family: 7s / 7ex; Family Jurisdictions: DE, EP, WO, AT, US; Legal Status:   Discontinued; Application No: 22536707; Filed:Mar 20, 2007; Published: Nov 4, 2010; Earliest Priority: Mar 20, 2006;",0,GLFKALLKLLKSLWKLLLKA
GRKKRRQRRRPPQ,13,Human immunodeficiency vi,Native peptide,,,,,,Anticancer,Tumor active peptide,,,,,,,"Granted Patent Family: 7s / 7ex; Family Jurisdictions: DE, EP, WO, AT, US; Legal Status:   Discontinued; Application No: 22536707; Filed:Mar 20, 2007; Published: Nov 4, 2010; Earliest Priority: Mar 20, 2006;",0,GRKKRRQRRRPPQ
KETWFETWFTEWSQPKKKRKV,21,Synthetic construct,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,,,,,"Granted Patent Family: 7s / 7ex; Family Jurisdictions: DE, EP, WO, AT, US; Legal Status:   Discontinued; Application No: 22536707; Filed:Mar 20, 2007; Published: Nov 4, 2010; Earliest Priority: Mar 20, 2006;",0,KETWFETWFTEWSQPKKKRKV
LGTYTQDFNKFHTFPQTAIGVGAP,24,Homo sapiens,Native peptide,,,,,,Anticancer,Tumor active peptide,,,,,,,"Granted Patent Family: 7s / 7ex; Family Jurisdictions: DE, EP, WO, AT, US; Legal Status:   Discontinued; Application No: 22536707; Filed:Mar 20, 2007; Published: Nov 4, 2010; Earliest Priority: Mar 20, 2006;",0,LGTYTQDFNKFHTFPQTAIGVGAP
LLIILRRRIRKQAHAHSK,18,Murinae gen. sp.,Native peptide,,,,,,Anticancer,Tumor active peptide,,,,,,,"Granted Patent Family: 7s / 7ex; Family Jurisdictions: DE, EP, WO, AT, US; Legal Status:   Discontinued; Application No: 22536707; Filed:Mar 20, 2007; Published: Nov 4, 2010; Earliest Priority: Mar 20, 2006;",0,LLIILRRRIRKQAHAHSK
MANLGYWLLALFVTMWTDVGLCKKRPKP,28,Mus sp.,Native peptide,,,,,,Anticancer,Tumor active peptide,,,,,,,"Granted Patent Family: 7s / 7ex; Family Jurisdictions: DE, EP, WO, AT, US; Legal Status:   Discontinued; Application No: 22536707; Filed:Mar 20, 2007; Published: Nov 4, 2010; Earliest Priority: Mar 20, 2006;",0,MANLGYWLLALFVTMWTDVGLCKKRPKP
RVIRVWFQNKRCKDKK,16,Rattus sp.,Native peptide,,,,,,Anticancer,Tumor active peptide,,,,,,,"Granted Patent Family: 7s / 7ex; Family Jurisdictions: DE, EP, WO, AT, US; Legal Status:   Discontinued; Application No: 22536707; Filed:Mar 20, 2007; Published: Nov 4, 2010; Earliest Priority: Mar 20, 2006;",0,RVIRVWFQNKRCKDKK
WEAKLAKALAKALAKHLAKALAKALKACEA,30,Synthetic construct,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,,,,,"Granted Patent Family: 7s / 7ex; Family Jurisdictions: DE, EP, WO, AT, US; Legal Status:   Discontinued; Application No: 22536707; Filed:Mar 20, 2007; Published: Nov 4, 2010; Earliest Priority: Mar 20, 2006;",0,WEAKLAKALAKALAKHLAKALAKALKACEA
AAYAAAKAAALAA,13,Synthetic construct,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,,,,,"Granted Patent Family: 9s / 9ex; Family Jurisdictions: EP, US, JP, CN, CA, AU, WO, FR; Legal Status:   Discontinued; Application No: 200913000302; Filed:Jun 20, 2009; Published: Jun 30, 2011; Earliest Priority: Jun 20, 2008;",0,AAYAAAKAAALAA
AEWAWGPCTPSSKDC,15,Synthetic construct,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,,,,,"Granted Patent Family: 9s / 9ex; Family Jurisdictions: EP, US, JP, CN, CA, AU, WO, FR; Legal Status:   Discontinued; Application No: 200913000302; Filed:Jun 20, 2009; Published: Jun 30, 2011; Earliest Priority: Jun 20, 2008;",0,AEWAWGPCTPSSKDC
AGDLLAIETDKATI,14,Synthetic construct,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,,,,,"Granted Patent Family: 9s / 9ex; Family Jurisdictions: EP, US, JP, CN, CA, AU, WO, FR; Legal Status:   Discontinued; Application No: 200913000302; Filed:Jun 20, 2009; Published: Jun 30, 2011; Earliest Priority: Jun 20, 2008;",0,AGDLLAIETDKATI
AKTIAYDEEARRGLE,15,Synthetic construct,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,,,,,"Granted Patent Family: 9s / 9ex; Family Jurisdictions: EP, US, JP, CN, CA, AU, WO, FR; Legal Status:   Discontinued; Application No: 200913000302; Filed:Jun 20, 2009; Published: Jun 30, 2011; Earliest Priority: Jun 20, 2008;",0,AKTIAYDEEARRGLE
ALLALTSAV,9,Synthetic construct,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,,,,,"Granted Patent Family: 9s / 9ex; Family Jurisdictions: EP, US, JP, CN, CA, AU, WO, FR; Legal Status:   Discontinued; Application No: 200913000302; Filed:Jun 20, 2009; Published: Jun 30, 2011; Earliest Priority: Jun 20, 2008;",0,ALLALTSAV
ALLALTSAVA,10,Synthetic construct,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,,,,,"Granted Patent Family: 9s / 9ex; Family Jurisdictions: EP, US, JP, CN, CA, AU, WO, FR; Legal Status:   Discontinued; Application No: 200913000302; Filed:Jun 20, 2009; Published: Jun 30, 2011; Earliest Priority: Jun 20, 2008;",0,ALLALTSAVA
AQCQETIRV,9,Synthetic construct,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,,,,,"Granted Patent Family: 9s / 9ex; Family Jurisdictions: EP, US, JP, CN, CA, AU, WO, FR; Legal Status:   Discontinued; Application No: 200913000302; Filed:Jun 20, 2009; Published: Jun 30, 2011; Earliest Priority: Jun 20, 2008;",0,AQCQETIRV
AQTQRIRCRV,10,Synthetic construct,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,,,,,"Granted Patent Family: 9s / 9ex; Family Jurisdictions: EP, US, JP, CN, CA, AU, WO, FR; Legal Status:   Discontinued; Application No: 200913000302; Filed:Jun 20, 2009; Published: Jun 30, 2011; Earliest Priority: Jun 20, 2008;",0,AQTQRIRCRV
ARYNAQCQETIRVTK,15,Synthetic construct,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,,,,,"Granted Patent Family: 9s / 9ex; Family Jurisdictions: EP, US, JP, CN, CA, AU, WO, FR; Legal Status:   Discontinued; Application No: 200913000302; Filed:Jun 20, 2009; Published: Jun 30, 2011; Earliest Priority: Jun 20, 2008;",0,ARYNAQCQETIRVTK
AYACNTSTL,9,Synthetic construct,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,,,,,"Granted Patent Family: 9s / 9ex; Family Jurisdictions: EP, US, JP, CN, CA, AU, WO, FR; Legal Status:   Discontinued; Application No: 200913000302; Filed:Jun 20, 2009; Published: Jun 30, 2011; Earliest Priority: Jun 20, 2008;",0,AYACNTSTL
CGVGFREGTCGAQ,13,Synthetic construct,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,,,,,"Granted Patent Family: 9s / 9ex; Family Jurisdictions: EP, US, JP, CN, CA, AU, WO, FR; Legal Status:   Discontinued; Application No: 200913000302; Filed:Jun 20, 2009; Published: Jun 30, 2011; Earliest Priority: Jun 20, 2008;",0,CGVGFREGTCGAQ
CKYKFENWGACDGGT,15,Synthetic construct,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,,,,,"Granted Patent Family: 9s / 9ex; Family Jurisdictions: EP, US, JP, CN, CA, AU, WO, FR; Legal Status:   Discontinued; Application No: 200913000302; Filed:Jun 20, 2009; Published: Jun 30, 2011; Earliest Priority: Jun 20, 2008;",0,CKYKFENWGACDGGT
CNWKKEFGADCKYKF,15,Synthetic construct,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,,,,,"Granted Patent Family: 9s / 9ex; Family Jurisdictions: EP, US, JP, CN, CA, AU, WO, FR; Legal Status:   Discontinued; Application No: 200913000302; Filed:Jun 20, 2009; Published: Jun 30, 2011; Earliest Priority: Jun 20, 2008;",0,CNWKKEFGADCKYKF
CRVPCNWKKEFGADC,15,Synthetic construct,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,,,,,"Granted Patent Family: 9s / 9ex; Family Jurisdictions: EP, US, JP, CN, CA, AU, WO, FR; Legal Status:   Discontinued; Application No: 200913000302; Filed:Jun 20, 2009; Published: Jun 30, 2011; Earliest Priority: Jun 20, 2008;",0,CRVPCNWKKEFGADC
EAEQLRAYLDGTGVE,15,Synthetic construct,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,,,,,"Granted Patent Family: 9s / 9ex; Family Jurisdictions: EP, US, JP, CN, CA, AU, WO, FR; Legal Status:   Discontinued; Application No: 200913000302; Filed:Jun 20, 2009; Published: Jun 30, 2011; Earliest Priority: Jun 20, 2008;",0,EAEQLRAYLDGTGVE
EKKYFAATQFEPLAARL,17,Synthetic construct,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,,,,,"Granted Patent Family: 9s / 9ex; Family Jurisdictions: EP, US, JP, CN, CA, AU, WO, FR; Legal Status:   Discontinued; Application No: 200913000302; Filed:Jun 20, 2009; Published: Jun 30, 2011; Earliest Priority: Jun 20, 2008;",0,EKKYFAATQFEPLAARL
ELTLGEFLKL,10,Synthetic construct,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,,,,,"Granted Patent Family: 9s / 9ex; Family Jurisdictions: EP, US, JP, CN, CA, AU, WO, FR; Legal Status:   Discontinued; Application No: 200913000302; Filed:Jun 20, 2009; Published: Jun 30, 2011; Earliest Priority: Jun 20, 2008;",0,ELTLGEFLKL
ENWGACDGGTGTKVR,15,Synthetic construct,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,,,,,"Granted Patent Family: 9s / 9ex; Family Jurisdictions: EP, US, JP, CN, CA, AU, WO, FR; Legal Status:   Discontinued; Application No: 200913000302; Filed:Jun 20, 2009; Published: Jun 30, 2011; Earliest Priority: Jun 20, 2008;",0,ENWGACDGGTGTKVR
ESWGAVWRIDTPDKLTGPFT,20,Synthetic construct,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,,,,,"Granted Patent Family: 9s / 9ex; Family Jurisdictions: EP, US, JP, CN, CA, AU, WO, FR; Legal Status:   Discontinued; Application No: 200913000302; Filed:Jun 20, 2009; Published: Jun 30, 2011; Earliest Priority: Jun 20, 2008;",0,ESWGAVWRIDTPDKLTGPFT
ETIRVTKPCTPKTKA,15,Synthetic construct,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,,,,,"Granted Patent Family: 9s / 9ex; Family Jurisdictions: EP, US, JP, CN, CA, AU, WO, FR; Legal Status:   Discontinued; Application No: 200913000302; Filed:Jun 20, 2009; Published: Jun 30, 2011; Earliest Priority: Jun 20, 2008;",0,ETIRVTKPCTPKTKA
GTKVRQGTLKKARYN,15,Synthetic construct,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,,,,,"Granted Patent Family: 9s / 9ex; Family Jurisdictions: EP, US, JP, CN, CA, AU, WO, FR; Legal Status:   Discontinued; Application No: 200913000302; Filed:Jun 20, 2009; Published: Jun 30, 2011; Earliest Priority: Jun 20, 2008;",0,GTKVRQGTLKKARYN
GTLKKARYNAQCQET,15,Synthetic construct,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,,,,,"Granted Patent Family: 9s / 9ex; Family Jurisdictions: EP, US, JP, CN, CA, AU, WO, FR; Legal Status:   Discontinued; Application No: 200913000302; Filed:Jun 20, 2009; Published: Jun 30, 2011; Earliest Priority: Jun 20, 2008;",0,GTLKKARYNAQCQET
KDKVKKGGPGSECAE,15,Synthetic construct,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,,,,,"Granted Patent Family: 9s / 9ex; Family Jurisdictions: EP, US, JP, CN, CA, AU, WO, FR; Legal Status:   Discontinued; Application No: 200913000302; Filed:Jun 20, 2009; Published: Jun 30, 2011; Earliest Priority: Jun 20, 2008;",0,KDKVKKGGPGSECAE
KEFGADCKYKFENWG,15,Synthetic construct,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,,,,,"Granted Patent Family: 9s / 9ex; Family Jurisdictions: EP, US, JP, CN, CA, AU, WO, FR; Legal Status:   Discontinued; Application No: 200913000302; Filed:Jun 20, 2009; Published: Jun 30, 2011; Earliest Priority: Jun 20, 2008;",0,KEFGADCKYKFENWG
KXVAAWTLKAA,11,Synthetic construct,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,,,,,"Granted Patent Family: 9s / 9ex; Family Jurisdictions: EP, US, JP, CN, CA, AU, WO, FR; Legal Status:   Discontinued; Application No: 200913000302; Filed:Jun 20, 2009; Published: Jun 30, 2011; Earliest Priority: Jun 20, 2008;",0,KXVAAWTLKAA
LALLALTSAV,10,Synthetic construct,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,,,,,"Granted Patent Family: 9s / 9ex; Family Jurisdictions: EP, US, JP, CN, CA, AU, WO, FR; Legal Status:   Discontinued; Application No: 200913000302; Filed:Jun 20, 2009; Published: Jun 30, 2011; Earliest Priority: Jun 20, 2008;",0,LALLALTSAV
LLALTSAVA,9,Synthetic construct,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,,,,,"Granted Patent Family: 9s / 9ex; Family Jurisdictions: EP, US, JP, CN, CA, AU, WO, FR; Legal Status:   Discontinued; Application No: 200913000302; Filed:Jun 20, 2009; Published: Jun 30, 2011; Earliest Priority: Jun 20, 2008;",0,LLALTSAVA
LLALTSAVAKKKDKV,15,Synthetic construct,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,,,,,"Granted Patent Family: 9s / 9ex; Family Jurisdictions: EP, US, JP, CN, CA, AU, WO, FR; Legal Status:   Discontinued; Application No: 200913000302; Filed:Jun 20, 2009; Published: Jun 30, 2011; Earliest Priority: Jun 20, 2008;",0,LLALTSAVAKKKDKV
LTLGEFLKL,9,Synthetic construct,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,,,,,"Granted Patent Family: 9s / 9ex; Family Jurisdictions: EP, US, JP, CN, CA, AU, WO, FR; Legal Status:   Discontinued; Application No: 200913000302; Filed:Jun 20, 2009; Published: Jun 30, 2011; Earliest Priority: Jun 20, 2008;",0,LTLGEFLKL
LTLLALLALTSAV,13,Synthetic construct,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,,,,,"Granted Patent Family: 9s / 9ex; Family Jurisdictions: EP, US, JP, CN, CA, AU, WO, FR; Legal Status:   Discontinued; Application No: 200913000302; Filed:Jun 20, 2009; Published: Jun 30, 2011; Earliest Priority: Jun 20, 2008;",0,LTLLALLALTSAV
LTLLALLALTSAVA,14,Synthetic construct,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,,,,,"Granted Patent Family: 9s / 9ex; Family Jurisdictions: EP, US, JP, CN, CA, AU, WO, FR; Legal Status:   Discontinued; Application No: 200913000302; Filed:Jun 20, 2009; Published: Jun 30, 2011; Earliest Priority: Jun 20, 2008;",0,LTLLALLALTSAVA
LTLLALLALTSAVAK,15,Synthetic construct,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,,,,,"Granted Patent Family: 9s / 9ex; Family Jurisdictions: EP, US, JP, CN, CA, AU, WO, FR; Legal Status:   Discontinued; Application No: 200913000302; Filed:Jun 20, 2009; Published: Jun 30, 2011; Earliest Priority: Jun 20, 2008;",0,LTLLALLALTSAVAK
MQHRGFLLLTLLALL,15,Synthetic construct,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,,,,,"Granted Patent Family: 9s / 9ex; Family Jurisdictions: EP, US, JP, CN, CA, AU, WO, FR; Legal Status:   Discontinued; Application No: 200913000302; Filed:Jun 20, 2009; Published: Jun 30, 2011; Earliest Priority: Jun 20, 2008;",0,MQHRGFLLLTLLALL
NAQCQETIRV,10,Synthetic construct,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,,,,,"Granted Patent Family: 9s / 9ex; Family Jurisdictions: EP, US, JP, CN, CA, AU, WO, FR; Legal Status:   Discontinued; Application No: 200913000302; Filed:Jun 20, 2009; Published: Jun 30, 2011; Earliest Priority: Jun 20, 2008;",0,NAQCQETIRV
PKYVKQNTLKLAT,13,Synthetic construct,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,,,,,"Granted Patent Family: 9s / 9ex; Family Jurisdictions: EP, US, JP, CN, CA, AU, WO, FR; Legal Status:   Discontinued; Application No: 200913000302; Filed:Jun 20, 2009; Published: Jun 30, 2011; Earliest Priority: Jun 20, 2008;",0,PKYVKQNTLKLAT
QTQRIRCRVPCNWKK,15,Synthetic construct,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,,,,,"Granted Patent Family: 9s / 9ex; Family Jurisdictions: EP, US, JP, CN, CA, AU, WO, FR; Legal Status:   Discontinued; Application No: 200913000302; Filed:Jun 20, 2009; Published: Jun 30, 2011; Earliest Priority: Jun 20, 2008;",0,QTQRIRCRVPCNWKK
RGFLLLTLLALLALT,15,Synthetic construct,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,,,,,"Granted Patent Family: 9s / 9ex; Family Jurisdictions: EP, US, JP, CN, CA, AU, WO, FR; Legal Status:   Discontinued; Application No: 200913000302; Filed:Jun 20, 2009; Published: Jun 30, 2011; Earliest Priority: Jun 20, 2008;",0,RGFLLLTLLALLALT
TERVRLVTRHIYNREE,16,Synthetic construct,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,,,,,"Granted Patent Family: 9s / 9ex; Family Jurisdictions: EP, US, JP, CN, CA, AU, WO, FR; Legal Status:   Discontinued; Application No: 200913000302; Filed:Jun 20, 2009; Published: Jun 30, 2011; Earliest Priority: Jun 20, 2008;",0,TERVRLVTRHIYNREE
TSAVAKKKDKVKKGG,15,Synthetic construct,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,,,,,"Granted Patent Family: 9s / 9ex; Family Jurisdictions: EP, US, JP, CN, CA, AU, WO, FR; Legal Status:   Discontinued; Application No: 200913000302; Filed:Jun 20, 2009; Published: Jun 30, 2011; Earliest Priority: Jun 20, 2008;",0,TSAVAKKKDKVKKGG
ALVRYKDPLFVWGFL,15,Synthetic construct,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,,,,,"Granted Patent Family: 19s / 19ex; Family Jurisdictions: US, JP, EP, WO, CN; Legal Status:   Active; Application No: 200913132580; Filed: Dec 3, 2009; Published: Dec 29, 2011; Earliest Priority: Dec 3, 2008; Granted: May 7, 2013",0,ALVRYKDPLFVWGFL
ATWLPPR,7,Synthetic construct,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,,,,,"Granted Patent Family: 19s / 19ex; Family Jurisdictions: US, JP, EP, WO, CN; Legal Status:   Active; Application No: 200913132580; Filed: Dec 3, 2009; Published: Dec 29, 2011; Earliest Priority: Dec 3, 2008; Granted: May 7, 2013",0,ATWLPPR
ATWLPPRGGGKLlLKlLkkLLKlLKKK,27,Synthetic,Synthetic peptide,,HEK293: IC50>20μM; MRC-5:>20μM,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,l=D-Leucine; k=D-Lysine,"Granted Patent Family: 19s / 19ex; Family Jurisdictions: US, JP, EP, WO, CN; Legal Status:   Active; Application No: 200913132580; Filed: Dec 3, 2009; Published: Dec 29, 2011; Earliest Priority: Dec 3, 2008; Granted: May 7, 2013",0,ATWLPPRGGGKLLLKLLKKLLKLLKKK
CGRRAGGSC,9,Synthetic construct,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,,,,,"Granted Patent Family: 19s / 19ex; Family Jurisdictions: US, JP, EP, WO, CN; Legal Status:   Active; Application No: 200913132580; Filed: Dec 3, 2009; Published: Dec 29, 2011; Earliest Priority: Dec 3, 2008; Granted: May 7, 2013",0,CGRRAGGSC
CQKHHNYLC,9,Synthetic construct,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,,,,,"Granted Patent Family: 19s / 19ex; Family Jurisdictions: US, JP, EP, WO, CN; Legal Status:   Active; Application No: 200913132580; Filed: Dec 3, 2009; Published: Dec 29, 2011; Earliest Priority: Dec 3, 2008; Granted: May 7, 2013",0,CQKHHNYLC
CTVALPGGYVRVC,13,Synthetic construct,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Cyclic,Cys1<--->Cys13,,,,"Granted Patent Family: 19s / 19ex; Family Jurisdictions: US, JP, EP, WO, CN; Legal Status:   Active; Application No: 200913132580; Filed: Dec 3, 2009; Published: Dec 29, 2011; Earliest Priority: Dec 3, 2008; Granted: May 7, 2013",0,CTVALPGGYVRVC
DTDMCWWWSREFGWECAGAG,20,Synthetic construct,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,,,,,"Granted Patent Family: 19s / 19ex; Family Jurisdictions: US, JP, EP, WO, CN; Legal Status:   Active; Application No: 200913132580; Filed: Dec 3, 2009; Published: Dec 29, 2011; Earliest Priority: Dec 3, 2008; Granted: May 7, 2013",0,DTDMCWWWSREFGWECAGAG
EWLS,4,Synthetic construct,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,,,,,"Granted Patent Family: 19s / 19ex; Family Jurisdictions: US, JP, EP, WO, CN; Legal Status:   Active; Application No: 200913132580; Filed: Dec 3, 2009; Published: Dec 29, 2011; Earliest Priority: Dec 3, 2008; Granted: May 7, 2013",0,EWLS
GGNECDAIRMWEWECFERL,19,Synthetic construct,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,,,,,"Granted Patent Family: 19s / 19ex; Family Jurisdictions: US, JP, EP, WO, CN; Legal Status:   Active; Application No: 200913132580; Filed: Dec 3, 2009; Published: Dec 29, 2011; Earliest Priority: Dec 3, 2008; Granted: May 7, 2013",0,GGNECDAIRMWEWECFERL
GRVPYPRGGLLkLLKklLKKLlKL,24,Synthetic,Synthetic peptide,,Pancreatic epithelium: IC50>50μM; HEK293T: IC50>20μM,Epidermal growth factor receptor (EGFR),,,Anticancer,Tumor active peptide##Cancer targeted peptides,,Linear,,Free,Free,l=D-Leucine; k=D-Lysine,"Granted Patent; Family: 19s / 19ex; Family Jurisdictions: US, JP, EP, WO, CN; Legal Status:  Active; Application No: 200913132580; Filed: Dec 3, 2009; Published: May 7, 2013; Earliest Priority: Dec 3, 2008; Granted: May 7, 2013",0,GRVPYPRGGLLKLLKKLLKKLLKL
KAYARIGNSYFK,12,Synthetic construct,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,,,,,"Granted Patent Family: 19s / 19ex; Family Jurisdictions: US, JP, EP, WO, CN; Legal Status:   Active; Application No: 200913132580; Filed: Dec 3, 2009; Published: Dec 29, 2011; Earliest Priority: Dec 3, 2008; Granted: May 7, 2013",0,KAYARIGNSYFK
KCCYSL,6,Synthetic construct,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,,,,,"Granted Patent Family: 19s / 19ex; Family Jurisdictions: US, JP, EP, WO, CN; Legal Status:   Active; Application No: 200913132580; Filed: Dec 3, 2009; Published: Dec 29, 2011; Earliest Priority: Dec 3, 2008; Granted: May 7, 2013",0,KCCYSL
KDLLLHLKKLFREGQFN,17,Synthetic construct,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,,,,,"Granted Patent Family: 19s / 19ex; Family Jurisdictions: US, JP, EP, WO, CN; Legal Status:   Active; Application No: 200913132580; Filed: Dec 3, 2009; Published: Dec 29, 2011; Earliest Priority: Dec 3, 2008; Granted: May 7, 2013",0,KDLLLHLKKLFREGQFN
KDLLLHLKKLFREGQFNGGGKLLLKLLKKLLKLLKKK,37,Synthetic construct,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,,,,,"Granted Patent Family: 19s / 19ex; Family Jurisdictions: US, JP, EP, WO, CN; Legal Status:   Active; Application No: 200913132580; Filed: Dec 3, 2009; Published: Dec 29, 2011; Earliest Priority: Dec 3, 2008; Granted: May 7, 2013",0,KDLLLHLKKLFREGQFNGGGKLLLKLLKKLLKLLKKK
KLLLKLLKKLLKLLKKK,17,Synthetic,Synthetic peptide,,PE: IC50>20μM; HEK293T: IC50=11.3±1.1μM; WI-38: IC50=14.4±1.3μM,Interleukin-4 (IL4) Receptor,,,Anticancer,Tumor active peptide##Cancer targeted peptides,,Linear,,Free,Free,,"Granted Patent Family: 19s / 19ex; Family Jurisdictions: US, JP, EP, WO, CN; Legal Status:   Active; Application No: 200913132580; Filed: Dec 3, 2009; Published: Dec 29, 2011; Earliest Priority: Dec 3, 2008; Granted: May 7, 2013",0,KLLLKLLKKLLKLLKKK
KQLIRFLKRLDRN,13,Synthetic construct,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,,,,,"Granted Patent Family: 19s / 19ex; Family Jurisdictions: US, JP, EP, WO, CN; Legal Status:   Active; Application No: 200913132580; Filed: Dec 3, 2009; Published: Dec 29, 2011; Earliest Priority: Dec 3, 2008; Granted: May 7, 2013",0,KQLIRFLKRLDRN
KQLIRFLKRLDRNGGGKLLLKLLKKLLKLLKKK,33,Synthetic,Synthetic peptide,,PE: IC50>20μM; HEK293T: IC50=7.2±0.7μM; WI-38: IC50=9.8±0.8μM,Interleukin-4 (IL4) Receptor,,,Anticancer,Tumor active peptide##Cancer targeted peptides,,Linear,,Free,Free,,"Granted Patent Family: 19s / 19ex; Family Jurisdictions: US, JP, EP, WO, CN; Legal Status:   Active; Application No: 200913132580; Filed: Dec 3, 2009; Published: Dec 29, 2011; Earliest Priority: Dec 3, 2008; Granted: May 7, 2013",0,KQLIRFLKRLDRNGGGKLLLKLLKKLLKLLKKK
LLGPYELWELSH,12,Synthetic construct,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,,,,,"Granted Patent Family: 19s / 19ex; Family Jurisdictions: US, JP, EP, WO, CN; Legal Status:   Active; Application No: 200913132580; Filed: Dec 3, 2009; Published: Dec 29, 2011; Earliest Priority: Dec 3, 2008; Granted: May 7, 2013",0,LLGPYELWELSH
LLkLLKklLKKLlKL,15,Synthetic,Synthetic peptide,,Pancreatic epithelium: IC50>50μM,Epidermal growth factor receptor (EGFR),,,Anticancer,Tumor active peptide##Cancer targeted peptides,,Linear,,Free,Free,l=D-Leucine; k=D-Lysine,"Granted Patent Family: 19s / 19ex; Family Jurisdictions: US, JP, EP, WO, CN; Legal Status:   Active; Application No: 200913132580; Filed: Dec 3, 2009; Published: Dec 29, 2011; Earliest Priority: Dec 3, 2008; Granted: May 7, 2013",0,LLKLLKKLLKKLLKL
MEPVDPRLEPWKHPGSQPKTACTNCYCKKCCFHCQVCFITKALGISYGRKKRRQRRRAHQNSQTHQASLSKQPTSQPRGDPTGPKE,86,Synthetic construct,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,,,,,"Granted Patent Family: 19s / 19ex; Family Jurisdictions: US, JP, EP, WO, CN; Legal Status:   Active; Application No: 200913132580; Filed: Dec 3, 2009; Published: Dec 29, 2011; Earliest Priority: Dec 3, 2008; Granted: May 7, 2013",0,MEPVDPRLEPWKHPGSQPKTACTNCYCKKCCFHCQVCFITKALGISYGRKKRRQRRRAHQNSQTHQASLSKQPTSQPRGDPTGPKE
MQLPLAT,7,Synthetic construct,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,,,,,"Granted Patent Family: 19s / 19ex; Family Jurisdictions: US, JP, EP, WO, CN; Legal Status:   Active; Application No: 200913132580; Filed: Dec 3, 2009; Published: Dec 29, 2011; Earliest Priority: Dec 3, 2008; Granted: May 7, 2013",0,MQLPLAT
NYQWVPYQGRVPYPR,15,Synthetic construct,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,,,,,"Granted Patent Family: 19s / 19ex; Family Jurisdictions: US, JP, EP, WO, CN; Legal Status:   Active; Application No: 200913132580; Filed: Dec 3, 2009; Published: Dec 29, 2011; Earliest Priority: Dec 3, 2008; Granted: May 7, 2013",0,NYQWVPYQGRVPYPR
NYQWVPYQGRVPYPRGGGKLLLKLLKKLLKlLKKK,35,Synthetic,Synthetic peptide,,Pancreatic epithelium: IC50>20μM; MRC-5: IC50>50μM; Human normalhepatocyte cell: IC50=37.5μM,Epidermal growth factor receptor (EGFR),,,Anticancer,Tumor active peptide##Cancer targeted peptides,,Linear,,Free,Free,l=D-Leucine; k=D-Lysine,"Granted Patent Family: 19s / 19ex; Family Jurisdictions: US, JP, EP, WO, CN; Legal Status:   Active; Application No: 200913132580; Filed: Dec 3, 2009; Published: Dec 29, 2011; Earliest Priority: Dec 3, 2008; Granted: May 7, 2013",0,NYQWVPYQGRVPYPRGGGKLLLKLLKKLLKLLKKK
NYQWVPYQGRVPYPRGGGKLLLKLLKKLLKLLKKK,35,Synthetic construct,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,,,,,"Granted Patent Family: 19s / 19ex; Family Jurisdictions: US, JP, EP, WO, CN; Legal Status:   Active; Application No: 200913132580; Filed: Dec 3, 2009; Published: Dec 29, 2011; Earliest Priority: Dec 3, 2008; Granted: May 7, 2013",0,NYQWVPYQGRVPYPRGGGKLLLKLLKKLLKLLKKK
NYQWVPYQGRVPYPRGGLLkLLKklLKKLlKL,32,Synthetic,Synthetic peptide,,Pancreatic epithelium: IC50>50μM; HEK293T: IC50>20μM,Epidermal growth factor receptor (EGFR),,,Anticancer,Tumor active peptide##Cancer targeted peptides,,Linear,,Free,Free,l=D-Leucine; k=D-Lysine,"Granted Patent Family: 19s / 19ex; Family Jurisdictions: US, JP, EP, WO, CN; Legal Status:   Active; Application No: 200913132580; Filed: Dec 3, 2009; Published: Dec 29, 2011; Earliest Priority: Dec 3, 2008; Granted: May 7, 2013",0,NYQWVPYQGRVPYPRGGLLKLLKKLLKKLLKL
RLLRRLLRRLLRK,13,Synthetic construct,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,,,,,"Granted Patent Family: 19s / 19ex; Family Jurisdictions: US, JP, EP, WO, CN; Legal Status:   Active; Application No: 200913132580; Filed: Dec 3, 2009; Published: Dec 29, 2011; Earliest Priority: Dec 3, 2008; Granted: May 7, 2013",0,RLLRRLLRRLLRK
RLLRRLLRRLLRRLLRRLLR,20,Synthetic construct,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,,,,,"Granted Patent Family: 19s / 19ex; Family Jurisdictions: US, JP, EP, WO, CN; Legal Status:   Active; Application No: 200913132580; Filed: Dec 3, 2009; Published: Dec 29, 2011; Earliest Priority: Dec 3, 2008; Granted: May 7, 2013",0,RLLRRLLRRLLRRLLRRLLR
RQIKIQFQNRRMKWKK,16,Synthetic construct,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,,,,,"Granted Patent Family: 19s / 19ex; Family Jurisdictions: US, JP, EP, WO, CN; Legal Status:   Active; Application No: 200913132580; Filed: Dec 3, 2009; Published: Dec 29, 2011; Earliest Priority: Dec 3, 2008; Granted: May 7, 2013",0,RQIKIQFQNRRMKWKK
RQIKIQFQNRRMKWKKKAYARIGNSYFK,28,Synthetic construct,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,,,,,"Granted Patent Family: 19s / 19ex; Family Jurisdictions: US, JP, EP, WO, CN; Legal Status:   Active; Application No: 200913132580; Filed: Dec 3, 2009; Published: Dec 29, 2011; Earliest Priority: Dec 3, 2008; Granted: May 7, 2013",0,RQIKIQFQNRRMKWKKKAYARIGNSYFK
SNEW,4,Synthetic construct,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,,,,,"Granted Patent Family: 19s / 19ex; Family Jurisdictions: US, JP, EP, WO, CN; Legal Status:   Active; Application No: 200913132580; Filed: Dec 3, 2009; Published: Dec 29, 2011; Earliest Priority: Dec 3, 2008; Granted: May 7, 2013",0,SNEW
THRPPMWSPVWP,12,Synthetic construct,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,,,,,"Granted Patent Family: 19s / 19ex; Family Jurisdictions: US, JP, EP, WO, CN; Legal Status:   Active; Application No: 200913132580; Filed: Dec 3, 2009; Published: Dec 29, 2011; Earliest Priority: Dec 3, 2008; Granted: May 7, 2013",0,THRPPMWSPVWP
VEPNCDIHVMWEWECFERL,19,Synthetic construct,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,,,,,"Granted Patent Family: 19s / 19ex; Family Jurisdictions: US, JP, EP, WO, CN; Legal Status:   Active; Application No: 200913132580; Filed: Dec 3, 2009; Published: Dec 29, 2011; Earliest Priority: Dec 3, 2008; Granted: May 7, 2013",0,VEPNCDIHVMWEWECFERL
WDLAWMFRLPVG,12,Synthetic construct,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,,,,,"Granted Patent Family: 19s / 19ex; Family Jurisdictions: US, JP, EP, WO, CN; Legal Status:   Active; Application No: 200913132580; Filed: Dec 3, 2009; Published: Dec 29, 2011; Earliest Priority: Dec 3, 2008; Granted: May 7, 2013",0,WDLAWMFRLPVG
WHSDMEWWYLLG,12,Synthetic construct,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,,,CONH2 is existing at C-terminal,,"Granted Patent Family: 19s / 19ex; Family Jurisdictions: US, JP, EP, WO, CN; Legal Status:   Active; Application No: 200913132580; Filed: Dec 3, 2009; Published: Dec 29, 2011; Earliest Priority: Dec 3, 2008; Granted: May 7, 2013",0,WHSDMEWWYLLG
WHSDMEWWYLLGGGGKLlLKlLkkLLKlLKKK,32,Synthetic construct,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,l=D-Leucine; k=D-Lysine,"Granted Patent Family: 19s / 19ex; Family Jurisdictions: US, JP, EP, WO, CN; Legal Status:   Active; Application No: 200913132580; Filed: Dec 3, 2009; Published: Dec 29, 2011; Earliest Priority: Dec 3, 2008; Granted: May 7, 2013",0,WHSDMEWWYLLGGGGKLLLKLLKKLLKLLKKK
WTGWCLNPEESTWGFCTGSF,20,Synthetic construct,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,,,,,"Granted Patent Family: 19s / 19ex; Family Jurisdictions: US, JP, EP, WO, CN; Legal Status:   Active; Application No: 200913132580; Filed: Dec 3, 2009; Published: Dec 29, 2011; Earliest Priority: Dec 3, 2008; Granted: May 7, 2013",0,WTGWCLNPEESTWGFCTGSF
YCDGFYACYMDV,12,Synthetic construct,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,,,,,"Granted Patent Family: 19s / 19ex; Family Jurisdictions: US, JP, EP, WO, CN; Legal Status:   Active; Application No: 200913132580; Filed: Dec 3, 2009; Published: Dec 29, 2011; Earliest Priority: Dec 3, 2008; Granted: May 7, 2013",0,YCDGFYACYMDV
YCDGFYACYMDVGGGKLlLKlLkkLLKlLKKK,32,Synthetic construct,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,l=D-Leucine; k=D-Lysine,"Granted Patent Family: 19s / 19ex; Family Jurisdictions: US, JP, EP, WO, CN; Legal Status:   Active; Application No: 200913132580; Filed: Dec 3, 2009; Published: Dec 29, 2011; Earliest Priority: Dec 3, 2008; Granted: May 7, 2013",0,YCDGFYACYMDVGGGKLLLKLLKKLLKLLKKK
YHWYGYTPQNVI,12,Synthetic construct,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,,,,,"Granted Patent Family: 19s / 19ex; Family Jurisdictions: US, JP, EP, WO, CN; Legal Status:   Active; Application No: 200913132580; Filed: Dec 3, 2009; Published: Dec 29, 2011; Earliest Priority: Dec 3, 2008; Granted: May 7, 2013",0,YHWYGYTPQNVI
YHWYGYTPQNVIGGGGGRLLRRLLRRLLRK,30,Synthetic construct,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,,,,,"Granted Patent Family: 19s / 19ex; Family Jurisdictions: US, JP, EP, WO, CN; Legal Status:   Active; Application No: 200913132580; Filed: Dec 3, 2009; Published: Dec 29, 2011; Earliest Priority: Dec 3, 2008; Granted: May 7, 2013",0,YHWYGYTPQNVIGGGGGRLLRRLLRRLLRK
YHWYGYTPQNVIGGGKLlLKlLkkLLKlLKKK,32,Synthetic,Synthetic peptide,,WI-38: IC50=46±2.7μM; MRC-5: 49±5.8μM; HEK293: IC50=44±2.8μM,Epidermal growth factor receptor (EGFR),,,Anticancer,Tumor active peptide##Cancer targeted peptides,,Linear,,Free,Free,l=D-Leucine; k=D-Lysine,"Granted Patent Family: 19s / 19ex; Family Jurisdictions: US, JP, EP, WO, CN; Legal Status:   Active; Application No: 200913132580; Filed: Dec 3, 2009; Published: Dec 29, 2011; Earliest Priority: Dec 3, 2008; Granted: May 7, 2013",0,YHWYGYTPQNVIGGGKLLLKLLKKLLKLLKKK
YHWYGYTPQNVIGGGLLkLLKklLKKLlKL,30,Synthetic construct,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,l=D-Leucine; k=D-Lysine,"Granted Patent Family: 19s / 19ex; Family Jurisdictions: US, JP, EP, WO, CN; Legal Status:   Active; Application No: 200913132580; Filed: Dec 3, 2009; Published: Dec 29, 2011; Earliest Priority: Dec 3, 2008; Granted: May 7, 2013",0,YHWYGYTPQNVIGGGLLKLLKKLLKKLLKL
YKWYGYTPQNVI,12,Synthetic construct,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,,,,,"Granted Patent Family: 19s / 19ex; Family Jurisdictions: US, JP, EP, WO, CN; Legal Status:   Active; Application No: 200913132580; Filed: Dec 3, 2009; Published: Dec 29, 2011; Earliest Priority: Dec 3, 2008; Granted: May 7, 2013",0,YKWYGYTPQNVI
YRWYGYTPQNVI,12,Synthetic construct,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,,,,,"Granted Patent Family: 19s / 19ex; Family Jurisdictions: US, JP, EP, WO, CN; Legal Status:   Active; Application No: 200913132580; Filed: Dec 3, 2009; Published: Dec 29, 2011; Earliest Priority: Dec 3, 2008; Granted: May 7, 2013",0,YRWYGYTPQNVI
YRWYGYTPQNVIGGGKLlLKlLkkLLKlLKKK,32,Synthetic,Synthetic peptide,,MRC-5: IC50>20μM; HEK293: IC50>20μM,Epidermal growth factor receptor (EGFR),,,Anticancer,Tumor active peptide##Cancer targeted peptides,,Linear,,Free,Free,l=D-Leucine; k=D-Lysine,"Granted Patent Family: 19s / 19ex; Family Jurisdictions: US, JP, EP, WO, CN; Legal Status:   Active; Application No: 200913132580; Filed: Dec 3, 2009; Published: Dec 29, 2011; Earliest Priority: Dec 3, 2008; Granted: May 7, 2013",0,YRWYGYTPQNVIGGGKLLLKLLKKLLKLLKKK
CQDLFGRAPSKAVNPDEA,18,Synthetic construct,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,,,,,"Granted Patent Family: 8s / 8ex; Family Jurisdictions: EP, US, WO, JP; Legal Status:   Inactive; Application No: 201013514755; Filed:Dec 9, 2010; Published: Nov 29, 2012; Earliest Priority: Dec 10, 2009; Granted: Nov 19, 2013",0,CQDLFGRAPSKAVNPDEA
DLFGR,5,Synthetic construct,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,,,,,"Granted Patent Family: 8s / 8ex; Family Jurisdictions: EP, US, WO, JP; Legal Status:   Inactive; Application No: 201013514755; Filed:Dec 9, 2010; Published: Nov 29, 2012; Earliest Priority: Dec 10, 2009; Granted: Nov 19, 2013",0,DLFGR
DLFGRAP,7,Synthetic construct,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,,,,,"Granted Patent Family: 8s / 8ex; Family Jurisdictions: EP, US, WO, JP; Legal Status:   Inactive; Application No: 201013514755; Filed:Dec 9, 2010; Published: Nov 29, 2012; Earliest Priority: Dec 10, 2009; Granted: Nov 19, 2013",0,DLFGRAP
EVILVG,6,Synthetic construct,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,,,,,"Granted Patent Family: 8s / 8ex; Family Jurisdictions: EP, US, WO, JP; Legal Status:   Inactive; Application No: 201013514755; Filed:Dec 9, 2010; Published: Nov 29, 2012; Earliest Priority: Dec 10, 2009; Granted: Nov 19, 2013",0,EVILVG
EVILVGGMT,9,Synthetic construct,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,,,,,"Granted Patent Family: 8s / 8ex; Family Jurisdictions: EP, US, WO, JP; Legal Status:   Inactive; Application No: 201013514755; Filed:Dec 9, 2010; Published: Nov 29, 2012; Earliest Priority: Dec 10, 2009; Granted: Nov 19, 2013",0,EVILVGGMT
KAMQDAEVSKSDIGEVI,17,Synthetic construct,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,,,,,"Granted Patent Family: 8s / 8ex; Family Jurisdictions: EP, US, WO, JP; Legal Status:   Inactive; Application No: 201013514755; Filed:Dec 9, 2010; Published: Nov 29, 2012; Earliest Priority: Dec 10, 2009; Granted: Nov 19, 2013",0,KAMQDAEVSKSDIGEVI
KAMQDAEVSKSDIGEVIC,18,Synthetic construct,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,,,,,"Granted Patent Family: 8s / 8ex; Family Jurisdictions: EP, US, WO, JP; Legal Status:   Inactive; Application No: 201013514755; Filed:Dec 9, 2010; Published: Nov 29, 2012; Earliest Priority: Dec 10, 2009; Granted: Nov 19, 2013",0,KAMQDAEVSKSDIGEVIC
KAMQDAEVSKSDIGEVILVGGMTRMPKVQQTVQDLFGRAPSKAVNPDEAV,50,Synthetic construct,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,,,,,"Granted Patent Family: 8s / 8ex; Family Jurisdictions: EP, US, WO, JP; Legal Status:   Inactive; Application No: 201013514755; Filed:Dec 9, 2010; Published: Nov 29, 2012; Earliest Priority: Dec 10, 2009; Granted: Nov 19, 2013",0,KAMQDAEVSKSDIGEVILVGGMTRMPKVQQTVQDLFGRAPSKAVNPDEAV
LFGRAP,6,Synthetic construct,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,,,,,"Granted Patent Family: 8s / 8ex; Family Jurisdictions: EP, US, WO, JP; Legal Status:   Inactive; Application No: 201013514755; Filed:Dec 9, 2010; Published: Nov 29, 2012; Earliest Priority: Dec 10, 2009; Granted: Nov 19, 2013",0,LFGRAP
QDLFGRAPSKAVNPDEA,17,Synthetic construct,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,,,,,"Granted Patent Family: 8s / 8ex; Family Jurisdictions: EP, US, WO, JP; Legal Status:   Inactive; Application No: 201013514755; Filed:Dec 9, 2010; Published: Nov 29, 2012; Earliest Priority: Dec 10, 2009; Granted: Nov 19, 2013",0,QDLFGRAPSKAVNPDEA
DWWPLAFEALLR,12,Synthetic construct,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,,,,,"Granted Patent Family: 8s / 8ex; Family Jurisdictions: CN, DK, US, EP, ES; Legal Status:   Active; Application No: 16168397; Filed:May 4, 2016; Published: Jul 17, 2019; Earliest Priority: May 7, 2015; Granted: Jul 17, 2019",0,DWWPLAFEALLR
DWWPLAFEALXR,12,Synthetic construct,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,,,,"X = Leu with F, Cl, Br, I, CH3, CF3, CN, OH, or NO2 at positions gamma, delta1 or delta2","Granted Patent Family: 8s / 8ex; Family Jurisdictions: CN, DK, US, EP, ES; Legal Status:   Active; Application No: 16168397; Filed:May 4, 2016; Published: Jul 17, 2019; Earliest Priority: May 7, 2015; Granted: Jul 17, 2019",0,DWWPLAFEALXR
DWWPLAFEXLLX,12,Synthetic construct,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,,,,X=an amino acid with an olefinic side chain ,"Granted Patent Family: 8s / 8ex; Family Jurisdictions: CN, DK, US, EP, ES; Legal Status:   Active; Application No: 16168397; Filed:May 4, 2016; Published: Jul 17, 2019; Earliest Priority: May 7, 2015; Granted: Jul 17, 2019",0,DWWPLAFEXLLX
DWWPLAFXALLX,12,Synthetic construct,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,,,,X=an amino acid with an olefinic side chain ,"Granted Patent Family: 8s / 8ex; Family Jurisdictions: CN, DK, US, EP, ES; Legal Status:   Active; Application No: 16168397; Filed:May 4, 2016; Published: Jul 17, 2019; Earliest Priority: May 7, 2015; Granted: Jul 17, 2019",0,DWWPLAFXALLX
DWWPLAXEALLR,12,Synthetic construct,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,,,,"X = Phe with F, Cl, Br, I, CH3, CF3, CN, OH, or NO2 at position 4","Granted Patent Family: 8s / 8ex; Family Jurisdictions: CN, DK, US, EP, ES; Legal Status:   Active; Application No: 16168397; Filed:May 4, 2016; Published: Jul 17, 2019; Earliest Priority: May 7, 2015; Granted: Jul 17, 2019",0,DWWPLAXEALLR
DWWPLAXEALXR,12,Synthetic construct,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,,,,"X(7) = Phe with F, Cl, Br, I, CH3, CF3, CN, OH, or NO2 at position 4; X(11) = Leu with F, Cl, Br, I, CH3, CF3, CN, OH, or NO2 at positions gamma, delta1 or delta2 ","Granted Patent Family: 8s / 8ex; Family Jurisdictions: CN, DK, US, EP, ES; Legal Status:   Active; Application No: 16168397; Filed:May 4, 2016; Published: Jul 17, 2019; Earliest Priority: May 7, 2015; Granted: Jul 17, 2019",0,DWWPLAXEALXR
DWWPLXFEALLX,12,Synthetic construct,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,,,,X=an amino acid with an olefinic side chain ,"Granted Patent Family: 8s / 8ex; Family Jurisdictions: CN, DK, US, EP, ES; Legal Status:   Active; Application No: 16168397; Filed:May 4, 2016; Published: Jul 17, 2019; Earliest Priority: May 7, 2015; Granted: Jul 17, 2019",0,DWWPLXFEALLX
DWWPLXFEXLLR,12,Synthetic construct,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,,,,X=an amino acid with an olefinic side chain ,"Granted Patent Family: 8s / 8ex; Family Jurisdictions: CN, DK, US, EP, ES; Legal Status:   Active; Application No: 16168397; Filed:May 4, 2016; Published: Jul 17, 2019; Earliest Priority: May 7, 2015; Granted: Jul 17, 2019",0,DWWPLXFEXLLR
DWWPXAFEALLX,12,Synthetic construct,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,,,,X=an amino acid with an olefinic side chain ,"Granted Patent Family: 8s / 8ex; Family Jurisdictions: CN, DK, US, EP, ES; Legal Status:   Active; Application No: 16168397; Filed:May 4, 2016; Published: Jul 17, 2019; Earliest Priority: May 7, 2015; Granted: Jul 17, 2019",0,DWWPXAFEALLX
DWWPXAFEXLLR,12,Synthetic construct,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,,,,X=an amino acid with an olefinic side chain ,"Granted Patent Family: 8s / 8ex; Family Jurisdictions: CN, DK, US, EP, ES; Legal Status:   Active; Application No: 16168397; Filed:May 4, 2016; Published: Jul 17, 2019; Earliest Priority: May 7, 2015; Granted: Jul 17, 2019",0,DWWPXAFEXLLR
DWXPLAFEALLR,12,Synthetic construct,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,,,,"X = Trp with F, Cl, Br, I, CH3, CF3, CN, OH, or NO2 at position 6 or position 7, or both positions 6 and 7 where the side group is the same or different ","Granted Patent Family: 8s / 8ex; Family Jurisdictions: CN, DK, US, EP, ES; Legal Status:   Active; Application No: 16168397; Filed:May 4, 2016; Published: Jul 17, 2019; Earliest Priority: May 7, 2015; Granted: Jul 17, 2019",0,DWXPLAFEALLR
DWXPLAFEALXR,12,Synthetic construct,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,,,,"X(3) = Trp with F, Cl, Br, I, CH3, CF3, CN, OH, or NO2 at position 6 or position 7, or both positions 6 and 7 where the side group is the same or different; X(11) = Leu with F, Cl, Br, I, CH3, CF3, CN, OH, or NO2 at positions gamma, delta1 or delta2","Granted Patent Family: 8s / 8ex; Family Jurisdictions: CN, DK, US, EP, ES; Legal Status:   Active; Application No: 16168397; Filed:May 4, 2016; Published: Jul 17, 2019; Earliest Priority: May 7, 2015; Granted: Jul 17, 2019",0,DWXPLAFEALXR
DWXPLAXEALLR,12,Synthetic construct,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,,,,"X = Trp with F, Cl, Br, I, CH3, CF3, CN, OH, or NO2 at position 6 or position 7, or both positions 6 and 7 where the side group is the same or different ","Granted Patent Family: 8s / 8ex; Family Jurisdictions: CN, DK, US, EP, ES; Legal Status:   Active; Application No: 16168397; Filed:May 4, 2016; Published: Jul 17, 2019; Earliest Priority: May 7, 2015; Granted: Jul 17, 2019",0,DWXPLAXEALLR
DWXPLAXEALXR,12,Synthetic construct,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,,,,"X(3) = Trp with F, Cl, Br, I, CH3, CF3, CN, OH, or NO2 at position 6 or position 7, or both positions 6 and 7 where the side group is the same or different; X(7) = Leu with F, Cl, Br, I, CH3, CF3, CN, OH, or NO2 at positions gamma, delta1 or delta2; X(11) = Leu with F, Cl, Br, I, CH3, CF3, CN, OH, or NO2 at positions gamma, delta1 or delta2 ","Granted Patent Family: 8s / 8ex; Family Jurisdictions: CN, DK, US, EP, ES; Legal Status:   Active; Application No: 16168397; Filed:May 4, 2016; Published: Jul 17, 2019; Earliest Priority: May 7, 2015; Granted: Jul 17, 2019",0,DWXPLAXEALXR
DXWPLAFEALLR,12,Synthetic construct,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,,,,"X(2) = Trp with F, Cl, Br, I, CH3, CF3, CN, OH, or NO2 at position 6 or position 7, or both positions 6 and 7 where the side group is the same or different ","Granted Patent Family: 8s / 8ex; Family Jurisdictions: CN, DK, US, EP, ES; Legal Status:   Active; Application No: 16168397; Filed:May 4, 2016; Published: Jul 17, 2019; Earliest Priority: May 7, 2015; Granted: Jul 17, 2019",0,DXWPLAFEALLR
DXWPLAFEALXR,12,Synthetic construct,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,,,,"X(2) = Trp with F, Cl, Br, I, CH3, CF3, CN, OH, or NO2 at position 6 or position 7, or both positions 6 and 7 where the side group is the same or different; X(11) = Leu with F, Cl, Br, I, CH3, CF3, CN, OH, or NO2 at positions gamma, delta1 or delta2","Granted Patent Family: 8s / 8ex; Family Jurisdictions: CN, DK, US, EP, ES; Legal Status:   Active; Application No: 16168397; Filed:May 4, 2016; Published: Jul 17, 2019; Earliest Priority: May 7, 2015; Granted: Jul 17, 2019",0,DXWPLAFEALXR
DXWPLAXEALLR,12,Synthetic construct,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,,,,"X(2) = Trp with F, Cl, Br, I, CH3, CF3, CN, OH, or NO2 at position 6 or position 7, or both positions 6 and 7 where the side group is the same or different; X(7) = Phe with F, Cl, Br, I, CH3, CF3, CN, OH, or NO2 at position 4 ","Granted Patent Family: 8s / 8ex; Family Jurisdictions: CN, DK, US, EP, ES; Legal Status:   Active; Application No: 16168397; Filed:May 4, 2016; Published: Jul 17, 2019; Earliest Priority: May 7, 2015; Granted: Jul 17, 2019",0,DXWPLAXEALLR
DXWPLAXEALXR,12,Synthetic construct,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,,,,"X(2) = Trp with F, Cl, Br, I, CH3, CF3, CN, OH, or NO2 at position 6 or position 7, or both positions 6 and 7 where the side group is the same or different; X(7) = Phe with F, Cl, Br, I, CH3, CF3, CN, OH, or NO2 at position 4; X(11) = Leu with F, Cl, Br, I, CH3, CF3, CN, OH, or NO2 at positions gamma, delta1 or delta2 ","Granted Patent Family: 8s / 8ex; Family Jurisdictions: CN, DK, US, EP, ES; Legal Status:   Active; Application No: 16168397; Filed:May 4, 2016; Published: Jul 17, 2019; Earliest Priority: May 7, 2015; Granted: Jul 17, 2019",0,DXWPLAXEALXR
DXXPLAFEALLR,12,Synthetic construct,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,,,,"X(2) = Trp with F, Cl, Br, I, CH3, CF3, CN, OH, or NO2 at position 6 or position 7, or both positions 6 and 7 where the side group is the same or different; X(3) = Trp with F, Cl, Br, I, CH3, CF3, CN, OH, or NO2 at position 6 or position 7, or both positions 6 and 7 where the side group is the same or different","Granted Patent Family: 8s / 8ex; Family Jurisdictions: CN, DK, US, EP, ES; Legal Status:   Active; Application No: 16168397; Filed:May 4, 2016; Published: Jul 17, 2019; Earliest Priority: May 7, 2015; Granted: Jul 17, 2019",0,DXXPLAFEALLR
DXXPLAFEALXR,12,Synthetic construct,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,,,,"X(2) = Trp with F, Cl, Br, I, CH3, CF3, CN, OH, or NO2 at position 6 or position 7, or both positions 6 and 7 where the side group is the same or different; X(3) = Trp with F, Cl, Br, I, CH3, CF3, CN, OH, or NO2 at position 6 or position 7, or both positions 6 and 7 where the side group is the same or different; X(11)= Leu with F, Cl, Br, I, CH3, CF3, CN, OH, or NO2 at positions gamma, delta1 or delta2","Granted Patent Family: 8s / 8ex; Family Jurisdictions: CN, DK, US, EP, ES; Legal Status:   Active; Application No: 16168397; Filed:May 4, 2016; Published: Jul 17, 2019; Earliest Priority: May 7, 2015; Granted: Jul 17, 2019",0,DXXPLAFEALXR
DXXPLAXEALLR,12,Synthetic construct,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,,,,"X(2) = Trp with F, Cl, Br, I, CH3, CF3, CN, OH, or NO2 at position 6 or position 7, or both positions 6 and 7 where the side group is the same or different; X(3) = Trp with F, Cl, Br, I, CH3, CF3, CN, OH, or NO2 at position 6 or position 7, or both positions 6 and 7 where the side group is the same or different; X(7) = Phe with F, Cl, Br, I, CH3, CF3, CN, OH, or NO2 at position 4","Granted Patent Family: 8s / 8ex; Family Jurisdictions: CN, DK, US, EP, ES; Legal Status:   Active; Application No: 16168397; Filed:May 4, 2016; Published: Jul 17, 2019; Earliest Priority: May 7, 2015; Granted: Jul 17, 2019",0,DXXPLAXEALLR
DXXPLAXEALXR,12,Synthetic construct,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,,,,"X(2) = Trp with F, Cl, Br, I, CH3, CF3, CN, OH, or NO2 at position 6 or position 7, or both positions 6 and 7 where the side group is the same or different; X(3) = Trp with F, Cl, Br, I, CH3, CF3, CN, OH, or NO2 at position 6 or position 7, or both positions 6 and 7 where the side group is the same or different; X(7) = Phe with F, Cl, Br, I, CH3, CF3, CN, OH, or NO2 at position 4; X(11)= Leu with F, Cl, Br, I, CH3, CF3, CN, OH, or NO2 at positions gamma, delta1 or delta2","Granted Patent Family: 8s / 8ex; Family Jurisdictions: CN, DK, US, EP, ES; Legal Status:   Active; Application No: 16168397; Filed:May 4, 2016; Published: Jul 17, 2019; Earliest Priority: May 7, 2015; Granted: Jul 17, 2019",0,DXXPLAXEALXR
TAWYANFEKLLR,12,Synthetic construct,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,,,,,"Granted Patent Family: 8s / 8ex; Family Jurisdictions: CN, DK, US, EP, ES; Legal Status:   Active; Application No: 16168397; Filed:May 4, 2016; Published: Jul 17, 2019; Earliest Priority: May 7, 2015; Granted: Jul 17, 2019",0,TAWYANFEKLLR
TAWYANFEKLXR,12,Synthetic construct,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,,,,"X = Leu with F, Cl, Br, I, CH3, CF3, CN, OH, or NO2 at positions gamma, delta1 or delta2 ","Granted Patent Family: 8s / 8ex; Family Jurisdictions: CN, DK, US, EP, ES; Legal Status:   Active; Application No: 16168397; Filed:May 4, 2016; Published: Jul 17, 2019; Earliest Priority: May 7, 2015; Granted: Jul 17, 2019",0,TAWYANFEKLXR
TAWYANFEXLLX,12,Synthetic construct,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,,,,X=an amino acid with an olefinic side chain ,"Granted Patent Family: 8s / 8ex; Family Jurisdictions: CN, DK, US, EP, ES; Legal Status:   Active; Application No: 16168397; Filed:May 4, 2016; Published: Jul 17, 2019; Earliest Priority: May 7, 2015; Granted: Jul 17, 2019",0,TAWYANFEXLLX
TAWYANFXKLLX,12,Synthetic construct,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,,,,X=an amino acid with an olefinic side chain ,"Granted Patent Family: 8s / 8ex; Family Jurisdictions: CN, DK, US, EP, ES; Legal Status:   Active; Application No: 16168397; Filed:May 4, 2016; Published: Jul 17, 2019; Earliest Priority: May 7, 2015; Granted: Jul 17, 2019",0,TAWYANFXKLLX
TAWYANXEKLLR,12,Synthetic construct,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,,,,"X = Phe with F, Cl, Br, I, CH3, CF3, CN, OH, or NO2 at position 4 ","Granted Patent Family: 8s / 8ex; Family Jurisdictions: CN, DK, US, EP, ES; Legal Status:   Active; Application No: 16168397; Filed:May 4, 2016; Published: Jul 17, 2019; Earliest Priority: May 7, 2015; Granted: Jul 17, 2019",0,TAWYANXEKLLR
TAWYANXEKLXR,12,Synthetic construct,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,,,,"X(7) = Phe with F, Cl, Br, I, CH3, CF3, CN, OH, or NO2 at position 4; X(11) = Leu with F, Cl, Br, I, CH3, CF3, CN, OH, or NO2 at positions gamma, delta1 or delta2 ","Granted Patent Family: 8s / 8ex; Family Jurisdictions: CN, DK, US, EP, ES; Legal Status:   Active; Application No: 16168397; Filed:May 4, 2016; Published: Jul 17, 2019; Earliest Priority: May 7, 2015; Granted: Jul 17, 2019",0,TAWYANXEKLXR
TAWYAXFEKLLX,12,Synthetic construct,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,,,,X=an amino acid with an olefinic side chain ,"Granted Patent Family: 8s / 8ex; Family Jurisdictions: CN, DK, US, EP, ES; Legal Status:   Active; Application No: 16168397; Filed:May 4, 2016; Published: Jul 17, 2019; Earliest Priority: May 7, 2015; Granted: Jul 17, 2019",0,TAWYAXFEKLLX
TAWYAXFEXLLR,12,Synthetic construct,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,,,,X=an amino acid with an olefinic side chain ,"Granted Patent Family: 8s / 8ex; Family Jurisdictions: CN, DK, US, EP, ES; Legal Status:   Active; Application No: 16168397; Filed:May 4, 2016; Published: Jul 17, 2019; Earliest Priority: May 7, 2015; Granted: Jul 17, 2019",0,TAWYAXFEXLLR
TAWYXNFEKLLX,12,Synthetic construct,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,,,,X=Orn ,"Granted Patent Family: 8s / 8ex; Family Jurisdictions: CN, DK, US, EP, ES; Legal Status:   Active; Application No: 16168397; Filed:May 4, 2016; Published: Jul 17, 2019; Earliest Priority: May 7, 2015; Granted: Jul 17, 2019",0,TAWYXNFEKLLX
TAWYXNFEXLLR,12,Synthetic construct,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,,,,X=Orn ,"Granted Patent Family: 8s / 8ex; Family Jurisdictions: CN, DK, US, EP, ES; Legal Status:   Active; Application No: 16168397; Filed:May 4, 2016; Published: Jul 17, 2019; Earliest Priority: May 7, 2015; Granted: Jul 17, 2019",0,TAWYXNFEXLLR
TAXYANFEKLLR,12,Synthetic construct,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,,,,"X = Trp with F, Cl, Br, I, CH3, CF3, CN, OH, or NO2 at position 6 or position 7, or both positions 6 and 7 where the side group is the same or different ","Granted Patent Family: 8s / 8ex; Family Jurisdictions: CN, DK, US, EP, ES; Legal Status:   Active; Application No: 16168397; Filed:May 4, 2016; Published: Jul 17, 2019; Earliest Priority: May 7, 2015; Granted: Jul 17, 2019",0,TAXYANFEKLLR
TAXYANXEKLLR,12,Synthetic construct,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,,,,"X(3) = Trp with F, Cl, Br, I, CH3, CF3, CN, OH, or NO2 at position 6 or position 7, or both positions 6 and 7 where the side group is the same or different; X(7) = Phe with F, Cl, Br, I, CH3, CF3, CN, OH, or NO2 at position 4 ","Granted Patent Family: 8s / 8ex; Family Jurisdictions: CN, DK, US, EP, ES; Legal Status:   Active; Application No: 16168397; Filed:May 4, 2016; Published: Jul 17, 2019; Earliest Priority: May 7, 2015; Granted: Jul 17, 2019",0,TAXYANXEKLLR
TAXYANXEKLXR,12,Synthetic construct,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,,,,"X(3) = Trp with F, Cl, Br, I, CH3, CF3, CN, OH, or NO2 at position 6 or position 7, or both positions 6 and 7 where the side group is the same or different; X(7) = Phe with F, Cl, Br, I, CH3, CF3, CN, OH, or NO2 at position 4 ","Granted Patent Family: 8s / 8ex; Family Jurisdictions: CN, DK, US, EP, ES; Legal Status:   Active; Application No: 16168397; Filed:May 4, 2016; Published: Jul 17, 2019; Earliest Priority: May 7, 2015; Granted: Jul 17, 2019",0,TAXYANXEKLXR
TNWYANLEKLLR,12,Synthetic construct,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,,,,,"Granted Patent Family: 8s / 8ex; Family Jurisdictions: CN, DK, US, EP, ES; Legal Status:   Active; Application No: 16168397; Filed:May 4, 2016; Published: Jul 17, 2019; Earliest Priority: May 7, 2015; Granted: Jul 17, 2019",0,TNWYANLEKLLR
TNWYANLEKLXR,12,Synthetic construct,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,,,,"X = Leu with F, Cl, Br, I, CH3, CF3, CN, OH, or NO2 at positions gamma, delta1 or delta2 ","Granted Patent Family: 8s / 8ex; Family Jurisdictions: CN, DK, US, EP, ES; Legal Status:   Active; Application No: 16168397; Filed:May 4, 2016; Published: Jul 17, 2019; Earliest Priority: May 7, 2015; Granted: Jul 17, 2019",0,TNWYANLEKLXR
TNWYANXEKLLR,12,Synthetic construct,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,,,,"X = Leu with F, Cl, Br, I, CH3, CF3, CN, OH, or NO2 at positions gamma, delta1 or delta2 ","Granted Patent Family: 8s / 8ex; Family Jurisdictions: CN, DK, US, EP, ES; Legal Status:   Active; Application No: 16168397; Filed:May 4, 2016; Published: Jul 17, 2019; Earliest Priority: May 7, 2015; Granted: Jul 17, 2019",0,TNWYANXEKLLR
TNWYANXEKLXR,12,Synthetic construct,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,,,,"X(7) = Leu with F, Cl, Br, I, CH3, CF3, CN, OH, or NO2 at positions gamma, delta1 or delta2; X(11) = Leu with F, Cl, Br, I, CH3, CF3, CN, OH, or NO2 at positions gamma, delta1 or delta2 ","Granted Patent Family: 8s / 8ex; Family Jurisdictions: CN, DK, US, EP, ES; Legal Status:   Active; Application No: 16168397; Filed:May 4, 2016; Published: Jul 17, 2019; Earliest Priority: May 7, 2015; Granted: Jul 17, 2019",0,TNWYANXEKLXR
TNXYANLEKLLR,12,Synthetic construct,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,,,,"X = Trp with F, Cl, Br, I, CH3, CF3, CN, OH, or NO2 at position 6 or position 7, or both positions 6 and 7 where the side group is the same or different ","Granted Patent Family: 8s / 8ex; Family Jurisdictions: CN, DK, US, EP, ES; Legal Status:   Active; Application No: 16168397; Filed:May 4, 2016; Published: Jul 17, 2019; Earliest Priority: May 7, 2015; Granted: Jul 17, 2019",0,TNXYANLEKLLR
TNXYANXEKLLR,12,Synthetic construct,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,,,,"X(3) = Trp with F, Cl, Br, I, CH3, CF3, CN, OH, or NO2 at position 6 or position 7, or both positions 6 and 7 where the side group is the same or different; X(7) = Leu with F, Cl, Br, I, CH3, CF3, CN, OH, or NO2 at positions gamma, delta1 or delta2 ","Granted Patent Family: 8s / 8ex; Family Jurisdictions: CN, DK, US, EP, ES; Legal Status:   Active; Application No: 16168397; Filed:May 4, 2016; Published: Jul 17, 2019; Earliest Priority: May 7, 2015; Granted: Jul 17, 2019",0,TNXYANXEKLLR
TNXYANXEKLXR,12,Synthetic construct,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,,,,"X(3) = Trp with F, Cl, Br, I, CH3, CF3, CN, OH, or NO2 at position 6 or position 7, or both positions 6 and 7 where the side group is the same or different; X(7) = Leu with F, Cl, Br, I, CH3, CF3, CN, OH, or NO2 at positions gamma, delta1 or delta2; X(11) = Leu with F, Cl, Br, I, CH3, CF3, CN, OH, or NO2 at positions gamma, delta1 or delta2 ","Granted Patent Family: 8s / 8ex; Family Jurisdictions: CN, DK, US, EP, ES; Legal Status:   Active; Application No: 16168397; Filed:May 4, 2016; Published: Jul 17, 2019; Earliest Priority: May 7, 2015; Granted: Jul 17, 2019",0,TNXYANXEKLXR
TSFAEYWNLLSP,12,Synthetic construct,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,,,,,"Granted Patent Family: 8s / 8ex; Family Jurisdictions: CN, DK, US, EP, ES; Legal Status:   Active; Application No: 16168397; Filed:May 4, 2016; Published: Jul 17, 2019; Earliest Priority: May 7, 2015; Granted: Jul 17, 2019",0,TSFAEYWNLLSP
WPLAFEALLR,10,Synthetic construct,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,,,,,"Granted Patent Family: 8s / 8ex; Family Jurisdictions: CN, DK, US, EP, ES; Legal Status:   Active; Application No: 16168397; Filed:May 4, 2016; Published: Jul 17, 2019; Earliest Priority: May 7, 2015; Granted: Jul 17, 2019",0,WPLAFEALLR
WPLAFEALXR,10,Synthetic construct,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,,,,"X = Leu with F, Cl, Br, I, CH3, CF3, CN, OH, or NO2 at positions gamma, delta1 or delta2","Granted Patent Family: 8s / 8ex; Family Jurisdictions: CN, DK, US, EP, ES; Legal Status:   Active; Application No: 16168397; Filed:May 4, 2016; Published: Jul 17, 2019; Earliest Priority: May 7, 2015; Granted: Jul 17, 2019",0,WPLAFEALXR
WPLAXEALLR,10,Synthetic construct,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,,,,"X = Phe with F, Cl, Br, I, CH3, CF3, CN, OH, or NO2 at position 4","Granted Patent Family: 8s / 8ex; Family Jurisdictions: CN, DK, US, EP, ES; Legal Status:   Active; Application No: 16168397; Filed:May 4, 2016; Published: Jul 17, 2019; Earliest Priority: May 7, 2015; Granted: Jul 17, 2019",0,WPLAXEALLR
WPLAXEALXR,10,Synthetic construct,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,,,,"X(7) = Phe with F, Cl, Br, I, CH3, CF3, CN, OH, or NO2 at position 4; X(11) = Leu with F, Cl, Br, I, CH3, CF3, CN, OH, or NO2 at positions gamma, delta1 or delta2 ","Granted Patent Family: 8s / 8ex; Family Jurisdictions: CN, DK, US, EP, ES; Legal Status:   Active; Application No: 16168397; Filed:May 4, 2016; Published: Jul 17, 2019; Earliest Priority: May 7, 2015; Granted: Jul 17, 2019",0,WPLAXEALXR
WYANFEKLLR,10,Synthetic construct,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,,,,,"Granted Patent Family: 8s / 8ex; Family Jurisdictions: CN, DK, US, EP, ES; Legal Status:   Active; Application No: 16168397; Filed:May 4, 2016; Published: Jul 17, 2019; Earliest Priority: May 7, 2015; Granted: Jul 17, 2019",0,WYANFEKLLR
WYANFEKLXR,10,Synthetic construct,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,,,,"X = Leu with F, Cl, Br, I, CH3, CF3, CN, OH, or NO2 at positions gamma, delta1 or delta2 ","Granted Patent Family: 8s / 8ex; Family Jurisdictions: CN, DK, US, EP, ES; Legal Status:   Active; Application No: 16168397; Filed:May 4, 2016; Published: Jul 17, 2019; Earliest Priority: May 7, 2015; Granted: Jul 17, 2019",0,WYANFEKLXR
WYANFEXLLX,10,Synthetic construct,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,,,,X=an amino acid with an olefinic side chain ,"Granted Patent Family: 8s / 8ex; Family Jurisdictions: CN, DK, US, EP, ES; Legal Status:   Active; Application No: 16168397; Filed:May 4, 2016; Published: Jul 17, 2019; Earliest Priority: May 7, 2015; Granted: Jul 17, 2019",0,WYANFEXLLX
WYANFXKLLX,10,Synthetic construct,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,,,,X=an amino acid with an olefinic side chain ,"Granted Patent Family: 8s / 8ex; Family Jurisdictions: CN, DK, US, EP, ES; Legal Status:   Active; Application No: 16168397; Filed:May 4, 2016; Published: Jul 17, 2019; Earliest Priority: May 7, 2015; Granted: Jul 17, 2019",0,WYANFXKLLX
WYANLEKLLR,10,Synthetic construct,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,,,,,"Granted Patent Family: 8s / 8ex; Family Jurisdictions: CN, DK, US, EP, ES; Legal Status:   Active; Application No: 16168397; Filed:May 4, 2016; Published: Jul 17, 2019; Earliest Priority: May 7, 2015; Granted: Jul 17, 2019",0,WYANLEKLLR
WYANLEKLXR,10,Synthetic construct,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,,,,"X = Leu with F, Cl, Br, I, CH3, CF3, CN, OH, or NO2 at positions gamma, delta1 or delta2 ","Granted Patent Family: 8s / 8ex; Family Jurisdictions: CN, DK, US, EP, ES; Legal Status:   Active; Application No: 16168397; Filed:May 4, 2016; Published: Jul 17, 2019; Earliest Priority: May 7, 2015; Granted: Jul 17, 2019",0,WYANLEKLXR
WYANXEKLLR,10,Synthetic construct,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,,,,"X = Phe with F, Cl, Br, I, CH3, CF3, CN, OH, or NO2 at position 4 ","Granted Patent Family: 8s / 8ex; Family Jurisdictions: CN, DK, US, EP, ES; Legal Status:   Active; Application No: 16168397; Filed:May 4, 2016; Published: Jul 17, 2019; Earliest Priority: May 7, 2015; Granted: Jul 17, 2019",0,WYANXEKLLR
WYANXEKLXR,10,Synthetic construct,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,,,,"X(5) = Phe with F, Cl, Br, I, CH3, CF3, CN, OH, or NO2 at position 4; X(9) = Leu with F, Cl, Br, I, CH3, CF3, CN, OH, or NO2 at positions gamma, delta1 or delta2 ","Granted Patent Family: 8s / 8ex; Family Jurisdictions: CN, DK, US, EP, ES; Legal Status:   Active; Application No: 16168397; Filed:May 4, 2016; Published: Jul 17, 2019; Earliest Priority: May 7, 2015; Granted: Jul 17, 2019",0,WYANXEKLXR
WYAXFEKLLX,10,Synthetic construct,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,,,,X=an amino acid with an olefinic side chain ,"Granted Patent Family: 8s / 8ex; Family Jurisdictions: CN, DK, US, EP, ES; Legal Status:   Active; Application No: 16168397; Filed:May 4, 2016; Published: Jul 17, 2019; Earliest Priority: May 7, 2015; Granted: Jul 17, 2019",0,WYAXFEKLLX
WYAXFEXLLR,10,Synthetic construct,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,,,,X=an amino acid with an olefinic side chain ,"Granted Patent Family: 8s / 8ex; Family Jurisdictions: CN, DK, US, EP, ES; Legal Status:   Active; Application No: 16168397; Filed:May 4, 2016; Published: Jul 17, 2019; Earliest Priority: May 7, 2015; Granted: Jul 17, 2019",0,WYAXFEXLLR
WYXNFEKLLX,10,Synthetic construct,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,,,,X=Orn ,"Granted Patent Family: 8s / 8ex; Family Jurisdictions: CN, DK, US, EP, ES; Legal Status:   Active; Application No: 16168397; Filed:May 4, 2016; Published: Jul 17, 2019; Earliest Priority: May 7, 2015; Granted: Jul 17, 2019",0,WYXNFEKLLX
WYXNFEXLLR,10,Synthetic construct,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,,,,X=Orn ,"Granted Patent Family: 8s / 8ex; Family Jurisdictions: CN, DK, US, EP, ES; Legal Status:   Active; Application No: 16168397; Filed:May 4, 2016; Published: Jul 17, 2019; Earliest Priority: May 7, 2015; Granted: Jul 17, 2019",0,WYXNFEXLLR
XPLAFEALLR,10,Synthetic construct,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,,,,"X = Trp with F, Cl, Br, I, CH3, CF3, CN, OH, or NO2 at position 6 or position 7, or both positions 6 and 7 where the side group is the same or different ","Granted Patent Family: 8s / 8ex; Family Jurisdictions: CN, DK, US, EP, ES; Legal Status:   Active; Application No: 16168397; Filed:May 4, 2016; Published: Jul 17, 2019; Earliest Priority: May 7, 2015; Granted: Jul 17, 2019",0,XPLAFEALLR
XPLAFEALXR,10,Synthetic construct,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,,,,"X(1) = Trp with F, Cl, Br, I, CH3, CF3, CN, OH, or NO2 at position 6 or position 7, or both positions 6 and 7 where the side group is the same or different; X(9) = Leu with F, Cl, Br, I, CH3, CF3, CN, OH, or NO2 at positions gamma, delta1 or delta2","Granted Patent Family: 8s / 8ex; Family Jurisdictions: CN, DK, US, EP, ES; Legal Status:   Active; Application No: 16168397; Filed:May 4, 2016; Published: Jul 17, 2019; Earliest Priority: May 7, 2015; Granted: Jul 17, 2019",0,XPLAFEALXR
XPLAXEALLR,10,Synthetic construct,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,,,,"X(1) = Trp with F, Cl, Br, I, CH3, CF3, CN, OH, or NO2 at position 6 or position 7, or both positions 6 and 7 where the side group is the same or different; X(5) = Phe with F, Cl, Br, I, CH3, CF3, CN, OH, or NO2 at position 4 ","Granted Patent Family: 8s / 8ex; Family Jurisdictions: CN, DK, US, EP, ES; Legal Status:   Active; Application No: 16168397; Filed:May 4, 2016; Published: Jul 17, 2019; Earliest Priority: May 7, 2015; Granted: Jul 17, 2019",0,XPLAXEALLR
XPLAXEALXR,10,Synthetic construct,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,,,,"X(1) = Trp with F, Cl, Br, I, CH3, CF3, CN, OH, or NO2 at position 6 or position 7, or both positions 6 and 7 where the side group is the same or different; X(5) = Phe with F, Cl, Br, I, CH3, CF3, CN, OH, or NO2 at position 4; X(9) = Leu with F, Cl, Br, I, CH3, CF3, CN, OH, or NO2 at positions gamma, delta1 or delta2","Granted Patent Family: 8s / 8ex; Family Jurisdictions: CN, DK, US, EP, ES; Legal Status:   Active; Application No: 16168397; Filed:May 4, 2016; Published: Jul 17, 2019; Earliest Priority: May 7, 2015; Granted: Jul 17, 2019",0,XPLAXEALXR
XYANFEKLLR,10,Synthetic construct,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,,,,"X = Trp with F, Cl, Br, I, CH3, CF3, CN, OH, or NO2 at position 6 or position 7, or both positions 6 and 7 where the side group is the same or different","Granted Patent Family: 8s / 8ex; Family Jurisdictions: CN, DK, US, EP, ES; Legal Status:   Active; Application No: 16168397; Filed:May 4, 2016; Published: Jul 17, 2019; Earliest Priority: May 7, 2015; Granted: Jul 17, 2019",0,XYANFEKLLR
XYANLEKLLR,10,Synthetic construct,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,,,,"X = Trp with F, Cl, Br, I, CH3, CF3, CN, OH, or NO2 at position 6 or position 7, or both positions 6 and 7 where the side group is the same or different ","Granted Patent Family: 8s / 8ex; Family Jurisdictions: CN, DK, US, EP, ES; Legal Status:   Active; Application No: 16168397; Filed:May 4, 2016; Published: Jul 17, 2019; Earliest Priority: May 7, 2015; Granted: Jul 17, 2019",0,XYANLEKLLR
XYANXEKLLR,10,Synthetic construct,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,,,,"X(1) = Trp with F, Cl, Br, I, CH3, CF3, CN, OH, or NO2 at position 6 or position 7, or both positions 6 and 7 where the side group is the same or different; X(5) = Phe with F, Cl, Br, I, CH3, CF3, CN, OH, or NO2 at position 4 ","Granted Patent Family: 8s / 8ex; Family Jurisdictions: CN, DK, US, EP, ES; Legal Status:   Active; Application No: 16168397; Filed:May 4, 2016; Published: Jul 17, 2019; Earliest Priority: May 7, 2015; Granted: Jul 17, 2019",0,XYANXEKLLR
XYANXEKLXR,10,Synthetic construct,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,,,,"X(3) = Trp with F, Cl, Br, I, CH3, CF3, CN, OH, or NO2 at position 6 or position 7, or both positions 6 and 7 where the side group is the same or different; X(5) = Phe with F, Cl, Br, I, CH3, CF3, CN, OH, or NO2 at position 4; X(9) = Leu with F, Cl, Br, I, CH3, CF3, CN, OH, or NO2 at positions gamma, delta1 or delta2 ","Granted Patent Family: 8s / 8ex; Family Jurisdictions: CN, DK, US, EP, ES; Legal Status:   Active; Application No: 16168397; Filed:May 4, 2016; Published: Jul 17, 2019; Earliest Priority: May 7, 2015; Granted: Jul 17, 2019",0,XYANXEKLXR
GKKLLKKGKGWLGGLWGK,18,Synthetic construct,Synthetic peptide,,,,,,Anticancer; Antimicrobial,Tumor active peptide,,,,,,,"Granted Patent Family: 6s / 6ex; Family Jurisdictions: EP, IL, AU, US, AT, DEUS, EP, CN, WO; Legal Status:   Active; Application No: 201716462586; Filed:Nov 21, 2017; Published: Mar 12, 2020; Earliest Priority: Nov 21, 2016; Granted: Mar 29, 2022",0,GKKLLKKGKGWLGGLWGK
GKKLLKKVKGWLGGLWGK,18,Synthetic construct,Synthetic peptide,,,,,,Anticancer; Antimicrobial,Tumor active peptide,,,,,,,"Granted Patent Family: 6s / 6ex; Family Jurisdictions: EP, IL, AU, US, AT, DEUS, EP, CN, WO; Legal Status:   Active; Application No: 201716462586; Filed:Nov 21, 2017; Published: Mar 12, 2020; Earliest Priority: Nov 21, 2016; Granted: Mar 29, 2022",0,GKKLLKKVKGWLGGLWGK
GVKKKWKKKLGLKLWLKISGVVLG,24,Synthetic construct,Synthetic peptide,,,,,,Anticancer; Antimicrobial,Tumor active peptide,,,,,,,"Granted Patent Family: 6s / 6ex; Family Jurisdictions: EP, IL, AU, US, AT, DEUS, EP, CN, WO; Legal Status:   Active; Application No: 201716462586; Filed:Nov 21, 2017; Published: Mar 12, 2020; Earliest Priority: Nov 21, 2016; Granted: Mar 29, 2022",0,GVKKKWKKKLGLKLWLKISGVVLG
ILKKWWGTSGGLLGGLLGKVTSVIKGLNNI,30,Synthetic construct,Synthetic peptide,,,,,,Anticancer; Antimicrobial,Tumor active peptide,,,,,,,"Granted Patent Family: 6s / 6ex; Family Jurisdictions: EP, IL, AU, US, AT, DEUS, EP, CN, WO; Legal Status:   Active; Application No: 201716462586; Filed:Nov 21, 2017; Published: Mar 12, 2020; Earliest Priority: Nov 21, 2016; Granted: Mar 29, 2022",0,ILKKWWGTSGGLLGGLLGKVTSVIKGLNNI
ILKKWWKKVKGLLGKLLGGVKKVIKGLNNI,30,Synthetic construct,Synthetic peptide,,,,,,Anticancer; Antimicrobial,Tumor active peptide,,,,,,,"Granted Patent Family: 6s / 6ex; Family Jurisdictions: EP, IL, AU, US, AT, DEUS, EP, CN, WO; Legal Status:   Active; Application No: 201716462586; Filed:Nov 21, 2017; Published: Mar 12, 2020; Earliest Priority: Nov 21, 2016; Granted: Mar 29, 2022",0,ILKKWWKKVKGLLGKLLGGVKKVIKGLNNI
ILKKWWKKVKGLLGKLLGGVKSVIKGLNNI,30,Synthetic construct,Synthetic peptide,,,,,,Anticancer; Antimicrobial,Tumor active peptide,,,,,,,"Granted Patent Family: 6s / 6ex; Family Jurisdictions: EP, IL, AU, US, AT, DEUS, EP, CN, WO; Legal Status:   Active; Application No: 201716462586; Filed:Nov 21, 2017; Published: Mar 12, 2020; Earliest Priority: Nov 21, 2016; Granted: Mar 29, 2022",0,ILKKWWKKVKGLLGKLLGGVKSVIKGLNNI
ILKKWWKTSGGLLGGLLGKVTSVIKGLNNI,30,Synthetic construct,Synthetic peptide,,,,,,Anticancer; Antimicrobial,Tumor active peptide,,,,,,,"Granted Patent Family: 6s / 6ex; Family Jurisdictions: EP, IL, AU, US, AT, DEUS, EP, CN, WO; Legal Status:   Active; Application No: 201716462586; Filed:Nov 21, 2017; Published: Mar 12, 2020; Earliest Priority: Nov 21, 2016; Granted: Mar 29, 2022",0,ILKKWWKTSGGLLGGLLGKVTSVIKGLNNI
ILKKWWKTSKGLLGGLLGGVTSVIKKLKKI,30,Synthetic construct,Synthetic peptide,,,,,,Anticancer; Antimicrobial,Tumor active peptide,,,,,,,"Granted Patent Family: 6s / 6ex; Family Jurisdictions: EP, IL, AU, US, AT, DEUS, EP, CN, WO; Legal Status:   Active; Application No: 201716462586; Filed:Nov 21, 2017; Published: Mar 12, 2020; Earliest Priority: Nov 21, 2016; Granted: Mar 29, 2022",0,ILKKWWKTSKGLLGGLLGGVTSVIKKLKKI
ILKKWWKTSKGLLGGLLGKVTSVIKGLKNI,30,Synthetic construct,Synthetic peptide,,,,,,Anticancer; Antimicrobial,Tumor active peptide,,,,,,,"Granted Patent Family: 6s / 6ex; Family Jurisdictions: EP, IL, AU, US, AT, DEUS, EP, CN, WO; Legal Status:   Active; Application No: 201716462586; Filed:Nov 21, 2017; Published: Mar 12, 2020; Earliest Priority: Nov 21, 2016; Granted: Mar 29, 2022",0,ILKKWWKTSKGLLGGLLGKVTSVIKGLKNI
ILKKWWKTSKGLLGGLLGKVTSVIKGLNNI,30,Synthetic construct,Synthetic peptide,,,,,,Anticancer; Antimicrobial,Tumor active peptide,,,,,,,"Granted Patent Family: 6s / 6ex; Family Jurisdictions: EP, IL, AU, US, AT, DEUS, EP, CN, WO; Legal Status:   Active; Application No: 201716462586; Filed:Nov 21, 2017; Published: Mar 12, 2020; Earliest Priority: Nov 21, 2016; Granted: Mar 29, 2022",0,ILKKWWKTSKGLLGGLLGKVTSVIKGLNNI
ILKKWWKTVKGLLGGLLGGVTSVIKKLKKI,30,Synthetic construct,Synthetic peptide,,,,,,Anticancer; Antimicrobial,Tumor active peptide,,,,,,,"Granted Patent Family: 6s / 6ex; Family Jurisdictions: EP, IL, AU, US, AT, DEUS, EP, CN, WO; Legal Status:   Active; Application No: 201716462586; Filed:Nov 21, 2017; Published: Mar 12, 2020; Earliest Priority: Nov 21, 2016; Granted: Mar 29, 2022",0,ILKKWWKTVKGLLGGLLGGVTSVIKKLKKI
ILKKWWXXXXGLLGXLLGXVXXVIKXLXXI,30,Synthetic construct,Synthetic peptide,,,,,,Anticancer; Antimicrobial,Tumor active peptide,,,,,,X(7/8/10/15/21/22/26/28/29)=Xaa is non - hydrophobic or hydrophilic amino; X(9/19)=Xaa is hydrophobic amino acid ,"Granted Patent Family: 6s / 6ex; Family Jurisdictions: EP, IL, AU, US, AT, DEUS, EP, CN, WO; Legal Status:   Active; Application No: 201716462586; Filed:Nov 21, 2017; Published: Mar 12, 2020; Earliest Priority: Nov 21, 2016; Granted: Mar 29, 2022",0,ILKKWWXXXXGLLGXLLGXVXXVIKXLXXI
ILKPGGGTSGGLLGGLLGKVTSVIPGLNNI,30,Synthetic construct,Synthetic peptide,,,,,,Anticancer; Antimicrobial,Tumor active peptide,,,,,,,"Granted Patent Family: 6s / 6ex; Family Jurisdictions: EP, IL, AU, US, AT, DEUS, EP, CN, WO; Legal Status:   Active; Application No: 201716462586; Filed:Nov 21, 2017; Published: Mar 12, 2020; Earliest Priority: Nov 21, 2016; Granted: Mar 29, 2022",0,ILKPGGGTSGGLLGGLLGKVTSVIPGLNNI
KKLGKKVVGKLGTSKVWKLIGWLL,24,Synthetic construct,Synthetic peptide,,,,,,Anticancer; Antimicrobial,Tumor active peptide,,,,,,,"Granted Patent Family: 6s / 6ex; Family Jurisdictions: EP, IL, AU, US, AT, DEUS, EP, CN, WO; Legal Status:   Active; Application No: 201716462586; Filed:Nov 21, 2017; Published: Mar 12, 2020; Earliest Priority: Nov 21, 2016; Granted: Mar 29, 2022",0,KKLGKKVVGKLGTSKVWKLIGWLL
KLWKKGKGGKLTKSLTWVLVGILV,24,Synthetic construct,Synthetic peptide,,,,,,Anticancer; Antimicrobial,Tumor active peptide,,,,,,,"Granted Patent Family: 6s / 6ex; Family Jurisdictions: EP, IL, AU, US, AT, DEUS, EP, CN, WO; Legal Status:   Active; Application No: 201716462586; Filed:Nov 21, 2017; Published: Mar 12, 2020; Earliest Priority: Nov 21, 2016; Granted: Mar 29, 2022",0,KLWKKGKGGKLTKSLTWVLVGILV
LKKLLKKVKGWLGGLWGK,18,Synthetic construct,Synthetic peptide,,,,,,Anticancer; Antimicrobial,Tumor active peptide,,,,,,,"Granted Patent Family: 6s / 6ex; Family Jurisdictions: EP, IL, AU, US, AT, DEUS, EP, CN, WO; Legal Status:   Active; Application No: 201716462586; Filed:Nov 21, 2017; Published: Mar 12, 2020; Earliest Priority: Nov 21, 2016; Granted: Mar 29, 2022",0,LKKLLKKVKGWLGGLWGK
LKKWLKKVLGLKGGLWGKVTSVIK,24,Synthetic construct,Synthetic peptide,,,,,,Anticancer; Antimicrobial,Tumor active peptide,,,,,,,"Granted Patent Family: 6s / 6ex; Family Jurisdictions: EP, IL, AU, US, AT, DEUS, EP, CN, WO; Legal Status:   Active; Application No: 201716462586; Filed:Nov 21, 2017; Published: Mar 12, 2020; Earliest Priority: Nov 21, 2016; Granted: Mar 29, 2022",0,LKKWLKKVLGLKGGLWGKVTSVIK
LKKWWKKVKGLLGGLLGK,18,Synthetic construct,Synthetic peptide,,,,,,Anticancer; Antimicrobial,Tumor active peptide,,,,,,,"Granted Patent Family: 6s / 6ex; Family Jurisdictions: EP, IL, AU, US, AT, DEUS, EP, CN, WO; Legal Status:   Active; Application No: 201716462586; Filed:Nov 21, 2017; Published: Mar 12, 2020; Earliest Priority: Nov 21, 2016; Granted: Mar 29, 2022",0,LKKWWKKVKGLLGGLLGK
LKKWWKKVKGLLGGLLGKVKKVIK,24,Synthetic construct,Synthetic peptide,,,,,,Anticancer; Antimicrobial,Tumor active peptide,,,,,,,"Granted Patent Family: 6s / 6ex; Family Jurisdictions: EP, IL, AU, US, AT, DEUS, EP, CN, WO; Legal Status:   Active; Application No: 201716462586; Filed:Nov 21, 2017; Published: Mar 12, 2020; Earliest Priority: Nov 21, 2016; Granted: Mar 29, 2022",0,LKKWWKKVKGLLGGLLGKVKKVIK
LKKWWKKVKGLLGGLLGKVKSVIK,24,Synthetic construct,Synthetic peptide,,,,,,Anticancer; Antimicrobial,Tumor active peptide,,,,,,,"Granted Patent Family: 6s / 6ex; Family Jurisdictions: EP, IL, AU, US, AT, DEUS, EP, CN, WO; Legal Status:   Active; Application No: 201716462586; Filed:Nov 21, 2017; Published: Mar 12, 2020; Earliest Priority: Nov 21, 2016; Granted: Mar 29, 2022",0,LKKWWKKVKGLLGGLLGKVKSVIK
LKKWWKKVKGLLGGLLGKVTSVIK,24,Synthetic construct,Synthetic peptide,,,,,,Anticancer; Antimicrobial,Tumor active peptide,,,,,,,"Granted Patent Family: 6s / 6ex; Family Jurisdictions: EP, IL, AU, US, AT, DEUS, EP, CN, WO; Legal Status:   Active; Application No: 201716462586; Filed:Nov 21, 2017; Published: Mar 12, 2020; Earliest Priority: Nov 21, 2016; Granted: Mar 29, 2022",0,LKKWWKKVKGLLGGLLGKVTSVIK
LKKWWKKVLGLLGGLKGKVTSVIK,24,Synthetic construct,Synthetic peptide,,,,,,Anticancer; Antimicrobial,Tumor active peptide,,,,,,,"Granted Patent Family: 6s / 6ex; Family Jurisdictions: EP, IL, AU, US, AT, DEUS, EP, CN, WO; Legal Status:   Active; Application No: 201716462586; Filed:Nov 21, 2017; Published: Mar 12, 2020; Earliest Priority: Nov 21, 2016; Granted: Mar 29, 2022",0,LKKWWKKVLGLLGGLKGKVTSVIK
LKKWWKTSKGLLGGLLGKVTSVIK,24,Synthetic construct,Synthetic peptide,,,,,,Anticancer; Antimicrobial,Tumor active peptide,,,,,,,"Granted Patent Family: 6s / 6ex; Family Jurisdictions: EP, IL, AU, US, AT, DEUS, EP, CN, WO; Legal Status:   Active; Application No: 201716462586; Filed:Nov 21, 2017; Published: Mar 12, 2020; Earliest Priority: Nov 21, 2016; Granted: Mar 29, 2022",0,LKKWWKTSKGLLGGLLGKVTSVIK
LKKWWKTVKGLLGGLLGKVTSVIK,24,Synthetic construct,Synthetic peptide,,,,,,Anticancer; Antimicrobial,Tumor active peptide,,,,,,,"Granted Patent Family: 6s / 6ex; Family Jurisdictions: EP, IL, AU, US, AT, DEUS, EP, CN, WO; Legal Status:   Active; Application No: 201716462586; Filed:Nov 21, 2017; Published: Mar 12, 2020; Earliest Priority: Nov 21, 2016; Granted: Mar 29, 2022",0,LKKWWKTVKGLLGGLLGKVTSVIK
LKKWWKXXKGLLGGLLGKVXXVIK,24,Synthetic construct,Synthetic peptide,,,,,,Anticancer; Antimicrobial,Tumor active peptide,,,,,,X(7/20/21)=Xaa is hydrophobic amino acid; X(8)=Xaa is hydrophobic amino acid ,"Granted Patent Family: 6s / 6ex; Family Jurisdictions: EP, IL, AU, US, AT, DEUS, EP, CN, WO; Legal Status:   Active; Application No: 201716462586; Filed:Nov 21, 2017; Published: Mar 12, 2020; Earliest Priority: Nov 21, 2016; Granted: Mar 29, 2022",0,LKKWWKXXKGLLGGLLGKVXXVIK
LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLLPRTES,37,Synthetic construct,Synthetic peptide,,,,,,Anticancer; Antimicrobial,Tumor active peptide,,,,,,,"Granted Patent Family: 6s / 6ex; Family Jurisdictions: EP, IL, AU, US, AT, DEUS, EP, CN, WO; Legal Status:   Active; Application No: 201716462586; Filed:Nov 21, 2017; Published: Mar 12, 2020; Earliest Priority: Nov 21, 2016; Granted: Mar 29, 2022",0,LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLLPRTES
RRWVRRVRRVWRRVVRVVRRWVRR,24,Synthetic construct,Synthetic peptide,,,,,,Anticancer; Antimicrobial,Tumor active peptide,,Linear,,,,,"Granted Patent Family: 6s / 6ex; Family Jurisdictions: EP, IL, AU, US, AT, DEUS, EP, CN, WO; Legal Status:   Active; Application No: 201716462586; Filed:Nov 21, 2017; Published: Mar 12, 2020; Earliest Priority: Nov 21, 2016; Granted: Mar 29, 2022",0,RRWVRRVRRVWRRVVRVVRRWVRR
RRWVRRvRRVWRRVvRvVRRWvRR,24,Synthetic construct,Synthetic peptide,,,,,,Anticancer; Antimicrobial,Tumor active peptide,,Linear,,,,,"Granted Patent Family: 6s / 6ex; Family Jurisdictions: EP, IL, AU, US, AT, DEUS, EP, CN, WO; Legal Status:   Active; Application No: 201716462586; Filed:Nov 21, 2017; Published: Mar 12, 2020; Earliest Priority: Nov 21, 2016; Granted: Mar 29, 2022",0,RRWVRRVRRVWRRVVRVVRRWVRR
RRWVRRvRRvWRRVvRvvRRWvRR,24,Synthetic construct,Synthetic peptide,,,,,,Anticancer; Antimicrobial,Tumor active peptide,,Linear,,,,,"Granted Patent Family: 6s / 6ex; Family Jurisdictions: EP, IL, AU, US, AT, DEUS, EP, CN, WO; Legal Status:   Active; Application No: 201716462586; Filed:Nov 21, 2017; Published: Mar 12, 2020; Earliest Priority: Nov 21, 2016; Granted: Mar 29, 2022",0,RRWVRRVRRVWRRVVRVVRRWVRR
RRWvRRvRRvWRRvvRvvRRWvRR,24,Synthetic construct,Synthetic peptide,,,,,,Anticancer; Antimicrobial,Tumor active peptide,,Linear,,,,,"Granted Patent Family: 6s / 6ex; Family Jurisdictions: EP, IL, AU, US, AT, DEUS, EP, CN, WO; Legal Status:   Active; Application No: 201716462586; Filed:Nov 21, 2017; Published: Mar 12, 2020; Earliest Priority: Nov 21, 2016; Granted: Mar 29, 2022",0,RRWVRRVRRVWRRVVRVVRRWVRR
VKKLLKKVKGWLGGLWGK,18,Synthetic construct,Synthetic peptide,,,,,,Anticancer; Antimicrobial,Tumor active peptide,,,,,,,"Granted Patent Family: 6s / 6ex; Family Jurisdictions: EP, IL, AU, US, AT, DEUS, EP, CN, WO; Legal Status:   Active; Application No: 201716462586; Filed:Nov 21, 2017; Published: Mar 12, 2020; Earliest Priority: Nov 21, 2016; Granted: Mar 29, 2022",0,VKKLLKKVKGWLGGLWGK
VWKWGKLGKLLKLGKLGK,18,Synthetic construct,Synthetic peptide,,,,,,Anticancer; Antimicrobial,Tumor active peptide,,,,,,,"Granted Patent Family: 6s / 6ex; Family Jurisdictions: EP, IL, AU, US, AT, DEUS, EP, CN, WO; Legal Status:   Active; Application No: 201716462586; Filed:Nov 21, 2017; Published: Mar 12, 2020; Earliest Priority: Nov 21, 2016; Granted: Mar 29, 2022",0,VWKWGKLGKLLKLGKLGK
XKKXXKKXKGXLGGLXGK,18,Synthetic construct,Synthetic peptide,,,,,,Anticancer; Antimicrobial,Tumor active peptide,,,,,,X=Xaa is hydrophobic amino acid ,"Granted Patent Family: 6s / 6ex; Family Jurisdictions: EP, IL, AU, US, AT, DEUS, EP, CN, WO; Legal Status:   Active; Application No: 201716462586; Filed:Nov 21, 2017; Published: Mar 12, 2020; Earliest Priority: Nov 21, 2016; Granted: Mar 29, 2022",0,XKKXXKKXKGXLGGLXGK
RNRVKLVNLXFATLREX,17,Synthetics,Synthetic peptide,,,,,,Anticancer; Antitumor,Tumor active peptide,,Linear,,Free,Free,"X=—(CH2)6—CH═CH—(CH2)3— (for the cases NS10, NS16 and Na05) links both Xs radicals in each sequence","Patent Application; Family: 8s / 8ex; Family Jurisdictions: CN, EP, CA, JP, AU, WO, US, KR; Legal Status:  Pending; Application No: 201816634067; Filed: Jul 24, 2018; Published: Jul 29, 2021; Earliest Priority: Jul 25, 2017",0,RNRVKLVNLXFATLREX
RNRVKXVNLXFATLREH,17,Synthetics,Synthetic peptide,,,,,,Anticancer; Antitumor,Tumor active peptide,,Linear,,Free,Free,"X=—(CH2)6—CH═CH—(CH2)3— (for the cases NS10, NS16 and Na05) links both Xs radicals in each sequence","Patent Application; Family: 8s / 8ex; Family Jurisdictions: CN, EP, CA, JP, AU, WO, US, KR; Legal Status:  Pending; Application No: 201816634067; Filed: Jul 24, 2018; Published: Jul 29, 2021; Earliest Priority: Jul 25, 2017",0,RNRVKXVNLXFATLREH
RRRRRRRRVKLVNLXFATLREXVP,24,Synthetics,Synthetic peptide,,,,,,Anticancer; Antitumor,Tumor active peptide,,Linear,,Free,Free,"X=—(CH2)6—CH═CH—(CH2)3— (for the cases NS10, NS16 and Na05) links both Xs radicals in each sequence","Patent Application; Family: 8s / 8ex; Family Jurisdictions: CN, EP, CA, JP, AU, WO, US, KR; Legal Status:  Pending; Application No: 201816634067; Filed: Jul 24, 2018; Published: Jul 29, 2021; Earliest Priority: Jul 25, 2017",0,RRRRRRRRVKLVNLXFATLREXVP
RVKLVNLXFAALREXVP,17,Synthetics,Synthetic peptide,,,,,,Anticancer; Antitumor,Tumor active peptide,,Linear,,Free,Free,"X=—(CH2)6—CH═CH—(CH2)3— (for the cases NS10, NS16 and Na05) links both Xs radicals in each sequence","Patent Application; Family: 8s / 8ex; Family Jurisdictions: CN, EP, CA, JP, AU, WO, US, KR; Legal Status:  Pending; Application No: 201816634067; Filed: Jul 24, 2018; Published: Jul 29, 2021; Earliest Priority: Jul 25, 2017",0,RVKLVNLXFAALREXVP
RVKLVNLXFATLRAXVP,17,Synthetics,Synthetic peptide,,,,,,Anticancer; Antitumor,Tumor active peptide,,Linear,,Free,Free,"X=—(CH2)6—CH═CH—(CH2)3— (for the cases NS10, NS16 and Na05) links both Xs radicals in each sequence","Patent Application; Family: 8s / 8ex; Family Jurisdictions: CN, EP, CA, JP, AU, WO, US, KR; Legal Status:  Pending; Application No: 201816634067; Filed: Jul 24, 2018; Published: Jul 29, 2021; Earliest Priority: Jul 25, 2017",0,RVKLVNLXFATLRAXVP
RVKLVNLXFATLREXVF,17,Synthetics,Synthetic peptide,,,,,,Anticancer; Antitumor,Tumor active peptide,,Linear,,Free,Free,"X=—(CH2)6—CH═CH—(CH2)3— (for the cases NS10, NS16 and Na05) links both Xs radicals in each sequence","Patent Application; Family: 8s / 8ex; Family Jurisdictions: CN, EP, CA, JP, AU, WO, US, KR; Legal Status:  Pending; Application No: 201816634067; Filed: Jul 24, 2018; Published: Jul 29, 2021; Earliest Priority: Jul 25, 2017",0,RVKLVNLXFATLREXVF
RVKLVNLXFATLREXVP,17,Synthetics,Synthetic peptide,,,,,,Anticancer; Antitumor,Tumor active peptide,,Linear,,Free,Free,"X=—(CH2)6—CH═CH—(CH2)3— (for the cases NS10, NS16 and Na05) links both Xs radicals in each sequence","Patent Application; Family: 8s / 8ex; Family Jurisdictions: CN, EP, CA, JP, AU, WO, US, KR; Legal Status:  Pending; Application No: 201816634067; Filed: Jul 24, 2018; Published: Jul 29, 2021; Earliest Priority: Jul 25, 2017",0,RVKLVNLXFATLREXVP
RVKLVNLXFATLREXVQ,17,Synthetics,Synthetic peptide,,,,,,Anticancer; Antitumor,Tumor active peptide,,Linear,,Free,Free,"X=—(CH2)6—CH═CH—(CH2)3— (for the cases NS10, NS16 and Na05) links both Xs radicals in each sequence","Patent Application; Family: 8s / 8ex; Family Jurisdictions: CN, EP, CA, JP, AU, WO, US, KR; Legal Status:  Pending; Application No: 201816634067; Filed: Jul 24, 2018; Published: Jul 29, 2021; Earliest Priority: Jul 25, 2017",0,RVKLVNLXFATLREXVQ
RVKLVNLXFATLREXVS,17,Synthetics,Synthetic peptide,,,,,,Anticancer; Antitumor,Tumor active peptide,,Linear,,Free,Free,"X=—(CH2)6—CH═CH—(CH2)3— (for the cases NS10, NS16 and Na05) links both Xs radicals in each sequence","Patent Application; Family: 8s / 8ex; Family Jurisdictions: CN, EP, CA, JP, AU, WO, US, KR; Legal Status:  Pending; Application No: 201816634067; Filed: Jul 24, 2018; Published: Jul 29, 2021; Earliest Priority: Jul 25, 2017",0,RVKLVNLXFATLREXVS
RVKLVNLXFATLRFXVP,17,Synthetics,Synthetic peptide,,,,,,Anticancer; Antitumor,Tumor active peptide,,Linear,,Free,Free,"X=—(CH2)6—CH═CH—(CH2)3— (for the cases NS10, NS16 and Na05) links both Xs radicals in each sequence","Patent Application; Family: 8s / 8ex; Family Jurisdictions: CN, EP, CA, JP, AU, WO, US, KR; Legal Status:  Pending; Application No: 201816634067; Filed: Jul 24, 2018; Published: Jul 29, 2021; Earliest Priority: Jul 25, 2017",0,RVKLVNLXFATLRFXVP
RVKLVNLXFATLRQXVP,17,Synthetics,Synthetic peptide,,,,,,Anticancer; Antitumor,Tumor active peptide,,Linear,,Free,Free,"X=—(CH2)6—CH═CH—(CH2)3— (for the cases NS10, NS16 and Na05) links both Xs radicals in each sequence","Patent Application; Family: 8s / 8ex; Family Jurisdictions: CN, EP, CA, JP, AU, WO, US, KR; Legal Status:  Pending; Application No: 201816634067; Filed: Jul 24, 2018; Published: Jul 29, 2021; Earliest Priority: Jul 25, 2017",0,RVKLVNLXFATLRQXVP
RVKLVNLXFQALRQXVP,17,Synthetics,Synthetic peptide,,,,,,Anticancer; Antitumor,Tumor active peptide,,Linear,,Free,Free,"X=—(CH2)6—CH═CH—(CH2)3— (for the cases NS10, NS16 and Na05) links both Xs radicals in each sequence","Patent Application; Family: 8s / 8ex; Family Jurisdictions: CN, EP, CA, JP, AU, WO, US, KR; Legal Status:  Pending; Application No: 201816634067; Filed: Jul 24, 2018; Published: Jul 29, 2021; Earliest Priority: Jul 25, 2017",0,RVKLVNLXFQALRQXVP
RVKLVNLXFQTLREXVP,17,Synthetics,Synthetic peptide,,,,,,Anticancer; Antitumor,Tumor active peptide,,Linear,,Free,Free,"X=—(CH2)6—CH═CH—(CH2)3— (for the cases NS10, NS16 and Na05) links both Xs radicals in each sequence","Patent Application; Family: 8s / 8ex; Family Jurisdictions: CN, EP, CA, JP, AU, WO, US, KR; Legal Status:  Pending; Application No: 201816634067; Filed: Jul 24, 2018; Published: Jul 29, 2021; Earliest Priority: Jul 25, 2017",0,RVKLVNLXFQTLREXVP
RVKLVQLXFATLREXVP,17,Synthetics,Synthetic peptide,,,,,,Anticancer; Antitumor,Tumor active peptide,,Linear,,Free,Free,"X=—(CH2)6—CH═CH—(CH2)3— (for the cases NS10, NS16 and Na05) links both Xs radicals in each sequence","Patent Application; Family: 8s / 8ex; Family Jurisdictions: CN, EP, CA, JP, AU, WO, US, KR; Legal Status:  Pending; Application No: 201816634067; Filed: Jul 24, 2018; Published: Jul 29, 2021; Earliest Priority: Jul 25, 2017",0,RVKLVQLXFATLREXVP
SASRALSDKPLAHVVANPQVEGQLQWL,27,Synthetic construct,Native peptide,,,,,,Antitumor,Tumor active peptide,,,,,,,"Granted Patent Family: 8s / 8ex; Family Jurisdictions: EP, JP, US, DE; Legal Status:   Expired; Application No: 62985384; Filed: Jul 11, 1984; Published: Jul 16, 1985; Earliest Priority: Jul 15, 1983; Granted: Jul 16, 1985",0,SASRALSDKPLAHVVANPQVEGQLQWL
XIXPPVF,7,Synthetic construct,Native peptide,,,,,,Antitumor,Tumor active peptide,,Linear,,,,X=Xaa,"Granted Patent Family: 92s / 92ex; Family Jurisdictions: AU, BR, EP, DK, RO, KR, SI, JP, CA, HU, CZ, DE, NZ, AT, NO, AR, MX, WO, SK, IL, CO, BG, MY, UA, PL, TR, ES, CN, PT, HR, TW, ZA, US; Legal Status:   Expired; Application No: 47245395; Filed:Jun 7, 1995; Published: Nov 3, 1998; Earliest Priority: May 20, 1992; Granted: Nov 3, 1998",0,XIXPPVF
XIXPX,5,Synthetic construct,Native peptide,,,,,,Antitumor,Tumor active peptide,,Linear,,,,X=Xaa,"Granted Patent Family: 92s / 92ex; Family Jurisdictions: AU, BR, EP, DK, RO, KR, SI, JP, CA, HU, CZ, DE, NZ, AT, NO, AR, MX, WO, SK, IL, CO, BG, MY, UA, PL, TR, ES, CN, PT, HR, TW, ZA, US; Legal Status:   Expired; Application No: 47245395; Filed:Jun 7, 1995; Published: Nov 3, 1998; Earliest Priority: May 20, 1992; Granted: Nov 3, 1998",0,XIXPX
XKXPP,5,Synthetic construct,Native peptide,,,,,,Antitumor,Tumor active peptide,,Linear,,,,X=Xaa,"Granted Patent Family: 92s / 92ex; Family Jurisdictions: AU, BR, EP, DK, RO, KR, SI, JP, CA, HU, CZ, DE, NZ, AT, NO, AR, MX, WO, SK, IL, CO, BG, MY, UA, PL, TR, ES, CN, PT, HR, TW, ZA, US; Legal Status:   Expired; Application No: 47245395; Filed:Jun 7, 1995; Published: Nov 3, 1998; Earliest Priority: May 20, 1992; Granted: Nov 3, 1998",0,XKXPP
XKXPPV,6,Synthetic construct,Native peptide,,,,,,Antitumor,Tumor active peptide,,Linear,,,,X=Xaa,"Granted Patent Family: 92s / 92ex; Family Jurisdictions: AU, BR, EP, DK, RO, KR, SI, JP, CA, HU, CZ, DE, NZ, AT, NO, AR, MX, WO, SK, IL, CO, BG, MY, UA, PL, TR, ES, CN, PT, HR, TW, ZA, US; Legal Status:   Expired; Application No: 47245395; Filed:Jun 7, 1995; Published: Nov 3, 1998; Earliest Priority: May 20, 1992; Granted: Nov 3, 1998",0,XKXPPV
XKXPPVF,7,Synthetic construct,Native peptide,,,,,,Antitumor,Tumor active peptide,,Linear,,,,X=Xaa,"Granted Patent Family: 92s / 92ex; Family Jurisdictions: AU, BR, EP, DK, RO, KR, SI, JP, CA, HU, CZ, DE, NZ, AT, NO, AR, MX, WO, SK, IL, CO, BG, MY, UA, PL, TR, ES, CN, PT, HR, TW, ZA, US; Legal Status:   Expired; Application No: 47245395; Filed:Jun 7, 1995; Published: Nov 3, 1998; Earliest Priority: May 20, 1992; Granted: Nov 3, 1998",0,XKXPPVF
XKXPX,5,Synthetic construct,Native peptide,,,,,,Antitumor,Tumor active peptide,,Linear,,,,X=Xaa,"Granted Patent Family: 92s / 92ex; Family Jurisdictions: AU, BR, EP, DK, RO, KR, SI, JP, CA, HU, CZ, DE, NZ, AT, NO, AR, MX, WO, SK, IL, CO, BG, MY, UA, PL, TR, ES, CN, PT, HR, TW, ZA, US; Legal Status:   Expired; Application No: 47245395; Filed:Jun 7, 1995; Published: Nov 3, 1998; Earliest Priority: May 20, 1992; Granted: Nov 3, 1998",0,XKXPX
XLXPPVF,7,Synthetic construct,Native peptide,,,,,,Antitumor,Tumor active peptide,,Linear,,,,X=Xaa,"Granted Patent Family: 92s / 92ex; Family Jurisdictions: AU, BR, EP, DK, RO, KR, SI, JP, CA, HU, CZ, DE, NZ, AT, NO, AR, MX, WO, SK, IL, CO, BG, MY, UA, PL, TR, ES, CN, PT, HR, TW, ZA, US; Legal Status:   Expired; Application No: 47245395; Filed:Jun 7, 1995; Published: Nov 3, 1998; Earliest Priority: May 20, 1992; Granted: Nov 3, 1998",0,XLXPPVF
XLXPPX,6,Synthetic construct,Native peptide,,,,,,Antitumor,Tumor active peptide,,Linear,,,,X=Xaa,"Granted Patent Family: 92s / 92ex; Family Jurisdictions: AU, BR, EP, DK, RO, KR, SI, JP, CA, HU, CZ, DE, NZ, AT, NO, AR, MX, WO, SK, IL, CO, BG, MY, UA, PL, TR, ES, CN, PT, HR, TW, ZA, US; Legal Status:   Expired; Application No: 47245395; Filed:Jun 7, 1995; Published: Nov 3, 1998; Earliest Priority: May 20, 1992; Granted: Nov 3, 1998",0,XLXPPX
XVPP,4,Synthetic construct,Native peptide,,,,,,Antitumor,Tumor active peptide,,Linear,,,,X=Xaa,"Granted Patent Family: 92s / 92ex; Family Jurisdictions: AU, BR, EP, DK, RO, KR, SI, JP, CA, HU, CZ, DE, NZ, AT, NO, AR, MX, WO, SK, IL, CO, BG, MY, UA, PL, TR, ES, CN, PT, HR, TW, ZA, US; Legal Status:   Expired; Application No: 47245395; Filed:Jun 7, 1995; Published: Nov 3, 1998; Earliest Priority: May 20, 1992; Granted: Nov 3, 1998",0,XVPP
XVPPVF,6,Synthetic construct,Native peptide,,,,,,Antitumor,Tumor active peptide,,Linear,,,,X=Xaa,"Granted Patent Family: 92s / 92ex; Family Jurisdictions: AU, BR, EP, DK, RO, KR, SI, JP, CA, HU, CZ, DE, NZ, AT, NO, AR, MX, WO, SK, IL, CO, BG, MY, UA, PL, TR, ES, CN, PT, HR, TW, ZA, US; Legal Status:   Expired; Application No: 47245395; Filed:Jun 7, 1995; Published: Nov 3, 1998; Earliest Priority: May 20, 1992; Granted: Nov 3, 1998",0,XVPPVF
XVXP,4,Synthetic construct,Native peptide,,,,,,Antitumor,Tumor active peptide,,Linear,,,,X=Xaa,"Granted Patent Family: 92s / 92ex; Family Jurisdictions: AU, BR, EP, DK, RO, KR, SI, JP, CA, HU, CZ, DE, NZ, AT, NO, AR, MX, WO, SK, IL, CO, BG, MY, UA, PL, TR, ES, CN, PT, HR, TW, ZA, US; Legal Status:   Expired; Application No: 47245395; Filed:Jun 7, 1995; Published: Nov 3, 1998; Earliest Priority: May 20, 1992; Granted: Nov 3, 1998",0,XVXP
XVXPPFF,7,Synthetic construct,Native peptide,,,,,,Antitumor,Tumor active peptide,,Linear,,,,X=Xaa,"Granted Patent Family: 92s / 92ex; Family Jurisdictions: AU, BR, EP, DK, RO, KR, SI, JP, CA, HU, CZ, DE, NZ, AT, NO, AR, MX, WO, SK, IL, CO, BG, MY, UA, PL, TR, ES, CN, PT, HR, TW, ZA, US; Legal Status:   Expired; Application No: 47245395; Filed:Jun 7, 1995; Published: Nov 3, 1998; Earliest Priority: May 20, 1992; Granted: Nov 3, 1998",0,XVXPPFF
XVXPPI,6,Synthetic construct,Native peptide,,,,,,Antitumor,Tumor active peptide,,Linear,,,,X=Xaa,"Granted Patent Family: 92s / 92ex; Family Jurisdictions: AU, BR, EP, DK, RO, KR, SI, JP, CA, HU, CZ, DE, NZ, AT, NO, AR, MX, WO, SK, IL, CO, BG, MY, UA, PL, TR, ES, CN, PT, HR, TW, ZA, US; Legal Status:   Expired; Application No: 47245395; Filed:Jun 7, 1995; Published: Nov 3, 1998; Earliest Priority: May 20, 1992; Granted: Nov 3, 1998",0,XVXPPI
XVXPPIF,7,Synthetic construct,Native peptide,,,,,,Antitumor,Tumor active peptide,,Linear,,,,X=Xaa,"Granted Patent Family: 92s / 92ex; Family Jurisdictions: AU, BR, EP, DK, RO, KR, SI, JP, CA, HU, CZ, DE, NZ, AT, NO, AR, MX, WO, SK, IL, CO, BG, MY, UA, PL, TR, ES, CN, PT, HR, TW, ZA, US; Legal Status:   Expired; Application No: 47245395; Filed:Jun 7, 1995; Published: Nov 3, 1998; Earliest Priority: May 20, 1992; Granted: Nov 3, 1998",0,XVXPPIF
XVXPPL,6,Synthetic construct,Native peptide,,,,,,Antitumor,Tumor active peptide,,Linear,,,,X=Xaa,"Granted Patent Family: 92s / 92ex; Family Jurisdictions: AU, BR, EP, DK, RO, KR, SI, JP, CA, HU, CZ, DE, NZ, AT, NO, AR, MX, WO, SK, IL, CO, BG, MY, UA, PL, TR, ES, CN, PT, HR, TW, ZA, US; Legal Status:   Expired; Application No: 47245395; Filed:Jun 7, 1995; Published: Nov 3, 1998; Earliest Priority: May 20, 1992; Granted: Nov 3, 1998",0,XVXPPL
XVXPPLF,7,Synthetic construct,Native peptide,,,,,,Antitumor,Tumor active peptide,,Linear,,,,X=Xaa,"Granted Patent Family: 92s / 92ex; Family Jurisdictions: AU, BR, EP, DK, RO, KR, SI, JP, CA, HU, CZ, DE, NZ, AT, NO, AR, MX, WO, SK, IL, CO, BG, MY, UA, PL, TR, ES, CN, PT, HR, TW, ZA, US; Legal Status:   Expired; Application No: 47245395; Filed:Jun 7, 1995; Published: Nov 3, 1998; Earliest Priority: May 20, 1992; Granted: Nov 3, 1998",0,XVXPPLF
XVXPPV,6,Synthetic construct,Native peptide,,,,,,Antitumor,Tumor active peptide,,Linear,,,,X=Xaa,"Granted Patent Family: 92s / 92ex; Family Jurisdictions: AU, BR, EP, DK, RO, KR, SI, JP, CA, HU, CZ, DE, NZ, AT, NO, AR, MX, WO, SK, IL, CO, BG, MY, UA, PL, TR, ES, CN, PT, HR, TW, ZA, US; Legal Status:   Expired; Application No: 47245395; Filed:Jun 7, 1995; Published: Nov 3, 1998; Earliest Priority: May 20, 1992; Granted: Nov 3, 1998",0,XVXPPV
XVXPPVA,7,Synthetic construct,Native peptide,,,,,,Antitumor,Tumor active peptide,,Linear,,,,X=Xaa,"Granted Patent Family: 92s / 92ex; Family Jurisdictions: AU, BR, EP, DK, RO, KR, SI, JP, CA, HU, CZ, DE, NZ, AT, NO, AR, MX, WO, SK, IL, CO, BG, MY, UA, PL, TR, ES, CN, PT, HR, TW, ZA, US; Legal Status:   Expired; Application No: 47245395; Filed:Jun 7, 1995; Published: Nov 3, 1998; Earliest Priority: May 20, 1992; Granted: Nov 3, 1998",0,XVXPPVA
XVXPPVF,7,Synthetic construct,Native peptide,,,,,,Antitumor,Tumor active peptide,,Linear,,,,X=Xaa,"Granted Patent Family: 92s / 92ex; Family Jurisdictions: AU, BR, EP, DK, RO, KR, SI, JP, CA, HU, CZ, DE, NZ, AT, NO, AR, MX, WO, SK, IL, CO, BG, MY, UA, PL, TR, ES, CN, PT, HR, TW, ZA, US; Legal Status:   Expired; Application No: 47245395; Filed:Jun 7, 1995; Published: Nov 3, 1998; Earliest Priority: May 20, 1992; Granted: Nov 3, 1998",0,XVXPPVF
XVXPPVH,7,Synthetic construct,Native peptide,,,,,,Antitumor,Tumor active peptide,,Linear,,,,X=Xaa,"Granted Patent Family: 92s / 92ex; Family Jurisdictions: AU, BR, EP, DK, RO, KR, SI, JP, CA, HU, CZ, DE, NZ, AT, NO, AR, MX, WO, SK, IL, CO, BG, MY, UA, PL, TR, ES, CN, PT, HR, TW, ZA, US; Legal Status:   Expired; Application No: 47245395; Filed:Jun 7, 1995; Published: Nov 3, 1998; Earliest Priority: May 20, 1992; Granted: Nov 3, 1998",0,XVXPPVH
XVXPPVK,7,Synthetic construct,Native peptide,,,,,,Antitumor,Tumor active peptide,,Linear,,,,X=Xaa,"Granted Patent Family: 92s / 92ex; Family Jurisdictions: AU, BR, EP, DK, RO, KR, SI, JP, CA, HU, CZ, DE, NZ, AT, NO, AR, MX, WO, SK, IL, CO, BG, MY, UA, PL, TR, ES, CN, PT, HR, TW, ZA, US; Legal Status:   Expired; Application No: 47245395; Filed:Jun 7, 1995; Published: Nov 3, 1998; Earliest Priority: May 20, 1992; Granted: Nov 3, 1998",0,XVXPPVK
XVXPPVX,7,Synthetic construct,Native peptide,,,,,,Antitumor,Tumor active peptide,,Linear,,,,X=Xaa,"Granted Patent Family: 92s / 92ex; Family Jurisdictions: AU, BR, EP, DK, RO, KR, SI, JP, CA, HU, CZ, DE, NZ, AT, NO, AR, MX, WO, SK, IL, CO, BG, MY, UA, PL, TR, ES, CN, PT, HR, TW, ZA, US; Legal Status:   Expired; Application No: 47245395; Filed:Jun 7, 1995; Published: Nov 3, 1998; Earliest Priority: May 20, 1992; Granted: Nov 3, 1998",0,XVXPPVX
XVXPPVY,7,Synthetic construct,Native peptide,,,,,,Antitumor,Tumor active peptide,,Linear,,,,X=Xaa,"Granted Patent Family: 92s / 92ex; Family Jurisdictions: AU, BR, EP, DK, RO, KR, SI, JP, CA, HU, CZ, DE, NZ, AT, NO, AR, MX, WO, SK, IL, CO, BG, MY, UA, PL, TR, ES, CN, PT, HR, TW, ZA, US; Legal Status:   Expired; Application No: 47245395; Filed:Jun 7, 1995; Published: Nov 3, 1998; Earliest Priority: May 20, 1992; Granted: Nov 3, 1998",0,XVXPPVY
XVXPPX,6,Synthetic construct,Native peptide,,,,,,Antitumor,Tumor active peptide,,Linear,,,,X=Xaa,"Granted Patent Family: 92s / 92ex; Family Jurisdictions: AU, BR, EP, DK, RO, KR, SI, JP, CA, HU, CZ, DE, NZ, AT, NO, AR, MX, WO, SK, IL, CO, BG, MY, UA, PL, TR, ES, CN, PT, HR, TW, ZA, US; Legal Status:   Expired; Application No: 47245395; Filed:Jun 7, 1995; Published: Nov 3, 1998; Earliest Priority: May 20, 1992; Granted: Nov 3, 1998",0,XVXPPX
XVXPPXF,7,Synthetic construct,Native peptide,,,,,,Antitumor,Tumor active peptide,,Linear,,,,X=Xaa,"Granted Patent Family: 92s / 92ex; Family Jurisdictions: AU, BR, EP, DK, RO, KR, SI, JP, CA, HU, CZ, DE, NZ, AT, NO, AR, MX, WO, SK, IL, CO, BG, MY, UA, PL, TR, ES, CN, PT, HR, TW, ZA, US; Legal Status:   Expired; Application No: 47245395; Filed:Jun 7, 1995; Published: Nov 3, 1998; Earliest Priority: May 20, 1992; Granted: Nov 3, 1998",0,XVXPPXF
XVXPPXX,7,Synthetic construct,Native peptide,,,,,,Antitumor,Tumor active peptide,,Linear,,,,X=Xaa,"Granted Patent Family: 92s / 92ex; Family Jurisdictions: AU, BR, EP, DK, RO, KR, SI, JP, CA, HU, CZ, DE, NZ, AT, NO, AR, MX, WO, SK, IL, CO, BG, MY, UA, PL, TR, ES, CN, PT, HR, TW, ZA, US; Legal Status:   Expired; Application No: 47245395; Filed:Jun 7, 1995; Published: Nov 3, 1998; Earliest Priority: May 20, 1992; Granted: Nov 3, 1998",0,XVXPPXX
XVXPX,5,Synthetic construct,Native peptide,,,,,,Antitumor,Tumor active peptide,,Linear,,,,X=Xaa,"Granted Patent Family: 92s / 92ex; Family Jurisdictions: AU, BR, EP, DK, RO, KR, SI, JP, CA, HU, CZ, DE, NZ, AT, NO, AR, MX, WO, SK, IL, CO, BG, MY, UA, PL, TR, ES, CN, PT, HR, TW, ZA, US; Legal Status:   Expired; Application No: 47245395; Filed:Jun 7, 1995; Published: Nov 3, 1998; Earliest Priority: May 20, 1992; Granted: Nov 3, 1998",0,XVXPX
XVXPXF,6,Synthetic construct,Native peptide,,,,,,Antitumor,Tumor active peptide,,Linear,,,,X=Xaa,"Granted Patent Family: 92s / 92ex; Family Jurisdictions: AU, BR, EP, DK, RO, KR, SI, JP, CA, HU, CZ, DE, NZ, AT, NO, AR, MX, WO, SK, IL, CO, BG, MY, UA, PL, TR, ES, CN, PT, HR, TW, ZA, US; Legal Status:   Expired; Application No: 47245395; Filed:Jun 7, 1995; Published: Nov 3, 1998; Earliest Priority: May 20, 1992; Granted: Nov 3, 1998",0,XVXPXF
XVXPXLF,7,Synthetic construct,Native peptide,,,,,,Antitumor,Tumor active peptide,,Linear,,,,X=Xaa,"Granted Patent Family: 92s / 92ex; Family Jurisdictions: AU, BR, EP, DK, RO, KR, SI, JP, CA, HU, CZ, DE, NZ, AT, NO, AR, MX, WO, SK, IL, CO, BG, MY, UA, PL, TR, ES, CN, PT, HR, TW, ZA, US; Legal Status:   Expired; Application No: 47245395; Filed:Jun 7, 1995; Published: Nov 3, 1998; Earliest Priority: May 20, 1992; Granted: Nov 3, 1998",0,XVXPXLF
XVXPXV,6,Synthetic construct,Native peptide,,,,,,Antitumor,Tumor active peptide,,Linear,,,,X=Xaa,"Granted Patent Family: 92s / 92ex; Family Jurisdictions: AU, BR, EP, DK, RO, KR, SI, JP, CA, HU, CZ, DE, NZ, AT, NO, AR, MX, WO, SK, IL, CO, BG, MY, UA, PL, TR, ES, CN, PT, HR, TW, ZA, US; Legal Status:   Expired; Application No: 47245395; Filed:Jun 7, 1995; Published: Nov 3, 1998; Earliest Priority: May 20, 1992; Granted: Nov 3, 1998",0,XVXPXV
XVXPXVF,7,Synthetic construct,Native peptide,,,,,,Antitumor,Tumor active peptide,,Linear,,,,X=Xaa,"Granted Patent Family: 92s / 92ex; Family Jurisdictions: AU, BR, EP, DK, RO, KR, SI, JP, CA, HU, CZ, DE, NZ, AT, NO, AR, MX, WO, SK, IL, CO, BG, MY, UA, PL, TR, ES, CN, PT, HR, TW, ZA, US; Legal Status:   Expired; Application No: 47245395; Filed:Jun 7, 1995; Published: Nov 3, 1998; Earliest Priority: May 20, 1992; Granted: Nov 3, 1998",0,XVXPXVF
XVXPXX,6,Synthetic construct,Native peptide,,,,,,Antitumor,Tumor active peptide,,Linear,,,,X=Xaa,"Granted Patent Family: 92s / 92ex; Family Jurisdictions: AU, BR, EP, DK, RO, KR, SI, JP, CA, HU, CZ, DE, NZ, AT, NO, AR, MX, WO, SK, IL, CO, BG, MY, UA, PL, TR, ES, CN, PT, HR, TW, ZA, US; Legal Status:   Expired; Application No: 47245395; Filed:Jun 7, 1995; Published: Nov 3, 1998; Earliest Priority: May 20, 1992; Granted: Nov 3, 1998",0,XVXPXX
XVXX,4,Synthetic construct,Native peptide,,,,,,Antitumor,Tumor active peptide,,Linear,,,,X=Xaa,"Granted Patent Family: 92s / 92ex; Family Jurisdictions: AU, BR, EP, DK, RO, KR, SI, JP, CA, HU, CZ, DE, NZ, AT, NO, AR, MX, WO, SK, IL, CO, BG, MY, UA, PL, TR, ES, CN, PT, HR, TW, ZA, US; Legal Status:   Expired; Application No: 47245395; Filed:Jun 7, 1995; Published: Nov 3, 1998; Earliest Priority: May 20, 1992; Granted: Nov 3, 1998",0,XVXX
XVXXPV,6,Synthetic construct,Native peptide,,,,,,Antitumor,Tumor active peptide,,Linear,,,,X=Xaa,"Granted Patent Family: 92s / 92ex; Family Jurisdictions: AU, BR, EP, DK, RO, KR, SI, JP, CA, HU, CZ, DE, NZ, AT, NO, AR, MX, WO, SK, IL, CO, BG, MY, UA, PL, TR, ES, CN, PT, HR, TW, ZA, US; Legal Status:   Expired; Application No: 47245395; Filed:Jun 7, 1995; Published: Nov 3, 1998; Earliest Priority: May 20, 1992; Granted: Nov 3, 1998",0,XVXXPV
XVXXPVF,7,Synthetic construct,Native peptide,,,,,,Antitumor,Tumor active peptide,,Linear,,,,X=Xaa,"Granted Patent Family: 92s / 92ex; Family Jurisdictions: AU, BR, EP, DK, RO, KR, SI, JP, CA, HU, CZ, DE, NZ, AT, NO, AR, MX, WO, SK, IL, CO, BG, MY, UA, PL, TR, ES, CN, PT, HR, TW, ZA, US; Legal Status:   Expired; Application No: 47245395; Filed:Jun 7, 1995; Published: Nov 3, 1998; Earliest Priority: May 20, 1992; Granted: Nov 3, 1998",0,XVXXPVF
XXPP,4,Synthetic construct,Native peptide,,,,,,Antitumor,Tumor active peptide,,Linear,,,,X=Xaa,"Granted Patent Family: 92s / 92ex; Family Jurisdictions: AU, BR, EP, DK, RO, KR, SI, JP, CA, HU, CZ, DE, NZ, AT, NO, AR, MX, WO, SK, IL, CO, BG, MY, UA, PL, TR, ES, CN, PT, HR, TW, ZA, US; Legal Status:   Expired; Application No: 47245395; Filed:Jun 7, 1995; Published: Nov 3, 1998; Earliest Priority: May 20, 1992; Granted: Nov 3, 1998",0,XXPP
XXPPV,5,Synthetic construct,Native peptide,,,,,,Antitumor,Tumor active peptide,,Linear,,,,X=Xaa,"Granted Patent Family: 92s / 92ex; Family Jurisdictions: AU, BR, EP, DK, RO, KR, SI, JP, CA, HU, CZ, DE, NZ, AT, NO, AR, MX, WO, SK, IL, CO, BG, MY, UA, PL, TR, ES, CN, PT, HR, TW, ZA, US; Legal Status:   Expired; Application No: 47245395; Filed:Jun 7, 1995; Published: Nov 3, 1998; Earliest Priority: May 20, 1992; Granted: Nov 3, 1998",0,XXPPV
XXPPVF,6,Synthetic construct,Native peptide,,,,,,Antitumor,Tumor active peptide,,Linear,,,,X=Xaa,"Granted Patent Family: 92s / 92ex; Family Jurisdictions: AU, BR, EP, DK, RO, KR, SI, JP, CA, HU, CZ, DE, NZ, AT, NO, AR, MX, WO, SK, IL, CO, BG, MY, UA, PL, TR, ES, CN, PT, HR, TW, ZA, US; Legal Status:   Expired; Application No: 47245395; Filed:Jun 7, 1995; Published: Nov 3, 1998; Earliest Priority: May 20, 1992; Granted: Nov 3, 1998",0,XXPPVF
XXPPX,5,Synthetic construct,Native peptide,,,,,,Antitumor,Tumor active peptide,,Linear,,,,X=Xaa,"Granted Patent Family: 92s / 92ex; Family Jurisdictions: AU, BR, EP, DK, RO, KR, SI, JP, CA, HU, CZ, DE, NZ, AT, NO, AR, MX, WO, SK, IL, CO, BG, MY, UA, PL, TR, ES, CN, PT, HR, TW, ZA, US; Legal Status:   Expired; Application No: 47245395; Filed:Jun 7, 1995; Published: Nov 3, 1998; Earliest Priority: May 20, 1992; Granted: Nov 3, 1998",0,XXPPX
XXPX,4,Synthetic construct,Native peptide,,,,,,Antitumor,Tumor active peptide,,Linear,,,,X=Xaa,"Granted Patent Family: 92s / 92ex; Family Jurisdictions: AU, BR, EP, DK, RO, KR, SI, JP, CA, HU, CZ, DE, NZ, AT, NO, AR, MX, WO, SK, IL, CO, BG, MY, UA, PL, TR, ES, CN, PT, HR, TW, ZA, US; Legal Status:   Expired; Application No: 47245395; Filed:Jun 7, 1995; Published: Nov 3, 1998; Earliest Priority: May 20, 1992; Granted: Nov 3, 1998",0,XXPX
XXPXF,5,Synthetic construct,Native peptide,,,,,,Antitumor,Tumor active peptide,,Linear,,,,X=Xaa,"Granted Patent Family: 92s / 92ex; Family Jurisdictions: AU, BR, EP, DK, RO, KR, SI, JP, CA, HU, CZ, DE, NZ, AT, NO, AR, MX, WO, SK, IL, CO, BG, MY, UA, PL, TR, ES, CN, PT, HR, TW, ZA, US; Legal Status:   Expired; Application No: 47245395; Filed:Jun 7, 1995; Published: Nov 3, 1998; Earliest Priority: May 20, 1992; Granted: Nov 3, 1998",0,XXPXF
XXXPP,5,Synthetic construct,Native peptide,,,,,,Antitumor,Tumor active peptide,,Linear,,,,X=Xaa,"Granted Patent Family: 92s / 92ex; Family Jurisdictions: AU, BR, EP, DK, RO, KR, SI, JP, CA, HU, CZ, DE, NZ, AT, NO, AR, MX, WO, SK, IL, CO, BG, MY, UA, PL, TR, ES, CN, PT, HR, TW, ZA, US; Legal Status:   Expired; Application No: 47245395; Filed:Jun 7, 1995; Published: Nov 3, 1998; Earliest Priority: May 20, 1992; Granted: Nov 3, 1998",0,XXXPP
XXXPPV,6,Synthetic construct,Native peptide,,,,,,Antitumor,Tumor active peptide,,Linear,,,,X=Xaa,"Granted Patent Family: 92s / 92ex; Family Jurisdictions: AU, BR, EP, DK, RO, KR, SI, JP, CA, HU, CZ, DE, NZ, AT, NO, AR, MX, WO, SK, IL, CO, BG, MY, UA, PL, TR, ES, CN, PT, HR, TW, ZA, US; Legal Status:   Expired; Application No: 47245395; Filed:Jun 7, 1995; Published: Nov 3, 1998; Earliest Priority: May 20, 1992; Granted: Nov 3, 1998",0,XXXPPV
XXXPPVF,7,Synthetic construct,Native peptide,,,,,,Antitumor,Tumor active peptide,,Linear,,,,X=Xaa,"Granted Patent Family: 92s / 92ex; Family Jurisdictions: AU, BR, EP, DK, RO, KR, SI, JP, CA, HU, CZ, DE, NZ, AT, NO, AR, MX, WO, SK, IL, CO, BG, MY, UA, PL, TR, ES, CN, PT, HR, TW, ZA, US; Legal Status:   Expired; Application No: 47245395; Filed:Jun 7, 1995; Published: Nov 3, 1998; Earliest Priority: May 20, 1992; Granted: Nov 3, 1998",0,XXXPPVF
XXXPPVW,7,Synthetic construct,Native peptide,,,,,,Antitumor,Tumor active peptide,,Linear,,,,X=Xaa,"Granted Patent Family: 92s / 92ex; Family Jurisdictions: AU, BR, EP, DK, RO, KR, SI, JP, CA, HU, CZ, DE, NZ, AT, NO, AR, MX, WO, SK, IL, CO, BG, MY, UA, PL, TR, ES, CN, PT, HR, TW, ZA, US; Legal Status:   Expired; Application No: 47245395; Filed:Jun 7, 1995; Published: Nov 3, 1998; Earliest Priority: May 20, 1992; Granted: Nov 3, 1998",0,XXXPPVW
XXXPX,5,Synthetic construct,Native peptide,,,,,,Antitumor,Tumor active peptide,,Linear,,,,X=Xaa,"Granted Patent Family: 92s / 92ex; Family Jurisdictions: AU, BR, EP, DK, RO, KR, SI, JP, CA, HU, CZ, DE, NZ, AT, NO, AR, MX, WO, SK, IL, CO, BG, MY, UA, PL, TR, ES, CN, PT, HR, TW, ZA, US; Legal Status:   Expired; Application No: 47245395; Filed:Jun 7, 1995; Published: Nov 3, 1998; Earliest Priority: May 20, 1992; Granted: Nov 3, 1998",0,XXXPX
FLGWLFKWASKVL,13,Synthetic construct,Synthetic peptide,,,,,,Anticancer; Antimicrobial,Tumor active peptide,,,,,,X=Xaa,"Granted Patent Family: 9s / 9ex; Family Jurisdictions: EP, KR, US, WO, JP, CN; Legal Status:   Active; Application No: 30102807; Filed:May 14, 2007; Published: Dec 13, 2011; Earliest Priority: May 16, 2006; Granted: Dec 13, 2011",0,FLGWLFKWASKVL
FLXWLFKWAXK,11,Synthetic construct,Synthetic peptide,,,,,,Anticancer; Antimicrobial,Tumor active peptide,,,,,,X=Xaa,"Granted Patent Family: 9s / 9ex; Family Jurisdictions: EP, KR, US, WO, JP, CN; Legal Status:   Active; Application No: 30102807; Filed:May 14, 2007; Published: Dec 13, 2011; Earliest Priority: May 16, 2006; Granted: Dec 13, 2011",0,FLXWLFKWAXK
KKKKKKXXKKWRKWLAKK,18,Cationic antimicrobial peptides (CAMPs),Synthetic peptide,human red blood cells: no hemolytic activity of the peptide was found even at 804 μM,"human fibroblast: When the peptide concentrations was 100μM, the Cell survival rate(%)  was 18%",,,,Anticancer,Tumor active peptide,,Linear,,Acetylization,Amidation,X=Nal=β-naphthylalanine,"Granted Patent; Family: 4s / 4ex; Family Jurisdictions: TW, US; Legal Status:  Active; Application No: 201615130709; Filed: Apr 15, 2016; Published: Oct 9, 2018; Earliest Priority: Nov 5, 2015; Granted: Oct 9, 2018",0,KKKKKKXXKKWRKWLAKK
KKKKRRXXKKWRKWLAKK,18,Cationic antimicrobial peptides (CAMPs),Synthetic peptide,human red blood cells: no hemolytic activity of the peptide was found even at 802 μM,"human fibroblast: When the peptide concentrations was 100μM, the Cell survival rate(%)  was 31%",,,,Anticancer,Tumor active peptide,,Linear,,Acetylization,Amidation,X=Nal=β-naphthylalanine,"Granted Patent; Family: 4s / 4ex; Family Jurisdictions: TW, US; Legal Status:  Active; Application No: 201615130709; Filed: Apr 15, 2016; Published: Oct 9, 2018; Earliest Priority: Nov 5, 2015; Granted: Oct 9, 2018",0,KKKKRRXXKKWRKWLAKK
KKWRKWLAK,9,Cationic antimicrobial peptides (CAMPs),Synthetic peptide,human red blood cells: no hemolytic activity of the peptide was found even at 800 μM,"human fibroblast: When the peptide concentrations was 100μM, the Cell survival rate(%)  was  80%",,,,Anticancer,Tumor active peptide,,Linear,,Acetylization,Amidation,,"Granted Patent; Family: 4s / 4ex; Family Jurisdictions: TW, US; Legal Status:  Active; Application No: 201615130709; Filed: Apr 15, 2016; Published: Oct 9, 2018; Earliest Priority: Nov 5, 2015; Granted: Oct 9, 2018",0,KKWRKWLAK
FLSaIVaMLaKLF,13,analogs of antimicrobial peptide temporin-SHa,Synthetic peptide,,NIH 3T3: IC50>100 μM,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,a=D-alanine,"Granted Patent; Family: 2s / 2ex; Family Jurisdictions: US; Legal Status:  Active; Application No: 201815937281; Filed: Mar 27, 2018; Published: Feb 4, 2020; Earliest Priority: Mar 27, 2018; Granted: Feb 4, 2020",0,FLSAIVAMLAKLF
FLSaIVaMLGKLF,13,analogs of antimicrobial peptide temporin-SHa,Synthetic peptide,,NIH 3T3: IC50>100 μM,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,a=D-alanine,"Granted Patent; Family: 2s / 2ex; Family Jurisdictions: US; Legal Status:  Active; Application No: 201815937281; Filed: Mar 27, 2018; Published: Feb 4, 2020; Earliest Priority: Mar 27, 2018; Granted: Feb 4, 2020",0,FLSAIVAMLGKLF
FLSaIVGMLGKLF,13,analogs of antimicrobial peptide temporin-SHa,Synthetic peptide,,NIH 3T3: IC50>100 μM,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,a=D-alanine,"Granted Patent; Family: 2s / 2ex; Family Jurisdictions: US; Legal Status:  Active; Application No: 201815937281; Filed: Mar 27, 2018; Published: Feb 4, 2020; Earliest Priority: Mar 27, 2018; Granted: Feb 4, 2020",0,FLSAIVGMLGKLF
FLSGIVaMLGKLF,13,analogs of antimicrobial peptide temporin-SHa,Synthetic peptide,,NIH 3T3: IC50>100 μM,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,a=D-alanine,"Granted Patent; Family: 2s / 2ex; Family Jurisdictions: US; Legal Status:  Active; Application No: 201815937281; Filed: Mar 27, 2018; Published: Feb 4, 2020; Earliest Priority: Mar 27, 2018; Granted: Feb 4, 2020",0,FLSGIVAMLGKLF
FLSGIVGMLaKLF,13,analogs of antimicrobial peptide temporin-SHa,Synthetic peptide,,NIH 3T3: IC50=16.02 ± 3.7 μM,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,a=D-alanine,"Granted Patent; Family: 2s / 2ex; Family Jurisdictions: US; Legal Status:  Active; Application No: 201815937281; Filed: Mar 27, 2018; Published: Feb 4, 2020; Earliest Priority: Mar 27, 2018; Granted: Feb 4, 2020",0,FLSGIVGMLAKLF
FLSGIVGMLGKLF,13,analogs of antimicrobial peptide temporin-SHa,Synthetic peptide,,NIH 3T3: IC50=73.3 ± 0.08 μM,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,"Granted Patent; Family: 2s / 2ex; Family Jurisdictions: US; Legal Status:  Active; Application No: 201815937281; Filed: Mar 27, 2018; Published: Feb 4, 2020; Earliest Priority: Mar 27, 2018; Granted: Feb 4, 2020",0,FLSGIVGMLGKLF
FAFAKIIAKIAKKII,15,FLAK peptides,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",0,FAFAKIIAKIAKKII
FAFGKGIGKIGKKGL,15,FLAK peptides,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",0,FAFGKGIGKIGKKGL
FAFGKGIGKVGKKLL,15,FLAK peptides,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",0,FAFGKGIGKVGKKLL
FAKAIAKIAFGKGIGKVGKKLL,22,FLAK peptides,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",0,FAKAIAKIAFGKGIGKVGKKLL
FAKALAKLAKKLL,13,FLAK peptides,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",0,FAKALAKLAKKLL
FAKALKALLKALKAL,15,FLAK peptides,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",0,FAKALKALLKALKAL
FAKFLAKFLKKAL,13,FLAK peptides,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",0,FAKFLAKFLKKAL
FAKGVGKVGKKAL,13,FLAK peptides,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",0,FAKGVGKVGKKAL
FAKIIAKIAKIAKKIL,16,FLAK peptides,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",0,FAKIIAKIAKIAKKIL
FAKIIAKIAKKI,12,FLAK peptides,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",0,FAKIIAKIAKKI
FAKKALKALKKL,12,FLAK peptides,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",0,FAKKALKALKKL
FAKKFAKKFKKFAKKFAKFAFAF,23,FLAK peptides,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",0,FAKKFAKKFKKFAKKFAKFAFAF
FAKKLAKALL,10,FLAK peptides,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",0,FAKKLAKALL
FAKKLAKKAKLAKKL,15,FLAK peptides,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",0,FAKKLAKKAKLAKKL
FAKKLAKKLAKAAL,14,FLAK peptides,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",0,FAKKLAKKLAKAAL
FAKKLAKKLAKAL,13,FLAK peptides,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",0,FAKKLAKKLAKAL
FAKKLAKKLAKLAL,14,FLAK peptides,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",0,FAKKLAKKLAKLAL
FAKKLAKKLAKLL,13,FLAK peptides,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",0,FAKKLAKKLAKLL
FAKKLAKKLKKLAKKLAK,18,FLAK peptides,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Free,,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",0,FAKKLAKKLKKLAKKLAK
FAKKLAKKLKKLAKKLAKKWKL,22,FLAK peptides,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Free,,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",0,FAKKLAKKLKKLAKKLAKKWKL
FAKKLAKKLKKLAKKLAKLAKKL,23,FLAK peptides,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",0,FAKKLAKKLKKLAKKLAKLAKKL
FAKKLAKKLKKLAKKLAKLALAL,23,FLAK peptides,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Free,,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",0,FAKKLAKKLKKLAKKLAKLALAL
FAKKLAKKLKKLAKKLAKLALALKALALKAL,31,FLAK peptides,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",0,FAKKLAKKLKKLAKKLAKLALALKALALKAL
FAKKLAKKLKKLAKKLIGAVLKV,23,FLAK peptides,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Free,,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",0,FAKKLAKKLKKLAKKLIGAVLKV
FAKKLAKKLKKLAKLALAK,19,FLAK peptides,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",0,FAKKLAKKLKKLAKLALAK
FAKKLAKKLKKLAKLALAL,19,FLAK peptides,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",0,FAKKLAKKLKKLAKLALAL
FAKKLAKKLL,10,FLAK peptides,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",0,FAKKLAKKLL
FAKKLAKLAKKALAL,15,FLAK peptides,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",0,FAKKLAKLAKKALAL
FAKKLAKLAKKL,12,FLAK peptides,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",0,FAKKLAKLAKKL
FAKKLAKLAKKLAKAL,16,FLAK peptides,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",0,FAKKLAKLAKKLAKAL
FAKKLAKLAKKLAKLAL,17,FLAK peptides,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Free,,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",0,FAKKLAKLAKKLAKLAL
VAKALKALLKALKAL,15,FLAK peptides,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",0,VAKALKALLKALKAL
FAKKLAKLAKKLAKLALAL,19,FLAK peptides,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",0,FAKKLAKLAKKLAKLALAL
FAKKLAKLAKKLLAL,15,FLAK peptides,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",0,FAKKLAKLAKKLLAL
FAKKLAKLALKLAKL,15,FLAK peptides,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",0,FAKKLAKLALKLAKL
FAKKLKKLAKKL,12,FLAK peptides,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",0,FAKKLKKLAKKL
FAKKLKKLAKLAKKL,15,FLAK peptides,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",0,FAKKLKKLAKLAKKL
FAKKLLAKALKL,12,FLAK peptides,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",0,FAKKLLAKALKL
FAKLA,5,FLAK peptides,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",0,FAKLA
FAKLAKKALAKLL,13,FLAK peptides,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",0,FAKLAKKALAKLL
FAKLAKKLL,9,FLAK peptides,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",0,FAKLAKKLL
FAKLF,5,FLAK peptides,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",0,FAKLF
FAKLFAKAFKKAL,13,FLAK peptides,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",0,FAKLFAKAFKKAL
FAKLFAKLAKKFAL,14,FLAK peptides,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",0,FAKLFAKLAKKFAL
FAKLLAKAFKKAL,13,FLAK peptides,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",0,FAKLLAKAFKKAL
FAKLLAKALKKAL,13,FLAK peptides,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",0,FAKLLAKALKKAL
FAKLLAKALKKFAL,14,FLAK peptides,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",0,FAKLLAKALKKFAL
FAKLLAKALKKFL,13,FLAK peptides,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",0,FAKLLAKALKKFL
FAKLLAKALKKL,12,FLAK peptides,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",0,FAKLLAKALKKL
FAKLLAKALKKLL,13,FLAK peptides,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",0,FAKLLAKALKKLL
FAKLLAKALKLKL,13,FLAK peptides,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",0,FAKLLAKALKLKL
FAKLLAKFLKKAL,13,FLAK peptides,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",0,FAKLLAKFLKKAL
FAKLLAKKLL,10,FLAK peptides,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",0,FAKLLAKKLL
FAKLLAKLAK,10,FLAK peptides,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",0,FAKLLAKLAK
FAKLLAKLAKAKA,13,FLAK peptides,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",0,FAKLLAKLAKAKA
FAKLLAKLAKAKG,13,FLAK peptides,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",0,FAKLLAKLAKAKG
FAKLLAKLAKAKL,13,FLAK peptides,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",0,FAKLLAKLAKAKL
FAKLLAKLAKK,11,FLAK peptides,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",0,FAKLLAKLAKK
FAKLLAKLAKKAA,13,FLAK peptides,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",0,FAKLLAKLAKKAA
FAKLLAKLAKKAL,13,FLAK peptides,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",0,FAKLLAKLAKKAL
FAKLLAKLAKKEL,13,FLAK peptides,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",0,FAKLLAKLAKKEL
FAKLLAKLAKKFAL,14,FLAK peptides,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",0,FAKLLAKLAKKFAL
FAKLLAKLAKKGL,13,FLAK peptides,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",0,FAKLLAKLAKKGL
FAKLLAKLAKKIL,13,FLAK peptides,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",0,FAKLLAKLAKKIL
FAKLLAKLAKKL,12,FLAK peptides,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",0,FAKLLAKLAKKL
FAKLLAKLAKKLL,13,FLAK peptides,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",0,FAKLLAKLAKKLL
FAKLLAKLAKKSL,13,FLAK peptides,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",0,FAKLLAKLAKKSL
FAKLLAKLAKKVL,13,FLAK peptides,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",0,FAKLLAKLAKKVL
FAKLLAKLAKLKL,13,FLAK peptides,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",0,FAKLLAKLAKLKL
FAKLLALALKLKL,13,FLAK peptides,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",0,FAKLLALALKLKL
FAKLLFKALKKAL,13,FLAK peptides,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",0,FAKLLFKALKKAL
FAKLLKLAAKKLL,13,FLAK peptides,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",0,FAKLLKLAAKKLL
FAKLWAKLAFGKGIGKVGKKLL,22,FLAK peptides,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",0,FAKLWAKLAFGKGIGKVGKKLL
FAKLWAKLAKKL,12,FLAK peptides,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",0,FAKLWAKLAKKL
FALA,4,FLAK peptides,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",0,FALA
FALAAKALKKLAKKLKKLAKKAL,23,FLAK peptides,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",0,FALAAKALKKLAKKLKKLAKKAL
FALAKALKKAL,11,FLAK peptides,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",0,FALAKALKKAL
FALAKKALKKAKKAL,15,FLAK peptides,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",0,FALAKKALKKAKKAL
FALAKLAKKAKAKLKKALKAL,21,FLAK peptides,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",0,FALAKLAKKAKAKLKKALKAL
FALALKA,7,FLAK peptides,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",0,FALALKA
FALALKAKKL,10,FLAK peptides,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",0,FALALKAKKL
FALALKALKK,10,FLAK peptides,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",0,FALALKALKK
FALALKALKKA,11,FLAK peptides,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",0,FALALKALKKA
FALALKALKKAL,12,FLAK peptides,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",0,FALALKALKKAL
FALALKALKKALkkLKKALKKAL,23,FLAK peptides,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Free,k=D-Lysine,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",0,FALALKALKKALKKLKKALKKAL
FALALKALKKALKKLKKALKKAL,23,FLAK peptides,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Free,,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",0,FALALKALKKALKKLKKALKKAL
FALALKALKKL,11,FLAK peptides,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",0,FALALKALKKL
FALALKALKKLAKKLKKLAKKAL,23,FLAK peptides,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",0,FALALKALKKLAKKLKKLAKKAL
FALALKALKKLKKALKKAL,19,FLAK peptides,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Free,,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",0,FALALKALKKLKKALKKAL
FALALKALKKLLKKLKKLAKKAL,23,FLAK peptides,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",0,FALALKALKKLLKKLKKLAKKAL
FALALKKALKALKKAL,16,FLAK peptides,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",0,FALALKKALKALKKAL
FALALKLAKKAL,12,FLAK peptides,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",0,FALALKLAKKAL
FALALKLAKKL,11,FLAK peptides,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",0,FALALKLAKKL
FALALKLKKL,10,FLAK peptides,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",0,FALALKLKKL
FALKALKK,8,FLAK peptides,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",0,FALKALKK
FALKALKKAL,10,FLAK peptides,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",0,FALKALKKAL
FALKALKKLKKALKKAL,17,FLAK peptides,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",0,FALKALKKLKKALKKAL
FALLKALKKAL,11,FLAK peptides,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",0,FALLKALKKAL
FALLKALLKKAL,12,FLAK peptides,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",0,FALLKALLKKAL
FALLKL,6,FLAK peptides,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",0,FALLKL
FAVGLRAIKRALKKLRRGVRKVAKDL,26,FLAK peptides,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",0,FAVGLRAIKRALKKLRRGVRKVAKDL
FGKGIGKVGKKLL,13,FLAK peptides,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",0,FGKGIGKVGKKLL
FKLAFKLAKKAFL,13,FLAK peptides,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",0,FKLAFKLAKKAFL
FKRLAKIKVLRLAKIKR,17,FLAK peptides,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",0,FKRLAKIKVLRLAKIKR
FKVKFKVKVK,10,FLAK peptides,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",0,FKVKFKVKVK
KWKLFKKKTKLFKKFAKKLAKKL,23,FLAK peptides,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Free,,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",0,KWKLFKKKTKLFKKFAKKLAKKL
KAKLAKKALAKLL,13,FLAK peptides,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",0,KAKLAKKALAKLL
KAKLF,5,FLAK peptides,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",0,KAKLF
KFKKLAKKF,9,FLAK peptides,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",0,KFKKLAKKF
KFKKLAKKW,9,FLAK peptides,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",0,KFKKLAKKW
KIAKVALAKLGIGAVLKVLTTGL,23,FLAK peptides,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",0,KIAKVALAKLGIGAVLKVLTTGL
KKVVFKVKFK,10,FLAK peptides,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",0,KKVVFKVKFK
KLAKKLAKLAKLAKAL,16,FLAK peptides,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Free,,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",0,KLAKKLAKLAKLAKAL
KLALKLALKALKAAKLA,17,FLAK peptides,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",0,KLALKLALKALKAAKLA
KLLKLLLKLYKKLLKLL,17,FLAK peptides,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Free,,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",0,KLLKLLLKLYKKLLKLL
KTKLFKKFAKKLAKKLKKLAKKL,23,FLAK peptides,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Free,,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",0,KTKLFKKFAKKLAKKLKKLAKKL
KWKKLAKKW,9,FLAK peptides,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",0,KWKKLAKKW
KWKLAKKALALL,12,FLAK peptides,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",0,KWKLAKKALALL
KWKLF,5,FLAK peptides,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",0,KWKLF
KWKLFKKALKKLKKALKKAL,20,FLAK peptides,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",0,KWKLFKKALKKLKKALKKAL
KYKKALKKLAKLL,13,FLAK peptides,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",0,KYKKALKKLAKLL
LKKLAKLALAF,11,FLAK peptides,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",0,LKKLAKLALAF
LPKWKVFKKIEKVGRNIRNGIVKAGPAIAVLGEAKALG,38,FLAK peptides,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",0,LPKWKVFKKIEKVGRNIRNGIVKAGPAIAVLGEAKALG
MPKEKVFLKIEKMGRNIRN,19,FLAK peptides,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",0,MPKEKVFLKIEKMGRNIRN
MPKWKVFKKIEKVGRNIRNGIVKAGPAIAVLGEAKALG,38,FLAK peptides,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Free,,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",0,MPKWKVFKKIEKVGRNIRNGIVKAGPAIAVLGEAKALG
VAKFLAKFLKKAL,13,FLAK peptides,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",0,VAKFLAKFLKKAL
VAKKFAKKFKKFAKKFAKFAFAF,23,FLAK peptides,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",0,VAKKFAKKFKKFAKKFAKFAFAF
VAKKLAKLAKKLAKLAL,17,FLAK peptides,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",0,VAKKLAKLAKKLAKLAL
VAKKLAKLAKKLAKLALAL,19,FLAK peptides,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",0,VAKKLAKLAKKLAKLALAL
VAKKLAKLAKKLLAL,15,FLAK peptides,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",0,VAKKLAKLAKKLLAL
VAKLLAKALKKLL,13,FLAK peptides,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",0,VAKLLAKALKKLL
VAKLLAKLAKKLL,13,FLAK peptides,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",0,VAKLLAKLAKKLL
VAKLLAKLAKKVL,13,FLAK peptides,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",0,VAKLLAKLAKKVL
VALALKALKKALKKLKKALKKAL,23,FLAK peptides,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Free,,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",0,VALALKALKKALKKLKKALKKAL
VALALKALKKL,11,FLAK peptides,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",0,VALALKALKKL
VALALKALKKLAKKLKKLAKKAL,23,FLAK peptides,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",0,VALALKALKKLAKKLKKLAKKAL
WALAL,5,FLAK peptides,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",0,WALAL
YAKLLAKLAKKAL,13,FLAK peptides,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,"Patent Application; Family: 1s / 24ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 13618605; Filed: May 24, 2005; Published: Sep 22, 2005; Earliest Priority: Mar 28, 2001",0,YAKLLAKLAKKAL
YLCAGRNDCIIAIKFEEKTAQHAAIENVFRLERRRRRRRRR,41,Synthetics,Synthetic peptide,,NIH 3T3: Barely toxic,,,,Anticancer; Antitumor,Tumor active peptide,,Linear,,Free,Free,,"Patent Application; Family: 2s / 2ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 23095205; Filed: Sep 19, 2005; Published: May 11, 2006; Earliest Priority: Sep 20, 2004",0,YLCAGRNDCIIAIKFEEKTAQHAAIENVFRLERRRRRRRRR
lKKllKKllKKl,12,Synthetic,Synthetic peptide,,NIH 3T3: LC50=50 μM,,,,Anticancer; Antimicrobial; Antifungal,Tumor active peptide,,Linear,,"CH3(CH2)10CO, Dodecanoic acid",Amidation,l=D-Leucine,"Patent Application; Family: 11s / 13ex; Family Jurisdictions: EP, US, AU, WO, CA; Legal Status:  Active; Application No: 56072704; Filed: Jun 18, 2004; Published: Mar 29, 2007; Earliest Priority: Jun 19, 2003; Granted: Mar 2, 2010",0,LKKLLKKLLKKL
lRRllRRllRRl,12,Synthetic,Synthetic peptide,,NIH 3T3: LC50=100 μM,,,,Anticancer; Antimicrobial; Antifungal,Tumor active peptide,,Linear,,"CH3(CH2)10CO, Dodecanoic acid",Amidation,l=D-Leucine,"Patent Application; Family: 11s / 13ex; Family Jurisdictions: EP, US, AU, WO, CA; Legal Status:  Active; Application No: 56072704; Filed: Jun 18, 2004; Published: Mar 29, 2007; Earliest Priority: Jun 19, 2003; Granted: Mar 2, 2010",0,LRRLLRRLLRRL
WRYMVm,6,,Synthetic peptide,,,,,,Anticancer; Antitumor,Tumor active peptide,,Linear,,Free,Free,m=D-Methionine,"Patent Application; Family: 15s / 15ex; Family Jurisdictions: KR, US, EP, CA, CN, JP, WO; Legal Status:  Active; Application No: 24622908; Filed: Oct 6, 2008; Published: May 7, 2009; Earliest Priority: Jan 29, 2002; Granted: Sep 13, 2011",0,WRYMVM
YLCAGRNDCIIAIKFEEKTAQHAAIENVFRLE,32,Synthetic construct,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,,,,,"Patent Application Family: 2s / 2ex; Family Jurisdictions: US; Legal Status:  Discontinued; Application No: 286507; Filed: Dec 19, 2007; Published: Aug 13, 2009; Earliest Priority: Sep 20, 2004",0,YLCAGRNDCIIAIKFEEKTAQHAAIENVFRLE
EARPALLTSRLRFIPK,16,,Synthetic peptide,,,,,,Anticancer; Antitumor,Tumor active peptide,,Linear,,Free,Free,,"Patent Application; Family: 14s / 14ex; Family Jurisdictions: CN, EP, US, JP, KR, WO; Legal Status:  Active; Application No: 201515303370; Filed: Apr 10, 2015; Published: Feb 2, 2017; Earliest Priority: Apr 11, 2014; Granted: Apr 10, 2018",0,EARPALLTSRLRFIPK
AQTGTGKT,8,Synthetics,Synthetic peptide,,,,,CAGE protein,Anticancer; Antitumor,Tumor active peptide,,Linear,,Free,Free,,"Patent Application; Family: 5s / 5ex; Family Jurisdictions: US, WO; Legal Status:  Active; Application No: 201715624906; Filed: Jun 16, 2017; Published: Mar 1, 2018; Earliest Priority: Dec 18, 2014; Granted: Mar 26, 2019",0,AQTGTGKT
GTGKA,5,,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,"Patent Application; Family: 2s / 2ex; Family Jurisdictions: US; Legal Status:  Active; Application No: 201514978256; Filed: Dec 22, 2015; Published: Mar 29, 2018; Earliest Priority: Dec 22, 2015; Granted: Jul 21, 2020",0,GTGKA
GTGKT,5,,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,"Patent Application; Family: 2s / 2ex; Family Jurisdictions: US; Legal Status:  Active; Application No: 201514978256; Filed: Dec 22, 2015; Published: Mar 29, 2018; Earliest Priority: Dec 22, 2015; Granted: Jul 21, 2020",0,GTGKT
GSNKNHKCYNSTGVDYRGTVSVTKSGRQCQPWNSQYPHTHTFTALRFPELNGGHSYCRNPGNQKEAPWCFTLDENFKSDLCDIPACDSKDS,91,,Synthetic peptide,,"293 Kidney fibroblasts: When the concentrations of peptides were 0.1 μg/ml, 1 μg/ml, and 10 μg/ml, the % Proliferation Inhibition was 0 ± 5, 0 ± 6, 0 ± 7.",tyrosine kinase orphan receptors (RORs),,,Anticancer,Tumor active peptide##Cancer targeted peptides,,Linear,,Free,Free,,"Patent Application; Family: 2s / 2ex; Family Jurisdictions: US; Legal Status:  Active; Application No: 201816184247; Filed: Nov 8, 2018; Published: May 16, 2019; Earliest Priority: Nov 10, 2017; Granted: Feb 2, 2021",0,GSNKNHKCYNSTGVDYRGTVSVTKSGRQCQPWNSQYPHTHTFTALRFPELNGGHSYCRNPGNQKEAPWCFTLDENFKSDLCDIPACDSKDS
NHKCYNSTGVDYRGTVSVTKSGRQCQPWNSQYPHTHTFTALRFPELNGGHSYCRNPGNQKEAPWCFTLDENFKSDLCDIPACDSKDSCD,89,,Synthetic peptide,,,tyrosine kinase orphan receptors (RORs),,,Anticancer,Tumor active peptide##Cancer targeted peptides,,Linear,,Free,Free,,"Patent Application; Family: 2s / 2ex; Family Jurisdictions: US; Legal Status:  Active; Application No: 201816184247; Filed: Nov 8, 2018; Published: May 16, 2019; Earliest Priority: Nov 10, 2017; Granted: Feb 2, 2021",0,NHKCYNSTGVDYRGTVSVTKSGRQCQPWNSQYPHTHTFTALRFPELNGGHSYCRNPGNQKEAPWCFTLDENFKSDLCDIPACDSKDSCD
AAKVVILKKATEYVES,16,Synthetics,Synthetic peptide,,,,,,Anticancer; Antitumor,Tumor active peptide,,Linear,,Free,Free,,"Patent Application; Family: 8s / 8ex; Family Jurisdictions: CA, CN, US, AU, JP, EP, WO, KR; Legal Status:  Pending; Application No: 201816635902; Filed: Jul 31, 2018; Published: May 21, 2020; Earliest Priority: Aug 1, 2017",0,AAKVVILKKATEYVES
AAXVVILKKXTEYVHS,16,Synthetics,Synthetic peptide,,,,,,Anticancer; Antitumor,Tumor active peptide,,Linear,,Free,Free,"X=—(CH2)6—CH═CH—(CH2)3— (for the cases NS10, NS16 and Na05) links both Xs radicals in each sequence","Patent Application; Family: 8s / 8ex; Family Jurisdictions: CA, CN, US, AU, JP, EP, WO, KR; Legal Status:  Pending; Application No: 201816635902; Filed: Jul 31, 2018; Published: May 21, 2020; Earliest Priority: Aug 1, 2017",0,AAXVVILKKXTEYVHS
APKVVILXKALEYLXA,16,Synthetics,Synthetic peptide,,,,,,Anticancer; Antitumor,Tumor active peptide,,Linear,,Free,Free,"X=—(CH2)6—CH═CH—(CH2)3— (for the cases NS10, NS16 and Na05) links both Xs radicals in each sequence","Patent Application; Family: 8s / 8ex; Family Jurisdictions: CA, CN, US, AU, JP, EP, WO, KR; Legal Status:  Pending; Application No: 201816635902; Filed: Jul 31, 2018; Published: May 21, 2020; Earliest Priority: Aug 1, 2017",0,APKVVILXKALEYLXA
APKVVXLSKALEXLQA,16,Synthetics,Synthetic peptide,,,,,,Anticancer; Antitumor,Tumor active peptide,,Linear,,Free,Free,"X=—(CH2)6—CH═CH—(CH2)3— (for the cases NS10, NS16 and Na05) links both Xs radicals in each sequence","Patent Application; Family: 8s / 8ex; Family Jurisdictions: CA, CN, US, AU, JP, EP, WO, KR; Legal Status:  Pending; Application No: 201816635902; Filed: Jul 31, 2018; Published: May 21, 2020; Earliest Priority: Aug 1, 2017",0,APKVVXLSKALEXLQA
RKRRNDLRSRFLALRDQ,17,Synthetics,Synthetic peptide,,,,,,Anticancer; Antitumor,Tumor active peptide##Stapled Peptides,,Linear,,Free,Free,,"Patent Application; Family: 8s / 8ex; Family Jurisdictions: CA, CN, US, AU, JP, EP, WO, KR; Legal Status:  Pending; Application No: 201816635902; Filed: Jul 31, 2018; Published: May 21, 2020; Earliest Priority: Aug 1, 2017",0,RKRRNDLRSRFLALRDQ
RKRRNDLRSXFLALRDX,17,Synthetics,Synthetic peptide,,,,,,Anticancer; Antitumor,Tumor active peptide,,Linear,,Free,Free,"X=—(CH2)6—CH═CH—(CH2)3— (for the cases NS10, NS16 and Na05) links both Xs radicals in each sequence","Patent Application; Family: 8s / 8ex; Family Jurisdictions: CA, CN, US, AU, JP, EP, WO, KR; Legal Status:  Pending; Application No: 201816635902; Filed: Jul 31, 2018; Published: May 21, 2020; Earliest Priority: Aug 1, 2017",0,RKRRNDLRSXFLALRDX
RKRRNDLXSRFLALXDQ,17,Synthetics,Synthetic peptide,,,,,,Anticancer; Antitumor,Tumor active peptide,,Linear,,Free,Free,"X=—(CH2)6—CH═CH—(CH2)3— (for the cases NS10, NS16 and Na05) links both Xs radicals in each sequence","Patent Application; Family: 8s / 8ex; Family Jurisdictions: CA, CN, US, AU, JP, EP, WO, KR; Legal Status:  Pending; Application No: 201816635902; Filed: Jul 31, 2018; Published: May 21, 2020; Earliest Priority: Aug 1, 2017",0,RKRRNDLXSRFLALXDQ
RKRXNDLRSRXLALRDQ,17,Synthetics,Synthetic peptide,,,,,,Anticancer; Antitumor,Tumor active peptide,,Linear,,Free,Free,"X=—(CH2)6—CH═CH—(CH2)3— (for the cases NS10, NS16 and Na05) links both Xs radicals in each sequence","Patent Application; Family: 8s / 8ex; Family Jurisdictions: CA, CN, US, AU, JP, EP, WO, KR; Legal Status:  Pending; Application No: 201816635902; Filed: Jul 31, 2018; Published: May 21, 2020; Earliest Priority: Aug 1, 2017",0,RKRXNDLRSRXLALRDQ
RQRRNDLXSSFLTLXDH,17,Synthetics,Synthetic peptide,,,,,,Anticancer; Antitumor,Tumor active peptide,,Linear,,Free,Free,"X=—(CH2)6—CH═CH—(CH2)3— (for the cases NS10, NS16 and Na05) links both Xs radicals in each sequence","Patent Application; Family: 8s / 8ex; Family Jurisdictions: CA, CN, US, AU, JP, EP, WO, KR; Legal Status:  Pending; Application No: 201816635902; Filed: Jul 31, 2018; Published: May 21, 2020; Earliest Priority: Aug 1, 2017",0,RQRRNDLXSSFLTLXDH
RQRRNKLRSKFLTLRDH,17,Synthetics,Synthetic peptide,,,,,,Anticancer; Antitumor,Tumor active peptide,,Linear,,Free,Free,,"Patent Application; Family: 8s / 8ex; Family Jurisdictions: CA, CN, US, AU, JP, EP, WO, KR; Legal Status:  Pending; Application No: 201816635902; Filed: Jul 31, 2018; Published: May 21, 2020; Earliest Priority: Aug 1, 2017",0,RQRRNKLRSKFLTLRDH
RRNDLRSXFLALRDXVP,17,Synthetics,Synthetic peptide,,,,,,Anticancer; Antitumor,Tumor active peptide,,Linear,,Free,Free,"X=—(CH2)6—CH═CH—(CH2)3— (for the cases NS10, NS16 and Na05) links both Xs radicals in each sequence","Patent Application; Family: 8s / 8ex; Family Jurisdictions: CA, CN, US, AU, JP, EP, WO, KR; Legal Status:  Pending; Application No: 201816635902; Filed: Jul 31, 2018; Published: May 21, 2020; Earliest Priority: Aug 1, 2017",0,RRNDLRSXFLALRDXVP
RRNDLRSXFLTLRDXVP,17,Synthetics,Synthetic peptide,,,,,,Anticancer; Antitumor,Tumor active peptide,,Linear,,Free,Free,"X=—(CH2)6—CH═CH—(CH2)3— (for the cases NS10, NS16 and Na07) links both Xs radicals in each sequence","Patent Application; Family: 8s / 8ex; Family Jurisdictions: CA, CN, US, AU, JP, EP, WO, KR; Legal Status:  Pending; Application No: 201816635902; Filed: Jul 31, 2018; Published: May 21, 2020; Earliest Priority: Aug 1, 2017",0,RRNDLRSXFLTLRDXVP
RRRRRRRAAKVVILKKATEYVHS,23,Synthetics,Synthetic peptide,,,,,,Anticancer; Antitumor,Tumor active peptide,,Linear,,Free,Free,,"Patent Application; Family: 8s / 8ex; Family Jurisdictions: CA, CN, US, AU, JP, EP, WO, KR; Legal Status:  Pending; Application No: 201816635902; Filed: Jul 31, 2018; Published: May 21, 2020; Earliest Priority: Aug 1, 2017",0,RRRRRRRAAKVVILKKATEYVHS
RRRRRRRRKRRNDLRSRFLALRDQ,24,Synthetics,Synthetic peptide,,,,,,Anticancer; Antitumor,Tumor active peptide##Stapled Peptides,,Linear,,Free,Free,,"Patent Application; Family: 8s / 8ex; Family Jurisdictions: CA, CN, US, AU, JP, EP, WO, KR; Legal Status:  Pending; Application No: 201816635902; Filed: Jul 31, 2018; Published: May 21, 2020; Earliest Priority: Aug 1, 2017",0,RRRRRRRRKRRNDLRSRFLALRDQ
RRRRRRRRQRRNDLRSSFLTLRDHVP,26,Synthetics,Synthetic peptide,,,,,,Anticancer; Antitumor,Tumor active peptide,,Linear,,Free,Free,CPP2 corresponds to penetratine peptide.,"Patent Application; Family: 8s / 8ex; Family Jurisdictions: CA, CN, US, AU, JP, EP, WO, KR; Legal Status:  Pending; Application No: 201816635902; Filed: Jul 31, 2018; Published: May 21, 2020; Earliest Priority: Aug 1, 2017",0,RRRRRRRRQRRNDLRSSFLTLRDHVP
RRRRRRRRVKLVNLGFATLREHVP,24,Synthetics,Synthetic peptide,,,,,,Anticancer; Antitumor,Tumor active peptide,,Linear,,Free,Free,,"Patent Application; Family: 8s / 8ex; Family Jurisdictions: CA, CN, US, AU, JP, EP, WO, KR; Legal Status:  Pending; Application No: 201816635902; Filed: Jul 31, 2018; Published: May 21, 2020; Earliest Priority: Aug 1, 2017",0,RRRRRRRRVKLVNLGFATLREHVP
RRRRRRRSKAPKVVILSKALEYLQA,25,Synthetics,Synthetic peptide,,,,,,Anticancer; Antitumor,Tumor active peptide####Coupling peptide,,Linear,,Free,Free,,"Patent Application; Family: 8s / 8ex; Family Jurisdictions: CA, CN, US, AU, JP, EP, WO, KR; Legal Status:  Pending; Application No: 201816635902; Filed: Jul 31, 2018; Published: May 21, 2020; Earliest Priority: Aug 1, 2017",0,RRRRRRRSKAPKVVILSKALEYLQA
RQIKWFQNRRMKWKKSKAPKVVILSKALEYLQA,25,Synthetics,Synthetic peptide,,,,,,Anticancer; Antitumor,Tumor active peptide####Coupling peptide,,Linear,,Free,Free,,"Patent Application; Family: 8s / 8ex; Family Jurisdictions: CA, CN, US, AU, JP, EP, WO, KR; Legal Status:  Pending; Application No: 201816635902; Filed: Jul 31, 2018; Published: May 21, 2020; Earliest Priority: Aug 1, 2017",0,RQIKWFQNRRMKWKKSKAPKVVILSKALEYLQA
RVKLVNLGFATLREHVP,17,Synthetics,Synthetic peptide,,,,,,Anticancer; Antitumor,Tumor active peptide,,Linear,,Free,Free,,"Patent Application; Family: 8s / 8ex; Family Jurisdictions: CA, CN, US, AU, JP, EP, WO, KR; Legal Status:  Pending; Application No: 201816635902; Filed: Jul 31, 2018; Published: May 21, 2020; Earliest Priority: Aug 1, 2017",0,RVKLVNLGFATLREHVP
SKAPKXVILSKAXEYL,16,Synthetics,Synthetic peptide,,,,,,Anticancer; Antitumor,Tumor active peptide,,Linear,,Free,Free,"X=—(CH2)6—CH═CH—(CH2)3— (for the cases NS10, NS16 and Na05) links both Xs radicals in each sequence","Patent Application; Family: 8s / 8ex; Family Jurisdictions: CA, CN, US, AU, JP, EP, WO, KR; Legal Status:  Pending; Application No: 201816635902; Filed: Jul 31, 2018; Published: May 21, 2020; Earliest Priority: Aug 1, 2017",0,SKAPKXVILSKAXEYL
SKAPXVVILSKXLEYL,16,Synthetics,Synthetic peptide,,,,,,Anticancer; Antitumor,Tumor active peptide,,Linear,,Free,Free,"X=—(CH2)6—CH═CH—(CH2)3— (for the cases NS10, NS16 and Na05) links both Xs radicals in each sequence","Patent Application; Family: 8s / 8ex; Family Jurisdictions: CA, CN, US, AU, JP, EP, WO, KR; Legal Status:  Pending; Application No: 201816635902; Filed: Jul 31, 2018; Published: May 21, 2020; Earliest Priority: Aug 1, 2017",0,SKAPXVVILSKXLEYL
SKAXKVVILSXALEYL,16,Synthetics,Synthetic peptide,,,,,,Anticancer; Antitumor,Tumor active peptide,,Linear,,Free,Free,"X=—(CH2)6—CH═CH—(CH2)3— (for the cases NS10, NS16 and Na05) links both Xs radicals in each sequence","Patent Application; Family: 8s / 8ex; Family Jurisdictions: CA, CN, US, AU, JP, EP, WO, KR; Legal Status:  Pending; Application No: 201816635902; Filed: Jul 31, 2018; Published: May 21, 2020; Earliest Priority: Aug 1, 2017",0,SKAXKVVILSXALEYL
SKXPKVVILXKALEYL,16,Synthetics,Synthetic peptide,,,,,,Anticancer; Antitumor,Tumor active peptide,,Linear,,Free,Free,"X=—(CH2)6—CH═CH—(CH2)3— (for the cases NS10, NS16 and Na05) links both Xs radicals in each sequence","Patent Application; Family: 8s / 8ex; Family Jurisdictions: CA, CN, US, AU, JP, EP, WO, KR; Legal Status:  Pending; Application No: 201816635902; Filed: Jul 31, 2018; Published: May 21, 2020; Earliest Priority: Aug 1, 2017",0,SKXPKVVILXKALEYL
SXAPKVVIXSKALEYL,16,Synthetics,Synthetic peptide,,,,,,Anticancer; Antitumor,Tumor active peptide,,Linear,,Free,Free,"X=—(CH2)6—CH═CH—(CH2)3— (for the cases NS10, NS16 and Na05) links both Xs radicals in each sequence","Patent Application; Family: 8s / 8ex; Family Jurisdictions: CA, CN, US, AU, JP, EP, WO, KR; Legal Status:  Pending; Application No: 201816635902; Filed: Jul 31, 2018; Published: May 21, 2020; Earliest Priority: Aug 1, 2017",0,SXAPKVVIXSKALEYL
XKAPKVVXLSKALEYL,16,Synthetics,Synthetic peptide,,,,,,Anticancer; Antitumor,Tumor active peptide,,Linear,,Free,Free,"X=—(CH2)6—CH═CH—(CH2)3— (for the cases NS10, NS16 and Na05) links both Xs radicals in each sequence","Patent Application; Family: 8s / 8ex; Family Jurisdictions: CA, CN, US, AU, JP, EP, WO, KR; Legal Status:  Pending; Application No: 201816635902; Filed: Jul 31, 2018; Published: May 21, 2020; Earliest Priority: Aug 1, 2017",0,XKAPKVVXLSKALEYL
KWKKLLKKPPPLLKKLLKKL,20,Synthetic,Synthetic peptide,no haemolytic activity,,,,,Anticancer; Antimicrobial; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,"Granted Patent; Family: 4s / 4ex; Family Jurisdictions: KR, US; Legal Status:  Expired; Application No: 8141802; Filed: Feb 22, 2002; Published: Oct 5, 2004; Earliest Priority: Sep 19, 2001; Granted: Oct 5, 2004",0,KWKKLLKKPPPLLKKLLKKL
LMXYLK,6,Synthetics,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,"X=Saa1, furanoid sugar amino acid","Granted Patent; Family: 2s / 2ex; Family Jurisdictions: US; Legal Status:  Inactive; Application No: 63810703; Filed: Aug 8, 2003; Published: Jun 13, 2006; Earliest Priority: Aug 8, 2003; Granted: Jun 13, 2006",0,LMXYLK
LMXTYLK,7,Synthetics,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,"X=Saa3, furanoid sugar amino acid","Granted Patent; Family: 2s / 2ex; Family Jurisdictions: US; Legal Status:  Inactive; Application No: 63810703; Filed: Aug 8, 2003; Published: Jun 13, 2006; Earliest Priority: Aug 8, 2003; Granted: Jun 13, 2006",0,LMXTYLK
LMYXYLK,7,Synthetics,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,"X=Saa1, furanoid sugar amino acid","Granted Patent; Family: 2s / 2ex; Family Jurisdictions: US; Legal Status:  Inactive; Application No: 63810703; Filed: Aug 8, 2003; Published: Jun 13, 2006; Earliest Priority: Aug 8, 2003; Granted: Jun 13, 2006",0,LMYXYLK
LMYXTYLK,8,Synthetics,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,"X=Saa2, furanoid sugar amino acid","Granted Patent; Family: 2s / 2ex; Family Jurisdictions: US; Legal Status:  Inactive; Application No: 63810703; Filed: Aug 8, 2003; Published: Jun 13, 2006; Earliest Priority: Aug 8, 2003; Granted: Jun 13, 2006",0,LMYXTYLK
MXYL,4,Synthetics,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,"X=Saa1, furanoid sugar amino acid","Granted Patent; Family: 2s / 2ex; Family Jurisdictions: US; Legal Status:  Inactive; Application No: 63810703; Filed: Aug 8, 2003; Published: Jun 13, 2006; Earliest Priority: Aug 8, 2003; Granted: Jun 13, 2006",0,MXYL
KWKLFKKIGIGRLLKRGLRKLLK,23,AMPs,Synthetic peptide,"Human red blood cells: When the concentration of peptide is 12.5, 25, 50, 100, 200 and 500 μg/ml, the hemolysis rate (%) is 0%, 0%, 0.5%, 0.8% and 1.5%, respectively.",Mouse NH-3T3: IC50>100 μg/ml,,,,Anticancer; Antitumor,Tumor active peptide,,Linear,,Free,Free,,"Patent Application; Family: 10s / 10ex; Family Jurisdictions: US, AU, CN, EP, AT, WO; Legal Status:  Pending; Application No: 0300522; Filed: Jul 1, 2003; Published: Mar 11, 2004; Earliest Priority: Sep 2, 2002",0,KWKLFKKIGIGRLLKRGLRKLLK
KWKLFKKIGIGRLLKRGLRKLLKLLR,26,AMPs,Synthetic peptide,"Human red blood cells: When the concentration of peptide is 12.5, 25, 50, 100, 200 and 500 μg/ml, the hemolysis rate (%) is 0%, 0%, 0.2%, 1.0% and 2%, respectively.",Mouse NH-3T3: IC50>100 μg/ml,,,,Anticancer; Antitumor,Tumor active peptide,,Linear,,Free,Free,,"Patent Application; Family: 10s / 10ex; Family Jurisdictions: US, AU, CN, EP, AT, WO; Legal Status:  Pending; Application No: 0300522; Filed: Jul 1, 2003; Published: Mar 11, 2004; Earliest Priority: Sep 2, 2002",0,KWKLFKKIGIGRLLKRGLRKLLKLLR
RWRLFKRIGIGRLLKRGLR,19,AMPs,Synthetic peptide,"Human red blood cells: When the concentration of peptide is 12.5, 25, 50, 100, 200 and 500 μg/ml, the hemolysis rate (%) is 0%, 0%, 0.6%, 1.1% and 1.9%, respectively.",Mouse NH-3T3: IC50>100 μg/ml,,,,Anticancer; Antitumor,Tumor active peptide,,Linear,,Free,Free,,"Patent Application; Family: 10s / 10ex; Family Jurisdictions: US, AU, CN, EP, AT, WO; Legal Status:  Pending; Application No: 0300522; Filed: Jul 1, 2003; Published: Mar 11, 2004; Earliest Priority: Sep 2, 2002",0,RWRLFKRIGIGRLLKRGLR
KAMKSIAKFIAK,12,Synthetics,Synthetic peptide,37% of red blood cells lysed at 200umol,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,"Patent Application; Family: 10s / 10ex; Family Jurisdictions: WO, CN, EP, JP, US; Legal Status:  Pending; Application No: 2008071804; Filed: Jul 30, 2008; Published: Feb 5, 2009; Earliest Priority: Jul 31, 2007",0,KAMKSIAKFIAK
KGWFKAMKSIAKFIAKEKLKEHL,23,Synthetics,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,"Patent Application; Family: 10s / 10ex; Family Jurisdictions: WO, CN, EP, JP, US; Legal Status:  Pending; Application No: 2008071804; Filed: Jul 30, 2008; Published: Feb 5, 2009; Earliest Priority: Jul 31, 2007",0,KGWFKAMKSIAKFIAKEKLKEHL
KGWFKAMKSIAKFIAKEKMKEHL,23,Synthetics,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,"Patent Application; Family: 10s / 10ex; Family Jurisdictions: WO, CN, EP, JP, US; Legal Status:  Pending; Application No: 2008071804; Filed: Jul 30, 2008; Published: Feb 5, 2009; Earliest Priority: Jul 31, 2007",0,KGWFKAMKSIAKFIAKEKMKEHL
RKGWFKAMKSIAKFIAKEKLKEHL,24,Synthetics,Synthetic peptide,19% of red blood cells lysed at 200umol,There were no notable toxic effects (within 48 hours) from subcutaneous injection into mice at 200 mg /kg body weight,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,"Patent Application; Family: 10s / 10ex; Family Jurisdictions: WO, CN, EP, JP, US; Legal Status:  Pending; Application No: 2008071804; Filed: Jul 30, 2008; Published: Feb 5, 2009; Earliest Priority: Jul 31, 2007",0,RKGWFKAMKSIAKFIAKEKLKEHL
WFKAMKSIAKFIAKEKLK,18,Synthetics,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,"Patent Application; Family: 10s / 10ex; Family Jurisdictions: WO, CN, EP, JP, US; Legal Status:  Pending; Application No: 2008071804; Filed: Jul 30, 2008; Published: Feb 5, 2009; Earliest Priority: Jul 31, 2007",0,WFKAMKSIAKFIAKEKLK
YRPWGSGSGF,10,Synthetics,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,"Patent Application; Family: 10s / 10ex; Family Jurisdictions: WO, CN, EP, JP, US; Legal Status:  Pending; Application No: 2008071804; Filed: Jul 30, 2008; Published: Feb 5, 2009; Earliest Priority: Jul 31, 2007",0,YRPWGSGSGF
YRPWGSGSGFG,11,Synthetics,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,"Patent Application; Family: 10s / 10ex; Family Jurisdictions: WO, CN, EP, JP, US; Legal Status:  Pending; Application No: 2008071804; Filed: Jul 30, 2008; Published: Feb 5, 2009; Earliest Priority: Jul 31, 2007",0,YRPWGSGSGFG
NQVSLTCLVK,10,AMPs,Synthetic peptide,,,,,,Anticancer; Antimicrobial; Antiviral,Tumor active peptide,,Linear,,Free,Free,,"Patent Application; Family: 1s / 1ex; Family Jurisdictions: WO; Legal Status:  Pending; Application No: 2010056763; Filed: Nov 15, 2010; Published: May 19, 2011; Earliest Priority: Nov 16, 2009",0,NQVSLTCLVK
TCRVDHRGLTF,11,AMPs,Synthetic peptide,,,,,,Anticancer; Antimicrobial; Antiviral,Tumor active peptide,,Linear,,Free,Free,,"Patent Application; Family: 1s / 1ex; Family Jurisdictions: WO; Legal Status:  Pending; Application No: 2010056763; Filed: Nov 15, 2010; Published: May 19, 2011; Earliest Priority: Nov 16, 2009",0,TCRVDHRGLTF
GQVWEATATVNAIRGSVTPAVSQFNARTAD,30,Derived from the MPT63 secreted protein,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,"Patent Application; Family: 8s / 8ex; Family Jurisdictions: JP, US, WO, EP; Legal Status:  Pending; Application No: 2011000680; Filed: Sep 30, 2011; Published: Apr 5, 2012; Earliest Priority: Oct 1, 2010",0,GQVWEATATVNAIRGSVTPAVSQFNARTAD
NHFTLKCPKTALTEPPTLAY,20,Derived from the SAG1 surface protein from the parasite Toxoplasma gondii,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,"Patent Application; Family: 8s / 8ex; Family Jurisdictions: JP, US, WO, EP; Legal Status:  Pending; Application No: 2011000680; Filed: Sep 30, 2011; Published: Apr 5, 2012; Earliest Priority: Oct 1, 2010",0,NHFTLKCPKTALTEPPTLAY
TAGIKLTVPIEKFPVTTQTFWG,22,Derived from the SAG1 surface protein from the parasite Toxoplasma gondii,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,"Patent Application; Family: 8s / 8ex; Family Jurisdictions: JP, US, WO, EP; Legal Status:  Pending; Application No: 2011000680; Filed: Sep 30, 2011; Published: Apr 5, 2012; Earliest Priority: Oct 1, 2010",0,TAGIKLTVPIEKFPVTTQTFWG
GRKKRRQRRRPQ,12,AMPs,Synthetic peptide,,,Hsp90,,,Anticancer,Tumor active peptide##Cancer targeted peptides,,Linear,,Free,Free,,"Patent Application; Family: 1s / 1ex; Family Jurisdictions: WO; Legal Status:  Pending; Application No: 2013028852; Filed: Mar 4, 2013; Published: Sep 12, 2013; Earliest Priority: Mar 5, 2012",0,GRKKRRQRRRPQ
CRKRLDRCGGGKLAKLAKKLAKLAK,25,Synthetics,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,"Patent Application; Family: 6s / 6ex; Family Jurisdictions: KR, US, WO, JP; Legal Status:  Pending; Application No: 2015012162; Filed: Nov 12, 2015; Published: Jan 5, 2017; Earliest Priority: Jun 30, 2015",0,CRKRLDRCGGGKLAKLAKKLAKLAK
ISGGNDKQGFPM,12,Synthetics,Synthetic peptide,,"Human normal hepatocyte ChangLiver: At 36 hours, it had little effect on the growth inhibition of normal human hepatocytes ChangLiver (only weak growth inhibition or weak growth promotion)",,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,"Patent Application; Family: 6s / 6ex; Family Jurisdictions: KR, US, WO, JP; Legal Status:  Pending; Application No: 2015012162; Filed: Nov 12, 2015; Published: Jan 5, 2017; Earliest Priority: Jun 30, 2015",0,ISGGNDKQGFPM
AVPSP,5,Synthetics,Synthetic peptide,,"HaCaT, NHDF: Almost no toxicity to normal cells (fig. 8)",,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,"Patent Application; Family: 3s / 3ex; Family Jurisdictions: WO, KR; Legal Status:  Pending; Application No: 2020009856; Filed: Jul 27, 2020; Published: Feb 11, 2021; Earliest Priority: Aug 8, 2019",0,AVPSP
AVPSPPPAS,9,Synthetics,Synthetic peptide,,"HaCaT, NHDF: Almost no toxicity to normal cells (fig. 8)",,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,"Patent Application; Family: 3s / 3ex; Family Jurisdictions: WO, KR; Legal Status:  Pending; Application No: 2020009856; Filed: Jul 27, 2020; Published: Feb 11, 2021; Earliest Priority: Aug 8, 2019",0,AVPSPPPAS
KRTGQYKLGSKT,12,API13 derived peptides,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,"Patent Application; Family: 3s / 3ex; Family Jurisdictions: WO, KR; Legal Status:  Pending; Application No: 2020009856; Filed: Jul 27, 2020; Published: Feb 11, 2021; Earliest Priority: Aug 8, 2019",0,KRTGQYKLGSKT
LEDVTGEEF,9,API5 derived peptides,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,"Patent Application; Family: 3s / 3ex; Family Jurisdictions: WO, KR; Legal Status:  Pending; Application No: 2020009856; Filed: Jul 27, 2020; Published: Feb 11, 2021; Earliest Priority: Aug 8, 2019",0,LEDVTGEEF
GLPVCGETCFGGTCNTPGCSCXTWPVCSRN,30,Viola arvensis (European field pansy) (Field violet),Native peptide,,,,,,Anticancer,Tumor active peptide##Membrane-targeted,,Cyclic,Cys5<--->Cys19; Cys9<--->Cys21; Cys14<--->Cys27,Free,Free,X=Glu-methylation,,0,GLPVCGETCFGGTCNTPGCSCXTWPVCSRN
GYPICGESCVGGTCNTPGCSCSWPVCTTN,29,Viola tricolor,Native peptide,HRBCs: HC50=225.90 μM,,,,,Anticancer; Antimicrobial,Tumor active peptide##Membrane-targeted,,Cyclic,Cys5<--->Cys19; Cys9<--->Cys21; Cys14<--->Cys26,Free,Free,,,0,GYPICGESCVGGTCNTPGCSCSWPVCTTN
GLPICGETCVGGTCNTPGCFCTWPVCTRN,29,Viola tricolor,Native peptide,HRBCs: HC50=11.53 μM,,,,,Anticancer; Antimicrobial,Tumor active peptide##Membrane-targeted,,Cyclic,Cys5<--->Cys19; Cys9<--->Cys21; Cys14<--->Cys26,Free,Free,,,0,GLPICGETCVGGTCNTPGCFCTWPVCTRN
GLPVCGETCFTGSCYTPGCSCNWPVCNRN,29,Viola tricolor,Native peptide,HRBCs: HC50=4.29 μM,,,,,Anticancer; Antimicrobial,Tumor active peptide##Membrane-targeted,,Cyclic,Cys5<--->Cys19; Cys9<--->Cys21; Cys14<--->Cys26,Free,Free,,,0,GLPVCGETCFTGSCYTPGCSCNWPVCNRN
GLPVCGETCVGGTCNTPGCSCSWPVCFRN,29,Viola tricolor,Native peptide,HRBCs: HC50=27.06 μM,,,,,Anticancer; Antimicrobial,Tumor active peptide##Membrane-targeted,,Cyclic,Cys5<--->Cys19; Cys9<--->Cys21; Cys14<--->Cys26,Free,Free,,,0,GLPVCGETCVGGTCNTPGCSCSWPVCFRN
GTLPCGESCVWIPCISSVVGCACKSKVCYKD,31,Viola tricolor,Native peptide,HRBCs: HC50=10.00 μM,,,,,Anticancer; Antimicrobial,Tumor active peptide##Membrane-targeted,,Cyclic,Cys5<--->Cys19; Cys9<--->Cys21; Cys14<--->Cys26,Free,Free,,,0,GTLPCGESCVWIPCISSVVGCACKSKVCYKD
GIPCGESCVWIPCITSAIGCSCKSKVCYRN,30,Viola tricolor,Native peptide,HRBCs: HC50=8.91 Μm,,,,,Anticancer; Antimicrobial,Tumor active peptide##Membrane-targeted,,Cyclic,Cys4<--->Cys20; Cys8<--->Cys22; Cys13<--->Cys27; NCB: Gly1<--->Asn30,Free,Free,,,0,GIPCGESCVWIPCITSAIGCSCKSKVCYRN
GRKKRRQRRRPQSKRKKNKKGKRK,24,Derived from the NLS of EPS8,Synthetic peptide,,,,,,Anticancer,Tumor active peptide##EPS8/NLS inhibitors,,Linear,,Acetylation,Amidation,,,0,GRKKRRQRRRPQSKRKKNKKGKRK
YADAIFTNSYRKVLGQLSARKLLQDIMSR,29,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide##Hormone stimulating peptides##GHRH antagonists,,Linear,,Phenylacetyl 12-aminododecanoyl,Amidation,,,0,YADAIFTNSYRKVLGQLSARKLLQDIMSR
YADAIFTXSYRKVLGQLSARKLLQDIMSR,29,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide##Hormone stimulating peptides##GHRH antagonists,,Linear,,Free,Free,X=N-methyl Ala,,0,YADAIFTXSYRKVLGQLSARKLLQDIMSR
YADAIFTAXXHKVLGQLSAHKLLQDIMSR,29,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide##Hormone stimulating peptides##GHRH antagonists,,Linear,,Free,Free,X(9)=homoArg; X(10)=Tyr methyl ether,,0,YADAIFTAXXHKVLGQLSAHKLLQDIMSR
FLPLLLAGLPSFLCLVFKKC,20,Rana amurensis,Native peptide,Horse erythrocytes: 50% Hemolysis=439.0 µM,HMEC-1: IC50=1545 µM,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide##Membrane-targeted,,Cyclic,Cys14<--->Cys20,Free,Free,,,0,FLPLLLAGLPSFLCLVFKKC
FLPKLLAGLPSFLCLVFKKC,20,Synthetic,Synthetic peptide,Horse erythrocytes: 50% Hemolysis=31.0	 µM,HMEC-1: IC50=85.2 µM,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide##Membrane-targeted,,Cyclic,Cys14<--->Cys20,Free,Free,,,0,FLPKLLAGLPSFLCLVFKKC
FLPLLLAGLPKFLCLVFKKC,20,Synthetic,Synthetic peptide,Horse erythrocytes: 50% Hemolysis=29.1	 µM,HMEC-1: IC50=52.1 µM,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide##Membrane-targeted,,Cyclic,Cys14<--->Cys20,Free,Free,,,0,FLPLLLAGLPKFLCLVFKKC
KRWRWRW,7,Synthetic,Synthetic peptide,Human erythrocytes: 50% Hemolysis=114 µM,Human fibroblasts: IC50=32.5 µM,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,C8,Free,,,0,KRWRWRW
NIlLWG,6,Synthetic,Synthetic peptide,,Vero cells: IC50=90.8 µg/ml,,,,Anticancer; Antibacterial,Tumor active peptide##Membrane-targeted,,Cyclic,NCB: Asn1<--->Gly6,Free,Free,l=D-Leu,,0,NILLWG
NVlLWX,6,Synthetic,Synthetic peptide,,Vero cells: IC50=73.2 µg/ml,,,,Anticancer; Antibacterial,Tumor active peptide##Membrane-targeted,,Cyclic,NCB: Asn1<--->X6,Free,Free,l=D-Leu; X=Orn,,0,NVLLWX
NGWLLI,6,Streptomyces scopuliridis SCSIO ZJ46,Native peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Cyclic,NCB: Asn1<--->Ile6,Free,Free,,,0,NGWLLI
XGNIlL,6,Streptomyces scopuliridis SCSIO ZJ47,Native peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Cyclic,NCB: X1<--->Leu6,Free,Free,X=N-formyl-kynurenine; l=D-Leu,,0,XGNILL
KFAK,4,Synthetic,Synthetic peptide,RBCs: 2.8%Hemolysis=250 µg/ml,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,"Granted Patent; Family: 2s / 2ex; Family Jurisdictions: US; Legal Status: Inactive; Application No: 78521004; Filed: Feb 24, 2004; Published: Aug 15, 2006; Earliest Priority: Feb 24, 2003; Granted: Aug 15, 2006",0,KFAK
KFAKKFAK,8,Synthetic,Synthetic peptide,RBCs: 2.2%Hemolysis=250 µg/ml,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,"Granted Patent; Family: 2s / 2ex; Family Jurisdictions: US; Legal Status: Inactive; Application No: 78521004; Filed: Feb 24, 2004; Published: Aug 15, 2006; Earliest Priority: Feb 24, 2003; Granted: Aug 15, 2006",0,KFAKKFAK
KFAKKFAKKFAK,12,Synthetic,Synthetic peptide,RBCs: 0.4%Hemolysis=250 µg/ml,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,"Granted Patent; Family: 2s / 2ex; Family Jurisdictions: US; Legal Status: Inactive; Application No: 78521004; Filed: Feb 24, 2004; Published: Aug 15, 2006; Earliest Priority: Feb 24, 2003; Granted: Aug 15, 2006",0,KFAKKFAKKFAK
KFAKKFAKKFAKKFAK,16,Synthetic,Synthetic peptide,RBCs: 0.1%Hemolysis=250 µg/ml,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,"Granted Patent; Family: 2s / 2ex; Family Jurisdictions: US; Legal Status: Inactive; Application No: 78521004; Filed: Feb 24, 2004; Published: Aug 15, 2006; Earliest Priority: Feb 24, 2003; Granted: Aug 15, 2006",0,KFAKKFAKKFAKKFAK
KFAKKFAKKFAKKFAKKFAK,20,Synthetic,Synthetic peptide,RBCs: 4.1%Hemolysis=250 µg/ml,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,"Granted Patent; Family: 2s / 2ex; Family Jurisdictions: US; Legal Status: Inactive; Application No: 78521004; Filed: Feb 24, 2004; Published: Aug 15, 2006; Earliest Priority: Feb 24, 2003; Granted: Aug 15, 2006",0,KFAKKFAKKFAKKFAKKFAK
KFAKKFAKKFAKKFAKKFAKKFAK,24,Synthetic,Synthetic peptide,RBCs: 7.3%Hemolysis=250 µg/ml,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,"Granted Patent; Family: 2s / 2ex; Family Jurisdictions: US; Legal Status: Inactive; Application No: 78521004; Filed: Feb 24, 2004; Published: Aug 15, 2006; Earliest Priority: Feb 24, 2003; Granted: Aug 15, 2006",0,KFAKKFAKKFAKKFAKKFAKKFAK
KFAKKFAKKFAKKFAKKFAKKFAKKFAK,28,Synthetic,Synthetic peptide,RBCs: 13.7%Hemolysis=250 µg/ml,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,"Granted Patent; Family: 2s / 2ex; Family Jurisdictions: US; Legal Status: Inactive; Application No: 78521004; Filed: Feb 24, 2004; Published: Aug 15, 2006; Earliest Priority: Feb 24, 2003; Granted: Aug 15, 2006",0,KFAKKFAKKFAKKFAKKFAKKFAKKFAK
KFAKKFAKKFAKKFAKKFAKKFAKKFAKKFAK,32,Synthetic,Synthetic peptide,RBCs: 48%Hemolysis=250 µg/ml,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,"Granted Patent; Family: 2s / 2ex; Family Jurisdictions: US; Legal Status: Inactive; Application No: 78521004; Filed: Feb 24, 2004; Published: Aug 15, 2006; Earliest Priority: Feb 24, 2003; Granted: Aug 15, 2006",0,KFAKKFAKKFAKKFAKKFAKKFAKKFAKKFAK
RFARRFARRFARRFARRFARRFAR,24,Synthetic,Synthetic peptide,RBCs: 72%Hemolysis=250 µg/ml,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,"Granted Patent; Family: 2s / 2ex; Family Jurisdictions: US; Legal Status: Inactive; Application No: 78521004; Filed: Feb 24, 2004; Published: Aug 15, 2006; Earliest Priority: Feb 24, 2003; Granted: Aug 15, 2006",0,RFARRFARRFARRFARRFARRFAR
RFARRFARRFARRFARRFARRFARRFAR,28,Synthetic,Synthetic peptide,RBCs: 100%Hemolysis=250 µg/ml,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,"Granted Patent; Family: 2s / 2ex; Family Jurisdictions: US; Legal Status: Inactive; Application No: 78521004; Filed: Feb 24, 2004; Published: Aug 15, 2006; Earliest Priority: Feb 24, 2003; Granted: Aug 15, 2006",0,RFARRFARRFARRFARRFARRFARRFAR
RFARRFARRFARRFARRFARRFARRFARRFAR,32,Synthetic,Synthetic peptide,RBCs: 100%Hemolysis=250 µg/ml,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,"Granted Patent; Family: 2s / 2ex; Family Jurisdictions: US; Legal Status: Inactive; Application No: 78521004; Filed: Feb 24, 2004; Published: Aug 15, 2006; Earliest Priority: Feb 24, 2003; Granted: Aug 15, 2006",0,RFARRFARRFARRFARRFARRFARRFARRFAR
FAKKFAKKFAKKFAKKFAKKFAKK,24,Synthetic,Synthetic peptide,RBCs: 7%Hemolysis=250 µg/ml,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,"Granted Patent; Family: 2s / 2ex; Family Jurisdictions: US; Legal Status: Inactive; Application No: 78521004; Filed: Feb 24, 2004; Published: Aug 15, 2006; Earliest Priority: Feb 24, 2003; Granted: Aug 15, 2006",0,FAKKFAKKFAKKFAKKFAKKFAKK
AKKFAKKFAKKFAKKFAKKFAKKF,24,Synthetic,Synthetic peptide,RBCs: 100%Hemolysis=250 µg/ml,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,"Granted Patent; Family: 2s / 2ex; Family Jurisdictions: US; Legal Status: Inactive; Application No: 78521004; Filed: Feb 24, 2004; Published: Aug 15, 2006; Earliest Priority: Feb 24, 2003; Granted: Aug 15, 2006",0,AKKFAKKFAKKFAKKFAKKFAKKF
KKFAKKFAKKFAKKFAKKFAKKFA,24,Synthetic,Synthetic peptide,RBCs: 2%Hemolysis=250 µg/ml,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,"Granted Patent; Family: 2s / 2ex; Family Jurisdictions: US; Legal Status: Inactive; Application No: 78521004; Filed: Feb 24, 2004; Published: Aug 15, 2006; Earliest Priority: Feb 24, 2003; Granted: Aug 15, 2006",0,KKFAKKFAKKFAKKFAKKFAKKFA
LKKLLKKLLKKLLKKLLKKL,20,Synthetic,Synthetic peptide,RBCs: 100%Hemolysis=250 µg/ml,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,"Granted Patent; Family: 2s / 2ex; Family Jurisdictions: US; Legal Status: Inactive; Application No: 78521004; Filed: Feb 24, 2004; Published: Aug 15, 2006; Earliest Priority: Feb 24, 2003; Granted: Aug 15, 2006",0,LKKLLKKLLKKLLKKLLKKL
LKKLLKKLLKKLLKKLLKKLLKKL,24,Synthetic,Synthetic peptide,RBCs: 100%Hemolysis=250 µg/ml,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,"Granted Patent; Family: 2s / 2ex; Family Jurisdictions: US; Legal Status: Inactive; Application No: 78521004; Filed: Feb 24, 2004; Published: Aug 15, 2006; Earliest Priority: Feb 24, 2003; Granted: Aug 15, 2006",0,LKKLLKKLLKKLLKKLLKKLLKKL
LKKLLKKLLKKLLKKLLKKLLKKLLKKL,28,Synthetic,Synthetic peptide,RBCs: 100%Hemolysis=250 µg/ml,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,"Granted Patent; Family: 2s / 2ex; Family Jurisdictions: US; Legal Status: Inactive; Application No: 78521004; Filed: Feb 24, 2004; Published: Aug 15, 2006; Earliest Priority: Feb 24, 2003; Granted: Aug 15, 2006",0,LKKLLKKLLKKLLKKLLKKLLKKLLKKL
LKKLLKKLLKKLLKKLLKKLLKKLLKKLLKKL,32,Synthetic,Synthetic peptide,RBCs: 100%Hemolysis=250 µg/ml,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,"Granted Patent; Family: 2s / 2ex; Family Jurisdictions: US; Legal Status: Inactive; Application No: 78521004; Filed: Feb 24, 2004; Published: Aug 15, 2006; Earliest Priority: Feb 24, 2003; Granted: Aug 15, 2006",0,LKKLLKKLLKKLLKKLLKKLLKKLLKKLLKKL
KFAFKFAFKFAFKFAFKFAFKFAFKFAF,28,Synthetic,Synthetic peptide,RBCs: 4%Hemolysis=250 µg/ml,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,"Granted Patent; Family: 2s / 2ex; Family Jurisdictions: US; Legal Status: Inactive; Application No: 78521004; Filed: Feb 24, 2004; Published: Aug 15, 2006; Earliest Priority: Feb 24, 2003; Granted: Aug 15, 2006",0,KFAFKFAFKFAFKFAFKFAFKFAFKFAF
KFFKKFFKKFFKKFFKKFFKKFFKKFFK,28,Synthetic,Synthetic peptide,RBCs: 100%Hemolysis=250 µg/ml,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,"Granted Patent; Family: 2s / 2ex; Family Jurisdictions: US; Legal Status: Inactive; Application No: 78521004; Filed: Feb 24, 2004; Published: Aug 15, 2006; Earliest Priority: Feb 24, 2003; Granted: Aug 15, 2006",0,KFFKKFFKKFFKKFFKKFFKKFFKKFFK
KAAKKAAKKAAKKAAKKAAKKAAKKAAK,28,Synthetic,Synthetic peptide,RBCs: -6%Hemolysis=250 µg/ml,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,"Granted Patent; Family: 2s / 2ex; Family Jurisdictions: US; Legal Status: Inactive; Application No: 78521004; Filed: Feb 24, 2004; Published: Aug 15, 2006; Earliest Priority: Feb 24, 2003; Granted: Aug 15, 2006",0,KAAKKAAKKAAKKAAKKAAKKAAKKAAK
KKAKKKAKKKAKKKAKKKAKKKAKKKAK,28,Synthetic,Synthetic peptide,RBCs: -6%Hemolysis=250 µg/ml,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,"Granted Patent; Family: 2s / 2ex; Family Jurisdictions: US; Legal Status: Inactive; Application No: 78521004; Filed: Feb 24, 2004; Published: Aug 15, 2006; Earliest Priority: Feb 24, 2003; Granted: Aug 15, 2006",0,KKAKKKAKKKAKKKAKKKAKKKAKKKAK
KFKKFKKFKKFKKFKKFK,18,Synthetic,Synthetic peptide,RBCs: -7%Hemolysis=250 µg/ml,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,"Granted Patent; Family: 2s / 2ex; Family Jurisdictions: US; Legal Status: Inactive; Application No: 78521004; Filed: Feb 24, 2004; Published: Aug 15, 2006; Earliest Priority: Feb 24, 2003; Granted: Aug 15, 2006",0,KFKKFKKFKKFKKFKKFK
KFKKFKKFKKFKKFKKFKKFK,21,Synthetic,Synthetic peptide,RBCs: -7%Hemolysis=250 µg/ml,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,"Granted Patent; Family: 2s / 2ex; Family Jurisdictions: US; Legal Status: Inactive; Application No: 78521004; Filed: Feb 24, 2004; Published: Aug 15, 2006; Earliest Priority: Feb 24, 2003; Granted: Aug 15, 2006",0,KFKKFKKFKKFKKFKKFKKFK
KFKKFKKFKKFKKFKKFKKFKKFK,24,Synthetic,Synthetic peptide,RBCs: -6%Hemolysis=250 µg/ml,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,"Granted Patent; Family: 2s / 2ex; Family Jurisdictions: US; Legal Status: Inactive; Application No: 78521004; Filed: Feb 24, 2004; Published: Aug 15, 2006; Earliest Priority: Feb 24, 2003; Granted: Aug 15, 2006",0,KFKKFKKFKKFKKFKKFKKFKKFK
KFKKFKKFKKFKKFKKFKKFKKFKKFK,27,Synthetic,Synthetic peptide,RBCs: -6%Hemolysis=250 µg/ml,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,"Granted Patent; Family: 2s / 2ex; Family Jurisdictions: US; Legal Status: Inactive; Application No: 78521004; Filed: Feb 24, 2004; Published: Aug 15, 2006; Earliest Priority: Feb 24, 2003; Granted: Aug 15, 2006",0,KFKKFKKFKKFKKFKKFKKFKKFKKFK
KFKKFKKFKKFKKFKKFKKFKKFKKFKKFK,30,Synthetic,Synthetic peptide,RBCs: 3%Hemolysis=250 µg/ml,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,"Granted Patent; Family: 2s / 2ex; Family Jurisdictions: US; Legal Status: Inactive; Application No: 78521004; Filed: Feb 24, 2004; Published: Aug 15, 2006; Earliest Priority: Feb 24, 2003; Granted: Aug 15, 2006",0,KFKKFKKFKKFKKFKKFKKFKKFKKFKKFK
FKAFKAFKAFKAFKAFKA,18,Synthetic,Synthetic peptide,RBCs: 28%Hemolysis=250 µg/ml,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,"Granted Patent; Family: 2s / 2ex; Family Jurisdictions: US; Legal Status: Inactive; Application No: 78521004; Filed: Feb 24, 2004; Published: Aug 15, 2006; Earliest Priority: Feb 24, 2003; Granted: Aug 15, 2006",0,FKAFKAFKAFKAFKAFKA
FKAFKAFKAFKAFKAFKAFKA,21,Synthetic,Synthetic peptide,RBCs: 11%Hemolysis=250 µg/ml,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,"Granted Patent; Family: 2s / 2ex; Family Jurisdictions: US; Legal Status: Inactive; Application No: 78521004; Filed: Feb 24, 2004; Published: Aug 15, 2006; Earliest Priority: Feb 24, 2003; Granted: Aug 15, 2006",0,FKAFKAFKAFKAFKAFKAFKA
FKAFKAFKAFKAFKAFKAFKAFKA,24,Synthetic,Synthetic peptide,RBCs: 10%Hemolysis=250 µg/ml,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,"Granted Patent; Family: 2s / 2ex; Family Jurisdictions: US; Legal Status: Inactive; Application No: 78521004; Filed: Feb 24, 2004; Published: Aug 15, 2006; Earliest Priority: Feb 24, 2003; Granted: Aug 15, 2006",0,FKAFKAFKAFKAFKAFKAFKAFKA
FKAFKAFKAFKAFKAFKAFKAFKAFKA,27,Synthetic,Synthetic peptide,RBCs: 24%Hemolysis=250 µg/ml,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,"Granted Patent; Family: 2s / 2ex; Family Jurisdictions: US; Legal Status: Inactive; Application No: 78521004; Filed: Feb 24, 2004; Published: Aug 15, 2006; Earliest Priority: Feb 24, 2003; Granted: Aug 15, 2006",0,FKAFKAFKAFKAFKAFKAFKAFKAFKA
FKAFKAFKAFKAFKAFKAFKAFKAFKAFKA,30,Synthetic,Synthetic peptide,RBCs: 51%Hemolysis=250 µg/ml,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,"Granted Patent; Family: 2s / 2ex; Family Jurisdictions: US; Legal Status: Inactive; Application No: 78521004; Filed: Feb 24, 2004; Published: Aug 15, 2006; Earliest Priority: Feb 24, 2003; Granted: Aug 15, 2006",0,FKAFKAFKAFKAFKAFKAFKAFKAFKAFKA
LKLKLKLKLKLKLK,14,Synthetic,Synthetic peptide,RBCs: 16%Hemolysis=250 µg/ml,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,"Granted Patent; Family: 2s / 2ex; Family Jurisdictions: US; Legal Status: Inactive; Application No: 78521004; Filed: Feb 24, 2004; Published: Aug 15, 2006; Earliest Priority: Feb 24, 2003; Granted: Aug 15, 2006",0,LKLKLKLKLKLKLK
LKLKLKLKLKLKLKLK,16,Synthetic,Synthetic peptide,RBCs: 13%Hemolysis=250 µg/ml,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,"Granted Patent; Family: 2s / 2ex; Family Jurisdictions: US; Legal Status: Inactive; Application No: 78521004; Filed: Feb 24, 2004; Published: Aug 15, 2006; Earliest Priority: Feb 24, 2003; Granted: Aug 15, 2006",0,LKLKLKLKLKLKLKLK
LKLKLKLKLKLKLKLKLK,18,Synthetic,Synthetic peptide,RBCs: 21%Hemolysis=250 µg/ml,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,"Granted Patent; Family: 2s / 2ex; Family Jurisdictions: US; Legal Status: Inactive; Application No: 78521004; Filed: Feb 24, 2004; Published: Aug 15, 2006; Earliest Priority: Feb 24, 2003; Granted: Aug 15, 2006",0,LKLKLKLKLKLKLKLKLK
LKLKLKLKLKLKLKLKLKLK,20,Synthetic,Synthetic peptide,RBCs: 27%Hemolysis=250 µg/ml,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,"Granted Patent; Family: 2s / 2ex; Family Jurisdictions: US; Legal Status: Inactive; Application No: 78521004; Filed: Feb 24, 2004; Published: Aug 15, 2006; Earliest Priority: Feb 24, 2003; Granted: Aug 15, 2006",0,LKLKLKLKLKLKLKLKLKLK
LKLKLKLKLKLKLKLKLKLKLK,22,Synthetic,Synthetic peptide,RBCs: 24%Hemolysis=250 µg/ml,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,"Granted Patent; Family: 2s / 2ex; Family Jurisdictions: US; Legal Status: Inactive; Application No: 78521004; Filed: Feb 24, 2004; Published: Aug 15, 2006; Earliest Priority: Feb 24, 2003; Granted: Aug 15, 2006",0,LKLKLKLKLKLKLKLKLKLKLK
LKLKLKLKLKLKLKLKLKLKLKLK,24,Synthetic,Synthetic peptide,RBCs: 35%Hemolysis=250 µg/ml,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,"Granted Patent; Family: 2s / 2ex; Family Jurisdictions: US; Legal Status: Inactive; Application No: 78521004; Filed: Feb 24, 2004; Published: Aug 15, 2006; Earliest Priority: Feb 24, 2003; Granted: Aug 15, 2006",0,LKLKLKLKLKLKLKLKLKLKLKLK
LRLRLRLRLRLRLR,14,Synthetic,Synthetic peptide,RBCs: 15%Hemolysis=250 µg/ml,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,"Granted Patent; Family: 2s / 2ex; Family Jurisdictions: US; Legal Status: Inactive; Application No: 78521004; Filed: Feb 24, 2004; Published: Aug 15, 2006; Earliest Priority: Feb 24, 2003; Granted: Aug 15, 2006",0,LRLRLRLRLRLRLR
LRLRLRLRLRLRLRLRLR,18,Synthetic,Synthetic peptide,RBCs: 24%Hemolysis=250 µg/ml,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,"Granted Patent; Family: 2s / 2ex; Family Jurisdictions: US; Legal Status: Inactive; Application No: 78521004; Filed: Feb 24, 2004; Published: Aug 15, 2006; Earliest Priority: Feb 24, 2003; Granted: Aug 15, 2006",0,LRLRLRLRLRLRLRLRLR
LRLRLRLRLRLRLRLRLRLRLR,22,Synthetic,Synthetic peptide,RBCs: 41%Hemolysis=250 µg/ml,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,"Granted Patent; Family: 2s / 2ex; Family Jurisdictions: US; Legal Status: Inactive; Application No: 78521004; Filed: Feb 24, 2004; Published: Aug 15, 2006; Earliest Priority: Feb 24, 2003; Granted: Aug 15, 2006",0,LRLRLRLRLRLRLRLRLRLRLR
fxisfSSxFSVix,13,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,C10,Free,f=D-Phe; x=D-Orn; i=D-Ile; s=D-Ser,,0,FXISFSSXFSVIX
fxisfSSxFSViX,13,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,C14OH,Free,f=D-Phe; x=D-Orn; i=D-Ile; s=D-Ser; X=Orn,,0,FXISFSSXFSVIX
fxiswSSxWSViX,13,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,C10,Free,f=D-Phe; x=D-Orn; i=D-Ile; s=D-Ser; w=D-Trp; X=Orn,,0,FXISWSSXWSVIX
fxisvSSxVSViX,13,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,C10,Free,f=D-Phe; x=D-Dab; i=D-Ile; s=D-Ser; v=D-Val; X=Dab,,0,FXISVSSXVSVIX
kLGvPLKRK,9,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,C14OH,Free,k=D-Lys; v=D-Val ,,0,KLGVPLKRK
kSGxKHKKK,9,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,C14OH,Free,k=D-Lys; x=D-Orn,,0,KSGXKHKKK
aLGvPLKRK,9,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,C14OH,Free,a=D-Ala; x=D-Orn,,0,ALGVPLKRK
kLGvALKRK,9,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,C14OH,Free,k=D-Lys; v=D-Val ,,0,KLGVALKRK
kLGvPLARK,9,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,C14OH,Free,k=D-Lys; v=D-Val ,,0,KLGVPLARK
kLGvPLKAK,9,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,C14OH,Free,k=D-Lys; v=D-Val ,,0,KLGVPLKAK
kLGvPLKRA,9,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,C14OH,Free,k=D-Lys; v=D-Val ,,0,KLGVPLKRA
WEXWtIW,7,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,C14OH,Free,t=D-Thr; X=Orn,,0,WEXWTIW
WyTxXxTwxWXY,12,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,C14OH,Free,y=D-TYR; x(4/6)=D-Orn; w=D-Trp; x(9)=D-Dab; X=Orn,,0,WYTXXXTWXWXY
XrIRL,5,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,C14OH,Free,X=Orn; r=D-Arg,,0,XRIRL
sRxRtLxTTnGT,12,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,C14OH,Free,s=D-Ser; x=D-Dab; t=D=Thr; n=D-Asn,,0,SRXRTLXTTNGT
GKEFKRIVWLSKTAKKL,17,Synthetic,Synthetic peptide,Human erythrocytes: 5%Hemolysis>128 µM,,,,,Anticancer; Antibacterial,Tumor active peptide##Membrane-targeted,,Linear,,Free,Amidation,,,0,GKEFKRIVWLSKTAKKL
GKEFKRIVKWPWWPWRR,17,Synthetic,Synthetic peptide,Human erythrocytes: 5%Hemolysis>128 µM,,,,,Anticancer; Antibacterial,Tumor active peptide##Membrane-targeted,,Linear,,Free,Amidation,,,0,GKEFKRIVKWPWWPWRR
GKEFKRIVGRIYRLCCR,17,Synthetic,Synthetic peptide,Human erythrocytes: 5%Hemolysis>128 µM,,,,,Anticancer; Antibacterial,Tumor active peptide##Membrane-targeted,,Linear,,Free,Amidation,,,0,GKEFKRIVGRIYRLCCR
VTCYCRRTRCGFRERLSGACGYRGRIYRLCCR,32,Rattus norvegicus,Native peptide,Human erythrocytes: 5%Hemolysis>128 µM,,,,,Anticancer; Antibacterial,Tumor active peptide##Membrane-targeted,,Cyclic,Cys3<--->Cys31; Cys5<--->Cys20; Cys10<--->Cys30,Free,Amidation,,,0,VTCYCRRTRCGFRERLSGACGYRGRIYRLCCR
KKIGQKIKNFFQKL,14,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Free,,,0,KKIGQKIKNFFQKL
KKIWQKIKNFFQKL,14,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Free,,,0,KKIWQKIKNFFQKL
KRIWQKIKNFFQKL,14,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Free,,,0,KRIWQKIKNFFQKL
KKIWQRIKNFFQKL,14,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Free,,,0,KKIWQRIKNFFQKL
KKIWQKIRNFFQKL,14,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Free,,,0,KKIWQKIRNFFQKL
KKIWQKIKRFFQKL,14,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Free,,,0,KKIWQKIKRFFQKL
KKIWQKIKNFFRKL,14,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Free,,,0,KKIWQKIKNFFRKL
FLSLIPKAISAVSALANHF,19,Synthetic,Synthetic peptide,Horse erythrocytes:50% Hemolysis=197.7µM,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,,0,FLSLIPKAISAVSALANHF
FLSLIPKAISAISALANHF,19,Synthetic,Synthetic peptide,Horse erythrocytes:50% Hemolysis=34.86µM,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,,0,FLSLIPKAISAISALANHF
FLSLIPKAISAISALINHF,19,Synthetic,Synthetic peptide,Horse erythrocytes:50% Hemolysis=9.266µM,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,,0,FLSLIPKAISAISALINHF
FLSLIPKIISAISALINHF,19,Synthetic,Synthetic peptide,Horse erythrocytes:50% Hemolysis=2.766µM,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,,0,FLSLIPKIISAISALINHF
FLSLIPKIISAISALIKHF,19,Synthetic,Synthetic peptide,Horse erythrocytes:50% Hemolysis=1.074µM,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,,0,FLSLIPKIISAISALIKHF
WFGKLYRGKTKVVKKVKGLLKG,22,Synthetic,Synthetic peptide,Human erythrocytes: 5% Hemolysis=3µM; 30% Hemolysis=50µM,HUVEC: 3.84% Killing=64 µM,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,WFGKLYRGKTKVVKKVKGLLKG
QLGKKKHRRRPSKKKRHW,18,Synthetic,Synthetic peptide,,HaCat: Not active up to 100 µM,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,QLGKKKHRRRPSKKKRHW
QLGRRRHRRRPSRRRRHW,18,Synthetic,Synthetic peptide,,HaCat: Not active up to 100 µM,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,QLGRRRHRRRPSRRRRHW
AAVALLPAVLLALLAPMPFSTGKRIMLGE,29,Synthetic,Synthetic peptide,,HEK293: Not active up to 100 µM; HFF: Not active up to 100 µM,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,AAVALLPAVLLALLAPMPFSTGKRIMLGE
AAVALLPAVLLALLAPQLGKKKHRRRPSKKKRHW,34,Synthetic,Synthetic peptide,,HEK293: 30%Killing=10 µM; HFF: 20%Killing=10 µM; 90%Killing=50 µM,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,AAVALLPAVLLALLAPQLGKKKHRRRPSKKKRHW
LTVSPWYGCGQLGKKKHRRRPSKKKRHW,28,Synthetic,Synthetic peptide,,CHO-K1: 0%Killing=50 µM; HFF: 10%Killing=50 µM; WI-38: 5%Killing=50 µM,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,LTVSPWYGCGQLGKKKHRRRPSKKKRHW
LTVSPWYGCGQLGRRRHRRRPSRRRRHW,28,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,LTVSPWYGCGQLGRRRHRRRPSRRRRHW
MPFSTGKRIMLGE,13,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,MPFSTGKRIMLGE
LTVSPWYGCGMPFSTGKRIMLGE,23,Synthetic,Synthetic peptide,,CHO-K1: 0%Killing=50 µM; HFF: 0%Killing=50 µM; WI-38: 0%Killing=50 µM,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,LTVSPWYGCGMPFSTGKRIMLGE
LTVSPWYGCGKLAKLAKKLAKLAK,24,Synthetic,Synthetic peptide,,CHO-K1: 100%Killing=50 µM; HFF: 80%Killing=50 µM; WI-38: 55%Killing=50 µM,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,LTVSPWYGCGKLAKLAKKLAKLAK
AAVALLPAVLLALLAPQLGRRRHRRRPSRRRRHW,34,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,AAVALLPAVLLALLAPQLGRRRHRRRPSRRRRHW
AAVALLPAVLLALLAPQLGKKILAARPSKKKRHW,34,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,AAVALLPAVLLALLAPQLGKKILAARPSKKKRHW
ALFGILKKAFGKILTIFAGLPGVV,24,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide##Membrane-targeted,,Linear,,Free,Amidation,,,0,ALFGILKKAFGKILTIFAGLPGVV
GLGDFIKAIAKHLGPLIGILPSKLKVAA,28,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide##Membrane-targeted,,Linear,,Free,Amidation,,,0,GLGDFIKAIAKHLGPLIGILPSKLKVAA
GLKDPLKSVAKHLVK,15,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide##Membrane-targeted,,Linear,,Free,Amidation,,,0,GLKDPLKSVAKHLVK
GLVMLVKKAGLT,12,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide##Membrane-targeted,,Linear,,Free,Amidation,,,0,GLVMLVKKAGLT
IIFGVIKALSG,11,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide##Membrane-targeted,,Linear,,Free,Amidation,,,0,IIFGVIKALSG
FLGPTIGKIAKFILKHIVGLGDAALV,26,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide##Membrane-targeted,,Linear,,Free,Amidation,,,0,FLGPTIGKIAKFILKHIVGLGDAALV
GIVTILKGAVGVILGGL,17,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide##Membrane-targeted,,Linear,,Free,Amidation,,,0,GIVTILKGAVGVILGGL
GLFKIISGIA,10,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide##Membrane-targeted,,Linear,,Free,Amidation,,,0,GLFKIISGIA
GLGMIAHGV,9,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide##Membrane-targeted,,Linear,,Free,Amidation,,,0,GLGMIAHGV
GLWKILKKGA,10,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide##Membrane-targeted,,Linear,,Free,Amidation,,,0,GLWKILKKGA
GLFAILKKLVNLVG,14,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide##Membrane-targeted,,Linear,,Free,Amidation,,,0,GLFAILKKLVNLVG
GLFKIISKLAKKA,13,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide##Membrane-targeted,,Linear,,Free,Amidation,,,0,GLFKIISKLAKKA
GLPLFLKKLGSAV,13,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide##Membrane-targeted,,Linear,,Free,Amidation,,,0,GLPLFLKKLGSAV
GLWGVIKALGGHVG,14,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide##Membrane-targeted,,Linear,,Free,Amidation,,,0,GLWGVIKALGGHVG
GLLALLGELAEHLGSKI,17,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide##Membrane-targeted,,Linear,,Free,Amidation,,,0,GLLALLGELAEHLGSKI
GTFAIIQ,7,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide##Membrane-targeted,,Linear,,Free,Amidation,,,0,GTFAIIQ
GDGDIMKGIAGH,12,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide##Membrane-targeted,,Linear,,Free,Amidation,,,0,GDGDIMKGIAGH
GLPQIISKVVKT,12,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide##Membrane-targeted,,Linear,,Free,Amidation,,,0,GLPQIISKVVKT
FLSLIPKLVKKIIKAFK,17,Synthetic,Synthetic peptide,Horse erythrocytes: 28% Hemolysis=5 µM; Horse erythrocytes: 100% Hemolysis=20 µM,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Free,,,0,FLSLIPKLVKKIIKAFK
FLGMIPKLIKKLIKAFK,17,Synthetic,Synthetic peptide,Horse erythrocytes: 28% Hemolysis=5 µM; Horse erythrocytes: 100% Hemolysis=20 µM,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Free,,,0,FLGMIPKLIKKLIKAFK
FLPIVGRLISGIL,13,Lithobates capito,Native peptide,Human erythrocytes: 50% Hemolysis>100 µM,HaCat: LC50>200 µM,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide##Membrane lysis,,Linear,,Free,Amidation,,,0,FLPIVGRLISGIL
SILPTIVSFLSKVF,14,Rana grylio,Native peptide,Human erythrocytes: 50% Hemolysis=12.5 µM,HaCat: LC50=40 µM,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide##Membrane lysis,,Linear,,Free,Amidation,,,0,SILPTIVSFLSKVF
FLPFLKSILGKIL,13,Rana okaloosae,Native peptide,Human erythrocytes: 50% Hemolysis=50 µM,HaCat: LC50=100 µM,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide##Membrane lysis,,Linear,,Free,Amidation,,,0,FLPFLKSILGKIL
FLSAITSILGKFF,13,Rana septentrionalis,Native peptide,Human erythrocytes: 50% Hemolysis=37.5 µM,HaCat: LC50=200 µM,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide##Membrane lysis,,Linear,,Free,Amidation,,,0,FLSAITSILGKFF
GIKKWLHSAKKFGKKFVKKIXNS,23,Synthetic,Synthetic peptide,Human kidney-derived GM cells: EC50=7.6±2.1 µM(pH=6); EC50=25.6±4.5 µM(pH=7.4),HEK293: EC50=15.7±1.8 µM(pH=7.4),,,,Anticancer,Tumor active peptide,,Linear,,Free,Amidation,X=Nle,,0,GIKKWLHSAKKFGKKFVKKIXNS
GIKXWLHSAKKFGXKFVKKIXNS,23,Synthetic,Synthetic peptide,Human kidney-derived GM cells: EC50=25.9±0.6 µM(pH=6); EC50=50.3±0.9 µM(pH=7.4),HEK293: EC50=27.2±3.1 µM(pH=7.4),,,,Anticancer,Tumor active peptide,,Linear,,Free,Amidation,X(4/14)=Dap; X(21)=Nle,,0,GIKXWLHSAKKFGXKFVKKIXNS
GIKXWLHSAXKFGXKFVKXIXNS,23,Synthetic,Synthetic peptide,Human kidney-derived GM cells: EC50=21.1±0.3 µM(pH=6); EC50=91.6±5.9 µM(pH=7.4),HEK293: EC50>100 µM(pH=7.4),,,,Anticancer,Tumor active peptide,,Linear,,Free,Amidation,X(4/10/14/19)=Dap; X(21)=Nle,,0,GIKXWLHSAXKFGXKFVKXIXNS
GIKXWLHSAXXFGXKFVXXIXNS,23,Synthetic,Synthetic peptide,Human kidney-derived GM cells: EC50=	19.8±0.3 µM(pH=6); EC50>100 µM(pH=7.4),HEK293: EC50>100 µM(pH=7.4),,,,Anticancer,Tumor active peptide,,Linear,,Free,Amidation,X(4/10/11/14/18/19)=Dap; X(21)=Nle,,0,GIKXWLHSAXXFGXKFVXXIXNS
GIXXWLHSAXXFGXXFVXXIXNS,23,Synthetic,Synthetic peptide,Human kidney-derived GM cells: EC50=7.6±2.1 µM(pH=6); EC50=25.6±4.5 µM(pH=7.4),HEK293: EC50=15.7±1.8 µM(pH=7.4),,,,Anticancer,Tumor active peptide,,Linear,,Free,Amidation,X(3/4/10/11/14/15/18/19)=Dap; X(21)=Nle,,0,GIXXWLHSAXXFGXXFVXXIXNS
LIAGLAANFLPQILCKIARKC,21,Synthetic,Synthetic peptide,Human erythrocytes: 37% Hemolysis=200 µM,HEK293: 50%Cytotoxicity>100 µg/ml; PBMC: 50%Cytotoxicity=75.1±1.46 µg/ml,,,,Anticancer; Antibacterial,Tumor active peptide##Membrane-targeted,,Linear,,Free,Amidation,,,0,LIAGLAANFLPQILCKIARKC
LAANFLPQILCKIARKC,17,Synthetic,Synthetic peptide,Human erythrocytes: 30% Hemolysis=200 µM,HEK293: 50%Cytotoxicity>100 µg/ml; PBMC: 50%Cytotoxicity>100 µg/ml,,,,Anticancer; Antibacterial,Tumor active peptide##Membrane-targeted,,Cyclic,Cys11<--->Cys17,Free,Amidation,,,0,LAANFLPQILCKIARKC
KIAGLAANFLPQILCKIARKC,21,Synthetic,Synthetic peptide,Human erythrocytes: 15% Hemolysis=200 µM,HEK293: 50%Cytotoxicity>100 µg/ml; PBMC: 50%Cytotoxicity=74.5±2.44 µg/ml,,,,Anticancer; Antibacterial,Tumor active peptide##Membrane-targeted,,Cyclic,Cys15<--->Cys21,Free,Amidation,,,0,KIAGLAANFLPQILCKIARKC
WIAGLAANFLPQILCKIARKC,21,Synthetic,Synthetic peptide,Human erythrocytes: 39.11% Hemolysis=200 µM,HEK293: 50%Cytotoxicity>100 µg/ml; PBMC: 50%Cytotoxicity>100 µg/ml,,,,Anticancer; Antibacterial,Tumor active peptide##Membrane-targeted,,Linear,Cys15<--->Cys21,Free,Amidation,,,0,WIAGLAANFLPQILCKIARKC
RIAGLAANFLPQILCKIARKC,21,Synthetic,Synthetic peptide,Human erythrocytes: 17.4% Hemolysis=200 µM,HEK293: 50%Cytotoxicity>100 µg/ml; PBMC: 50%Cytotoxicity=75.1±1.46 µg/ml,,,,Anticancer; Antibacterial,Tumor active peptide##Membrane-targeted,,Linear,Cys15<--->Cys21,Free,Amidation,,,0,RIAGLAANFLPQILCKIARKC
HIAGLAANFLPQILCKIARKC,21,Synthetic,Synthetic peptide,Human erythrocytes: 30.4% Hemolysis=200 µg/ml,HEK293: 50%Cytotoxicity>100 µg/ml; PBMC: 50%Cytotoxicity=90±2.56 µg/ml,,,,Anticancer; Antibacterial,Tumor active peptide##Membrane-targeted,,Linear,Cys15<--->Cys21,Free,Amidation,,,0,HIAGLAANFLPQILCKIARKC
liaGlaanflpqilckiarkc,21,Synthetic,Synthetic peptide,Human erythrocytes: 40.22% Hemolysis=200 µg/ml,HEK293: 50%Cytotoxicity>100 µg/ml; PBMC: 50%Cytotoxicity=71.4±2.3 µg/ml,,,,Anticancer; Antibacterial,Tumor active peptide##Membrane-targeted,,Cyclic,Cys15<--->Cys21,Free,Amidation,,,0,LIAGLAANFLPQILCKIARKC
AIIKKIIKKIIKKI,14,Synthetic,Synthetic peptide,Human erythrocytes: 5% Hemolysis=300 µM; Human erythrocytes: 10% Hemolysis=500 µM,Human chondrocytes-articular cells Hca: 25% Killing=40 µM,,,,Anticancer,Tumor active peptide##Membrane-targeted,,Linear,,Free,Amidation,,,0,AIIKKIIKKIIKKI
EIIKKIIKKIIKKI,14,Synthetic,Synthetic peptide,Human erythrocytes: 5% Hemolysis=300 µM; Human erythrocytes: 7% Hemolysis=500 µM,Human chondrocytes-articular cells Hca: 23% Killing=40 µM,,,,Anticancer,Tumor active peptide##Membrane-targeted,,Linear,,Free,Amidation,,,0,EIIKKIIKKIIKKI
KIIKKIIKKIIKKI,14,Synthetic,Synthetic peptide,Human erythrocytes: 5% Hemolysis=300 µM; Human erythrocytes: 8% Hemolysis=500 µM,Human chondrocytes-articular cells Hca: 40% Killing=40 µM,,,,Anticancer,Tumor active peptide##Membrane-targeted,,Linear,,Free,Amidation,,,0,KIIKKIIKKIIKKI
VIIKKIIKKIIKKI,14,Synthetic,Synthetic peptide,Human erythrocytes: 7% Hemolysis=300 µM; Human erythrocytes: 12% Hemolysis=500 µM,Human chondrocytes-articular cells Hca: 25% Killing=40 µM,,,,Anticancer,Tumor active peptide##Membrane-targeted,,Linear,,Free,Amidation,,,0,VIIKKIIKKIIKKI
GIIKKIIKKIIKKA,14,Synthetic,Synthetic peptide,Human erythrocytes: 5% Hemolysis=300 µM; Human erythrocytes: 15% Hemolysis=500 µM,Human chondrocytes-articular cells Hca: 25% Killing=40 µM,,,,Anticancer,Tumor active peptide##Membrane-targeted,,Linear,,Free,Amidation,,,0,GIIKKIIKKIIKKA
GIIKKIIKKIIKKE,14,Synthetic,Synthetic peptide,Human erythrocytes: 0%  Hemolysis=500 µM,Not active up to 40 µM,,,,Anticancer,Tumor active peptide##Membrane-targeted,,Linear,,Free,Amidation,,,0,GIIKKIIKKIIKKE
GIIKKIIKKIIKKK,14,Synthetic,Synthetic peptide,Human erythrocytes: 0%  Hemolysis=500 µM,Human chondrocytes-articular cells Hca: 10% Killing=40 µM,,,,Anticancer,Tumor active peptide##Membrane-targeted,,Linear,,Free,Amidation,,,0,GIIKKIIKKIIKKK
GIIKKIIKKIIKKV,14,Synthetic,Synthetic peptide,Human erythrocytes: 22% Hemolysis=300 µM; Human erythrocytes: 35% Hemolysis=500 µM,Human chondrocytes-articular cells Hca: 50% Killing=40 µM,,,,Anticancer,Tumor active peptide##Membrane-targeted,,Linear,,Free,Amidation,,,0,GIIKKIIKKIIKKV
KLWKKIEKLIKKLLTSIR,18,Synthetic,Synthetic peptide,Human erythrocytes: 50% Hemolysis=236±13 µM,,,,,Anticancer,Tumor active peptide##Membrane-targeted,,Linear,,Free,Amidation,,,0,KLWKKIEKLIKKLLTSIR
YIWARAERVWLWWGKFLSL,19,Synthetic,Synthetic peptide,Human erythrocytes: Not active up to 400 µM,,,,,Anticancer,Tumor active peptide##Membrane-targeted,,Linear,,Free,Amidation,,,0,YIWARAERVWLWWGKFLSL
DLFKQLQRLFLGILYCLYKIW,21,Synthetic,Synthetic peptide,Human erythrocytes：50% Hemolysis=132±16 µM,,,,,Anticancer,Tumor active peptide##Membrane-targeted,,Linear,,Free,Amidation,,,0,DLFKQLQRLFLGILYCLYKIW
AIKKFGPLAKIVAKV,15,Synthetic,Synthetic peptide,Human erythrocytes: Not active up to 400 µM,,,,,Anticancer,Tumor active peptide##Membrane-targeted,,Linear,,Free,Amidation,,,0,AIKKFGPLAKIVAKV
RWNGRIIKGFYNLVKIWKDLKG,22,Synthetic,Synthetic peptide,Human erythrocytes：50% Hemolysis=89±6 µM,,,,,Anticancer,Tumor active peptide##Membrane-targeted,,Linear,,Free,Amidation,,,0,RWNGRIIKGFYNLVKIWKDLKG
KVWKIKKNIRRLLHGIKRGWKG,22,Synthetic,Synthetic peptide,Human erythrocytes: Not active up to 400 µM,,,,,Anticancer,Tumor active peptide##Membrane-targeted,,Linear,,Free,Amidation,,,0,KVWKIKKNIRRLLHGIKRGWKG
GFWARIGKVFAAVKNL,16,Synthetic,Synthetic peptide,Human erythrocytes: Not active up to 400 µM,,,,,Anticancer,Tumor active peptide##Membrane-targeted,,Linear,,Free,Amidation,,,0,GFWARIGKVFAAVKNL
AFLYRLTRQIRPWWRWLYKW,20,Synthetic,Synthetic peptide,Human erythrocytes: 50% Hemolysis=34±5 µM,,,,,Anticancer,Tumor active peptide##Membrane-targeted,,Linear,,Free,Amidation,,,0,AFLYRLTRQIRPWWRWLYKW
RIWGKHSRYIKIVKRLIQ,18,Synthetic,Synthetic peptide,Human erythrocytes: Not active up to 400 µM,,,,,Anticancer,Tumor active peptide##Membrane-targeted,,Linear,,Free,Amidation,,,0,RIWGKHSRYIKIVKRLIQ
QIWHKIRKLWQIIKDGF,17,Synthetic,Synthetic peptide,Human erythrocytes: 50% Hemolysis=23±5 µM,,,,,Anticancer,Tumor active peptide##Membrane-targeted,,Linear,,Free,Amidation,,,0,QIWHKIRKLWQIIKDGF
RPFTRAQWFAIQHISPRTIAMRAINNYRWR,30,Synthetic,Synthetic peptide,Sheep erythrocytes: 50% Hemolysis=178.33±81.72 µM; Horse erythrocytes: 44±4% Hemolysis=250 µM,MRC-5: IC50>150 µM,,,,Anticancer; Antibacterial,Tumor active peptide##Membrane-targeted,,Linear,,Free,Free,,,0,RPFTRAQWFAIQHISPRTIAMRAINNYRWR
RPFIRAQWFAIQHISPRTIAMRAINNYRWR,30,Synthetic,Synthetic peptide,Sheep erythrocytes:50% Hemolysis>150 µM,MRC-5: IC50>150 µM,,,,Anticancer; Antibacterial,Tumor active peptide##Membrane-targeted,,Linear,,Free,Free,,,0,RPFIRAQWFAIQHISPRTIAMRAINNYRWR
RPFTRAQIFAIQHISPRTIAMRAINNYRWR,30,Synthetic,Synthetic peptide,Sheep erythrocytes: 50% Hemolysis>150 µM,MRC-5: IC50>150 µM,,,,Anticancer; Antibacterial,Tumor active peptide##Membrane-targeted,,Linear,,Free,Free,,,0,RPFTRAQIFAIQHISPRTIAMRAINNYRWR
RPFTRAQWFAIIHISPRTIAMRAINNYRWR,30,Synthetic,Synthetic peptide,Sheep erythrocytes: 50% Hemolysis>100µM,MRC-5: IC50>100 µM,,,,Anticancer; Antibacterial,Tumor active peptide##Membrane-targeted,,Linear,,Free,Free,,,0,RPFTRAQWFAIIHISPRTIAMRAINNYRWR
MRGENMSEGNRPEGTPHGLRSTPARELPIPAFLEPAR,37,Tistrella mobilis (strain KA081020-065),Native peptide,,,,,,Anticancer,,,Linear,,Free,Free,,,0,MRGENMSEGNRPEGTPHGLRSTPARELPIPAFLEPAR
GTTCYCGKTIGIYWFGKYSCPTNRGYTGSCPYFLGICCYPVD,42,Anthopleura elegantissima (Green aggregating anemone) (Actinia elegantissima),Native peptide,,NIH-3T3: KV10.1 Expression Level (Undetectable); Human epithelial cell line hTERT RPE-1: KV10.1 Expression Level (Moderate),,,"APETx4 is able to selectively inhibit the human ether-à-go-go channel (hEag1 or KV10.1), which a cancer-relevant voltage-gated potassium channel that is overexpressed in a majority of human tumors. ",Anticancer,Tumor active peptide##KV10.1 inhibitor,,Linear,,Free,Free,,,0,GTTCYCGKTIGIYWFGKYSCPTNRGYTGSCPYFLGICCYPVD
EGKLSSNDTEGGLCKEFLHPSKVDLPR,27,Blarina brevicauda ,Native peptide,,,,,"SOR-C13 and SOR-C27, derived from the C-terminus of soricidin, are high-affinity antagonists of human TRPV6 channels that are up-regulated in a number of cancers",Anticancer,"Tumor active peptide##TRPV6 antagonists
Tumor active peptide##TRPV6 antagonists
Tumor active peptide##TRPV6 antagonists",,Linear,,Free,Free,,,0,EGKLSSNDTEGGLCKEFLHPSKVDLPR
KEFLHPSKVDLPR,13,Blarina brevicauda ,Native peptide,,,,,"SOR-C13 and SOR-C27, derived from the C-terminus of soricidin, are high-affinity antagonists of human TRPV6 channels that are up-regulated in a number of cancers",Anticancer,Tumor active peptide##TRPV6 antagonists,,Linear,,Free,Free,,,0,KEFLHPSKVDLPR
NEPCDSDGDCCTSSEQCISTGSKYFC,26,Tityus serrulatus,Native peptide,,"HUV-EC-C, HFF-1, MCR-5, HEK-293, BHK-21, MDCK: sub peptide was unable to cross the cell membrane",,,As a drug delivery system targeting cancer cell nucleus using CPP-Ts’s nuclear-targeting property.,Anticancer,Cell-penetrating peptides,,Linear,,Free,Free,,,0,NEPCDSDGDCCTSSEQCISTGSKYFC
GKWMSFLKHILK,12,Synthetic,Synthetic peptide,Rat erythrocytes: IC50=69 μM,HUVEC: IC50=55±9 μM,,,,Anticancer; Antimicrobial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,,0,GKWMSFLKHILK
GKWMSLLKHILK,12,Halictines and their analogs,Native peptide,Rat erythrocytes: IC50=78.1 μM,HUVEC: IC50=23±9 μM,,,,Anticancer; Antimicrobial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,,0,GKWMSLLKHILK
gkwmsllkhilk,12,Synthetic,Synthetic peptide,Rat erythrocytes: IC50=54 μM,HUVEC: IC50=22±7 μM,,,,Anticancer; Antimicrobial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,,0,GKWMSLLKHILK
GKwMSLLKHILK,12,Synthetic,Synthetic peptide,Rat erythrocytes: IC50=99 μM,HUVEC: IC50=52±3 μM,,,,Anticancer; Antimicrobial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,w=D-Trp,,0,GKWMSLLKHILK
GKWMSLLKHIWK,12,Synthetic,Synthetic peptide,Rat erythrocytes: IC50=87 μM,HUVEC: IC50=56±9 μM,,,,Anticancer; Antimicrobial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,,0,GKWMSLLKHIWK
GKWMSLLKHWLK,12,Synthetic,Synthetic peptide,Rat erythrocytes: IC50=106 μM,HUVEC: IC50=40±1 μM,,,,Anticancer; Antimicrobial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,,0,GKWMSLLKHWLK
GKWMSLLKKILK,12,Synthetic,Synthetic peptide,Rat erythrocytes: IC50=126 μM,HUVEC: IC50> 100 μM,,,,Anticancer; Antimicrobial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,,0,GKWMSLLKKILK
GKWMSLWKHILK,12,Synthetic,Synthetic peptide,Rat erythrocytes: IC50>100 μM,HUVEC: IC50=73±3 μM,,,,Anticancer; Antimicrobial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,,0,GKWMSLWKHILK
GKWMTLLKHILK,12,Synthetic,Synthetic peptide,Rat erythrocytes: IC50=86 μM,HUVEC: IC50=60±12 μM,,,,Anticancer; Antimicrobial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,,0,GKWMTLLKHILK
GKWSKILGHLIR,12,Synthetic,Synthetic peptide,Rat erythrocytes: IC50>200  μM,HUVEC: IC50> 100 μM,,,,Anticancer; Antimicrobial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,,0,GKWSKILGHLIR
GKWSKILGKLIR,12,Synthetic,Synthetic peptide,Rat erythrocytes: IC50>200 μM,HUVEC: IC50> 100 μM,,,,Anticancer; Antimicrobial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,,0,GKWSKILGKLIR
GMWKKILGHLIR,12,Synthetic,Synthetic peptide,Rat erythrocytes: IC50=93 μM,HUVEC: IC50=49±16 μM,,,,Anticancer; Antimicrobial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,,0,GMWKKILGHLIR
GMWKKILGKLIR,12,Synthetic,Synthetic peptide,Rat erythrocytes: IC50>200 μM,HUVEC: IC50=63±13 μM,,,,Anticancer; Antimicrobial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,,0,GMWKKILGKLIR
GMWSKILGHLIk,12,Synthetic,Synthetic peptide,Rat erythrocytes: IC50=132 μM,HUVEC: IC50=≥40 μM,,,,Anticancer; Antimicrobial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,,0,GMWSKILGHLIK
GMWSKILGHLIR,12,Halictines and their analogs,Native peptide,Rat erythrocytes: IC50=82 μM,HUVEC: IC50=48±19 μM,,,,Anticancer; Antimicrobial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,,0,GMWSKILGHLIR
gmwskilghlir,12,Synthetic,Synthetic peptide,Rat erythrocytes: IC50=52 μM,HUVEC: IC50=42±7 μM,,,,Anticancer; Antimicrobial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,,0,GMWSKILGHLIR
GMWSkILGHLIR,12,Synthetic,Synthetic peptide,Rat erythrocytes: IC50>200 μM,HUVEC: IC50> 100 μM,,,,Anticancer; Antimicrobial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,k=D-Lys,,0,GMWSKILGHLIR
GMWSKILGHLKR,12,Synthetic,Synthetic peptide,Rat erythrocytes: IC50>200 μM,HUVEC: IC50=NA μM,,,,Anticancer; Antimicrobial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,,0,GMWSKILGHLKR
GMWSKILGKLIR,12,Synthetic,Synthetic peptide,Rat erythrocytes: IC50=143 μM,HUVEC: IC50=≥40 μM,,,,Anticancer; Antimicrobial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,,0,GMWSKILGKLIR
GMWSKILKHLIR,12,Synthetic,Synthetic peptide,Rat erythrocytes: IC50=45 μM,HUVEC: IC50=20±4 μM,,,,Anticancer; Antimicrobial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,,0,GMWSKILKHLIR
CVRRFPWWYPFLRRC,15,porcine cathelicidin peptide,Synthetic peptide,RBC: IC50=20.9 µM,PBMC: IC50=26.2 µM,,,,Anticancer,Tumor active peptide,,Cyclic,Cys1<--->Cys15,Free,Amidation,,,0,CVRRFPWWYPFLRRC
FRVTXRTKXXKG,12,porcine cathelicidin peptide,Synthetic peptide,RBC: IC50 ≥ 65 µM,PBMC: IC50 ≥ 65 µM,,,,Anticancer,Tumor active peptide,,Linear,,Free,Amidation,X=HTrp=5-hydroxytryptophan,,0,FRVTXRTKXXKG
GALFLGFLGAAGSTMGAWSQPKKKRKV,27,porcine cathelicidin peptide,Synthetic peptide,RBC: IC50 ≥ 65 µM,PBMC: IC50 ≥ 65 µM,,,,Anticancer,Tumor active peptide,,Linear,,Free,Cysteamidation,,,0,GALFLGFLGAAGSTMGAWSQPKKKRKV
FPVTWKWWKWWKG,13,porcine cathelicidin peptide,Synthetic peptide,RBC: IC50 ≥ 65 µM,PBMC: IC50=23.0 µM,,,,Anticancer,Tumor active peptide,,Linear,,Free,Amidation,,,0,FPVTWKWWKWWKG
FRVTWRTKWWKG,12,porcine cathelicidin peptide,Synthetic peptide,RBC: IC50 ≥ 65 µM,PBMC: IC50 ≥ 65 µM,,,,Anticancer,Tumor active peptide,,Linear,,Free,Amidation,,,0,FRVTWRTKWWKG
GIGKWLHSAKKFGKAFVGEIMNS,23,porcine cathelicidin peptide,Synthetic peptide,RBC: IC50 ≥ 65 µM,PBMC: IC50 ≥ 65 µM,,,,Anticancer,Tumor active peptide,,Linear,,Free,Amidation,,,0,GIGKWLHSAKKFGKAFVGEIMNS
FPVTWRWWRWWRG,13,porcine cathelicidin peptide,Synthetic peptide,RBC: IC50 ≥ 65 µM,PBMC: IC50=34.3 µM,,,,Anticancer,Tumor active peptide,,Linear,,Free,Amidation,,,0,FPVTWRWWRWWRG
FRWWHR,6,porcine cathelicidin peptide,Synthetic peptide,RBC: IC50 ≥ 65 µM,PBMC: IC50 ≥ 65 µM,,,,Anticancer,Tumor active peptide,,Linear,,Free,Amidation,,,0,FRWWHR
GIGRWLHSARRFGRAFVGEIMNS,23,porcine cathelicidin peptide,Synthetic peptide,RBC: IC50 ≥ 65 µM,PBMC: IC50 ≥ 65 µM,,,,Anticancer,Tumor active peptide,,Linear,,Free,Amidation,,,0,GIGRWLHSARRFGRAFVGEIMNS
ACSAG,5,Eisenia fetida (Red wiggler worm),Native peptide,,,,,"Mechanisms of EP5 may be directed to enter into cells to influence duplication and synthesis. Another mechanism was to form multimers by the connection of disulfide bonds with cysteins, also to make a hole in the cell membrane and induce the contents out of the cell.",Anticancer; Antimicrobial; Antifungal,Tumor active peptide,,Linear,,Free,Free,,,0,ACSAG
AMVGT,5,Eisenia fetida,Native peptide,,,,,"Short peptides with 5–7 amino acid residuals formed multimers in the PB buffer, which was a more likely explanation for the mechanism of EP3.",Anticancer; Antimicrobial; Antifungal,Tumor active peptide,,Linear,,Acetylation,Free,,,0,AMVGT
CHHNLTHAC,9,Synthetic,Synthetic peptide,,,PTPRJ,,PTPRJ is a receptor-type protein tyrosine phosphatase whose expression is strongly reduced in the majority of investigated cancer cell lines and tumor specimens.It showed tumor suppressor activity in several models.,Anticancer,Tumor active peptide##Cancer targeted peptides##PTPRJ agonist,,Cyclic,Cys1<--->Cys9,Free,Free,,,0,CHHNLTHAC
CAHNLTHAC,9,Synthetic (Derived from PTPRJ pep-19),Synthetic peptide,,,PTPRJ,,PTPRJ is a receptor-type protein tyrosine phosphatase whose expression is strongly reduced in the majority of investigated cancer cell lines and tumor specimens.It showed tumor suppressor activity in several models.,Anticancer,Tumor active peptide##Cancer targeted peptides##PTPRJ agonist,,Cyclic,Cys1<--->Cys9,Free,Free,,,0,CAHNLTHAC
CHANLTHAC,9,Synthetic (Derived from PTPRJ pep-19),Synthetic peptide,,,PTPRJ,,PTPRJ is a receptor-type protein tyrosine phosphatase whose expression is strongly reduced in the majority of investigated cancer cell lines and tumor specimens.It showed tumor suppressor activity in several models.,Anticancer,Tumor active peptide##Cancer targeted peptides##PTPRJ agonist,,Cyclic,Cys1<--->Cys9,Free,Free,,,0,CHANLTHAC
CHHALTHAC,9,Synthetic (Derived from PTPRJ pep-19),Synthetic peptide,,HUVEC: ~5% Inhibition=160 μM (24 h); ~25% Inhibition=160 μM (48 h); ~35% Inhibition=160 μM (24 h),PTPRJ,,PTPRJ is a receptor-type protein tyrosine phosphatase whose expression is strongly reduced in the majority of investigated cancer cell lines and tumor specimens.It showed tumor suppressor activity in several models.,Anticancer,Tumor active peptide##Cancer targeted peptides##PTPRJ agonist,,Cyclic,Cys1<--->Cys9,Free,Free,,,0,CHHALTHAC
CHHNATHAC,9,Synthetic (Derived from PTPRJ pep-19),Synthetic peptide,,,PTPRJ,,PTPRJ is a receptor-type protein tyrosine phosphatase whose expression is strongly reduced in the majority of investigated cancer cell lines and tumor specimens.It showed tumor suppressor activity in several models.,Anticancer,Tumor active peptide##Cancer targeted peptides##PTPRJ agonist,,Cyclic,Cys1<--->Cys9,Free,Free,,,0,CHHNATHAC
CHHNLAHAC,9,Synthetic (Derived from PTPRJ pep-19),Synthetic peptide,,,PTPRJ,,PTPRJ is a receptor-type protein tyrosine phosphatase whose expression is strongly reduced in the majority of investigated cancer cell lines and tumor specimens.It showed tumor suppressor activity in several models.,Anticancer,Tumor active peptide##Cancer targeted peptides##PTPRJ agonist,,Cyclic,Cys1<--->Cys9,Free,Free,,,0,CHHNLAHAC
CHHNLTAAC,9,Synthetic (Derived from PTPRJ pep-19),Synthetic peptide,,,PTPRJ,,PTPRJ is a receptor-type protein tyrosine phosphatase whose expression is strongly reduced in the majority of investigated cancer cell lines and tumor specimens.It showed tumor suppressor activity in several models.,Anticancer,Tumor active peptide##Cancer targeted peptides##PTPRJ agonist,,Cyclic,Cys1<--->Cys9,Free,Free,,,0,CHHNLTAAC
KAaK,4,Synthetic,Synthetic peptide,Human erythrocytes: 50% Hemolysis=60 µM,,,,,Anticancer; Antimicrobial; Antifungal,Tumor active peptide,,Linear,,Cholesterol,Amidation,k=D-Lys,,0,KAAK
HFLGTLVNLAKKIL,14,Rana draytonii,Native peptide,Human erythrocytes: 50% Hemolysis=65 µM,Mouse fibroblasts L929: LC50=18 µM,,,,Anticancer; Antimicrobial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,X=AIB (Aminoisobutyric acid),,0,HFLGTLVNLAKKIL
XFLGTLVNLAKKIL,14,Synthetic (Derived from Temporin-1DRa),Synthetic peptide,Human erythrocytes: 50% Hemolysis=60 µM,Mouse fibroblasts L929: LC50=17 µM,,,,Anticancer; Antimicrobial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,X=AIB (Aminoisobutyric acid),,0,XFLGTLVNLAKKIL
HXLGTLVNLAKKIL,14,Synthetic (Derived from Temporin-1DRa),Synthetic peptide,Human erythrocytes: 50% Hemolysis=100 µM,Mouse fibroblasts L929: LC50=30 µM,,,,Anticancer; Antimicrobial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,X=AIB (Aminoisobutyric acid),,0,HXLGTLVNLAKKIL
HFXGTLVNLAKKIL,14,Synthetic (Derived from Temporin-1DRa),Synthetic peptide,Human erythrocytes: 50% Hemolysis=90 µM,Mouse fibroblasts L929: LC50=20 µM,,,,Anticancer; Antimicrobial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,X=AIB (Aminoisobutyric acid),,0,HFXGTLVNLAKKIL
HFLXTLVNLAKKIL,14,Synthetic (Derived from Temporin-1DRa),Synthetic peptide,Human erythrocytes: 50% Hemolysis=25 µM,Mouse fibroblasts L929: LC50=9 µM,,,,Anticancer; Antimicrobial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,X=AIB (Aminoisobutyric acid),,0,HFLXTLVNLAKKIL
HFLGXLVNLAKKIL,14,Synthetic (Derived from Temporin-1DRa),Synthetic peptide,Human erythrocytes: 50% Hemolysis=40 µM,Mouse fibroblasts L929: LC50=16 µM,,,,Anticancer; Antimicrobial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,X=AIB (Aminoisobutyric acid),,0,HFLGXLVNLAKKIL
HFLGTXVNLAKKIL,14,Synthetic (Derived from Temporin-1DRa),Synthetic peptide,Human erythrocytes: 50% Hemolysis>200 µM,Mouse fibroblasts L929: LC50>200 µM,,,,Anticancer; Antimicrobial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,X=AIB (Aminoisobutyric acid),,0,HFLGTXVNLAKKIL
HFLGTLXNLAKKIL,14,Synthetic (Derived from Temporin-1DRa),Synthetic peptide,Human erythrocytes: 50% Hemolysis=22 µM,Mouse fibroblasts L929: LC50=13 µM,,,,Anticancer; Antimicrobial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,X=AIB (Aminoisobutyric acid),,0,HFLGTLXNLAKKIL
HFLGTLVXLAKKIL,14,Synthetic (Derived from Temporin-1DRa),Synthetic peptide,Human erythrocytes: 50% Hemolysis=10 µM,Mouse fibroblasts L929: LC50=6 µM,,,,Anticancer; Antimicrobial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,X=AIB (Aminoisobutyric acid),,0,HFLGTLVXLAKKIL
HFLGTLVNXAKKIL,14,Synthetic (Derived from Temporin-1DRa),Synthetic peptide,Human erythrocytes: 50% Hemolysis=75 µM,Mouse fibroblasts L929: LC50=42 µM,,,,Anticancer; Antimicrobial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,X=AIB (Aminoisobutyric acid),,0,HFLGTLVNXAKKIL
HFLGTLVNLXKKIL,14,Synthetic (Derived from Temporin-1DRa),Synthetic peptide,Human erythrocytes: 50% Hemolysis=10 µM,Mouse fibroblasts L929: LC50=8 µM,,,,Anticancer; Antimicrobial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,X=AIB (Aminoisobutyric acid),,0,HFLGTLVNLXKKIL
HFLGTLVNLAKKXL,14,Synthetic (Derived from Temporin-1DRa),Synthetic peptide,Human erythrocytes: 50% Hemolysis=0 µM,Mouse fibroblasts L929: LC50=55 µM,,,,Anticancer; Antimicrobial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,X=AIB (Aminoisobutyric acid),,0,HFLGTLVNLAKKXL
HFLGTLVNLAKKIX,14,Synthetic (Derived from Temporin-1DRa),Synthetic peptide,Human erythrocytes: 50% Hemolysis=130 µM,Mouse fibroblasts L929: LC50=90 µM,,,,Anticancer; Antimicrobial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,X=AIB (Aminoisobutyric acid),,0,HFLGTLVNLAKKIX
GAKALTKAATAFTKFYKTIW,20,Synthetic,Synthetic peptide,,NIH 3T3: IC50>500 μM,,,,Anticancer; Antimicrobial,Tumor active peptide,,Linear,,Free,Free,,,0,GAKALTKAATAFTKFYKTIW
GANAAKKLATFAKKIFTAYW,20,Synthetic,Synthetic peptide,,NIH 3T3: IC50>500 μM,,,,Anticancer; Antimicrobial,Tumor active peptide,,Linear,,Free,Free,,,0,GANAAKKLATFAKKIFTAYW
KYLNFAKWLKGANLAKYANA,20,Synthetic,Synthetic peptide,,NIH 3T3: IC50>500 μM,,,,Anticancer; Antimicrobial,Tumor active peptide,,Linear,,Free,Free,,,0,KYLNFAKWLKGANLAKYANA
FFHHIFRGIVHVGKTIHRLVTG,22,Morone saxatilis (Striped bass) (Perca saxatilis),Native peptide,Human erythrocytes: 50% Hemolysis=3.12 µg/ml; 100% Hemolysis=25 µg/ml,HEK293: LC90=50 µg/ml (>90% cells killed),,,,Anticancer; Antimicrobial; Antifungal; Antiviral; Anti-Inflammatory,Tumor active peptide,,Linear,,Free,Free,,,0,FFHHIFRGIVHVGKTIHRLVTG
FIHHIFRGIVHAGRSIGRFLTG,22,Morone saxatilis (Striped bass) (Perca saxatilis),Native peptide,,,,,,Anticancer; Antimicrobial; Antifungal; Antiviral; Anti-Inflammatory,Tumor active peptide,,Linear,,Free,Free,,,0,FIHHIFRGIVHAGRSIGRFLTG
ILGKLLSTAAGLLSNL,16,Alytes obstetricans,Native peptide,Human erythrocytes: 50% Hemolysis=140 µM,,,,,Anticancer; Antimicrobial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,,0,ILGKLLSTAAGLLSNL
ILKKLLSTAAGLLSNL,16,Synthetic (Derived from Alyteserin-2a),Synthetic peptide,Human erythrocytes: 50% Hemolysis=105 µM,,,,,Anticancer; Antimicrobial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,,0,ILKKLLSTAAGLLSNL
ILGKLLKTAAGLLSNL,16,Synthetic (Derived from Alyteserin-2a),Synthetic peptide,Human erythrocytes: 50% Hemolysis=28 µM,,,,,Anticancer; Antimicrobial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,,0,ILGKLLKTAAGLLSNL
ILGKLLkTAAGLLSNL,16,Synthetic (Derived from Alyteserin-2a),Synthetic peptide,Human erythrocytes: 50% Hemolysis=105 µM,,,,,Anticancer; Antimicrobial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,k=D-Lys,,0,ILGKLLKTAAGLLSNL
ILGKLLSTAAKLLSNL,16,Synthetic (Derived from Alyteserin-2a),Synthetic peptide,Human erythrocytes: 50% Hemolysis=24 µM,,,,,Anticancer; Antimicrobial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,,0,ILGKLLSTAAKLLSNL
ILGKLLSTAAkLLSNL,16,Synthetic (Derived from Alyteserin-2a),Synthetic peptide,Human erythrocytes: 50% Hemolysis=42 µM,,,,,Anticancer; Antimicrobial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,k=D-Lys,,0,ILGKLLSTAAKLLSNL
ILGKLLSTAAGLLKNL,16,Synthetic (Derived from Alyteserin-2a),Synthetic peptide,Human erythrocytes: 50% Hemolysis=55 µM,,,,,Anticancer; Antimicrobial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,,0,ILGKLLSTAAGLLKNL
ILGKLLSTAAGLLSKL,16,Synthetic (Derived from Alyteserin-2a),Synthetic peptide,Human erythrocytes: 50% Hemolysis=50 µM,,,,,Anticancer; Antimicrobial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,,0,ILGKLLSTAAGLLSKL
ILGKLLSTAAGLLSkL,16,Synthetic (Derived from Alyteserin-2a),Synthetic peptide,Human erythrocytes: 50% Hemolysis=310 µM,,,,,Anticancer; Antimicrobial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,k=D-Lys,,0,ILGKLLSTAAGLLSKL
ILGKLLKTAAKLLSNL,16,Synthetic (Derived from Alyteserin-2a),Synthetic peptide,Human erythrocytes: 50% Hemolysis=38 µM,,,,,Anticancer; Antimicrobial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,,0,ILGKLLKTAAKLLSNL
ILGKLLkTAAkLLSNL,16,Synthetic (Derived from Alyteserin-2a),Synthetic peptide,Human erythrocytes: 50% Hemolysis=185 µM,,,,,Anticancer; Antimicrobial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,k=D-Lys,,0,ILGKLLKTAAKLLSNL
ILGKLLSTAAKLLSKL,16,Synthetic (Derived from Alyteserin-2a),Synthetic peptide,Human erythrocytes: 50% Hemolysis=16 µM,,,,,Anticancer; Antimicrobial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,,0,ILGKLLSTAAKLLSKL
ILGKLLSTAAkLLSKL,16,Synthetic (Derived from Alyteserin-2a),Synthetic peptide,Human erythrocytes: 50% Hemolysis=195 µM,,,,,Anticancer; Antimicrobial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,k=D-Lys,,0,ILGKLLSTAAKLLSKL
ILGKLLSWAAGLLSNL,16,Synthetic (Derived from Alyteserin-2a),Synthetic peptide,Human erythrocytes: 50% Hemolysis=13 µM,,,,,Anticancer; Antimicrobial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,,0,ILGKLLSWAAGLLSNL
ILGKLLSTWAGLLSNL,16,Synthetic (Derived from Alyteserin-2a),Synthetic peptide,Human erythrocytes: 50% Hemolysis=39 µM,,,,,Anticancer; Antimicrobial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,,0,ILGKLLSTWAGLLSNL
ILGKLLSTAWGLLSNL,16,Synthetic (Derived from Alyteserin-2a),Synthetic peptide,Human erythrocytes: 50% Hemolysis=11 µM,,,,,Anticancer; Antimicrobial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,,0,ILGKLLSTAWGLLSNL
ILGKLLSTAWkLLSNL,16,Synthetic (Derived from Alyteserin-2a),Synthetic peptide,Human erythrocytes: 50% Hemolysis=21 µM,,,,,Anticancer; Antimicrobial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,k=D-Lys,,0,ILGKLLSTAWKLLSNL
ILGKLLSTAWGLLSKL,16,Synthetic (Derived from Alyteserin-2a),Synthetic peptide,Human erythrocytes: 50% Hemolysis=6 µM,,,,,Anticancer; Antimicrobial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,,0,ILGKLLSTAWGLLSKL
ILGKLLSTAWALLSkL,16,Synthetic (Derived from Alyteserin-2a),Synthetic peptide,Human erythrocytes: 50% Hemolysis=27 µM,,,,,Anticancer; Antimicrobial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,k=D-Lys,,0,ILGKLLSTAWALLSKL
ILGKLLSTAWkLLSkL,16,Synthetic (Derived from Alyteserin-2a),Synthetic peptide,Human erythrocytes: 50% Hemolysis=68 µM,,,,,Anticancer; Antimicrobial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,k=D-Lys,,0,ILGKLLSTAWKLLSKL
KLKLKFKLKQ,10,Synthetic,Synthetic peptide,Human erythrocytes: 84 ± 6.9% Hemolysis=375 µM,,,,,Anticancer; Antimicrobial,Tumor active peptide##Induce apoptosis,,Cyclic,NCB: Lys1<--->Gln10,Free,Free,,,0,KLKLKFKLKQ
KKKKKFLLLQ,10,Synthetic,Synthetic peptide,Human erythrocytes: 6 ± 0.5% Hemolysis=375 µM,,,,,Anticancer; Antimicrobial,Tumor active peptide##Induce apoptosis,,Cyclic,NCB: Lys1<--->Gln10,Free,Free,,,0,KKKKKFLLLQ
KKKKLFKLLQ,10,Synthetic,Synthetic peptide,Human erythrocytes: 72 ± 5.5% Hemolysis=375 µM,,,,,Anticancer; Antimicrobial,Tumor active peptide##Induce apoptosis,,Cyclic,NCB: Lys1<--->Gln10,Free,Free,,,0,KKKKLFKLLQ
KKKLKFKLLQ,10,Synthetic,Synthetic peptide,Human erythrocytes: 6 ± 0.6% Hemolysis=375 µM,,,,,Anticancer; Antimicrobial,Tumor active peptide##Induce apoptosis,,Cyclic,NCB: Lys1<--->Gln10,Free,Free,,,0,KKKLKFKLLQ
KKLKKFKLLQ,10,Synthetic,Synthetic peptide,Human erythrocytes: 10 ± 2.0% Hemolysis=375 µM,,,,,Anticancer; Antimicrobial,Tumor active peptide##Induce apoptosis,,Cyclic,NCB: Lys1<--->Gln10,Free,Free,,,0,KKLKKFKLLQ
KLKKKFKLLQ,10,Synthetic,Synthetic peptide,Human erythrocytes: 22 ± 4.0% Hemolysis=375 µM,,,,,Anticancer; Antimicrobial,Tumor active peptide##Induce apoptosis,,Cyclic,NCB: Lys1<--->Gln10,Free,Free,,,0,KLKKKFKLLQ
LKKKKFKLLQ,10,Synthetic,Synthetic peptide,Human erythrocytes: 0 ± 0.5% Hemolysis=375 µM,,,,,Anticancer; Antimicrobial,Tumor active peptide##Induce apoptosis,,Cyclic,NCB: Leu1<--->Gln10,Free,Free,,,0,LKKKKFKLLQ
KKKKLFLKLQ,10,Synthetic,Synthetic peptide,Human erythrocytes: 19 ± 0.5% Hemolysis=375 µM,,,,,Anticancer; Antimicrobial,Tumor active peptide##Induce apoptosis,,Cyclic,NCB: Lys1<--->Gln10,Free,Free,,,0,KKKKLFLKLQ
KKKLKFLKLQ,10,Synthetic,Synthetic peptide,Human erythrocytes: 7 ± 2.0% Hemolysis=375 µM,,,,,Anticancer; Antimicrobial,Tumor active peptide##Induce apoptosis,,Cyclic,NCB: Lys1<--->Gln10,Free,Free,,,0,KKKLKFLKLQ
KKLKKFLKLQ,10,Synthetic,Synthetic peptide,Human erythrocytes: 36 ± 1.7% Hemolysis=375 µM,,,,,Anticancer; Antimicrobial,Tumor active peptide##Induce apoptosis,,Cyclic,NCB: Lys1<--->Gln10,Free,Free,,,0,KKLKKFLKLQ
KLKKKFLKLQ,10,Synthetic,Synthetic peptide,Human erythrocytes: 13 ± 1.9% Hemolysis=375 µM,,,,,Anticancer; Antimicrobial,Tumor active peptide##Induce apoptosis,,Cyclic,NCB: Lys1<--->Gln10,Free,Free,,,0,KLKKKFLKLQ
LKKKKFLKLQ,10,Synthetic,Synthetic peptide,Human erythrocytes: 0 ± 0.4% Hemolysis=375 µM,,,,,Anticancer; Antimicrobial,Tumor active peptide##Induce apoptosis,,Cyclic,NCB: Leu1<--->Gln10,Free,Free,,,0,LKKKKFLKLQ
KKKLLFKKLQ,10,Synthetic,Synthetic peptide,Human erythrocytes: 19 ± 0.7% Hemolysis=375 µM,,,,,Anticancer; Antimicrobial,Tumor active peptide##Induce apoptosis,,Cyclic,NCB: Lys1<--->Gln10,Free,Free,,,0,KKKLLFKKLQ
KKLKLFKKLQ,10,Synthetic,Synthetic peptide,Human erythrocytes: 36 ± 2.5% Hemolysis=375 µM,,,,,Anticancer; Antimicrobial,Tumor active peptide##Induce apoptosis,,Cyclic,NCB: Lys1<--->Gln10,Free,Free,,,0,KKLKLFKKLQ
KLKKLFKKLQ,10,Synthetic,Synthetic peptide,Human erythrocytes: 45 ± 3.5% Hemolysis=375 µM,,,,,Anticancer; Antimicrobial,Tumor active peptide##Induce apoptosis,,Cyclic,NCB: Lys1<--->Gln10,Free,Free,,,0,KLKKLFKKLQ
LKKKLFKKLQ,10,Synthetic,Synthetic peptide,Human erythrocytes: 8 ± 0.9% Hemolysis=375 µM,,,,,Anticancer; Antimicrobial,Tumor active peptide##Induce apoptosis,,Cyclic,NCB: Leu1<--->Gln10,Free,Free,,,0,LKKKLFKKLQ
KKKKLFLLKQ,10,Synthetic,Synthetic peptide,Human erythrocytes: 1.8 ± 0.8% Hemolysis=375 µM,,,,,Anticancer; Antimicrobial,Tumor active peptide##Induce apoptosis,,Cyclic,NCB: Lys1<--->Gln10,Free,Free,,,0,KKKKLFLLKQ
KKKLKFLLKQ,10,Synthetic,Synthetic peptide,Human erythrocytes: 26 ± 3.0% Hemolysis=375 µM,,,,,Anticancer; Antimicrobial,Tumor active peptide##Induce apoptosis,,Cyclic,NCB: Lys1<--->Gln10,Free,Free,,,0,KKKLKFLLKQ
KKLKKFLLKQ,10,Synthetic,Synthetic peptide,Human erythrocytes: 15 ± 2.2% Hemolysis=375 µM,,,,,Anticancer; Antimicrobial,Tumor active peptide##Induce apoptosis,,Cyclic,NCB: Lys1<--->Gln10,Free,Free,,,0,KKLKKFLLKQ
KLKKKFLLKQ,10,Synthetic,Synthetic peptide,Human erythrocytes: 0 ± 0.1% Hemolysis=375 µM,,,,,Anticancer; Antimicrobial,Tumor active peptide##Induce apoptosis,,Cyclic,NCB: Lys1<--->Gln10,Free,Free,,,0,KLKKKFLLKQ
LKKKKFLLKQ,10,Synthetic,Synthetic peptide,Human erythrocytes: 2 ± 0.2% Hemolysis=375 µM,,,,,Anticancer; Antimicrobial,Tumor active peptide##Induce apoptosis,,Cyclic,NCB: Leu1<--->Gln10,Free,Free,,,0,LKKKKFLLKQ
KKKLLFKLKQ,10,Synthetic,Synthetic peptide,Human erythrocytes: 9 ± 0.4% Hemolysis=375 µM,,,,,Anticancer; Antimicrobial,Tumor active peptide##Induce apoptosis,,Cyclic,NCB: Lys1<--->Gln10,Free,Free,,,0,KKKLLFKLKQ
KKLKLFKLKQ,10,Synthetic,Synthetic peptide,Human erythrocytes: 1 ± 0.1% Hemolysis=375 µM,,,,,Anticancer; Antimicrobial,Tumor active peptide##Induce apoptosis,,Cyclic,NCB: Lys1<--->Gln10,Free,Free,,,0,KKLKLFKLKQ
KLKKLFKLKQ,10,Synthetic,Synthetic peptide,Human erythrocytes: 24 ± 1.8% Hemolysis=375 µM,,,,,Anticancer; Antimicrobial,Tumor active peptide##Induce apoptosis,,Cyclic,NCB: Lys1<--->Gln10,Free,Free,,,0,KLKKLFKLKQ
LKKKLFKLKQ,10,Synthetic,Synthetic peptide,Human erythrocytes: 13 ± 0.9% Hemolysis=375 µM,,,,,Anticancer; Antimicrobial,Tumor active peptide##Induce apoptosis,,Cyclic,NCB: Leu1<--->Gln10,Free,Free,,,0,LKKKLFKLKQ
KKLLKFKLKQ,10,Synthetic,Synthetic peptide,Human erythrocytes: 6 ± 0.6% Hemolysis=375 µM,,,,,Anticancer; Antimicrobial,Tumor active peptide##Induce apoptosis,,Cyclic,NCB: Lys1<--->Gln10,Free,Free,,,0,KKLLKFKLKQ
LKKLKFKLKQ,10,Synthetic,Synthetic peptide,Human erythrocytes: 8 ± 1.6% Hemolysis=375 µM,,,,,Anticancer; Antimicrobial,Tumor active peptide##Induce apoptosis,,Cyclic,NCB: Leu1<--->Gln10,Free,Free,,,0,LKKLKFKLKQ
KLLKKFKLKQ,10,Synthetic,Synthetic peptide,Human erythrocytes: 4 ± 1.3% Hemolysis=375 µM,,,,,Anticancer; Antimicrobial,Tumor active peptide##Induce apoptosis,,Cyclic,NCB: Lys1<--->Gln10,Free,Free,,,0,KLLKKFKLKQ
LKLKKFKLKQ,10,Synthetic,Synthetic peptide,Human erythrocytes: 3 ± 0.1% Hemolysis=375 µM,,,,,Anticancer; Antimicrobial,Tumor active peptide##Induce apoptosis,,Cyclic,NCB: Leu1<--->Gln10,Free,Free,,,0,LKLKKFKLKQ
LLKKKFKLKQ,10,Synthetic,Synthetic peptide,Human erythrocytes: 4 ± 0.6% Hemolysis=375 µM,,,,,Anticancer; Antimicrobial,Tumor active peptide##Induce apoptosis,,Cyclic,NCB: Leu1<--->Gln10,Free,Free,,,0,LLKKKFKLKQ
KKKLLFLKKQ,10,Synthetic,Synthetic peptide,Human erythrocytes: 1 ± 0.3% Hemolysis=375 µM,,,,,Anticancer; Antimicrobial,Tumor active peptide##Induce apoptosis,,Cyclic,NCB: Lys1<--->Gln10,Free,Free,,,0,KKKLLFLKKQ
KKLKLFLKKQ,10,Synthetic,Synthetic peptide,Human erythrocytes: 6 ± 3.0% Hemolysis=375 µM,,,,,Anticancer; Antimicrobial,Tumor active peptide##Induce apoptosis,,Cyclic,NCB: Lys1<--->Gln10,Free,Free,,,0,KKLKLFLKKQ
KLKKLFLKKQ,10,Synthetic,Synthetic peptide,Human erythrocytes: 4 ± 0.9% Hemolysis=375 µM,,,,,Anticancer; Antimicrobial,Tumor active peptide##Induce apoptosis,,Cyclic,NCB: Lys1<--->Gln10,Free,Free,,,0,KLKKLFLKKQ
LKKKLFLKKQ,10,Synthetic,Synthetic peptide,Human erythrocytes: 2 ± 0.3% Hemolysis=375 µM,,,,,Anticancer; Antimicrobial,Tumor active peptide##Induce apoptosis,,Cyclic,NCB: Leu1<--->Gln10,Free,Free,,,0,LKKKLFLKKQ
KKLLKFLKKQ,10,Synthetic,Synthetic peptide,Human erythrocytes: 41 ± 1.8% Hemolysis=375 µM,,,,,Anticancer; Antimicrobial,Tumor active peptide##Induce apoptosis,,Cyclic,NCB: Lys1<--->Gln10,Free,Free,,,0,KKLLKFLKKQ
KLKLKFLKKQ,10,Synthetic,Synthetic peptide,Human erythrocytes: 5 ± 0.9% Hemolysis=375 µM,,,,,Anticancer; Antimicrobial,Tumor active peptide##Induce apoptosis,,Cyclic,NCB: Lys1<--->Gln10,Free,Free,,,0,KLKLKFLKKQ
LKKLKFLKKQ,10,Synthetic,Synthetic peptide,Human erythrocytes: 23 ± 1.1% Hemolysis=375 µM,,,,,Anticancer; Antimicrobial,Tumor active peptide##Induce apoptosis,,Cyclic,NCB: Leu1<--->Gln10,Free,Free,,,0,LKKLKFLKKQ
KLLKKFLKKQ,10,Synthetic,Synthetic peptide,Human erythrocytes: 14 ± 1.6% Hemolysis=375 µM,,,,,Anticancer; Antimicrobial,Tumor active peptide##Induce apoptosis,,Cyclic,NCB: Lys1<--->Gln10,Free,Free,,,0,KLLKKFLKKQ
LKLKKFLKKQ,10,Synthetic,Synthetic peptide,Human erythrocytes: 9 ± 1.9% Hemolysis=375 µM,,,,,Anticancer; Antimicrobial,Tumor active peptide##Induce apoptosis,,Cyclic,NCB: Leu1<--->Gln10,Free,Free,,,0,LKLKKFLKKQ
LLKKKFLKKQ,10,Synthetic,Synthetic peptide,Human erythrocytes: 3 ± 0.5% Hemolysis=375 µM,,,,,Anticancer; Antimicrobial,Tumor active peptide##Induce apoptosis,,Cyclic,NCB: Leu1<--->Gln10,Free,Free,,,0,LLKKKFLKKQ
KKLLLFKKKQ,10,Synthetic,Synthetic peptide,Human erythrocytes: 1 ± 0.2% Hemolysis=375 µM,,,,,Anticancer; Antimicrobial,Tumor active peptide##Induce apoptosis,,Cyclic,NCB: Lys1<--->Gln10,Free,Free,,,0,KKLLLFKKKQ
KLKLLFKKKQ,10,Synthetic,Synthetic peptide,Human erythrocytes: 4 ± 0.2% Hemolysis=375 µM,,,,,Anticancer; Antimicrobial,Tumor active peptide##Induce apoptosis,,Cyclic,NCB: Lys1<--->Gln10,Free,Free,,,0,KLKLLFKKKQ
LKKLLFKKKQ,10,Synthetic,Synthetic peptide,Human erythrocytes: 2 ± 0.1% Hemolysis=375 µM,,,,,Anticancer; Antimicrobial,Tumor active peptide##Induce apoptosis,,Cyclic,NCB: Leu1<--->Gln10,Free,Free,,,0,LKKLLFKKKQ
KLLKLFKKKQ,10,Synthetic,Synthetic peptide,Human erythrocytes: 11 ± 1.7% Hemolysis=375 µM,,,,,Anticancer; Antimicrobial,Tumor active peptide##Induce apoptosis,,Cyclic,NCB: Lys1<--->Gln10,Free,Free,,,0,KLLKLFKKKQ
LKLKLFKKKQ,10,Synthetic,Synthetic peptide,Human erythrocytes: 3 ± 0.4% Hemolysis=375 µM,,,,,Anticancer; Antimicrobial,Tumor active peptide##Induce apoptosis,,Cyclic,NCB: Leu1<--->Gln10,Free,Free,,,0,LKLKLFKKKQ
LLKKLFKKKQ,10,Synthetic,Synthetic peptide,Human erythrocytes: 9 ± 0.7% Hemolysis=375 µM,,,,,Anticancer; Antimicrobial,Tumor active peptide##Induce apoptosis,,Cyclic,NCB: Leu1<--->Gln10,Free,Free,,,0,LLKKLFKKKQ
KLLLKFKKKQ,10,Synthetic,Synthetic peptide,Human erythrocytes: 3 ± 0.4% Hemolysis=375 µM,,,,,Anticancer; Antimicrobial,Tumor active peptide##Induce apoptosis,,Cyclic,NCB: Lys1<--->Gln10,Free,Free,,,0,KLLLKFKKKQ
LKLLKFKKKQ,10,Synthetic,Synthetic peptide,Human erythrocytes: 2 ± 0.8% Hemolysis=375 µM,,,,,Anticancer; Antimicrobial,Tumor active peptide##Induce apoptosis,,Cyclic,NCB: Leu1<--->Gln10,Free,Free,,,0,LKLLKFKKKQ
LLKLKFKKKQ,10,Synthetic,Synthetic peptide,Human erythrocytes: 4 ± 0.5% Hemolysis=375 µM,,,,,Anticancer; Antimicrobial,Tumor active peptide##Induce apoptosis,,Cyclic,NCB: Leu1<--->Gln10,Free,Free,,,0,LLKLKFKKKQ
LLLKKFKKKQ,10,Synthetic,Synthetic peptide,Human erythrocytes: 0 ± 0.1% Hemolysis=375 µM,,,,,Anticancer; Antimicrobial,Tumor active peptide##Induce apoptosis,,Cyclic,NCB: Leu1<--->Gln10,Free,Free,,,0,LLLKKFKKKQ
KKLLKFKKLQ,10,Synthetic,Synthetic peptide,Human erythrocytes: 33 ± 3.3% Hemolysis=375 µM; IC50=33 ± 3.3 µM,Human non-malignant fibroblasts: IC50=42.0 ± 7.1 µM,,,,Anticancer; Antimicrobial,Tumor active peptide##Induce apoptosis,,Cyclic,NCB: Lys1<--->Gln10,Free,Free,,,0,KKLLKFKKLQ
KLKLKFKKLQ,10,Synthetic,Synthetic peptide,Human erythrocytes: 30 ± 4.1% Hemolysis=375 µM,,,,,Anticancer; Antimicrobial,Tumor active peptide##Induce apoptosis,,Cyclic,NCB: Lys1<--->Gln10,Free,Free,,,0,KLKLKFKKLQ
LKKLKFKKLQ,10,Synthetic,Synthetic peptide,Human erythrocytes: 7 ± 0.7% Hemolysis=375 µM,,,,,Anticancer; Antimicrobial,Tumor active peptide##Induce apoptosis,,Cyclic,NCB: Leu1<--->Gln10,Free,Free,,,0,LKKLKFKKLQ
KLLKKFKKLQ,10,Synthetic,Synthetic peptide,Human erythrocytes: 73 ± 1.6% Hemolysis=375 µM; IC50=73 ± 1.6 µM,,,,,Anticancer; Antimicrobial,Tumor active peptide##Induce apoptosis,,Cyclic,NCB: Lys1<--->Gln10,Free,Free,,,0,KLLKKFKKLQ
LKLKKFKKLQ,10,Synthetic,Synthetic peptide,Human erythrocytes: 32 ± 7.2% Hemolysis=375 µM; IC50=32 ± 7.2 µM,Human non-malignant fibroblasts: IC50=39.0 ± 9.9 µM,,,,Anticancer; Antimicrobial,Tumor active peptide##Induce apoptosis,,Cyclic,NCB: Leu1<--->Gln10,Free,Free,,,0,LKLKKFKKLQ
LLKKKFKKLQ,10,Synthetic,Synthetic peptide,Human erythrocytes: 36 ± 3.7% Hemolysis=375 µM; IC50=36 ± 3.7 µM,Human non-malignant fibroblasts: IC50=58.5 ± 2.1 µM,,,,Anticancer; Antimicrobial,Tumor active peptide##Induce apoptosis,,Cyclic,NCB: Leu1<--->Gln10,Free,Free,,,0,LLKKKFKKLQ
KLLLKFKKLQ,10,Synthetic,Synthetic peptide,Human erythrocytes: 89 ± 5.3% Hemolysis=375 µM; IC50=89 ± 5.3 µM,,,,,Anticancer; Antimicrobial,Tumor active peptide##Induce apoptosis,,Cyclic,NCB: Lys1<--->Gln10,Free,Free,,,0,KLLLKFKKLQ
KKKLKFKKLQ,10,Synthetic,Synthetic peptide,Human erythrocytes: 0 ± 0.4% Hemolysis=375 µM,,,,,Anticancer; Antimicrobial,Tumor active peptide##Induce apoptosis,,Cyclic,NCB: Lys1<--->Gln10,Free,Free,,,0,KKKLKFKKLQ
LLLKKFKKLQ,10,Synthetic,Synthetic peptide,Human erythrocytes: 87 ± 6.5% Hemolysis=375 µM,,,,,Anticancer; Antimicrobial,Tumor active peptide##Induce apoptosis,,Cyclic,NCB: Leu1<--->Gln10,Free,Free,,,0,LLLKKFKKLQ
LKKKKFKKLQ,10,Synthetic,Synthetic peptide,Human erythrocytes: Not active up to 375 µM,,,,,Anticancer; Antimicrobial,Tumor active peptide##Induce apoptosis,,Cyclic,NCB: Leu1<--->Gln10,Free,Free,,,0,LKKKKFKKLQ
LKLLKFKKLQ,10,Synthetic,Synthetic peptide,Human erythrocytes: 49 ± 7.7% Hemolysis=375 µM,,,,,Anticancer; Antimicrobial,Tumor active peptide##Induce apoptosis,,Cyclic,NCB: Leu1<--->Gln10,Free,Free,,,0,LKLLKFKKLQ
KKLKKFKKLQ,10,Synthetic,Synthetic peptide,Human erythrocytes: 17 ± 1.7% Hemolysis=375 µM; IC50=17 ± 1.7 µM,Human non-malignant fibroblasts: IC50=56.5 ± 0.7 µM,,,,Anticancer; Antimicrobial,Tumor active peptide##Induce apoptosis,,Cyclic,NCB: Lys1<--->Gln10,Free,Free,,,0,KKLKKFKKLQ
LLKLKFKKLQ,10,Synthetic,Synthetic peptide,Human erythrocytes: 47 ± 7.2% Hemolysis=375 µM,,,,,Anticancer; Antimicrobial,Tumor active peptide##Induce apoptosis,,Cyclic,NCB: Leu1<--->Gln10,Free,Free,,,0,LLKLKFKKLQ
KLKKKFKKLQ,10,Synthetic,Synthetic peptide,Human erythrocytes: 14 ± 1.4% Hemolysis=375 µM; IC50=14 ± 1.4 µM,Human non-malignant fibroblasts: IC50=7.5 ± 0.7 µM,,,,Anticancer; Antimicrobial,Tumor active peptide##Induce apoptosis,,Cyclic,NCB: Lys1<--->Gln10,Free,Free,,,0,KLKKKFKKLQ
LLLLKFKKLQ,10,Synthetic,Synthetic peptide,Human erythrocytes: 71 ± 11.7% Hemolysis=375 µM,,,,,Anticancer; Antimicrobial,Tumor active peptide##Induce apoptosis,,Cyclic,NCB: Leu1<--->Gln10,Free,Free,,,0,LLLLKFKKLQ
KKKKKFKKLQ,10,Synthetic,Synthetic peptide,Human erythrocytes: 2 ± 0.2% Hemolysis=375 µM; IC50=2 ± 0.2 µM,,,,,Anticancer; Antimicrobial,Tumor active peptide##Induce apoptosis,,Cyclic,NCB: Lys1<--->Gln10,Free,Free,,,0,KKKKKFKKLQ
PGMGIYLPM,9,Annona cherimola,Native peptide,,,,,,Anticancer,Tumor active peptide,,Cyclic,NCB: Pro1<--->Met9,Free,Free,,,0,PGMGIYLPM
RIIDLLWRVRRPQKPKFVTVWVR,23,Sus scrofa,Native peptide,Human erythrocytes: 4.8% Hemolysis=100 µM,Human keratinocytes HaCat: 25% Killing=100 µM,,,,Anticancer; Antimicrobial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,,0,RIIDLLWRVRRPQKPKFVTVWVR
RIIDLLWRVWRPQKPKFVTVWVR,23,Synthetic (Derived from PMAP-23),Synthetic peptide,,,,,,Anticancer; Antimicrobial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,,0,RIIDLLWRVWRPQKPKFVTVWVR
RIIDLLWRVRRPWKPKFVTVWVR,23,Synthetic (Derived from PMAP-23),Synthetic peptide,,,,,,Anticancer; Antimicrobial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,,0,RIIDLLWRVRRPWKPKFVTVWVR
RIIDLLWRVRRPQWPKFVTVWVR,23,Synthetic (Derived from PMAP-23),Synthetic peptide,,,,,,Anticancer; Antimicrobial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,,0,RIIDLLWRVRRPQWPKFVTVWVR
RIIDLLWRVRRPWWPKFVTVWVR,23,Synthetic (Derived from PMAP-23),Synthetic peptide,,,,,,Anticancer; Antimicrobial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,,0,RIIDLLWRVRRPWWPKFVTVWVR
RIIDLLWRVWRPWKPKFVTVWVR,23,Synthetic (Derived from PMAP-23),Synthetic peptide,,,,,,Anticancer; Antimicrobial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,,0,RIIDLLWRVWRPWKPKFVTVWVR
RIIDLLWRVWRPWWPKFVTVWVR,23,Synthetic (Derived from PMAP-23),Synthetic peptide,,,,,,Anticancer; Antimicrobial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,,0,RIIDLLWRVWRPWWPKFVTVWVR
GEKLKKIGQKIKNFFQKL,18,Mus musculus (Mouse),Synthetic peptide,Human erythrocytes: Not active up to 100 µM,,,,,Anticancer; Antimicrobial; Antifungal,Tumor active peptide##Membrane lysis,,Linear,,Free,Free,,,0,GEKLKKIGQKIKNFFQKL
GKKLKKIGQKIKNFFQKL,18,Synthetic (Derived from CRAMP-18),Synthetic peptide,Human erythrocytes: Not active up to 100 µM,,,,,Anticancer; Antimicrobial; Antifungal,Tumor active peptide##Membrane lysis,,Linear,,Free,Free,,,0,GKKLKKIGQKIKNFFQKL
GEKLKKIGKKIKNFFQKL,18,Synthetic (Derived from CRAMP-18),Synthetic peptide,Human erythrocytes: Not active up to 100 µM,,,,,Anticancer; Antimicrobial; Antifungal,Tumor active peptide##Membrane lysis,,Linear,,Free,Free,,,0,GEKLKKIGKKIKNFFQKL
GEKLKKIGQKIKKFFQKL,18,Synthetic (Derived from CRAMP-18),Synthetic peptide,Human erythrocytes: Not active up to 100 µM,,,,,Anticancer; Antimicrobial; Antifungal,Tumor active peptide##Membrane lysis,,Linear,,Free,Free,,,0,GEKLKKIGQKIKKFFQKL
GEKLKKIGQKIKNFFKKL,18,Synthetic (Derived from CRAMP-18),Synthetic peptide,Human erythrocytes: 0.2% Hemolysis=100 µM,,,,,Anticancer; Antimicrobial; Antifungal,Tumor active peptide##Membrane lysis,,Linear,,Free,Free,,,0,GEKLKKIGQKIKNFFKKL
GLLxRIkTLL,10,Synthetic (Derived from Anoplin),Synthetic peptide,Mouse erythrocytes: 10% Hemolysis>256 µM,,,,,Anticancer; Antimicrobial; Antifungal,Tumor active peptide##Membrane lysis,,Linear,,Free,Amidation,x=D-Lys-C4 (D-Lysine with butyrylated side group); k=D-Lys,,0,GLLXRIKTLL
GLLkRIxTLL,10,Synthetic (Derived from Anoplin),Synthetic peptide,Mouse erythrocytes: 10% Hemolysis>256 µM,,,,,Anticancer; Antimicrobial; Antifungal,Tumor active peptide##Membrane lysis,,Linear,,Free,Amidation,x=D-Lys-C4 (D-Lysine with butyrylated side group); k=D-Lys,,0,GLLKRIXTLL
RLLRLIRKLII,11,Synthetic (Derived from Decoralin),Synthetic peptide,,HDMEC: EC50=141±1 μM,,,,Anticancer,Tumor active peptide##Membrane lysis##Cell-penetrating peptides,,Linear,,Free,Amidation,,,0,RLLRLIRKLII
RLLRLIRKLIL,11,Synthetic (Derived from Decoralin),Synthetic peptide,,HDMEC: EC50=125–250 μM,,,,Anticancer,Tumor active peptide##Membrane lysis##Cell-penetrating peptides,,Linear,,Free,Amidation,,,0,RLLRLIRKLIL
LLLLLIRKLIK,11,Synthetic (Derived from Decoralin),Synthetic peptide,,HDMEC: EC50=125–250 μM,,,,Anticancer,Tumor active peptide##Membrane lysis##Cell-penetrating peptides,,Linear,,Free,Amidation,,,0,LLLLLIRKLIK
YLLYLIRKLIL,11,Synthetic (Derived from Decoralin),Synthetic peptide,,HDMEC: EC50=256±2 μM,,,,Anticancer,Tumor active peptide##Membrane lysis##Cell-penetrating peptides,,Linear,,Free,Amidation,,,0,YLLYLIRKLIL
RLLRLIRKLIR,11,Synthetic (Derived from Decoralin),Synthetic peptide,,HDMEC: EC50=138±7 μM,,,,Anticancer,Tumor active peptide##Membrane lysis##Cell-penetrating peptides,,Linear,,Free,Amidation,,,0,RLLRLIRKLIR
QLLQLIRKLII,11,Synthetic (Derived from Decoralin),Synthetic peptide,,HDMEC: EC50=171±1 μM,,,,Anticancer,Tumor active peptide##Membrane lysis##Cell-penetrating peptides,,Linear,,Free,Amidation,,,0,QLLQLIRKLII
QLLQLIRKLIM,11,Synthetic (Derived from Decoralin),Synthetic peptide,,HDMEC: EC50=142±2 μM,,,,Anticancer,Tumor active peptide##Membrane lysis##Cell-penetrating peptides,,Linear,,Free,Amidation,,,0,QLLQLIRKLIM
MLLMLIRKLIL,11,Synthetic (Derived from Decoralin),Synthetic peptide,,HDMEC: EC50=262±1 μM,,,,Anticancer,Tumor active peptide##Membrane lysis##Cell-penetrating peptides,,Linear,,Free,Amidation,,,0,MLLMLIRKLIL
QLLQLIRKLIR,11,Synthetic (Derived from Decoralin),Synthetic peptide,,HDMEC: EC50=260±1 μM,,,,Anticancer,Tumor active peptide##Membrane lysis##Cell-penetrating peptides,,Linear,,Free,Amidation,,,0,QLLQLIRKLIR
QLLQLIRKLIK,11,Synthetic (Derived from Decoralin),Synthetic peptide,,HDMEC: EC50~=250 μM,,,,Anticancer,Tumor active peptide##Membrane lysis##Cell-penetrating peptides,,Linear,,Free,Amidation,,,0,QLLQLIRKLIK
QLLQLIRKLIY,11,Synthetic (Derived from Decoralin),Synthetic peptide,,HDMEC: EC50=349±1 μM,,,,Anticancer,Tumor active peptide##Membrane lysis##Cell-penetrating peptides,,Linear,,Free,Amidation,,,0,QLLQLIRKLIY
LLLQLIRKLIL,11,Synthetic (Derived from Decoralin),Synthetic peptide,,HDMEC: EC50=154±1 μM,,,,Anticancer,Tumor active peptide##Membrane lysis##Tumor-homing peptides,,Linear,,Free,Amidation,,,0,LLLQLIRKLIL
TLLLLIRKLIL,11,Synthetic (Derived from Decoralin),Synthetic peptide,,HDMEC: EC50=348±1 μM,,,,Anticancer,Tumor active peptide##Membrane lysis##Tumor-homing peptides,,Linear,,Free,Amidation,,,0,TLLLLIRKLIL
RLLLLIRKLIL,11,Synthetic (Derived from Decoralin),Synthetic peptide,,HDMEC: EC50=160±1 μM,,,,Anticancer,Tumor active peptide##Membrane lysis##Tumor-homing peptides,,Linear,,Free,Amidation,,,0,RLLLLIRKLIL
LLLLLIRKLIL,11,Synthetic (Derived from Decoralin),Synthetic peptide,,HDMEC: EC50=278±1 μM,,,,Anticancer,Tumor active peptide##Membrane lysis##Tumor-homing peptides,,Linear,,Free,Amidation,,,0,LLLLLIRKLIL
QLLLLIRKLIL,11,Synthetic (Derived from Decoralin),Synthetic peptide,,HDMEC: EC50=271±1 μM,,,,Anticancer,Tumor active peptide##Membrane lysis##Tumor-homing peptides,,Linear,,Free,Amidation,,,0,QLLLLIRKLIL
QLLLLIRKLIV,11,Synthetic (Derived from Decoralin),Synthetic peptide,,HDMEC: EC50=339±1 μM,,,,Anticancer,Tumor active peptide##Membrane lysis##Tumor-homing peptides,,Linear,,Free,Amidation,,,0,QLLLLIRKLIV
CLLLLIRKLIL,11,Synthetic (Derived from Decoralin),Synthetic peptide,,HDMEC: EC50~=500 μM,,,,Anticancer,Tumor active peptide##Membrane lysis##Tumor-homing peptides,,Linear,,Free,Amidation,,,0,CLLLLIRKLIL
ILRWKWRWWRWRR,13,Synthetic,Synthetic peptide,,,,,,Anticancer; Antimicrobial,Tumor active peptide,,Linear,,Free,Free,,,0,ILRWKWRWWRWRR
ILPWKWRWWKWRR,13,Synthetic,Synthetic peptide,,,,,,Anticancer; Antimicrobial,Tumor active peptide,,Linear,,Free,Free,,,0,ILPWKWRWWKWRR
RWRRKWWWW,9,Synthetic,Synthetic peptide,,,,,,Anticancer; Antimicrobial,Tumor active peptide,,Linear,,Free,Free,,,0,RWRRKWWWW
WRKFWKYLK,9,Synthetic,Synthetic peptide,,,,,,Anticancer; Antimicrobial,Tumor active peptide,,Linear,,Free,Free,,,0,WRKFWKYLK
RRWWKWWWR,9,Synthetic,Synthetic peptide,,,,,,Anticancer; Antimicrobial,Tumor active peptide,,Linear,,Free,Free,,,0,RRWWKWWWR
KIWWWWRKR,9,Synthetic,Synthetic peptide,,,,,,Anticancer; Antimicrobial,Tumor active peptide,,Linear,,Free,Free,,,0,KIWWWWRKR
RLWWWWRRK,9,Synthetic,Synthetic peptide,,,,,,Anticancer; Antimicrobial,Tumor active peptide,,Linear,,Free,Free,,,0,RLWWWWRRK
KWKWWWRKI,9,Synthetic,Synthetic peptide,,,,,,Anticancer; Antimicrobial,Tumor active peptide,,Linear,,Free,Free,,,0,KWKWWWRKI
RIRRWKFRW,9,Synthetic,Synthetic peptide,,,,,,Anticancer; Antimicrobial,Tumor active peptide,,Linear,,Free,Free,,,0,RIRRWKFRW
RLKRWWKFL,9,Synthetic,Synthetic peptide,,,,,,Anticancer; Antimicrobial,Tumor active peptide,,Linear,,Free,Free,,,0,RLKRWWKFL
RWWRWRKWW,9,Synthetic,Synthetic peptide,,,,,,Anticancer; Antimicrobial,Tumor active peptide,,Linear,,Free,Free,,,0,RWWRWRKWW
KRWWWWRFR,9,Synthetic,Synthetic peptide,,,,,,Anticancer; Antimicrobial,Tumor active peptide,,Linear,,Free,Free,,,0,KRWWWWRFR
KRWWRKWWR,9,Synthetic,Synthetic peptide,,,,,,Anticancer; Antimicrobial,Tumor active peptide,,Linear,,Free,Free,,,0,KRWWRKWWR
RRWWRWVVW,9,Synthetic,Synthetic peptide,,,,,,Anticancer; Antimicrobial,Tumor active peptide,,Linear,,Free,Free,,,0,RRWWRWVVW
WFKMRWWGR,9,Synthetic,Synthetic peptide,,,,,,Anticancer; Antimicrobial,Tumor active peptide,,Linear,,Free,Free,,,0,WFKMRWWGR
KFKWWRMLI,9,Synthetic,Synthetic peptide,,,,,,Anticancer; Antimicrobial,Tumor active peptide,,Linear,,Free,Free,,,0,KFKWWRMLI
FIKWKFRWWKWRK,13,Synthetic,Synthetic peptide,,,,,,Anticancer; Antimicrobial,Tumor active peptide,,Linear,,Free,Free,,,0,FIKWKFRWWKWRK
RIKRWWWWR,9,Synthetic,Synthetic peptide,,,,,,Anticancer; Antimicrobial,Tumor active peptide,,Linear,,Free,Free,,,0,RIKRWWWWR
RWRWWWRVY,9,Synthetic,Synthetic peptide,,,,,,Anticancer; Antimicrobial,Tumor active peptide,,Linear,,Free,Free,,,0,RWRWWWRVY
HQFRFRFRVRRK,12,Synthetic,Synthetic peptide,,,,,,Anticancer; Antimicrobial,Tumor active peptide,,Linear,,Free,Free,,,0,HQFRFRFRVRRK
LKRRWKWWI,9,Synthetic,Synthetic peptide,,,,,,Anticancer; Antimicrobial,Tumor active peptide,,Linear,,Free,Free,,,0,LKRRWKWWI
RRRIKIRWY,9,Synthetic,Synthetic peptide,,,,,,Anticancer; Antimicrobial,Tumor active peptide,,Linear,,Free,Free,,,0,RRRIKIRWY
RLWWKIWLK,9,Synthetic,Synthetic peptide,,,,,,Anticancer; Antimicrobial,Tumor active peptide,,Linear,,Free,Free,,,0,RLWWKIWLK
KRRWRIWLV,9,Synthetic,Synthetic peptide,,,,,,Anticancer; Antimicrobial,Tumor active peptide,,Linear,,Free,Free,,,0,KRRWRIWLV
FFIYVWRRR,9,Synthetic,Synthetic peptide,,,,,,Anticancer; Antimicrobial,Tumor active peptide,,Linear,,Free,Free,,,0,FFIYVWRRR
IRMRIRVLL,9,Synthetic,Synthetic peptide,,,,,,Anticancer; Antimicrobial,Tumor active peptide,,Linear,,Free,Free,,,0,IRMRIRVLL
RWWRKIWKW,9,Synthetic,Synthetic peptide,,,,,,Anticancer; Antimicrobial,Tumor active peptide,,Linear,,Free,Free,,,0,RWWRKIWKW
LRFILWWKR,9,Synthetic,Synthetic peptide,,,,,,Anticancer; Antimicrobial,Tumor active peptide,,Linear,,Free,Free,,,0,LRFILWWKR
RWWIRIRWH,9,Synthetic,Synthetic peptide,,,,,,Anticancer; Antimicrobial,Tumor active peptide,,Linear,,Free,Free,,,0,RWWIRIRWH
RRRWWKLMM,9,Synthetic,Synthetic peptide,,,,,,Anticancer; Antimicrobial,Tumor active peptide,,Linear,,Free,Free,,,0,RRRWWKLMM
LRRWIRIRW,9,Synthetic,Synthetic peptide,,,,,,Anticancer; Antimicrobial,Tumor active peptide,,Linear,,Free,Free,,,0,LRRWIRIRW
RKFRWWVIR,9,Synthetic,Synthetic peptide,,,,,,Anticancer; Antimicrobial,Tumor active peptide,,Linear,,Free,Free,,,0,RKFRWWVIR
WKIVFWWRR,9,Synthetic,Synthetic peptide,,,,,,Anticancer; Antimicrobial,Tumor active peptide,,Linear,,Free,Free,,,0,WKIVFWWRR
RQRRVVIWW,9,Synthetic,Synthetic peptide,,,,,,Anticancer; Antimicrobial,Tumor active peptide,,Linear,,Free,Free,,,0,RQRRVVIWW
RRWRVIVKW,9,Synthetic,Synthetic peptide,,,,,,Anticancer; Antimicrobial,Tumor active peptide,,Linear,,Free,Free,,,0,RRWRVIVKW
RRWKIVVIRWRR,12,Synthetic,Synthetic peptide,,,,,,Anticancer; Antimicrobial,Tumor active peptide,,Linear,,Free,Free,,,0,RRWKIVVIRWRR
RLWRIVVIRVKR,12,Synthetic,Synthetic peptide,,,,,,Anticancer; Antimicrobial,Tumor active peptide,,Linear,,Free,Free,,,0,RLWRIVVIRVKR
RLRRIVVIRVFR,12,Synthetic,Synthetic peptide,,,,,,Anticancer; Antimicrobial,Tumor active peptide,,Linear,,Free,Free,,,0,RLRRIVVIRVFR
VRLRIRVRVIRK,12,Synthetic,Synthetic peptide,,,,,,Anticancer; Antimicrobial,Tumor active peptide,,Linear,,Free,Free,,,0,VRLRIRVRVIRK
RRYHWRIYI,9,Synthetic,Synthetic peptide,,,,,,Anticancer; Antimicrobial,Tumor active peptide,,Linear,,Free,Free,,,0,RRYHWRIYI
RKWKIKWYW,9,Synthetic,Synthetic peptide,,,,,,Anticancer; Antimicrobial,Tumor active peptide,,Linear,,Free,Free,,,0,RKWKIKWYW
YRLRVKWKW,9,Synthetic,Synthetic peptide,,,,,,Anticancer; Antimicrobial,Tumor active peptide,,Linear,,Free,Free,,,0,YRLRVKWKW
WKWRVRVTI,9,Synthetic,Synthetic peptide,,,,,,Anticancer; Antimicrobial,Tumor active peptide,,Linear,,Free,Free,,,0,WKWRVRVTI
RTKKWIVWI,9,Synthetic,Synthetic peptide,,,,,,Anticancer; Antimicrobial,Tumor active peptide,,Linear,,Free,Free,,,0,RTKKWIVWI
NWRKLYRRK,9,Synthetic,Synthetic peptide,,,,,,Anticancer; Antimicrobial,Tumor active peptide,,Linear,,Free,Free,,,0,NWRKLYRRK
YKFRWRIYI,9,Synthetic,Synthetic peptide,,,,,,Anticancer; Antimicrobial,Tumor active peptide,,Linear,,Free,Free,,,0,YKFRWRIYI
KRKKRFKWW,9,Synthetic,Synthetic peptide,,,,,,Anticancer; Antimicrobial,Tumor active peptide,,Linear,,Free,Free,,,0,KRKKRFKWW
VXLfPFfNQY,10,Bacillus subtilis; Bacillus aneurinolyticus; Bacillus brevis,Native peptide,Human erythrocytes: 50% Hemolysis=4.5 µM,,,,,Anticancer; Antimicrobial; Antifungal,Tumor active peptide##Membrane lysis,,Cyclic,NCB: Val1<--->Tyr10,Free,Free,X=Orn; f=D-Phe,,0,VXLFPFFNQY
VKLfPFfNQY,10,Bacillus aneurinolyticus; Bacillus brevis,Native peptide,Human erythrocytes: 50% Hemolysis=4.1 µM,,,,,Anticancer; Antimicrobial; Antifungal,Tumor active peptide##Membrane lysis,,Cyclic,NCB: Val1<--->Tyr10,Free,Free,f=D-Phe,,0,VKLFPFFNQY
VXLfPWfNQY,10,Bacillus aneurinolyticus; Bacillus brevis,Native peptide,Human erythrocytes: 50% Hemolysis=2.6 µM,,,,,Anticancer; Antimicrobial; Antifungal,Tumor active peptide##Membrane lysis,,Cyclic,NCB: Val1<--->Tyr10,Free,Free,X=Orn; f=D-Phe,,0,VXLFPWFNQY
VKLfPWfNQY,10,Bacillus aneurinolyticus; Bacillus brevis,Native peptide,Human erythrocytes: 50% Hemolysis=8.6 µM,,,,,Anticancer; Antimicrobial; Antifungal,Tumor active peptide##Membrane lysis,,Cyclic,NCB: Val1<--->Tyr10,Free,Free,f=D-Phe,,0,VKLFPWFNQY
VXLfPWwNQY,10,Bacillus aneurinolyticus; Bacillus brevis,Native peptide,Human erythrocytes: 50% Hemolysis=3.2 µM,,,,,Anticancer; Antimicrobial; Antifungal,Tumor active peptide##Membrane lysis,,Cyclic,NCB: Val1<--->Tyr10,Free,Free,X=Orn; f=D-Phe,,0,VXLFPWWNQY
VKLfPWwNQY,10,Bacillus aneurinolyticus; Bacillus brevis,Native peptide,Human erythrocytes: 50% Hemolysis=5.4 µM,,,,,Anticancer; Antimicrobial; Antifungal,Tumor active peptide##Membrane lysis,,Cyclic,NCB: Val1<--->Tyr10,Free,Free,f=D-Phe,,0,VKLFPWWNQY
RWKIFKKIEKVGQNIRDGIVKAGPAVAVVGQAATI,35,Bombyx mori,Native peptide,Human erythrocytes: Not active up to 200 µM,HEK293: Not active up to 80 µM; Human PBMC: Not active up to 80 µM,,,,Anticancer; Antifungal,Tumor active peptide##Membrane lysis,,Linear,,Free,Amidation,,,0,RWKIFKKIEKVGQNIRDGIVKAGPAVAVVGQAATI
FLGALWNVAKSVF,13,Vaejovis mexicanus smithi,Native peptide,Human erythrocytes: ~0% Hemolytic=6.3 µM,MCF-10A: Not active up to 25 μM,,,,Anticancer; Antimicrobial; Antifungal,Tumor active peptide##Membrane lysis,,Linear,,Free,Amidation,,,0,FLGALWNVAKSVF
KLGALWNVAKSVF,13,Synthetic,Synthetic peptide,Human erythrocytes: ~0% Hemolytic=12.5 µM,MCF-10A: Not active up to 25 μM,,,,Anticancer; Antimicrobial; Antifungal,Tumor active peptide##Membrane lysis,,Linear,,Free,Amidation,,,0,KLGALWNVAKSVF
FLGALWNVKKSVF,13,Synthetic,Synthetic peptide,Human erythrocytes: ~0% Hemolytic>100 µM,MCF-10A: Not active up to 25 μM,,,,Anticancer; Antimicrobial; Antifungal,Tumor active peptide##Membrane lysis,,Linear,,Free,Amidation,,,0,FLGALWNVKKSVF
KLGALWNVAKSKF,13,Synthetic,Synthetic peptide,Human erythrocytes: ~0% Hemolytic>100 µM,MCF-10A: Not active up to 25 μM,,,,Anticancer; Antimicrobial; Antifungal,Tumor active peptide##Membrane lysis,,Linear,,Free,Amidation,,,0,KLGALWNVAKSKF
FLKALWKVAKSVF,13,Synthetic,Synthetic peptide,Human erythrocytes: ~0% Hemolytic=1.6 µM,MCF-10A: Not active up to 25 μM,,,,Anticancer; Antimicrobial; Antifungal,Tumor active peptide##Membrane lysis,,Linear,,Free,Amidation,,,0,FLKALWKVAKSVF
FLKALWNVAKKVF,13,Synthetic,Synthetic peptide,Human erythrocytes: ~0% Hemolytic=3.1 µM,MCF-10A: Not active up to 25 μM,,,,Anticancer; Antimicrobial; Antifungal,Tumor active peptide##Membrane lysis,,Linear,,Free,Amidation,,,0,FLKALWNVAKKVF
FLGALWKVAKKVF,13,Synthetic,Synthetic peptide,Human erythrocytes: ~0% Hemolytic=3.1 µM,MCF-10A: Not active up to 25 μM,,,,Anticancer; Antimicrobial; Antifungal,Tumor active peptide##Membrane lysis,,Linear,,Free,Amidation,,,0,FLGALWKVAKKVF
FLKALWKVAKKVF,13,Synthetic,Synthetic peptide,Human erythrocytes: ~0% Hemolytic=3.1 µM,MCF-10A: Not active up to 25 μM,,,,Anticancer; Antimicrobial; Antifungal,Tumor active peptide##Membrane lysis,,Linear,,Free,Amidation,,,0,FLKALWKVAKKVF
FLPLLASLFSRLF,13,Rana ornativentris,Native peptide,Human erythrocytes: 50% Hemolysis<12.5 µM,HaCat: LC50=50 µM,,,,Anticancer; Antimicrobial; Antifungal,Tumor active peptide##Membrane lysis,,Linear,,Free,Amidation,,,0,FLPLLASLFSRLF
IPPFIKKVLTTVF,13,Rana capito,Native peptide,Human erythrocytes: 50% Hemolysis>100 µM,HaCat: LC50=100 µM,,,,Anticancer; Antimicrobial; Antifungal,Tumor active peptide##Membrane lysis,,Linear,,Free,Amidation,,,0,IPPFIKKVLTTVF
GILGKLWEGFKSIV,14,Pandinus imperator,Native peptide,,HGF-1: IC50=97.5 ± 1.0 μM,,,,Anticancer; Antimicrobial; Antifungal,Tumor active peptide##Membrane lysis,,Linear,,Free,Amidation,,,0,GILGKLWEGFKSIV
IFGAIWKGISSLL,13,Pandinus imperator,Native peptide,,HGF-1: IC50=43.5 ± 2.0 μM,,,,Anticancer; Antimicrobial; Antifungal,Tumor active peptide##Membrane lysis,,Linear,,Free,Amidation,,,0,IFGAIWKGISSLL
FLSTIWNGIKSLL,13,Pandinus imperator,Native peptide,,HGF-1: IC50=26.0 ± 1.0 μM,,,,Anticancer; Antimicrobial; Antifungal,Tumor active peptide##Membrane lysis,,Linear,,Free,Amidation,,,0,FLSTIWNGIKSLL
FLPILASLAAKFGPKLFCLVTKKC,24,Rana boylii,Native peptide,Human erythrocytes: LC50=10 μM ,,,,,Anticancer; Antimicrobial; Antifungal,Tumor active peptide,,Cyclic,Cys18<--->Cys24,Free,Free,,,0,FLPILASLAAKFGPKLFCLVTKKC
FLPILASLAAKFGPKLFXLVTKKX,24,Synthetic,Synthetic peptide,Human erythrocytes: LC50=4 μM ,,,,,Anticancer; Antimicrobial; Antifungal,Tumor active peptide,,Cyclic,DCB: X18<--->X24,Free,Free,X=Allylglycine,,0,FLPILASLAAKFGPKLFXLVTKKX
FLPILASLAAKFGPKLFSLVTKKS,24,Synthetic,Synthetic peptide,Human erythrocytes: LC50=75 μM ,,,,,Anticancer; Antimicrobial; Antifungal,Tumor active peptide,,Cyclic,NCB: Ser18<--->Ser24,Free,Free,,,0,FLPILASLAAKFGPKLFSLVTKKS
LFRLIKSLIKRLVSAFK,17,Synthetic,Synthetic peptide,,Vero cells: 50% Cytotoxicity=70.46 µg/ml; MDCK: 50% Cytotoxicity=83.35 µg/ml,,,,Anticancer; Antimicrobial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,,0,LFRLIKSLIKRLVSAFK
IKLSPETKDNLKKVLKGAIKGAIAVAKMV,29,Hymenochirus boettgeri,Native peptide,Human erythrocytes: LC50=213 ± 18 μM ,,,,,Anticancer; Antimicrobial; Antifungal,Tumor active peptide##Membrane lysis,,Linear,,Free,Amidation,,,0,IKLSPETKDNLKKVLKGAIKGAIAVAKMV
LKIPGFVKDTLKKVAKGIFSAVAGAMTPS,29,Hymenochirus boettgeri,Native peptide,Human erythrocytes: LC50=210 ± 21 μM ,,,,,Anticancer; Antimicrobial; Antifungal,Tumor active peptide##Membrane lysis,,Linear,,Free,Free,,,0,LKIPGFVKDTLKKVAKGIFSAVAGAMTPS
IKIPAVVKDTLKKVAKGVLSAVAGALTQ,28,Hymenochirus boettgeri,Native peptide,Human erythrocytes: LC50> 400 μM ,,,,,Anticancer; Antimicrobial; Antifungal,Tumor active peptide##Membrane lysis,,Linear,,Free,Free,,,0,IKIPAVVKDTLKKVAKGVLSAVAGALTQ
IKIPAFVKDTLKKVAKGVISAVAGALTQ,28,Hymenochirus boettgeri,Native peptide,Human erythrocytes: LC50=158 ± 6 μM ,,,,,Anticancer; Antimicrobial; Antifungal,Tumor active peptide##Membrane lysis,,Linear,,Free,Free,,,0,IKIPAFVKDTLKKVAKGVISAVAGALTQ
IKLSKETKDNLKKVLKGAIKGAIAVAKMV,29,Synthetic (Derived from Hymenochirin-1B),Synthetic peptide,Human erythrocytes: LC50=205 ± 15 μM ,,,,,Anticancer,Tumor active peptide##Membrane lysis,,Linear,,Free,Amidation,,,0,IKLSKETKDNLKKVLKGAIKGAIAVAKMV
IKLSPKTKDNLKKVLKGAIKGAIAVAKMV,29,Synthetic (Derived from Hymenochirin-1B),Synthetic peptide,Human erythrocytes: LC50=186 ± 4 μM ,,,,,Anticancer,Tumor active peptide##Membrane lysis,,Linear,,Free,Amidation,,,0,IKLSPKTKDNLKKVLKGAIKGAIAVAKMV
IKLSPETKKNLKKVLKGAIKGAIAVAKMV,29,Synthetic (Derived from Hymenochirin-1B),Synthetic peptide,Human erythrocytes: LC50=174 ± 12 μM,,,,,Anticancer,Tumor active peptide##Membrane lysis,,Linear,,Free,Amidation,,,0,IKLSPETKKNLKKVLKGAIKGAIAVAKMV
IKLSKKTKDNLKKVLKGAIKGAIAVAKMV,29,Synthetic (Derived from Hymenochirin-1B),Synthetic peptide,Human erythrocytes: LC50=137 ± 11 μM,,,,,Anticancer,Tumor active peptide##Membrane lysis,,Linear,,Free,Amidation,,,0,IKLSKKTKDNLKKVLKGAIKGAIAVAKMV
IKLSKETKKNLKKVLKGAIKGAIAVAKMV,29,,Synthetic peptide,Human erythrocytes: LC50=127 ± 9 μM,,,,,Anticancer,Tumor active peptide##Membrane lysis,,Linear,,Free,Amidation,,,0,IKLSKETKKNLKKVLKGAIKGAIAVAKMV
IKLSPKTKKNLKKVLKGAIKGAIAVAKMV,29,,Synthetic peptide,Human erythrocytes: LC50=85 ± 5 μM,,,,,Anticancer,Tumor active peptide##Membrane lysis,,Linear,,Free,Amidation,,,0,IKLSPKTKKNLKKVLKGAIKGAIAVAKMV
IKLSPkTKDNLKKVLKGAIKGAIAVAKMV,29,,Synthetic peptide,Human erythrocytes: LC50=188 ± 8 μM,,,,,Anticancer,Tumor active peptide##Membrane lysis,,Linear,,Free,Amidation,k=D-Lys,,0,IKLSPKTKDNLKKVLKGAIKGAIAVAKMV
IKLSPETKkNLKKVLKGAIKGAIAVAKMV,29,,Synthetic peptide,Human erythrocytes: LC50> 400 μM,,,,,Anticancer,Tumor active peptide##Membrane lysis,,Linear,,Free,Amidation,k=D-Lys,,0,IKLSPETKKNLKKVLKGAIKGAIAVAKMV
IKLSPkTKkNLKKVLKGAIKGAIAVAKMV,29,,Synthetic peptide,Human erythrocytes: LC50=302 ± 21 μM,,,,,Anticancer,Tumor active peptide##Membrane lysis,,Linear,,Free,Amidation,k=D-Lys,,0,IKLSPKTKKNLKKVLKGAIKGAIAVAKMV
QRSVSNAATRVCRTGRSRWRDVCRNFMRR,29,Synthetic,Synthetic peptide,,,,,,Anticancer; Antimicrobial,Tumor active peptide##Induce apoptosis,,Cyclic,Cys12<--->Cys23,Free,Free,,,0,QRSVSNAATRVCRTGRSRWRDVCRNFMRR
QRSVSNAATRVSRTGRSRWRDVSRNFMRR,29,Synthetic,Synthetic peptide,,,,,,Anticancer; Antimicrobial,Tumor active peptide##Induce apoptosis,,Linear,,Free,Free,,,0,QRSVSNAATRVSRTGRSRWRDVSRNFMRR
QRSVSNAATRVCRT,14,Synthetic,Synthetic peptide,,,,,,Anticancer; Antimicrobial,Tumor active peptide##Induce apoptosis,,Linear,,Free,Free,,,0,QRSVSNAATRVCRT
RDVCRNFMRR,10,Synthetic,Synthetic peptide,,,,,,Anticancer; Antimicrobial,Tumor active peptide##Induce apoptosis,,Linear,,Free,Free,,,0,RDVCRNFMRR
RDVCRNFMRRYQSRVIQGLV,20,Synthetic,Synthetic peptide,,,,,,Anticancer; Antimicrobial,Tumor active peptide##Induce apoptosis,,Linear,,Free,Free,,,0,RDVCRNFMRRYQSRVIQGLV
QRSVSNAATRVCRTGRSRW,19,Synthetic,Synthetic peptide,,,,,,Anticancer; Antimicrobial,Tumor active peptide##Induce apoptosis,,Linear,,Free,Free,,,0,QRSVSNAATRVCRTGRSRW
GRSRWRDVCRNFMRR,15,Synthetic,Synthetic peptide,,,,,,Anticancer; Antimicrobial,Tumor active peptide##Induce apoptosis,,Linear,,Free,Free,,,0,GRSRWRDVCRNFMRR
GQSQWRDVCRNFMRR,15,Synthetic,Synthetic peptide,,,,,,Anticancer; Antimicrobial,Tumor active peptide##Induce apoptosis,,Linear,,Free,Free,,,0,GQSQWRDVCRNFMRR
FLFSLIPKAIGGLISAFK,18,Synthetic,Synthetic peptide,Horse erythrocytes: 53% Hemolysis=100 µM; 52% Hemolysis=80 µM,HMEC-1: IC50=40.35 µM,,,,Anticancer; Antimicrobial; Antifungal,Tumor active peptide##Membrane lysis,,Linear,,Free,Amidation,,,0,FLFSLIPKAIGGLISAFK
FLSLIPHIVSGVASIAKHF,19,Phyllomedusa sauvagii; Rana bicolor,Native peptide,Human erythrocytes: LC50=39 µM,,,,,Anticancer; Antimicrobial; Antifungal,Tumor active peptide##Membrane lysis,,Linear,,Free,Amidation,,,0,FLSLIPHIVSGVASIAKHF
FLSLIPHIVSGVASLAKHF,19,Phyllomedusa sauvagii,Native peptide,Human erythrocytes: LC50=25 µM,,,,,Anticancer; Antimicrobial; Antifungal,Tumor active peptide##Membrane lysis,,Linear,,Free,Amidation,,,0,FLSLIPHIVSGVASLAKHF
FLSMIPHIVSGVAALAKHL,19,Phyllomedusa sauvagii,Native peptide,Human erythrocytes: LC50=33 µM,,,,,Anticancer; Antimicrobial; Antifungal,Tumor active peptide##Membrane lysis,,Linear,,Free,Amidation,,,0,FLSMIPHIVSGVAALAKHL
ILGPVLGLVSDTLDDVLGIL,20,Bombina maxima,Native peptide,Human erythrocytes: 20% Hemolysis=90 µM,SVGp12: ~10% Cell death=125 µM,,,,Anticancer; Antimicrobial; Antifungal; Antiviral,Tumor active peptide##Membrane lysis,,Linear,,Free,Amidation,,,0,ILGPVLGLVSDTLDDVLGIL
KTCENLADTYKGPCFTTGSCDDHCKNKEHLRSGRCRDDFRCWCTKNC,47,Phaseolus vulgaris,Native peptide,,MCF-10a: 50% Cell death=7 µM,,,,Anticancer; Antifungal,Tumor active peptide##Induce apoptosis,,Cyclic,Cys3<--->Cys47; Cys14<--->Cys35; Cys20<--->Cys41; Cys24<--->Cys43,Free,Free,,,0,KTCENLADTYKGPCFTTGSCDDHCKNKEHLRSGRCRDDFRCWCTKNC
KRKCPKTPFDNTPGAWFAHLILGC,24,Lactobacillus casei; Lactobacillus paracasei,Native peptide,,H184B5F5/M10: ~20% Cell death=40 µg/ml; CHO-K1: ~40% Cell death=40 µg/ml,,,,Anticancer; Antibacterial,Tumor active peptide##Induce apoptosis,,Cyclic,Cys4<--->Cys24,Free,Free,,,0,KRKCPKTPFDNTPGAWFAHLILGC
DSIRDVSPTFNKIRRWFDGLFK,22,Lactobacillus casei; Lactobacillus paracasei,Native peptide,,H184B5F5/M10: ~20% Cell death=40 µg/ml; CHO-K1: ~35% Cell death=40 µg/ml,,,,Anticancer; Antibacterial,Tumor active peptide##Induce apoptosis,,Linear,,Free,Free,,,0,DSIRDVSPTFNKIRRWFDGLFK
MQFITDLIKKAVDFFKGLFGNK,22,Staphylococcus warneri RK; Staphylococcus epidermidis,Native peptide,Human erythrocytes: 10% Hemolysis=2.78 µM,,,,,Anticancer; Antibacterial,Tumor active peptide##Membrane lysis,,Linear,,Free,Free,,,0,MQFITDLIKKAVDFFKGLFGNK
DSMGAVKLAKLLIDKMKCEVTKAC,24,Amolops jingdongensis,Native peptide,Human erythrocytes: 50% Hemolysis=150 µM; Rabbit erythrocytes: 50% Hemolysis=150 µM,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Cyclic,Cys18<--->Cys24,Free,Free,,,0,DSMGAVKLAKLLIDKMKCEVTKAC
GFMDTAKNVAKNVAVTLIDKLRCKVTGGC,29,Amolops jingdongensis,Native peptide,Human erythrocytes: 50% Hemolysis=150 µM; Rabbit erythrocytes: 50% Hemolysis=150 µM,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Cyclic,Cys23<--->Cys29,Free,Free,,,0,GFMDTAKNVAKNVAVTLIDKLRCKVTGGC
GFSSIFRGVAKFASKGLGKDLAKLGVDLVACKISKQC,37,Lithobates chiricahuensis,Native peptide,Human erythrocytes: 50% Hemolysis=150 µM,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Cyclic,Cys31<--->Cys37,Free,Free,,,0,GFSSIFRGVAKFASKGLGKDLAKLGVDLVACKISKQC
GFSSIFRGVAKFASKGLGKKLAKLGVKLVACKISKQC,37,Synthetic,Synthetic peptide,Human erythrocytes: 50% Hemolysis=11 µM,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Free,,,0,GFSSIFRGVAKFASKGLGKKLAKLGVKLVACKISKQC
GFSSIFRGVAKFASKGLGKDLAKLGVDLVASKISKQS,37,Synthetic,Synthetic peptide,Human erythrocytes: 50% Hemolysis>200 µM,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Free,,,0,GFSSIFRGVAKFASKGLGKDLAKLGVDLVASKISKQS
RGVAKFASKGLGKDLAKLGVDLVACKISKQC,31,Synthetic,Synthetic peptide,Human erythrocytes: 50% Hemolysis>200 µM,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Cyclic,Cys25<--->Cys31,Free,Free,,,0,RGVAKFASKGLGKDLAKLGVDLVACKISKQC
KPPPWVPV,8,Phyllomedusa sauvagii,Native peptide,Horse erythrocytes: Not active up to 160 µM,,,,,Anticancer,Tumor active peptide##Membrane lysis,,Linear,,Free,Free,,,0,KPPPWVPV
GIPCGESCVFIPCTVTALLGCSCKDKVCYKN,31,Clitoria ternatea,Native peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Cyclic,Cys4<--->Cys21; Cys8<--->Cys23; Cys13<--->Cys28; NCB: Gly1<--->Asn31,Free,Free,,,0,GIPCGESCVFIPCTVTALLGCSCKDKVCYKN
GVPCAESCVWIPCTVTALLGCSCKDKVCYLN,31,Clitoria ternatea,Native peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Cyclic,Cys4<--->Cys21; Cys8<--->Cys23; Cys13<--->Cys28; NCB: Gly1<--->Asn31,Free,Free,,,0,GVPCAESCVWIPCTVTALLGCSCKDKVCYLN
GIPCGESCVYIPCTVTALLGCSCKDKVCYKN,31,Clitoria ternatea,Native peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Cyclic,Cys4<--->Cys21; Cys8<--->Cys23; Cys13<--->Cys28; NCB: Gly1<--->Asn31,Free,Free,,,0,GIPCGESCVYIPCTVTALLGCSCKDKVCYKN
GSVIKCGESCLLGKCYTPGCTCSRPICKKD,30,Clitoria ternatea,Native peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Cyclic,Cys6<--->Cys20; Cys10<--->Cys22; Cys15<--->Cys27; NCB: Gly1<--->Asn30,Free,Free,,,0,GSVIKCGESCLLGKCYTPGCTCSRPICKKD
GSAIRCGESCLLGKCYTPGCTCDRPICKKN,30,Clitoria ternatea,Native peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Cyclic,Cys6<--->Cys20; Cys10<--->Cys22; Cys15<--->Cys27; NCB: Gly1<--->Asn30,Free,Free,,,0,GSAIRCGESCLLGKCYTPGCTCDRPICKKN
GNPANPLNLKKHHGVFCDVCKALVEGGEKVGDDDLDAWLDVNIGTLCWTMLLPLHHECEEELKKVKKELKKDIENKDSPDKACKDVDLC,89,Caenorhabditis elegans,Native peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Cyclic,Cys17<--->Cys89; Cys20<--->Cys83; Cys47<--->Cys58,Free,Free,,,0,GNPANPLNLKKHHGVFCDVCKALVEGGEKVGDDDLDAWLDVNIGTLCWTMLLPLHHECEEELKKVKKELKKDIENKDSPDKACKDVDLC
GSHGAFCHLCEDLIKDGKEAGDVALDVWLDEEIGSRCKDFGVLASECFKELKVAEHDIWEAIDQEIPEDKTCKEAKLC,78,Caenorhabditis elegans,Native peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Cyclic,Cys7<--->Cys78; Cys10<--->Cys72; Cys37<--->Cys47,Free,Free,,,0,GSHGAFCHLCEDLIKDGKEAGDVALDVWLDEEIGSRCKDFGVLASECFKELKVAEHDIWEAIDQEIPEDKTCKEAKLC
RRQRRTSKLMKRGGKLAKLAKKLAKLAKLAK,31,Synthetic,Synthetic peptide,,,,,It is possible that the DP1 fusion peptide can be used to facilitate an immune response against tumor antigens by triggering massive apoptosis within tumors,Anticancer,Tumor active peptide##Coupling peptide##Pro-apoptotic peptide##Induce apoptosis,,Linear,,Free,Free,,,0,RRQRRTSKLMKRGGKLAKLAKKLAKLAKLAK
KRIIQRILSRNS,12,Synthetic,Synthetic peptide,,,,,, --,Transducing peptide,,Linear,,Free,Free,,,0,KRIIQRILSRNS
KRIHPRLTRSIR,12,Synthetic,Synthetic peptide,,,,,, --,Transducing peptide,,Linear,,Free,Free,,,0,KRIHPRLTRSIR
PPRLRKRRQLNM,12,Synthetic,Synthetic peptide,,,,,, --,Transducing peptide,,Linear,,Free,Free,,,0,PPRLRKRRQLNM
PIRRRKKLRRLK,12,Synthetic,Synthetic peptide,,,,,, --,Transducing peptide,,Linear,,Free,Free,,,0,PIRRRKKLRRLK
RRQRRTSKLMKR,12,Synthetic,Synthetic peptide,,,,,, --,Transducing peptide,,Linear,,Free,Free,,,0,RRQRRTSKLMKR
MHKRPTTPSRKM,12,Synthetic,Synthetic peptide,,,,,, --,Transducing peptide,,Linear,,Free,Free,,,0,MHKRPTTPSRKM
KLAKLAKKLAKLAK,14,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide##Membrane lysis,,Linear,,Free,Free,,,0,KLAKLAKKLAKLAK
klaklakklaklak,14,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide##Membrane lysis,,Linear,,Free,Free,,,0,KLAKLAKKLAKLAK
Cklaklakklaklak,15,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide##Membrane lysis,,Linear,,Free,Free,k=D-Lys; l=D-Leu; a=D-Ala,,0,CKLAKLAKKLAKLAK
klaklakklaklakC,15,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide##Membrane lysis,,Linear,,Free,Free,k=D-Lys; l=D-Leu; a=D-Ala,,0,KLAKLAKKLAKLAKC
GLWNSIKIAGKKLFVNVLDKIRCKVAGGC,29,Synthetic,Synthetic peptide,Horse erythrocytes: 10% Hemolysis=5.86 µM; 50% Hemolysis=33.03 µM,Human keratinocytes HaCat: IC50=5.05 µM,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Cyclic,Cys23<--->Cys29,Free,Free,,,0,GLWNSIKIAGKKLFVNVLDKIRCKVAGGC
GLWNSIKIAGKKLFVNVLDKIR,22,Synthetic,Synthetic peptide,Horse erythrocytes: 10% Hemolysis=87.304 µM; 50% Hemolysis=254.11 µM,Human keratinocytes HaCat: IC50=38.90 µM,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,,0,GLWNSIKIAGKKLFVNVLDKIR
YKQCHKKGGHCFPKEKICLPPSSDFGKMDCRWRWKCCKKGSG,42,Crotalus durissus terrificus,Native peptide,,HEK293: 50% Cell death>50 µM; BMDMs: 3% Cell death=50 µg/ml,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide##Cell-penetrating peptides,,Cyclic,Cys4<--->Cys36; Cys11<--->Cys30; Cys18<--->Cys37,Free,Free,,,0,YKQCHKKGGHCFPKEKICLPPSSDFGKMDCRWRWKCCKKGSG
SQLGDLGSGAGQGGGGGGSIRAAGGAFGKLEAAREEEFFYKKQKEQLERLKNDQIHQAEFHHQQIKEHEEAIQRHKDFLNNLHK,84,Drosophila virilis,Native peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Free,,,0,SQLGDLGSGAGQGGGGGGSIRAAGGAFGKLEAAREEEFFYKKQKEQLERLKNDQIHQAEFHHQQIKEHEEAIQRHKDFLNNLHK
ILGAILPLVSGLLSNKL,17,Alytes obstetricans,Native peptide,Human erythrocytes: 50% Hemolysis=115 µM,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,,0,ILGAILPLVSGLLSNKL
GLLDTLKGAAKNVVGSLASKVMEKL,25,Leptodactylus pentadactylus,Native peptide,,Human fibroblasts FHN: IC50=35.9 µM,,,"In the present study the rounding and cell shrinkage, DNA fragmentation, mitochondrial membrane potential alteration and S phase arrest support the apoptogenic nature of pentadactylin, whereas cell growth inhibition and reduction of cell viability indicate its anti-proliferative and cytotoxic activity. ",Anticancer; Antibacterial; Antifungal,Tumor active peptide##Induce apoptosis,,Linear,,Free,Amidation,,,0,GLLDTLKGAAKNVVGSLASKVMEKL
XLPICGETCVLGTCYTPGCRCQYPICVR,28,Steinchisma laxum (Panicum laxum),Native peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Cyclic,Cys5<--->Cys19; Cys9<--->Cys21; Cys14<--->Cys26,Free,Free,X=PYA (Pyroglutamic acid),,0,XLPICGETCVLGTCYTPGCRCQYPICVR
XLPICGETCVLGRCYTPNCRCQYPICVR,28,Steinchisma laxum (Panicum laxum),Native peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Cyclic,Cys5<--->Cys19; Cys9<--->Cys21; Cys14<--->Cys26,Free,Free,X=PYA (Pyroglutamic acid),,0,XLPICGETCVLGRCYTPNCRCQYPICVR
XAFCGETCLLGKCYTPGCSCHTGICLK,27,Steinchisma laxum (Panicum laxum),Native peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Cyclic,Cys4<--->Cys18; Cys8<--->Cys20; Cys13<--->Cys25,Free,Free,X=PYA (Pyroglutamic acid),,0,XAFCGETCLLGKCYTPGCSCHTGICLK
XAFCGETCLLGTCYTPGCRCTAGICLK,27,Steinchisma laxum (Panicum laxum),Native peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Cyclic,Cys4<--->Cys18; Cys8<--->Cys20; Cys13<--->Cys25,Free,Free,X=PYA (Pyroglutamic acid),,0,XAFCGETCLLGTCYTPGCRCTAGICLK
XLPICGETCVLGTCYTPGCSCAYPICAR,28,Steinchisma laxum (Panicum laxum),Native peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Cyclic,Cys5<--->Cys19; Cys9<--->Cys21; Cys14<--->Cys26,Free,Free,X=PYA (Pyroglutamic acid),,0,XLPICGETCVLGTCYTPGCSCAYPICAR
XLPICGETCVLGTCYTPGCSCAYPICVR,28,Steinchisma laxum (Panicum laxum),Native peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Cyclic,Cys5<--->Cys19; Cys9<--->Cys21; Cys14<--->Cys26,Free,Free,X=PYA (Pyroglutamic acid),,0,XLPICGETCVLGTCYTPGCSCAYPICVR
XAFCGETCVLGTCYTPGCSCNFGICLK,27,Steinchisma laxum (Panicum laxum),Native peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Cyclic,Cys4<--->Cys18; Cys8<--->Cys20; Cys13<--->Cys25,Free,Free,X=PYA (Pyroglutamic acid),,0,XAFCGETCVLGTCYTPGCSCNFGICLK
XDCGETCVLGTCYTPGCSCSAYPLCV,26,Steinchisma laxum (Panicum laxum),Native peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Cyclic,Cys3<--->Cys17; Cys7<--->Cys19; Cys12<--->Cys25,Free,Free,X=PYA (Pyroglutamic acid),,0,XDCGETCVLGTCYTPGCSCSAYPLCV
ACGILHDNCVYVPAQNPCCRGLQCRYGKCLVQV,33,Psalmopoeus cambridgei,Native peptide,Human erythrocytes: Not active at 10 µM,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Cyclic,Cys2<--->Cys19; Cys9<--->Cys24; Cys18<--->Cys29,Free,Free,,,0,ACGILHDNCVYVPAQNPCCRGLQCRYGKCLVQV
RCLPAGKTCVRGPMRVPCCGSCSQNKCT,28,Psalmopoeus cambridgei,Native peptide,Human erythrocytes: Not active at 10 µM,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Cyclic,Cys2<--->Cys19; Cys9<--->Cys22; Cys18<--->Cys27,Free,Free,,,0,RCLPAGKTCVRGPMRVPCCGSCSQNKCT
FLGALFHALSHLL,13,Synthetic,Synthetic peptide,Human erythrocytes: 0% Hemolysis=30 µM,MCF-10A: IC50>120 μM,,,,Anticancer; Antibacterial,Tumor active peptide##Membrane lysis,,Linear,,Free,Free,,,0,FLGALFHALSHLL
FLGALWKALSKLL,13,Synthetic,Synthetic peptide,Human erythrocytes: 41% Hemolysis=30 µM,MCF-10A: IC50=9 μM,,,,Anticancer; Antibacterial,Tumor active peptide##Membrane lysis,,Linear,,Free,Free,,,0,FLGALWKALSKLL
FLGALWHALSKLL,13,Synthetic,Synthetic peptide,Human erythrocytes: 15% Hemolysis=30 µM,MCF-10A: IC50=65 μM,,,,Anticancer; Antibacterial,Tumor active peptide##Membrane lysis,,Linear,,Free,Free,,,0,FLGALWHALSKLL
FLGALWKALSHLL,13,Synthetic,Synthetic peptide,Human erythrocytes: 15% Hemolysis=30 µM,MCF-10A: IC50=49 μM,,,,Anticancer; Antibacterial,Tumor active peptide##Membrane lysis,,Linear,,Free,Free,,,0,FLGALWKALSHLL
FLGALWHALSHLL,13,Synthetic,Synthetic peptide,Human erythrocytes: 0% Hemolysis=30 µM,MCF-10A: IC50>120 μM,,,,Anticancer; Antibacterial,Tumor active peptide##Membrane lysis,,Linear,,Free,Free,,,0,FLGALWHALSHLL
PAWHHAFHWAWRMLKKAA,18,Synthetic,Synthetic peptide,,CHO: IC50=13 ± 2 μM(pH=7.4); IC50=8 ± 1 μM(pH=5.5),,,,Anticancer,Tumor active peptide##Membrane lysis,,Linear,,Free,Free,,,0,PAWHHAFHWAWRMLKKAA
PAWRKAFRWAWHMLHHAA,18,Synthetic,Synthetic peptide,,CHO: IC50=12 ± 1 μM(pH=7.4); IC50=6 ± 2 μM(pH=5.5),,,,Anticancer,Tumor active peptide##Membrane lysis,,Linear,,Free,Free,,,0,PAWRKAFRWAWHMLHHAA
PAWRHAFHWAWHMLHKAA,18,Synthetic,Synthetic peptide,,CHO: IC50=67 ± 3 μM(pH=7.4); IC50=7 ± 2 μM(pH=5.5),,,,Anticancer,Tumor active peptide##Membrane lysis,,Linear,,Free,Free,,,0,PAWRHAFHWAWHMLHKAA
GLFAVIHKVASVIGGL,16,Synthetic,Synthetic peptide,,CHO: IC50=78 ± 2 μM(pH=7.4); IC50=47 ± 3 μM(pH=5.5),,,,Anticancer,Tumor active peptide##Membrane lysis,,Linear,,Free,Free,,,0,GLFAVIHKVASVIGGL
GLFAVIKHVASVIGGL,16,Synthetic,Synthetic peptide,,CHO: IC50=76 ± 4 μM(pH=7.4); IC50=41 ± 5 μM(pH=5.5),,,,Anticancer,Tumor active peptide##Membrane lysis,,Linear,,Free,Free,,,0,GLFAVIKHVASVIGGL
GLFAVIHHVASVIGGL,16,Synthetic,Synthetic peptide,,CHO: IC50>120 μM(pH=7.4); IC50>120 μM(pH=5.5),,,,Anticancer,Tumor active peptide##Membrane lysis,,Linear,,Free,Free,,,0,GLFAVIHHVASVIGGL
FVDLKKIANIINSIFGK,17,Rana chensinensis,Native peptide,Human erythrocytes: LC50=95.74 µM,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,,,0,FVDLKKIANIINSIFGK
KWLRRVWRWWR,11,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide##Membrane lysis,,Linear,,Free,Amidation,,,0,KWLRRVWRWWR
FLSGIVGMLGKLE,13,Pelophylax saharicus (Sahara frog) (Rana saharica),Native peptide,Rat erythrocytes: LC50=25 µM,Human fibroblasts: LC50>100 µM,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,"Patent Application; Family: 11s / 11ex; Family Jurisdictions: CA, EP, JP, BR, US, WO, ES; Legal Status:  Discontinued; Application No: 13306344; Filed: Sep 27, 2013; Published: Apr 1, 2015; Earliest Priority: Sep 27, 2013",0,FLSGIVGMLGKLE
FLKGIVGMLGKLE,13,Synthetic (Derived from Temporin-1Sa),Synthetic peptide,Rat erythrocytes: LC50=26 µM,Human fibroblasts: LC50>100 µM,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,"Patent Application; Family: 11s / 11ex; Family Jurisdictions: CA, EP, JP, BR, US, WO, ES; Legal Status:  Discontinued; Application No: 13306344; Filed: Sep 27, 2013; Published: Apr 1, 2015; Earliest Priority: Sep 27, 2013",0,FLKGIVGMLGKLE
KGIVGMLGKLE,11,Synthetic (Derived from Temporin-1Sa),Synthetic peptide,Rat erythrocytes: LC50=618 µM,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,"Patent Application; Family: 11s / 11ex; Family Jurisdictions: CA, EP, JP, BR, US, WO, ES; Legal Status:  Discontinued; Application No: 13306344; Filed: Sep 27, 2013; Published: Apr 1, 2015; Earliest Priority: Sep 27, 2013",0,KGIVGMLGKLE
FLKGIKGMLGKLF,13,Synthetic (Derived from Temporin-1Sa),Synthetic peptide,Rat erythrocytes: LC50=590 µM,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,"Patent Application; Family: 11s / 11ex; Family Jurisdictions: CA, EP, JP, BR, US, WO, ES; Legal Status:  Discontinued; Application No: 13306344; Filed: Sep 27, 2013; Published: Apr 1, 2015; Earliest Priority: Sep 27, 2013",0,FLKGIKGMLGKLF
FLKGIVGKLGKLF,13,Synthetic (Derived from Temporin-1Sa),Synthetic peptide,Rat erythrocytes: LC50=530 µM,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,"Patent Application; Family: 11s / 11ex; Family Jurisdictions: CA, EP, JP, BR, US, WO, ES; Legal Status:  Discontinued; Application No: 13306344; Filed: Sep 27, 2013; Published: Apr 1, 2015; Earliest Priority: Sep 27, 2013",0,FLKGIVGKLGKLF
FLKGIVGMLGKLL,13,Synthetic (Derived from Temporin-1Sa),Synthetic peptide,Rat erythrocytes: LC50=45 µM,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,"Patent Application; Family: 11s / 11ex; Family Jurisdictions: CA, EP, JP, BR, US, WO, ES; Legal Status:  Discontinued; Application No: 13306344; Filed: Sep 27, 2013; Published: Apr 1, 2015; Earliest Priority: Sep 27, 2013",0,FLKGIVGMLGKLL
FLKGIKGMLGKLL,13,Synthetic (Derived from Temporin-1Sa),Synthetic peptide,Rat erythrocytes: LC50>800 µM,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,"Patent Application; Family: 11s / 11ex; Family Jurisdictions: CA, EP, JP, BR, US, WO, ES; Legal Status:  Discontinued; Application No: 13306344; Filed: Sep 27, 2013; Published: Apr 1, 2015; Earliest Priority: Sep 27, 2013",0,FLKGIKGMLGKLL
FLKGIVGMLGKLW,13,Synthetic (Derived from Temporin-1Sa),Synthetic peptide,Rat erythrocytes: LC50=32 µM,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,"Patent Application; Family: 11s / 11ex; Family Jurisdictions: CA, EP, JP, BR, US, WO, ES; Legal Status:  Discontinued; Application No: 13306344; Filed: Sep 27, 2013; Published: Apr 1, 2015; Earliest Priority: Sep 27, 2013",0,FLKGIVGMLGKLW
KRKILILIKRK,11,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,KRKILILIKRK
KRKILILILIL,11,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,KRKILILILIL
ILILILILKRK,11,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,ILILILILKRK
KRKILILIGSG,11,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,KRKILILIGSG
GSGILILIKRK,11,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,GSGILILIKRK
KRKSGSGSKRK,11,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,KRKSGSGSKRK
KRKRKILILIKRK,13,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,KRKRKILILIKRK
RKRKILILIKRK,12,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,RKRKILILIKRK
RKILILIKRK,10,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,RKILILIKRK
KILILIKRK,9,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,KILILIKRK
ILILIKRK,8,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,ILILIKRK
LILIKRK,7,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,LILIKRK
ILIKRK,6,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,ILIKRK
LIKRK,5,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,LIKRK
KRKILILIKRKRK,13,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,KRKILILIKRKRK
KRKILILIKRKR,12,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,KRKILILIKRKR
KRKILILIKR,10,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,KRKILILIKR
KRKILILIK,9,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,KRKILILIK
KRKILILI,8,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,KRKILILI
KRKILIL,7,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,KRKILIL
KRKILI,6,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,KRKILI
KRKIL,5,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,KRKIL
KRKILILILIKRK,13,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,KRKILILILIKRK
KRKLILIKRK,10,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,KRKLILIKRK
KRKILIKRK,9,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,KRKILIKRK
KRKLIKRK,8,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,KRKLIKRK
KRKIKRK,7,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,KRKIKRK
KRKKRK,6,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,KRKKRK
KRKGKRK,7,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,KRKGKRK
KRKGSGKRK,9,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,KRKGSGKRK
RKRKLILILIKRKR,14,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,RKRKLILILIKRKR
KRKLILKRILIKRK,14,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,KRKLILKRILIKRK
RKLILKRKRILIKR,14,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,RKLILKRKRILIKR
KLILKRKRKRILIK,14,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,KLILKRKRKRILIK
LILKRKRKRKRILI,14,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,LILKRKRKRKRILI
RRRIIIIIRRR,11,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,RRRIIIIIRRR
KKKIIIIIKKK,11,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,KKKIIIIIKKK
RRRLLLLLRRR,11,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,RRRLLLLLRRR
KKKLLLLLKKK,11,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,KKKLLLLLKKK
RRRVVVVVRRR,11,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,RRRVVVVVRRR
KKKVVVVVKKK,11,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,KKKVVVVVKKK
RRRFFFFFRRR,11,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,RRRFFFFFRRR
KKKFFFFFKKK,11,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,KKKFFFFFKKK
KKKIIIIIIKKK,12,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,KKKIIIIIIKKK
XGLXGGLXGIX,11,Trichoderma longibrachiatum,Native peptide,,Human dermal fibroblasts: EC50=4 μM ,,,,Anticancer,Tumor active peptide##Membrane lysis,,Linear,,Oct (Fatty acid 1-Octanoyl),Free,X(1/4/8)=Aib; X(11)=Lol (Amino alcohol leucinol),,0,XGLXGGLXGIX
XGLXGKLXGIX,11,Synthetic (Derived from TG),Synthetic peptide,,Human dermal fibroblasts: EC50=2 μM ,,,,Anticancer,Tumor active peptide##Membrane lysis,,Linear,,Oct (Fatty acid 1-Octanoyl),Free,X(1/4/8)=Aib; X(11)=Lol (Amino alcohol leucinol),,0,XGLXGKLXGIX
XRLXGGLXGIX,11,Synthetic (Derived from TG),Synthetic peptide,,Human dermal fibroblasts: EC50=8 μM,,,,Anticancer,Tumor active peptide##Membrane lysis,,Linear,,Oct (Fatty acid 1-Octanoyl),Free,X(1/4/8)=Aib; X(11)=Lol (Amino alcohol leucinol),,0,XRLXGGLXGIX
XGLXGGLXRIX,11,Synthetic (Derived from TG),Synthetic peptide,,Human dermal fibroblasts: EC50=8 μM,,,,Anticancer,Tumor active peptide##Membrane lysis,,Linear,,Oct (Fatty acid 1-Octanoyl),Free,X(1)=TOAC; X(4/8)=Aib; X(11)=Lol (Amino alcohol leucinol),,0,XGLXGGLXRIX
XGLXKKLXGIX,11,Synthetic (Derived from TG),Synthetic peptide,,Human dermal fibroblasts: EC50=15 μM,,,,Anticancer,Tumor active peptide##Membrane lysis,,Linear,,Oct (Fatty acid 1-Octanoyl),Free,X(1/4/8)=Aib; X(11)=Lol (Amino alcohol leucinol),,0,XGLXKKLXGIX
XGLLGGLXGIX,11,Synthetic (Derived from TG),Synthetic peptide,,Human dermal fibroblasts: Not active up to 20 μM,,,,Anticancer,Tumor active peptide##Membrane lysis,,Linear,,Oct (Fatty acid 1-Octanoyl),Free,X(1/4/8)=Aib; X(11)=Lol (Amino alcohol leucinol),,0,XGLLGGLXGIX
XGLXGGLLGIX,11,Synthetic (Derived from TG),Synthetic peptide,,Human dermal fibroblasts: Not active up to 20 μM,,,,Anticancer,Tumor active peptide##Membrane lysis,,Linear,,Oct (Fatty acid 1-Octanoyl),Free,X(1)=TOAC; X(4)=Aib; X(11)=Lol (Amino alcohol leucinol),,0,XGLXGGLLGIX
GFKDLLKGAAKALVKTVLF,19,Ascaphus truei,Native peptide,Human erythrocytes: LC50=55 µM ,L929 fibroblast-derived cells: LC50=7 µM ,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide##Membrane lysis,,Linear,,Free,Amidation,,,0,GFKDLLKGAAKALVKTVLF
GFKKLLKGAAKALVKTVLF,19,Synthetic (Derived from Ascaphin-8),Synthetic peptide,Human erythrocytes: LC50=24 µM ,L929 fibroblast-derived cells: LC50=5 µM ,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide##Membrane lysis,,Linear,,Free,Amidation,,,0,GFKKLLKGAAKALVKTVLF
GFKDLLKKAAKALVKTVLF,19,Synthetic (Derived from Ascaphin-8),Synthetic peptide,Human erythrocytes: LC50=11 µM,L929 fibroblast-derived cells: LC50=5 µM,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide##Membrane lysis,,Linear,,Free,Amidation,,,0,GFKDLLKKAAKALVKTVLF
GFKDLLKGAKKALVKTVLF,19,Synthetic (Derived from Ascaphin-8),Synthetic peptide,Human erythrocytes: LC50>500 µM,L929 fibroblast-derived cells: LC50>200 µM,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide##Membrane lysis,,Linear,,Free,Amidation,,,0,GFKDLLKGAKKALVKTVLF
GFKDLLKGAAKALKKTVLF,19,Synthetic (Derived from Ascaphin-8),Synthetic peptide,Human erythrocytes: LC50>500 µM,L929 fibroblast-derived cells: LC50=110 µM,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide##Membrane lysis,,Linear,,Free,Amidation,,,0,GFKDLLKGAAKALKKTVLF
GFKDLLKGAAKALVKTVKF,19,Synthetic (Derived from Ascaphin-8),Synthetic peptide,Human erythrocytes: LC50>500 µM,L929 fibroblast-derived cells: LC50=55 µM,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide##Membrane lysis,,Linear,,Free,Amidation,,,0,GFKDLLKGAAKALVKTVKF
GFKDLLKkAAKALVKTVLF,19,Synthetic (Derived from Ascaphin-8),Synthetic peptide,Human erythrocytes: LC50=150 µM,L929 fibroblast-derived cells: LC50=9 µM,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide##Membrane lysis,,Linear,,Free,Amidation,,,0,GFKDLLKKAAKALVKTVLF
GFKDLLKGAkKALVKTVLF,19,Synthetic (Derived from Ascaphin-8),Synthetic peptide,Human erythrocytes: LC50>500 µm,L929 fibroblast-derived cells: LC50>200 µM,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide##Membrane lysis,,Linear,,Free,Amidation,,,0,GFKDLLKGAKKALVKTVLF
GFKDLLKGAAKALkKTVLF,19,Synthetic (Derived from Ascaphin-8),Synthetic peptide,Human erythrocytes: LC50>500 µM,L929 fibroblast-derived cells: LC50=140 µM,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide##Membrane lysis,,Linear,,Free,Amidation,,,0,GFKDLLKGAAKALKKTVLF
GFKDLLKGAAKALVKTVkF,19,Synthetic (Derived from Ascaphin-8),Synthetic peptide,Human erythrocytes: LC50>500 µM,L929 fibroblast-derived cells: LC50=65 µM,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide##Membrane lysis,,Linear,,Free,Amidation,,,0,GFKDLLKGAAKALVKTVKF
GFKDLLKGAAKALVKAVLF,19,Synthetic (Derived from Ascaphin-8),Synthetic peptide,Human erythrocytes: LC50=22 µM,L929 fibroblast-derived cells: LC50=5 µM,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide##Membrane lysis,,Linear,,Free,Amidation,,,0,GFKDLLKGAAKALVKAVLF
KLLGPLLKIAAKVGSNLL,18,Synthetic (Derived from XT-7),Synthetic peptide,Human erythrocytes: LC50=400 µM,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide##Membrane lysis,,Linear,,Free,Amidation,,,0,KLLGPLLKIAAKVGSNLL
GLLGKLLKIAAKVGSNLL,18,Synthetic (Derived from XT-7),Synthetic peptide,Human erythrocytes: LC50=15 µM,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide##Membrane lysis,,Linear,,Free,Amidation,,,0,GLLGKLLKIAAKVGSNLL
GLLGPLLKIAKKVGSNLL,18,Synthetic (Derived from XT-7),Synthetic peptide,Human erythrocytes: LC50=350 µM,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide##Membrane lysis,,Linear,,Free,Amidation,,,0,GLLGPLLKIAKKVGSNLL
GLLGPLLKIAAKVGKNLL,18,Synthetic (Derived from XT-7),Synthetic peptide,Human erythrocytes: LC50=110 µM,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide##Membrane lysis,,Linear,,Free,Amidation,,,0,GLLGPLLKIAAKVGKNLL
GLLGPLLKIAAKVGSKLL,18,Synthetic (Derived from XT-7),Synthetic peptide,Human erythrocytes: LC50=80 µM,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide##Membrane lysis,,Linear,,Free,Amidation,,,0,GLLGPLLKIAAKVGSKLL
GLLGPLLKIAAKVGKKLL,18,Synthetic (Derived from XT-7),Synthetic peptide,Human erythrocytes: LC50=60 µM,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide##Membrane lysis,,Linear,,Free,Amidation,,,0,GLLGPLLKIAAKVGKKLL
GLLGKLLKIAAKVGKKLL,18,Synthetic (Derived from XT-7),Synthetic peptide,Human erythrocytes: LC50=25 µM,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide##Membrane lysis,,Linear,,Free,Amidation,,,0,GLLGKLLKIAAKVGKKLL
GLLKKLLKIAAKVGKKLL,18,Synthetic (Derived from XT-7),Synthetic peptide,Human erythrocytes: LC50=25 µM,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide##Membrane lysis,,Linear,,Free,Amidation,,,0,GLLKKLLKIAAKVGKKLL
RRPKGRGKRRREKQRP,16,Synthetic,Synthetic peptide,,,VEGF165,,"Its mechanism that involves competition for VEGF165 binding at either the VEGFR-2/NP-1 complex or NP-1, without affecting VEGF signaling through other pathways.",Anticancer,Tumor active peptide##Cancer targeted peptides##Antiangiogenic##Antagonists of VEGF165 signaling through,,Linear,,Free,Free,,"Patent Application; Family: 5s / 5ex; Family Jurisdictions: AU, US, WO; Legal Status:  Expired; Application No: 26316202; Filed: Oct 2, 2002; Published: Oct 2, 2003; Earliest Priority: Oct 3, 2001; Granted: May 30, 2006",1,RRPKGRGKRRREKQRP
RRPKGRGKRRREKQRPCDKPRR,22,Synthetic,Synthetic peptide,,,VEGF165,,"Its mechanism that involves competition for VEGF165 binding at either the VEGFR-2/NP-1 complex or NP-2, without affecting VEGF signaling through other pathways.",Anticancer,Tumor active peptide##Cancer targeted peptides##Antiangiogenic##Antagonists of VEGF165 signaling through,,Linear,,Free,Free,,"Patent Application; Family: 5s / 5ex; Family Jurisdictions: AU, US, WO; Legal Status:  Expired; Application No: 26316202; Filed: Oct 2, 2002; Published: Oct 2, 2003; Earliest Priority: Oct 3, 2001; Granted: May 30, 2006",1,RRPKGRGKRRREKQRPCDKPRR
RRPKGRGKRRREKQRPSDKPRR,22,Synthetic,Synthetic peptide,,,VEGF165,,"Its mechanism that involves competition for VEGF165 binding at either the VEGFR-2/NP-1 complex or NP-3, without affecting VEGF signaling through other pathways.",Anticancer,Tumor active peptide##Cancer targeted peptides##Antiangiogenic##Antagonists of VEGF165 signaling through,,Linear,,Free,Free,,"Patent Application; Family: 5s / 5ex; Family Jurisdictions: AU, US, WO; Legal Status:  Expired; Application No: 26316202; Filed: Oct 2, 2002; Published: Oct 2, 2003; Earliest Priority: Oct 3, 2001; Granted: May 30, 2006",1,RRPKGRGKRRREKQRPSDKPRR
RRPKGRGKRRREKQRPDAVPRR,22,Synthetic,Synthetic peptide,,,VEGF165,,"Its mechanism that involves competition for VEGF165 binding at either the VEGFR-2/NP-1 complex or NP-4, without affecting VEGF signaling through other pathways.",Anticancer,Tumor active peptide##Cancer targeted peptides##Antiangiogenic##Antagonists of VEGF165 signaling through,,Linear,,Free,Free,,"Patent Application; Family: 5s / 5ex; Family Jurisdictions: AU, US, WO; Legal Status:  Expired; Application No: 26316202; Filed: Oct 2, 2002; Published: Oct 2, 2003; Earliest Priority: Oct 3, 2001; Granted: May 30, 2006",1,RRPKGRGKRRREKQRPDAVPRR
CKGRGKRCREKQRPSDKPRR,20,Synthetic,Synthetic peptide,,,VEGF165,,"Its mechanism that involves competition for VEGF165 binding at either the VEGFR-2/NP-1 complex or NP-5, without affecting VEGF signaling through other pathways.",Anticancer,Tumor active peptide##Cancer targeted peptides##Antiangiogenic##Antagonists of VEGF165 signaling through,,Cyclic,Cys1<--->Cys8,Free,Free,,"Patent Application; Family: 5s / 5ex; Family Jurisdictions: AU, US, WO; Legal Status:  Expired; Application No: 26316202; Filed: Oct 2, 2002; Published: Oct 2, 2003; Earliest Priority: Oct 3, 2001; Granted: May 30, 2006",1,CKGRGKRCREKQRPSDKPRR
KGRGKRRREKQRPCDKPRR,19,Synthetic,Synthetic peptide,,,VEGF165,,"Its mechanism that involves competition for VEGF165 binding at either the VEGFR-2/NP-1 complex or NP-6, without affecting VEGF signaling through other pathways.",Anticancer,Tumor active peptide##Cancer targeted peptides##Antiangiogenic##Antagonists of VEGF165 signaling through,,Linear,,Free,Free,,"Patent Application; Family: 5s / 5ex; Family Jurisdictions: AU, US, WO; Legal Status:  Expired; Application No: 26316202; Filed: Oct 2, 2002; Published: Oct 2, 2003; Earliest Priority: Oct 3, 2001; Granted: May 30, 2006",1,KGRGKRRREKQRPCDKPRR
RRREKQRPCDKPRR,14,Synthetic,Synthetic peptide,,,VEGF165,,"Its mechanism that involves competition for VEGF165 binding at either the VEGFR-2/NP-1 complex or NP-7, without affecting VEGF signaling through other pathways.",Anticancer,Tumor active peptide##Cancer targeted peptides##Antiangiogenic##Antagonists of VEGF165 signaling through,,Linear,,Free,Free,,"Patent Application; Family: 5s / 5ex; Family Jurisdictions: AU, US, WO; Legal Status:  Expired; Application No: 26316202; Filed: Oct 2, 2002; Published: Oct 2, 2003; Earliest Priority: Oct 3, 2001; Granted: May 30, 2006",1,RRREKQRPCDKPRR
KGRGKRRREKQRPSDKPR,18,Synthetic,Synthetic peptide,,,VEGF165,,"Its mechanism that involves competition for VEGF165 binding at either the VEGFR-2/NP-1 complex or NP-8, without affecting VEGF signaling through other pathways.",Anticancer,Tumor active peptide##Cancer targeted peptides##Antiangiogenic##Antagonists of VEGF165 signaling through,,Linear,,Free,Free,,"Patent Application; Family: 5s / 5ex; Family Jurisdictions: AU, US, WO; Legal Status:  Expired; Application No: 26316202; Filed: Oct 2, 2002; Published: Oct 2, 2003; Earliest Priority: Oct 3, 2001; Granted: May 30, 2006",1,KGRGKRRREKQRPSDKPR
KGRGKRRREKQRPSDKP,17,Synthetic,Synthetic peptide,,,VEGF165,,"Its mechanism that involves competition for VEGF165 binding at either the VEGFR-2/NP-1 complex or NP-9, without affecting VEGF signaling through other pathways.",Anticancer,Tumor active peptide##Cancer targeted peptides##Antiangiogenic##Antagonists of VEGF165 signaling through,,Linear,,Free,Free,,"Patent Application; Family: 5s / 5ex; Family Jurisdictions: AU, US, WO; Legal Status:  Expired; Application No: 26316202; Filed: Oct 2, 2002; Published: Oct 2, 2003; Earliest Priority: Oct 3, 2001; Granted: May 30, 2006",1,KGRGKRRREKQRPSDKP
KGRGKRRREKQRPSDKPRR,19,Synthetic,Synthetic peptide,,,VEGF165,,"Its mechanism that involves competition for VEGF165 binding at either the VEGFR-2/NP-1 complex or NP-10, without affecting VEGF signaling through other pathways.",Anticancer,Tumor active peptide##Cancer targeted peptides##Antiangiogenic##Antagonists of VEGF165 signaling through,,Linear,,Free,Free,,"Patent Application; Family: 5s / 5ex; Family Jurisdictions: AU, US, WO; Legal Status:  Expired; Application No: 26316202; Filed: Oct 2, 2002; Published: Oct 2, 2003; Earliest Priority: Oct 3, 2001; Granted: May 30, 2006",1,KGRGKRRREKQRPSDKPRR
RRPKGRAAARREKQRPSDKPRR,22,Synthetic,Synthetic peptide,,,VEGF165,,"Its mechanism that involves competition for VEGF165 binding at either the VEGFR-2/NP-1 complex or NP-11, without affecting VEGF signaling through other pathways.",Anticancer,Tumor active peptide##Cancer targeted peptides##Antiangiogenic##Antagonists of VEGF165 signaling through,,Linear,,Free,Free,,"Patent Application; Family: 5s / 5ex; Family Jurisdictions: AU, US, WO; Legal Status:  Expired; Application No: 26316202; Filed: Oct 2, 2002; Published: Oct 2, 2003; Earliest Priority: Oct 3, 2001; Granted: May 30, 2006",1,RRPKGRAAARREKQRPSDKPRR
RRPKGRGKRAAAKQRPSDKPRR,22,Synthetic,Synthetic peptide,,,VEGF165,,"Its mechanism that involves competition for VEGF165 binding at either the VEGFR-2/NP-1 complex or NP-12, without affecting VEGF signaling through other pathways.",Anticancer,Tumor active peptide##Cancer targeted peptides##Antiangiogenic##Antagonists of VEGF165 signaling through,,Linear,,Free,Free,,"Patent Application; Family: 5s / 5ex; Family Jurisdictions: AU, US, WO; Legal Status:  Expired; Application No: 26316202; Filed: Oct 2, 2002; Published: Oct 2, 2003; Earliest Priority: Oct 3, 2001; Granted: May 30, 2006",1,RRPKGRGKRAAAKQRPSDKPRR
AGRGKRRREKQRPSDKPRR,19,Synthetic,Synthetic peptide,,,VEGF165,,"Its mechanism that involves competition for VEGF165 binding at either the VEGFR-2/NP-1 complex or NP-13, without affecting VEGF signaling through other pathways.",Anticancer,Tumor active peptide##Cancer targeted peptides##Antiangiogenic##Antagonists of VEGF165 signaling through,,Linear,,Free,Free,,"Patent Application; Family: 5s / 5ex; Family Jurisdictions: AU, US, WO; Legal Status:  Expired; Application No: 26316202; Filed: Oct 2, 2002; Published: Oct 2, 2003; Earliest Priority: Oct 3, 2001; Granted: May 30, 2006",1,AGRGKRRREKQRPSDKPRR
KGRGARRREKQRPSDKPRR,19,Synthetic,Synthetic peptide,,,VEGF165,,"Its mechanism that involves competition for VEGF165 binding at either the VEGFR-2/NP-1 complex or NP-14, without affecting VEGF signaling through other pathways.",Anticancer,Tumor active peptide##Cancer targeted peptides##Antiangiogenic##Antagonists of VEGF165 signaling through,,Linear,,Free,Free,,"Patent Application; Family: 5s / 5ex; Family Jurisdictions: AU, US, WO; Legal Status:  Expired; Application No: 26316202; Filed: Oct 2, 2002; Published: Oct 2, 2003; Earliest Priority: Oct 3, 2001; Granted: May 30, 2006",1,KGRGARRREKQRPSDKPRR
KGAGKRRREKQRPSDKPRR,19,Synthetic,Synthetic peptide,,,VEGF165,,"Its mechanism that involves competition for VEGF165 binding at either the VEGFR-2/NP-1 complex or NP-15, without affecting VEGF signaling through other pathways.",Anticancer,Tumor active peptide##Cancer targeted peptides##Antiangiogenic##Antagonists of VEGF165 signaling through,,Linear,,Free,Free,,"Patent Application; Family: 5s / 5ex; Family Jurisdictions: AU, US, WO; Legal Status:  Expired; Application No: 26316202; Filed: Oct 2, 2002; Published: Oct 2, 2003; Earliest Priority: Oct 3, 2001; Granted: May 30, 2006",1,KGAGKRRREKQRPSDKPRR
KGRGKARREKQRPSDKPRR,19,Synthetic,Synthetic peptide,,,VEGF165,,"Its mechanism that involves competition for VEGF165 binding at either the VEGFR-2/NP-1 complex or NP-16, without affecting VEGF signaling through other pathways.",Anticancer,Tumor active peptide##Cancer targeted peptides##Antiangiogenic##Antagonists of VEGF165 signaling through,,Linear,,Free,Free,,"Patent Application; Family: 5s / 5ex; Family Jurisdictions: AU, US, WO; Legal Status:  Expired; Application No: 26316202; Filed: Oct 2, 2002; Published: Oct 2, 2003; Earliest Priority: Oct 3, 2001; Granted: May 30, 2006",1,KGRGKARREKQRPSDKPRR
KGRGKRRREKQGPSDKPRR,19,Synthetic,Synthetic peptide,,,VEGF165,,"Its mechanism that involves competition for VEGF165 binding at either the VEGFR-2/NP-1 complex or NP-17, without affecting VEGF signaling through other pathways.",Anticancer,Tumor active peptide##Cancer targeted peptides##Antiangiogenic##Antagonists of VEGF165 signaling through,,Linear,,Free,Free,,"Patent Application; Family: 5s / 5ex; Family Jurisdictions: AU, US, WO; Legal Status:  Expired; Application No: 26316202; Filed: Oct 2, 2002; Published: Oct 2, 2003; Earliest Priority: Oct 3, 2001; Granted: May 30, 2006",1,KGRGKRRREKQGPSDKPRR
KGRGKRRREKQRPSDAPAA,19,Synthetic,Synthetic peptide,,,VEGF165,,"Its mechanism that involves competition for VEGF165 binding at either the VEGFR-2/NP-1 complex or NP-18, without affecting VEGF signaling through other pathways.",Anticancer,Tumor active peptide##Cancer targeted peptides##Antiangiogenic##Antagonists of VEGF165 signaling through,,Linear,,Free,Free,,"Patent Application; Family: 5s / 5ex; Family Jurisdictions: AU, US, WO; Legal Status:  Expired; Application No: 26316202; Filed: Oct 2, 2002; Published: Oct 2, 2003; Earliest Priority: Oct 3, 2001; Granted: May 30, 2006",1,KGRGKRRREKQRPSDAPAA
KGRGKRAAEAQRPSDKPRR,19,Synthetic,Synthetic peptide,,,VEGF165,,"Its mechanism that involves competition for VEGF165 binding at either the VEGFR-2/NP-1 complex or NP-19, without affecting VEGF signaling through other pathways.",Anticancer,Tumor active peptide##Cancer targeted peptides##Antiangiogenic##Antagonists of VEGF165 signaling through,,Linear,,Free,Free,,"Patent Application; Family: 5s / 5ex; Family Jurisdictions: AU, US, WO; Legal Status:  Expired; Application No: 26316202; Filed: Oct 2, 2002; Published: Oct 2, 2003; Earliest Priority: Oct 3, 2001; Granted: May 30, 2006",1,KGRGKRAAEAQRPSDKPRR
KGRGKRAAEKQAPSDKPRR,19,Synthetic,Synthetic peptide,,,VEGF165,,"Its mechanism that involves competition for VEGF165 binding at either the VEGFR-2/NP-1 complex or NP-20, without affecting VEGF signaling through other pathways.",Anticancer,Tumor active peptide##Cancer targeted peptides##Antiangiogenic##Antagonists of VEGF165 signaling through,,Linear,,Free,Free,,"Patent Application; Family: 5s / 5ex; Family Jurisdictions: AU, US, WO; Legal Status:  Expired; Application No: 26316202; Filed: Oct 2, 2002; Published: Oct 2, 2003; Earliest Priority: Oct 3, 2001; Granted: May 30, 2006",1,KGRGKRAAEKQAPSDKPRR
AGRGARAAEAQRPSDKPRR,19,Synthetic,Synthetic peptide,,,VEGF165,,"Its mechanism that involves competition for VEGF165 binding at either the VEGFR-2/NP-1 complex or NP-21, without affecting VEGF signaling through other pathways.",Anticancer,Tumor active peptide##Cancer targeted peptides##Antiangiogenic##Antagonists of VEGF165 signaling through,,Linear,,Free,Free,,"Patent Application; Family: 5s / 5ex; Family Jurisdictions: AU, US, WO; Legal Status:  Expired; Application No: 26316202; Filed: Oct 2, 2002; Published: Oct 2, 2003; Earliest Priority: Oct 3, 2001; Granted: May 30, 2006",1,AGRGARAAEAQRPSDKPRR
RRPKGRGKRRREKQRPSDAAAR,22,Synthetic,Synthetic peptide,,,VEGF165,,"Its mechanism that involves competition for VEGF165 binding at either the VEGFR-2/NP-1 complex or NP-22, without affecting VEGF signaling through other pathways.",Anticancer,Tumor active peptide##Cancer targeted peptides##Antiangiogenic##Antagonists of VEGF165 signaling through,,Linear,,Free,Free,,"Patent Application; Family: 5s / 5ex; Family Jurisdictions: AU, US, WO; Legal Status:  Expired; Application No: 26316202; Filed: Oct 2, 2002; Published: Oct 2, 2003; Earliest Priority: Oct 3, 2001; Granted: May 30, 2006",1,RRPKGRGKRRREKQRPSDAAAR
NGRKACLNPASPIVKKIIEKMLNS,24,Homo sapiens (CXCL1/Gro-α),Native peptide,,,CXCR,,,Anticancer,Tumor active peptide##Cancer targeted peptides##Antiangiogenic,,Linear,,Free,Free,,,0,NGRKACLNPASPIVKKIIEKMLNS
NGKKACLNPASPMVQKIIEKIL,22,Homo sapiens (CXCL3/Gro-γ),Native peptide,,,CXCR,,,Anticancer,Tumor active peptide##Cancer targeted peptides##Antiangiogenic,,Linear,,Free,Free,,,0,NGKKACLNPASPMVQKIIEKIL
NGKEICLDPEAPFLKKVIQKILD,23,Homo sapiens (CXCL5/ENA-78),Native peptide,,,CXCR,,,Anticancer,Tumor active peptide##Cancer targeted peptides##Antiangiogenic,,Linear,,Free,Free,,,0,NGKEICLDPEAPFLKKVIQKILD
NGKQVCLDPEAPFLKKVIQKILDS,24,Homo sapiens (CXCL6/GCP-2),Native peptide,,,CXCR,,,Anticancer,Tumor active peptide##Cancer targeted peptides##Antiangiogenic,,Linear,,Free,Free,,,0,NGKQVCLDPEAPFLKKVIQKILDS
DGRKICLDPDAPRIKKIVQKKL,22,Homo sapiens (CXCL7/PBP),Native peptide,,,CXCR,,,Anticancer,Tumor active peptide##Cancer targeted peptides##Antiangiogenic,,Linear,,Free,Free,,,0,DGRKICLDPDAPRIKKIVQKKL
DGRELCLDPKENWVQRVVEKFLK,23,Homo sapiens (CXCL8/IL-8),Native peptide,,,CXCR,,,Anticancer,Tumor active peptide##Cancer targeted peptides##Antiangiogenic,,Linear,,Free,Free,,,0,DGRELCLDPKENWVQRVVEKFLK
KILRGVSKKIMRTFLRR,17,Synthetic,Synthetic peptide,Human erythrocytes: <5% Hemolysis=100 µg/ml,,,,,Anticancer; Antibacterial,Tumor active peptide##Membrane lysis,,Linear,,Free,Amidation,,,0,KILRGVSKKIMRTFLRR
KKIMRTFLRR,10,Synthetic,Synthetic peptide,Human erythrocytes: <5% Hemolysis=100 µg/ml,,,,,Anticancer; Antibacterial,Tumor active peptide##Membrane lysis,,Linear,,Free,Amidation,,,0,KKIMRTFLRR
KKIMRTFLRRISKDILTGKK,20,Synthetic,Synthetic peptide,Human erythrocytes: <5% Hemolysis=100 µg/ml,,,,,Anticancer; Antibacterial,Tumor active peptide##Membrane lysis,,Linear,,Free,Amidation,,,0,KKIMRTFLRRISKDILTGKK
KKIMRTFLRRISKKILTGKK,20,Synthetic,Synthetic peptide,Human erythrocytes: <5% Hemolysis=100 µg/ml,,,,,Anticancer; Antibacterial,Tumor active peptide##Membrane lysis,,Linear,,Free,Amidation,,,0,KKIMRTFLRRISKKILTGKK
KILRGVSKKIMRRISKDILTGKK,23,Synthetic,Synthetic peptide,Human erythrocytes: <5% Hemolysis=100 µg/ml,,,,,Anticancer; Antibacterial,Tumor active peptide##Membrane lysis,,Linear,,Free,Amidation,,,0,KILRGVSKKIMRRISKDILTGKK
KILGVSKKIMRRISKDILTGKK,22,Synthetic,Synthetic peptide,Human erythrocytes: <5% Hemolysis=100 µg/ml,,,,,Anticancer; Antibacterial,Tumor active peptide##Membrane lysis,,Linear,,Free,Amidation,,,0,KILGVSKKIMRRISKDILTGKK
KISKKIMRTFLRRILTGKK,19,Synthetic,Synthetic peptide,Human erythrocytes: 100% Hemolysis=100 µg/ml,,,,,Anticancer; Antibacterial,Tumor active peptide##Membrane lysis,,Linear,,Free,Amidation,,,0,KISKKIMRTFLRRILTGKK
KILRGVSKKIMRRILTGKK,19,Synthetic,Synthetic peptide,Human erythrocytes: <5% Hemolysis=100 µg/ml,,,,,Anticancer; Antibacterial,Tumor active peptide##Membrane lysis,,Linear,,Free,Amidation,,,0,KILRGVSKKIMRRILTGKK
RILRGVSRRIMRRILTGRR,19,Synthetic,Synthetic peptide,Human erythrocytes: <10% Hemolysis=100 µg/ml,,,,,Anticancer; Antibacterial,Tumor active peptide##Membrane lysis,,Linear,,Free,Amidation,,,0,RILRGVSRRIMRRILTGRR
KILRGVSKRILTGKK,15,Synthetic,Synthetic peptide,Human erythrocytes: <5% Hemolysis=100 µg/ml,,,,,Anticancer; Antibacterial,Tumor active peptide##Membrane lysis,,Linear,,Free,Amidation,,,0,KILRGVSKRILTGKK
KILGVSKRILTGKK,14,Synthetic,Synthetic peptide,Human erythrocytes: <5% Hemolysis=100 µg/ml,,,,,Anticancer; Antibacterial,Tumor active peptide##Membrane lysis,,Linear,,Free,Amidation,,,0,KILGVSKRILTGKK
KISKKIMRTFLRR,13,Synthetic,Synthetic peptide,Human erythrocytes: <5% Hemolysis=100 µg/ml,,,,,Anticancer; Antibacterial,Tumor active peptide##Membrane lysis,,Linear,,Free,Amidation,,,0,KISKKIMRTFLRR
ISKRILTGKK,10,Synthetic,Synthetic peptide,Human erythrocytes: <5% Hemolysis=100 µg/ml,,,,,Anticancer; Antibacterial,Tumor active peptide##Membrane lysis,,Linear,,Free,Amidation,,,0,ISKRILTGKK
KISKRILTGKK,11,Synthetic,Synthetic peptide,Human erythrocytes: <5% Hemolysis=100 µg/ml,,,,,Anticancer; Antibacterial,Tumor active peptide##Membrane lysis,,Linear,,Free,Amidation,,,0,KISKRILTGKK
CLB,3,Synthetic,Synthetic peptide,,NIH 3T3: IC50=152.5 ± 5.6 µM,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,,,0,CLB
CLBCREKA,8,Synthetic,Synthetic peptide,,NIH 3T3: IC50>200 µM,,,,Anticancer; Antibacterial,Coupling peptide,,Linear,,Free,Amidation,,,0,CLBCREKA
KWKKLLKKLLKLLKKLLK,18,Synthetic,Synthetic peptide,Human erythrocytes: 55% Hemolysis=100 µM,NIH 3T3: IC50=1.8 µM,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,,,0,KWKKLLKKLLKLLKKLLK
KWKKLLKKXLKLLKKLLK,18,Synthetic,Synthetic peptide,Human erythrocytes: 5% Hemolysis=100 µM,NIH 3T3: IC50=7.1 µM,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,X=NAla,,0,KWKKLLKKXLKLLKKLLK
KWKKLLKKLXKLLKKLLK,18,Synthetic,Synthetic peptide,Human erythrocytes: 23% Hemolysis=100 µM,NIH 3T3: IC50=2 µM,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,X=NAla,,0,KWKKLLKKLXKLLKKLLK
KWKKLLKKLLXLLKKLLK,18,Synthetic,Synthetic peptide,Human erythrocytes: 50% Hemolysis=100 µM,NIH 3T3: IC50=1 µM,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,X=NAla,,0,KWKKLLKKLLXLLKKLLK
KWKKLLKKXLKLXKKLLK,18,Synthetic,Synthetic peptide,Human erythrocytes: 0% Hemolysis=100 µM,NIH 3T3: IC50>100 µM,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,X=NAla,,0,KWKKLLKKXLKLXKKLLK
KWKKLLXKLLXLLKKLLK,18,Synthetic,Synthetic peptide,Human erythrocytes: 27% Hemolysis=100 µM,NIH 3T3: IC50=2 µM,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,X=NAla,,0,KWKKLLXKLLXLLKKLLK
RGDfX,5,RGD Fibronectin,Synthetic peptide,,,"Integrins αvβ3, αvβ5",,,Anticancer,Tumor active peptide##Cancer targeted peptides##Antiangiogenic##Inhibitor of the integrins ανβ3 and ανβ5,,Cyclic,NCB: Arg1<--->X5,Free,Free,f=D-Phe,,0,RGDFX
PHSCN,5,Fibronectin,Synthetic peptide,,,"Integrins α5β1, αvβ3",,,Anticancer,"Tumor active peptide##Cancer targeted peptides##Antiangiogenic##Inhibitor of the integrins α5β1, αvβ3",,Linear,,Acetylation,Amidation,,,0,PHSCN
RQIRIWFQNRRMRWRR,16,Synthetic,Synthetic peptide,Human erythrocytes: HD50>128 μM,,,,,Anticancer; Antibacterial,Cell-penetrating peptides,,Linear,,Free,Amidation,,,0,RQIRIWFQNRRMRWRR
KQIKIWFQNKKMKWKK,16,Synthetic,Synthetic peptide,Human erythrocytes: HD50>128 μM,,,,,Anticancer; Antibacterial,Cell-penetrating peptides,,Linear,,Free,Amidation,,,0,KQIKIWFQNKKMKWKK
RQIKIWFQNRRLKWKK,16,Synthetic,Synthetic peptide,Human erythrocytes: HD50>128 μM,,,,,Anticancer; Antibacterial,Cell-penetrating peptides,,Linear,,Free,Amidation,,,0,RQIKIWFQNRRLKWKK
KIWFQNRRMKWKK,13,Synthetic,Synthetic peptide,Human erythrocytes: HD50>128 μM,,,,,Anticancer; Antibacterial,Cell-penetrating peptides,,Linear,,Free,Amidation,,,0,KIWFQNRRMKWKK
RIWFQNRRMRWRR,13,Synthetic,Synthetic peptide,Human erythrocytes: HD50>128 μM,,,,,Anticancer; Antibacterial,Cell-penetrating peptides,,Linear,,Free,Amidation,,,0,RIWFQNRRMRWRR
KIWFQNKKMKWKK,13,Synthetic,Synthetic peptide,Human erythrocytes: HD50>128 μM,,,,,Anticancer; Antibacterial,Cell-penetrating peptides,,Linear,,Free,Amidation,,,0,KIWFQNKKMKWKK
FQNRRMKWKK,10,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Cell-penetrating peptides,,Linear,,Free,Amidation,,,0,FQNRRMKWKK
RWFKIQMQIRRWKNKK,16,Synthetic,Synthetic peptide,Human erythrocytes: HD50>128 μM,,,,,Anticancer; Antibacterial,Cell-penetrating peptides,,Linear,,Free,Amidation,,,0,RWFKIQMQIRRWKNKK
RWFKIQLQIRRWKNKK,16,Synthetic,Synthetic peptide,Human erythrocytes: HD50=65 ± 2.5 μM,,,,,Anticancer; Antibacterial,Cell-penetrating peptides,,Linear,,Free,Amidation,,,0,RWFKIQLQIRRWKNKK
KWFKIQLQIKKWKNKK,16,Synthetic,Synthetic peptide,Human erythrocytes: HD50=91 ± 2.3 μM,,,,,Anticancer; Antibacterial,Cell-penetrating peptides,,Linear,,Free,Amidation,,,0,KWFKIQLQIKKWKNKK
RWFRIQLQIRRWRNRR,16,Synthetic,Synthetic peptide,Human erythrocytes: HD50=39 ± 1.4 μM,,,,,Anticancer; Antibacterial,Cell-penetrating peptides,,Linear,,Free,Amidation,,,0,RWFRIQLQIRRWRNRR
WRRRRRRRR,9,Synthetic,Synthetic peptide,Human erythrocytes: HD50>128 μM,,,,,Anticancer; Antibacterial,Cell-penetrating peptides,,Linear,,Free,Amidation,,,0,WRRRRRRRR
GFXGXKKXGXFXGXGKKXKKKK,22,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Acetylation,Amidation,X=A6c (1-aminocyclohexane carboxylic acid),,0,GFXGXKKXGXFXGXGKKXKKKK
GFXGXRXGXFXGXGRXRRRR,20,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Acetylation,Amidation,X=A6c (1-aminocyclohexane carboxylic acid),,0,GFXGXRXGXFXGXGRXRRRR
GFXGXXXGXFXGXGXXXXXX,20,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Acetylation,Amidation,X(3/5/7/9/11/13/16)=A6c (1-aminocyclohexane carboxylic acid); X(6/15/17/18/19/20)=Orn (Ornithine),,0,GFXGXXXGXFXGXGXXXXXX
GFXGXKXGXFXGXGKXKKKK,20,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Acetylation,Amidation,X=A5c (1-aminocyclopentane carboxylic acid),,0,GFXGXKXGXFXGXGKXKKKK
KKKKGFXGXKXGXFXGXGKX,20,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Acetylation,Amidation,X=A6c (1-aminocyclohexane carboxylic acid),,0,KKKKGFXGXKXGXFXGXGKX
KKWWKKWWK,9,Synthetic,Synthetic peptide,,MRC-5: IC50>357 µM,,,,Anticancer,Tumor active peptide##Membrane lysis,,Linear,,Free,Amidation,,,0,KKWWKKWWK
KKXWKKWWK,9,Synthetic,Synthetic peptide,,MRC-5: IC50=488 ± 52 µM,,,,Anticancer,Tumor active peptide##Membrane lysis,,Linear,,Free,Amidation,X=Dip (Diphenylalanine),,0,KKXWKKWWK
KKWXKKWWK,9,Synthetic,Synthetic peptide,,MRC-5: IC50=287 ± 52 µM,,,,Anticancer,Tumor active peptide##Membrane lysis,,Linear,,Free,Amidation,X=Dip (Diphenylalanine),,0,KKWXKKWWK
KKWWKKXWK,9,Synthetic,Synthetic peptide,,MRC-5: IC50=102 ± 7.6 µM,,,,Anticancer,Tumor active peptide##Membrane lysis,,Linear,,Free,Amidation,X=Dip (Diphenylalanine),,0,KKWWKKXWK
KKWXKKWXK,9,Synthetic,Synthetic peptide,,MRC-5: IC50=80.0 ± 7.0 µM,,,,Anticancer,Tumor active peptide##Membrane lysis,,Linear,,Free,Amidation,X=Dip (Diphenylalanine),,0,KKWXKKWXK
kkxwkkwwk,9,Synthetic,Synthetic peptide,,MRC-5: IC50=87.0 ± 15.1 µM,,,,Anticancer,Tumor active peptide##Membrane lysis,,Linear,,Free,Amidation,X=D-Bip (D-Biphenylalanine),,0,KKXWKKWWK
RRWXRRWWR,9,Synthetic,Synthetic peptide,,MRC-5: IC50=76.0 ± 9.5 µM,,,,Anticancer,Tumor active peptide##Membrane lysis,,Linear,,Free,Amidation,X=Dip (Diphenylalanine),,0,RRWXRRWWR
kkWXkkWWk,9,Synthetic,Synthetic peptide,,MRC-5: IC50>347 µM,,,,Anticancer,Tumor active peptide##Membrane lysis,,Linear,,Free,Amidation,k=D-Lys; X=Dip (Diphenylalanine),,0,KKWXKKWWK
KWWKKWXK,8,Synthetic,Synthetic peptide,,MRC-5: IC50=43.9 ± 19.3 µM,,,,Anticancer,Tumor active peptide##Membrane lysis,,Linear,,Free,Amidation,X=Dip (Diphenylalanine),,0,KWWKKWXK
WWKKWXK,7,Synthetic,Synthetic peptide,,MRC-5: IC50=53.2 ± 21.2 µM,,,,Anticancer,Tumor active peptide##Membrane lysis,,Linear,,Free,Amidation,X=Dip (Diphenylalanine),,0,WWKKWXK
WKKWXK,6,Synthetic,Synthetic peptide,,MRC-5: IC50=460 ± 71 µM,,,,Anticancer,Tumor active peptide##Membrane lysis,,Linear,,Free,Amidation,X=Dip (Diphenylalanine),,0,WKKWXK
GLPVCGETCVGGTCYTPGCTCSWPVCTRN,29,Synthetic,Synthetic peptide,Human erythrocytes: 50% Hemolysis=6.9±0.3 µM,HFF-1: CC50=6.7±0.6 µM; PBMCs: CC50=1.0±0.1 µM,,,,Anticancer,Tumor active peptide##Membrane lysis,,Cyclic,Cys5<--->Cys19; Cys9<--->Cys21; Cys14<--->Cys26; NCB: Gly1<--->Asn29,Free,Free,,,0,GLPVCGETCVGGTCYTPGCTCSWPVCTRN
GLPVCGETCVGGTCDTPGCTCSWPVCTRN,29,Synthetic,Synthetic peptide,Human erythrocytes: Not active up to 50 µM,HFF-1: Not active up to 60 µM; PBMCs: Not active up to 60 µM,,,,Anticancer,Tumor active peptide##Membrane lysis,,Cyclic,Cys5<--->Cys19; Cys9<--->Cys21; Cys14<--->Cys26; NCB: Gly1<--->Asn29,Free,Free,,,0,GLPVCGETCVGGTCDTPGCTCSWPVCTRN
GLPVCGETCVGGTCNYPGCTCSWPVCTRN,29,Synthetic,Synthetic peptide,Human erythrocytes: Not active up to 50 µM,HFF-1: Not active up to 60 µM; PBMCs: Not active up to 60 µM,,,,Anticancer,Tumor active peptide##Membrane lysis,,Cyclic,Cys5<--->Cys19; Cys9<--->Cys21; Cys14<--->Cys26; NCB: Gly1<--->Asn29,Free,Free,,,0,GLPVCGETCVGGTCNYPGCTCSWPVCTRN
GLPVCGETCVGGTCNSPGCTCSWPVCTRN,29,Synthetic,Synthetic peptide,Human erythrocytes: Weak active up to 50 µM,,,,,Anticancer,Tumor active peptide##Membrane lysis,,Cyclic,Cys5<--->Cys19; Cys9<--->Cys21; Cys14<--->Cys26; NCB: Gly1<--->Asn29,Free,Free,,,0,GLPVCGETCVGGTCNSPGCTCSWPVCTRN
GLPVCGETCVGGTCNTPGCTCSYPVCTRN,29,Synthetic,Synthetic peptide,Human erythrocytes: Not active up to 50 µM,HFF-1: Not active up to 60 µM; PBMCs: Not active up to 60 µM,,,,Anticancer,Tumor active peptide##Membrane lysis,,Cyclic,Cys5<--->Cys19; Cys9<--->Cys21; Cys14<--->Cys26; NCB: Gly1<--->Asn29,Free,Free,,,0,GLPVCGETCVGGTCNTPGCTCSYPVCTRN
GLPVCGETCVGGTCNTPGCTCSWWPVCTRN,30,Synthetic,Synthetic peptide,Human erythrocytes: 50% Hemolysis=14.0±0.7 µM,HFF-1: CC50=9.2±0.7 µM,,,,Anticancer,Tumor active peptide##Membrane lysis,,Cyclic,Cys5<--->Cys19; Cys9<--->Cys21; Cys14<--->Cys27; NCB: Gly1<--->Asn30,Free,Free,,,0,GLPVCGETCVGGTCNTPGCTCSWWPVCTRN
KKLIKVWAKGFKKAKKLFKGIG,22,Synthetic,Synthetic peptide,Sheep erythrocytes: 10% Hemolysis=15 µM,,,,,Anticancer; Antibacterial,Tumor active peptide##Membrane lysis,,Linear,,Free,Free,,,0,KKLIKVWAKGFKKAKKLFKGIG
KKLIKVFAKGWKKAKKLFKGIG,22,Synthetic,Synthetic peptide,Sheep erythrocytes: 0% Hemolysis=15 µM,,,,,Anticancer; Antibacterial,Tumor active peptide##Membrane lysis,,Linear,,Free,Free,,,0,KKLIKVFAKGWKKAKKLFKGIG
KKLIKVFAKGFKKAKKLWKGIG,22,Synthetic,Synthetic peptide,Sheep erythrocytes: 0% Hemolysis=15 µM,,,,,Anticancer; Antibacterial,Tumor active peptide##Membrane lysis,,Linear,,Free,Free,,,0,KKLIKVFAKGFKKAKKLWKGIG
XXLIXVWAXGFXXAXXLFXGIG,22,Synthetic,Synthetic peptide,Sheep erythrocytes: 0% Hemolysis=15 µM,,,,,Anticancer; Antibacterial,Tumor active peptide##Membrane lysis,,Linear,,Free,Free,X=Diaminopropionic acid,,0,XXLIXVWAXGFXXAXXLFXGIG
KKAAKAWAKGAKKAKKLAKGAG,22,Synthetic,Synthetic peptide,Sheep erythrocytes: 0% Hemolysis=15 µM,,,,,Anticancer; Antibacterial,Tumor active peptide##Membrane lysis,,Linear,,Free,Free,,,0,KKAAKAWAKGAKKAKKLAKGAG
WLlXNG,6,Streptomyces nov. sp.,Native peptide,,,,,,Anticancer; Antibacterial; Antifungal ,Tumor active peptide,,Cyclic,NCB: Trp1<--->Gly6,Free,Free,X=Allo-Ile,,0,WLLXNG
WLlVNG,6,Streptomyces nov. sp.,Native peptide,,,,,,Anticancer; Antibacterial; Antifungal ,Tumor active peptide,,Cyclic,NCB: Trp1<--->Gly6,Free,Free,,,0,WLLVNG
WLvXNG,6,Streptomyces nov. sp.,Native peptide,,,,,,Anticancer; Antibacterial; Antifungal ,Tumor active peptide,,Cyclic,NCB: Trp1<--->Gly6,Free,Free,X=Allo-Ile; v=D-Val,,0,WLVXNG
WLxXNG,6,Streptomyces nov. sp.,Native peptide,,,,,,Anticancer; Antibacterial; Antifungal ,Tumor active peptide,,Cyclic,NCB: Trp1<--->Gly6,Free,Free,x=D-Allo-Ile; X=Allo-Ile,,0,WLXXNG
WLlXNx,6,Streptomyces nov. sp.,Native peptide,,,,,,Anticancer; Antibacterial; Antifungal ,Tumor active peptide,,Cyclic,NCB: Trp1<--->Gly6,Free,Free,X=Allo-Ile; x=D-Orn,,0,WLLXNX
WLlVNx,6,Streptomyces nov. sp.,Native peptide,,,,,,Anticancer; Antibacterial; Antifungal ,Targeted peptide conjugates,,Cyclic,NCB: Trp1<--->Gly6,Free,Free,x=D-Orn,,0,WLLVNX
WLRRIGKGVKIIGGAALDHL,20,Synthetic,Synthetic peptide,Human erythrocytes: 50% Hemolysis>256 µg/ml,Zebrafish embryos: No killing,,,,Anticancer,Tumor active peptide,,Linear,,Free,Amidation,,,0,WLRRIGKGVKIIGGAALDHL
GFLGILFHGVHHGRKKALHMNSERRS,26,Synthetic,Synthetic peptide,Human erythrocytes: 50% Hemolysis>256 µg/ml,"Zebrafish embryos: >10% Killing=25 µg/ml (4, 28, 52hpf embryo)",,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,GFLGILFHGVHHGRKKALHMNSERRS
GWKDWFRKAKKVGKTVGGLALNHYL,25,Synthetic,Synthetic peptide,Human erythrocytes: 50% Hemolysis>256 µg/ml,"Zebrafish embryos: >10% Killing=5 µg/ml (4, 28, 52hpf embryo)",,,,Anticancer,Tumor active peptide,,Linear,,Free,Amidation,,,0,GWKDWFRKAKKVGKTVGGLALNHYL
GIRKWFKKAAHVGKEVGKVALNACL,25,Synthetic,Synthetic peptide,Human erythrocytes: 50% Hemolysis>256 µg/ml,"Zebrafish embryos: >10% Killing=5 µg/ml (4, 52hpf embryo); >10% Killing=25 µg/ml (28hpf embryo)",,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,GIRKWFKKAAHVGKEVGKVALNACL
GLKKWFKKAVHVGKKVGKVALNAYL,25,Synthetic,Synthetic peptide,Human erythrocytes: 50% Hemolysis>256 µg/ml,"Zebrafish embryos: >10% Killing=5 µg/ml (4, 28, 52hpf embryo)",,,,Anticancer,Tumor active peptide,,Linear,,Free,Amidation,,,0,GLKKWFKKAVHVGKKVGKVALNAYL
GWRKWIKKATHVGKHIGKAALDAYI,25,Synthetic,Synthetic peptide,Human erythrocytes: 50% Hemolysis>256 µg/ml,"Zebrafish embryos: >10% Killing=5 µg/ml (4, 52hpf embryo)",,,,Anticancer,Tumor active peptide,,Linear,,Free,Amidation,,,0,GWRKWIKKATHVGKHIGKAALDAYI
GCKKWFKKAAHVGKNVGKVALNAYL,25,Synthetic,Synthetic peptide,Human erythrocytes: 50% Hemolysis>256 µg/ml,"Zebrafish embryos: >10% Killing=5 µg/ml (4, 28hpf embryo); >10% Killing=25 µg/ml (52hpf embryo)",,,,Anticancer,Tumor active peptide,,Linear,,Free,Amidation,,,0,GCKKWFKKAAHVGKNVGKVALNAYL
GIRKWFKKAAHVGKKVGKVALNAYL,25,Synthetic,Synthetic peptide,Human erythrocytes: 50% Hemolysis>256 µg/ml,"Zebrafish embryos: >10% Killing=5 µg/ml (28, 52hpf embryo); >10% Killing=25 µg/ml (4hpf embryo)",,,,Anticancer,Tumor active peptide,,Linear,,Free,Amidation,,,0,GIRKWFKKAAHVGKKVGKVALNAYL
GrrkrkWLrrIGkGVkIIGGAALDHL,26,Synthetic,Synthetic peptide,Human erythrocytes: 50% Hemolysis>256 µg/ml,Zebrafish embryos: No killing,,,,Anticancer,Tumor active peptide,,Linear,,Free,Amidation,r=D-Arg; k=D-Lys,,0,GRRKRKWLRRIGKGVKIIGGAALDHL
GLVGTLLGHIGKAILG,16,Sphaenorhynchus lacteus,Native peptide,Human erythrocytes: HC50=167 ± 8 µM,,,,,Anticancer; Antibacterial; Antifungal ,Tumor active peptide##Immune system stimulating peptides,,Linear,,Free,Amidation,,,0,GLVGTLLGHIGKAILG
GLVGTLLGHIGKAILS,16,Sphaenorhynchus lacteus,Native peptide,Human erythrocytes: HC50=169 ± 7 µM,,,,,Anticancer; Antibacterial; Antifungal ,Tumor active peptide##Immune system stimulating peptides,,Linear,,Free,Amidation,,,0,GLVGTLLGHIGKAILS
FLGFLKNLF,9,Bacillus subtilis,Native peptide,Human erythrocytes: HC50=137.9 µg/ml,,,,,Anticancer; Antiviral,Tumor active peptide,,Linear,,Free,Amidation,,,0,FLGFLKNLF
FLGFLHHLF,9,Synthetic,Synthetic peptide,Human erythrocytes: HC50=203.3 µg/ml,,,,,Anticancer; Antiviral,Tumor active peptide,,Linear,,Free,Amidation,,,0,FLGFLHHLF
FLHFLHHLF,9,Synthetic,Synthetic peptide,Human erythrocytes: HC50=416.4 µg/ml,,,,,Anticancer; Antiviral,Tumor active peptide,,Linear,,Free,Amidation,,,0,FLHFLHHLF
ELLVDLL,7,Bacillus subtilis,Native peptide,,,,,,Anticancer; Antibacterial; Antifungal ,Tumor active peptide##Lipopeptides ,,Linear,,3-β-hydroxy-11-methyltridecanoic,Free,,,0,ELLVDLL
GIMDTIKGAAKDLAGQLLDKLKCKITKC,28,Lithobates vaillanti,Native peptide,Huµan erythrocytes: HC50>200 µM,,,,,Anticancer; Antibacterial; Antifungal ,Tumor active peptide,,Cyclic,Cys23<--->Cys28,Free,Free,,,0,GIMDTIKGAAKDLAGQLLDKLKCKITKC
FLGAIAGVAAKFLPKVFCFITKKC,24,Lithobates vaillanti,Native peptide,Huµan erythrocytes: HC50=8 µM,,,,,Anticancer; Antibacterial; Antifungal ,Tumor active peptide,,Cyclic,Cys18<--->Cys24,Free,Free,,,0,FLGAIAGVAAKFLPKVFCFITKKC
FLPLIAGVAANFLPKIFCLISKKC,24,Lithobates vaillanti,Native peptide,Huµan erythrocytes: HC50=7 µM,,,,,Anticancer; Antibacterial; Antifungal ,Tumor active peptide,,Cyclic,Cys18<--->Cys24,Free,Free,,,0,FLPLIAGVAANFLPKIFCLISKKC
FLPVIASVAAKVLPKVFCFITKKC,24,Lithobates vaillanti,Native peptide,Huµan erythrocytes: HC50=5 µM,,,,,Anticancer; Antibacterial; Antifungal ,Tumor active peptide,,Cyclic,Cys18<--->Cys24,Free,Free,,,0,FLPVIASVAAKVLPKVFCFITKKC
FLPLIAGVAASILPKIFCFITKKC,24,Lithobates vaillanti,Native peptide,Huµan erythrocytes: HC50=5 µM,,,,,Anticancer; Antibacterial; Antifungal ,Tumor active peptide,,Cyclic,Cys18<--->Cys24,Free,Free,,,0,FLPLIAGVAASILPKIFCFITKKC
GGVKRFKKFFRKLKKSV,17,Synthetic,Synthetic peptide,Human erythrocytes: <20% Hemolysis	=160 µM,GES-1: IC50=85.1 ± 6.9 µM; HEK293: IC50=72.2 ± 6.9 µM,,,,Anticancer,Tumor active peptide##Lipopeptides##Membrane lysis##Induce apoptosis,,Linear,,"CH3(CH2)8CO, Decanoic acid",Amidation,,,0,GGVKRFKKFFRKLKKSV
inlkalaalakkil,14,Synthetic,Synthetic peptide,,,,,,Anticancer; Antimicrobial,Tumor active peptide##Cell-penetrating peptides##Induce apoptosis,,Linear,,Free,Amidation,,,0,INLKALAALAKKIL
LIKKALAALAKLNI,14,Synthetic,Synthetic peptide,,,,,,Anticancer; Antimicrobial,Tumor active peptide##Cell-penetrating peptides##Induce apoptosis,,Linear,,Free,Amidation,,,0,LIKKALAALAKLNI
likkalaalaklni,14,Synthetic,Synthetic peptide,,,,,,Anticancer; Antimicrobial,Tumor active peptide##Cell-penetrating peptides##Induce apoptosis,,Linear,,Free,Amidation,,,0,LIKKALAALAKLNI
INLKKLAKLXKKIL,14,Synthetic,Synthetic peptide,,,,,,Anticancer; Antimicrobial,Tumor active peptide##Cell-penetrating peptides##Induce apoptosis,,Linear,,Free,Amidation,X=AIB (Aminoisobutyric acid),,0,INLKKLAKLXKKIL
inlkklaklXkkil,14,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide##Cell-penetrating peptides##Induce apoptosis,,Linear,,Free,Amidation,X=AIB (Aminoisobutyric acid),,0,INLKKLAKLXKKIL
LIKKXLKALKKLNI,14,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide##Cell-penetrating peptides##Induce apoptosis,,Linear,,Free,Amidation,X=AIB (Aminoisobutyric acid),,0,LIKKXLKALKKLNI
likkXlkalkklni,14,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide##Cell-penetrating peptides##Induce apoptosis,,Linear,,Free,Amidation,X=AIB (Aminoisobutyric acid),,0,LIKKXLKALKKLNI
GNNKPVYRPQPRPPHPRL,18,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,GNNKPVYRPQPRPPHPRL
VDKGSYLPRPTPPRPIYNRN,20,Pyrrhocoris apterus,Native peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,VDKGSYLPRPTPPRPIYNRN
VDKGSYRPRPTPPKPIYNRN,20,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,VDKGSYRPRPTPPKPIYNRN
VDKPPYLPRPRPPRXIYNX,19,Synthetic,Synthetic peptide,,HEK293: Not active up to 600 µg/ml,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,X=Orn,,0,VDKPPYLPRPRPPRXIYNX
VRKPPYLPRPRWPRXIYNX,19,Synthetic,Synthetic peptide,,HEK293: Not active up to 600 µg/ml,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,X=Orn,,0,VRKPPYLPRPRWPRXIYNX
VXKPPYLPRPRWPRXIYNX,19,Synthetic,Synthetic peptide,,HEK293: Not active up to 600 µg/ml,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,X=Orn,,0,VXKPPYLPRPRWPRXIYNX
VrKPPYLPRPRWPRXIYNX,19,Synthetic,Synthetic peptide,,HEK293: Not active up to 600 µg/ml,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,r=D-Arg; X=Orn,,0,VRKPPYLPRPRWPRXIYNX
VDKPPYLPRPRPxRxXYNX,19,Synthetic,Synthetic peptide,,HEK293: Not active up to 600 µg/ml,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,x=trans-4-hydroxyproline; X(16)=tert-Leu; X(19)=Orn,,0,VDKPPYLPRPRPXRXXYNX
VDKPPYLPRPRPPRrIYNr,19,Synthetic,Synthetic peptide,,HEK293: 20% Cytotoxicity=600 µg/ml,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,r=D-Arg,,0,VDKPPYLPRPRPPRRIYNR
VRKPPYLPRPRWPRrIYNr,19,Synthetic,Synthetic peptide,,HEK293: 50-60% Cytotoxicity=600 µg/ml,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,r=D-Arg,,0,VRKPPYLPRPRWPRRIYNR
VXKPPYLPRPRWPRrIYNr,19,Synthetic,Synthetic peptide,,HEK293: 50-60% Cytotoxicity=600 µg/ml,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,r=D-Arg; X=Orn,,0,VXKPPYLPRPRWPRRIYNR
VrKPPYLPRPRWPRrIYNr,19,Synthetic,Synthetic peptide,,HEK293: 50-60% Cytotoxicity=600 µg/ml,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,r=D-Arg,,0,VRKPPYLPRPRWPRRIYNR
KIVPAMICAVTKKC,14,Synthetic (Derived from Ranalexin),Synthetic peptide,,CHO-K1: IC50=17 µg/ml; PBMC: IC50=15 µg/ml,,,,Anticancer; Antibacterial,Tumor active peptide##Lipopeptides##Membrane-targeted,,Cyclic,Cys8<--->Cys14,"CH3(CH2)12CO, Myristic acid",Free,,,0,KIVPAMICAVTKKC
GLLKKLLKKLLKKL,14,Synthetic,Synthetic peptide,Human erythrocytes: HC50=30 µM,Human keratinocytes HaCat: >90% Killing=40 µM,,,,Anticancer; Antibacterial,Tumor active peptide##Membrane-targeted,,Linear,,Free,Amidation,,,0,GLLKKLLKKLLKKL
GXXKKXXKKXXKKX,14,Synthetic,Synthetic peptide,Human erythrocytes: HC50=30 µM,Human keratinocytes HaCat: 30% Killing=40 µM,,,,Anticancer; Antibacterial,Tumor active peptide##Membrane-targeted,,Linear,,Free,Amidation,X=Norleucine,,0,GXXKKXXKKXXKKX
GVVKKVVKKVVKKV,14,Synthetic,Synthetic peptide,Human erythrocytes: Not active up to 250 µM,Human keratinocytes HaCat: <30% Killing=40 µM,,,,Anticancer; Antibacterial,Tumor active peptide##Membrane-targeted,,Linear,,Free,Amidation,,,0,GVVKKVVKKVVKKV
GIIXXIIXXIIXXI,14,Synthetic,Synthetic peptide,Human erythrocytes: HC50>250 µM,Human keratinocytes HaCat: <5% Killing=40 µM,,,,Anticancer; Antibacterial,Tumor active peptide##Membrane-targeted,,Linear,,Free,Amidation,X=Orn,,0,GIIXXIIXXIIXXI
AEEASKKAEEASKKAEEASKKAEEASKKAEEASKKXK,37,Synthetic,Synthetic peptide,,,,,,Anticancer; Antiviral,Tumor active peptide##Lipopeptides,,Linear,,Acetylation,"CH3(CH2)14CONH2, Hexadecanamide",X= β-Ala,,0,AEEASKKAEEASKKAEEASKKAEEASKKAEEASKKXK
VEEVSKKVEEVSKKVEEVSKKVEEVSKKVEEVSKKXK,37,Synthetic,Synthetic peptide,,,,,,Anticancer; Antiviral,Tumor active peptide##Lipopeptides,,Linear,,Acetylation,"CH3(CH2)14CONH2, Hexadecanamide",X= β-Ala,,0,VEEVSKKVEEVSKKVEEVSKKVEEVSKKVEEVSKKXK
FEEFSKKFEEFSKKFEEFSKKFEEFSKKFEEFSKKXK,37,Synthetic,Synthetic peptide,,,,,,Anticancer; Antiviral,Tumor active peptide##Lipopeptides,,Linear,,Acetylation,"CH3(CH2)14CONH2, Hexadecanamide",X= β-Ala,,0,FEEFSKKFEEFSKKFEEFSKKFEEFSKKFEEFSKKXK
YEEYSKKYEEYSKKYEEYSKKYEEYSKKYEEYSKKXK,37,Synthetic,Synthetic peptide,,,,,,Anticancer; Antiviral,Tumor active peptide##Lipopeptides,,Linear,,Acetylation,"CH3(CH2)14CONH2, Hexadecanamide",X= β-Ala,,0,YEEYSKKYEEYSKKYEEYSKKYEEYSKKYEEYSKKXK
LEELSKKLEELSKKLEELSKKLEELSKKLEELSKKXK,37,Synthetic,Synthetic peptide,,,,,,Anticancer; Antiviral,Tumor active peptide##Lipopeptides,,Linear,,Acetylation,"CH3(CH2)14CONH2, Hexadecanamide",X= β-Ala,,0,LEELSKKLEELSKKLEELSKKLEELSKKLEELSKKXK
IEEISKKIEEISKKIEEISKKIEEISKKIEEISKKXK,37,Synthetic,Synthetic peptide,,,,,,Anticancer; Antiviral,Tumor active peptide##Lipopeptides,,Linear,,Acetylation,"CH3(CH2)14CONH2, Hexadecanamide",X= β-Ala,,0,IEEISKKIEEISKKIEEISKKIEEISKKIEEISKKXK
IEEIYKKIEEIYKKIEEIYKKIEEIYKKIEEIYKKXK,37,Synthetic,Synthetic peptide,,,,,,Anticancer; Antiviral,Tumor active peptide##Lipopeptides,,Linear,,Acetylation,"CH3(CH2)14CONH2, Hexadecanamide",X= β-Ala,,0,IEEIYKKIEEIYKKIEEIYKKIEEIYKKIEEIYKKXK
IEEIWKKIEEIWKKIEEIWKKIEEIWKKIEEIWKKXK,37,Synthetic,Synthetic peptide,,,,,,Anticancer; Antiviral,Tumor active peptide##Lipopeptides,,Linear,,Acetylation,"CH3(CH2)14CONH2, Hexadecanamide",X= β-Ala,,0,IEEIWKKIEEIWKKIEEIWKKIEEIWKKIEEIWKKXK
IEEIHKKIEEIHKKIEEIHKKIEEIHKKIEEIHKKXK,37,Synthetic,Synthetic peptide,,,,,,Anticancer; Antiviral,Tumor active peptide##Lipopeptides,,Linear,,Acetylation,"CH3(CH2)14CONH2, Hexadecanamide",X= β-Ala,,0,IEEIHKKIEEIHKKIEEIHKKIEEIHKKIEEIHKKXK
IEEIQKKIEEIQKKIEEIQKKIEEIQKKIEEIQKKXK,37,Synthetic,Synthetic peptide,,,,,,Anticancer; Antiviral,Tumor active peptide##Lipopeptides,,Linear,,Acetylation,"CH3(CH2)14CONH2, Hexadecanamide",X= β-Ala,,0,IEEIQKKIEEIQKKIEEIQKKIEEIQKKIEEIQKKXK
IEEIKKKIEEIKKKIEEIKKKIEEIKKKIEEIKKKXK,37,Synthetic,Synthetic peptide,,,,,,Anticancer; Antiviral,Tumor active peptide##Lipopeptides,,Linear,,Acetylation,"CH3(CH2)14CONH2, Hexadecanamide",X= β-Ala,,0,IEEIKKKIEEIKKKIEEIKKKIEEIKKKIEEIKKKXK
IEEIEKKIEEIEKKIEEIEKKIEEIEKKIEEIEKKXK,37,Synthetic,Synthetic peptide,,,,,,Anticancer; Antiviral,Tumor active peptide##Lipopeptides,,Linear,,Acetylation,"CH3(CH2)14CONH2, Hexadecanamide",X= β-Ala,,0,IEEIEKKIEEIEKKIEEIEKKIEEIEKKIEEIEKKXK
SLTQINTTLLDLEYEMKKLEEVVKKLEESYIDLKEL,36,Synthetic,Synthetic peptide,,,,,,Anticancer; Antiviral,Tumor active peptide##Lipopeptides,,Linear,,Free,Free,,,0,SLTQINTTLLDLEYEMKKLEEVVKKLEESYIDLKEL
QGSWFGCTWMNSTGF,15,Synthetic,Synthetic peptide,,,,,,Anticancer; Antiviral,Tumor active peptide,,Linear,,Free,Free,,,0,QGSWFGCTWMNSTGF
FGCTWMNSTGFTKTC,15,Synthetic,Synthetic peptide,,,,,,Anticancer; Antiviral,Tumor active peptide,,Linear,,Free,Free,,,0,FGCTWMNSTGFTKTC
GLLHLHQNIVDVQYM,15,Synthetic,Synthetic peptide,,,,,,Anticancer; Antiviral,Tumor active peptide,,Linear,,Free,Free,,,0,GLLHLHQNIVDVQYM
LHQNIVDVQYMYGLS,15,Synthetic,Synthetic peptide,,,,,,Anticancer; Antiviral,Tumor active peptide,,Linear,,Free,Free,,,0,LHQNIVDVQYMYGLS
FLWIKLGKLAGAVLKLILGLKKVV,24,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide##Membrane-targeted,,Linear,,Free,Amidation,,,0,FLWIKLGKLAGAVLKLILGLKKVV
GLWAIAVKAGKVILKLIVFIWIRV,24,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide##Membrane-targeted,,Linear,,Free,Amidation,,,0,GLWAIAVKAGKVILKLIVFIWIRV
GLLDIAGGNAETLAGHAV,18,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide##Membrane-targeted,,Linear,,Free,Amidation,,,0,GLLDIAGGNAETLAGHAV
GLFDVIGSQAGGAAPHFLG,19,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide##Membrane-targeted,,Linear,,Free,Amidation,,,0,GLFDVIGSQAGGAAPHFLG
KWVKKVHNWLRRWIKVFEALFG,22,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide##Membrane-targeted,,Linear,,Free,Amidation,,,0,KWVKKVHNWLRRWIKVFEALFG
KIFKKFKTIIKKVWRIFGRF,20,Synthetic,Synthetic peptide,Human erythrocytes: HC50=16 ± 2 µM,HDMEC: EC50=3.3 ± 0.2 µM ,,,,Anticancer,Tumor active peptide##Membrane-targeted,,Linear,,Free,Amidation,,,0,KIFKKFKTIIKKVWRIFGRF
AFRHSVKEELNYIRRRLERFPNRL,24,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide##Membrane-targeted,,Linear,,Free,Amidation,,,0,AFRHSVKEELNYIRRRLERFPNRL
RIENGLRKRLQSIYRHLEE,19,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide##Membrane-targeted,,Linear,,Free,Amidation,,,0,RIENGLRKRLQSIYRHLEE
KWVRIWIKVLRGLFVWVWFF,20,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide##Membrane-targeted,,Linear,,Free,Amidation,,,0,KWVRIWIKVLRGLFVWVWFF
AWLKRIKKFLKALFWVWVW,19,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide##Membrane-targeted,,Linear,,Free,Amidation,,,0,AWLKRIKKFLKALFWVWVW
KVVDNFENILII,12,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide##Membrane-targeted,,Linear,,Free,Amidation,,,0,KVVDNFENILII
RVNAAIPNIIV,11,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide##Membrane-targeted,,Linear,,Free,Amidation,,,0,RVNAAIPNIIV
RVFKKFHPIYHRVWRLWGHL,20,Synthetic,Synthetic peptide,Human erythrocytes: HC50>200 µM,HDMEC: EC50=56 ± 7 µM ,,,,Anticancer,Tumor active peptide##Membrane-targeted,,Linear,,Free,Free,,,0,RVFKKFHPIYHRVWRLWGHL
HIIKKIRTWYRKAWHVLGKV,20,Synthetic,Synthetic peptide,Human erythrocytes: HC50>200 µM,HDMEC: EC50=32 ± 3 µM ,,,,Anticancer,Tumor active peptide##Membrane-targeted,,Linear,,Free,Free,,,0,HIIKKIRTWYRKAWHVLGKV
KLYKKFRHILKKVWHYVGKI,20,Synthetic,Synthetic peptide,Human erythrocytes: HC50=29 ± 3 µM,HDMEC: EC50=10 ± 3 µM,,,,Anticancer,Tumor active peptide##Membrane-targeted,,Linear,,Free,Free,,,0,KLYKKFRHILKKVWHYVGKI
KYIRHLKTWFKKVFKLIGEV,20,Synthetic,Synthetic peptide,Human erythrocytes: HC50=20 ± 3 µM,HDMEC: EC50=7.1 ± 0.1 µM,,,,Anticancer,Tumor active peptide##Membrane-targeted,,Linear,,Free,Free,,,0,KYIRHLKTWFKKVFKLIGEV
KIFKKFKDFLKKIFQYLGKV,20,Synthetic,Synthetic peptide,Human erythrocytes: HC50=15 ± 2 µM,HDMEC: EC50=10.1 ± 0.2 µM,,,,Anticancer,Tumor active peptide##Membrane-targeted,,Linear,,Free,Free,,,0,KIFKKFKDFLKKIFQYLGKV
HIFKKVKTYWKKLFRILGRF,20,Synthetic,Synthetic peptide,Human erythrocytes: HC50=16 ± 2 µM,HDMEC: EC50=5.0 ± 0.7 µM,,,,Anticancer,Tumor active peptide##Membrane-targeted,,Linear,,Free,Free,,,0,HIFKKVKTYWKKLFRILGRF
RLIKRLKTFVRKTWKWVGHF,20,Synthetic,Synthetic peptide,Human erythrocytes: HC50=95 ± 7 µM,HDMEC: EC50=12 ± 3 µM,,,,Anticancer,Tumor active peptide##Membrane-targeted,,Linear,,Free,Free,,,0,RLIKRLKTFVRKTWKWVGHF
RFLKHFKTVYKRYWKVLGRL,20,Synthetic,Synthetic peptide,Human erythrocytes: HC50=144 ± 4 µM,HDMEC: EC50=14.3 ± 0.2 µM,,,,Anticancer,Tumor active peptide##Membrane-targeted,,Linear,,Free,Free,,,0,RFLKHFKTVYKRYWKVLGRL
KLIHRLKTVFKKVWHFLGHL,20,Synthetic,Synthetic peptide,Human erythrocytes: HC50=41 ± 3 µM,HDMEC: EC50=22 ± 3 µM,,,,Anticancer,Tumor active peptide##Membrane-targeted,,Linear,,Free,Free,,,0,KLIHRLKTVFKKVWHFLGHL
HRIRQLKTTIKKFWEIWPKI,20,Synthetic,Synthetic peptide,Human erythrocytes: HC50>200 µM,HDMEC: EC50=58.1 ± 0.3 µM,,,,Anticancer,Tumor active peptide##Membrane-targeted,,Linear,,Free,Free,,,0,HRIRQLKTTIKKFWEIWPKI
QVFKKFRPFYRRPWELFGKL,20,Synthetic,Synthetic peptide,Human erythrocytes: HC50>200 µM,HDMEC: EC50=173 ± 1 µM,,,,Anticancer,Tumor active peptide##Membrane-targeted,,Linear,,Free,Free,,,0,QVFKKFRPFYRRPWELFGKL
QIIKKIRTWYRKAWHVLGKV,20,Synthetic,Synthetic peptide,Human erythrocytes: HC50>200 µM,HDMEC: EC50=42 ± 7 µM,,,,Anticancer,Tumor active peptide##Membrane-targeted,,Linear,,Free,Free,,,0,QIIKKIRTWYRKAWHVLGKV
TLYKKFRHFLKKPWHVVGKI,20,Synthetic,Synthetic peptide,Human erythrocytes: HC50>200 µM,HDMEC: EC50=167 ± 13 µM,,,,Anticancer,Tumor active peptide##Membrane-targeted,,Linear,,Free,Free,,,0,TLYKKFRHFLKKPWHVVGKI
HYIRHLKTWFHKPFKLIGKV,20,Synthetic,Synthetic peptide,Human erythrocytes: HC50>200 µM,HDMEC: EC50=169 ± 28 µM,,,,Anticancer,Tumor active peptide##Membrane-targeted,,Linear,,Free,Free,,,0,HYIRHLKTWFHKPFKLIGKV
KIFKKFKDWFKKAFHVLGKV,20,Synthetic,Synthetic peptide,Human erythrocytes: HC50>100 µM,HDMEC: EC50=22 ± 1 µM,,,,Anticancer,Tumor active peptide##Membrane-targeted,,Linear,,Free,Free,,,0,KIFKKFKDWFKKAFHVLGKV
QIFKKVKTWYKKAFQILGRL,20,Synthetic,Synthetic peptide,Human erythrocytes: HC50>100 µM,HDMEC: EC50=21 ± 2 µM,,,,Anticancer,Tumor active peptide##Membrane-targeted,,Linear,,Free,Free,,,0,QIFKKVKTWYKKAFQILGRL
RLIKRIKTWYRKAWKVVGKF,20,Synthetic,Synthetic peptide,Human erythrocytes: HC50>200 µM,HDMEC: EC50=23 ± 5 µM,,,,Anticancer,Tumor active peptide##Membrane-targeted,,Linear,,Free,Free,,,0,RLIKRIKTWYRKAWKVVGKF
RFLKHLHTYYERAWHVIGHL,20,Synthetic,Synthetic peptide,Human erythrocytes: HC50>200 µM,HDMEC: EC50=2 ± 2 µM,,,,Anticancer,Tumor active peptide##Membrane-targeted,,Linear,,Free,Free,,,0,RFLKHLHTYYERAWHVIGHL
HLIHRLHTYWHKPWHYLGKL,20,Synthetic,Synthetic peptide,Human erythrocytes: HC50>200 µM,HDMEC: EC50=135 ± 2 µM,,,,Anticancer,Tumor active peptide##Membrane-targeted,,Linear,,Free,Free,,,0,HLIHRLHTYWHKPWHYLGKL
QRIRQLHTWIKKAWHIWPKI,20,Synthetic,Synthetic peptide,Human erythrocytes: HC50>200 µM,HDMEC: EC50=39.7 ± 0.3 µM,,,,Anticancer,Tumor active peptide##Membrane-targeted,,Linear,,Free,Free,,,0,QRIRQLHTWIKKAWHIWPKI
QVVKKIRTWYHKAWHVLGKV,20,Synthetic,Synthetic peptide,Human erythrocytes: HC50>200 µM,HDMEC: EC50=96 ± 7 µM,,,,Anticancer,Tumor active peptide##Membrane-targeted,,Linear,,Free,Free,,,0,QVVKKIRTWYHKAWHVLGKV
QLIHKIRTWYRKAWHVLGKV,20,Synthetic,Synthetic peptide,Human erythrocytes: HC50>200 µM,HDMEC: EC50=28 ± 3 µM,,,,Anticancer,Tumor active peptide##Membrane-targeted,,Linear,,Free,Free,,,0,QLIHKIRTWYRKAWHVLGKV
HLLKKWRTWLRKAWHIVGKV,20,Synthetic,Synthetic peptide,Human erythrocytes: HC50=59 ± 6 µM,HDMEC: EC50=6.1 ± 0.5 µM,,,,Anticancer,Tumor active peptide##Membrane-targeted,,Linear,,Free,Free,,,0,HLLKKWRTWLRKAWHIVGKV
QVLKKVRTWYRKAFHVIGKV,20,Synthetic,Synthetic peptide,Human erythrocytes: HC50>200 µM,HDMEC: EC50>100 µM,,,,Anticancer,Tumor active peptide##Membrane-targeted,,Linear,,Free,Free,,,0,QVLKKVRTWYRKAFHVIGKV
QLLKKVRTWYRKAWHLYGKV,20,Synthetic,Synthetic peptide,Human erythrocytes: HC50>200 µM,HDMEC: EC50=27.2 ± 0.5 µM,,,,Anticancer,Tumor active peptide##Membrane-targeted,,Linear,,Free,Free,,,0,QLLKKVRTWYRKAWHLYGKV
QLIKKLRTWYRKAWHVLGKL,20,Synthetic,Synthetic peptide,Human erythrocytes: HC50>200 µM,HDMEC: EC50=9 ± 1 µM,,,,Anticancer,Tumor active peptide##Membrane-targeted,,Linear,,Free,Free,,,0,QLIKKLRTWYRKAWHVLGKL
QIIKKVRTWIKKAWHLIGKI,20,Synthetic,Synthetic peptide,Human erythrocytes: HC50>100 µM,HDMEC: EC50=17 ± 1 µM,,,,Anticancer,Tumor active peptide##Membrane-targeted,,Linear,,Free,Free,,,0,QIIKKVRTWIKKAWHLIGKI
QYLRRVRTWLRRAWHILGKV,20,Synthetic,Synthetic peptide,Human erythrocytes: HC50=21 ± 1 µM,HDMEC: EC50=10.3 ± 0.3 µM,,,,Anticancer,Tumor active peptide##Membrane-targeted,,Linear,,Free,Free,,,0,QYLRRVRTWLRRAWHILGKV
QLLKKIRTWYRKAWHVYGKV,20,Synthetic,Synthetic peptide,Human erythrocytes: HC50>200 µM,HDMEC: EC50=21 ± 2 µM,,,,Anticancer,Tumor active peptide##Membrane-targeted,,Linear,,Free,Free,,,0,QLLKKIRTWYRKAWHVYGKV
QIYKKYRTWYRKAWKVLGKV,20,Synthetic,Synthetic peptide,Human erythrocytes: HC50>200 µM,HDMEC: EC50=71 ± 12 µM,,,,Anticancer,Tumor active peptide##Membrane-targeted,,Linear,,Free,Free,,,0,QIYKKYRTWYRKAWKVLGKV
CXGRCLLIIKLAKLAKKLAKLAK,23,Synthetic,Synthetic peptide,,HUVEC: IC50=861 µg/ml; HFF: IC50=912 µg/ml,CD13-/αvβ3+ tumor cells,,"AMPs containing CisoDGRC selectively kill CD13-/αvβ3+ breast cancer cells by inducing apoptosis and inhibiting proliferation. Furthermore, the vivo experiments showed that AMPs containing CisoDGRC could significantly inhibited CD13-/αvβ3+ tumor progression and angiogenesis.",Anticancer,Tumor active peptide##Cancer targeted peptides##Coupling peptide##Induce apoptosis##Antiangiogenic##Proliferation inhibition,,Cyclic,Cys1<--->Cys5,Free,Free,X=iso-Asp,,0,CXGRCLLIIKLAKLAKKLAKLAK
RFRLPFRRPPIRIHPPPFYPPFRRFL,26,Capra hircus,Native peptide,Human erythrocytes: <5% Hemolysis=64 µM,Human PBMC: IC50=18.6 ± 0.8 µM ,,,,Anticancer; Antibacterial,Tumor active peptide##Induce apoptosis,,Linear,,Free,Amidation,,,0,RFRLPFRRPPIRIHPPPFYPPFRRFL
RFRLPFRRIHPPPFVRIHPPPFYRRFL,27,Synthetic,Synthetic peptide,Human erythrocytes: <5% Hemolysis=64 µM,Human PBMC: IC50=12.1 ± 0.8 µM,,,,Anticancer; Antibacterial,Tumor active peptide##Induce apoptosis,,Linear,,Free,Amidation,,,0,RFRLPFRRIHPPPFVRIHPPPFYRRFL
RFRRFRLPFRRIHPPPFVRIHPPPFYRRFL,30,Synthetic,Synthetic peptide,Human erythrocytes: <5% Hemolysis=64 µM,Human PBMC: IC50=18.3 ± 4.1 µM,,,,Anticancer; Antibacterial,Tumor active peptide##Induce apoptosis,,Linear,,Free,Amidation,,,0,RFRRFRLPFRRIHPPPFVRIHPPPFYRRFL
RFRLPFRRPWPIRIHPPPFYPWPFRRFL,28,Synthetic,Synthetic peptide,Human erythrocytes: 25 ± 2% Hemolysis=64 µM,Human PBMC: IC50=20.2 ± 4.5 µM,,,,Anticancer; Antibacterial,Tumor active peptide##Induce apoptosis,,Linear,,Free,Free,,,0,RFRLPFRRPWPIRIHPPPFYPWPFRRFL
RFRLPFRRPPIRIPPPFYPPFRRFL,25,Synthetic,Synthetic peptide,Human erythrocytes: <5% Hemolysis=64 µM,Human PBMC: IC50=34.7 ± 7.3 µM,,,,Anticancer; Antibacterial,Tumor active peptide##Induce apoptosis,,Linear,,Free,Amidation,,,0,RFRLPFRRPPIRIPPPFYPPFRRFL
RIHPPPFYPPFRRFL,15,Synthetic,Synthetic peptide,Human erythrocytes: <5% Hemolysis=64 µM,Human PBMC: IC50=43.3 ± 7.7 µM,,,,Anticancer; Antibacterial,Tumor active peptide##Induce apoptosis,,Linear,,Free,Amidation,,,0,RIHPPPFYPPFRRFL
RFRLPFRRPPIRIHPPPFY,19,Synthetic,Synthetic peptide,Human erythrocytes: <5% Hemolysis=64 µM,Human PBMC: IC50>64 µM,,,,Anticancer; Antibacterial,Tumor active peptide##Induce apoptosis,,Linear,,Free,Amidation,,,0,RFRLPFRRPPIRIHPPPFY
RFRLPFRRPPIRIH,14,Synthetic,Synthetic peptide,Human erythrocytes: <5% Hemolysis=64 µM,Human PBMC: IC50>64 µM,,,,Anticancer; Antibacterial,Tumor active peptide##Induce apoptosis,,Linear,,Free,Amidation,,,0,RFRLPFRRPPIRIH
RFRRFRLPFRRPPIRIH,17,Synthetic,Synthetic peptide,Human erythrocytes: <5% Hemolysis=64 µM,Human PBMC: IC50>64 µM,,,,Anticancer; Antibacterial,Tumor active peptide##Induce apoptosis,,Linear,,Free,Amidation,,,0,RFRRFRLPFRRPPIRIH
FTILKKLKSFIK,12,Synthetic,Synthetic peptide,Human erythrocytes: <10% Hemolysis=50 µM,,,,,Anticancer; Antibacterial,Tumor active peptide##Membrane-targeted,,Linear,,Free,Free,,,0,FTILKKLKSFIK
KLVKKLLKKYITF,13,Synthetic,Synthetic peptide,Human erythrocytes: <10% Hemolysis=50 µM,,,,,Anticancer; Antibacterial,Tumor active peptide##Membrane-targeted,,Linear,,Free,Free,,,0,KLVKKLLKKYITF
LARFVLRILKYGFK,14,Synthetic,Synthetic peptide,Human erythrocytes: 10% Hemolysis=9.38 µM,,,,,Anticancer; Antibacterial,Tumor active peptide##Membrane-targeted,,Linear,,Free,Free,,,0,LARFVLRILKYGFK
IPLLRKGKKIIWW,13,Synthetic,Synthetic peptide,Human erythrocytes: <10% Hemolysis=50 µM,,,,,Anticancer; Antibacterial,Tumor active peptide##Membrane-targeted,,Linear,,Free,Free,,,0,IPLLRKGKKIIWW
GLKKVIKLLRPLL,13,Synthetic,Synthetic peptide,Human erythrocytes: <10% Hemolysis=50 µM,,,,,Anticancer; Antibacterial,Tumor active peptide##Membrane-targeted,,Linear,,Free,Free,,,0,GLKKVIKLLRPLL
ILKPKLWKLTVVARKIIK,18,Synthetic,Synthetic peptide,Human erythrocytes: <10% Hemolysis=50 µM,,,,,Anticancer; Antibacterial,Tumor active peptide##Membrane-targeted,,Linear,,Free,Free,,,0,ILKPKLWKLTVVARKIIK
IVIKSLGKFLKNVGGFAG,18,Synthetic,Synthetic peptide,Human erythrocytes: <10% Hemolysis=50 µM,,,,,Anticancer; Antibacterial,Tumor active peptide##Membrane-targeted,,Linear,,Free,Free,,,0,IVIKSLGKFLKNVGGFAG
FKLVWKLLKKLALKL,15,Synthetic,Synthetic peptide,Human erythrocytes: 10% Hemolysis=5.96 µM,,,,,Anticancer; Antibacterial,Tumor active peptide##Membrane-targeted,,Linear,,Free,Free,,,0,FKLVWKLLKKLALKL
ITKWLLNAIKKGFKL,15,Synthetic,Synthetic peptide,Human erythrocytes: 10% Hemolysis=21.9 µM,,,,,Anticancer; Antibacterial,Tumor active peptide##Membrane-targeted,,Linear,,Free,Free,,,0,ITKWLLNAIKKGFKL
IHKLVKLWLNLGKKF,15,Synthetic,Synthetic peptide,Human erythrocytes: 10% Hemolysis=39.3 µM,,,,,Anticancer; Antibacterial,Tumor active peptide##Membrane-targeted,,Linear,,Free,Free,,,0,IHKLVKLWLNLGKKF
LFSIIWKLNRKLIKA,15,Synthetic,Synthetic peptide,Human erythrocytes: 10% Hemolysis=37.3 µM,,,,,Anticancer; Antibacterial,Tumor active peptide##Membrane-targeted,,Linear,,Free,Free,,,0,LFSIIWKLNRKLIKA
KKK,3,Synthetic,Synthetic peptide,Human erythrocytes:HC50=90.0 ± 6.5 µg/ml,HaCat: IC50=5.2 ± 0.6 µg/ml,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide##Lipopeptides##Membrane lysis,,Linear,,"CH3(CH2)14CO, Palmitic acid",Amidation,,,0,KKK
CKKKKC,6,Synthetic,Synthetic peptide,Human erythrocytes:HC50=30.6 ± 1.1 µg/ml,HaCat: IC50=26.9 ± 1.9 µg/ml,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide##Lipopeptides##Membrane lysis,,Cyclic,Cys1<--->Cys6,"CH3(CH2)14CO, Palmitic acid",Amidation,,,0,CKKKKC
KRKK,4,Synthetic,Synthetic peptide,Human erythrocytes:HC50=79.8 ± 9.0 µg/ml,HaCat: IC50=4.3 ± 0.9 µg/ml,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide##Lipopeptides##Membrane lysis,,Linear,,"CH3(CH2)14CO, Palmitic acid",Amidation,,,0,KRKK
CKRKKC,6,Synthetic,Synthetic peptide,Human erythrocytes:HC50=122.4 ± 16.5 µg/ml,HaCat: IC50=33.8 ± 3.1 µg/ml,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide##Lipopeptides##Membrane lysis,,Cyclic,Cys1<--->Cys6,"CH3(CH2)14CO, Palmitic acid",Amidation,,,0,CKRKKC
RRKK,4,Synthetic,Synthetic peptide,Human erythrocytes:HC50=65.4 ± 1.5 µg/ml,HaCat: IC50=8.1 ± 1.1 µg/ml,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide##Lipopeptides##Membrane lysis,,Linear,,"CH3(CH2)14CO, Palmitic acid",Amidation,,,0,RRKK
CRRKKC,6,Synthetic,Synthetic peptide,Human erythrocytes:HC50=92.0 ± 9.6 µg/ml,HaCat: IC50=21.3 ± 8.2 µg/ml,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide##Lipopeptides##Membrane lysis,,Cyclic,Cys1<--->Cys6,"CH3(CH2)14CO, Palmitic acid",Amidation,,,0,CRRKKC
FPVTWRWWKWWKGKFPVTWRWWKWWKG,27,Synthetic,Synthetic peptide,Sheep erythrocytes: No hemolysis up tp 500 µg/ml,NIH 3T3: IC50=250 µg/ml,,,"Dual mechanism, with the disruption of the membrane integrity possibly being the main cause of cell death, but only after peptide translocation and binding to intracellular targets.",Anticancer; Antibacterial; Antifungal,Tumor active peptide##Membrane lysis##Binding intracellular targets,,Linear,,Free,Amidation,,,0,FPVTWRWWKWWKGKFPVTWRWWKWWKG
RRRRWRWWRWWRR,13,Synthetic,Synthetic peptide,Sheep erythrocytes: No hemolysis up tp 500 µg/ml,NIH 3T3: IC50>250 µg/ml,,,"Dual mechanism, with the disruption of the membrane integrity possibly being the main cause of cell death, but only after peptide translocation and binding to intracellular targets.",Anticancer; Antibacterial; Antifungal,Tumor active peptide##Membrane lysis##Binding intracellular targets,,Linear,,Free,Amidation,,,0,RRRRWRWWRWWRR
RKRWWRWWKWWKR,13,Synthetic,Synthetic peptide,Sheep erythrocytes: No hemolysis up tp 500 µg/ml,NIH 3T3: IC50=250 µg/ml,,,"Dual mechanism, with the disruption of the membrane integrity possibly being the main cause of cell death, but only after peptide translocation and binding to intracellular targets.",Anticancer; Antibacterial; Antifungal,Tumor active peptide##Membrane lysis##Binding intracellular targets,,Linear,,Free,Amidation,,,0,RKRWWRWWKWWKR
RKrWWrWwkWWkR,13,Synthetic,Synthetic peptide,Sheep erythrocytes: No hemolysis up tp 500 µg/ml,NIH 3T3: IC50=250 µg/ml,,,"Dual mechanism, with the disruption of the membrane integrity possibly being the main cause of cell death, but only after peptide translocation and binding to intracellular targets.",Anticancer; Antibacterial; Antifungal,Tumor active peptide##Membrane lysis##Binding intracellular targets,,Linear,,Free,Amidation,r=D-Arg; w=D-Trp,,0,RKRWWRWWKWWKR
RWWKWW,6,Synthetic,Synthetic peptide,Sheep erythrocytes: No hemolysis up tp 500 µg/ml,NIH 3T3: IC50=250 µg/ml,,,"Dual mechanism, with the disruption of the membrane integrity possibly being the main cause of cell death, but only after peptide translocation and binding to intracellular targets.",Anticancer; Antibacterial; Antifungal,Tumor active peptide##Membrane lysis##Binding intracellular targets,,Linear,,Free,Amidation,,,0,RWWKWW
RWWKWWK,7,Synthetic,Synthetic peptide,Sheep erythrocytes: No hemolysis up tp 500 µg/ml,NIH 3T3: IC50=250 µg/ml,,,"Dual mechanism, with the disruption of the membrane integrity possibly being the main cause of cell death, but only after peptide translocation and binding to intracellular targets.",Anticancer; Antibacterial; Antifungal,Tumor active peptide##Membrane lysis##Binding intracellular targets,,Linear,,Free,Amidation,,,0,RWWKWWK
WRWWKWW,7,Synthetic,Synthetic peptide,Sheep erythrocytes: No hemolysis up tp 500 µg/ml,NIH 3T3: IC50=250 µg/ml,,,"Dual mechanism, with the disruption of the membrane integrity possibly being the main cause of cell death, but only after peptide translocation and binding to intracellular targets.",Anticancer; Antibacterial; Antifungal,Tumor active peptide##Membrane lysis##Binding intracellular targets,,Linear,,Free,Amidation,,,0,WRWWKWW
WrWwkWW,7,Synthetic,Synthetic peptide,Sheep erythrocytes: No hemolysis up tp 500 µg/ml,NIH 3T3: IC50>250 µg/ml,,,"Dual mechanism, with the disruption of the membrane integrity possibly being the main cause of cell death, but only after peptide translocation and binding to intracellular targets.",Anticancer; Antibacterial; Antifungal,Tumor active peptide##Membrane lysis##Binding intracellular targets,,Linear,,Free,Amidation,r=D-Arg; w=D-Trp,,0,WRWWKWW
WRWWKWWK,8,Synthetic,Synthetic peptide,Sheep erythrocytes: No hemolysis up tp 500 µg/ml,NIH 3T3: IC50>250 µg/ml,,,"Dual mechanism, with the disruption of the membrane integrity possibly being the main cause of cell death, but only after peptide translocation and binding to intracellular targets.",Anticancer; Antibacterial; Antifungal,Tumor active peptide##Membrane lysis##Binding intracellular targets,,Linear,,Free,Amidation,,,0,WRWWKWWK
WWRWWKWW,8,Synthetic,Synthetic peptide,Sheep erythrocytes: No hemolysis up tp 500 µg/ml,NIH 3T3: IC50>250 µg/ml,,,"Dual mechanism, with the disruption of the membrane integrity possibly being the main cause of cell death, but only after peptide translocation and binding to intracellular targets.",Anticancer; Antibacterial; Antifungal,Tumor active peptide##Membrane lysis##Binding intracellular targets,,Linear,,Free,Amidation,,,0,WWRWWKWW
WWrWwkWW,8,Synthetic,Synthetic peptide,Sheep erythrocytes: No hemolysis up tp 500 µg/ml,NIH 3T3: IC50=250 µg/ml,,,"Dual mechanism, with the disruption of the membrane integrity possibly being the main cause of cell death, but only after peptide translocation and binding to intracellular targets.",Anticancer; Antibacterial; Antifungal,Tumor active peptide##Membrane lysis##Binding intracellular targets,,Linear,,Free,Amidation,r=D-Arg; w=D-Trp,,0,WWRWWKWW
AFALIAGALYRIFHRR,16,Lactobacillus casei HZ1,Synthetic peptide,Goat erythrocytes: HC50=187.2 µM ,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide##Membrane lysis##Induce apoptosis,,Linear,,Free,Free,,,0,AFALIAGALYRIFHRR
GARELRRLERELRRLEGGGGGGGKLAALKFKLLWLKLAC,39,Synthetic,Synthetic peptide,Human erythrocytes: 50% Hemolysis>64 µM,HFF-1: CC50=11.9 ± 1.0 µM; MCF-10A: CC50=8.0 ± 0.8 µM; Human PBMC: CC50=48.9 ± 5.3 µM,,,"(1) The positively charged peptide targets the negative surface of cancer cells via electrostatic attractions; (2) The peptide inserts into cell membranes and enters inside cells very efficaciously; (3) Once inside cells, the peptide induces toxicity through fusion and/or disruption of intracellular organelles; (4) The cell membrane is disrupted and the cells die.",Anticancer,Tumor active peptide##Membrane lysis##Cell-penetrating peptides,,Cyclic,TIE: N-terminal Chloroacetic acid<--->Cys39,"CAA, Chloroacetic acid",Free,,,0,GARELRRLERELRRLEGGGGGGGKLAALKFKLLWLKLAC
GARELRRLERELRRLEKGGGGGGKLAALKFKLLWLKLAC,39,Synthetic,Synthetic peptide,Human erythrocytes: 50% Hemolysis>64 µM,HFF-1: CC50=8.8 ± 1.2 µM; MCF-10A: CC50=25.7 ± 3.2 µM; Human PBMC: CC50=42.8 ± 7.0  µM,,,"(1) The positively charged peptide targets the negative surface of cancer cells via electrostatic attractions; (2) The peptide inserts into cell membranes and enters inside cells very efficaciously; (3) Once inside cells, the peptide induces toxicity through fusion and/or disruption of intracellular organelles; (4) The cell membrane is disrupted and the cells die.",Anticancer,Tumor active peptide##Membrane lysis##Cell-penetrating peptides,,Cyclic,TIE: N-terminal Chloroacetic acid<--->Cys39,"CAA, Chloroacetic acid",Free,,,0,GARELRRLERELRRLEKGGGGGGKLAALKFKLLWLKLAC
GARELRRLERELRRLEKGGGGGGKLAALTFEHYWAQLTSC,40,Synthetic,Synthetic peptide,Human erythrocytes: 50% Hemolysis>64 µM,HFF-1: CC50>64 µM; MCF-10A: CC50>64 µM; Human PBMC: CC50>64 µM,,,"(1) The positively charged peptide targets the negative surface of cancer cells via electrostatic attractions; (2) The peptide inserts into cell membranes and enters inside cells very efficaciously; (3) Once inside cells, the peptide induces toxicity through fusion and/or disruption of intracellular organelles; (4) The cell membrane is disrupted and the cells die.",Anticancer,Tumor active peptide##Membrane lysis##Cell-penetrating peptides,,Cyclic,TIE: N-terminal Chloroacetic acid<--->Cys39,"CAA, Chloroacetic acid",Free,,,0,GARELRRLERELRRLEKGGGGGGKLAALTFEHYWAQLTSC
GARELRRLERELRRLEGGGGGGGKLAALKAKLLWLKLAC,39,Synthetic,Synthetic peptide,Human erythrocytes: 50% Hemolysis>64 µM,HFF-1: CC50>64 µM; MCF-10A: CC50>64 µM; Human PBMC: CC50>64 µM,,,"(1) The positively charged peptide targets the negative surface of cancer cells via electrostatic attractions; (2) The peptide inserts into cell membranes and enters inside cells very efficaciously; (3) Once inside cells, the peptide induces toxicity through fusion and/or disruption of intracellular organelles; (4) The cell membrane is disrupted and the cells die.",Anticancer,Tumor active peptide##Membrane lysis##Cell-penetrating peptides,,Cyclic,TIE: N-terminal Chloroacetic acid<--->Cys39,"CAA, Chloroacetic acid",Free,,,0,GARELRRLERELRRLEGGGGGGGKLAALKAKLLWLKLAC
GFCWYVCARRNGARVCYRRCN,21,Synthetic (Derived from Arenicin-3),Synthetic peptide,Human erythrocytes: HC10= µg/ml,HEK-293: CC50>300 µg/ml; HK-2: CC50>250 µg/ml,,,,Anticancer; Antibacterial,Tumor active peptide##Membrane-targeted,,Cyclic,Cys3<--->Cys20; Cys7<--->Cys16,Free,Free,,,0,GFCWYVCARRNGARVCYRRCN
GFCWRVCASRNGLRVCYRRCN,21,Synthetic (Derived from Arenicin-3),Synthetic peptide,Human erythrocytes: HC10= µg/ml,HEK-293: CC50=250 µg/ml; HK-2: CC50=110 µg/ml,,,,Anticancer; Antibacterial,Tumor active peptide##Membrane-targeted,,Cyclic,Cys3<--->Cys20; Cys7<--->Cys16,Free,Free,,,0,GFCWRVCASRNGLRVCYRRCN
GFCWYACAKRNGLRVCYRRCN,21,Synthetic (Derived from Arenicin-3),Synthetic peptide,Human erythrocytes: HC10= µg/ml,HEK-293: CC50>300 µg/ml; HK-2: CC50>250 µg/ml,,,,Anticancer; Antibacterial,Tumor active peptide##Membrane-targeted,,Cyclic,Cys3<--->Cys20; Cys7<--->Cys16,Free,Free,,,0,GFCWYACAKRNGLRVCYRRCN
GFCWNVCVRRNGVRVCHRRCN,21,Synthetic (Derived from Arenicin-3),Synthetic peptide,Human erythrocytes: HC10= µg/ml,HEK-293: CC50>300 µg/ml; HK-2: CC50>250 µg/ml,,,,Anticancer; Antibacterial,Tumor active peptide##Membrane-targeted,,Cyclic,Cys3<--->Cys20; Cys7<--->Cys16,Free,Free,,,0,GFCWNVCVRRNGVRVCHRRCN
GFCWYVCVKRNGVRSCYRRCN,21,Synthetic (Derived from Arenicin-3),Synthetic peptide,Human erythrocytes: HC10= µg/ml,HEK-293: CC50>300 µg/ml; HK-2: CC50>250 µg/ml,,,,Anticancer; Antibacterial,Tumor active peptide##Membrane-targeted,,Cyclic,Cys3<--->Cys20; Cys7<--->Cys16,Free,Free,,,0,GFCWYVCVKRNGVRSCYRRCN
GFCWNVCVYRNGVRICHRRCN,21,Synthetic (Derived from Arenicin-3),Synthetic peptide,Human erythrocytes: HC10= µg/ml,HEK-293: CC50>300 µg/ml; HK-2: CC50>250 µg/ml,,,,Anticancer; Antibacterial,Tumor active peptide##Membrane-targeted,,Cyclic,Cys3<--->Cys20; Cys7<--->Cys16,Free,Free,,,0,GFCWNVCVYRNGVRICHRRCN
GFCWHVCARRNGVRVCYRRCN,21,Synthetic (Derived from Arenicin-3),Synthetic peptide,Human erythrocytes: HC10= µg/ml,HEK-293: CC50>300 µg/ml; HK-2: CC50>250 µg/ml,,,,Anticancer; Antibacterial,Tumor active peptide##Membrane-targeted,,Cyclic,Cys3<--->Cys20; Cys7<--->Cys16,Free,Free,,,0,GFCWHVCARRNGVRVCYRRCN
GFCWRACVYRNGVRACYRRCN,21,Synthetic (Derived from Arenicin-3),Synthetic peptide,Human erythrocytes: HC10= µg/ml,HEK-293: CC50>300 µg/ml; HK-2: CC50>250 µg/ml,,,,Anticancer; Antibacterial,Tumor active peptide##Membrane-targeted,,Cyclic,Cys3<--->Cys20; Cys7<--->Cys16,Free,Free,,,0,GFCWRACVYRNGVRACYRRCN
GFCWRACVYRNGVRVCYRRCN,21,Synthetic (Derived from Arenicin-3),Synthetic peptide,Human erythrocytes: HC10= µg/ml,HEK-293: CC50=223 µg/ml; HK-2: CC50>250 µg/ml,,,,Anticancer; Antibacterial,Tumor active peptide##Membrane-targeted,,Cyclic,Cys3<--->Cys20; Cys7<--->Cys16,Free,Free,,,0,GFCWRACVYRNGVRVCYRRCN
GLHKVMREVLGYERNSYKKFFLR,23,Ixodes sinensis,Native peptide,,HEK-293: Not active up to 32 µM,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,,0,GLHKVMREVLGYERNSYKKFFLR
GLAKVMREVLGYERNSYKKFFLR,23,Synthetic,Synthetic peptide,,HEK-293: Not active up to 16 µM,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,,0,GLAKVMREVLGYERNSYKKFFLR
KVMREVLGYERNSYKKFFLR,20,Synthetic,Synthetic peptide,,HEK-293: Not active up to 128 µM,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,,0,KVMREVLGYERNSYKKFFLR
GLHKVMRKVLGYLRNVYK,18,Synthetic,Synthetic peptide,,HEK-293: 14% Killing=1 µM,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,,0,GLHKVMRKVLGYLRNVYK
GLAKVMRKVLGYLRNVYK,18,Synthetic,Synthetic peptide,,HEK-293: 23% Killing=2-4 µM,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,,0,GLAKVMRKVLGYLRNVYK
KVMRKVLGYLRNVYK,15,Synthetic,Synthetic peptide,,HEK-293: 15% Killing=2 µM,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,,0,KVMRKVLGYLRNVYK
GLHKVMREVLGY,12,Synthetic,Synthetic peptide,,HEK-293: 3% Killing>128 µM,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,,0,GLHKVMREVLGY
YERNSYKKFFLR,12,Synthetic,Synthetic peptide,,HEK-293: 10% Killing>128 µM,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,,0,YERNSYKKFFLR
GLHKVMREVLGYERNSYK,18,Synthetic,Synthetic peptide,,HEK-293: 6% Killing>128 µM,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,,0,GLHKVMREVLGYERNSYK
KVMREVLGYERNSYK,15,Synthetic,Synthetic peptide,,HEK-293: 14% Killing>128 µM,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,,0,KVMREVLGYERNSYK
REVLGYERNSYK,12,Synthetic,Synthetic peptide,,HEK-293: 18% Killing>128 µM,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,,0,REVLGYERNSYK
LKRIVQRIKDFLR,13,Synthetic,Synthetic peptide,Human erythrocytes: Not active up to 500 µg/ml,DLF lung fibroblasts: IC50=56.9 μg/ml,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,,0,LKRIVQRIKDFLR
AKRIVQRIKDFLR,13,Synthetic,Synthetic peptide,Human erythrocytes: Not active up to 500 µg/ml,DLF lung fibroblasts: Not active up to 200 µg/ml,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,,0,AKRIVQRIKDFLR
FKRIVQRILDFLR,13,Synthetic,Synthetic peptide,Human erythrocytes: HC50=450 µg/ml,DLF lung fibroblasts: IC50=20.1 μg/ml,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Acetylation,Amidation,,,0,FKRIVQRILDFLR
FXRIVQRILDFLR,13,Synthetic,Synthetic peptide,Human erythrocytes: Not active up to 500 µg/ml,DLF lung fibroblasts: IC50=24.3 μg/ml,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Acetylation,Amidation,X=Sialic acid-Lys,,0,FXRIVQRILDFLR
FKRIVQRIRDFLR,13,Synthetic,Synthetic peptide,Human erythrocytes: Not active up to 500 µg/ml,DLF lung fibroblasts: Not active up to 200 µg/ml,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,,0,FKRIVQRIRDFLR
FKRIVQKIKDFLR,13,Synthetic,Synthetic peptide,Human erythrocytes: Not active up to 500 µg/ml,DLF lung fibroblasts: Not active up to 200 µg/ml,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,,0,FKRIVQKIKDFLR
FKRIVQLIKDFLR,13,Synthetic,Synthetic peptide,Human erythrocytes: HC50=114 µg/ml,DLF lung fibroblasts: IC50=23.5 μg/ml,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,,0,FKRIVQLIKDFLR
FKRIVQRIKDLLR,13,Synthetic,Synthetic peptide,Human erythrocytes: Not active up to 500 µg/ml,DLF lung fibroblasts: Not active up to 200 µg/ml,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,,0,FKRIVQRIKDLLR
FKRIVQIIKKFLR,13,Synthetic,Synthetic peptide,Human erythrocytes: HC50=361 µg/ml,DLF lung fibroblasts: IC50=27 μg/ml,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,,0,FKRIVQIIKKFLR
FKRIVQLLKKLLR,13,Synthetic,Synthetic peptide,Human erythrocytes: HC50=411 µg/ml,DLF lung fibroblasts: IC50=23.7 μg/ml,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,,0,FKRIVQLLKKLLR
FKRILQRIKDFLR,13,Synthetic,Synthetic peptide,Human erythrocytes: Not active up to 500 µg/ml,DLF lung fibroblasts: IC50=76.8 μg/ml,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,,0,FKRILQRIKDFLR
GXFKKTFHKVSHAVKSGIHAGQRGCSALGF,30,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial; Anti-inflammatory,Tumor active peptide,,Linear,,Free,Free,X=Br-Trp,,0,GXFKKTFHKVSHAVKSGIHAGQRGCSALGF
GWFKKTFHKVSHAVKSGIHAGQRGCSALGF,30,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial; Anti-inflammatory,Tumor active peptide,,Linear,,Free,Free,,,0,GWFKKTFHKVSHAVKSGIHAGQRGCSALGF
GWFKKTFHKVSHAVKSGIHA,20,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial; Anti-inflammatory,Tumor active peptide,,Linear,,Free,Free,,,0,GWFKKTFHKVSHAVKSGIHA
GWFKKTFHKVSHAVKSGIHAGQRGSSALGF,30,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial; Anti-inflammatory,Tumor active peptide,,Linear,,Free,Free,,,0,GWFKKTFHKVSHAVKSGIHAGQRGSSALGF
IKLSKKTKKNLKKVLKGAIKGAIAVAKMV,29,Synthetic (Derived from Hymenochirin-1B),Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,IKLSKKTKKNLKKVLKGAIKGAIAVAKMV
IKLXKEXKKXLKKVLKGXIKGXIAVAKMV,29,Synthetic (Derived from Hymenochirin-1B),Synthetic peptide,,,,,,Anticancer,Tumor active peptide##Glycosylated peptide##Induce apoptosis,,Linear,X18<--->X22,Free,Free,X(4)=Ser-GlcNAc; X(7)=Thr-GlcNAc; X(10)=Asn-GlcNAc; X(18/22)=(S)-N-Fmoc-2-(4′-pentenyl)alanine,,0,IKLXKEXKKXLKKVLKGXIKGXIAVAKMV
IKLXKKXKKXLKKVLKGXIKGXIAVAKMV,29,Synthetic (Derived from Hymenochirin-1B),Synthetic peptide,,,,,,Anticancer,Tumor active peptide##Glycosylated peptide##Induce apoptosis,,Linear,X18<--->X22,Free,Free,X(4)=Ser-GlcNAc; X(7)=Thr-GlcNAc; X(10)=Asn-GlcNAc; X(18/22)=(S)-N-Fmoc-2-(4′-pentenyl)alanine,,0,IKLXKKXKKXLKKVLKGXIKGXIAVAKMV
ALWMTLLKKVLKAAAKAALNAVLVGA,26,Synthetic,Synthetic peptide,Human erythrocytes: 74.2±5.82% Hemolysis=256 µg/ml,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,,,0,ALWMTLLKKVLKAAAKAALNAVLVGA
ALWMTLLKKVLKAAAKAALNAVLV,24,Synthetic,Synthetic peptide,Human erythrocytes: 57.1±6.34% Hemolysis=256 µg/ml,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,,,0,ALWMTLLKKVLKAAAKAALNAVLV
ALWMTLLKKVLKAAAKAALNAV,22,Synthetic,Synthetic peptide,Human erythrocytes: 80±1.12% Hemolysis=256 µg/ml,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,,,0,ALWMTLLKKVLKAAAKAALNAV
WMTLLKKVLKAAAKAALNAVLVGANA,26,Synthetic,Synthetic peptide,Human erythrocytes: 68.5±7.58% Hemolysis=256 µg/ml,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,,,0,WMTLLKKVLKAAAKAALNAVLVGANA
LKKVLKAAAKAALNAVLVGANA,22,Synthetic,Synthetic peptide,Human erythrocytes: 35.4±6.28% Hemolysis=256 µg/ml,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,,,0,LKKVLKAAAKAALNAVLVGANA
GLRKRLRKFFNKIKEK,16,Synthetic,Synthetic peptide,Human erythrocytes: <10% Hemolysis	=40 µM,HEK293: <20% Killing=40 µM,,,,Anticancer; Antibacterial,Tumor active peptide##Cell-penetrating peptides##Membrane-targeted,,Linear,,Free,Amidation,,,0,GLRKRLRKFFNKIKEK
GLRKRLRKFRNKIKFK,16,Synthetic,Synthetic peptide,Human erythrocytes: <10% Hemolysis	=40 µM,HEK293: <10% Killing=40 µM,,,,Anticancer; Antibacterial,Tumor active peptide##Cell-penetrating peptides##Membrane-targeted,,Linear,,Free,Amidation,,,0,GLRKRLRKFRNKIKFK
GLRKRLRKFRNKIKEF,16,Synthetic,Synthetic peptide,Human erythrocytes: <10% Hemolysis	=40 µM,HEK293: Not active up to 40 µM,,,,Anticancer; Antibacterial,Tumor active peptide##Cell-penetrating peptides##Membrane-targeted,,Linear,,Free,Amidation,,,0,GLRKRLRKFRNKIKEF
GLEKRKRKFFNKIKFK,16,Synthetic,Synthetic peptide,Human erythrocytes: <10% Hemolysis	=40 µM,HEK293: 20% Killing=40 µM,,,,Anticancer; Antibacterial,Tumor active peptide##Cell-penetrating peptides##Membrane-targeted,,Linear,,Free,Amidation,,,0,GLEKRKRKFFNKIKFK
GLRKRLRKFFNKIKEF,16,Synthetic,Synthetic peptide,Human erythrocytes: <10% Hemolysis	=40 µM,HEK293: <5% Killing=40 µM,,,,Anticancer; Antibacterial,Tumor active peptide##Cell-penetrating peptides##Membrane-targeted,,Linear,,Free,Amidation,,,0,GLRKRLRKFFNKIKEF
GLRKRLRKFRNKIKFF,16,Synthetic,Synthetic peptide,Human erythrocytes: <10% Hemolysis	=40 µM,HEK293: Not active up to 40 µM,,,,Anticancer; Antibacterial,Tumor active peptide##Cell-penetrating peptides##Membrane-targeted,,Linear,,Free,Amidation,,,0,GLRKRLRKFRNKIKFF
GLRKRLRKFFNKIKFF,16,Synthetic,Synthetic peptide,Human erythrocytes: <10% Hemolysis	=40 µM,HEK293: 40% Killing=40 µM,,,,Anticancer; Antibacterial,Tumor active peptide##Cell-penetrating peptides##Membrane-targeted,,Linear,,Free,Amidation,,,0,GLRKRLRKFFNKIKFF
GLRKRLRKFRNKIKK,15,Synthetic,Synthetic peptide,Human erythrocytes: <10% Hemolysis	=40 µM,HEK293: <10% Killing=40 µM,,,,Anticancer; Antibacterial,Tumor active peptide##Cell-penetrating peptides##Membrane-targeted,,Linear,,Free,Amidation,,,0,GLRKRLRKFRNKIKK
GLRKRLRKFFNKIKF,15,Synthetic,Synthetic peptide,Human erythrocytes: <10% Hemolysis	=40 µM,HEK293: 20% Killing=40 µM,,,,Anticancer; Antibacterial,Tumor active peptide##Cell-penetrating peptides##Membrane-targeted,,Linear,,Free,Amidation,,,0,GLRKRLRKFFNKIKF
GLRKRLRKFXNKIKX,15,Synthetic,Synthetic peptide,Human erythrocytes: <10% Hemolysis	=40 µM,HEK293: <10% Killing=40 µM,,,,Anticancer; Antibacterial,Tumor active peptide##Cell-penetrating peptides##Membrane-targeted,,Linear,,Free,Amidation,X=4-F-Phe,,0,GLRKRLRKFXNKIKX
PWIPLTPL,8,Phakellia fusca,Native peptide,,,,,,Anticancer,Tumor active peptide,,Cyclic,NCB: Pro1<--->Leu8,Free,Free,,,0,PWIPLTPL
PFDSRAVTY,9,Phakellia fusca,Native peptide,,,,,,Anticancer,Tumor active peptide,,Cyclic,NCB: Pro1<--->Tyr9,Free,Free,,,0,PFDSRAVTY
PWVPLIPI,8,Phakellia fusca,Native peptide,,,,,,Anticancer,Tumor active peptide,,Cyclic,NCB: Pro1<--->Ile8,Free,Free,,,0,PWVPLIPI
PYPIFPI,7,Phakellia fusca,Native peptide,,,,,,Anticancer,Tumor active peptide,,Cyclic,NCB: Pro1<--->Ile7,Free,Free,,,0,PYPIFPI
IPWFPLTP,8,Phakellia fusca,Native peptide,,,,,,Anticancer,Tumor active peptide,,Cyclic,NCB: Ile1<--->Pro8,Free,Free,,,0,IPWFPLTP
PFNAXAI,7,Stylissa flabelliformis,Native peptide,,,,,,Anticancer,Tumor active peptide,,Cyclic,NCB: Pro1<--->Ile7,Free,Free,X=Methionine sulfone,,0,PFNAXAI
PPXFELPPYI,10,Stylissa flabelliformis,Native peptide,,,,,,Anticancer,Tumor active peptide,,Cyclic,NCB: Pro1<--->Ile7,Free,Free,X=Methionine sulfone,,0,PPXFELPPYI
IxPYPFP,7,Stylotella aurantium,Native peptide,,,,,,Anticancer,Tumor active peptide,,Cyclic,NCB: Ile1<--->Pro7,Free,Free,x=D-Allo-Ile,,0,IXPYPFP
PtPfiFS,7,Phakellia costata,Native peptide,,,,,,Anticancer,Tumor active peptide,,Cyclic,NCB: Pro1<--->Ser7,Free,Free,t=D-Thr; f=D-Phe; i=D-Ile,,0,PTPFIFS
lPPYvPPXfv,10,Phakellia costata,Native peptide,,,,,,Anticancer,Tumor active peptide,,Cyclic,NCB: Ile1<--->val10,Free,Free,X=Allo-Ile,,0,LPPYVPPXFV
QPFPfifp,8,Phakellia sp.,Native peptide,,,,,,Anticancer,Tumor active peptide,,Cyclic,NCB: Gln1<--->pro10,Free,Free,f=D-Phe; i=D-Ile,,0,QPFPFIFP
IFVLPPYIPP,10,Phakellia fusca,Native peptide,,,,,,Anticancer,Tumor active peptide,,Cyclic,NCB: Ile1<--->Pro10,Free,Free,,,0,IFVLPPYIPP
ANPRYPYT,8,Axinella carteri,Native peptide,,,,,,Anticancer,Tumor active peptide,,Cyclic,NCB: Ala1<--->Thr8,Free,Free,,,0,ANPRYPYT
IPYVPLTP,8,Phakellia sp.,Native peptide,,,,,,Anticancer,Tumor active peptide,,Cyclic,NCB: Glu1<--->Pro8,Free,Free,,,0,IPYVPLTP
AIPFNAM,7,Phakellia costada,Native peptide,,,,,,Anticancer,Tumor active peptide,,Cyclic,NCB: Ala1<--->Met7,Free,Free,,,0,AIPFNAM
PIPIFPY,7,Phakellia costata; Stylotella aurantium,Native peptide,,,,,,Anticancer,Tumor active peptide,,Cyclic,NCB: Pro1<--->Tyr7,Free,Free,,,0,PIPIFPY
PFGPTIX,7,Phakellia carteri,Native peptide,,,,,,Anticancer,Tumor active peptide,,Cyclic,NCB: Pro1<--->X7,Free,Free,X=Photo-Trp,,0,PFGPTIX
PFPWLPI,7,Phakellia costata,Native peptide,,,,,,Anticancer,Tumor active peptide,,Cyclic,NCB: Pro1<--->Ile7,Free,Free,,,0,PFPWLPI
PPIFALPPYI,10,Phakellia costata,Native peptide,,,,,,Anticancer,Tumor active peptide,,Cyclic,NCB: Pro1<--->Ile10,Free,Free,,,0,PPIFALPPYI
PPIFTLPPYI,10,Phakellia sp.,Native peptide,,,,,,Anticancer,Tumor active peptide,,Cyclic,NCB: Pro1<--->Ile10,Free,Free,,,0,PPIFTLPPYI
AIPFXAX,7,Phakellia sp,Native peptide,,,,,,Anticancer,Tumor active peptide,,Cyclic,NCB: Ala1<--->X7,Free,Free,X(5)=β-OMe-Asp; X(7)=Met(SO),,0,AIPFXAX
XP,2,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Cyclic,NCB: X1<--->Pro2,Free,Free,X=Prenylated-Trp,,0,XP
XG,2,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Cyclic,NCB: X1<--->Gly2,Free,Free,X=Prenylated-Trp,,0,XG
XL,2,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Cyclic,NCB: X1<--->Leu2,Free,Free,X=Prenylated-Trp,,0,XL
XW,2,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Cyclic,NCB: X1<--->Trp2,Free,Free,X=Prenylated-Trp,,0,XW
XY,2,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Cyclic,NCB: X1<--->Tyr2,Free,Free,X=Prenylated-Trp,,0,XY
XF,2,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Cyclic,NCB: X1<--->Phe2,Free,Free,X=Prenylated-Trp,,0,XF
Xp,2,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Cyclic,NCB: X1<--->pro2,Free,Free,X=Prenylated-Trp,,0,XP
XA,2,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Cyclic,NCB: X1<--->Ala2,Free,Free,X=Prenylated-Trp,,0,XA
Xa,2,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Cyclic,NCB: X1<--->ala2,Free,Free,X=Prenylated-Trp,,0,XA
xa,2,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Cyclic,NCB: X1<--->ala2,Free,Free,x=Prenylated-D-Trp,,0,XA
xA,2,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Cyclic,NCB: X1<--->Ala2,Free,Free,x=Prenylated-D-Trp,,0,XA
XH,2,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Cyclic,NCB: X1<--->His2,Free,Free,X=Prenylated-Trp,,0,XH
GL,2,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Cyclic,NCB: Gly1<--->Leu2,Free,Free,,,0,GL
GI,2,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Cyclic,NCB: Gly1<--->Ile2,Free,Free,,,0,GI
GV,2,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Cyclic,NCB: Gly1<--->Val2,Free,Free,,,0,GV
Gv,2,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Cyclic,NCB: Gly1<--->val2,Free,Free,,,0,GV
GC,2,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Cyclic,NCB: Gly1<--->Cys2,Free,Free,,,0,GC
YC,2,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Cyclic,NCB: Tyr1<--->Cys2,Free,Free,,,0,YC
VWKPPYLPRPRPPRrIYNr,19,Synthetic,Synthetic peptide,,HEK293: 32% Killing=600 µg/ml,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,,,0,VWKPPYLPRPRPPRRIYNR
VDRPPYLPRPRPPRrIYNr,19,Synthetic,Synthetic peptide,,HEK293: 42% Killing=600 µg/ml,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,,,0,VDRPPYLPRPRPPRRIYNR
VDKKPYLPRPRPPRrIYNr,19,Synthetic,Synthetic peptide,,HEK293: 42% Killing=600 µg/ml,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,,,0,VDKKPYLPRPRPPRRIYNR
VDKFPYLPRPRPPRrIYNr,19,Synthetic,Synthetic peptide,,HEK293: 48% Killing=600 µg/ml,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,,,0,VDKFPYLPRPRPPRRIYNR
VDKYPYLPRPRPPRrIYNr,19,Synthetic,Synthetic peptide,,HEK293: 45% Killing=600 µg/ml,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,,,0,VDKYPYLPRPRPPRRIYNR
VDKPFYLPRPRPPRrIYNr,19,Synthetic,Synthetic peptide,,HEK293: 44% Killing=600 µg/ml,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,,,0,VDKPFYLPRPRPPRRIYNR
VDKPYYLPRPRPPRrIYNr,19,Synthetic,Synthetic peptide,,HEK293: 45% Killing=600 µg/ml,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,,,0,VDKPYYLPRPRPPRRIYNR
VDKPHYLPRPRPPRrIYNr,19,Synthetic,Synthetic peptide,,HEK293: 46% Killing=600 µg/ml,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,,,0,VDKPHYLPRPRPPRRIYNR
VDKPRYLPRPRPPRrIYNr,19,Synthetic,Synthetic peptide,,HEK293: 42% Killing=600 µg/ml,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,,,0,VDKPRYLPRPRPPRRIYNR
VDKPPWLPRPRPPRrIYNr,19,Synthetic,Synthetic peptide,,HEK293: 55% Killing=600 µg/ml,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,,,0,VDKPPWLPRPRPPRRIYNR
VDKPPFLPRPRPPRrIYNr,19,Synthetic,Synthetic peptide,,HEK293: 45% Killing=600 µg/ml,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,,,0,VDKPPFLPRPRPPRRIYNR
VDKPPHLPRPRPPRrIYNr,19,Synthetic,Synthetic peptide,,HEK293: 56% Killing=600 µg/ml,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,,,0,VDKPPHLPRPRPPRRIYNR
VDKPPXLPRPRPPRrIYNr,19,Synthetic,Synthetic peptide,,HEK293: 44% Killing=600 µg/ml,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,"X=3,5‐Diiodotyrosine",,0,VDKPPXLPRPRPPRRIYNR
VDKPPYXPRPRPPRrIYNr,19,Synthetic,Synthetic peptide,,HEK293: 60% Killing=600 µg/ml,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,X=nor-Leu,,0,VDKPPYXPRPRPPRRIYNR
VDKPPYRPRPRPPRrIYNr,19,Synthetic,Synthetic peptide,,HEK293: 42% Killing=600 µg/ml,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,,,0,VDKPPYRPRPRPPRRIYNR
VDKPPYMPRPRPPRrIYNr,19,Synthetic,Synthetic peptide,,HEK293: 50% Killing=600 µg/ml,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,,,0,VDKPPYMPRPRPPRRIYNR
VDKPPYFPRPRPPRrIYNr,19,Synthetic,Synthetic peptide,,HEK293: 38% Killing=600 µg/ml,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,,,0,VDKPPYFPRPRPPRRIYNR
VDKPPYLPRWRPPRrIYNr,19,Synthetic,Synthetic peptide,,HEK293: 43% Killing=600 µg/ml,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,,,0,VDKPPYLPRWRPPRRIYNR
VDKPPYLPRPWPPRrIYNr,19,Synthetic,Synthetic peptide,,HEK293: 43% Killing=600 µg/ml,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,,,0,VDKPPYLPRPWPPRRIYNR
VDKPPYLPRPHPPRrIYNr,19,Synthetic,Synthetic peptide,,HEK293: 50% Killing=600 µg/ml,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,,,0,VDKPPYLPRPHPPRRIYNR
VDKPPYLPRPKPPRrIYNr,19,Synthetic,Synthetic peptide,,HEK293: 59% Killing=600 µg/ml,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,,,0,VDKPPYLPRPKPPRRIYNR
VDKPPYLPRPFPPRrIYNr,19,Synthetic,Synthetic peptide,,HEK293: 38% Killing=600 µg/ml,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,,,0,VDKPPYLPRPFPPRRIYNR
VDKPPYLPRPXPPRrIYNr,19,Synthetic,Synthetic peptide,,HEK293: 41% Killing=600 µg/ml,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,X=Homoarginine,,0,VDKPPYLPRPXPPRRIYNR
VDKPPYLPRPRPPRrIXNr,19,Synthetic,Synthetic peptide,,HEK293: 44% Killing=600 µg/ml,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,"X=3,5‐Diiodotyrosine",,0,VDKPPYLPRPRPPRRIXNR
VDKPPYLPRPRWPRrIYNr,19,Synthetic,Synthetic peptide,,HEK293: 38% Killing=600 µg/ml,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,,,0,VDKPPYLPRPRWPRRIYNR
VDKPPYLPRPRWERrIYNr,19,Synthetic,Synthetic peptide,,HEK293: 38% Killing=600 µg/ml,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,,,0,VDKPPYLPRPRWERRIYNR
VDKPPYLPRPRWRRrIYNr,19,Synthetic,Synthetic peptide,,HEK293: 44% Killing=600 µg/ml,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,,,0,VDKPPYLPRPRWRRRIYNR
VDKPPYLPRPRWWRrIYNr,19,Synthetic,Synthetic peptide,,HEK293: 57% Killing=600 µg/ml,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,,,0,VDKPPYLPRPRWWRRIYNR
VDKPPYLPRPRWKRrIYNr,19,Synthetic,Synthetic peptide,,HEK293: 48% Killing=600 µg/ml,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,,,0,VDKPPYLPRPRWKRRIYNR
VDKPPYLPRPRWHRrIYNr,19,Synthetic,Synthetic peptide,,HEK293: 50% Killing=600 µg/ml,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,,,0,VDKPPYLPRPRWHRRIYNR
VDKPPYLPRPRWIRrIYNr,19,Synthetic,Synthetic peptide,,HEK293: 44% Killing=600 µg/ml,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,,,0,VDKPPYLPRPRWIRRIYNR
VDKPPYLPRPRWFRrIYNr,19,Synthetic,Synthetic peptide,,HEK293: 48% Killing=600 µg/ml,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,,,0,VDKPPYLPRPRWFRRIYNR
VDKPPYLPRPRWLRrIYNr,19,Synthetic,Synthetic peptide,,HEK293: 44% Killing=600 µg/ml,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,,,0,VDKPPYLPRPRWLRRIYNR
VDKPPYLPRPRWARrIYNr,19,Synthetic,Synthetic peptide,,HEK293: 46% Killing=600 µg/ml,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,,,0,VDKPPYLPRPRWARRIYNR
VDKPPYLPRPRWNRrIYNr,19,Synthetic,Synthetic peptide,,HEK293: 42% Killing=600 µg/ml,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,,,0,VDKPPYLPRPRWNRRIYNR
VDKPPYLPRPRWVRrIYNr,19,Synthetic,Synthetic peptide,,HEK293: 28% Killing=600 µg/ml,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,,,0,VDKPPYLPRPRWVRRIYNR
VDKPPYLPRPRWGRrIYNr,19,Synthetic,Synthetic peptide,,HEK293: 28% Killing=600 µg/ml,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,,,0,VDKPPYLPRPRWGRRIYNR
VDKPPYLPRPRWSRrIYNr,19,Synthetic,Synthetic peptide,,HEK293: 34% Killing=600 µg/ml,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,,,0,VDKPPYLPRPRWSRRIYNR
VDKPPYLPRPRWQRrIYNr,19,Synthetic,Synthetic peptide,,HEK293: 36% Killing=600 µg/ml,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,,,0,VDKPPYLPRPRWQRRIYNR
VDKPPYLPRPRWYRrIYNr,19,Synthetic,Synthetic peptide,,HEK293: 42% Killing=600 µg/ml,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,,,0,VDKPPYLPRPRWYRRIYNR
VDKPPYLPRPRWDRrIYNr,19,Synthetic,Synthetic peptide,,HEK293: 28% Killing=600 µg/ml,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,,,0,VDKPPYLPRPRWDRRIYNR
VDKPPYLPRPRWTRrIYNr,19,Synthetic,Synthetic peptide,,HEK293: 38% Killing=600 µg/ml,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,,,0,VDKPPYLPRPRWTRRIYNR
VDKPPYLPRPRWXRrIYNr,19,Synthetic,Synthetic peptide,,HEK293: 42% Killing=600 µg/ml,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,X=Orn,,0,VDKPPYLPRPRWXRRIYNR
VLPILLLVL,9,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide##Induce apoptosis,,Cyclic,NCB: Val1<--->Leu9,Free,Free,,,0,VLPILLLVL
VLPILLLVA,9,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide##Induce apoptosis,,Cyclic,NCB: Val1<--->Ala9,Free,Free,,,0,VLPILLLVA
VLPILLLAL,9,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide##Induce apoptosis,,Cyclic,NCB: Val1<--->Leu9,Free,Free,,,0,VLPILLLAL
VLPILLAVL,9,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide##Induce apoptosis,,Cyclic,NCB: Val1<--->Leu9,Free,Free,,,0,VLPILLAVL
VLPILALVL,9,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide##Induce apoptosis,,Cyclic,NCB: Val1<--->Leu9,Free,Free,,,0,VLPILALVL
VLPIALLVL,9,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide##Induce apoptosis,,Cyclic,NCB: Val1<--->Leu9,Free,Free,,,0,VLPIALLVL
VLPALLLVL,9,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide##Induce apoptosis,,Cyclic,NCB: Val1<--->Leu9,Free,Free,,,0,VLPALLLVL
VAPILLLVL,9,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide##Induce apoptosis,,Cyclic,NCB: Val1<--->Leu9,Free,Free,,,0,VAPILLLVL
ALPILLLVL,9,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide##Induce apoptosis,,Cyclic,NCB: Ala1<--->Leu9,Free,Free,,,0,ALPILLLVL
VLPILLLV,8,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide##Induce apoptosis,,Cyclic,NCB: Val1<--->Val8,Free,Free,,,0,VLPILLLV
VLPILLL,7,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide##Induce apoptosis,,Cyclic,NCB: Val1<--->Leu7,Free,Free,,,0,VLPILLL
VLPILL,6,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide##Induce apoptosis,,Cyclic,NCB: Val1<--->Leu6,Free,Free,,,0,VLPILL
VLPIL,5,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide##Induce apoptosis,,Cyclic,NCB: Val1<--->Leu5,Free,Free,,,0,VLPIL
EQWAREIGAQLRRMADDLNA,20,Synthetic,Synthetic peptide,,,Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,EQWAREIGAQLRRMADDLNA
RPEIWYAQGLKRFGDEFNAYYAR,23,Synthetic,Synthetic peptide,,,Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,RPEIWYAQGLKRFGDEFNAYYAR
RPEIWYAQWLKRFGDQFNAYYAR,23,Synthetic,Synthetic peptide,,,Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,RPEIWYAQWLKRFGDQFNAYYAR
RPEIWIAQGLKRFGDEFNAYYAR,23,Synthetic,Synthetic peptide,,,Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,RPEIWIAQGLKRFGDEFNAYYAR
RPEIWYAQELKRFGDEFNAYYAR,23,Synthetic,Synthetic peptide,,,Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Bcl-xL inhibitors##BH3 peptides and mimeticss and mimetics,,Linear,,Free,Free,,,0,RPEIWYAQELKRFGDEFNAYYAR
RPEIWYAQGLRRFGDEFNAYYAR,23,Synthetic,Synthetic peptide,,,Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,RPEIWYAQGLRRFGDEFNAYYAR
RPEIWYAQGLKRIGDEFNAYYAR,23,Synthetic,Synthetic peptide,,,Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,RPEIWYAQGLKRIGDEFNAYYAR
RPEIWYAQGLKRFGDEFNAYKAR,23,Synthetic,Synthetic peptide,,,Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,RPEIWYAQGLKRFGDEFNAYKAR
IWYAQGLKRFGDEFNAYK,18,Synthetic,Synthetic peptide,,,Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,IWYAQGLKRFGDEFNAYK
RPEIWYAQGLKRFGDEFNAYK,21,Synthetic,Synthetic peptide,,,Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,RPEIWYAQGLKRFGDEFNAYK
LRPEIRYAQELRRIGDEFNE,20,Synthetic,Synthetic peptide,,,Bcl-2/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Bcl-xL/Bac-2 inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,LRPEIRYAQELRRIGDEFNE
LWAAIRIAQELRRIGDEFNE,20,Synthetic,Synthetic peptide,,,Bcl-2/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Bcl-xL/Bac-2 inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,LWAAIRIAQELRRIGDEFNE
LRPEIRIARELRRIGDEFNE,20,Synthetic,Synthetic peptide,,,Bcl-2/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Bcl-xL/Bac-2 inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,LRPEIRIARELRRIGDEFNE
LRPEIRIAQELRRMGDEFNE,20,Synthetic,Synthetic peptide,,,Bcl-2/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Bcl-xL/Bac-2 inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,LRPEIRIAQELRRMGDEFNE
LRPEIRYARELRRIGDEFNE,20,Synthetic,Synthetic peptide,,,Bcl-2/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Bcl-xL/Bac-2 inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,LRPEIRYARELRRIGDEFNE
LRPEIRYAQELRRMGDEFNE,20,Synthetic,Synthetic peptide,,,Bcl-2/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Bcl-xL/Bac-2 inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,LRPEIRYAQELRRMGDEFNE
PQMVILQLLRFIFRLVWRRH,20,Synthetic,Synthetic peptide,,,Bcl-2/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Bcl-xL/Bac-2 inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,PQMVILQLLRFIFRLVWRRH
PQMVELQLLRFIFRLVWRRH,20,Synthetic,Synthetic peptide,,,Bcl-2/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Bcl-xL/Bac-2 inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,PQMVELQLLRFIFRLVWRRH
PQMVILQLERFIFRLVWRRH,20,Synthetic,Synthetic peptide,,,Bcl-2/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Bcl-xL/Bac-2 inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,PQMVILQLERFIFRLVWRRH
PQMVILQLLRFEFRLVWRRH,20,Synthetic,Synthetic peptide,,,Bcl-2/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Bcl-xL/Bac-2 inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,PQMVILQLLRFEFRLVWRRH
PQMVILQLLRFIFRLEWRRH,20,Synthetic,Synthetic peptide,,,Bcl-2/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Bcl-xL/Bac-2 inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,PQMVILQLLRFIFRLEWRRH
PQMVILQLLAFIFALVWRRH,20,Synthetic,Synthetic peptide,,,Bcl-2/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Bcl-xL/Bac-2 inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,PQMVILQLLAFIFALVWRRH
IWIAQELRRIGDEFNA,16,Synthetic,Synthetic peptide,,,Bcl-2,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Bac-2 inhibitors##BH3 peptides and mimetics,,Linear,,Acetylation,Amidation,,,0,IWIAQELRRIGDEFNA
IWIAQELRRIGDEF,14,Synthetic,Synthetic peptide,,,Bcl-2,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Bac-2 inhibitors##BH3 peptides and mimetics,,Linear,,Acetylation,Amidation,,,0,IWIAQELRRIGDEF
IAQELRRIGDEFNA,14,Synthetic,Synthetic peptide,,,Bcl-2,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Bac-2 inhibitors##BH3 peptides and mimetics,,Linear,,Acetylation,Amidation,,,0,IAQELRRIGDEFNA
WIAQELRRIGDEFN,14,Synthetic,Synthetic peptide,,,Bcl-2,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Bac-2 inhibitors##BH3 peptides and mimetics,,Linear,,Acetylation,Amidation,,,0,WIAQELRRIGDEFN
IAQELRRIGDEF,12,Synthetic,Synthetic peptide,,,Bcl-2,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Bac-2 inhibitors##BH3 peptides and mimetics,,Linear,,Acetylation,Amidation,,,0,IAQELRRIGDEF
EIWIAQELRRRGDSFNAYYAR,21,Synthetic,Synthetic peptide,,,Bcl-2/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Bcl-xL/Bac-2 inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,EIWIAQELRRRGDSFNAYYAR
EIWIAQELRRRGDXFNAYYAR,21,Synthetic,Synthetic peptide,,,Bcl-2/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Bcl-xL/Bac-2 inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,X=Phosphorylated-Ser,,0,EIWIAQELRRRGDXFNAYYAR
EIWIAQELRRRGDAFNAYYAR,21,Synthetic,Synthetic peptide,,,Bcl-2/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Bcl-xL/Bac-2 inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,EIWIAQELRRRGDAFNAYYAR
EIWIAQELRSRGDSFNAYYAR,21,Synthetic,Synthetic peptide,,,Bcl-2/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Bcl-xL/Bac-2 inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,EIWIAQELRSRGDSFNAYYAR
EIWIAQELRSRGDXFNAYYAR,21,Synthetic,Synthetic peptide,,,Bcl-2/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Bcl-xL/Bac-2 inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,X=Phosphorylated-Ser,,0,EIWIAQELRSRGDXFNAYYAR
EIWIAQELRRIGDSFNAYYAR,21,Synthetic,Synthetic peptide,,,Bcl-2/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Bcl-xL/Bac-2 inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,EIWIAQELRRIGDSFNAYYAR
LWAAQRYGRELRRMSDEFEGSFKGL,25,Synthetic,Synthetic peptide,,,Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,LWAAQRYGRELRRMSDEFEGSFKGL
RPEIWMTQGLRRLGDEINAYYAR,23,Synthetic,Synthetic peptide,,,Mcl-1,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1 inhibitors##BH3 peptides and mimetics,,Linear,,5/6-Fluorescein amidite,Amidation,,,0,RPEIWMTQGLRRLGDEINAYYAR
RPEIWLTQSLQRLGDEINAYYAR,23,Synthetic,Synthetic peptide,,,Mcl-1,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1 inhibitors##BH3 peptides and mimetics,,Linear,,5/6-Fluorescein amidite,Amidation,,,0,RPEIWLTQSLQRLGDEINAYYAR
RPEIWLTQHLQRLGDEINAYYAR,23,Synthetic,Synthetic peptide,,,Mcl-1,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1 inhibitors##BH3 peptides and mimetics,,Linear,,5/6-Fluorescein amidite,Amidation,,,0,RPEIWLTQHLQRLGDEINAYYAR
RPEIWMGQGLRRLGDEINAYYAR,23,Synthetic,Synthetic peptide,,,Mcl-1,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1 inhibitors##BH3 peptides and mimetics,,Linear,,5/6-Fluorescein amidite,Amidation,,,0,RPEIWMGQGLRRLGDEINAYYAR
RPEIWLGQSLQRLGDEINAYYAR,23,Synthetic,Synthetic peptide,,,Mcl-1,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1 inhibitors##BH3 peptides and mimetics,,Linear,,5/6-Fluorescein amidite,Amidation,,,0,RPEIWLGQSLQRLGDEINAYYAR
RPEIWLGQHLQRLGDEINAYYAR,23,Synthetic,Synthetic peptide,,,Mcl-1,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1 inhibitors##BH3 peptides and mimetics,,Linear,,5/6-Fluorescein amidite,Amidation,,,0,RPEIWLGQHLQRLGDEINAYYAR
AELPPEFAAQLRKIGDKVYC,20,Synthetic,Synthetic peptide,,,Mcl-1,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1 inhibitors##BH3 peptides and mimetics,,Linear,,5/6-Fluorescein amidite,Amidation,,,0,AELPPEFAAQLRKIGDKVYC
RPEIWIAQELRRIGDEFNAYYAR,23,Synthetic,Synthetic peptide,,,Mcl-1,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1 inhibitors##BH3 peptides and mimetics,,Linear,,5/6-Fluorescein amidite,Amidation,,,0,RPEIWIAQELRRIGDEFNAYYAR
RPEIWITQELRRIGDEFNAYYAR,23,Synthetic,Synthetic peptide,,,Mcl-1,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1 inhibitors##BH3 peptides and mimetics,,Linear,,5/6-Fluorescein amidite,Amidation,,,0,RPEIWITQELRRIGDEFNAYYAR
RPEIWMTQELRRIGDEFNAYYAR,23,Synthetic,Synthetic peptide,,,Mcl-1,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1 inhibitors##BH3 peptides and mimetics,,Linear,,5/6-Fluorescein amidite,Amidation,,,0,RPEIWMTQELRRIGDEFNAYYAR
RPEIWITQGLRRIGDEFNAYYAR,23,Synthetic,Synthetic peptide,,,Mcl-1,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1 inhibitors##BH3 peptides and mimetics,,Linear,,5/6-Fluorescein amidite,Amidation,,,0,RPEIWITQGLRRIGDEFNAYYAR
RPEIWITQELRRLGDEFNAYYAR,23,Synthetic,Synthetic peptide,,,Mcl-1,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1 inhibitors##BH3 peptides and mimetics,,Linear,,5/6-Fluorescein amidite,Amidation,,,0,RPEIWITQELRRLGDEFNAYYAR
RPEIWITQELRRIGDEINAYYAR,23,Synthetic,Synthetic peptide,,,Mcl-1,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1 inhibitors##BH3 peptides and mimetics,,Linear,,5/6-Fluorescein amidite,Amidation,,,0,RPEIWITQELRRIGDEINAYYAR
RPEIWLAQYLRRLGDQINAYYAR,23,Synthetic,Synthetic peptide,,,Bfl-1,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Bfl-1 inhibitors##BH3 peptides and mimetics,,Linear,,Acetylation,Amidation,,,0,RPEIWLAQYLRRLGDQINAYYAR
RPEIWMAQVLRRFGDLLNAYYAR,23,Synthetic,Synthetic peptide,,,Bfl-1,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Bfl-1 inhibitors##BH3 peptides and mimetics,,Linear,,Free,Amidation,,,0,RPEIWMAQVLRRFGDLLNAYYAR
RPEIWIAQELRRAGDVLNAYYAR,23,Synthetic,Synthetic peptide,,,Bfl-1,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Bfl-1 inhibitors##BH3 peptides and mimetics,,Linear,,Acetylation,Amidation,,,0,RPEIWIAQELRRAGDVLNAYYAR
RPEIWIAQGLRRIGDTWNAYYAR,23,Synthetic,Synthetic peptide,,,Bfl-1,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Bfl-1 inhibitors##BH3 peptides and mimetics,,Linear,,Acetylation,Amidation,,,0,RPEIWIAQGLRRIGDTWNAYYAR
MRPEIWIAQELRRIGDEVNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWIAQELRRIGDEVNAYYARRVZ
MRPEIWIAQELRRIGDENNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWIAQELRRIGDENNAYYARRVZ
MRPEIWIAQELRRFGDEFNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWIAQELRRFGDEFNAYYARRVZ
MRPEIWIAQELRRFGDEVNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWIAQELRRFGDEVNAYYARRVZ
MRPEIWIAQELRRFGDENNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWIAQELRRFGDENNAYYARRVZ
MRPEIWIAQELRRDGDEFNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWIAQELRRDGDEFNAYYARRVZ
MRPEIWIAQELRRDGDEVNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWIAQELRRDGDEVNAYYARRVZ
MRPEIWIAQELRRDGDENNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWIAQELRRDGDENNAYYARRVZ
MRPEIWIAQELRRNGDEFNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWIAQELRRNGDEFNAYYARRVZ
MRPEIWIAQELRRNGDEVNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWIAQELRRNGDEVNAYYARRVZ
MRPEIWIAQELRRNGDENNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWIAQELRRNGDENNAYYARRVZ
MRPEIWIAQELRRAGDEFNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWIAQELRRAGDEFNAYYARRVZ
MRPEIWIAQELRRAGDEVNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWIAQELRRAGDEVNAYYARRVZ
MRPEIWIAQELRRAGDENNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWIAQELRRAGDENNAYYARRVZ
MRPEIWIAQELDRIGDEFNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWIAQELDRIGDEFNAYYARRVZ
MRPEIWIAQELDRIGDEVNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWIAQELDRIGDEVNAYYARRVZ
MRPEIWIAQELDRIGDENNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWIAQELDRIGDENNAYYARRVZ
MRPEIWIAQELDRFGDEFNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWIAQELDRFGDEFNAYYARRVZ
MRPEIWIAQELDRFGDEVNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWIAQELDRFGDEVNAYYARRVZ
MRPEIWIAQELDRFGDENNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWIAQELDRFGDENNAYYARRVZ
MRPEIWIAQELDRDGDEFNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWIAQELDRDGDEFNAYYARRVZ
MRPEIWIAQELDRDGDEVNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWIAQELDRDGDEVNAYYARRVZ
MRPEIWIAQELDRDGDENNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWIAQELDRDGDENNAYYARRVZ
MRPEIWIAQELDRNGDEFNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWIAQELDRNGDEFNAYYARRVZ
MRPEIWIAQELDRNGDEVNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWIAQELDRNGDEVNAYYARRVZ
MRPEIWIAQELDRNGDENNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWIAQELDRNGDENNAYYARRVZ
MRPEIWIAQELDRAGDEFNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWIAQELDRAGDEFNAYYARRVZ
MRPEIWIAQELDRAGDEVNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWIAQELDRAGDEVNAYYARRVZ
MRPEIWIAQELDRAGDENNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWIAQELDRAGDENNAYYARRVZ
MRPEIWIAQEIRRIGDEFNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWIAQEIRRIGDEFNAYYARRVZ
MRPEIWIAQEIRRIGDEVNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWIAQEIRRIGDEVNAYYARRVZ
MRPEIWIAQEIRRIGDENNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWIAQEIRRIGDENNAYYARRVZ
MRPEIWIAQEIRRFGDEFNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWIAQEIRRFGDEFNAYYARRVZ
MRPEIWIAQEIRRFGDEVNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWIAQEIRRFGDEVNAYYARRVZ
MRPEIWIAQEIRRFGDENNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWIAQEIRRFGDENNAYYARRVZ
MRPEIWIAQEIRRDGDEFNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWIAQEIRRDGDEFNAYYARRVZ
MRPEIWIAQEIRRDGDEVNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWIAQEIRRDGDEVNAYYARRVZ
MRPEIWIAQEIRRDGDENNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWIAQEIRRDGDENNAYYARRVZ
MRPEIWIAQEIRRNGDEFNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWIAQEIRRNGDEFNAYYARRVZ
MRPEIWIAQEIRRNGDEVNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWIAQEIRRNGDEVNAYYARRVZ
MRPEIWIAQEIRRNGDENNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWIAQEIRRNGDENNAYYARRVZ
MRPEIWIAQEIRRAGDEFNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWIAQEIRRAGDEFNAYYARRVZ
MRPEIWIAQEIRRAGDEVNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWIAQEIRRAGDEVNAYYARRVZ
MRPEIWIAQEIRRAGDENNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWIAQEIRRAGDENNAYYARRVZ
MRPEIWIAQEIDRIGDEFNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWIAQEIDRIGDEFNAYYARRVZ
MRPEIWIAQEIDRIGDEVNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWIAQEIDRIGDEVNAYYARRVZ
MRPEIWIAQEIDRIGDENNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWIAQEIDRIGDENNAYYARRVZ
MRPEIWIAQEIDRFGDEFNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWIAQEIDRFGDEFNAYYARRVZ
MRPEIWIAQEIDRFGDEVNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWIAQEIDRFGDEVNAYYARRVZ
MRPEIWIAQEIDRFGDENNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWIAQEIDRFGDENNAYYARRVZ
MRPEIWIAQEIDRDGDEFNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWIAQEIDRDGDEFNAYYARRVZ
MRPEIWIAQEIDRDGDEVNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWIAQEIDRDGDEVNAYYARRVZ
MRPEIWIAQEIDRDGDENNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWIAQEIDRDGDENNAYYARRVZ
MRPEIWIAQEIDRNGDEFNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWIAQEIDRNGDEFNAYYARRVZ
MRPEIWIAQEIDRNGDEVNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWIAQEIDRNGDEVNAYYARRVZ
MRPEIWIAQEIDRNGDENNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWIAQEIDRNGDENNAYYARRVZ
MRPEIWIAQEIDRAGDEFNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWIAQEIDRAGDEFNAYYARRVZ
MRPEIWIAQEIDRAGDEVNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWIAQEIDRAGDEVNAYYARRVZ
MRPEIWIAQEIDRAGDENNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWIAQEIDRAGDENNAYYARRVZ
MRPEIWIAQEFRRIGDEFNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWIAQEFRRIGDEFNAYYARRVZ
MRPEIWIAQEFRRIGDEVNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWIAQEFRRIGDEVNAYYARRVZ
MRPEIWIAQEFRRIGDENNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWIAQEFRRIGDENNAYYARRVZ
MRPEIWIAQEFRRFGDEFNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWIAQEFRRFGDEFNAYYARRVZ
MRPEIWIAQEFRRFGDEVNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWIAQEFRRFGDEVNAYYARRVZ
MRPEIWIAQEFRRFGDENNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWIAQEFRRFGDENNAYYARRVZ
MRPEIWIAQEFRRDGDEFNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWIAQEFRRDGDEFNAYYARRVZ
MRPEIWIAQEFRRDGDEVNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWIAQEFRRDGDEVNAYYARRVZ
MRPEIWIAQEFRRDGDENNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWIAQEFRRDGDENNAYYARRVZ
MRPEIWIAQEFRRNGDEFNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWIAQEFRRNGDEFNAYYARRVZ
MRPEIWIAQEFRRNGDEVNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWIAQEFRRNGDEVNAYYARRVZ
MRPEIWIAQEFRRNGDENNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWIAQEFRRNGDENNAYYARRVZ
MRPEIWIAQEFRRAGDEFNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWIAQEFRRAGDEFNAYYARRVZ
MRPEIWIAQEFRRAGDEVNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWIAQEFRRAGDEVNAYYARRVZ
MRPEIWIAQEFRRAGDENNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWIAQEFRRAGDENNAYYARRVZ
MRPEIWIAQEFDRIGDEFNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWIAQEFDRIGDEFNAYYARRVZ
MRPEIWIAQEFDRIGDEVNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWIAQEFDRIGDEVNAYYARRVZ
MRPEIWIAQEFDRIGDENNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWIAQEFDRIGDENNAYYARRVZ
MRPEIWIAQEFDRFGDEFNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWIAQEFDRFGDEFNAYYARRVZ
MRPEIWIAQEFDRFGDEVNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWIAQEFDRFGDEVNAYYARRVZ
MRPEIWIAQEFDRFGDENNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWIAQEFDRFGDENNAYYARRVZ
MRPEIWIAQEFDRDGDEFNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWIAQEFDRDGDEFNAYYARRVZ
MRPEIWIAQEFDRDGDEVNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWIAQEFDRDGDEVNAYYARRVZ
MRPEIWIAQEFDRDGDENNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWIAQEFDRDGDENNAYYARRVZ
MRPEIWIAQEFDRNGDEFNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWIAQEFDRNGDEFNAYYARRVZ
MRPEIWIAQEFDRNGDEVNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWIAQEFDRNGDEVNAYYARRVZ
MRPEIWIAQEFDRNGDENNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWIAQEFDRNGDENNAYYARRVZ
MRPEIWIAQEFDRAGDEFNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWIAQEFDRAGDEFNAYYARRVZ
MRPEIWIAQEFDRAGDEVNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWIAQEFDRAGDEVNAYYARRVZ
MRPEIWIAQEFDRAGDENNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWIAQEFDRAGDENNAYYARRVZ
MRPEIWIAQEARRIGDEFNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWIAQEARRIGDEFNAYYARRVZ
MRPEIWIAQEARRIGDEVNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWIAQEARRIGDEVNAYYARRVZ
MRPEIWIAQEARRIGDENNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWIAQEARRIGDENNAYYARRVZ
MRPEIWIAQEARRFGDEFNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWIAQEARRFGDEFNAYYARRVZ
MRPEIWIAQEARRFGDEVNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWIAQEARRFGDEVNAYYARRVZ
MRPEIWIAQEARRFGDENNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWIAQEARRFGDENNAYYARRVZ
MRPEIWIAQEARRDGDEFNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWIAQEARRDGDEFNAYYARRVZ
MRPEIWIAQEARRDGDEVNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWIAQEARRDGDEVNAYYARRVZ
MRPEIWIAQEARRDGDENNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWIAQEARRDGDENNAYYARRVZ
MRPEIWIAQEARRNGDEFNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWIAQEARRNGDEFNAYYARRVZ
MRPEIWIAQEARRNGDEVNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWIAQEARRNGDEVNAYYARRVZ
MRPEIWIAQEARRNGDENNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWIAQEARRNGDENNAYYARRVZ
MRPEIWIAQEARRAGDEFNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWIAQEARRAGDEFNAYYARRVZ
MRPEIWIAQEARRAGDEVNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWIAQEARRAGDEVNAYYARRVZ
MRPEIWIAQEARRAGDENNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWIAQEARRAGDENNAYYARRVZ
MRPEIWIAQEADRIGDEFNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWIAQEADRIGDEFNAYYARRVZ
MRPEIWIAQEADRIGDEVNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWIAQEADRIGDEVNAYYARRVZ
MRPEIWIAQEADRIGDENNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWIAQEADRIGDENNAYYARRVZ
MRPEIWIAQEADRFGDEFNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWIAQEADRFGDEFNAYYARRVZ
MRPEIWIAQEADRFGDEVNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWIAQEADRFGDEVNAYYARRVZ
MRPEIWIAQEADRFGDENNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWIAQEADRFGDENNAYYARRVZ
MRPEIWIAQEADRDGDEFNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWIAQEADRDGDEFNAYYARRVZ
MRPEIWIAQEADRDGDEVNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWIAQEADRDGDEVNAYYARRVZ
MRPEIWIAQEADRDGDENNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWIAQEADRDGDENNAYYARRVZ
MRPEIWIAQEADRNGDEFNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWIAQEADRNGDEFNAYYARRVZ
MRPEIWIAQEADRNGDEVNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWIAQEADRNGDEVNAYYARRVZ
MRPEIWIAQEADRNGDENNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWIAQEADRNGDENNAYYARRVZ
MRPEIWIAQEADRAGDEFNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWIAQEADRAGDEFNAYYARRVZ
MRPEIWIAQEADRAGDEVNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWIAQEADRAGDEVNAYYARRVZ
MRPEIWIAQEADRAGDENNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWIAQEADRAGDENNAYYARRVZ
MRPEIWAAQELRRIGDEFNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWAAQELRRIGDEFNAYYARRVZ
MRPEIWAAQELRRIGDEVNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWAAQELRRIGDEVNAYYARRVZ
MRPEIWAAQELRRIGDENNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWAAQELRRIGDENNAYYARRVZ
MRPEIWAAQELRRFGDEFNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWAAQELRRFGDEFNAYYARRVZ
MRPEIWAAQELRRFGDEVNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWAAQELRRFGDEVNAYYARRVZ
MRPEIWAAQELRRFGDENNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWAAQELRRFGDENNAYYARRVZ
MRPEIWAAQELRRDGDEFNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWAAQELRRDGDEFNAYYARRVZ
MRPEIWAAQELRRDGDEVNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWAAQELRRDGDEVNAYYARRVZ
MRPEIWAAQELRRDGDENNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWAAQELRRDGDENNAYYARRVZ
MRPEIWAAQELRRNGDEFNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWAAQELRRNGDEFNAYYARRVZ
MRPEIWAAQELRRNGDEVNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWAAQELRRNGDEVNAYYARRVZ
MRPEIWAAQELRRNGDENNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWAAQELRRNGDENNAYYARRVZ
MRPEIWAAQELRRAGDEFNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWAAQELRRAGDEFNAYYARRVZ
MRPEIWAAQELRRAGDEVNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWAAQELRRAGDEVNAYYARRVZ
MRPEIWAAQELRRAGDENNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWAAQELRRAGDENNAYYARRVZ
MRPEIWAAQELDRIGDEFNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWAAQELDRIGDEFNAYYARRVZ
MRPEIWAAQELDRIGDEVNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWAAQELDRIGDEVNAYYARRVZ
MRPEIWAAQELDRIGDENNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWAAQELDRIGDENNAYYARRVZ
MRPEIWAAQELDRFGDEFNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWAAQELDRFGDEFNAYYARRVZ
MRPEIWAAQELDRFGDEVNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWAAQELDRFGDEVNAYYARRVZ
MRPEIWAAQELDRFGDENNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWAAQELDRFGDENNAYYARRVZ
MRPEIWAAQELDRDGDEFNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWAAQELDRDGDEFNAYYARRVZ
MRPEIWAAQELDRDGDEVNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWAAQELDRDGDEVNAYYARRVZ
MRPEIWAAQELDRDGDENNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWAAQELDRDGDENNAYYARRVZ
MRPEIWAAQELDRNGDEFNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWAAQELDRNGDEFNAYYARRVZ
MRPEIWAAQELDRNGDEVNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWAAQELDRNGDEVNAYYARRVZ
MRPEIWAAQELDRNGDENNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWAAQELDRNGDENNAYYARRVZ
MRPEIWAAQELDRAGDEFNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWAAQELDRAGDEFNAYYARRVZ
MRPEIWAAQELDRAGDEVNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWAAQELDRAGDEVNAYYARRVZ
MRPEIWAAQELDRAGDENNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWAAQELDRAGDENNAYYARRVZ
MRPEIWAAQEIRRIGDEFNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWAAQEIRRIGDEFNAYYARRVZ
MRPEIWAAQEIRRIGDEVNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWAAQEIRRIGDEVNAYYARRVZ
MRPEIWAAQEIRRIGDENNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWAAQEIRRIGDENNAYYARRVZ
MRPEIWAAQEIRRFGDEFNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWAAQEIRRFGDEFNAYYARRVZ
MRPEIWAAQEIRRFGDEVNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWAAQEIRRFGDEVNAYYARRVZ
MRPEIWAAQEIRRFGDENNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWAAQEIRRFGDENNAYYARRVZ
MRPEIWAAQEIRRDGDEFNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWAAQEIRRDGDEFNAYYARRVZ
MRPEIWAAQEIRRDGDEVNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWAAQEIRRDGDEVNAYYARRVZ
MRPEIWAAQEIRRDGDENNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWAAQEIRRDGDENNAYYARRVZ
MRPEIWAAQEIRRNGDEFNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWAAQEIRRNGDEFNAYYARRVZ
MRPEIWAAQEIRRNGDEVNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWAAQEIRRNGDEVNAYYARRVZ
MRPEIWAAQEIRRNGDENNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWAAQEIRRNGDENNAYYARRVZ
MRPEIWAAQEIRRAGDEFNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWAAQEIRRAGDEFNAYYARRVZ
MRPEIWAAQEIRRAGDEVNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWAAQEIRRAGDEVNAYYARRVZ
MRPEIWAAQEIRRAGDENNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWAAQEIRRAGDENNAYYARRVZ
MRPEIWAAQEIDRIGDEFNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWAAQEIDRIGDEFNAYYARRVZ
MRPEIWAAQEIDRIGDEVNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWAAQEIDRIGDEVNAYYARRVZ
MRPEIWAAQEIDRIGDENNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWAAQEIDRIGDENNAYYARRVZ
MRPEIWAAQEIDRFGDEFNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWAAQEIDRFGDEFNAYYARRVZ
MRPEIWAAQEIDRFGDEVNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWAAQEIDRFGDEVNAYYARRVZ
MRPEIWAAQEIDRFGDENNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWAAQEIDRFGDENNAYYARRVZ
MRPEIWAAQEIDRDGDEFNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWAAQEIDRDGDEFNAYYARRVZ
MRPEIWAAQEIDRDGDEVNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWAAQEIDRDGDEVNAYYARRVZ
MRPEIWAAQEIDRDGDENNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWAAQEIDRDGDENNAYYARRVZ
MRPEIWAAQEIDRNGDEFNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWAAQEIDRNGDEFNAYYARRVZ
MRPEIWAAQEIDRNGDEVNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWAAQEIDRNGDEVNAYYARRVZ
MRPEIWAAQEIDRNGDENNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWAAQEIDRNGDENNAYYARRVZ
MRPEIWAAQEIDRAGDEFNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWAAQEIDRAGDEFNAYYARRVZ
MRPEIWAAQEIDRAGDEVNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWAAQEIDRAGDEVNAYYARRVZ
MRPEIWAAQEIDRAGDENNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWAAQEIDRAGDENNAYYARRVZ
MRPEIWAAQEFRRIGDEFNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWAAQEFRRIGDEFNAYYARRVZ
MRPEIWAAQEFRRIGDEVNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWAAQEFRRIGDEVNAYYARRVZ
MRPEIWAAQEFRRIGDENNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWAAQEFRRIGDENNAYYARRVZ
MRPEIWAAQEFRRFGDEFNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWAAQEFRRFGDEFNAYYARRVZ
MRPEIWAAQEFRRFGDEVNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWAAQEFRRFGDEVNAYYARRVZ
MRPEIWAAQEFRRFGDENNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWAAQEFRRFGDENNAYYARRVZ
MRPEIWAAQEFRRDGDEFNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWAAQEFRRDGDEFNAYYARRVZ
MRPEIWAAQEFRRDGDEVNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWAAQEFRRDGDEVNAYYARRVZ
MRPEIWAAQEFRRDGDENNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWAAQEFRRDGDENNAYYARRVZ
MRPEIWAAQEFRRNGDEFNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWAAQEFRRNGDEFNAYYARRVZ
MRPEIWAAQEFRRNGDEVNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWAAQEFRRNGDEVNAYYARRVZ
MRPEIWAAQEFRRNGDENNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWAAQEFRRNGDENNAYYARRVZ
MRPEIWAAQEFRRAGDEFNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWAAQEFRRAGDEFNAYYARRVZ
MRPEIWAAQEFRRAGDEVNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWAAQEFRRAGDEVNAYYARRVZ
MRPEIWAAQEFRRAGDENNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWAAQEFRRAGDENNAYYARRVZ
MRPEIWAAQEFDRIGDEFNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWAAQEFDRIGDEFNAYYARRVZ
MRPEIWAAQEFDRIGDEVNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWAAQEFDRIGDEVNAYYARRVZ
MRPEIWAAQEFDRIGDENNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWAAQEFDRIGDENNAYYARRVZ
MRPEIWAAQEFDRFGDEFNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWAAQEFDRFGDEFNAYYARRVZ
MRPEIWAAQEFDRFGDEVNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWAAQEFDRFGDEVNAYYARRVZ
MRPEIWAAQEFDRFGDENNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWAAQEFDRFGDENNAYYARRVZ
MRPEIWAAQEFDRDGDEFNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWAAQEFDRDGDEFNAYYARRVZ
MRPEIWAAQEFDRDGDEVNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWAAQEFDRDGDEVNAYYARRVZ
MRPEIWAAQEFDRDGDENNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWAAQEFDRDGDENNAYYARRVZ
MRPEIWAAQEFDRNGDEFNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWAAQEFDRNGDEFNAYYARRVZ
MRPEIWAAQEFDRNGDEVNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWAAQEFDRNGDEVNAYYARRVZ
MRPEIWAAQEFDRNGDENNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWAAQEFDRNGDENNAYYARRVZ
MRPEIWAAQEFDRAGDEFNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWAAQEFDRAGDEFNAYYARRVZ
MRPEIWAAQEFDRAGDEVNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWAAQEFDRAGDEVNAYYARRVZ
MRPEIWAAQEFDRAGDENNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWAAQEFDRAGDENNAYYARRVZ
MRPEIWAAQEARRIGDEFNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWAAQEARRIGDEFNAYYARRVZ
MRPEIWAAQEARRIGDEVNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWAAQEARRIGDEVNAYYARRVZ
MRPEIWAAQEARRIGDENNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWAAQEARRIGDENNAYYARRVZ
MRPEIWAAQEARRFGDEFNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWAAQEARRFGDEFNAYYARRVZ
MRPEIWAAQEARRFGDEVNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWAAQEARRFGDEVNAYYARRVZ
MRPEIWAAQEARRFGDENNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWAAQEARRFGDENNAYYARRVZ
MRPEIWAAQEARRDGDEFNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWAAQEARRDGDEFNAYYARRVZ
MRPEIWAAQEARRDGDEVNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWAAQEARRDGDEVNAYYARRVZ
MRPEIWAAQEARRDGDENNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWAAQEARRDGDENNAYYARRVZ
MRPEIWAAQEARRNGDEFNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWAAQEARRNGDEFNAYYARRVZ
MRPEIWAAQEARRNGDEVNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWAAQEARRNGDEVNAYYARRVZ
MRPEIWAAQEARRNGDENNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWAAQEARRNGDENNAYYARRVZ
MRPEIWAAQEARRAGDEFNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWAAQEARRAGDEFNAYYARRVZ
MRPEIWAAQEARRAGDEVNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWAAQEARRAGDEVNAYYARRVZ
MRPEIWAAQEARRAGDENNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWAAQEARRAGDENNAYYARRVZ
MRPEIWAAQEADRIGDEFNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWAAQEADRIGDEFNAYYARRVZ
MRPEIWAAQEADRIGDEVNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWAAQEADRIGDEVNAYYARRVZ
MRPEIWAAQEADRIGDENNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWAAQEADRIGDENNAYYARRVZ
MRPEIWAAQEADRFGDEFNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWAAQEADRFGDEFNAYYARRVZ
MRPEIWAAQEADRFGDEVNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWAAQEADRFGDEVNAYYARRVZ
MRPEIWAAQEADRFGDENNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWAAQEADRFGDENNAYYARRVZ
MRPEIWAAQEADRDGDEFNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWAAQEADRDGDEFNAYYARRVZ
MRPEIWAAQEADRDGDEVNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWAAQEADRDGDEVNAYYARRVZ
MRPEIWAAQEADRDGDENNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWAAQEADRDGDENNAYYARRVZ
MRPEIWAAQEADRNGDEFNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWAAQEADRNGDEFNAYYARRVZ
MRPEIWAAQEADRNGDEVNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWAAQEADRNGDEVNAYYARRVZ
MRPEIWAAQEADRNGDENNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWAAQEADRNGDENNAYYARRVZ
MRPEIWAAQEADRAGDEFNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWAAQEADRAGDEFNAYYARRVZ
MRPEIWAAQEADRAGDEVNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWAAQEADRAGDEVNAYYARRVZ
MRPEIWAAQEADRAGDENNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWAAQEADRAGDENNAYYARRVZ
MRPEIWFAQELRRIGDEFNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWFAQELRRIGDEFNAYYARRVZ
MRPEIWFAQELRRIGDEVNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWFAQELRRIGDEVNAYYARRVZ
MRPEIWFAQELRRIGDENNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWFAQELRRIGDENNAYYARRVZ
MRPEIWFAQELRRFGDEFNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWFAQELRRFGDEFNAYYARRVZ
MRPEIWFAQELRRFGDEVNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWFAQELRRFGDEVNAYYARRVZ
MRPEIWFAQELRRFGDENNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWFAQELRRFGDENNAYYARRVZ
MRPEIWFAQELRRDGDEFNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWFAQELRRDGDEFNAYYARRVZ
MRPEIWFAQELRRDGDEVNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWFAQELRRDGDEVNAYYARRVZ
MRPEIWFAQELRRDGDENNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWFAQELRRDGDENNAYYARRVZ
MRPEIWFAQELRRNGDEFNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWFAQELRRNGDEFNAYYARRVZ
MRPEIWFAQELRRNGDEVNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWFAQELRRNGDEVNAYYARRVZ
MRPEIWFAQELRRNGDENNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWFAQELRRNGDENNAYYARRVZ
MRPEIWFAQELRRAGDEFNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWFAQELRRAGDEFNAYYARRVZ
MRPEIWFAQELRRAGDEVNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWFAQELRRAGDEVNAYYARRVZ
MRPEIWFAQELRRAGDENNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWFAQELRRAGDENNAYYARRVZ
MRPEIWFAQELDRIGDEFNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWFAQELDRIGDEFNAYYARRVZ
MRPEIWFAQELDRIGDEVNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWFAQELDRIGDEVNAYYARRVZ
MRPEIWFAQELDRIGDENNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWFAQELDRIGDENNAYYARRVZ
MRPEIWFAQELDRFGDEFNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWFAQELDRFGDEFNAYYARRVZ
MRPEIWFAQELDRFGDEVNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWFAQELDRFGDEVNAYYARRVZ
MRPEIWFAQELDRFGDENNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWFAQELDRFGDENNAYYARRVZ
MRPEIWFAQELDRDGDEFNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWFAQELDRDGDEFNAYYARRVZ
MRPEIWFAQELDRDGDEVNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWFAQELDRDGDEVNAYYARRVZ
MRPEIWFAQELDRDGDENNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWFAQELDRDGDENNAYYARRVZ
MRPEIWFAQELDRNGDEFNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWFAQELDRNGDEFNAYYARRVZ
MRPEIWFAQELDRNGDEVNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWFAQELDRNGDEVNAYYARRVZ
MRPEIWFAQELDRNGDENNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWFAQELDRNGDENNAYYARRVZ
MRPEIWFAQELDRAGDEFNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWFAQELDRAGDEFNAYYARRVZ
MRPEIWFAQELDRAGDEVNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWFAQELDRAGDEVNAYYARRVZ
MRPEIWFAQELDRAGDENNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWFAQELDRAGDENNAYYARRVZ
MRPEIWFAQEIRRIGDEFNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWFAQEIRRIGDEFNAYYARRVZ
MRPEIWFAQEIRRIGDEVNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWFAQEIRRIGDEVNAYYARRVZ
MRPEIWFAQEIRRIGDENNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWFAQEIRRIGDENNAYYARRVZ
MRPEIWFAQEIRRFGDEFNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWFAQEIRRFGDEFNAYYARRVZ
MRPEIWFAQEIRRFGDEVNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWFAQEIRRFGDEVNAYYARRVZ
MRPEIWFAQEIRRFGDENNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWFAQEIRRFGDENNAYYARRVZ
MRPEIWFAQEIRRDGDEFNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWFAQEIRRDGDEFNAYYARRVZ
MRPEIWFAQEIRRDGDEVNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWFAQEIRRDGDEVNAYYARRVZ
MRPEIWFAQEIRRDGDENNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWFAQEIRRDGDENNAYYARRVZ
MRPEIWFAQEIRRNGDEFNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWFAQEIRRNGDEFNAYYARRVZ
MRPEIWFAQEIRRNGDEVNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWFAQEIRRNGDEVNAYYARRVZ
MRPEIWFAQEIRRNGDENNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWFAQEIRRNGDENNAYYARRVZ
MRPEIWFAQEIRRAGDEFNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWFAQEIRRAGDEFNAYYARRVZ
MRPEIWFAQEIRRAGDEVNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWFAQEIRRAGDEVNAYYARRVZ
MRPEIWFAQEIRRAGDENNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWFAQEIRRAGDENNAYYARRVZ
MRPEIWFAQEIDRIGDEFNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWFAQEIDRIGDEFNAYYARRVZ
MRPEIWFAQEIDRIGDEVNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWFAQEIDRIGDEVNAYYARRVZ
MRPEIWFAQEIDRIGDENNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWFAQEIDRIGDENNAYYARRVZ
MRPEIWFAQEIDRFGDEFNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWFAQEIDRFGDEFNAYYARRVZ
MRPEIWFAQEIDRFGDEVNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWFAQEIDRFGDEVNAYYARRVZ
MRPEIWFAQEIDRFGDENNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWFAQEIDRFGDENNAYYARRVZ
MRPEIWFAQEIDRDGDEFNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWFAQEIDRDGDEFNAYYARRVZ
MRPEIWFAQEIDRDGDEVNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWFAQEIDRDGDEVNAYYARRVZ
MRPEIWFAQEIDRDGDENNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWFAQEIDRDGDENNAYYARRVZ
MRPEIWFAQEIDRNGDEFNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWFAQEIDRNGDEFNAYYARRVZ
MRPEIWFAQEIDRNGDEVNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWFAQEIDRNGDEVNAYYARRVZ
MRPEIWFAQEIDRNGDENNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWFAQEIDRNGDENNAYYARRVZ
MRPEIWFAQEIDRAGDEFNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWFAQEIDRAGDEFNAYYARRVZ
MRPEIWFAQEIDRAGDEVNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWFAQEIDRAGDEVNAYYARRVZ
MRPEIWFAQEIDRAGDENNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWFAQEIDRAGDENNAYYARRVZ
MRPEIWFAQEFRRIGDEFNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWFAQEFRRIGDEFNAYYARRVZ
MRPEIWFAQEFRRIGDEVNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWFAQEFRRIGDEVNAYYARRVZ
MRPEIWFAQEFRRIGDENNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWFAQEFRRIGDENNAYYARRVZ
MRPEIWFAQEFRRFGDEFNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWFAQEFRRFGDEFNAYYARRVZ
MRPEIWFAQEFRRFGDEVNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWFAQEFRRFGDEVNAYYARRVZ
MRPEIWFAQEFRRFGDENNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWFAQEFRRFGDENNAYYARRVZ
MRPEIWFAQEFRRDGDEFNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWFAQEFRRDGDEFNAYYARRVZ
MRPEIWFAQEFRRDGDEVNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWFAQEFRRDGDEVNAYYARRVZ
MRPEIWFAQEFRRDGDENNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWFAQEFRRDGDENNAYYARRVZ
MRPEIWFAQEFRRNGDEFNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWFAQEFRRNGDEFNAYYARRVZ
MRPEIWFAQEFRRNGDEVNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWFAQEFRRNGDEVNAYYARRVZ
MRPEIWFAQEFRRNGDENNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWFAQEFRRNGDENNAYYARRVZ
MRPEIWFAQEFRRAGDEFNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWFAQEFRRAGDEFNAYYARRVZ
MRPEIWFAQEFRRAGDEVNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWFAQEFRRAGDEVNAYYARRVZ
MRPEIWFAQEFRRAGDENNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWFAQEFRRAGDENNAYYARRVZ
MRPEIWFAQEFDRIGDEFNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWFAQEFDRIGDEFNAYYARRVZ
MRPEIWFAQEFDRIGDEVNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWFAQEFDRIGDEVNAYYARRVZ
MRPEIWFAQEFDRIGDENNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWFAQEFDRIGDENNAYYARRVZ
MRPEIWFAQEFDRFGDEFNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWFAQEFDRFGDEFNAYYARRVZ
MRPEIWFAQEFDRFGDEVNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWFAQEFDRFGDEVNAYYARRVZ
MRPEIWFAQEFDRFGDENNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWFAQEFDRFGDENNAYYARRVZ
MRPEIWFAQEFDRDGDEFNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWFAQEFDRDGDEFNAYYARRVZ
MRPEIWFAQEFDRDGDEVNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWFAQEFDRDGDEVNAYYARRVZ
MRPEIWFAQEFDRDGDENNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWFAQEFDRDGDENNAYYARRVZ
MRPEIWFAQEFDRNGDEFNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWFAQEFDRNGDEFNAYYARRVZ
MRPEIWFAQEFDRNGDEVNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWFAQEFDRNGDEVNAYYARRVZ
MRPEIWFAQEFDRNGDENNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWFAQEFDRNGDENNAYYARRVZ
MRPEIWFAQEFDRAGDEFNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWFAQEFDRAGDEFNAYYARRVZ
MRPEIWFAQEFDRAGDEVNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWFAQEFDRAGDEVNAYYARRVZ
MRPEIWFAQEFDRAGDENNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWFAQEFDRAGDENNAYYARRVZ
MRPEIWFAQEARRIGDEFNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWFAQEARRIGDEFNAYYARRVZ
MRPEIWFAQEARRIGDEVNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWFAQEARRIGDEVNAYYARRVZ
MRPEIWFAQEARRIGDENNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWFAQEARRIGDENNAYYARRVZ
MRPEIWFAQEARRFGDEFNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWFAQEARRFGDEFNAYYARRVZ
MRPEIWFAQEARRFGDEVNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWFAQEARRFGDEVNAYYARRVZ
MRPEIWFAQEARRFGDENNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWFAQEARRFGDENNAYYARRVZ
MRPEIWFAQEARRDGDEFNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWFAQEARRDGDEFNAYYARRVZ
MRPEIWFAQEARRDGDEVNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWFAQEARRDGDEVNAYYARRVZ
MRPEIWFAQEARRDGDENNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWFAQEARRDGDENNAYYARRVZ
MRPEIWFAQEARRNGDEFNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWFAQEARRNGDEFNAYYARRVZ
MRPEIWFAQEARRNGDEVNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWFAQEARRNGDEVNAYYARRVZ
MRPEIWFAQEARRNGDENNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWFAQEARRNGDENNAYYARRVZ
MRPEIWFAQEARRAGDEFNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWFAQEARRAGDEFNAYYARRVZ
MRPEIWFAQEARRAGDEVNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWFAQEARRAGDEVNAYYARRVZ
MRPEIWFAQEARRAGDENNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWFAQEARRAGDENNAYYARRVZ
MRPEIWFAQEADRIGDEFNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWFAQEADRIGDEFNAYYARRVZ
MRPEIWFAQEADRIGDEVNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWFAQEADRIGDEVNAYYARRVZ
MRPEIWFAQEADRIGDENNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWFAQEADRIGDENNAYYARRVZ
MRPEIWFAQEADRFGDEFNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWFAQEADRFGDEFNAYYARRVZ
MRPEIWFAQEADRFGDEVNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWFAQEADRFGDEVNAYYARRVZ
MRPEIWFAQEADRFGDENNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWFAQEADRFGDENNAYYARRVZ
MRPEIWFAQEADRDGDEFNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWFAQEADRDGDEFNAYYARRVZ
MRPEIWFAQEADRDGDEVNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWFAQEADRDGDEVNAYYARRVZ
MRPEIWFAQEADRDGDENNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWFAQEADRDGDENNAYYARRVZ
MRPEIWFAQEADRNGDEFNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWFAQEADRNGDEFNAYYARRVZ
MRPEIWFAQEADRNGDEVNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWFAQEADRNGDEVNAYYARRVZ
MRPEIWFAQEADRNGDENNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWFAQEADRNGDENNAYYARRVZ
MRPEIWFAQEADRAGDEFNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWFAQEADRAGDEFNAYYARRVZ
MRPEIWFAQEADRAGDEVNAYYARRVZ,27,Synthetic,Synthetic peptide,,,Mcl-1/Bcl-xL,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Mcl-1/Bcl-xL inhibitors##BH3 peptides and mimetics,,Linear,,Free,Free,,,0,MRPEIWFAQEADRAGDEVNAYYARRVZ
LKlLKkLlkKLLkLL,15,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,,,0,LKLLKKLLKKLLKLL
TRSSRAGLQWPVGRVHRLLRK,21,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,TRSSRAGLQWPVGRVHRLLRK
AKIPIKAIKTVGKAVGKGLRAINIASTANDVFNFLKPKKRKH,42,Animalia,Native peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,AKIPIKAIKTVGKAVGKGLRAINIASTANDVFNFLKPKKRKH
GYPICGESCVGGICNIPGCSCSWPVCTTN,29,Plantae,Native peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,GYPICGESCVGGICNIPGCSCSWPVCTTN
rlylriGrr,9,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antiparasitic,Tumor active peptide,,Linear,,Free,Amidation,,,0,RLYLRIGRR
rlrlriGrr,9,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antiparasitic,Tumor active peptide,,Linear,,Free,Amidation,,,0,RLRLRIGRR
alylairrr,9,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antiparasitic,Tumor active peptide,,Linear,,Free,Amidation,,,0,ALYLAIRRR
rlllriGrr,9,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antiparasitic,Tumor active peptide,,Linear,,Free,Amidation,,,0,RLLLRIGRR
KLWKKWKKWLK,11,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,,0,KLWKKWKKWLK
GmwskilGhlir,12,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,,0,GMWSKILGHLIR
GMWSKILGHLIK,12,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,,,0,GMWSKILGHLIK
Gkwmsllkhilk,12,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,,,0,GKWMSLLKHILK
fPFfNQYVXL,10,Synthetic,Native peptide,,,,,,Anticancer; Antibacterial; Antiparasitic; Antifungal,Tumor active peptide,,Linear,,Free,Free,,,0,FPFFNQYVXL
LLGDFFRKSKEK,12,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,LLGDFFRKSKEK
LLGDFKRIVQRIKDF,15,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,,,0,LLGDFKRIVQRIKDF
FKRiVQRiKDFlRNLV,16,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,,,0,FKRIVQRIKDFLRNLV
vnwkkilGkiikvvk,15,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,,0,VNWKKILGKIIKVVK
vnwkkllGkllkvvk,15,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Amidation,,,0,VNWKKLLGKLLKVVK
GfGmalkllkkvl,13,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,,0,GFGMALKLLKKVL
RRQRRTSKLMKRGGKLAKLAKKLAKLAK,28,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,RRQRRTSKLMKRGGKLAKLAKKLAKLAK
ILGKLLSTAWGLLSkL,16,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Amidation,,,0,ILGKLLSTAWGLLSKL
GFSSIFRGVAKFASKGLGKDLAKLGVDLVA,30,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,GFSSIFRGVAKFASKGLGKDLAKLGVDLVA
KFASKGLGKDLAKLGVDLVACKISKQC,27,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,KFASKGLGKDLAKLGVDLVACKISKQC
SWLRDIWDWICEVLSDFK,18,Synthetic,Synthetic peptide,,,,,,Anticancer; Antiviral,Tumor active peptide,,Linear,,Free,Free,,,0,SWLRDIWDWICEVLSDFK
KWKSFLkTFKSLKkTVLHTLLkAISS,26,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Acetylation,Amidation,,,0,KWKSFLKTFKSLKKTVLHTLLKAISS
gwgsffkkaahvgkhvgkaalthyl,25,Synthetic,Synthetic peptide,,HEK293: IC50=61.4 ± 3.9 µg/ml,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,,,0,GWGSFFKKAAHVGKHVGKAALTHYL
GlpvcGetcvGGtcntpGctcswpvctrn,29,Synthetic,Synthetic peptide,,,,,,Anticancer; Antiviral,Tumor active peptide,,Linear,,Free,Free,,,0,GLPVCGETCVGGTCNTPGCTCSWPVCTRN
GLPVCGETCFGGTCNTPGCSCTWPICTRD,29,Synthetic,Native peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Free,,,0,GLPVCGETCFGGTCNTPGCSCTWPICTRD
GLPVCGETCTLGTCYTQGCTCSWPICKRN,29,Synthetic,Native peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Free,,,0,GLPVCGETCTLGTCYTQGCTCSWPICKRN
RRIRPRPPRLPRPRPRPLPFPRPGPRPIPRPLPFP,35,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Free,,,0,RRIRPRPPRLPRPRPRPLPFPRPGPRPIPRPLPFP
RRIRPRPPRLPRPRPRPLPFPRP,23,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,RRIRPRPPRLPRPRPRPLPFPRP
WaxVlL,6,Bacteria,Native peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Free,,,0,WAXVLL
KRFKKFFKKVKKSVKKRLKKIFKKPMVIGVTIPF,34,Synthetic,Native peptide,,,,,,Anticancer; Antibacterial; Antiparasitic; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,,0,KRFKKFFKKVKKSVKKRLKKIFKKPMVIGVTIPF
RAGLQFPVGRLLRRLLR,17,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,RAGLQFPVGRLLRRLLR
ILPIRSLIKKLL,12,Animalia,Native peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,,0,ILPIRSLIKKLL
FLPLKKLRFGLL,12,Animalia,Native peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,,0,FLPLKKLRFGLL
GFLDIIKDTGKEFAVKILNNLKCKLAGGCPP,31,Animalia,Native peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Free,,,0,GFLDIIKDTGKEFAVKILNNLKCKLAGGCPP
KTCENLADTFRGPCFATSNCDDHCKNKEHLLSGRCRDDFRCWCTRNC,47,Plantae,Native peptide,,,,,,Anticancer; Antibacterial; Antiviral; Antifungal,Tumor active peptide,,Linear,,Free,Free,,,0,KTCENLADTFRGPCFATSNCDDHCKNKEHLLSGRCRDDFRCWCTRNC
MRKWFHNVLSSGQLLADKWPAWDYNWK,27,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,MRKWFHNVLSSGQLLADKWPAWDYNWK
GRFKRFRKKFKKLFKKLSPVIPLLHL,26,Animalia,Native peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,,,0,GRFKRFRKKFKKLFKKLSPVIPLLHL
YTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWF,36,Synthetic,Synthetic peptide,,,,,,Anticancer; Antiviral,Tumor active peptide,,Linear,,Free,Free,,,0,YTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWF
GFKRIVQRIKDFLRNLV,17,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antiviral,Tumor active peptide,,Linear,,Free,Amidation,,,0,GFKRIVQRIKDFLRNLV
fPFfNQYVKL,10,Bacteria,Native peptide,,,,,,Anticancer; Antibacterial; Antiparasitic,Tumor active peptide,,Linear,,Free,Free,,,0,FPFFNQYVKL
fPWfNQYVXL,10,Synthetic,Native peptide,,,,,,Anticancer; Antibacterial; Antiparasitic; Antifungal,Tumor active peptide,,Linear,,Free,Free,,,0,FPWFNQYVXL
fPWfNQYVKL,10,Bacteria,Native peptide,,,,,,Anticancer; Antibacterial; Antiparasitic,Tumor active peptide,,Linear,,Free,Free,,,0,FPWFNQYVKL
fPWwNQYVXL,10,Synthetic,Native peptide,,,,,,Anticancer; Antibacterial; Antiparasitic; Antifungal,Tumor active peptide,,Linear,,Free,Free,,,0,FPWWNQYVXL
fPWwNQYVKL,10,Bacteria,Native peptide,,,,,,Anticancer; Antibacterial; Antiparasitic,Tumor active peptide,,Linear,,Free,Free,,,0,FPWWNQYVKL
YPLPFIP,7,Animalia,Native peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Free,,,0,YPLPFIP
AISYGNGVYCNKEKCWVNKAENKQAITGIVIGGWASSLAGMGH,43,Bacteria,Native peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,AISYGNGVYCNKEKCWVNKAENKQAITGIVIGGWASSLAGMGH
VNYGNGVSCSKTKCSVNWGQAFQERYTAGINSFVSGVASGAGSIGRRP,48,Bacteria,Native peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,VNYGNGVSCSKTKCSVNWGQAFQERYTAGINSFVSGVASGAGSIGRRP
KWXWKXVKXAK,11,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antiparasitic; Antifungal,Tumor active peptide,,Linear,,Acetylation,Amidation,,,0,KWXWKXVKXAK
KAXWKXVKXAK,11,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antiparasitic; Antifungal,Tumor active peptide,,Linear,,Acetylation,Amidation,,,0,KAXWKXVKXAK
KWXWKXAKXAK,11,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antiparasitic; Antifungal,Tumor active peptide,,Linear,,Acetylation,Amidation,,,0,KWXWKXAKXAK
QSHLSMCSVCCNCCKNYKGCGFCCRF,26,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,QSHLSMCSVCCNCCKNYKGCGFCCRF
MGSSHHHHHHSSGLVPRGSHMIPVNGVTELEEAASNDTPVAARHEMSMQSWMMPNHIREKRQSHLSMCSVCCNCCKNYKGCGFCCRF,87,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,MGSSHHHHHHSSGLVPRGSHMIPVNGVTELEEAASNDTPVAARHEMSMQSWMMPNHIREKRQSHLSMCSVCCNCCKNYKGCGFCCRF
RPPQFTRAQWFAIQHISLNPPRSTIAMRAINNYRWRSKNQNTFLR,45,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Free,,,0,RPPQFTRAQWFAIQHISLNPPRSTIAMRAINNYRWRSKNQNTFLR
FLPLLLSALPSFLCLVFKKC,20,Animalia,Native peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Free,,,0,FLPLLLSALPSFLCLVFKKC
yf,2,Synthetic,Native peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,YF
pF,2,Synthetic,Native peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Free,,,0,PF
PF,2,Synthetic,Native peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Free,,,0,PF
VXVXXVXVXTVX,12,Bacteria,Native peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,VXVXXVXVXTVX
LV,2,Bacteria,Native peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Free,,,0,LV
pf,2,Fungi,Native peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Free,,,0,PF
AXEGSnXX,8,Fungi,Native peptide,,,,,,Anticancer; Antifungal,Tumor active peptide,,Linear,,3-OH-Me-C16,Free,,,0,AXEGSNXX
DKPKKKPPPPAGPPPPPPPPPGPPPPGP,28,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Cell-penetrating peptides,,Linear,,Free,Free,,,0,DKPKKKPPPPAGPPPPPPPPPGPPPPGP
KPKGMTSSQWFKIQHMQPSPQASNSAMKNINKHTKRSKDLNTFLH,45,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Free,,,0,KPKGMTSSQWFKIQHMQPSPQASNSAMKNINKHTKRSKDLNTFLH
WP,2,Synthetic,Native peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Free,,,0,WP
WY,2,Synthetic,Native peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Free,,,0,WY
WL,2,Synthetic,Native peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Free,,,0,WL
WF,2,Synthetic,Native peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Free,,,0,WF
VDKPPYLPRPRPPRRIYNR,19,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,,,0,VDKPPYLPRPRPPRRIYNR
GFCWNVCVYRNGVRVCHRRCN,21,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Free,,,0,GFCWNVCVYRNGVRVCHRRCN
KGCALVKVRGLTLKVCK,17,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,KGCALVKVRGLTLKVCK
KWCRKWQWRGVKFIKCV,17,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,KWCRKWQWRGVKFIKCV
HKCAKIKWRGVHVKYCA,17,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,HKCAKIKWRGVHVKYCA
NGVQPKYRWWRWWRRWW,17,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,,,0,NGVQPKYRWWRWWRRWW
KESRAKKFQRQHMDSDSSPSSSSTYSNQMMRRRNMTQGRSKPVNTFVH,48,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Free,,,0,KESRAKKFQRQHMDSDSSPSSSSTYSNQMMRRRNMTQGRSKPVNTFVH
KPPQFTWAQWFETQHINMTSQQSTNAMQVINNYQRRSKNQNTFLL,45,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Free,,,0,KPPQFTWAQWFETQHINMTSQQSTNAMQVINNYQRRSKNQNTFLL
QDGMYQRFLRQHVHPEETGGSDRYSNLMMQRRKMTLYHSKRFNTFIH,47,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Free,,,0,QDGMYQRFLRQHVHPEETGGSDRYSNLMMQRRKMTLYHSKRFNTFIH
QDNSRYTHFLTQHYDAKPQGRDDRYSESIMRRRGLTSPSKDINTFIH,47,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Free,,,0,QDNSRYTHFLTQHYDAKPQGRDDRYSESIMRRRGLTSPSKDINTFIH
WPKRLTKAHWFEIQHIQPSPLQSNRAMSGINNYTQHSKHQNTFLH,45,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Free,,,0,WPKRLTKAHWFEIQHIQPSPLQSNRAMSGINNYTQHSKHQNTFLH
KPKDMTSSQWFKTQHVQPSPQASNSAMSIINKYTERSKDLNTFLH,45,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Free,,,0,KPKDMTSSQWFKTQHVQPSPQASNSAMSIINKYTERSKDLNTFLH
RAGLQFPVGRVHRLLRK,17,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,,,0,RAGLQFPVGRVHRLLRK
VIHRAGLQFPVGRVHRLLRK,20,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,,,0,VIHRAGLQFPVGRVHRLLRK
KFFKKLKNSVKKRAKKFFKKPRVIGVSIPF,30,Synthetic,Native peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Free,,,0,KFFKKLKNSVKKRAKKFFKKPRVIGVSIPF
RCpGRTRQIGTIFpGRIKCRSW,22,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Acetylation,Free,,,0,RCPGRTRQIGTIFPGRIKCRSW
GG,2,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,DiMIQ,Free,,,0,GG
GP,2,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,DiMIQ,Free,,,0,GP
PG,2,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,DiMIQ,Free,,,0,PG
KWKVFKKIEKMGRNIRNGIVKAGPKWKVFKKIEK,34,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,,,0,KWKVFKKIEKMGRNIRNGIVKAGPKWKVFKKIEK
CVLIGQRCDNDRGPRCCSGQGNCVPLPFLGGVCAV,35,Plantae,Native peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Free,,,0,CVLIGQRCDNDRGPRCCSGQGNCVPLPFLGGVCAV
KGK,3,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,3-OH-C16,Amidation,,,0,KGK
kQrWlWlW,8,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,KQRWLWLW
ILPIIGKILSTIFGK,15,Animalia,Native peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,ILPIIGKILSTIFGK
GLLSVFKGVLKTAGKNVAKNVAGSLLDQLKCKISGGC,37,Synthetic,Native peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,GLLSVFKGVLKTAGKNVAKNVAGSLLDQLKCKISGGC
GLWDSIKNFGKTIALNVMDKIKCKIGGGCPP,31,Animalia,Native peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,GLWDSIKNFGKTIALNVMDKIKCKIGGGCPP
LLCIALRKK,9,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,,0,LLCIALRKK
YPFX,4,Bacteria,Native peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Free,,,0,YPFX
RRRRWWWW,8,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,RRRRWWWW
CNGRCGGKLAKLAKKLAKLAK,21,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,CNGRCGGKLAKLAKKLAKLAK
LRLKSIVSYAKKVL,14,Animalia,Native peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Free,,,0,LRLKSIVSYAKKVL
FLFSLIPSVIAGLVSAIRN,19,Animalia,Native peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,,0,FLFSLIPSVIAGLVSAIRN
FLFSLIPSAIAGLVSAIRN,19,Animalia,Native peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,,0,FLFSLIPSAIAGLVSAIRN
FLFKLIPKVIKGLVKAIRK,19,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,,0,FLFKLIPKVIKGLVKAIRK
FLFKLIPKAIKGLVKAIRK,19,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,,0,FLFKLIPKAIKGLVKAIRK
KFFKRLLKSVRRAVKKFRKKPRLIGLSTLL,30,Synthetic,Native peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Free,,,0,KFFKRLLKSVRRAVKKFRKKPRLIGLSTLL
FFSLIPSLVGGLISAFK,17,Synthetic,Native peptide,,,,,,Anticancer; Antibacterial; Antiparasitic; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,,0,FFSLIPSLVGGLISAFK
FLKGIVGMLGKLF,13,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antiviral; Antiparasitic; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,,0,FLKGIVGMLGKLF
KGIRGYKGGYCKGAFKQTCKCY,22,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Free,,,0,KGIRGYKGGYCKGAFKQTCKCY
KGIRGYKGGYKGAFKQTKY,19,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Free,,,0,KGIRGYKGGYKGAFKQTKY
GLPLCGETCVGGTCNTPGCSCGWPVCVRN,29,Plantae,Native peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,GLPLCGETCVGGTCNTPGCSCGWPVCVRN
DEDDD,5,Animalia,Native peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,DEDDD
HTASDAAAAAALTAANAAAAAAASMA,26,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antiviral; Antifungal,Tumor active peptide,,Linear,,Free,Free,,,0,HTASDAAAAAALTAANAAAAAAASMA
GILGKLWEGVKSIF,14,Synthetic,Native peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,,,0,GILGKLWEGVKSIF
GIGAVLKVLTTGLPALKSWIKRKRQQ,26,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,GIGAVLKVLTTGLPALKSWIKRKRQQ
IIGAVLKVLTTGLPALISWIKRKRQQ,26,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,IIGAVLKVLTTGLPALISWIKRKRQQ
GWWRRTVDKVRNAGRKVAGFASKACGALGH,30,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Free,,,0,GWWRRTVDKVRNAGRKVAGFASKACGALGH
PMLRVRLASHLRKLRKRLLR,20,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,PMLRVRLASHLRKLRKRLLR
LRVRLASHLRKLRKRLLR,18,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,LRVRLASHLRKLRKRLLR
MPRRRRSSSRPVRRRRRPRVSRRRRRRGGRRR,32,Animalia,Native peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,MPRRRRSSSRPVRRRRRPRVSRRRRRRGGRRR
GMWSKIKETAMAAAKEAAKAAGKTISDMIKQ,31,Animalia,Native peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,,0,GMWSKIKETAMAAAKEAAKAAGKTISDMIKQ
GMWSKIKNAGKAAAKAAAKAAGKAALDAVSEAI,33,Animalia,Native peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,,0,GMWSKIKNAGKAAAKAAAKAAGKAALDAVSEAI
RGSALTHLP,9,Animalia,Native peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,RGSALTHLP
FLPAALAGIGGILGKLF,17,Animalia,Native peptide,,,,,,Anticancer; Antibacterial; Antiparasitic; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,,0,FLPAALAGIGGILGKLF
ffflsrif,8,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,,,0,FFFLSRIF
firslfff,8,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,,,0,FIRSLFFF
FIRSLFFF,8,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,,,0,FIRSLFFF
FFFLRRIF,8,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,,0,FFFLRRIF
INLKILARLAKKIL,14,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Free,,,0,INLKILARLAKKIL
XFFLSRIF,8,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,,0,XFFLSRIF
FXFLRRIF,8,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,,0,FXFLRRIF
ACVNQCPDAIDRFIVKDKGCHGVEKKYYKQVYVACMNGQHLYCRTEWGGPCQL,53,Synthetic,Native peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,ACVNQCPDAIDRFIVKDKGCHGVEKKYYKQVYVACMNGQHLYCRTEWGGPCQL
KWRRWIRWL,9,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,,0,KWRRWIRWL
IKIPSFFrNILKKVGKEAVSLIAGALKQS,29,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,IKIPSFFRNILKKVGKEAVSLIAGALKQS
GSPE,4,Synthetic,Native peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Free,,,0,GSPE
GYPFV,5,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,GYPFV
ADMDFTGIAESIIKKIKETNAKPPA,25,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Free,,,0,ADMDFTGIAESIIKKIKETNAKPPA
GrkkrrqrrrGGwmwvtnlrtd,22,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Free,,,0,GRKKRRQRRRGGWMWVTNLRTD
KWKSFLKTFKSAKkTVLHTALKAISS,26,Synthetic,Synthetic peptide,MHC (minimal hemolytic concentration) =125μM,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Acetylation,Amidation,,,0,KWKSFLKTFKSAKKTVLHTALKAISS
KWKSFLKTFKsAKkTVLHTALKAISS,26,Synthetic,Synthetic peptide,MHC (minimal hemolytic concentration) =125μM,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Acetylation,Amidation,,,0,KWKSFLKTFKSAKKTVLHTALKAISS
KWKSFLKTFKSAKktVLHTALKAISS,26,Synthetic,Synthetic peptide,MHC (minimal hemolytic concentration) =250μM,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Acetylation,Amidation,,,0,KWKSFLKTFKSAKKTVLHTALKAISS
KWKSFLKTFKsAKktVLHTALKAISS,26,Synthetic,Synthetic peptide,MHC (minimal hemolytic concentration) =250μM,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Acetylation,Amidation,,,0,KWKSFLKTFKSAKKTVLHTALKAISS
KWKSFLKTFKSaKKTVLHTALKAISS,26,Synthetic,Synthetic peptide,MHC (minimal hemolytic concentration) =125μM,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Acetylation,Amidation,,,0,KWKSFLKTFKSAKKTVLHTALKAISS
KWKSFLKTfKSaKKTVLHTALKAISS,26,Synthetic,Synthetic peptide,MHC (minimal hemolytic concentration) =250μM,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Acetylation,Amidation,,,0,KWKSFLKTFKSAKKTVLHTALKAISS
KWKSFLKTFKSaKKTvLHTALKAISS,26,Synthetic,Synthetic peptide,MHC (minimal hemolytic concentration) >500μM,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Acetylation,Amidation,,,0,KWKSFLKTFKSAKKTVLHTALKAISS
KWKSFLKTfKSaKKTvLHTALKAISS,26,Synthetic,Synthetic peptide,MHC (minimal hemolytic concentration) >500μM,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Acetylation,Amidation,,,0,KWKSFLKTFKSAKKTVLHTALKAISS
XRWRWRW,7,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,XRWRWRW
XGX,3,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,C20,Amidation,,,0,XGX
NLVSALIEGRKYLKNVLKKLNRLKEKNKAKNSKENN,36,Animalia,Native peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Free,,,0,NLVSALIEGRKYLKNVLKKLNRLKEKNKAKNSKENN
LIXFXPx,7,Fungi,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Boc,OMe,,,0,LIXFXPX
XFXILxP,7,Fungi,Native peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Free,,,0,XFXILXP
XFXVLxP,7,Plantae,Native peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,XFXVLXP
XFXXLxP,7,Plantae,Native peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,XFXXLXP
FFSLIPKLVKGLISAFK,17,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antiparasitic; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,,0,FFSLIPKLVKGLISAFK
FFKLIPKLVKGLISAFK,17,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antiparasitic; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,,0,FFKLIPKLVKGLISAFK
XAaQyI,6,Fusarium ,Native peptide,,,,,,Anticancer; Parasite; Antifungal,Tumor active peptide##Amphiphilic,,Linear,Ester bond: N-terminal<--->leu6,3-OH-4-Me-C15,Free,X=Allo-Thr,,0,XAAQYI
GILSKLGKALKKAAKHAAKA,20,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,,,0,GILSKLGKALKKAAKHAAKA
GLLRRLRDFLKKIGEKFKKIGY,22,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,,,0,GLLRRLRDFLKKIGEKFKKIGY
GLGKAQCAALWLQCASGGTIGXGGGAVACQNYRQFCR,37,Synthetic,Native peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,GLGKAQCAALWLQCASGGTIGXGGGAVACQNYRQFCR
CKILSKTIKCRIPCGRRKEY,20,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,CKILSKTIKCRIPCGRRKEY
KRCKNKMEGDDVAVSGRGARKAAKK,25,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,KRCKNKMEGDDVAVSGRGARKAAKK
EEEEEEEEEEKKRLKKIFKKPMVIGVTIPF,30,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,,,0,EEEEEEEEEEKKRLKKIFKKPMVIGVTIPF
ALWKSLLKNVGKAAGKAALNAVTDMVNQ,28,Animalia,Native peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,,0,ALWKSLLKNVGKAAGKAALNAVTDMVNQ
GRKKRRQRRRGALWKSLLKNVGKA,24,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,,0,GRKKRRQRRRGALWKSLLKNVGKA
AAAARRRR,8,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,AAAARRRR
YYYYRRRR,8,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,YYYYRRRR
FFFFRRRR,8,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Cyclic,NCB: Phe1<--->Arg8,Free,Free,,,0,FFFFRRRR
IIIIRRRR,8,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,IIIIRRRR
LLLLRRRR,8,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,LLLLRRRR
LYPFA,5,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,LYPFA
GLRKRLRKFRNK,12,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Cell-penetrating peptides,,Linear,,Free,Amidation,,,0,GLRKRLRKFRNK
KCVRQNNKRVCK,12,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Cell-penetrating peptides,,Linear,,Free,Amidation,,,0,KCVRQNNKRVCK
KCVRQNNKRVCKGLRKRLRKFRNK,24,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Cell-penetrating peptides,,Linear,,Free,Amidation,,,0,KCVRQNNKRVCKGLRKRLRKFRNK
GLLEALAELLEGLRKRLRKFRNKIKEK,27,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Amidation,,,0,GLLEALAELLEGLRKRLRKFRNKIKEK
GLLEALAELLEGRKKRRQRRRPPQ,24,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Amidation,,,0,GLLEALAELLEGRKKRRQRRRPPQ
ALWKTMLKKLGTVALHAGKAALGAVADTISQ,31,Animalia,Native peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,,0,ALWKTMLKKLGTVALHAGKAALGAVADTISQ
PKILNKILGKILRLAAAFK,19,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,PKILNKILGKILRLAAAFK
KPWRFRRAIRRVRWRKVAPYIPFVVKTVGKK,31,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Amidation,,,0,KPWRFRRAIRRVRWRKVAPYIPFVVKTVGKK
GIMDTVKNAAKNLAGQLLDKLKCKITAC,28,Animalia,Native peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Free,,,0,GIMDTVKNAAKNLAGQLLDKLKCKITAC
GIMDTVKNAAKNLAGQLLDKLK,22,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Free,,,0,GIMDTVKNAAKNLAGQLLDKLK
LVPFIGRTLGGLLARF,16,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,,,0,LVPFIGRTLGGLLARF
LLGAALSALSSVIPSVISWFQK,22,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,,,0,LLGAALSALSSVIPSVISWFQK
GFWSSVWDGAKNVGTAIIKNAKVCVYAVCVSHK,33,Animalia,Native peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,GFWSSVWDGAKNVGTAIIKNAKVCVYAVCVSHK
GFWSSVWDGAKNVGTAI,17,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,GFWSSVWDGAKNVGTAI
IKNAKVCVYAVCVSHK,16,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,IKNAKVCVYAVCVSHK
SVAGRAQGM,9,Synthetic,Native peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,,0,SVAGRAQGM
HARIKpTFRRlKWKYKGKFW,20,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Acetylation,Free,,,0,HARIKPTFRRLKWKYKGKFW
HARIKPTFRRLKWKYKGKFW,20,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,HARIKPTFRRLKWKYKGKFW
TRSRWRRFIRGAGRFARRYGWRIA,24,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,TRSRWRRFIRGAGRFARRYGWRIA
FLSLLPHIASGIASLVSKF,19,Animalia,Native peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,,0,FLSLLPHIASGIASLVSKF
FLSLIPHIASGIASLVKNF,19,Animalia,Native peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,,0,FLSLIPHIASGIASLVKNF
FLSLIPHIVSGVAALANHL,19,Animalia,Native peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,,,0,FLSLIPHIVSGVAALANHL
IETFLKQLRSAANKIVGL,18,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,IETFLKQLRSAANKIVGL
LESLASSAVRTANKARAKL,19,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,LESLASSAVRTANKARAKL
GLFSKKGGKGGKSWIKGVFKGIKGIGKEVGGDVIRTGIEIAACKIKGEC,49,Animalia,Native peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Free,,,0,GLFSKKGGKGGKSWIKGVFKGIKGIGKEVGGDVIRTGIEIAACKIKGEC
TRGRWGRFKRRAGRFIRRNRWQIISTGLKLIG,32,Animalia,Native peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Free,,,0,TRGRWGRFKRRAGRFIRRNRWQIISTGLKLIG
CLGENVPCDKDRPNCCSRYECLEPTGYGWWYASYYCYKKRS,41,Animalia,Native peptide,,,,,,Anticancer; Insect,Tumor active peptide,,Linear,,Free,Amidation,,,0,CLGENVPCDKDRPNCCSRYECLEPTGYGWWYASYYCYKKRS
KKPSKKPKPQAMTFPKVTVEYFPASFSTAALTVPED,36,Animalia,Native peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Free,,,0,KKPSKKPKPQAMTFPKVTVEYFPASFSTAALTVPED
GLPLLISWIKRKRQQAGPGSKKPVPIIYCNRRTGKCQRM,39,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,GLPLLISWIKRKRQQAGPGSKKPVPIIYCNRRTGKCQRM
XXKKWRKWLAKK,12,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Acetylation,Amidation,,,0,XXKKWRKWLAKK
FIVPSIFLLKKAFCIALKKC,20,Animalia,Native peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,FIVPSIFLLKKAFCIALKKC
KKLLPIVANLLKSLL,15,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,,0,KKLLPIVANLLKSLL
XXXXKKK,7,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,,,0,XXXXKKK
KKLKXFX,7,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,,,0,KKLKXFX
XFXLKKK,7,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,,,0,XFXLKKK
INLKKLAKLXKKIS,14,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,,0,INLKKLAKLXKKIS
INLKKLAXLXKKIS,14,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,,0,INLKKLAXLXKKIS
INLKKLAKLXKKIT,14,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,,0,INLKKLAKLXKKIT
KLKNFAKGVAQSLLNKASCKLSGQC,25,Animalia,Native peptide,,,,,,Anticancer; Antibacterial; Antiparasitic,Tumor active peptide,,Linear,,Free,Free,,,0,KLKNFAKGVAQSLLNKASCKLSGQC
RWKIFKKIEKMGRNIRDGIVKAGPAIQVLGSAKAI,35,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,,0,RWKIFKKIEKMGRNIRDGIVKAGPAIQVLGSAKAI
RTCQSQSHRFRGPCLRRSNCANVCRTEGFPGGRCRGFRRRCFCTTHC,47,Plantae,Native peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Free,,,0,RTCQSQSHRFRGPCLRRSNCANVCRTEGFPGGRCRGFRRRCFCTTHC
YLARAIRRTLARLLL,15,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Free,,,0,YLARAIRRTLARLLL
SWKKFFKKARSLPKLF,16,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Free,,,0,SWKKFFKKARSLPKLF
RRSRFGRFFKKVRKQLGRVLRHSRITVGGRMRF,33,Animalia,Native peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Free,,,0,RRSRFGRFFKKVRKQLGRVLRHSRITVGGRMRF
ITKVITKLLNRLTKILSK,18,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,ITKVITKLLNRLTKILSK
GGKKLFKKILKYL,13,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,C18,Amidation,,,0,GGKKLFKKILKYL
RWCRRYRVRVRGVLVYAYVCW,21,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,RWCRRYRVRVRGVLVYAYVCW
RRWCVYAYVRVRGVRVYAYVCW,22,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,RRWCVYAYVRVRGVRVYAYVCW
WCRRYRVLVRGVLVRYRRCW,20,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,WCRRYRVLVRGVLVRYRRCW
RFCVYAYVRVRGVLVRYRRCF,21,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,RFCVYAYVRVRGVLVRYRRCF
RWXVYAYVRVRGVLVRYRRXW,21,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,RWXVYAYVRVRGVLVRYRRXW
VRKPPYLPRPRWXRXXYNX,19,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,,,0,VRKPPYLPRPRWXRXXYNX
VXKPPYLPRPRWXRXXYNX,19,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,,,0,VXKPPYLPRPRWXRXXYNX
VrKPPYLPRPRWXRXXYNX,19,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,,,0,VRKPPYLPRPRWXRXXYNX
GLFSVVKGVLKGVGKNVSGSLLDQLKCKISGGC,33,Animalia,Native peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Free,,,0,GLFSVVKGVLKGVGKNVSGSLLDQLKCKISGGC
SFLTTVKKLVTNLAALAGTVIDTIKCKVTGGCRT,34,Animalia,Native peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Free,,,0,SFLTTVKKLVTNLAALAGTVIDTIKCKVTGGCRT
SFLTTVKKLVTNLAALAGTVIDTIKCKVTGGC,32,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Free,,,0,SFLTTVKKLVTNLAALAGTVIDTIKCKVTGGC
SFLTTVKKLVTNLAAL,16,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,,0,SFLTTVKKLVTNLAAL
FLFSLIPHAISGLISAFK,18,Synthetic,Native peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,,0,FLFSLIPHAISGLISAFK
FLFKLIPKAIKGLIKAFK,18,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,,0,FLFKLIPKAIKGLIKAFK
FLFSLIPNAISGLLSAFK,18,Animalia,Native peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,,0,FLFSLIPNAISGLLSAFK
FLFKLIPKAIKGLLKAFK,18,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,,0,FLFKLIPKAIKGLLKAFK
SRSSRAGLQFPVGRIHRLLRK,21,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,SRSSRAGLQFPVGRIHRLLRK
RKKRRQRRRCWTKSIPPKPC,20,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Free,,,0,RKKRRQRRRCWTKSIPPKPC
IIKKIIKKIIKKI,13,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,,,0,IIKKIIKKIIKKI
GIIKKIIKKIIKK,13,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,,,0,GIIKKIIKKIIKK
IIKKIIKKIIKK,12,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,,,0,IIKKIIKKIIKK
XCRRLCYRNRCVTYCRGR,18,Animalia,Native peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,,,0,XCRRLCYRNRCVTYCRGR
RWCFRVCYRGICYRKCRG,18,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,RWCFRVCYRGICYRKCRG
KWCFRVCYRGICYRKCRG,18,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,KWCFRVCYRGICYRKCRG
ELLSRVD,7,Bacteria,Native peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,C14H24O2,Free,,,0,ELLSRVD
FLPAIAGLAAKFLPKIFCAITKKC,24,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,FLPAIAGLAAKFLPKIFCAITKKC
FLPAIAGVAAKFLPKIFCAITKKC,24,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,FLPAIAGVAAKFLPKIFCAITKKC
KKLRLKIAFK,10,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,KKLRLKIAFK
VRRFKWWWKFLRR,13,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,,,0,VRRFKWWWKFLRR
CFQWKRAMRKVR,12,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,,0,CFQWKRAMRKVR
FLSGIVaMLaKLF,13,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,,,0,FLSGIVAMLAKLF
FLSaIVGMLaKLF,13,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,,,0,FLSAIVGMLAKLF
FLSAIVGMLAKLF,13,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,,,0,FLSAIVGMLAKLF
RKWWK,5,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,,,0,RKWWK
RWRPPIRRPPIRPPFYP,17,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,RWRPPIRRPPIRPPFYP
RFRWPIRRPPIRPPFYP,17,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,RFRWPIRRPPIRPPFYP
RFRPPIRRPPIRPPWYP,17,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,RFRPPIRRPPIRPPWYP
SKVWRHWRRFWHRAHRKL,18,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,C16,Free,,,0,SKVWRHWRRFWHRAHRKL
VKRTKRGARRGLTKVLKKIFGSIVKKAVSKGV,32,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,VKRTKRGARRGLTKVLKKIFGSIVKKAVSKGV
WYQLIRTFGNLIHQKYRKLLEAYRKLRD,28,Animalia,Native peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,WYQLIRTFGNLIHQKYRKLLEAYRKLRD
VRRSKRGIKVPSFVKKVLKDVVSESIS,27,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,VRRSKRGIKVPSFVKKVLKDVVSESIS
PL,2,Synthetic,Native peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Cyclic,Amide bond: Pro1<--->Leu2,Free,Free,,,0,PL
AGGKRIVQRIKDFLRGAGGKRIVQRIKDFLRG,32,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Free,,,0,AGGKRIVQRIKDFLRGAGGKRIVQRIKDFLRG
AGGKRIVKRIKKFLRGAGGKRIVKRIKKFLRG,32,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Free,,,0,AGGKRIVKRIKKFLRGAGGKRIVKRIKKFLRG
KRIVARIKAFLR,12,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Free,,,0,KRIVARIKAFLR
KRIVKRIKKFLR,12,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Free,,,0,KRIVKRIKKFLR
LPIP,4,Bacteria,Native peptide,,,,,,Anticancer,Tumor active peptide,,Cyclic,Amide bond: Leu1<--->Pro4,Free,Free,,,0,LPIP
FPYG,4,Bacteria,Native peptide,,,,,,Anticancer,Tumor active peptide,,Cyclic,Amide bond: Phe1<--->Gly4,Free,Free,,,0,FPYG
LRKVRRLLRRL,11,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,,0,LRKVRRLLRRL
LRKVWRWLRRL,11,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,,0,LRKVWRWLRRL
LRKFRRLLRRL,11,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,,0,LRKFRRLLRRL
LRRLRRLLRRL,11,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,,0,LRRLRRLLRRL
KAAKKWAKAAKKWAKAWKKAA,21,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,KAAKKWAKAAKKWAKAWKKAA
KAAKKAWKAWKKAAKAWKKAA,21,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,KAAKKAWKAWKKAAKAWKKAA
KAAKKAWKAAKKAWKAWKKAA,21,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,KAAKKAWKAAKKAWKAWKKAA
KWAKKAAKWAKKAAKWAKKAA,21,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,KWAKKAAKWAKKAAKWAKKAA
KAWKKAWKAAKKAWKAAKKAA,21,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,KAWKKAWKAAKKAWKAAKKAA
AAKKWAKAKKWAKAKKWAKAA,21,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,AAKKWAKAKKWAKAKKWAKAA
ELlVDlL,7,Synthetic,Native peptide,,,,,,Anticancer; Antibacterial; Antiviral; Antifungal,Tumor active peptide,,Linear,,3-OH-Me-C14,Free,,,0,ELLVDLL
swlrdiwdwicevlsdfk,18,Synthetic,Synthetic peptide,,,,,,Anticancer; Antiviral,Tumor active peptide,,Linear,,Free,Free,,,0,SWLRDIWDWICEVLSDFK
CWVRLGRYLLRRLKTLFT,18,Synthetic,Synthetic peptide,,,,,,Anticancer; Antiviral,Tumor active peptide,,Linear,,Free,Free,,,0,CWVRLGRYLLRRLKTLFT
GFGCPFNQGQCHKHCQSIRRRGGYCDGFLKTRCVCYR,37,Synthetic,Native peptide,,,,,,Anticancer; Antibacterial; Antiviral,Tumor active peptide,,Linear,,Free,Free,,,0,GFGCPFNQGQCHKHCQSIRRRGGYCDGFLKTRCVCYR
FLGALFKVASKLVPAAICSISKKC,24,Animalia,Native peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Free,,,0,FLGALFKVASKLVPAAICSISKKC
EKIXQSLXFIXKSDXLLHNV,20,Synthetic,Synthetic peptide,,,,,,Anticancer; Antiviral,Tumor active peptide,,Linear,,Free,Free,,,0,EKIXQSLXFIXKSDXLLHNV
EXINXSLXFIRXSDELLHNV,20,Synthetic,Synthetic peptide,,,,,,Anticancer; Antiviral,Tumor active peptide,,Linear,,Free,Free,,,0,EXINXSLXFIRXSDELLHNV
AEIEADRSY,9,Synthetic,Synthetic peptide,,,HLA-A*44,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,AEIEADRSY
GIFDVLKNLAKGVITSLAS,19,Synthetic,Native peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,,0,GIFDVLKNLAKGVITSLAS
GLFDVIKKVASVIGPLG,17,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,GLFDVIKKVASVIGPLG
FLPLIGKLLSGLY,13,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,,,0,FLPLIGKLLSGLY
TTKKEELEKKKKT,13,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,,,0,TTKKEELEKKKKT
FQWQRNIRKVRPRVKRINRQWQF,23,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Amidation,,,0,FQWQRNIRKVRPRVKRINRQWQF
FWRIRIRRPRRIRIRWF,17,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Amidation,,,0,FWRIRIRRPRRIRIRWF
PFWRIRIRRPFWRIRIRR,18,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,PFWRIRIRRPFWRIRIRR
PWRIRIRRPRRIRIWP,16,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Amidation,,,0,PWRIRIRRPRRIRIWP
PWRIRIRRRRIRIRWPPWRIRIRR,24,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Amidation,,,0,PWRIRIRRRRIRIRWPPWRIRIRR
RRWFWRRRRWFWRR,14,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Amidation,,,0,RRWFWRRRRWFWRR
FLFKLIKHAIKGLIKAFK,18,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,FLFKLIKHAIKGLIKAFK
RRRRRRRXPTSNHSPTSCPPTCPGYRWMCLRRF,33,Synthetic,Synthetic peptide,,,,,,Anticancer; Antiviral,Tumor active peptide,,Linear,,Free,Free,,,0,RRRRRRRXPTSNHSPTSCPPTCPGYRWMCLRRF
RRRRRRRXGSLLGRMKGA,18,Synthetic,Synthetic peptide,,,,,,Anticancer; Antiviral,Tumor active peptide,,Linear,,Free,Free,,,0,RRRRRRRXGSLLGRMKGA
RRRRRRRXPLSPPLRNTHPQAMQWNSTTF,29,Synthetic,Synthetic peptide,,,,,,Anticancer; Antiviral,Tumor active peptide,,Linear,,Free,Free,,,0,RRRRRRRXPLSPPLRNTHPQAMQWNSTTF
RRRRRRRXLDPAFR,14,Synthetic,Synthetic peptide,,,,,,Anticancer; Antiviral,Tumor active peptide,,Linear,,Free,Free,,,0,RRRRRRRXLDPAFR
LLCLDGTRKPVTEAQSCHLAVAPNHAVVSR,30,Synthetic,Synthetic peptide,,,,,,Anticancer; Antifungal,Tumor active peptide,,Linear,,Free,Free,,,0,LLCLDGTRKPVTEAQSCHLAVAPNHAVVSR
DGRCLLIIKLAKLAKKLAKLAK,22,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,DGRCLLIIKLAKLAKKLAKLAK
KKWRKWLKWLAKK,13,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,,,0,KKWRKWLKWLAKK
GLFDIVKKVLKLLK,14,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,,0,GLFDIVKKVLKLLK
XTXCXfXRXc,10,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,C12,Free,,,0,XTXCXFXRXC
XTXCXxXXXc,10,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,C12,Free,,,0,XTXCXXXXXC
EKKRLLKWWR,10,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,,,0,EKKRLLKWWR
KWWKLLRKKR,10,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,,,0,KWWKLLRKKR
INLKAIAAMAKKLL,14,Animalia,Native peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,INLKAIAAMAKKLL
FLPIAGKLLSGLSGLL,16,Animalia,Native peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,FLPIAGKLLSGLSGLL
FLSLIPKIAGGIAALVKNL,19,Animalia,Native peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,,0,FLSLIPKIAGGIAALVKNL
KKCNFFCKLKKKVKSVGSRNLIGSATHHHRIYRV,34,Animalia,Native peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Free,,,0,KKCNFFCKLKKKVKSVGSRNLIGSATHHHRIYRV
EGCNILCLLKRKVKAVKNVVKNVVKSVVG,29,Animalia,Native peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Free,,,0,EGCNILCLLKRKVKAVKNVVKNVVKSVVG
IFWLFRGKADVAL,13,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,,0,IFWLFRGKADVAL
IFGTILGFLKGL,12,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,,0,IFGTILGFLKGL
CVRRFPWWWPFLRRC,15,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,CVRRFPWWWPFLRRC
XXXAXLX,7,Bacteria,Native peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Free,,,0,XXXAXLX
WRWRW,5,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,RuC(O),Amidation,,,0,WRWRW
LWKIWKKIWRVGWNWR,16,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Free,,,0,LWKIWKKIWRVGWNWR
LWKIWKKIWRVWKNWR,16,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Free,,,0,LWKIWKKIWRVWKNWR
LWKIGKKIWRVLWNWR,16,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Free,,,0,LWKIGKKIWRVLWNWR
LWKIWWKIWRVWKNWR,16,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Free,,,0,LWKIWWKIWRVWKNWR
KWWKKWKKWW,10,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,,,0,KWWKKWKKWW
LSYXXxXWXXASpP,14,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,LSYXXXXWXXASPP
WCVASpPLSYCGXTXXXlLXXT,22,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,WCVASPPLSYCGXTXXXLLXXT
GSTLLSLL,8,Synthetic,Native peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,C16,Free,,,0,GSTLLSLL
GXFKKTFHKVSHAVKSGIHA,20,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,GXFKKTFHKVSHAVKSGIHA
GIFDVVKGVLKGVGKNVAGSLLEQLKCKLSGGC,33,Synthetic,Native peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,GIFDVVKGVLKGVGKNVAGSLLEQLKCKLSGGC
GKLRLIKKLWVKKWKKKGWKA,21,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,,,0,GKLRLIKKLWVKKWKKKGWKA
GLFDIVKKVLRLLK,14,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Amidation,,,0,GLFDIVKKVLRLLK
GWFDILKHVFRLLK,14,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Amidation,,,0,GWFDILKHVFRLLK
GWYEIIKKIYKWLK,14,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Amidation,,,0,GWYEIIKKIYKWLK
VKAWAKVLKGFGKLLKGFGKL,21,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Amidation,,,0,VKAWAKVLKGFGKLLKGFGKL
FHAWAKLLKGVGRFFKGIGRW,21,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Amidation,,,0,FHAWAKLLKGVGRFFKGIGRW
IRAWAKVLKGVGKILKGVGRW,21,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Amidation,,,0,IRAWAKVLKGVGKILKGVGRW
WRAWAKIYHGVGKLLKGVGRW,21,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Amidation,,,0,WRAWAKIYHGVGKLLKGVGRW
KVNHAACAAHCLLKRKRGGYCNKRRICVCRN,31,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,KVNHAACAAHCLLKRKRGGYCNKRRICVCRN
RSKKWRKIEKRVKKIFEKTKEALPVIQGVATIVGAVGR,38,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Free,,,0,RSKKWRKIEKRVKKIFEKTKEALPVIQGVATIVGAVGR
GSKRWRKFEKRVKKIFEETKEALPVIQGVATIVGAVGR,38,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Free,,,0,GSKRWRKFEKRVKKIFEETKEALPVIQGVATIVGAVGR
nfwxXGxWTIGS,12,Bacteria,Native peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,4-ME-C6,Free,,,0,NFWXXGXWTIGS
nywxXGxWTIGS,12,Synthetic,Native peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,4-ME-C6,Free,,,0,NYWXXGXWTIGS
PFRLRLRL,8,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,,,0,PFRLRLRL
PWRLRLRL,8,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,,,0,PWRLRLRL
GIKEFKRIVQRIKDFLRNLV,20,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antiviral,Tumor active peptide,,Linear,,Free,Amidation,,,0,GIKEFKRIVQRIKDFLRNLV
Gikefkrivqrikdflrnlv,20,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antiviral,Tumor active peptide,,Linear,,Free,Amidation,,,0,GIKEFKRIVQRIKDFLRNLV
IRIILRAQGALKI,13,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,IRIILRAQGALKI
ALWKDLLKNVGIAAGKAALNKVTDMVNQ,28,Animalia,Native peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,,0,ALWKDLLKNVGIAAGKAALNKVTDMVNQ
RLMRIFRILKLAR,13,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,RLMRIFRILKLAR
RMMRIFWVIKLAR,13,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,RMMRIFWVIKLAR
vTVvpXxxxvFXV,13,Animalia,Native peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,5-ME-C6,Free,,,0,VTVVPXXXXVFXV
XsfATX,6,Fungi,Native peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Free,,,0,XSFATX
AFXGVL,6,Bacteria,Native peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Free,,,0,AFXGVL
XVTXVXVXXVXV,12,Bacteria,Native peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,XVTXVXVXXVXV
XXPXxX,6,Bacteria,Native peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,XXPXXX
LXIGxP,6,Bacteria,Native peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,2-OH-ME-C5,OMe,,,0,LXIGXP
XxXAlV,6,Fungi,Native peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,XXXALV
Xaix,4,Fungi,Native peptide,,,,,,Anticancer; Antiviral,Tumor active peptide,,Linear,,Free,Free,,,0,XAIX
lLFXF,5,Fungi,Native peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,LLFXF
NNXnyNQP,8,Bacteria,Native peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Free,,,0,NNXNYNQP
XXVXXV,6,Bacteria,Native peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,XXVXXV
XXPXXV,6,Bacteria,Native peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,XXPXXV
XTXPX,5,Bacteria,Native peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,DiMe-C8,Free,,,0,XTXPX
GIINTLQKYYCRVRGGRCAVLSCRSQEYRIGRCSTRGRKCCRRKK,45,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,GIINTLQKYYCRVRGGRCAVLSCRSQEYRIGRCSTRGRKCCRRKK
GlXGVY,6,Fungi,Native peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,GLXGVY
AFxX,4,Fungi,Native peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,AFXX
PVVXY,5,Fungi,Native peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,PVVXY
FPVPLPI,7,Animalia,Native peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,FPVPLPI
ATPFVPP,7,Animalia,Native peptide,,,,,,Anticancer; Antibacterial; Antiviral; Antiparasitic,Tumor active peptide,,Linear,,Free,Free,,,0,ATPFVPP
LFPXSXP,7,Animalia,Native peptide,,,,,,Anticancer; Antibacterial; Antiviral; Antiparasitic,Tumor active peptide,,Linear,,Free,Free,,,0,LFPXSXP
FPXFSPX,7,Animalia,Native peptide,,,,,,Anticancer; Antibacterial; Antiviral; Antiparasitic,Tumor active peptide,,Linear,,Free,Free,,,0,FPXFSPX
WPISFVP,7,Synthetic,Native peptide,,,,,,Anticancer; Antibacterial; Antiviral; Antiparasitic,Tumor active peptide,,Linear,,Free,Free,,,0,WPISFVP
IIILPPXP,8,Animalia,Native peptide,,,,,,Anticancer; Antibacterial; Antiviral; Antiparasitic,Tumor active peptide,,Linear,,Free,Free,,,0,IIILPPXP
LLPFPYPTPF,10,Animalia,Native peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,LLPFPYPTPF
IFSPIPL,7,Animalia,Native peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,IFSPIPL
AXXlXX,6,Bacteria,Native peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,PivOH,Free,,,0,AXXLXX
XXXXPX,6,Bacteria,Native peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,MeOya,Free,,,0,XXXXPX
fXXXXXNfPPR,11,Animalia,Native peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,MeOAc,Free,,,0,FXXXXXNFPPR
ExYxEaPQyI,10,Synthetic,Native peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,3-OH-C16,Free,,,0,EXYXEAPQYI
nnsNXNQPy,9,Synthetic,Native peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Free,,,0,NNSNXNQPY
AFXGVl,6,Fungi,Native peptide,,,,,,Anticancer; Antibacterial; Antiviral,Tumor active peptide,,Linear,,Free,Free,,,0,AFXGVL
ALXGVl,6,Fungi,Native peptide,,,,,,Anticancer; Antibacterial; Antiparasitic,Tumor active peptide,,Linear,,Free,Free,,,0,ALXGVL
AYXGVl,6,Fungi,Native peptide,,,,,,Anticancer; Antibacterial; Antiparasitic,Tumor active peptide,,Linear,,Free,Free,,,0,AYXGVL
AMXGVl,6,Fungi,Native peptide,,,,,,Anticancer; Antibacterial; Antiparasitic,Tumor active peptide,,Linear,,Free,Free,,,0,AMXGVL
AAXGVL,6,Fungi,Native peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,AAXGVL
XFXFLPX,7,Fungi,Native peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,XFXFLPX
XFXFLXX,7,Fungi,Native peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,XFXFLXX
GMFTNMLKGIGKLAGKAALGAVKTLA,26,Animalia,Native peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,,,0,GMFTNMLKGIGKLAGKAALGAVKTLA
XPX,3,Fungi,Native peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,XPX
GRLIDKIARKLVKKIQRFARKFF,23,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,GRLIDKIARKLVKKIQRFARKFF
NLRTYKKRYMFY,12,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antiparasitic,Tumor active peptide,,Linear,,Free,Amidation,,,0,NLRTYKKRYMFY
YNKKYMKHLKPCKKA,15,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antiparasitic,Tumor active peptide,,Linear,,Free,Amidation,,,0,YNKKYMKHLKPCKKA
YNKKYRYHLKSCKKADK,17,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antiparasitic,Tumor active peptide,,Linear,,Free,Amidation,,,0,YNKKYRYHLKSCKKADK
RKKAIKLVKKLVKKLKKALK,20,Synthetic,,,,,,,Anticancer,Tumor active peptide,,Linear,,,,,,0,RKKAIKLVKKLVKKLKKALK
FLKAIKKFGKEFKKIGAKLK,20,Synthetic,,,,,,,Anticancer,Tumor active peptide,,Linear,,,,,,0,FLKAIKKFGKEFKKIGAKLK
RRRR,4,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,C12,C12,,,0,RRRR
HHHH,4,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,C12,C12,,,0,HHHH
VG,2,Synthetic,Synthetic peptide,,,,,,Anticancer; Parasite,Tumor active peptide,,Linear,,Free,Free,,,0,VG
WA,2,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Free,,,0,WA
WX,2,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,WX
WG,2,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Free,,,0,WG
WW,2,Synthetic,Native peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Free,,,0,WW
Wp,2,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,WP
wp,2,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,WP
Wa,2,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,WA
wa,2,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,WA
wA,2,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,WA
WH,2,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,WH
VRKPPYLPRPRPPRrIYNr,19,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,,,0,VRKPPYLPRPRPPRRIYNR
Pr,2,Bacteria,Native peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,PR
LX,2,Fungi,Native peptide,,,,,,Anticancer; Antifungal,Tumor active peptide,,Linear,,Free,Free,,,0,LX
FX,2,Synthetic,Native peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,X=Hyp,,0,FX
PV,2,Synthetic,Native peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Free,,,0,PV
IP,2,Bacteria,Native peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,IP
XI,2,Bacteria,Native peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,XI
PP,2,Bacteria,Native peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,PP
LXFX,4,Bacteria,Native peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,LXFX
xi,2,Animalia,Native peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,XI
FC,2,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,FC
HF,2,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Free,,,0,HF
HY,2,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Free,,,0,HY
WS,2,Bacteria,Native peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,WS
ws,2,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,WS
wS,2,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,WS
Ws,2,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,WS
WT,2,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,WT
WE,2,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,WE
WK,2,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,WK
HA,2,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Free,,,0,HA
HG,2,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Free,,,0,HG
PI,2,Fungi,Native peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,PI
SIFSLFKMGAKALGKTLLKQAGKAGAEYAACKATNQC,37,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,,,0,SIFSLFKMGAKALGKTLLKQAGKAGAEYAACKATNQC
SILSLFKMGAKALGKTLIKQAGKAGAEYVACKATNQC,37,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,,,0,SILSLFKMGAKALGKTLIKQAGKAGAEYVACKATNQC
GLWSKIKNVAAAAGKAALGAL,21,Animalia,Native peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,,0,GLWSKIKNVAAAAGKAALGAL
GLWKKIKNVAAAAGKAALGAL,21,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,,0,GLWKKIKNVAAAAGKAALGAL
GLWKKIKNVAKAAGKAALGAL,21,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,,0,GLWKKIKNVAKAAGKAALGAL
GLWKKIKNVAKAAGKAAKGAL,21,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,,0,GLWKKIKNVAKAAGKAAKGAL
WLWKKIKNVAKAAGKAAKGAL,21,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,,0,WLWKKIKNVAKAAGKAAKGAL
XLXVVVKVVKYLX,13,Bacteria,Native peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,2-OH-ME-C5,Free,,,0,XLXVVVKVVKYLX
XLXIIVKIVKYLX,13,Bacteria,Native peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,2-OH-ME-C5,Free,,,0,XLXIIVKIVKYLX
XLXIIVKVVKYLX,13,Synthetic,Native peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,2-OH-ME-C5,Free,,,0,XLXIIVKVVKYLX
XLXIVVKVVKYLX,13,Synthetic,Native peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,2-OH-ME-C5,Free,,,0,XLXIVVKVVKYLX
PxTXXLPX,8,Synthetic,Native peptide,,,,,,Anticancer; Antiviral,Tumor active peptide,,Linear,,C3H3O2,Free,,,0,PXTXXLPX
GVITDTLKGVAKTVAAELLRKAHCKLTNSC,30,Animalia,Native peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Free,,,0,GVITDTLKGVAKTVAAELLRKAHCKLTNSC
GFGCPWNAYECDRHCVSKGYTGGNCRGKIRQTCHCY,36,Bacteria,Native peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,GFGCPWNAYECDRHCVSKGYTGGNCRGKIRQTCHCY
xVXvxVXvxVXv,12,Bacteria,Native peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Free,x(1/9)=2R-hydroxy-3S-methyl-valeryl-R-valine; x(5)=2R-hydroxy-4-methyl-valeryl-R-valine; X=S-lactic acid-S-Val,,0,XVXVXVXVXVXV
GXVFXPI,7,Bacteria,Native peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Cyclic,Amide bond: Gly1<--->Ile7,Free,Free,"X(2)=2,2-dimethyl-3-hydroxy-7-octynoic (Dhoya); X(5)=2-Hydroxy 3-methyl pentanoic acid (Hmpa)",,0,GXVFXPI
GXVXXPV,7,Bacteria,Native peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Cyclic,Amide bond: Gly1<--->Val7,Free,Free,"X(2)=2,2-dimethyl-3-hydroxy-7-octynoic (Dhoya); X(4)=N-Me-Phe; X(5)=2-Hydroxy 3-methyl pentanoic acid (Hmpa)",,0,GXVXXPV
SYEKKINRHFKILKKNLKKK,20,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,SYEKKINRHFKILKKNLKKK
KP,2,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,KP
FKGLAKLLKIGLKALAKVIQ,9,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,,,,,0,FKGLAKLLKIGLKALAKVIQ
NKGLAKLLKIGLKALESVIQ,20,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,NKGLAKLLKIGLKALESVIQ
NXV,3,Fungi,Native peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,3-OH-C14,Free,,,0,NXV
NXL,3,Fungi,Native peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,3-OH-C14,Free,,,0,NXL
NQL,3,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,C8,Free,,,0,NQL
NQX,3,Fungi,Native peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,NQX
GNHDCCMGQLPKCMLGPGQGAATCQGK,27,Synthetic,Native peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,GNHDCCMGQLPKCMLGPGQGAATCQGK
GFGCPFNQGKCHRHCRSIRRRGGYCDGFLKQRCVCYRK,38,Animalia,Native peptide,,,,,,Anticancer; Antiviral,Tumor active peptide,,Linear,,Free,Free,,,0,GFGCPFNQGKCHRHCRSIRRRGGYCDGFLKQRCVCYRK
GLLGKILGAGKKVLCGVSGLC,21,Animalia,Native peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Free,,,0,GLLGKILGAGKKVLCGVSGLC
GLLGKILGAGKKVLLGVSGLL,21,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Free,,,0,GLLGKILGAGKKVLLGVSGLL
MGRFKRFRKKFKKLFKKLS,19,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antiviral,Tumor active peptide,,Linear,,Free,Free,,,0,MGRFKRFRKKFKKLFKKLS
RRIRIRPPRLPRPRPRPYFMPRP,23,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,RRIRIRPPRLPRPRPRPYFMPRP
KRWKKFFRKVIKFF,14,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,,,0,KRWKKFFRKVIKFF
KRLKKIFKKMIKIF,14,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,,,0,KRLKKIFKKMIKIF
WKRFHPFRVVRKIFRRRIKR,20,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,WKRFHPFRVVRKIFRRRIKR
xXxXxX,6,Fungi,Native peptide,,,,,,Anticancer; Antibacterial; Antiparasitic,Tumor active peptide,,Linear,,Free,Free,,,0,XXXXXX
AAQYVXX,7,Fungi,Native peptide,,,,,,Anticancer; Antibacterial; Antiparasitic; Antifungal,Tumor active peptide,,Linear,,Free,Free,,,0,AAQYVXX
XxXxXxXx,8,Fungi,Native peptide,,,,,,Anticancer; Antibacterial; Antiparasitic,Tumor active peptide,,Linear,,Free,Free,"X=MeLeu; x=D-HIV, 2-d-hydroxyisovaleric acid ",,0,XXXXXXXX
VCIIIIC,7,Animalia,Native peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,PEA,,,0,VCIIIIC
XXXVIAfX,8,Bacteria,Native peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,OMe,,,0,XXXVIAFX
KWKLFKKIGAVLKVLC,16,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,KWKLFKKIGAVLKVLC
KWKLFKKLGAVLKVLC,16,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,KWKLFKKLGAVLKVLC
GLRRALLRLLRSLRRLLLRAC,21,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,GLRRALLRLLRSLRRLLLRAC
GLARALTRLLRQLTRQLTRAC,21,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,GLARALTRLLRQLTRQLTRAC
LCXIIKKIIKKIIKKII,17,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Amidation,,,0,LCXIIKKIIKKIIKKII
KKMMKKGGKFGTFMAIGMGIR,21,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,KKMMKKGGKFGTFMAIGMGIR
KKMMKKGGKFGTFMAIGGIR,20,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,KKMMKKGGKFGTFMAIGGIR
SWKSMAKKLKEYMEKLKQRA,20,Animalia,Native peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,SWKSMAKKLKEYMEKLKQRA
LAKKLKEYLEKLV,13,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,LAKKLKEYLEKLV
LIKKLKEYLKKLI,13,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,LIKKLKEYLKKLI
LAKKLAKYLKKAL,13,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,LAKKLAKYLKKAL
rGDFV,5,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,RGDFV
RGdFV,5,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,RGDFV
RGDfV,5,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,RGDFV
RGDFv,5,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,RGDFV
GRGDS,5,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,GRGDS
RGDfK,5,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,RGDFK
WNWTKRF,7,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,WNWTKRF
XXXXXXXAXXX,11,Bacteria,Native peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,"X(1)=Me2Val; X(2)=Hva, α-Hydroxyisovaleric acid; X(3)=Me2Ser; X(4)=MeLeu; X(5)=MeThr(Trt); X(6)=MeSer(Me); X(7)=MeIle; M(9)=MeLeu; X(10)=MeTyr; X(11)=MeAla",,0,XXXXXXXAXXX
XXXXXXXAXXx,11,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,"X(1)=Me2Val; X(2)=Hva, α-Hydroxyisovaleric acid; X(3)=Me2Ser; X(4)=MeLeu; X(5)=MeThr(Trt); X(6)=MeSer(Me); X(7)=MeIle; M(9)=MeLeu; X(10)=MeTyr; X(12)=D-MeAla",,0,XXXXXXXAXXX
XLLXL,5,Synthetic,Native peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,XLLXL
XLFXL,5,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,X=METH-Leu,,0,XLFXL
XLfXL,5,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,X=METH-Leu,,0,XLFXL
XLFxL,5,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,X(1)=METH-Leu; x(4)=D-METH-Leu,,0,XLFXL
XLFXl,5,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,X=METH-Leu,,0,XLFXL
xLFXL,5,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,x(1)=D-METH-Leu; X(4)=METH-Leu,,0,XLFXL
XlFXL,5,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,X=METH-Leu,,0,XLFXL
LXVLF,5,Fungi,Native peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,LXVLF
GGGGGGGRGDLPETGGS,17,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,GGGGGGGRGDLPETGGS
GGGGRGDRGDLPETGGS,17,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,GGGGRGDRGDLPETGGS
GRGDRGDRGDLPETGGS,17,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,GRGDRGDRGDLPETGGS
AWIWLV,6,Bacteria,Native peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,AWIWLV
PNVIPLL,7,Animalia,Native peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,PNVIPLL
PIFYLPL,7,Animalia,Native peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,PIFYLPL
PIFPIYF,7,Animalia,Native peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,PIFPIYF
PFPFIFP,7,Synthetic,Native peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,PFPFIFP
PLWPVIPI,8,Synthetic,Native peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,PLWPVIPI
GHPLFPP,7,Animalia,Native peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,GHPLFPP
DFVLPPP,7,Synthetic,Native peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,DFVLPPP
GFVPFTIP,8,Plantae,Native peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,GFVPFTIP
NPFTIFP,7,Animalia,Native peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,NPFTIFP
LVPWPFPT,8,Animalia,Native peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,LVPWPFPT
FXX,3,Fungi,Native peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,FXX
FyXrXGeX,8,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Amidation,,,0,FYXRXGEX
EKRWRRLIFNYF,12,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,EKRWRRLIFNYF
FILYGLIRFGRLLRK,15,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,FILYGLIRFGRLLRK
RAVIYKIPYNAIASRWIIAPKKC,23,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,RAVIYKIPYNAIASRWIIAPKKC
VGALAGFLYWHFLRKGTKMVGK,22,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,VGALAGFLYWHFLRKGTKMVGK
GPFYVI,6,Plantae,Native peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,GPFYVI
GSLPPIF,7,Plantae,Native peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,GSLPPIF
GPISFV,6,Plantae,Native peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,GPISFV
LVFPIFPP,8,Synthetic,Native peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,LVFPIFPP
MKKLLLILFCLALALAGCKKAP,22,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,,,0,MKKLLLILFCLALALAGCKKAP
VLGLALIVGGALLIKKKQAKS,21,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,,,0,VLGLALIVGGALLIKKKQAKS
GIFKVLKNLAKGVITSLAS,19,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,,0,GIFKVLKNLAKGVITSLAS
GIFDVLKNLAKGVITSLKS,19,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Amidation,,,0,GIFDVLKNLAKGVITSLKS
GIFKVLKNLAKGVITSLKS,19,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Free,,,0,GIFKVLKNLAKGVITSLKS
CLLFVY,6,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,CLLFVY
FSLVNADQTT,10,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Free,,,0,FSLVNADQTT
FAKKLAKLKKKLAKLALAL,19,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,FAKKLAKLKKKLAKLALAL
FAKKLAKLKKKLAKLAKKR,19,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,FAKKLAKLKKKLAKLAKKR
LXLPL,5,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,LXLPL
LPLPL,5,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,LPLPL
lPLPL,5,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,LPLPL
LPlPL,5,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,LPLPL
LPLPl,5,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,LPLPL
lPLPl,5,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,LPLPL
LPlPl,5,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,LPLPL
lPlPl,5,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,LPLPL
KLLPSVVGLFKKKKQ,15,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Acetylation,Amidation,,,0,KLLPSVVGLFKKKKQ
KLLKKVVKLFKKKKK,15,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Acetylation,Amidation,,,0,KLLKKVVKLFKKKKK
KLLKKVVKLFKKLLK,15,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Acetylation,Amidation,,,0,KLLKKVVKLFKKLLK
KLLKKLLKLLKKLLK,15,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Acetylation,Amidation,,,0,KLLKKLLKLLKKLLK
KIIKKIIKIIKKIIK,15,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Acetylation,Amidation,,,0,KIIKKIIKIIKKIIK
KVVKKVVKVVKKVVK,15,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Acetylation,Amidation,,,0,KVVKKVVKVVKKVVK
KIIKKIKKKIKKIIK,15,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Acetylation,Amidation,,,0,KIIKKIKKKIKKIIK
KLLKKLKKKLKKLLK,15,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Acetylation,Amidation,,,0,KLLKKLKKKLKKLLK
KVVKKVKKKVKKVVK,15,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Acetylation,Amidation,,,0,KVVKKVKKKVKKVVK
IKKIIKIIKKIIKKI,15,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Acetylation,Amidation,,,0,IKKIIKIIKKIIKKI
IIIKKIKKKIKKIII,15,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Acetylation,Amidation,,,0,IIIKKIKKKIKKIII
KIIIKIKKKIKIIIK,15,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Acetylation,Amidation,,,0,KIIIKIKKKIKIIIK
ARCCLVMPVPPFACVKFCS,19,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Free,,,0,ARCCLVMPVPPFACVKFCS
GSRGWGFEPGVRCLIWCD,18,Bacteria,Native peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,GSRGWGFEPGVRCLIWCD
GGGGRGYEYNKQCLIFC,17,Bacteria,Native peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,GGGGRGYEYNKQCLIFC
LKTKALNKLKQKLQAVGNLIGSVIKG,26,Animalia,Native peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Free,,,0,LKTKALNKLKQKLQAVGNLIGSVIKG
rlfrrvkkvagkiakriwk,19,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,,,0,RLFRRVKKVAGKIAKRIWK
LKLKLKLTGKLKLKL,15,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,,,0,LKLKLKLTGKLKLKL
LKLKLKVpPTKLKLKL,16,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,,,0,LKLKLKVPPTKLKLKL
LKLKLKpGKLKLKL,14,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,,,0,LKLKLKPGKLKLKL
LKLKLKINGKKLKLKL,16,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,,,0,LKLKLKINGKKLKLKL
LKLKLKpNKLKLKL,14,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,,,0,LKLKLKPNKLKLKL
GWGSFFRRAAHVGRHVGRAALTHYL,25,Synthetic,Synthetic peptide,,HEK293: IC50=40.1 ± 4.1 µg/ml,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,,,0,GWGSFFRRAAHVGRHVGRAALTHYL
gwgsffrraahvgrhvgraalthyl,25,Synthetic,Synthetic peptide,,HEK293: IC50=36.4 ± 4.3 µg/ml,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,,,0,GWGSFFRRAAHVGRHVGRAALTHYL
GWGSFFKKAAHAGKHAGKAALTHYL,25,Synthetic,Synthetic peptide,,HEK293: IC50~400 µg/ml,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,,,0,GWGSFFKKAAHAGKHAGKAALTHYL
gwgsffkkaahagkhagkaalthyl,25,Synthetic,Synthetic peptide,,HEK293: IC50=217.3 ± 46.5 µg/ml,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Amidation,,,0,GWGSFFKKAAHAGKHAGKAALTHYL
LPGP,4,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,LPGP
DYVP,4,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,DYVP
GYVPLWP,7,Plantae,Native peptide,,,,,,Anticancer; Antifungal,Tumor active peptide,,Linear,,Free,Free,,,0,GYVPLWP
AFPGLSF,7,Plantae,Native peptide,,,,,,Anticancer; Antibacterial; Antifungal,Tumor active peptide,,Linear,,Free,Free,,,0,AFPGLSF
GGYGPFP,7,Synthetic,Native peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,GGYGPFP
GIGFYSP,7,Synthetic,Native peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,GIGFYSP
IFPYPIP,7,Animalia,Native peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,IFPYPIP
GYPFA,5,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,GYPFA
AYPFG,5,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,AYPFG
FSPFG,5,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,FSPFG
VYPIA,5,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,VYPIA
PYVFA,5,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,PYVFA
FYPVG,5,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,FYPVG
FYPFV,5,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,FYPFV
FYPFA,5,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,FYPFA
TVPFA,5,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,TVPFA
FYPFI,5,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,FYPFI
VTPFL,5,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,VTPFL
PYFFL,5,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,PYFFL
PYGFV,5,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,PYGFV
FTPFV,5,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,FTPFV
FSPFA,5,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,FSPFA
FSPAG,5,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,FSPAG
FYPFG,5,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,FYPFG
AAWIPPG,7,Plantae,Native peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,AAWIPPG
NVlLWK,6,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,NVLLWK
FfXTG,5,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,FFXTG
FxTkVf,6,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,FXTKVF
FxTxVf,6,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,FXTXVF
FkTrVf,6,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,FKTRVF
FrTrVf,6,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,FRTRVF
wSxXxSwF,8,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,WSXXXSWF
xXxFfF,6,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,XXXFFF
vTxXxWavvF,10,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,VTXXXWAVVF
AvVWXyWS,8,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,AVVWXYWS
VxvvXtKf,8,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,VXVVXTKF
WFkXxFf,7,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,WFKXXFF
xTxXwTavvF,10,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,XTXXWTAVVF
fXaTlF,6,Synthetic,Native peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,X=Enduracididine,,0,FXATLF
vLnSxF,6,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,VLNSXF
VrTtFf,6,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,VRTTFF
fVrtF,5,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,FVRTF
WkTkVwWava,10,Synthetic,Synthetic peptide,,,,,,Anticancer; Antibacterial,Tumor active peptide,,Linear,,Free,Free,,,0,WKTKVWWAVA
GLLSVLGSVAKHVLPHVVPVIAEHL,25,Litoria splendida,Native peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Amidation,Acetylation,,,0,GLLSVLGSVAKHVLPHVVPVIAEHL
DHYNCVSSGGQCLYSACPIFTKIQGTCYRGKAKCCK,36,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,DHYNCVSSGGQCLYSACPIFTKIQGTCYRGKAKCCK
GLFGVLAKVAAHVVPAIAEHF,21,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Amidation,Amidation,,,0,GLFGVLAKVAAHVVPAIAEHF
AGRGKQGGKVRAKAKTRSSRAGLQFPVGRVHRLLRKGNY,39,Bufo bufo,Native peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,AGRGKQGGKVRAKAKTRSSRAGLQFPVGRVHRLLRKGNY
GFVDFLKKVAGTIANVVT,18,Litoria genimaculata,Native peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Amidation,Amidation,,,0,GFVDFLKKVAGTIANVVT
GLFDIIKKVASVVGGL,16,Litoria citropa,Native peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Amidation,Amidation,,,0,GLFDIIKKVASVVGGL
GLLSVLGSVAKHVLPHVVPVIAEKL,25,Litoria rothii,Native peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Amidation,Amidation,,,0,GLLSVLGSVAKHVLPHVVPVIAEKL
GRFKRFRKKFKKLFKKLSPVIPLLHLG,27,Bos taurus,Native peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Amidation,Amidation,,,0,GRFKRFRKKFKKLFKKLSPVIPLLHLG
GLLDIVKKVVGAFGSL,16,Litoria raniformis,Native peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Amidation,Amidation,,,0,GLLDIVKKVVGAFGSL
GLLQTIKEKLESLESLAKGIVSGIQA,26,Litoria genimaculata,Native peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Amidation,Amidation,,,0,GLLQTIKEKLESLESLAKGIVSGIQA
RRRPRPPYLPRPRPPPFFPPRLPPRIPPGFPPRFPPRFP,39,Sus scrofa,Native peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Amidation,Amidation,,,0,RRRPRPPYLPRPRPPPFFPPRLPPRIPPGFPPRFPPRFP
GGLRSLGRKILRAWKKYGPIIVPIIRIG,28,Bos taurus,Native peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Amidation,Amidation,,,0,GGLRSLGRKILRAWKKYGPIIVPIIRIG
GLFDIIKKIAESI,13,Litoria aurea,Native peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Amidation,Amidation,,,0,GLFDIIKKIAESI
GLFDIIKKVASVIGGL,16,Litoria citropa,Native peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Amidation,Amidation,,,0,GLFDIIKKVASVIGGL
GLFDIVKKVVGAIGSL,16,Litoria aurea,Native peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Amidation,Amidation,,,0,GLFDIVKKVVGAIGSL
GLFDIVKKVVGALGSL,16,Litoria aurea,Native peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Amidation,Amidation,,,0,GLFDIVKKVVGALGSL
GLFGVLAKVASHVVPAIAEHFQA,23,Litoria genimaculata,Native peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Amidation,,,0,GLFGVLAKVASHVVPAIAEHFQA
GLFKVLGSVAKHLLPHVAPVIAEK,24,Litoria xanthomera,Native peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Amidation,Amidation,,,0,GLFKVLGSVAKHLLPHVAPVIAEK
GLMSSIGKALGGLIVDVLKPKTPAS,25,Litoria aurea,Native peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,GLMSSIGKALGGLIVDVLKPKTPAS
ILGPVISTIGGVLGGLLKNL,20,Bombina maxima,Native peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Amidation,Amidation,,,0,ILGPVISTIGGVLGGLLKNL
LKLKSIVSWAKKVL,14,Torpedo marmorata,Native peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Amidation,Amidation,,,0,LKLKSIVSWAKKVL
AVPDVAFNAYG,11,Halobacteroides halobius,Native peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,AVPDVAFNAYG
GLFKVLGSVAKHLLPHVVPVIAEK,24,Litoria chloris,Native peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Amidation,Amidation,,,0,GLFKVLGSVAKHLLPHVVPVIAEK
GLFSVLGAVAKHVLPHVVPVIAEKL,25,Litoria xanthomera,Native peptide,,,,,,Anticancer,Tumor active peptide,,,,Amidation,Amidation,,,0,GLFSVLGAVAKHVLPHVVPVIAEKL
ITSISLCTPGCKTGALMGCNMKTATCHCSIHVSK,34,Bacteria,Native peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,ITSISLCTPGCKTGALMGCNMKTATCHCSIHVSK
GLFGVLGSIAKHVLPHVVPVIAEKL,25,Litoria splendida,Native peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Amidation,Amidation,,,0,GLFGVLGSIAKHVLPHVVPVIAEKL
GLLGLLGSVVSHVLPAITQHL,21,Litoria chloris,Native peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Amidation,Amidation,,,0,GLLGLLGSVVSHVLPAITQHL
GLLSVLGSVVKHVIPHVVPVIAEHL,25,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Amidation,Amidation,,,0,GLLSVLGSVVKHVIPHVVPVIAEHL
GRRRRSVQWCAVSQPEATKCFQWQRNMRKVRGPPVSCIKRDSPIQCIQA,49,Arabidopsis thaliana,Native peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Amidation,Amidation,,,0,GRRRRSVQWCAVSQPEATKCFQWQRNMRKVRGPPVSCIKRDSPIQCIQA
KSSAYSLQMGATAIKQVKKLFKKWGW,26,Lactobacillus plantarum,Native peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,KSSAYSLQMGATAIKQVKKLFKKWGW
TESYFVFSVGM,11,Treponema succinifaciens,Native peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Amidation,Amidation,,,0,TESYFVFSVGM
VNWKKILGKIIKVAK,15,Lasioglossum laticeps,Native peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Amidation,Amidation,,,0,VNWKKILGKIIKVAK
VNWKKVLGKIIKVAK,15,Helicobacter mustelae,Native peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Amidation,Amidation,,,0,VNWKKVLGKIIKVAK
ECRRLCYKQRCVTYCRGR,18,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,,Amidation,Amidation,,,0,ECRRLCYKQRCVTYCRGR
FKCRRWQWRMKKLGA,15,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Acetylation,,,0,FKCRRWQWRMKKLGA
FLPIIAGVAAKVLPKIFCAISKKC,24,Lithobates blairi,Native peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,FLPIIAGVAAKVLPKIFCAISKKC
GLLGLLGSVVSHVVPAIVGHF,21,Litoria eucnemis,Native peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Amidation,,,0,GLLGLLGSVVSHVVPAIVGHF
GLLSVLGSVAQHVLPHVVPVIAEHL,25,Litoria caerulea,Native peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Amidation,,,0,GLLSVLGSVAQHVLPHVVPVIAEHL
ITSISLCTPGCKTGALMGCNMKTATCNCSIHVSK,34,Lactococcus lactis,Native peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,ITSISLCTPGCKTGALMGCNMKTATCNCSIHVSK
KSCCPNTTGRNIYNACRLTGAPRPTCAKLSGCKIISGSTCPSDYPK,46,Viscum album,Native peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,KSCCPNTTGRNIYNACRLTGAPRPTCAKLSGCKIISGSTCPSDYPK
ATPATPTVAQFVIQGSTICLVC,22,Streptomyces,Native peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,ATPATPTVAQFVIQGSTICLVC
FFSLLPSLIGGLVSAIK,17,,,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Amidation,,,0,FFSLLPSLIGGLVSAIK
GLFDIVKKVVGTLAGL,16,Litoria raniformis,Native peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Amidation,,,0,GLFDIVKKVVGTLAGL
GLFGVLGSIAKHVLPHVVPVIAEK,24,Litoria chloris,Native peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Amidation,,,0,GLFGVLGSIAKHVLPHVVPVIAEK
KSCCPNTTGRNIYNTCRFAGGSRERCAKLSGCKIISASTCPSDYPK,46,Viscum album,Native peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,KSCCPNTTGRNIYNTCRFAGGSRERCAKLSGCKIISASTCPSDYPK
KSCCPNTTGRNIYNTCRLGGGSRERCASLSGCKIISASTCPSDYPK,46,Viscum album,Native peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,KSCCPNTTGRNIYNTCRLGGGSRERCASLSGCKIISASTCPSDYPK
ADDKNPLEEFRETNYEVFLEIAKNGLKATSNPKRVVIVGAGMAGLSAAY,49,Bothrops pirajai,Native peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,ADDKNPLEEFRETNYEVFLEIAKNGLKATSNPKRVVIVGAGMAGLSAAY
ALWKNMLKGIGKLAGQAALGAVKTLVGAE,29,Phyllomedusa bicolor,Native peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,ALWKNMLKGIGKLAGQAALGAVKTLVGAE
GETDPNTQLLNDLGNNMAWGAALGAPGGLGSAALGAAGGALQTVGQGLIDHGPVNVFIPVLIGPSWNGSGSGYNSATSSSGSGS,84,Klebsiella pneumoniae,Native peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,GETDPNTQLLNDLGNNMAWGAALGAPGGLGSAALGAAGGALQTVGQGLIDHGPVNVFIPVLIGPSWNGSGSGYNSATSSSGSGS
GLICESCRKIIQKLEDMVGPQPNEDTVTQAASRVCDKMKILRGVCKKIMRTFLRRISKDILTGKKPQAICVDIKICKE,78,Sus scrofa,Native peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,GLICESCRKIIQKLEDMVGPQPNEDTVTQAASRVCDKMKILRGVCKKIMRTFLRRISKDILTGKKPQAICVDIKICKE
GLPVCGETCFGGTCNTPGCSCDPWPMCSRN,30,Viola arvensis,Native peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,GLPVCGETCFGGTCNTPGCSCDPWPMCSRN
GVPICGETCVGGTCNTPGCSCSWPVCTRN,29,Oldenlandia affinis,Native peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,GVPICGETCVGGTCNTPGCSCSWPVCTRN
GVPVCGETCFGGTCNTPGCSCDPWPVCSRN,30,Viola arvensis,Native peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,GVPVCGETCFGGTCNTPGCSCDPWPVCSRN
ILPILSLIGGLLGK,14,Rana amurensis,Native peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Amidation,,,0,ILPILSLIGGLLGK
GIPCGESCVFIPCLTSAIDCSCKSKVCYRN,30,Viola philippica,Native peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,GIPCGESCVFIPCLTSAIDCSCKSKVCYRN
GLFDIVKKVVGTIAGL,16,Litoria aurea,Native peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Amidation,,,0,GLFDIVKKVVGTIAGL
GRDYRTCLTIVQKLKKMVDKPTQRSVSNAATRVCRTGRSRWRDVCRNFMRRYQSRVTQGLVAGETAQQICEDLRLCIPSTGPL,83,Homo sapiens,Native peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,GRDYRTCLTIVQKLKKMVDKPTQRSVSNAATRVCRTGRSRWRDVCRNFMRRYQSRVTQGLVAGETAQQICEDLRLCIPSTGPL
GSIPCEGSCVFIPCISAIIGCSCSNKVCYKN,31,Oldenlandia affinis,Native peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,GSIPCEGSCVFIPCISAIIGCSCSNKVCYKN
KSCCPNTTGRNIYNTCRLTGSSRETCAKLSGCKIISASTCPSNYPK,46,Viscum album,Native peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,KSCCPNTTGRNIYNTCRLTGSSRETCAKLSGCKIISASTCPSNYPK
LCPLDVLQLSSELLDIDGNEVEASRILSDITAFGGIRCPLTVVQSRGIGTIISSPYRFIAEGHPLSLKDMDGWFRVSDDEFNNYK,85,Curcuma longa,Native peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,LCPLDVLQLSSELLDIDGNEVEASRILSDITAFGGIRCPLTVVQSRGIGTIISSPYRFIAEGHPLSLKDMDGWFRVSDDEFNNYK
QICKAPSQTFPGLCFMDSSCRKYCIKEKFTGGHCSKLQRKCLCTKPC,47,Planctomyces brasiliensis,Native peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,QICKAPSQTFPGLCFMDSSCRKYCIKEKFTGGHCSKLQRKCLCTKPC
RWRWRWRW,8,Synthetic,Synthetic peptide,,,,,,Anticancer,Cell-penetrating peptides,,,Native peptide,Free,Amidation,,,0,RWRWRWRW
VYINKLTPPCGTMYYACEAV,20,Pleurotus citrinopileatus,,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,VYINKLTPPCGTMYYACEAV
CGETCVGGTCNTPGCTCSWPVCTRNGLPV,29,Oldenlandia affinis,Native peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,CGETCVGGTCNTPGCTCSWPVCTRNGLPV
FDIVKKVVGTIAGL,14,Litoria aurea,Native peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,FDIVKKVVGTIAGL
FLHHIVGLIHHGLSLFGDRAD,21,Gadus morhua,Native peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,FLHHIVGLIHHGLSLFGDRAD
GIPCAESCVWIPPCTITALMGCSCKNNVCYNN,32,Clitoria ternatea,Native peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,GIPCAESCVWIPPCTITALMGCSCKNNVCYNN
GLFVGLAKVAAHNNPAIAEHFQA,23,Litoria eucnemis,Native peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Amidation,,,0,GLFVGLAKVAAHNNPAIAEHFQA
GLFVGVLAKVAAHVVPAIAEHF,22,Litoria genimaculata,Native peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Amidation,,,0,GLFVGVLAKVAAHVVPAIAEHF
KSCCKNTTGRNIYNTCRFAGGSRERCAKLSGCKIISASTCPSDYPK,46,Viscum album,Native peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,KSCCKNTTGRNIYNTCRFAGGSRERCAKLSGCKIISASTCPSDYPK
KSCCPNTTGRNIYNTCRFGGGSREVCARISGCKIISASTCPSDYPK,46,Viscum album,Native peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,KSCCPNTTGRNIYNTCRFGGGSREVCARISGCKIISASTCPSDYPK
KSCCPNTTGRNIYNTCRFGGGSRQVCASLSGCKIISASTCPSDYPK,46,Viscum album,Native peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,KSCCPNTTGRNIYNTCRFGGGSRQVCASLSGCKIISASTCPSDYPK
GRKKRRQRRR,10,Synthetic,Synthetic peptide,,,,,,Anticancer,Cell-penetrating peptides,,,Native peptide,Free,Free,,,0,GRKKRRQRRR
MFTLKKSLLLLFFLGTISLSLCEEERNADEEEKRDVEVEKRFLGALFKVASKVLPSVFCAITKKC,65,Glandirana rugosa,Native peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,MFTLKKSLLLLFFLGTISLSLCEEERNADEEEKRDVEVEKRFLGALFKVASKVLPSVFCAITKKC
WAIVLL,6,,,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,WAIVLL
AACARFIDDFCDTLTPNIYRPRDNGQRCYAVNGHRCDFTVFNTNNGGNPIRASTPNCKTVLRTAANRCPTGGRGKINPNAPFLFAIDPNDGDCSTNF,97,,,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,AACARFIDDFCDTLTPNIYRPRDNGQRCYAVNGHRCDFTVFNTNNGGNPIRASTPNCKTVLRTAANRCPTGGRGKINPNAPFLFAIDPNDGDCSTNF
AKKVFKRLEKLFSKIQNWK,19,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Amidation,,,0,AKKVFKRLEKLFSKIQNWK
AKKVFKRLEKLFSKIWNDK,19,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Amidation,,,0,AKKVFKRLEKLFSKIWNDK
AKKVFKRLEKLFSKIWNWK,19,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Amidation,,,0,AKKVFKRLEKLFSKIWNWK
AKKVFKRLEKSFSKIQNDK,19,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Amidation,,,0,AKKVFKRLEKSFSKIQNDK
AKKVSKRLEKLFSKIQNDK,19,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Amidation,,,0,AKKVSKRLEKLFSKIQNDK
CETPSKHFNGLCIRSSNCASVCHGEHFTDGRCQGVRRRCMCLKPC,45,Persea americana,Native peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,CETPSKHFNGLCIRSSNCASVCHGEHFTDGRCQGVRRRCMCLKPC
FCTCNVKGFNAKNKRGIIYP,20,,,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Amidation,,,0,FCTCNVKGFNAKNKRGIIYP
GIPCGXSCVWIPCISSAIGCSCKSKVCYRN,30,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,Native peptide,Free,Free,X=Glu(Me),,0,GIPCGXSCVWIPCISSAIGCSCKSKVCYRN
KSCCPSTTGRNIYNTCRLTGSSRETCAKLSGCKIISASTCPSNYPK,46,Viscum album,Native peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,KSCCPSTTGRNIYNTCRLTGSSRETCAKLSGCKIISASTCPSNYPK
LLDVLLE,7,Bacillus subtilis,Native peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,LLDVLLE
MFTLKKSLLLLFFLGTISSSLCEQERDSDDEDQGEVTEQVVKRLVRGCWTKSYPPKPCFVRG,62,Lithobates pipiens,Native peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,MFTLKKSLLLLFFLGTISSSLCEQERDSDDEDQGEVTEQVVKRLVRGCWTKSYPPKPCFVRG
RKKRRQRRR,9,,,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,RKKRRQRRR
SKWQHQQDSCRKQLQGVNLTPCEKHIMEKIQGRGDDDDDDDDD,43,Glycine max,Native peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,SKWQHQQDSCRKQLQGVNLTPCEKHIMEKIQGRGDDDDDDDDD
TPATPTVAQFVIQGSTICLVC,21,Streptomyces,Native peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,TPATPTVAQFVIQGSTICLVC
WKLFDDGV,8,Cycas revoluta,Native peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,WKLFDDGV
ADDINPKEECFFEDDYYEFE,20,Daboia russelii,Native peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,ADDINPKEECFFEDDYYEFE
ADDKNPLEECFCEDDDYCEG,20,Daboia russelii,Native peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,ADDKNPLEECFCEDDDYCEG
ADDRNPLEEFRENNYEEFL,19,Deinagkistrodon acutus,Native peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,ADDRNPLEEFRENNYEEFL
CGESCVWIPCISSAIGCSCKSKVCYRNGIP,30,Viola odorata,Native peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,CGESCVWIPCISSAIGCSCKSKVCYRNGIP
CHTNGGYCVRAICPPSARRPGSCFPEKNPCCKYM,34,Mus musculus,Native peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,CHTNGGYCVRAICPPSARRPGSCFPEKNPCCKYM
FDIVKKIAGHIAGSI,15,Litoria aurea,Native peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,FDIVKKIAGHIAGSI
FDIVKKIAGHIVSSI,15,Litoria raniformis,Native peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,FDIVKKIAGHIVSSI
FKRIVQRIKDFLX,13,Homo sapiens,Native peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,FKRIVQRIKDFLX
GLFDIVKKIAGHIA,14,Litoria aurea,Native peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,GLFDIVKKIAGHIA
GLICESCRKIIQKLEDMVGPQPNEDTVTQAASQVCDKLKILRGLCKKIMRSFLRRISWDILTGKKPQAICVDIKICKEKTGLI,83,Sus scrofa,Native peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,GLICESCRKIIQKLEDMVGPQPNEDTVTQAASQVCDKLKILRGLCKKIMRSFLRRISWDILTGKKPQAICVDIKICKEKTGLI
GRDYRTCLTIVQKLKKMVDKPTQRSVSNAATRVCRTGRSRWRDVCRNFMRRYQSRVTQGLVAGETAQQICEDLR,74,Homo sapiens,Native peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,GRDYRTCLTIVQKLKKMVDKPTQRSVSNAATRVCRTGRSRWRDVCRNFMRRYQSRVTQGLVAGETAQQICEDLR
KLLKKPLKLKL,11,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Amidation,,,0,KLLKKPLKLKL
KPLLKKLLKKL,11,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Amidation,,,0,KPLLKKLLKKL
KWKKLLKKPLKLKL,14,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Amidation,,,0,KWKKLLKKPLKLKL
KWKKLLKKPLLKKLLKKL,18,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Acetylation,,,0,KWKKLLKKPLLKKLLKKL
KWKLKPLLKKLLKKL,15,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Amidation,,,0,KWKLKPLLKKLLKKL
XGLXGGLXGI,10,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,Native peptide,C8,OMe,X=AIB (Aminoisobutyric acid),,0,XGLXGGLXGI
ADDKNPLEECFREDDYEEFLEIAKNGLKKTSNPKHIVYPVKPSEQLYEESLRDQLPTSMHRYPSMIQKIFFAGEYTANAHGWIDSTIK,88,Vipera berus,Native peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,ADDKNPLEECFREDDYEEFLEIAKNGLKKTSNPKHIVYPVKPSEQLYEESLRDQLPTSMHRYPSMIQKIFFAGEYTANAHGWIDSTIK
ADDKNPLEECFRETDYEEFLEIARNGLKATSNPKRVV,37,Bothrops jararaca,Native peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,ADDKNPLEECFRETDYEEFLEIARNGLKATSNPKRVV
ADPRNPLEECFRETD,15,Bothrops fonsecai,Native peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,ADPRNPLEECFRETD
ALWKEVLKNAGKAALNEINNLV,22,,,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,ALWKEVLKNAGKAALNEINNLV
AXQNMEILEXTPLTXVX,17,Anabaena laxa,Native peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,AXQNMEILEXTPLTXVX
CGETCTLGTCYTAGCSCSWPVCTRNGVPI,29,,,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,CGETCTLGTCYTAGCSCSWPVCTRNGVPI
CGETCVGGTCNTPGCTCSWPVCTRNGLNPV,30,,,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,CGETCVGGTCNTPGCTCSWPVCTRNGLNPV
DEVD,4,,,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,DEVD
FG,2,,,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,FG
FV,2,,,,,,,,Anticancer,Tumor active peptide,,,Native peptide,OtBu,"Boc=Tert-Butyloxycarbonyl, Sar",,,0,FV
fXYwKXT,7,,,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,FXYWKXT
GF,2,,,,,,,,Anticancer,Tumor active peptide,,,Native peptide,OtBu,"Boc=Tert-Butyloxycarbonyl, Sar",,,0,GF
GIGVLLSAGKAALKGLAKVLAEKYAN,26,Bombina maxima,Native peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Amidation,,,0,GIGVLLSAGKAALKGLAKVLAEKYAN
GIIKKI,6,,,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Amidation,,,0,GIIKKI
GIPCGESCVWIPCISSAIGCSCXSXVCYRN,30,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,Native peptide,Free,Free,X=Lys(Ac)2,,0,GIPCGESCVWIPCISSAIGCSCXSXVCYRN
HHPHG,5,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,HHPHG
HHPHGHHPHG,10,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Acetylation,,,0,HHPHGHHPHG
HHPHGHHPHGHHPHG,15,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Acetylation,,,0,HHPHGHHPHGHHPHG
ITCPQVTQSLAPCVPYLISG,20,Peganum harmala,Native peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,ITCPQVTQSLAPCVPYLISG
IVRRADRAAVP,11,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,IVRRADRAAVP
KILRGVAKKILRTFLRRISKDILTGKK,27,,,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Amidation,,,0,KILRGVAKKILRTFLRRISKDILTGKK
KKKFPWWWPFKKKKKKFPWWWPFKKKK,27,,,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Amidation,,,0,KKKFPWWWPFKKKKKKFPWWWPFKKKK
MTLTG,5,Immunomodulatory bursal-derived Pentapeptide-II,Native peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,MTLTG
RRRQRRKKRGGGDTRLNTVWMW,22,,,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,RRRQRRKKRGGGDTRLNTVWMW
STRUCTUREGIVEN,14,Bovine lactoferrin (Lf-B),Native peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Amidation,,,0,STRUCTUREGIVEN
TPFVXV,6,,,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,TPFVXV
VF,2,,,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,VF
VKX,3,,,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,VKX
VV,2,,,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,"Boc=Tert-Butyloxycarbonyl, Sar",,,0,VV
Vx,2,,,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,VX
WRWRWRWRW,9,,,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,"Dox, Doxorubicin",,,0,WRWRWRWRW
XXEXXXFLIILG,12,Anabaena laxa,Native peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,XXEXXXFLIILG
YGRKKRRQRRRREADFFWSLCTADMS,26,,,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,YGRKKRRQRRRREADFFWSLCTADMS
YRXG,4,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,"X=Cα -dialkylated glycine (Aaa2,2 )",,0,YRXG
YSX,3,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,"X=Cα -dialkylated glycine (Aaa2,2 )",,0,YSX
YSXG,4,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,"X=Cα -dialkylated glycine (Aaa2,2 )",,0,YSXG
zV,2,,,,,,,,Anticancer,Tumor active peptide,,,Native peptide,OtBu,"Boc=Tert-Butyloxycarbonyl, Sar",,,0,ZV
AAPFLECQGRQGTCHFFAN,19,Homo sapiens (α4 CIV),Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,AAPFLECQGRQGTCHFFAN
ALARQPLTGSPPNERAFFCSSLRR,24,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,ALARQPLTGSPPNERAFFCSSLRR
ANIKLSVQMKLFKRHLKWKIIVKLNDGRELSLDA,34,PF4,Synthetic peptide,,,Galectin 1,,,Anticancer,Tumor active peptide##Cancer targeted peptides,,,Native peptide,Free,Free,,,0,ANIKLSVQMKLFKRHLKWKIIVKLNDGRELSLDA
ARPAKAAATQKKVERKAPDA,20,Fibrinogen,Synthetic peptide,,,αvβ3,,,Anticancer,Tumor active peptide##Cancer targeted peptides,,,Native peptide,Free,Free,,,0,ARPAKAAATQKKVERKAPDA
ASWSACSVSCGGGARQRTR,19,Homo sapiens (Fibulin-6),Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,ASWSACSVSCGGGARQRTR
ATPFIECSGARGTCHYFAN,19,Homo sapiens (α6 CIV),Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,ATPFIECSGARGTCHYFAN
AWYRGAAPPKQEFLDIEDP,19,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,AWYRGAAPPKQEFLDIEDP
CDSDSDITWDQLWDLMK,17,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,CDSDSDITWDQLWDLMK
CEGSCVFIPCISAIIGCSCSNKVCYKNGSIP,31,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,CEGSCVFIPCISAIIGCSCSNKVCYKNGSIP
CELDENNTPMC,11,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,CELDENNTPMC
CETWRTETTGATGQASSLLSGRLLEQKAASCHNSYIVLCIENSFMTSFSK,50,Collagen XVIII,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,CETWRTETTGATGQASSLLSGRLLEQKAASCHNSYIVLCIENSFMTSFSK
CGESCVFIPCISAIIGCSCSSKVCYKNGSIP,31,Viola philippica,Native peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,CGESCVFIPCISAIIGCSCSSKVCYKNGSIP
CGESCVFIPCISAVIGCSCSNKVCYKNGSIP,31,Viola philippica,Native peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,CGESCVFIPCISAVIGCSCSNKVCYKNGSIP
CGESCVFIPCISSVIGCACKSKVCYKNGSIP,31,Viola philippica,Native peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,CGESCVFIPCISSVIGCACKSKVCYKNGSIP
CGESCVFIPCISSVIGCSCSSKVCYRNGIP,30,Viola philippica,Native peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,CGESCVFIPCISSVIGCSCSSKVCYRNGIP
CGESCVFIPCLTSAIDCSCKSKVCYRNGIP,30,Viola philippica,Native peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,CGESCVFIPCLTSAIDCSCKSKVCYRNGIP
CGETCVGGTCNTPGCACSWPVCTRNGLPV,29,Viola philippica,Native peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,CGETCVGGTCNTPGCACSWPVCTRNGLPV
CGETCVGGTCNTPGCGCSWPVCTRNGLPV,29,Viola philippica,Native peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,CGETCVGGTCNTPGCGCSWPVCTRNGLPV
CKITRCPMIPCYISSPDECLWMDWVTEKNINGHQAKFFAC,40,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,CKITRCPMIPCYISSPDECLWMDWVTEKNINGHQAKFFAC
CKITRCPMIPCYISSPDECLWMDWVTEKNINGHQAKFFACIKRSDGSC,48,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,CKITRCPMIPCYISSPDECLWMDWVTEKNINGHQAKFFACIKRSDGSC
CLWMDWVTEKNINGHQAKFFAC,22,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,CLWMDWVTEKNINGHQAKFFAC
CQNHHAKHGKVC,12,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,CQNHHAKHGKVC
CTTHWGFTLC,10,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,CTTHWGFTLC
DAINSPVTCCYTLTSKKISMQRLMSYRRVTSSKCPKEAVIFKTIAGKEICAEPKXXWVQDSISHLDKKNQXPKP,74,Bos taurus,Native peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,DAINSPVTCCYTLTSKKISMQRLMSYRRVTSSKCPKEAVIFKTIAGKEICAEPKXXWVQDSISHLDKKNQXPKP
DDDDDNDKIPDDRDN,15,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,DDDDDNDKIPDDRDN
DDDDKRAGSPSGGPFCALARQPLTGSPPNERAFFCSSRDV,40,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,DDDDKRAGSPSGGPFCALARQPLTGSPPNERAFFCSSRDV
DFKLFAVTIKYR,12,Laminin,Synthetic peptide,,,"αvβ3, α5β1",,,Anticancer,Tumor active peptide##Cancer targeted peptides,,,Native peptide,Free,Free,,,0,DFKLFAVTIKYR
DFKLFAVYIKYR,12,Laminin,Synthetic peptide,,,"αvβ3, α5β1",,,Anticancer,Tumor active peptide##Cancer targeted peptides,,,Native peptide,Free,Free,,,0,DFKLFAVYIKYR
DGGWSHWSPWSSC,13,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,DGGWSHWSPWSSC
DLWIRETLTSPKSLID,16,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,DLWIRETLTSPKSLID
DLWIRETLTSPKSLTG,16,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,DLWIRETLTSPKSLTG
DPFFKVPVNKLAAAVSNFGYDLYRVRSSTSPTTN,34,PEDF,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,DPFFKVPVNKLAAAVSNFGYDLYRVRSSTSPTTN
DPFFKVPVNKLAAVSNFGYDLYRVRSSMSPTTN,33,PEDF,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,DPFFKVPVNKLAAVSNFGYDLYRVRSSMSPTTN
DRSTREPIYMSTI,13,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,DRSTREPIYMSTI
DSSPVSTEQLAPTA,14,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,DSSPVSTEQLAPTA
DTAVTGLASPLSTGKILDQKAYSCANRLIVLCIENSFMTDARK,43,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,DTAVTGLASPLSTGKILDQKAYSCANRLIVLCIENSFMTDARK
ECLWMDWVTEKNINGHQAKFFACI,24,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,ECLWMDWVTEKNINGHQAKFFACI
EDMNQKLFDLRGKFKRPPLRRVRMSADAML,30,Troponin I,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,EDMNQKLFDLRGKFKRPPLRRVRMSADAML
EGLPGPQGPKGFPGLPGLTG,20,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,EGLPGPQGPKGFPGLPGLTG
EIPSCESSASPDQSDSSVPPEE,22,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,EIPSCESSASPDQSDSSVPPEE
EKSSRPEFYKVILGAHEEYIRG,22,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,EKSSRPEFYKVILGAHEEYIRG
EKYEGKISKTMSGLDCQAWDS,21,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,EKYEGKISKTMSGLDCQAWDS
ESLARPCAPGAPAEARL,17,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,ESLARPCAPGAPAEARL
EVHHQKLVFF,10,β-amyloid,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,EVHHQKLVFF
FCNINNVCNFASRNDYSYW,19,Homo sapiens (α5 CIV),Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,FCNINNVCNFASRNDYSYW
FDIVKKVVGTIAG,13,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,FDIVKKVVGTIAG
FLKDHRISTFKNWPF,15,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,FLKDHRISTFKNWPF
FLSSRLQDLYSIVRRADRAA,20,Collagen XVIII,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,FLSSRLQDLYSIVRRADRAA
GDGVDITRIR,10,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,GDGVDITRIR
GDVIDTDRDIDR,12,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,GDVIDTDRDIDR
GETCAGGTCNTPGCSCSWPICTRNGLPVC,29,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,GETCAGGTCNTPGCSCSWPICTRNGLPVC
GETCFGGTCNTPGCTCDPWPVCTRNGLPVC,30,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,GETCFGGTCNTPGCTCDPWPVCTRNGLPVC
GETDPNTQLLNDLGNNMAWGAALGAPGGLGSAALGAAGGALQTVGQ,46,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,GETDPNTQLLNDLGNNMAWGAALGAPGGLGSAALGAAGGALQTVGQ
GFHDHGPCDPPSHK,14,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,GFHDHGPCDPPSHK
GGWSHWSPWSS,11,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,GGWSHWSPWSS
GHRATSDLASTGEESQD,17,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,GHRATSDLASTGEESQD
GIPCGESCVWIPCISSAIGCSCKSKVCYXN,30,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,X=ARG(CHD),,0,GIPCGESCVWIPCISSAIGCSCKSKVCYXN
GIPCGESCVWIPCISSAIGCSCXSXVCYXN,30,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,X(24)=Lys(Ac)2; X(28)=ARG(CHD),,0,GIPCGESCVWIPCISSAIGCSCXSXVCYXN
GLFDIAKKVIGVIGS,15,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,GLFDIAKKVIGVIGS
GLFDIVKKVVGAFGS,15,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,GLFDIVKKVVGAFGS
GPWAPCSASCGGGSQSRS,18,Homo sapiens (Papilin),Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,GPWAPCSASCGGGSQSRS
GPWEDCSVSCGGGEQLRSR,19,Homo sapiens (SCO-spondin),Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,GPWEDCSVSCGGGEQLRSR
GPWEPCSVTCSKGTRTRRR,19,Homo sapiens (Properdin),Synthetic peptide,,,CD36,,,Anticancer,Tumor active peptide##Cancer targeted peptides,,,Native peptide,Free,Free,,,0,GPWEPCSVTCSKGTRTRRR
GPWERCTAQCGGGIQARRR,19,Homo sapiens (Sema 5A),Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,GPWERCTAQCGGGIQARRR
GPWGDCSRTCGGGVQFSSR,19,Homo sapiens (ADAMTS-4),Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,GPWGDCSRTCGGGVQFSSR
GPWGPCSGSCGPGRRLRRR,19,Homo sapiens (CILP-2),Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,GPWGPCSGSCGPGRRLRRR
GRGKRRREKQRPCDKPRR,18,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,GRGKRRREKQRPCDKPRR
GVDITVIRPNH,11,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,GVDITVIRPNH
GYCSWYRGWAPPDKSIINATDP,22,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,GYCSWYRGWAPPDKSIINATDP
HGLGHGHEQQHGLGHGHKFKLDDDLEHQGGHVLD,34,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,HGLGHGHEQQHGLGHGHKFKLDDDLEHQGGHVLD
HGSTTLRDITV,11,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,HGSTTLRDITV
HKLINTEGHHS,11,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,HKLINTEGHHS
HNRTPENFPCKNL,13,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,HNRTPENFPCKNL
HTHQDFQPVLHLVALNTPLSGGMRGIR,27,Collagen XVIII,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,HTHQDFQPVLHLVALNTPLSGGMRGIR
IARALFEKKV,10,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,IARALFEKKV
IMRIKQGQIGQMTI,14,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,IMRIKQGQIGQMTI
INEFLERSGIPRQRNQ,16,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,INEFLERSGIPRQRNQ
INGSLDKRLLPDVET,15,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,INGSLDKRLLPDVET
INGSLDKRVQDCYHG,15,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,INGSLDKRVQDCYHG
INLEACLGRTLMD,13,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,INLEACLGRTLMD
INLEACLKRGRT,12,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,INLEACLKRGRT
ITMQGIQGQKIRMIMF,16,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,ITMQGIQGQKIRMIMF
IYSFDGRDIMTDPSWPQKVIWHGSSPHGVRLVDNYCEAWRTA,42,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,IYSFDGRDIMTDPSWPQKVIWHGSSPHGVRLVDNYCEAWRTA
KAFDITYVRLKF,12,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,KAFDITYVRLKF
KCGHKHQCAVHN,12,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,KCGHKHQCAVHN
KGRGKRRRCKQRPSDCPRR,19,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,KGRGKRRRCKQRPSDCPRR
KGRGKRRRECQRPSCKPRR,19,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,KGRGKRRRECQRPSCKPRR
KIKSCYYLPCFVTS,14,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,KIKSCYYLPCFVTS
KITRCPMIPC,10,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,KITRCPMIPC
KITRCPMIPCYISSPDE,17,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,KITRCPMIPCYISSPDE
KNECLWTDMLSNFGYPGYQSKHYACIRQKG,30,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,KNECLWTDMLSNFGYPGYQSKHYACIRQKG
KRFKQDGGWSHWSPWSSC,18,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,KRFKQDGGWSHWSPWSSC
KRRREKQRPCDKPRR,15,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,KRRREKQRPCDKPRR
KSCCKNTTGRNIYNTCRFAGGSRERCAKLSGCKIISAST,39,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,KSCCKNTTGRNIYNTCRFAGGSRERCAKLSGCKIISAST
KSCCPNTTGRNIYNACRLTGAPRPTCAKLSGCKIISGST,39,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,KSCCPNTTGRNIYNACRLTGAPRPTCAKLSGCKIISGST
KSCCPNTTGRNIYNTCRFAGGSRERCAKLSGCKIISAST,39,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,KSCCPNTTGRNIYNTCRFAGGSRERCAKLSGCKIISAST
KSCCPNTTGRNIYNTCRFGGGSREVCARISGCKIISAST,39,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,KSCCPNTTGRNIYNTCRFGGGSREVCARISGCKIISAST
KSCCPNTTGRNIYNTCRFGGGSRQVCASLSGCKIISAST,39,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,KSCCPNTTGRNIYNTCRFGGGSRQVCASLSGCKIISAST
KSCCPNTTGRNIYNTCRLGGGSRERCASLSGCKIISAST,39,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,KSCCPNTTGRNIYNTCRLGGGSRERCASLSGCKIISAST
KSCCPNTTGRNIYNTCRLTGSSRETCAKLSGCKIISAST,39,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,KSCCPNTTGRNIYNTCRLTGSSRETCAKLSGCKIISAST
KSCCRNTWARNCYNVCRLPGTISREICAKKCDCKIISGT,39,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,KSCCRNTWARNCYNVCRLPGTISREICAKKCDCKIISGT
KSVRGKGKGQKRKRKKSRYK,20,Exon 6a of VEGF gene,Synthetic peptide,,,VEGFR2,,,Anticancer,Tumor active peptide##Cancer targeted peptides,,,Native peptide,Free,Free,,,1,KSVRGKGKGQKRKRKKSRYK
LGTNPLKSSGIE,12,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,LGTNPLKSSGIE
LHCPALVTYNTDTFESMPNPEGRYTFGASCV,31,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,LHCPALVTYNTDTFESMPNPEGRYTFGASCV
LLRISLLLIQSWLE,14,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,LLRISLLLIQSWLE
LPGLTGSKGVRGISGLPGFSG,21,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,LPGLTGSKGVRGISGLPGFSG
LPRFSTMPFIYCNINEVCHY,20,Homo sapiens (α6 CIV),Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,LPRFSTMPFIYCNINEVCHY
LPVFSTLPFAYCNIHQVCH,19,Homo sapiens (α4 CIV),Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,LPVFSTLPFAYCNIHQVCH
LRRFSTMPFMFCNINNVCNF,20,Homo sapiens (α5 CIV),Synthetic peptide,,,"αvβ3, αvβ1",,,Anticancer,Tumor active peptide##Cancer targeted peptides,,,Native peptide,Free,Free,,,0,LRRFSTMPFMFCNINNVCNF
LRSRGELVAKFLAGEQSPEDYVAE,24,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,LRSRGELVAKFLAGEQSPEDYVAE
LSSTCILVLVKDILVLVVKEILVLVVKDKPI,31,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,LSSTCILVLVKDILVLVVKEILVLVVKDKPI
LSSTCILVLVKSTY,14,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,LSSTCILVLVKSTY
LVPLPKIKNSTFT,13,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,LVPLPKIKNSTFT
LVPRGSRAGSPSGGPFCALARQPLTGARLMSGLFFALHET,40,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,LVPRGSRAGSPSGGPFCALARQPLTGARLMSGLFFALHET
MAFLKKSLFLVLFLALVPLSICEEKKSEEENEEKQEDDQSEEKRGLVTSLIKGAGKLLGGLFGSVTGGQS,70,Phyllomedusa bicolor,Native peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,MAFLKKSLFLVLFLALVPLSICEEKKSEEENEEKQEDDQSEEKRGLVTSLIKGAGKLLGGLFGSVTGGQS
MAFLKKSLFLVLFLGLVSLSICEKEKRQNEEDEDENEAANHEEGSEEKRGLFDIVKKVVGAFGSLGKRNDLE,72,Litoria aurea,Native peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,MAFLKKSLFLVLFLGLVSLSICEKEKRQNEEDEDENEAANHEEGSEEKRGLFDIVKKVVGAFGSLGKRNDLE
MAFLKKSLFLVLFLGLVSLSICEKEKRQNEEDEDENEAANHEEGSEEKRGLFDIVKKVVGALGSLGKRNDLE,72,Litoria aurea,Native peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,MAFLKKSLFLVLFLGLVSLSICEKEKRQNEEDEDENEAANHEEGSEEKRGLFDIVKKVVGALGSLGKRNDLE
MAFLKKSLFLVLFLGLVSLSICEKEKRQNGEDEDENEAANHEEGSEEKRGLFDIVKKVVGAIGSLGKRNDVE,72,Litoria aurea,Native peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,MAFLKKSLFLVLFLGLVSLSICEKEKRQNGEDEDENEAANHEEGSEEKRGLFDIVKKVVGAIGSLGKRNDVE
MARRASVGTD,10,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,MARRASVGTD
MDSNKDERAYAQWVIIILHNVGSSPFKIANLGLSWGKLYADGNKDKEVY,49,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,MDSNKDERAYAQWVIIILHNVGSSPFKIANLGLSWGKLYADGNKDKEVY
MDSNKDERAYAQWVIIILHNVGSSPFKIANLGLSWGKLYADGNKDKEVYP,50,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,MDSNKDERAYAQWVIIILHNVGSSPFKIANLGLSWGKLYADGNKDKEVYP
MEPECNLNCTD,11,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,MEPECNLNCTD
MFSPILSLEIILALATLQSVFAQPVICTTVGSAAEGS,37,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,MFSPILSLEIILALATLQSVFAQPVICTTVGSAAEGS
MFTLKKSLLLLFFLGTINLSLCEEERDADEEERRDDPEERAVEVEKRFVDLKKIANIINSIFGK,64,Rana chensinensis,Native peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,MFTLKKSLLLLFFLGTINLSLCEEERDADEEERRDDPEERAVEVEKRFVDLKKIANIINSIFGK
MLQNSAVLLLLVISASA,17,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,MLQNSAVLLLLVISASA
MNFQQRLQSLWTLARPFCPPLLATASQMQMVVLPCLGFTLLLWSQVSG,48,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,MNFQQRLQSLWTLARPFCPPLLATASQMQMVVLPCLGFTLLLWSQVSG
MPTWAWWLFLVLLLALWAPARG,22,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,MPTWAWWLFLVLLLALWAPARG
MRLLVLSSLLCILLLCFSIFSTEGKRRPAKAWSGRRTRLCCHRVPSPNSTNLKGHHVRLCKPCKLEPEPRLWVVPGALPQV,81,Homo sapiens,Native peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,MRLLVLSSLLCILLLCFSIFSTEGKRRPAKAWSGRRTRLCCHRVPSPNSTNLKGHHVRLCKPCKLEPEPRLWVVPGALPQV
NFGYDLYRVRSSTSPTTN,18,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,NFGYDLYRVRSSTSPTTN
NGREACLDPEAPMVQKIVQKMLKG,24,CXCL1,Synthetic peptide,,,CXCR3,,,Anticancer,Tumor active peptide##Cancer targeted peptides,,,Native peptide,Free,Free,,,0,NGREACLDPEAPMVQKIVQKMLKG
NGRKISLDLRAPLYKKIIKKLLES,24,PF4,Synthetic peptide,,,VEGF FGF2,,,Anticancer,Tumor active peptide##Cancer targeted peptides,,,Native peptide,Free,Free,,,1,NGRKISLDLRAPLYKKIIKKLLES
NITVTLKKFPL,11,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,NITVTLKKFPL
NVLLSPLSVATALSALSLGAEQRTES,26,PEDF,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,NVLLSPLSVATALSALSLGAEQRTES
PGLKGKRGDSGSPATWTTRG,20,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,PGLKGKRGDSGSPATWTTRG
PIDERLRTCERLSYP,15,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,PIDERLRTCERLSYP
PTGERLRTCERLSYP,15,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,PTGERLRTCERLSYP
QDRPKFCYLPADPAECNAYMPRFYYDSASNKCKEFIYGGCRGNANNFKNRAECRHTCVAS,60,Macrovipera lebetina,Native peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,QDRPKFCYLPADPAECNAYMPRFYYDSASNKCKEFIYGGCRGNANNFKNRAECRHTCVAS
QEPHRHSIFTPQTNPRADLEKN,22,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,QEPHRHSIFTPQTNPRADLEKN
QMIVIELGTNPLK,13,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,QMIVIELGTNPLK
QMIVIELGTNPLKSSGIENGAFQGMK,26,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,QMIVIELGTNPLKSSGIENGAFQGMK
QPVGINTSTTCCYRFINKKIPKQRLESYRRTTSSHCPREAVIFKTKLDKEICADPTQKWV,60,Homo sapiens,Native peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,QPVGINTSTTCCYRFINKKIPKQRLESYRRTTSSHCPREAVIFKTKLDKEICADPTQKWV
QPWGTCSESCGKGTQTRAR,19,Homo sapiens (Fibulin-6),Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,QPWGTCSESCGKGTQTRAR
QPWSQCSATCGDGVRERRR,19,Homo sapiens (TSRC-1),Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,QPWSQCSATCGDGVRERRR
QQMNQKDFLSLIVS,14,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,QQMNQKDFLSLIVS
QRTESIIHRALYYDLIS,17,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,QRTESIIHRALYYDLIS
RAGSPSGGPFCALARQPLTGSPPNERAFFCSSRDV,35,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,RAGSPSGGPFCALARQPLTGSPPNERAFFCSSRDV
RCRLAERRQIAK,12,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,RCRLAERRQIAK
RGFTKMPHVQIHTEASESL,19,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,RGFTKMPHVQIHTEASESL
RIFGESVSLRVQDWEW,16,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,RIFGESVSLRVQDWEW
RPFVEMYSEIPE,12,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,RPFVEMYSEIPE
RQVFQVAYIIIKA,13,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,RQVFQVAYIIIKA
RREKQRPCDKPRR,13,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,RREKQRPCDKPRR
RRPAAAGKRRREKQRPSDKPRR,22,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,RRPAAAGKRRREKQRPSDKPRR
RRPKGRAMRREKQRPSDKPRR,21,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,RRPKGRAMRREKQRPSDKPRR
RRPKGRGKRRREKQRPTDCHLCGDAVPRR,29,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,RRPKGRGKRRREKQRPTDCHLCGDAVPRR
SAPFIECHGRGTCNYYANS,19,Homo sapiens (α5 CIV),Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,SAPFIECHGRGTCNYYANS
SAWRACSVTCGKGIQKRSR,19,Homo sapiens (Fibulin-6),Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,SAWRACSVTCGKGIQKRSR
SEWSDCSVTCGKGMRTRQR,19,Homo sapiens (F-spondin ),Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,SEWSDCSVTCGKGMRTRQR
SKRKSRPVSVKTFEDIPLEEP,21,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,SKRKSRPVSVKTFEDIPLEEP
SKWSECSRTCGGGVKFQER,19,Homo sapiens (ADAMTS-18),Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,SKWSECSRTCGGGVKFQER
SPNITVTLKKFPL,13,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,SPNITVTLKKFPL
SPSTHPNEGLEENYCRNPDN,20,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,SPSTHPNEGLEENYCRNPDN
SPWDIASVTAGGVQKRS,17,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,SPWDIASVTAGGVQKRS
SPWDICSVTCGGGVQKRSR,19,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,SPWDICSVTCGGGVQKRSR
SPWSKCSAACGQTGVQTRTR,20,Homo sapiens (CILP-1),Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,SPWSKCSAACGQTGVQTRTR
SPWSPCSGNCSTGKQQRTR,19,Homo sapiens (TSRC-3),Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,SPWSPCSGNCSTGKQQRTR
SPWSPCSTSCGLGVSTR,17,Homo sapiens (WISP-1),Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,SPWSPCSTSCGLGVSTR
SPWSPCSTSCGLGVSTRI,18,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,SPWSPCSTSCGLGVSTRI
SPWSQCSVRCGRGQRSRQVR,20,Homo sapiens (TSRC1),Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,SPWSQCSVRCGRGQRSRQVR
SPWSQCTASCGGGVQTR,17,Homo sapiens (ADAMTS-16),Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,SPWSQCTASCGGGVQTR
SPWSSASVTAGDGVDITRIR,20,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,SPWSSASVTAGDGVDITRIR
SPWSSASVTAGDGVITRI,18,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,SPWSSASVTAGDGVITRI
SPWSSCSVTCGDGVITRIR,19,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,SPWSSCSVTCGDGVITRIR
SPWTKCSATCGGGHYMRTR,19,Homo sapiens (Sema 5A),Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,SPWTKCSATCGGGHYMRTR
SQWSPCSRTCGGGVSFRER,19,Homo sapiens (Papilin),Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,SQWSPCSRTCGGGVSFRER
SRTVRKTSRLWSSLSLNTCNNVHSKS,26,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,SRTVRKTSRLWSSLSLNTCNNVHSKS
SSGIENGAFQGMK,13,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,SSGIENGAFQGMK
SSTSPHRPRFS,11,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,SSTSPHRPRFS
STNITVTLKKFPL,13,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,STNITVTLKKFPL
SVSGGGHHHHHHGGG,15,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,SVSGGGHHHHHHGGG
SVSRAGSPSGGPFC,14,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,SVSRAGSPSGGPFC
TAWGPCSTTCGLGMATRV,18,Homo sapiens (WISP-2),Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,TAWGPCSTTCGLGMATRV
TCTLGTCYTAGCSCSWPVCTRNGVPICGE,29,Viola arvensis,Native peptide,,,,,,Anticancer,Tumor active peptide,,,,Free,Free,,,0,TCTLGTCYTAGCSCSWPVCTRNGVPICGE
TEENRELVSELKRP,14,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,,Free,Free,,,0,TEENRELVSELKRP
TEWSACNVRCGRGWQKRSR,19,Homo sapiens (UNC-5D),Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,TEWSACNVRCGRGWQKRSR
TEWSACSKTCGMGISTRV,18,Homo sapiens (CTGF),Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,TEWSACSKTCGMGISTRV
TEWSVCNSRCGRGYQKRTR,19,Homo sapiens (UNC-5C),Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,TEWSVCNSRCGRGYQKRTR
TEWTACSKSCGMGFSTRV,18,Homo sapiens (NOVH),Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,TEWTACSKSCGMGFSTRV
TGALVEEEDPF,11,PEDF,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,TGALVEEEDPF
TGALVQQQDP,10,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,TGALVQQQDP
TGASSEEEDPF,11,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,TGASSEEEDPF
TKWTPCSRTCGMGISNRV,18,Homo sapiens (WISP-3),Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,TKWTPCSRTCGMGISNRV
TLPFAYCNIHQVCHYAQRNDRSYWL,25,Homo sapiens (α4 CIV),Synthetic peptide,,,αvβ3,,,Anticancer,Tumor active peptide##Cancer targeted peptides,,,Native peptide,Free,Free,,,0,TLPFAYCNIHQVCHYAQRNDRSYWL
TMPFLFCNVNDCNFASRNDYSYWL,24,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,TMPFLFCNVNDCNFASRNDYSYWL
TQWTSCSKTCNSGTQSRHR,19,Homo sapiens (Complement comp. C6),Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,TQWTSCSKTCNSGTQSRHR
TRCPMIPCYI,10,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,TRCPMIPCYI
TSLDASIIWAMMQN,14,TGFβ Receptor,Synthetic peptide,,,TGFβ,,,Anticancer,Tumor active peptide##Cancer targeted peptides,,,Native peptide,Free,Free,,,0,TSLDASIIWAMMQN
TSWSPCSASCGGGHYQRTR,19,Homo sapiens (Sema 5B),Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,TSWSPCSASCGGGHYQRTR
TSWSQCSKTCGTGISTRV,18,Homo sapiens (CYR61),Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,TSWSQCSKTCGTGISTRV
TTITGKKCQSWAAMFPHRHSKT,22,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,TTITGKKCQSWAAMFPHRHSKT
VGSGGCMFGNGK,12,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,VGSGGCMFGNGK
VIFEWTLLQVLSESDQDQSLEVFLT,25,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,VIFEWTLLQVLSESDQDQSLEVFLT
VRSCMFGNGK,10,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,VRSCMFGNGK
VTCGDGVITR,10,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,VTCGDGVITR
VTCGGGVQKRSRL,13,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,VTCGGGVQKRSRL
VVGSPSAQDEASPL,14,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,VVGSPSAQDEASPL
WDLVVVSAGVAEVGV,15,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,WDLVVVSAGVAEVGV
WTRCSSSCGRGVSVRSR,17,Homo sapiens (TSRC-6),Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,WTRCSSSCGRGVSVRSR
XFXPXLV,7,,,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,XFXPXLV
XHXLLPPVPLFG,12,,,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Amidation,,,0,XHXLLPPVPLFG
XIIFPXPLPINAI,13,,,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Amidation,,,0,XIIFPXPLPINAI
XIXIILPPLPII,12,,,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Amidation,,,0,XIXIILPPLPII
XIXVILPPLPIFG,13,,,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Amidation,,,0,XIXVILPPLPIFG
XLPFFPPVPIIG,12,,,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Amidation,,,0,XLPFFPPVPIIG
XLPPPPLPFFF,11,,,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Amidation,,,0,XLPPPPLPFFF
XVPVFPPLFI,10,,,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Amidation,,,0,XVPVFPPLFI
XVPVFPPLPI,10,,,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Amidation,,,0,XVPVFPPLPI
YCNIHQVCHYAQRNDRSYWL,20,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,YCNIHQVCHYAQRNDRSYWL
YCNINEVCHYARRNDKSYWL,20,Homo sapiens (α6 CIV),Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,YCNINEVCHYARRNDKSYWL
YKQCHKKGGHCFPKEKICLPPSSDFGKMDCRWRWK,35,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,YKQCHKKGGHCFPKEKICLPPSSDFGKMDCRWRWK
YLKNYRIATFKNWPF,15,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,YLKNYRIATFKNWPF
YPYDVPDYASL,11,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,YPYDVPDYASL
YRIPIVRRLQRR,12,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,YRIPIVRRLQRR
YTMNPRKLFDY,11,Kringle 5,Synthetic peptide,,,cSrc ERK,,,Anticancer,Tumor active peptide##Cancer targeted peptides,,,Native peptide,Free,Free,,,0,YTMNPRKLFDY
YTYGLCTSSR,10,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,,Native peptide,Free,Free,,,0,YTYGLCTSSR
LGISYGRKKRRQRRRPPQ,18,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Labelled with Cys-acetamidomethyl,Fluorescein maleimide,,,0,LGISYGRKKRRQRRRPPQ
FITKALGISYGRKKRRQRRRPPQ,23,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Labelled with Cys-acetamidomethyl,Fluorescein maleimide,,,0,FITKALGISYGRKKRRQRRRPPQ
FITKALGISYGRKKRR,16,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Labelled with Cys-acetamidomethyl,Fluorescein maleimide,,,0,FITKALGISYGRKKRR
RKKRRQRR,8,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,fluorescein with 6-aminohexanoic acid (Ahx) spacer,Free,,,0,RKKRRQRR
RKKRRQR,7,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,fluorescein with 6-aminohexanoic acid (Ahx) spacer,Free,,,0,RKKRRQR
KKRRQRRR,8,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,fluorescein with 6-aminohexanoic acid (Ahx) spacer,Free,,,0,KKRRQRRR
KRRQRRR,7,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,fluorescein with 6-aminohexanoic acid (Ahx) spacer,Free,,,0,KRRQRRR
rkkrrqrrr,9,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,fluorescein with 6-aminohexanoic acid (Ahx) spacer,Free,,,0,RKKRRQRRR
RRRQRRKKR,9,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,fluorescein with 6-aminohexanoic acid (Ahx) spacer,Free,,,0,RRRQRRKKR
rrrqrrkkr,9,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,fluorescein with 6-aminohexanoic acid (Ahx) spacer,Free,,,0,RRRQRRKKR
AKKRRQRRR,9,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,fluorescein with 6-aminohexanoic acid (Ahx) spacer,Free,,,0,AKKRRQRRR
RAKRRQRRR,9,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,fluorescein with 6-aminohexanoic acid (Ahx) spacer,Free,,,0,RAKRRQRRR
RKARRQRRR,9,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,fluorescein with 6-aminohexanoic acid (Ahx) spacer,Free,,,0,RKARRQRRR
RKKARQRRR,9,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,fluorescein with 6-aminohexanoic acid (Ahx) spacer,Free,,,0,RKKARQRRR
RKKRAQRRR,9,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,fluorescein with 6-aminohexanoic acid (Ahx) spacer,Free,,,0,RKKRAQRRR
RKKRRARRR,9,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,fluorescein with 6-aminohexanoic acid (Ahx) spacer,Free,,,0,RKKRRARRR
RKKRRQARR,9,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,fluorescein with 6-aminohexanoic acid (Ahx) spacer,Free,,,0,RKKRRQARR
RKKRRQRAR,9,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,fluorescein with 6-aminohexanoic acid (Ahx) spacer,Free,,,0,RKKRRQRAR
RKKRRQRRA,9,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,fluorescein with 6-aminohexanoic acid (Ahx) spacer,Free,,,0,RKKRRQRRA
GRKKRRQRRPPQC,13,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Fluorescein,,,0,GRKKRRQRRPPQC
GRKKRRQRPPQC,12,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Fluorescein,,,0,GRKKRRQRPPQC
GRKKRRQPPQC,11,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Fluorescein,,,0,GRKKRRQPPQC
GRKKRRQRRRC,11,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Fluorescein,,,0,GRKKRRQRRRC
GRKKRRQRARPPQC,14,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Fluorescein,,,0,GRKKRRQRARPPQC
GRKKRRQARAPPQC,14,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Fluorescein,,,0,GRKKRRQARAPPQC
RRRRRR,6,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,fluorescein with 6-aminohexanoic acid (Ahx) spacer,Free,,,0,RRRRRR
rrrrr,5,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,fluorescein with 6-aminohexanoic acid (Ahx) spacer,Free,,,0,RRRRR
rrrrrrr,7,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,fluorescein with 6-aminohexanoic acid (Ahx) spacer,Free,,,0,RRRRRRR
RQIKIWFQNRRMKWK,15,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Biotinylation (Labeled with Biotinyl-beta-Alanine),Amidation,,,0,RQIKIWFQNRRMKWK
RQIKIWFQNRRMKW,14,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Biotinylation (Labeled with Biotinyl-beta-Alanine),Amidation,,,0,RQIKIWFQNRRMKW
RQIKIWFQNRRMK,13,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Biotinylation (Labeled with Biotinyl-beta-Alanine),Amidation,,,0,RQIKIWFQNRRMK
RQIKIWFQNRRM,12,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Biotinylation (Labeled with Biotinyl-beta-Alanine),Amidation,,,0,RQIKIWFQNRRM
RQIKIWFQNRR,11,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Biotinylation (Labeled with Biotinyl-beta-Alanine),Amidation,,,0,RQIKIWFQNRR
RQIKIWFQNR,10,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Biotinylation (Labeled with Biotinyl-beta-Alanine),Amidation,,,0,RQIKIWFQNR
RQIKIWFQN,9,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Biotinylation (Labeled with Biotinyl-beta-Alanine),Amidation,,,0,RQIKIWFQN
RQIKIWFQ,8,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Biotinylation (Labeled with Biotinyl-beta-Alanine),Amidation,,,0,RQIKIWFQ
RQIKIW,6,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Biotinylation (Labeled with Biotinyl-beta-Alanine),Amidation,,,0,RQIKIW
QIKIWFQNRRMKWKK,15,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Biotinylation (Labeled with Biotinyl-beta-Alanine),Amidation,,,0,QIKIWFQNRRMKWKK
IKIWFQNRRMKWKK,14,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Biotinylation (Labeled with Biotinyl-beta-Alanine),Amidation,,,0,IKIWFQNRRMKWKK
IWFQNRRMKWKK,12,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Biotinylation (Labeled with Biotinyl-beta-Alanine),Amidation,,,0,IWFQNRRMKWKK
WFQNRRMKWKK,11,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Biotinylation (Labeled with Biotinyl-beta-Alanine),Amidation,,,0,WFQNRRMKWKK
QNRRMKWKK,9,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Biotinylation (Labeled with Biotinyl-beta-Alanine),Amidation,,,0,QNRRMKWKK
NRRMKWKK,8,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Biotinylation (Labeled with Biotinyl-beta-Alanine),Amidation,,,0,NRRMKWKK
RRMKWKK,7,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Biotinylation (Labeled with Biotinyl-beta-Alanine),Amidation,,,0,RRMKWKK
RMKWKK,6,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Biotinylation (Labeled with Biotinyl-beta-Alanine),Amidation,,,0,RMKWKK
AQIKIWFQNRRMKWKK,16,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Biotinylation (Labeled with Biotinyl-beta-Alanine),Amidation,,,0,AQIKIWFQNRRMKWKK
RAIKIWFQNRRMKWKK,16,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Biotinylation (Labeled with Biotinyl-beta-Alanine),Amidation,,,0,RAIKIWFQNRRMKWKK
RQAKIWFQNRRMKWKK,16,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Biotinylation (Labeled with Biotinyl-beta-Alanine),Amidation,,,0,RQAKIWFQNRRMKWKK
RQIAIWFQNRRMKWKK,16,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Biotinylation (Labeled with Biotinyl-beta-Alanine),Amidation,,,0,RQIAIWFQNRRMKWKK
RQIKAWFQNRRMKWKK,16,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Biotinylation (Labeled with Biotinyl-beta-Alanine),Amidation,,,0,RQIKAWFQNRRMKWKK
RQIKIAFQNRRMKWKK,16,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Biotinylation (Labeled with Biotinyl-beta-Alanine),Amidation,,,0,RQIKIAFQNRRMKWKK
RQIKIWAQNRRMKWKK,16,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Biotinylation (Labeled with Biotinyl-beta-Alanine),Amidation,,,0,RQIKIWAQNRRMKWKK
RQIKIWFANRRMKWKK,16,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Biotinylation (Labeled with Biotinyl-beta-Alanine),Amidation,,,0,RQIKIWFANRRMKWKK
RQIKIWFQARRMKWKK,16,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Biotinylation (Labeled with Biotinyl-beta-Alanine),Amidation,,,0,RQIKIWFQARRMKWKK
RQIKIWFQNARMKWKK,16,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Biotinylation (Labeled with Biotinyl-beta-Alanine),Amidation,,,0,RQIKIWFQNARMKWKK
RQIKIWFQNRAMKWKK,16,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Biotinylation (Labeled with Biotinyl-beta-Alanine),Amidation,,,0,RQIKIWFQNRAMKWKK
RQIKIWFQNRRAKWKK,16,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Biotinylation (Labeled with Biotinyl-beta-Alanine),Amidation,,,0,RQIKIWFQNRRAKWKK
RQIKIWFQNRRMAWKK,16,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Biotinylation (Labeled with Biotinyl-beta-Alanine),Amidation,,,0,RQIKIWFQNRRMAWKK
RQIKIWFQNRRMKAKK,16,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Biotinylation (Labeled with Biotinyl-beta-Alanine),Amidation,,,0,RQIKIWFQNRRMKAKK
RQIKIWFQNRRMKWAK,16,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Biotinylation (Labeled with Biotinyl-beta-Alanine),Amidation,,,0,RQIKIWFQNRRMKWAK
RQIKIWFQNRRMKWKA,16,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Biotinylation (Labeled with Biotinyl-beta-Alanine),Amidation,,,0,RQIKIWFQNRRMKWKA
CRQIKIWFPNRRMKWKKC,18,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Biotinylation (Labeled with Biotinyl-Ahx),Unknown,,,0,CRQIKIWFPNRRMKWKKC
RQIKIWFPNRRMKWKK,16,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,fluorescein,Amidation,,,0,RQIKIWFPNRRMKWKK
RKKRRRESRKKRRRES,16,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Cys addition,Free,,,0,RKKRRRESRKKRRRES
GRPRESGKKRKRKRLKP,17,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Cys addition,Free,,,0,GRPRESGKKRKRKRLKP
GKRKKKGKLGKKRDP,15,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Cys addition,Free,,,0,GKRKKKGKLGKKRDP
GKRKKKGKLGKKRPRSR,17,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Cys addition,Free,,,0,GKRKKKGKLGKKRPRSR
RKKRRRESRRARRSPRHL,18,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Cys addition,Free,,,0,RKKRRRESRRARRSPRHL
SRRARRSPRESGKKRKRKR,19,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Cys addition,Free,,,0,SRRARRSPRESGKKRKRKR
VKRGLKLRHVRPRVTRMDV,19,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Cys addition,Free,,,0,VKRGLKLRHVRPRVTRMDV
SRRARRSPRHLGSG,14,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Cys addition,Free,,,0,SRRARRSPRHLGSG
LRRERQSRLRRERQSR,16,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Cys addition,Free,,,0,LRRERQSRLRRERQSR
GAYDLRRRERQSRLRRRERQSR,22,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Cys addition,Free,,,0,GAYDLRRRERQSRLRRRERQSR
VPTLK,5,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Fluorescein,Free,,,0,VPTLK
VNADIKATTVFGGKYVSLTTP,21,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free (peptide coated FITC labelled microspheres),Free,,,0,VNADIKATTVFGGKYVSLTTP
GKYVSLTTPKNPTKRRITPKDV,22,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free (peptide coated FITC labelled microspheres),Free,,,0,GKYVSLTTPKNPTKRRITPKDV
TKRRITPKDVIDVRSVTTEINT,22,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free (peptide coated FITC labelled microspheres),Free,,,0,TKRRITPKDVIDVRSVTTEINT
RSVTTEINTLFQTLTSIAEKVDP,23,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free (peptide coated FITC labelled microspheres),Free,,,0,RSVTTEINTLFQTLTSIAEKVDP
VNADIKATTVFGGKYVSLTTPKNPTKRRITPKDVIDVRSVTTEINTLFQTLTSIAEKVDP,60,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free (peptide coated FITC labelled microspheres),Free,,,0,VNADIKATTVFGGKYVSLTTPKNPTKRRITPKDVIDVRSVTTEINTLFQTLTSIAEKVDP
AEKVDPVKLNLTLSAAAEALTGLGDK,26,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free (peptide coated FITC labelled microspheres),Free,,,0,AEKVDPVKLNLTLSAAAEALTGLGDK
GLGDKFGESIVNANTVLDDLNSRMPQSRHDIQQL,34,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free (peptide coated FITC labelled microspheres),Free,,,0,GLGDKFGESIVNANTVLDDLNSRMPQSRHDIQQL
GDVYADAAPDLFDFLDSSVTTARTINA,27,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free (peptide coated FITC labelled microspheres),Free,,,0,GDVYADAAPDLFDFLDSSVTTARTINA
ARTINAQQAELDSALLAAAGFGNTTADVFDRG,32,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free (peptide coated FITC labelled microspheres),Free,,,0,ARTINAQQAELDSALLAAAGFGNTTADVFDRG
ADVFDRGGPYLQRGVADLVPTATLLDTYSP,30,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free (peptide coated FITC labelled microspheres),Free,,,0,ADVFDRGGPYLQRGVADLVPTATLLDTYSP
LDTYSPELFCTIRNFYDADRPDRGAAA,27,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free (peptide coated FITC labelled microspheres),Free,,,0,LDTYSPELFCTIRNFYDADRPDRGAAA
TKRRITPDDVIDVRSVTTEINT,22,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free (peptide coated FITC labelled microspheres),Free,,,0,TKRRITPDDVIDVRSVTTEINT
TKRRITPKKVIDVRSVTTEINT,22,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free (peptide coated FITC labelled microspheres),Free,,,0,TKRRITPKKVIDVRSVTTEINT
TKRRITPKDVIDVRSVTTKINT,22,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free (peptide coated FITC labelled microspheres),Free,,,0,TKRRITPKDVIDVRSVTTKINT
TKRRITPKDVIDV,13,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free (peptide coated FITC labelled microspheres),Free,,,0,TKRRITPKDVIDV
TKRRITPKDVIDVESVTTEINT,22,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free (peptide coated FITC labelled microspheres),Free,,,0,TKRRITPKDVIDVESVTTEINT
TARRITPKDVIDVRSVTTEINT,22,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free (peptide coated FITC labelled microspheres),Free,,,0,TARRITPKDVIDVRSVTTEINT
TKAARITPKDVIDVRSVTTEINT,23,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free (peptide coated FITC labelled microspheres),Free,,,0,TKAARITPKDVIDVRSVTTEINT
HHHHHHTKRRITPKDVIDVRSVTTEINT,28,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free (peptide coated FITC labelled microspheres),Free,,,0,HHHHHHTKRRITPKDVIDVRSVTTEINT
KLWMRWYSPTTRRYG,15,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Carboxyfluorescein,Free,,,0,KLWMRWYSPTTRRYG
RTLVNEYKNTLKFSK,15,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Carboxyfluorescein,Free,,,0,RTLVNEYKNTLKFSK
IPSRWKDQFWKRWHY,15,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Carboxyfluorescein,Free,,,0,IPSRWKDQFWKRWHY
GYGNCRHFKQKPRRD,15,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Carboxyfluorescein,Free,,,0,GYGNCRHFKQKPRRD
KNAWKHSSCHHRHQI,15,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Carboxyfluorescein,Free,,,0,KNAWKHSSCHHRHQI
RVREWWYTITLKQES,15,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Carboxyfluorescein,Free,,,0,RVREWWYTITLKQES
QQHLLIAINGYPRYN,15,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Carboxyfluorescein,Free,,,0,QQHLLIAINGYPRYN
WKCRRQCFRVLHHWN,15,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Carboxyfluorescein,Free,,,0,WKCRRQCFRVLHHWN
MVRRFLVTLRIRRACGPPRVRV,22,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,fluorescein,Amidation,,,0,MVRRFLVTLRIRRACGPPRVRV
FVTRGCPRRLVARLIRVMVPRR,22,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,fluorescein,Amidation,,,0,FVTRGCPRRLVARLIRVMVPRR
VRRFLVTLRIRRA,13,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,fluorescein,Amidation,,,0,VRRFLVTLRIRRA
RVRILARFLRTRV,13,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,fluorescein,Amidation,,,0,RVRILARFLRTRV
RVRVFVVHIPRLT,13,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,fluorescein,Amidation,,,0,RVRVFVVHIPRLT
VIRVHFRLPVRTV,13,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,fluorescein,Amidation,,,0,VIRVHFRLPVRTV
MVRRFLVTLRIRRACGPPRVRVFVVHIPRLTGEWAAP,37,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,fluorescein,Amidation,,,0,MVRRFLVTLRIRRACGPPRVRVFVVHIPRLTGEWAAP
FRVPLRIRPCVVAPRLVMVRHTFGRIARWVAGPLETR,37,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,fluorescein,Amidation,,,0,FRVPLRIRPCVVAPRLVMVRHTFGRIARWVAGPLETR
MDAQTRRRERRAEKQAQWKAANGC,24,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Conjugation with fluorescein by C-terminal Gly Cys amide,,,0,MDAQTRRRERRAEKQAQWKAANGC
KCFQWQRNMRKVRGPPVSC,19,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Fluorescein,Amidation,,,0,KCFQWQRNMRKVRGPPVSC
KCFQWQRNMRKVRGPPVSSIKR,22,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Fluorescein,Amidation,,,0,KCFQWQRNMRKVRGPPVSSIKR
KCFQWQRNMRKVR,13,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Fluorescein,Amidation,,,0,KCFQWQRNMRKVR
FQWQRNMRKVRGPPVS,16,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Fluorescein,Amidation,,,0,FQWQRNMRKVRGPPVS
QWQRNMRKVRGPPVSCIKR,19,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Fluorescein,Amidation,,,0,QWQRNMRKVRGPPVSCIKR
QWQRNMRKVR,10,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Fluorescein,Amidation,,,0,QWQRNMRKVR
KCFMWQEMLNKAGVPKLRCARK,22,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Fluorescein,Amidation,,,0,KCFMWQEMLNKAGVPKLRCARK
KWFETWFTEWPKKRK,15,Chimeric,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Acetylation,Cysteamide,,,0,KWFETWFTEWPKKRK
GLWWRLWWRLRSWFRLWFRA,20,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Acetylation,Cysteamide,,,0,GLWWRLWWRLRSWFRLWFRA
GALFLGFLGAAGSTMGAWSQPKSKRKV,27,Chimeric,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Acetylation,Cysteamide group,,,0,GALFLGFLGAAGSTMGAWSQPKSKRKV
AKVKDEPQRRSARLSAKPAPPKPEPKPKKAPAKK,34,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,fluorescein with 6-aminohexanoic acid (Ahx) spacer,Free,,,0,AKVKDEPQRRSARLSAKPAPPKPEPKPKKAPAKK
akvkdepqrrsarlsakpappkpepkpkkapakk,34,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,fluorescein with 6-aminohexanoic acid (Ahx) spacer,Free,,,0,AKVKDEPQRRSARLSAKPAPPKPEPKPKKAPAKK
PSSSSSSRIGDP,12,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,EGFP,Free,,,0,PSSSSSSRIGDP
vrlpppvrlpppvrlppp,18,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Fluorescein,Free,,,0,VRLPPPVRLPPPVRLPPP
VELPPPVELPPPVELPPP,18,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Fluorescein/ Rhodamine B,Free,,,0,VELPPPVELPPPVELPPP
ALWKTLLKKVLKA,13,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Rhodamine B,Amidation,,,0,ALWKTLLKKVLKA
ALWKTLLKKVLKAPKKKRKV,20,Chimeric,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Rhodamine B,Amidation,,,0,ALWKTLLKKVLKAPKKKRKV
PKKKRKVALWKTLLKKVLKA,20,Chimeric,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Rhodamine B,Amidation,,,0,PKKKRKVALWKTLLKKVLKA
VKRKKKPALWKTLLKKVLKA,20,Chimeric,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Rhodamine B,Amidation,,,0,VKRKKKPALWKTLLKKVLKA
RQARRNRRRALWKTLLKKVLKA,22,Chimeric,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Rhodamine B,Amidation,,,0,RQARRNRRRALWKTLLKKVLKA
RQARRNRRRC,10,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Rhodamine B,Amidation,,,0,RQARRNRRRC
GRKKRRQRRRPPQC,14,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Rhodamine B,Amidation,,,0,GRKKRRQRRRPPQC
MVTVLFRRLRIRRACGPPRVRV,22,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Fluorescein,Amidation,,,0,MVTVLFRRLRIRRACGPPRVRV
VQRKRQKLMP,10,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,fluorescein,Amidation,,,0,VQRKRQKLMP
SKKKKTKV,8,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,fluorescein,Amidation,,,0,SKKKKTKV
GRKRKKRT,8,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,fluorescein,Amidation,,,0,GRKRKKRT
GKKKKRKREKL,11,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,fluorescein,Amidation,,,0,GKKKKRKREKL
PKKKRKV,7,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,fluorescein,Amidation,,,0,PKKKRKV
ERKKRRRE,8,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,fluorescein,Amidation,,,0,ERKKRRRE
FKKFRKF,7,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,fluorescein,Amidation,,,0,FKKFRKF
RGGRLSYSRRRFSTSTGR,18,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,NBD and TAMRA,Free,,,0,RGGRLSYSRRRFSTSTGR
rggrlsysrrrfststgr,18,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,NBD,Free,,,0,RGGRLSYSRRRFSTSTGR
RRLSYSRRRF,10,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,NBD and TAMRA,Free,,,0,RRLSYSRRRF
rrlsysrrrf,10,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,NBD,Free,,,0,RRLSYSRRRF
RGGRLAYLRRRWAVLGR,17,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,NBD and TAMRA,Free,,,0,RGGRLAYLRRRWAVLGR
RHIKIWFQNRRMKWKK,16,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,FITC,Free,,,0,RHIKIWFQNRRMKWKK
MLLLTRRRST,10,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Biotinylation or Conjugation with TMR,Free,,,0,MLLLTRRRST
CGNKRTRGC,9,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,fluorescein,Amidation,,,0,CGNKRTRGC
TSPLNIHNGQKL,12,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides,,,,fluorescein/ FITC/texas red,Amidation,,,0,TSPLNIHNGQKL
VRLPPP,6,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Fluorescein,Free,,,0,VRLPPP
VRLPPPVRLPPP,12,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Fluorescein,Free,,,0,VRLPPPVRLPPP
VRLPPPVRLPPPVRLPPP,18,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Fluorescein,Free,,,0,VRLPPPVRLPPPVRLPPP
VHLPPP,6,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Fluorescein,Free,,,0,VHLPPP
VHLPPPVHLPPP,12,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Fluorescein,Free,,,0,VHLPPPVHLPPP
VHLPPPVHLPPPVHLPPP,18,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Fluorescein,Free,,,0,VHLPPPVHLPPPVHLPPP
VKLPPP,6,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Fluorescein,Free,,,0,VKLPPP
VKLPPPVKLPPP,12,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Fluorescein,Free,,,0,VKLPPPVKLPPP
VKLPPPVKLPPPVKLPPP,18,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Fluorescein,Free,,,0,VKLPPPVKLPPPVKLPPP
GSGKKGGKKHCQKY,14,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Rhodamine B,Free,,,0,GSGKKGGKKHCQKY
GSGKKGGKKICQKY,14,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Rhodamine B,Free,,,0,GSGKKGGKKICQKY
YTAIAWVKAFIRKLRK,16,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,fluorescein,Amidation,,,0,YTAIAWVKAFIRKLRK
IAWVKAFIRKLRKGPLG,17,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,fluorescein,Amidation,,,0,IAWVKAFIRKLRKGPLG
LIRLWSHLIHIWFQNRRLKWKKK,23,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Amidation,,,0,LIRLWSHLIHIWFQNRRLKWKKK
GPFHFYQFLFPPV,13,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,FITC,Free,,,0,GPFHFYQFLFPPV
GSPWGLQHHPPRT,13,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,FITC,Free,,,0,GSPWGLQHHPPRT
WEAALAEALAEALAEHLAEALAEALEALAA,30,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Free,,,0,WEAALAEALAEALAEHLAEALAEALEALAA
GLFRALLRLLRSLWRLLLRA,20,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Free,,,0,GLFRALLRLLRSLWRLLLRA
CGAYDLRRRERQSRLRRRERQSR,23,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Free,,,0,CGAYDLRRRERQSRLRRRERQSR
RKKRRRESRKKRRRESC,17,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Free,,,0,RKKRRRESRKKRRRESC
CVKRGLKLRHVRPRVTRDV,19,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Free,,,0,CVKRGLKLRHVRPRVTRDV
MIIYRDLISH,10,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Rhodamine B,Amidation,,,0,MIIYRDLISH
MIIYRDLIS,9,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Rhodamine B,Amidation,,,0,MIIYRDLIS
MIIYRDLI,8,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Rhodamine B,Amidation,,,0,MIIYRDLI
IIYRDLISH,9,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Rhodamine B,Amidation,,,0,IIYRDLISH
MIIYRDL,7,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Rhodamine B,Amidation,,,0,MIIYRDL
MIIYRD,6,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Rhodamine B,Amidation,,,0,MIIYRD
IYRDLISH,8,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Rhodamine B,Amidation,,,0,IYRDLISH
AIIYRDLIS,9,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Rhodamine B,Amidation,,,0,AIIYRDLIS
MAIYRDLIS,9,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Rhodamine B,Amidation,,,0,MAIYRDLIS
MIAYRDLIS,9,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Rhodamine B,Amidation,,,0,MIAYRDLIS
MIIARDLIS,9,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Rhodamine B,Amidation,,,0,MIIARDLIS
MIIYADLIS,9,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Rhodamine B,Amidation,,,0,MIIYADLIS
MIIYRALIS,9,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Rhodamine B,Amidation,,,0,MIIYRALIS
MIIYRDAIS,9,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Rhodamine B,Amidation,,,0,MIIYRDAIS
MIIYRDLAS,9,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Rhodamine B,Amidation,,,0,MIIYRDLAS
MIIYRDLIA,9,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Rhodamine B,Amidation,,,0,MIIYRDLIA
MIIYRDLISKK,11,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,FITC,Amidation,,,0,MIIYRDLISKK
MIIYRDKKSH,10,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,FITC,Amidation,,,0,MIIYRDKKSH
MIIFRDLISH,10,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,FITC,Amidation,,,0,MIIFRDLISH
MIISRDLISH,10,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,FITC,Amidation,,,0,MIISRDLISH
QIISRDLISH,10,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,FITC,Amidation,,,0,QIISRDLISH
CIISRDLISH,10,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,FITC,Amidation,,,0,CIISRDLISH
MIIYRALISHKK,12,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,FITC,Amidation,,,0,MIIYRALISHKK
MIIYRIAASHKK,12,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,FITC,Amidation,,,0,MIIYRIAASHKK
MIIRRDLISE,10,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,FITC,Amidation,,,0,MIIRRDLISE
MIIYRAEISH,10,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,FITC,Amidation,,,0,MIIYRAEISH
MIIYARRAEE,10,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,FITC,Amidation,,,0,MIIYARRAEE
MIIFRIAASHKK,12,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,FITC,Amidation,,,0,MIIFRIAASHKK
MIIFRALISHKK,12,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,FITC,Amidation,,,0,MIIFRALISHKK
MIIFRAAASHKK,12,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,FITC,Amidation,,,0,MIIFRAAASHKK
FIIFRIAASHKK,12,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,FITC,Amidation,,,0,FIIFRIAASHKK
LIIFRIAASHKK,12,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,FITC,Amidation,,,0,LIIFRIAASHKK
WIIFRIAASHKK,12,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,FITC,Amidation,,,0,WIIFRIAASHKK
WIIFRAAASHKK,12,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,FITC,Amidation,,,0,WIIFRAAASHKK
WIIFRALISHKK,12,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,FITC,Amidation,,,0,WIIFRALISHKK
MIIFRIAAYHKK,12,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,FITC,Amidation,,,0,MIIFRIAAYHKK
WIIFRIAAYHKK,12,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,FITC,Amidation,,,0,WIIFRIAAYHKK
MIIFRIAATHKK,12,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,FITC,Amidation,,,0,MIIFRIAATHKK
WIIFRIAATHKK,12,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,FITC,Amidation,,,0,WIIFRIAATHKK
MIIFKIAASHKK,12,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,FITC,Amidation,,,0,MIIFKIAASHKK
WIIFKIAASHKK,12,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,FITC,Amidation,,,0,WIIFKIAASHKK
MIIFAIAASHKK,12,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,FITC,Amidation,,,0,MIIFAIAASHKK
LIIFRILISHKK,12,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,FITC,Amidation,,,0,LIIFRILISHKK
MIIFRILISHKK,12,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,FITC,Amidation,,,0,MIIFRILISHKK
LIIFRILISHRR,12,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,FITC,Amidation,,,0,LIIFRILISHRR
LIIFRILISHHH,12,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,FITC,Amidation,,,0,LIIFRILISHHH
LIIFRILISHK,11,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,FITC,Amidation,,,0,LIIFRILISHK
LIIFRILISHR,11,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,FITC,Amidation,,,0,LIIFRILISHR
LIIFRILISH,10,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,FITC,Amidation,,,0,LIIFRILISH
LIIFAIAASHKK,12,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,FITC,Amidation,,,0,LIIFAIAASHKK
LIIFAILISHKK,12,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,FITC,Amidation,,,0,LIIFAILISHKK
RILQQLLFIHFRIGCRHSRI,20,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Nanoparticle,,,0,RILQQLLFIHFRIGCRHSRI
RILQQLLFIHFRIGCRH,17,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Nanoparticle,,,0,RILQQLLFIHFRIGCRH
RILQQLLFIHFRIGC,15,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Nanoparticle,,,0,RILQQLLFIHFRIGC
RIFIHFRIGC,10,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Nanoparticle,,,0,RIFIHFRIGC
RIFIRIGC,8,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Nanoparticle,,,0,RIFIRIGC
RILQQLLFIHF,11,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Nanoparticle,,,0,RILQQLLFIHF
RIFIGC,6,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Nanoparticle,,,0,RIFIGC
FIRIGC,6,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Nanoparticle,,,0,FIRIGC
DTWAGVEAIIRILQQLLFIHFR,22,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Nanoparticle,,,0,DTWAGVEAIIRILQQLLFIHFR
IGCRH,5,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Nanoparticle,,,0,IGCRH
GYGRKKRRGRRRTHRLPRRRRRR,23,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Nanoparticle,,,0,GYGRKKRRGRRRTHRLPRRRRRR
GLWRALWRLLRSLWRLLWKA,20,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Acetylation,Cysteamide group,,,0,GLWRALWRLLRSLWRLLWKA
GLWRALWRALWRSLWKLKRKV,21,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Acetylation,Cysteamide group,,,0,GLWRALWRALWRSLWKLKRKV
GLWRALWRALRSLWKLKRKV,20,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Acetylation,Cysteamide group,,,0,GLWRALWRALRSLWKLKRKV
GLWRALWRGLRSLWKLKRKV,20,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Acetylation,Cysteamide group,,,0,GLWRALWRGLRSLWKLKRKV
GLWRALWRGLRSLWKKKRKV,20,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Acetylation,Cysteamide group,,,0,GLWRALWRGLRSLWKKKRKV
GLWRALWRALWRSLWKLKWKV,21,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Acetylation,Cysteamide group,,,0,GLWRALWRALWRSLWKLKWKV
GLWRALWRALWRSLWKSKRKV,21,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Acetylation,Cysteamide group,,,0,GLWRALWRALWRSLWKSKRKV
GLWRALWRALWRSLWKKKRKV,21,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Acetylation,Cysteamide group,,,0,GLWRALWRALWRSLWKKKRKV
GLWRALWRLLRSLWRLLWSQPKKKRKV,27,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Acetylation,Cysteamide group,,,0,GLWRALWRLLRSLWRLLWSQPKKKRKV
PARAARRAARR,11,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Fusion with beta-Gal,,,0,PARAARRAARR
YPRAARRAARR,11,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Fusion with beta-Gal,,,0,YPRAARRAARR
YRRAARRAARA,11,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Fusion with beta-Gal,,,0,YRRAARRAARA
YGRAARRAARR,11,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Fusion with beta-Gal,,,0,YGRAARRAARR
YAREARRAARR,11,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Fusion with beta-Gal,,,0,YAREARRAARR
YEREARRAARR,11,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Fusion with beta-Gal,,,0,YEREARRAARR
YKRAARRAARR,11,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Fusion with beta-Gal,,,0,YKRAARRAARR
YARKARRAARR,11,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Fusion with beta-Gal,,,0,YARKARRAARR
YKRKARRAARR,11,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Fusion with beta-Gal,,,0,YKRKARRAARR
YGRRARRAARR,11,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Fusion with beta-Gal,,,0,YGRRARRAARR
YGRRARRRARR,11,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Fusion with beta-Gal,,,0,YGRRARRRARR
YGRRARRRRRR,11,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Fusion with beta-Gal,,,0,YGRRARRRRRR
YGRRRRRRRRR,11,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Fusion with beta-Gal,,,0,YGRRRRRRRRR
YRRRRRRRRRR,11,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Fusion with beta-Gal,,,0,YRRRRRRRRRR
CWKKK,5,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Acetylation,Free,,,0,CWKKK
CWKKKKKKKK,10,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Acetylation,Free,,,0,CWKKKKKKKK
CWKKKKKKKKKKKKK,15,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Acetylation,Free,,,0,CWKKKKKKKKKKKKK
CWKKKKKKKKKKKKKKKKKK,20,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Acetylation,Free,,,0,CWKKKKKKKKKKKKKKKKKK
KKKKKKKKKKKKKKKKKKK,19,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Free,,,0,KKKKKKKKKKKKKKKKKKK
GGVCPKILAACRRDSDCPGACICRGNGYCGSGSD,34,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Cyclic,,Alexa-488,Cyclization,,,0,GGVCPKILAACRRDSDCPGACICRGNGYCGSGSD
GGVCPAILKKCRRDSDCPGACICRGNGYCGSGSD,34,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Cyclic,,Alexa-488,Cyclization,,,0,GGVCPAILKKCRRDSDCPGACICRGNGYCGSGSD
GGVCPKILAKCRRDSDCPGACICRGNGYCGSGSD,34,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Cyclic,,Alexa-488,Cyclization,,,0,GGVCPKILAKCRRDSDCPGACICRGNGYCGSGSD
GGVCPKILKACRRDSDCPGACICRGNGYCGSGSD,34,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Cyclic,,Alexa-488,Cyclization,,,0,GGVCPKILKACRRDSDCPGACICRGNGYCGSGSD
GLPVCGETCVGGTCNTPGCKCSWPVCTRN,29,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Cyclic,,Alexa-488,Cyclization,,,0,GLPVCGETCVGGTCNTPGCKCSWPVCTRN
GLPVCGETCVGGTCNTPGCTCSWPKCTRN,29,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Cyclic,,Alexa-488,Cyclization,,,0,GLPVCGETCVGGTCNTPGCTCSWPKCTRN
RQIKIWFQNRRMKWKKTYADFIASGRTGRRNAI,33,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Rhodamine B,Free,,,0,RQIKIWFQNRRMKWKKTYADFIASGRTGRRNAI
GRKKRRQRRRPPQTYADFIASGRTGRRNAI,30,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Rhodamine B,Free,,,0,GRKKRRQRRRPPQTYADFIASGRTGRRNAI
AGYLLGKINLKALAALAKKILTYADFIASGRTGRRNAI,38,Chimeric,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Rhodamine B,Free,,,0,AGYLLGKINLKALAALAKKILTYADFIASGRTGRRNAI
RRRRRRRRRRRTYADFIASGRTGRRNAI,28,Chimeric,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Rhodamine B,Free,,,0,RRRRRRRRRRRTYADFIASGRTGRRNAI
RRRRRRRRR,9,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Rhodamine B,Amidation,,,0,RRRRRRRRR
rrrrrrrrr,9,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Rhodamine B,Amidation,,,0,RRRRRRRRR
rqikiwfqnrrmkwkk,16,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Fluorescein,Amidation,,,0,RQIKIWFQNRRMKWKK
KCFQWQRNMRKVRGPPVSCIKR,22,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Fluorescein,Amidation,,,0,KCFQWQRNMRKVRGPPVSCIKR
kcfqwqrnmrkvrgppvscikr,22,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Fluorescein,Amidation,,,0,KCFQWQRNMRKVRGPPVSCIKR
KLALKLALKALKAALKLAGC,20,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Acetylation,fluorescein,,,0,KLALKLALKALKAALKLAGC
KLULKLULKULKAULKLUGC,20,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Acetylation,fluorescein,"U=Aib, α-aminoisobutyric acid",,0,KLULKLULKULKAULKLUGC
GGGARKKAAKAARKKAAKAARKKAAKAARKKAAKA,35,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,GFP,,,0,GGGARKKAAKAARKKAAKAARKKAAKAARKKAAKA
TRQARRNRRRRWRERQRGC,19,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Amidation,Conjugation with Alexa 488 at glycyl cysteine sequence,,0,TRQARRNRRRRWRERQRGC
RRRRNRTRRNRRRVRGC,17,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Amidation,Conjugation with Alexa 488 at glycyl cysteine sequence,,0,RRRRNRTRRNRRRVRGC
KMTRAQRRAAARRNRWTARGC,21,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Amidation,Conjugation with Alexa 488 at glycyl cysteine sequence,,0,KMTRAQRRAAARRNRWTARGC
TRRQRTRRARRNRGC,15,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Amidation,Conjugation with Alexa 488 at glycyl cysteine sequence,,0,TRRQRTRRARRNRGC
RIKAERKRMRNRIAASKSRKRKLERIARGC,30,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Amidation,Conjugation with Alexa 488 at glycyl cysteine sequence,,0,RIKAERKRMRNRIAASKSRKRKLERIARGC
KRRIRRERNKMAAAKSRNRRRELTDTGC,28,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Amidation,Conjugation with Alexa 488 at glycyl cysteine sequence,,0,KRRIRRERNKMAAAKSRNRRRELTDTGC
crkkrrqrrr,10,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Insulin,Free,,,0,CRKKRRQRRR
GRKKRRQRRRPP,12,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,fluorescein,Free,,,0,GRKKRRQRRRPP
rrrrrrrrrcqcrrkn,16,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Free,,,0,RRRRRRRRRCQCRRKN
RRRRRRRGGIYLATALAKWALKQGF,25,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Free,,,0,RRRRRRRGGIYLATALAKWALKQGF
IYLATALAKWALKQGFGGRRRRRRR,25,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Free,,,0,IYLATALAKWALKQGFGGRRRRRRR
RRRRRRRGGIYLATALAKWALKQ,23,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Free,,,0,RRRRRRRGGIYLATALAKWALKQ
IYLATALAKWALKQGGRRRRRRR,23,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Free,,,0,IYLATALAKWALKQGGRRRRRRR
RRRRRRRGGKLAKLAKKLAKLAK,23,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Free,,,0,RRRRRRRGGKLAKLAKKLAKLAK
KLAKLAKKLAKLAKGGRRRRRRR,23,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Free,,,0,KLAKLAKKLAKLAKGGRRRRRRR
WRWKKKKA,8,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Cyclic,,Free,Free,,,0,WRWKKKKA
NYRWRCKNQN,10,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Free,,,0,NYRWRCKNQN
NYQRRCKNQN,10,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Free,,,0,NYQRRCKNQN
NYQWRCKNQN,10,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Free,,,0,NYQWRCKNQN
NYRRRCKNQN,10,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Free,,,0,NYRRRCKNQN
YRWRCKNQN,9,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Free,,,0,YRWRCKNQN
NYRWRCKNQ,9,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Free,,,0,NYRWRCKNQ
YRWRCKNQ,8,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Free,,,0,YRWRCKNQ
NYRWRCKN,8,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Free,,,0,NYRWRCKN
RWRCKNQN,8,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Free,,,0,RWRCKNQN
NYRWRCK,7,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Free,,,0,NYRWRCK
GRKKRRQRRRP,11,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Free,,,0,GRKKRRQRRRP
KLAKLAKKLAKLAKGRKKRRQRRRP,25,Chimeric,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Free,,,0,KLAKLAKKLAKLAKGRKKRRQRRRP
KLAKLAKKLAKLAKNYRWRCKNQN,24,Chimeric,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Free,,,0,KLAKLAKKLAKLAKNYRWRCKNQN
AGYLLGXINLKALAALAKKIL,21,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Stearylation,Amidation,X=Ornithine,,0,AGYLLGXINLKALAALAKKIL
NHQQQNPHQPPM,12,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,5(6)-Carboxyfluorescein,Amidation,,,0,NHQQQNPHQPPM
LLIILRRRIRKQAHAHSKNHQQQNPHQPPM,30,Chimeric,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,5(6)-Carboxyfluorescein,Amidation,,,0,LLIILRRRIRKQAHAHSKNHQQQNPHQPPM
NHQQQNPHQPPMLLIILRRRIRKQAHAHSK,30,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,5(6)-Carboxyfluorescein,Amidation,,,0,NHQQQNPHQPPMLLIILRRRIRKQAHAHSK
CLLIILRRRIRKQAHAHSKNHQQQNPHQPPM,31,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Succinimidyl-4-(N-mal-eimidomethyl) cyclohexane-1-carboxylate (SMCC),Amidation,,,0,CLLIILRRRIRKQAHAHSKNHQQQNPHQPPM
RKKRRQRRRGC,11,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Amidation,,,0,RKKRRQRRRGC
RGDXRRRRRRRR,12,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Free,X=12-aminododecanoic acid (ADDA),,0,RGDXRRRRRRRR
RGDRRRRRRRR,11,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Free,,,0,RGDRRRRRRRR
KETWWETWWTEWSQPKKKRKVC,22,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Free,,,0,KETWWETWWTEWSQPKKKRKVC
RRRRR,5,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Free,,,0,RRRRR
RRRRRRRRRRR,11,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Free,,,0,RRRRRRRRRRR
CRGDKGPDC,9,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Free,,,0,CRGDKGPDC
CRGDK,5,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Free,,,0,CRGDK
LSTAADMQGVVTDGMASGLDKDYLKPDD,28,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Free,,,0,LSTAADMQGVVTDGMASGLDKDYLKPDD
RXRRXRILFQYRXRRXR,17,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,N-terminal alkyne is introduced using 4-pentynoic acid,Amidation,X=aminohexyl residue,,0,RXRRXRILFQYRXRRXR
RXRRXRYQFLIRXRRXR,17,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,N-terminal alkyne is introduced using 4-pentynoic acid,Amidation,X=aminohexyl residue,,0,RXRRXRYQFLIRXRRXR
RXRRXRFLQIYRXRRXR,17,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,N-terminal alkyne is introduced using 4-pentynoic acid,Amidation,X=aminohexyl residue,,0,RXRRXRFLQIYRXRRXR
RXRRXRAAAAARXRRXR,17,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,N-terminal alkyne is introduced using 4-pentynoic acid,Amidation,X=aminohexyl residue,,0,RXRRXRAAAAARXRRXR
RXRRXRIKFQYRXRRXR,17,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,N-terminal alkyne is introduced using 4-pentynoic acid,Amidation,X=aminohexyl residue,,0,RXRRXRIKFQYRXRRXR
RXRRXRIEFQYRXRRXR,17,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,N-terminal alkyne is introduced using 4-pentynoic acid,Amidation,X=aminohexyl residue,,0,RXRRXRIEFQYRXRRXR
RXRRXRIWFQYRXRRXR,17,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,N-terminal alkyne is introduced using 4-pentynoic acid,Amidation,X=aminohexyl residue,,0,RXRRXRIWFQYRXRRXR
RXRRXRIPFQYRXRRXR,17,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,N-terminal alkyne is introduced using 4-pentynoic acid,Amidation,X=aminohexyl residue,,0,RXRRXRIPFQYRXRRXR
KXRKXRILFQYKXRKXR,17,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,N-terminal alkyne is introduced using 4-pentynoic acid,Amidation,X=aminohexyl residue,,0,KXRKXRILFQYKXRKXR
HXRHXRILFQYHXRHXR,17,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,N-terminal alkyne is introduced using 4-pentynoic acid,Amidation,X=aminohexyl residue,,0,HXRHXRILFQYHXRHXR
SXRSXRILFQYSXRSXR,17,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,N-terminal alkyne is introduced using 4-pentynoic acid,Amidation,X=aminohexyl residue,,0,SXRSXRILFQYSXRSXR
EXREXRILFQYEXREXR,17,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,N-terminal alkyne is introduced using 4-pentynoic acid,Amidation,X=aminohexyl residue,,0,EXREXRILFQYEXREXR
RMKWKKILFQYRXRRXR,17,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,N-terminal alkyne is introduced using 4-pentynoic acid,Amidation,X=aminohexyl residue,,0,RMKWKKILFQYRXRRXR
RXRRXRILFQYRMKWKK,17,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,N-terminal alkyne is introduced using 4-pentynoic acid,Amidation,X=aminohexyl residue,,0,RXRRXRILFQYRMKWKK
KKWKMRILFQYRXRRXR,17,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,N-terminal alkyne is introduced using 4-pentynoic acid,Amidation,X=aminohexyl residue,,0,KKWKMRILFQYRXRRXR
RXRRXRILFQYKKWKMR,17,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,N-terminal alkyne is introduced using 4-pentynoic acid,Amidation,X=aminohexyl residue,,0,RXRRXRILFQYKKWKMR
AGYLLGHINLHHLAHLHHILC,21,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Free,,,0,AGYLLGHINLHHLAHLHHILC
AGYLLGHINLHHLAHLHHIL,20,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Amidation,,,0,AGYLLGHINLHHLAHLHHIL
AGYLLGKINLKKLAKLLLIL,20,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Amidation,,,0,AGYLLGKINLKKLAKLLLIL
HHHHHHHHRRRRRRRR,16,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Stearylation,Amidation,,,0,HHHHHHHHRRRRRRRR
RRRRRRRRRRRRRRR,15,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Acetylation,Amidation,,,0,RRRRRRRRRRRRRRR
HHHHHHHHRRRRRRRRRRRRRRR,23,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Acetylation,Amidation,,,0,HHHHHHHHRRRRRRRRRRRRRRR
HHHHHHHHHHHHRRRRRRRRRRRRRRR,27,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Stearylation,Amidation,,,0,HHHHHHHHHHHHRRRRRRRRRRRRRRR
HHHHHHHHHHHHHHHHRRRRRRRRRRRRRRR,31,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Acetylation,Amidation,,,0,HHHHHHHHHHHHHHHHRRRRRRRRRRRRRRR
HHHHHHHHHHHHHHHHHHHHRRRRRRRRRRRRRRR,35,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Stearylation,Amidation,,,0,HHHHHHHHHHHHHHHHHHHHRRRRRRRRRRRRRRR
RLLRLLRLL,9,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,5(6)-Carboxyfluorescein,Amidation,,,0,RLLRLLRLL
RLLRLLRLX,9,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,5(6)-Carboxyfluorescein,Amidation,X=1-aminocyclopentane-1-carboxylic acids (Ac5c),,0,RLLRLLRLX
RLLRLXRLX,9,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,5(6)-Carboxyfluorescein,Amidation,X=1-aminocyclopentane-1-carboxylic acids (Ac5c),,0,RLLRLXRLX
RLXRLXRLX,9,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,5(6)-Carboxyfluorescein,Amidation,X=1-aminocyclopentane-1-carboxylic acids (Ac5c),,0,RLXRLXRLX
RLXRLXRXX,9,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,5(6)-Carboxyfluorescein,Amidation,X=1-aminocyclopentane-1-carboxylic acids (Ac5c),,0,RLXRLXRXX
RLXRXRXX,8,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,5(6)-Carboxyfluorescein,Amidation,X=1-aminocyclopentane-1-carboxylic acids (Ac5c),,0,RLXRXRXX
RXXRXRXX,8,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,5(6)-Carboxyfluorescein,Amidation,X=1-aminocyclopentane-1-carboxylic acids (Ac5c),,0,RXXRXRXX
PKKKRKVWKLLQQFFGLM,18,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane lysis##Cell-penetrating peptides,,Linear,,Free,Amidation,,,0,PKKKRKVWKLLQQFFGLM
CSKSSDYQC,9,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides##Targeted peptide conjugates,,Cyclic,,Free,Free,"Coupling to polyoxyethylene (40) steartae (SA-PEG2000), peptide ligand modified salmon calcitonin (sCT)-loaded SLNs",,0,CSKSSDYQC
KCFQAQRNMRKVRGPPVSCIKR,22,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Fluorescein,Amidation,,,0,KCFQAQRNMRKVRGPPVSCIKR
KCFQWARNMRKVRGPPVSCIKR,22,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Fluorescein,Amidation,,,0,KCFQWARNMRKVRGPPVSCIKR
KCFQWQRNARKVRGPPVSCIKR,22,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Fluorescein,Amidation,,,0,KCFQWQRNARKVRGPPVSCIKR
KCFQWQRNMRKVRGAPVSCIKR,22,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Fluorescein,Amidation,,,0,KCFQWQRNMRKVRGAPVSCIKR
KCFQWQRNMRKRRGPPVSCIKR,22,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Fluorescein,Amidation,,,0,KCFQWQRNMRKRRGPPVSCIKR
KCFQWQANMRKVRGPPVSCIKR,22,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Fluorescein,Amidation,,,0,KCFQWQANMRKVRGPPVSCIKR
KCFQWQRNMRKVAGPPVSCIKR,22,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Fluorescein,Amidation,,,0,KCFQWQRNMRKVAGPPVSCIKR
KCFQWQANMRKRRGPPVSCIKR,22,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Fluorescein,Amidation,,,0,KCFQWQANMRKRRGPPVSCIKR
KCFQWQRNMRKVAGRPVSCIKR,22,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Fluorescein,Amidation,,,0,KCFQWQRNMRKVAGRPVSCIKR
KCFRWQRNRRKVRGRPVRCIKR,22,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Fluorescein,Amidation,,,0,KCFRWQRNRRKVRGRPVRCIKR
KRFRWQRNMRKVRGRPVRSIKR,22,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Fluorescein,Amidation,,,0,KRFRWQRNMRKVRGRPVRSIKR
RCFQWQRNMRRVRGPPVSCIRR,22,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Fluorescein,Amidation,,,0,RCFQWQRNMRRVRGPPVSCIRR
KCFQWQKNMKKVKGPPVSCIKK,22,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Fluorescein,Amidation,,,0,KCFQWQKNMKKVKGPPVSCIKK
KXFQWQRNMRKVRGPPVSXIKR,22,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Fluorescein,Amidation,"X=Hcy, homocysteine in which the side chain is one methylene group longer than in cysteine",,0,KXFQWQRNMRKVRGPPVSXIKR
GRGDSPRR,8,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Acetylation,Free,Phosphorylation,,0,GRGDSPRR
GRGDSPRRSPRR,12,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Acetylation,Free,Phosphorylation,,0,GRGDSPRRSPRR
GRGDSPRRKKKKSPRRKKKKSPRR,24,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Acetylation,Free,Phosphorylation,,0,GRGDSPRRKKKKSPRRKKKKSPRR
GRGDGPRRKKKKGPRRKKKKGPRR,24,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Acetylation,Free,,,0,GRGDGPRRKKKKGPRRKKKKGPRR
BRRXRRXRRX,10,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,"FAM, fluorescein",Amidation,B=Beta-Alanine; X=α-amino isobutyric acid,,0,BRRXRRXRRX
BrrXrrXrrX,10,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,"FAM, fluorescein",Amidation,B=Beta-Alanine; X=α-amino isobutyric acid,,0,BRRXRRXRRX
BRrXRrXRrX,10,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,"FAM, fluorescein",Amidation,B=Beta-Alanine; X=α-amino isobutyric acid,,0,BRRXRRXRRX
BXRXRXXRXRXXRXRX,16,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,"FAM, fluorescein",Amidation,B=Beta-Alanine; X=α-amino isobutyric acid,,0,BXRXRXXRXRXXRXRX
IPLVVPLC,8,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Free,,,0,IPLVVPLC
YARVRRRGPRR,11,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,6-histidine tag,Free,,,0,YARVRRRGPRR
CRQIKIWFQNRRMKWKK,17,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Acetylation,Amidation,,,0,CRQIKIWFQNRRMKWKK
CRQIKIWFQNRRMKWKKKLAKLAKKLAKLAK,31,Chimeric,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Acetylation,Amidation,,,0,CRQIKIWFQNRRMKWKKKLAKLAKKLAKLAK
CRRLRHLRHHYRRRWHRFRC,20,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Free,Addition of cysteine in Mgpe3 sequence makes Mgpe9,,0,CRRLRHLRHHYRRRWHRFRC
CLLYWFRRRHRHHRRRHRRC,20,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Free,Addition of cysteine in Mgpe4 sequence makes Mgpe10,,0,CLLYWFRRRHRHHRRRHRRC
RRLRHLRHHYRRRWHRFR,18,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Free,,,0,RRLRHLRHHYRRRWHRFR
LLYWFRRRHRHHRRRHRR,18,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Free,,,0,LLYWFRRRHRHHRRRHRR
KXGRKKRRQRRRPPQY,16,Protein derived,Native peptide,,,,,,Anticancer,Targeted peptide conjugates##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Amidation,"X=Dex, dexamethasone",,0,KXGRKKRRQRRRPPQY
RRRRRRRRRXDEXLI,15,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Acetylation,Amidation,"Φ=L-2-naphthylalanine; X(10)=miniPEG, 8-amino-3,6-dioxaoctanoic acid; X(13)=Pcap, phosphocoumaryl aminopropionic acid",,0,RRRRRRRRRXDEXLI
RKKRRQRRRXDEXLI,15,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Acetylation,Amidation,"Φ=L-2-naphthylalanine; X(10)=miniPEG, 8-amino-3,6-dioxaoctanoic acid; X(13)=Pcap, phosphocoumaryl aminopropionic acid",,0,RKKRRQRRRXDEXLI
RQIKIWFQNRRMKWKKXDEXLI,22,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Acetylation,Amidation,"Φ=L-2-naphthylalanine; X(17)=miniPEG, 8-amino-3,6-dioxaoctanoic acid; X(20)=Pcap, phosphocoumaryl aminopropionic acid",,0,RQIKIWFQNRRMKWKKXDEXLI
ISFDELLDYYGESGS,15,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Acetylation,Free,,,0,ISFDELLDYYGESGS
PKKKRKVAGYLLGKINLKALAALAKKILPQMQQNVFQYPGAGMVPQGEANF,51,Chimeric,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Free,,,0,PKKKRKVAGYLLGKINLKALAALAKKILPQMQQNVFQYPGAGMVPQGEANF
PKKKRKVRRRRRRRYSQTSHKLVQLLTTAEQQ,32,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Free,,,0,PKKKRKVRRRRRRRYSQTSHKLVQLLTTAEQQ
PKKKRKVRRRRRRRPQMQQNVFQYPGAGMVPQGEANF,37,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,NLS,Free,,,0,PKKKRKVRRRRRRRPQMQQNVFQYPGAGMVPQGEANF
LCLRPVG,7,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Free,,,0,LCLRPVG
LCLRP,5,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Free,,,0,LCLRP
LCLR,4,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Free,,,0,LCLR
LLR,3,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Free,,,0,LLR
LLLR,4,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Free,,,0,LLLR
LLLLR,5,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Free,,,0,LLLLR
LLLRR,5,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Free,,,0,LLLRR
IIIR,4,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Free,,,0,IIIR
VVVR,4,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Free,,,0,VVVR
LCLK,4,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Free,,,0,LCLK
LCLH,4,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Free,,,0,LCLH
LCLE,4,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Free,,,0,LCLE
LCLN,4,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Free,,,0,LCLN
LCLQ,4,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Free,,,0,LCLQ
lclrpvg,7,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Free,,,0,LCLRPVG
lclrp,5,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Free,,,0,LCLRP
lclr,4,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Free,,,0,LCLR
lcl,3,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Free,,,0,LCL
icir,4,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Free,,,0,ICIR
vcvr,4,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Free,,,0,VCVR
vlclr,5,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Free,,,0,VLCLR
EEEEEEEEPLGLAGRRRRRRRRN,23,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Free,,,0,EEEEEEEEPLGLAGRRRRRRRRN
FSGSGSGSGRRRRRRRRGC,19,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Acetylation,Amidation,,,0,FSGSGSGSGRRRRRRRRGC
GSGSGSGSGRRRRRRRRGC,19,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Acetylation,Amidation,,,0,GSGSGSGSGRRRRRRRRGC
FSGSGSGSGRQIKIWFQNRRMKWKKGC,27,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Acetylation,Amidation,,,0,FSGSGSGSGRQIKIWFQNRRMKWKKGC
GSGSGSGSGRQIKIWFQNRRMKWKKGC,27,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Acetylation,Amidation,,,0,GSGSGSGSGRQIKIWFQNRRMKWKKGC
FSGSGSGSGAGYLLGKINLKALAALAKKILGC,32,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Acetylation,Amidation,,,0,FSGSGSGSGAGYLLGKINLKALAALAKKILGC
GSGSGSGSGAGYLLGKINLKALAALAKKILGC,32,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Acetylation,Amidation,,,0,GSGSGSGSGAGYLLGKINLKALAALAKKILGC
CGGKDCERRFSRSDQLKRHQRRHTGVKPFQ,30,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Biotinylation,Amidation,,,0,CGGKDCERRFSRSDQLKRHQRRHTGVKPFQ
KDCERRFSRSDQLKRHQRRHTGVKPFQK,28,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Free,,,0,KDCERRFSRSDQLKRHQRRHTGVKPFQK
GGGGRRRRRRRRRLLLL,17,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Maleimide addition,Free,,,0,GGGGRRRRRRRRRLLLL
CGGGRRRRRRRRRLLLL,17,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Free,,,0,CGGGRRRRRRRRRLLLL
RIMRILRILKLAR,13,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Free,,,0,RIMRILRILKLAR
RKKRRQRRRGGG,12,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Amidation,,,0,RKKRRQRRRGGG
RKKRRQRRRGGGKLLKLLLKLLLKLLK,27,Chimeric,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Amidation,,,0,RKKRRQRRRGGGKLLKLLLKLLLKLLK
GALFLAFLAAALSLMGLWSQPKKKRKV,27,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Acetylation,Cysteamide group,,,0,GALFLAFLAAALSLMGLWSQPKKKRKV
KLPVM,5,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Free,,,0,KLPVM
KLFMALVAFLRFLTIPPTAGILKRWGTI,28,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Rhodamine B,Free,,,0,KLFMALVAFLRFLTIPPTAGILKRWGTI
LKRWGTIKKSKAINVLRGFRKEIGRMLNILNRRRR,35,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Rhodamine B,Free,,,0,LKRWGTIKKSKAINVLRGFRKEIGRMLNILNRRRR
CELAGIGILTVRKKRRQRRR,20,Chimeric,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Conjugation with Alexa488 C5 maleimide,Free,,,0,CELAGIGILTVRKKRRQRRR
CELAGIGILTVKKKKKQKKK,20,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Free,,,0,CELAGIGILTVKKKKKQKKK
YGRGGRRGRRR,11,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,ELPBC,Free,,,0,YGRGGRRGRRR
XACSGSGSGCGSGSGSCG,18,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Cyclic,All cysteines form disulfide bridges with the T3-scaffold.,FITC,Amidation,"X=Ahx, 6-aminohexanoic acid",,0,XACSGSGSGCGSGSGSCG
XACSGRGSGCGSGRGSCG,18,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Cyclic,All cysteines form disulfide bridges with the T3-scaffold.,FITC,Amidation,"X=Ahx, 6-aminohexanoic acid",,0,XACSGRGSGCGSGRGSCG
XACRGSGRGCGRGSGRCG,18,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Cyclic,All cysteines form disulfide bridges with the T3-scaffold.,FITC,Amidation,"X=Ahx, 6-aminohexanoic acid",,0,XACRGSGRGCGRGSGRCG
XACSGRGRGCGRGRGSCG,18,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Cyclic,All cysteines form disulfide bridges with the T3-scaffold.,FITC,Amidation,"X=Ahx, 6-aminohexanoic acid",,0,XACSGRGRGCGRGRGSCG
XACRGRGRGCGRGRGRCG,18,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Cyclic,All cysteines form disulfide bridges with the T3-scaffold.,FITC,Amidation,"X=Ahx, 6-aminohexanoic acid",,0,XACRGRGRGCGRGRGRCG
XACGRGRGRCRGRGRGCG,18,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Cyclic,All cysteines form disulfide bridges with the T3-scaffold.,FITC,Amidation,"X=Ahx, 6-aminohexanoic acid",,0,XACGRGRGRCRGRGRGCG
XACRGRGRGCRGRGRGCG,18,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Cyclic,All cysteines form disulfide bridges with the T3-scaffold.,FITC,Amidation,"X=Ahx, 6-aminohexanoic acid",,0,XACRGRGRGCRGRGRGCG
XACGRGRGRCGRGRGRCG,18,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Cyclic,All cysteines form disulfide bridges with the T3-scaffold.,FITC,Amidation,"X=Ahx, 6-aminohexanoic acid",,0,XACGRGRGRCGRGRGRCG
XACRGRRRGCGRRRGRCG,18,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Cyclic,All cysteines form disulfide bridges with the T3-scaffold.,FITC,Amidation,"X=Ahx, 6-aminohexanoic acid",,0,XACRGRRRGCGRRRGRCG
XACRRSRRGCGRRSRRCG,18,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Cyclic,All cysteines form disulfide bridges with the T3-scaffold.,FITC,Amidation,"X=Ahx, 6-aminohexanoic acid",,0,XACRRSRRGCGRRSRRCG
XACSDRFRNCPADEALCG,18,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Cyclic,All cysteines form disulfide bridges with the T3-scaffold.,FITC,Amidation,"X=Ahx, 6-aminohexanoic acid",,0,XACSDRFRNCPADEALCG
XACRDRFRNCPADEALCG,18,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Cyclic,All cysteines form disulfide bridges with the T3-scaffold.,FITC,Amidation,"X=Ahx, 6-aminohexanoic acid",,0,XACRDRFRNCPADEALCG
XACRDRFRNCPADERLCG,18,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Cyclic,All cysteines form disulfide bridges with the T3-scaffold.,FITC,Amidation,"X=Ahx, 6-aminohexanoic acid",,0,XACRDRFRNCPADERLCG
XACRDRFRRCPADERLCG,18,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Cyclic,All cysteines form disulfide bridges with the T3-scaffold.,FITC,Amidation,"X=Ahx, 6-aminohexanoic acid",,0,XACRDRFRRCPADERLCG
XACRDRFRRCPADRRLCG,18,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Cyclic,All cysteines form disulfide bridges with the T3-scaffold.,FITC,Amidation,"X=Ahx, 6-aminohexanoic acid",,0,XACRDRFRRCPADRRLCG
XACSGRGRGCGSGSGSCG,18,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Cyclic,All cysteines form disulfide bridges with the T3-scaffold.,FITC,Amidation,"X=Ahx, 6-aminohexanoic acid",,0,XACSGRGRGCGSGSGSCG
XACRGRGRGCGSGSGSCG,18,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Cyclic,All cysteines form disulfide bridges with the T3-scaffold.,FITC,Amidation,"X=Ahx, 6-aminohexanoic acid",,0,XACRGRGRGCGSGSGSCG
XACRGRGRGCGSGSRSCG,18,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Cyclic,All cysteines form disulfide bridges with the T3-scaffold.,FITC,Amidation,"X=Ahx, 6-aminohexanoic acid",,0,XACRGRGRGCGSGSRSCG
XACRGRGRRCGSGSRSCG,18,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Cyclic,All cysteines form disulfide bridges with the T3-scaffold.,FITC,Amidation,"X=Ahx, 6-aminohexanoic acid",,0,XACRGRGRRCGSGSRSCG
XACRGRGRRCGSGRRSCG,18,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Cyclic,All cysteines form disulfide bridges with the T3-scaffold.,FITC,Amidation,"X=Ahx, 6-aminohexanoic acid",,0,XACRGRGRRCGSGRRSCG
XARCSGSGSGCGSGSGSCGR,20,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Cyclic,All cysteines form disulfide bridges with the T3-scaffold.,FITC,Amidation,"X=Ahx, 6-aminohexanoic acid",,0,XARCSGSGSGCGSGSGSCGR
XARRCSGSGSGCGSGSGSCGRR,22,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Cyclic,All cysteines form disulfide bridges with the T3-scaffold.,FITC,Amidation,"X=Ahx, 6-aminohexanoic acid",,0,XARRCSGSGSGCGSGSGSCGRR
XARRRCSGSGSGCGSGSGSCGRRR,24,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Cyclic,All cysteines form disulfide bridges with the T3-scaffold.,FITC,Amidation,"X=Ahx, 6-aminohexanoic acid",,0,XARRRCSGSGSGCGSGSGSCGRRR
XARRRRCSGSGSGCGSGSGSCGRRRR,26,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Cyclic,All cysteines form disulfide bridges with the T3-scaffold.,FITC,Amidation,"X=Ahx, 6-aminohexanoic acid",,0,XARRRRCSGSGSGCGSGSGSCGRRRR
XACSGSGSGCGSGSGSCGRRRRRRRR,26,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Cyclic,All cysteines form disulfide bridges with the T3-scaffold.,FITC,Amidation,"X=Ahx, 6-aminohexanoic acid",,0,XACSGSGSGCGSGSGSCGRRRRRRRR
XARCSDRFRNCPADEALCGR,20,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Cyclic,All cysteines form disulfide bridges with the T3-scaffold.,FITC,Amidation,"X=Ahx, 6-aminohexanoic acid",,0,XARCSDRFRNCPADEALCGR
XARRCSDRFRNCPADEALCGRR,22,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Cyclic,All cysteines form disulfide bridges with the T3-scaffold.,FITC,Amidation,"X=Ahx, 6-aminohexanoic acid",,0,XARRCSDRFRNCPADEALCGRR
XARRRCSDRFRNCPADEALCGRRR,24,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Cyclic,All cysteines form disulfide bridges with the T3-scaffold.,FITC,Amidation,"X=Ahx, 6-aminohexanoic acid",,0,XARRRCSDRFRNCPADEALCGRRR
XARRRRCSDRFRNCPADEALCGRRRR,26,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Cyclic,All cysteines form disulfide bridges with the T3-scaffold.,FITC,Amidation,"X=Ahx, 6-aminohexanoic acid",,0,XARRRRCSDRFRNCPADEALCGRRRR
XACSDRFRNCPADEALCGRRRRRRRR,26,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Cyclic,All cysteines form disulfide bridges with the T3-scaffold.,FITC,Amidation,"X=Ahx, 6-aminohexanoic acid",,0,XACSDRFRNCPADEALCGRRRRRRRR
XACSHSGHGCGHGSHSCGRRRRRRRR,26,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Cyclic,All cysteines form disulfide bridges with the T3-scaffold.,FITC,Amidation,"X=Ahx, 6-aminohexanoic acid",,0,XACSHSGHGCGHGSHSCGRRRRRRRR
XACSHSGWGCGHGSWSCGRRRRRRRR,26,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Cyclic,All cysteines form disulfide bridges with the T3-scaffold.,FITC,Amidation,"X=Ahx, 6-aminohexanoic acid",,0,XACSHSGWGCGHGSWSCGRRRRRRRR
XACHGRRWGCGRHRGRCG,18,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Cyclic,All cysteines form disulfide bridges with the T3-scaffold.,FITC,Amidation,"X=Ahx, 6-aminohexanoic acid",,0,XACHGRRWGCGRHRGRCG
HEHEHEHEHEHEHEHEEFGGGGGYGRGRGRGRGRGRG,37,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Glutathione S-transferase,Free,,,0,HEHEHEHEHEHEHEHEEFGGGGGYGRGRGRGRGRGRG
HEHEHEHEHEHEHEHEHEHEEFGGGGGYGRGRGRGRGRGRG,41,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Glutathione S-transferase,Free,,,0,HEHEHEHEHEHEHEHEHEHEEFGGGGGYGRGRGRGRGRGRG
HEHEHEHEHEHEHEHEHEHEHEHEEFGGGGGYGRGRGRGRGRGRG,45,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Glutathione S-transferase,Free,,,0,HEHEHEHEHEHEHEHEHEHEHEHEEFGGGGGYGRGRGRGRGRGRG
HEHEHEHEHEHEHEHEEFGGGGGYGRRRRRRGGGGGG,37,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Glutathione S-transferase,Free,,,0,HEHEHEHEHEHEHEHEEFGGGGGYGRRRRRRGGGGGG
HEHEHEHEHEHEHEHEHEHEEFGGGGGYGRRRRRRGGGGGG,41,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Glutathione S-transferase,Free,,,0,HEHEHEHEHEHEHEHEHEHEEFGGGGGYGRRRRRRGGGGGG
HEHEHEHEHEHEHEHEHEHEHEHEEFGGGGGYGRRRRRRGGGGGG,45,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Glutathione S-transferase,Free,,,0,HEHEHEHEHEHEHEHEHEHEHEHEEFGGGGGYGRRRRRRGGGGGG
HEHEHEHEHEHEHEHEHEHEHEHEEFGGGGGYGRKKRRQRRR,42,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Glutathione S-transferase,Free,,,0,HEHEHEHEHEHEHEHEHEHEHEHEEFGGGGGYGRKKRRQRRR
WELVVLGKLYGRKKRRQRRR,20,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Free,,,0,WELVVLGKLYGRKKRRQRRR
ELVVLGKLYGRKKRRQRRR,19,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Free,,,0,ELVVLGKLYGRKKRRQRRR
LVVLGKLYGRKKRRQRRR,18,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Free,,,0,LVVLGKLYGRKKRRQRRR
VVLGKLYGRKKRRQRRR,17,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Free,,,0,VVLGKLYGRKKRRQRRR
WELVVLGKYGRKKRRQRRR,19,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Free,,,0,WELVVLGKYGRKKRRQRRR
WELVVLGYGRKKRRQRRR,18,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Free,,,0,WELVVLGYGRKKRRQRRR
WELVVLYGRKKRRQRRR,17,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Free,,,0,WELVVLYGRKKRRQRRR
WELVVYGRKKRRQRRR,16,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Free,,,0,WELVVYGRKKRRQRRR
WELVYGRKKRRQRRR,15,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Free,,,0,WELVYGRKKRRQRRR
WELYGRKKRRQRRR,14,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Free,,,0,WELYGRKKRRQRRR
WEYGRKKRRQRRR,13,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Free,,,0,WEYGRKKRRQRRR
WELVVAYGRKKRRQRRR,17,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Free,,,0,WELVVAYGRKKRRQRRR
WEAVVLYGRKKRRQRRR,17,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Free,,,0,WEAVVLYGRKKRRQRRR
WEAVVAYGRKKRRQRRR,17,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Free,,,0,WEAVVAYGRKKRRQRRR
GLKKLARLFHKLLKLGC,17,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Amidation,,,0,GLKKLARLFHKLLKLGC
GLKKLAELFHKLLKLGC,17,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Amidation,,,0,GLKKLAELFHKLLKLGC
GLKKLARLAHKLLKLGC,17,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Amidation,,,0,GLKKLARLAHKLLKLGC
GLKKLAELAHKLLKLGC,17,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Amidation,,,0,GLKKLAELAHKLLKLGC
YGRKKRRQRRRGC,13,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Amidation,,,0,YGRKKRRQRRRGC
RLRLRLRLRLRLRLRLKRLKRLKRLKRLKKKKKKKGYK,38,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Amidation,,,0,RLRLRLRLRLRLRLRLKRLKRLKRLKRLKKKKKKKGYK
RLRLRLRLRLRLRLRLKLLKLLKLLKLLKKKKKKKGYK,38,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Amidation,,,0,RLRLRLRLRLRLRLRLKLLKLLKLLKLLKKKKKKKGYK
RLRLRLRLRLRLRLRLKNNKNNKNNKNNKKKKKKKGYK,38,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Amidation,,,0,RLRLRLRLRLRLRLRLKNNKNNKNNKNNKKKKKKKGYK
GYGYGYGYGYGYGYGYKKRKKRKKRKKRKQQKQQKRRK,38,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Amidation,,,0,GYGYGYGYGYGYGYGYKKRKKRKKRKKRKQQKQQKRRK
ALALALALALALALALKIKKIKKIKKIKKLAKLAKKIK,38,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Amidation,,,0,ALALALALALALALALKIKKIKKIKKIKKLAKLAKKIK
LALALALALALALALAKKLKKLKKLKKLKKLKKLKYAK,38,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Amidation,,,0,LALALALALALALALAKKLKKLKKLKKLKKLKKLKYAK
IKIKIKIKIKIKIKIKKLAKLAKLAKLAKLAKLAKKIK,38,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Amidation,,,0,IKIKIKIKIKIKIKIKKLAKLAKLAKLAKLAKLAKKIK
LALALALALALALALAKIKKIKKIKKIKKLAKLAKKIK,38,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Amidation,,,0,LALALALALALALALAKIKKIKKIKKIKKLAKLAKKIK
LALALALALALALAKLAKLAKLAKLAKIKKIKKKIK,36,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Amidation,,,0,LALALALALALALAKLAKLAKLAKLAKIKKIKKKIK
LALALALALALALALAKLAKLAKLAKLAKLAKKIK,35,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Amidation,,,0,LALALALALALALALAKLAKLAKLAKLAKLAKKIK
LILILILILILILILIKRKKRKKRKKRKKRAKRAKHSK,38,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Amidation,,,0,LILILILILILILILIKRKKRKKRKKRKKRAKRAKHSK
LKKLLKLLKKLLKLAG,16,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Acetylation,Amidation,,,0,LKKLLKLLKKLLKLAG
LKKLCKLLKKLCKLAG,16,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Acetylation,Amidation,,,0,LKKLCKLLKKLCKLAG
VTPHHVLVDEYTGEWVDSQFK,21,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Free,,,0,VTPHHVLVDEYTGEWVDSQFK
AGYLLGKTNLKALAALAKKIL,21,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,"Stearylation,  CH3(CH2)16CO",Amidation,,,0,AGYLLGKTNLKALAALAKKIL
YGRKKRRQRRRYGRKKRRQRRRYGRKKRRQRRR,33,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Coupled to signal peptide,mCherry,,,0,YGRKKRRQRRRYGRKKRRQRRRYGRKKRRQRRR
GGVCPKILKKCRRDSDCPGACICRGNGWCGSGSD,34,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Cyclic,Cys4<--->Cys21; Cys11<--->Cys23; Cys11<--->Cys29; NCB: Gly1<--->Asp34,Conjugation with Alexa Flour 488,Free,,,0,GGVCPKILKKCRRDSDCPGACICRGNGWCGSGSD
GGVCPKILRRCRRDSDCPGACICRGNGYCGSGSD,34,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Cyclic,Cys4<--->Cys21; Cys11<--->Cys23; Cys11<--->Cys29; NCB: Gly1<--->Asp34,Conjugation with Alexa Flour 488,Free,,,0,GGVCPKILRRCRRDSDCPGACICRGNGYCGSGSD
GGVCPKILRRCRRDSDCPGACICRGNGWCGSGSD,34,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Cyclic,Cys4<--->Cys21; Cys11<--->Cys23; Cys11<--->Cys29; NCB: Gly1<--->Asp34,Conjugation with Alexa Flour 488,Free,,,0,GGVCPKILRRCRRDSDCPGACICRGNGWCGSGSD
GGVCPKILRRCRRDSDCPGACICRGNGYCGSGSR,34,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Cyclic,Cys4<--->Cys21; Cys11<--->Cys23; Cys11<--->Cys29; NCB: Gly1<--->Asp34,Conjugation with Alexa Flour 488,Free,,,0,GGVCPKILRRCRRDSDCPGACICRGNGYCGSGSR
GGVCPRILRRCRRDSDCPGACICRGNGYCGSGSK,34,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Cyclic,Cys4<--->Cys21; Cys11<--->Cys23; Cys11<--->Cys29; NCB: Gly1<--->Asp34,Conjugation with Alexa Flour 488,Free,,,0,GGVCPRILRRCRRDSDCPGACICRGNGYCGSGSK
GRCTKSIPPICFPD,14,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Cyclic,Cys3<--->Cys11; NCB: Gly1<--->Asp14,Conjugation with Alexa Flour 488,Free,,,0,GRCTKSIPPICFPD
grctksippicfpd,14,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Cyclic,cys3<--->cys11; NCB: gly1<--->asp14,Conjugation with Alexa Flour 488,Free,,,0,GRCTKSIPPICFPD
GACTKSIPPICFPD,14,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Cyclic,Cys3<--->Cys11; NCB: Gly1<--->Asp14,Conjugation with Alexa Flour 488,Free,,,0,GACTKSIPPICFPD
GRCTKSIPPICFPA,14,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Cyclic,Cys3<--->Cys11; NCB: Gly1<--->Asp14,Conjugation with Alexa Flour 488,Free,,,0,GRCTKSIPPICFPA
GRCTKSIPPICWPD,14,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Cyclic,Cys3<--->Cys11; NCB: Gly1<--->Asp14,Conjugation with Alexa Flour 488,Free,,,0,GRCTKSIPPICWPD
GRCTKSIPPICWPK,14,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Cyclic,Cys3<--->Cys11; NCB: Gly1<--->Asp14,Conjugation with Alexa Flour 488,Free,,,0,GRCTKSIPPICWPK
GRCTRSIPPKCWPD,14,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Cyclic,Cys3<--->Cys11; NCB: Gly1<--->Asp14,Conjugation with Alexa Flour 488,Free,,,0,GRCTRSIPPKCWPD
GRXTKSIPPIXFPD,14,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Cyclic,NCB: Gly1<--->Asp14,Conjugation with Alexa Flour 488,Free,"X=Abu, α-aminobutyric acid",,0,GRXTKSIPPIXFPD
YGRKKRRQRRRPPQG,15,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Conjugation with Alexa Flour 488,Free,,,0,YGRKKRRQRRRPPQG
VSRRRRRRGGRRRR,14,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Free,,,0,VSRRRRRRGGRRRR
XGLFGCGRKKRRQRRRPPQ,19,Protein derived,Native peptide,,,,,,Anticancer,Targeted peptide conjugates##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Amidation,X=Doxorubicin,,0,XGLFGCGRKKRRQRRRPPQ
XCGRKKRRQRRRPPQ,15,Protein derived,Native peptide,,,,,,Anticancer,Targeted peptide conjugates##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Amidation,X=Doxorubicin,,0,XCGRKKRRQRRRPPQ
XGLFGXGRKKRRQRRRPPQ,19,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Amidation,"X(1)=Doxorubicin; X(6)=(C16)Cys, Cys-Palmitoylation",,0,XGLFGXGRKKRRQRRRPPQ
IRQRRRR,7,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Conjugation to solid lipid nanoparticle,,,0,IRQRRRR
RRRRRRRRRGDfK,13,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,Arg9<--->Lys13,Free,Free,Cysteine modified octa-arginine conjugated to the branch of lysine,,0,RRRRRRRRRGDFK
XFrFKFrFK,9,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Amidation,Amidation,"X=Ahx, 6-aminohexanoic acid",,0,XFRFKFRFK
MGVADLIKKFESISKEEGGGGKXGGrRrRrRRR,33,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Free,"X=Ahx-FITC(Ahx, ε-aminocaproic acid; FITC, fluorescein isothiocyanate)",,0,MGVADLIKKFESISKEEGGGGKXGGRRRRRRRR
RKKRRQRRRRKKRRQRRR,18,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,FITC,Natamycin,,,0,RKKRRQRRRRKKRRQRRR
AKKRRQRRRAKKRRQRRR,18,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,FITC,Natamycin,,,0,AKKRRQRRRAKKRRQRRR
CAYGRKKRRQRRR,13,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Cysteine addition,Rhodamine LP,,,0,CAYGRKKRRQRRR
CHAIYPRH,8,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Rhodamine LP,,,0,CHAIYPRH
GWTLNSAGYLLGKINLKALAALAKKIL,27,Chimeric,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,FITC labelled streptavidin,Amidation,,,0,GWTLNSAGYLLGKINLKALAALAKKIL
GWTLNSAGYLLGXINLKALAALAKKIL,27,Chimeric,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Amidation,X=Lys-Biotinylation,,0,GWTLNSAGYLLGXINLKALAALAKKIL
KWSFRVSYRGISYRRSRGK,19,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Biotinylation,Free,,,0,KWSFRVSYRGISYRRSRGK
KWFRVYRGIYRRRGK,15,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Biotinylation,Free,,,0,KWFRVYRGIYRRRGK
KWCFAVCYAGICYAACAGK,19,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Biotinylation,,,,0,KWCFAVCYAGICYAACAGK
rRrGrKkRr,9,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Cyclic,,Free,GFP,,,0,RRRGRKKRR
RRGRRG,6,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Conjugated to FITC modified folding domain via β-alanine–glycine– glycine linker,Amidation,,,0,RRGRRG
HHHRRRRRRRR,11,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Free,,,0,HHHRRRRRRRR
YGRKKRRQRRREILSRXPAYRKIL,24,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,5(6)-Carboxyfluorescein,Free,X=ATP-binding site inhibitors,,0,YGRKKRRQRRREILSRXPAYRKIL
KKWKMRRNQFWIKIQREILSRXPAYRKIL,29,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,5(6)-Carboxyfluorescein,Free,X=ATP-binding site inhibitors,,0,KKWKMRRNQFWIKIQREILSRXPAYRKIL
CKYGRKKRRQRRR,13,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Extra Cys and Lys added for labeling of TMR,Free,,,0,CKYGRKKRRQRRR
RRRQRRKKRGYCKCKYGRKKRRQRRR,26,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Extra Cys and Lys added for labeling of TMR and dimerization,Free,,,0,RRRQRRKKRGYCKCKYGRKKRRQRRR
AYGRKKRRQRRR,12,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Free,,,0,AYGRKKRRQRRR
IPLVVPLRRRRRRRRC,16,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Free,,,0,IPLVVPLRRRRRRRRC
GLRKRLRKFRNKIKEK,16,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Carboxyfluorescein ,Free,,,0,GLRKRLRKFRNKIKEK
BGLRKXRLRKFRNKIKEK,18,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Amidation,Free,"B=Beta-Alanine; X=NIA, 2-(2-nitroimidazol-1-yl)acetic acid",,0,BGLRKXRLRKFRNKIKEK
RXRXRXRXRXRXRXRXB,17,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Free,X=6-aminohexanoic acid (Ahx); B=Beta-Alanine,,0,RXRXRXRXRXRXRXRXB
RXRRXRRXRRXRXB,14,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Free,X=6-aminohexanoic acid (Ahx); B=Beta-Alanine,,0,RXRRXRRXRRXRXB
RXRRBRRXRRBRXB,14,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Free,X=6-aminohexanoic acid (Ahx); B=Beta-Alanine,,0,RXRRBRRXRRBRXB
RKKRRQRRRHRRKKR,15,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Free,,,0,RKKRRQRRRHRRKKR
MAMPGEPRRANVMAHKLEPASLQLRNSCA,29,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Free,,,0,MAMPGEPRRANVMAHKLEPASLQLRNSCA
MAPQRDTVGGRTTPPSWGPAKAQLRNSCA,29,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Free,,,0,MAPQRDTVGGRTTPPSWGPAKAQLRNSCA
XrXrXr,6,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Free,"X=Fx, cyclohexylalanine",,0,XRXRXR
XrXrXrXr,8,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Free,"X=Fx, cyclohexylalanine",,0,XRXRXRXR
XrXrXrXrXr,10,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Free,"X=Fx, cyclohexylalanine",,0,XRXRXRXRXR
XrXrXrXrXrXr,12,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Free,"X=Fx, cyclohexylalanine",,0,XRXRXRXRXRXR
RRRRRRRRRGPGVTWTPQAWFQWV,24,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Free,,,0,RRRRRRRRRGPGVTWTPQAWFQWV
HEHEHEHEHEHEHEHEHEHEGGGGGKLALKLALKALKAALKLA,43,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Free,,,0,HEHEHEHEHEHEHEHEHEHEGGGGGKLALKLALKALKAALKLA
RRR,3,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Free,,,0,RRR
FFLIPKGRRRRRRRR,15,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Amidation,,,0,FFLIPKGRRRRRRRR
LILIGRRRRRRRRGC,15,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Amidation,,,0,LILIGRRRRRRRRGC
FFGRRRRRRR,10,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Amidation,,,0,FFGRRRRRRR
FFFFGRRRRRRRR,13,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Amidation,,,0,FFFFGRRRRRRRR
FFFFFFGRRRRRRRR,15,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Amidation,,,0,FFFFFFGRRRRRRRR
fflipkgrrrrrrrr,15,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Amidation,,,0,FFLIPKGRRRRRRRR
ffffgrrrrrrrr,13,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Amidation,,,0,FFFFGRRRRRRRR
GCGGGYGRKKRRQRRR,16,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Free,,,0,GCGGGYGRKKRRQRRR
YGRKKRRQRRRGTALDWSWLQTE,23,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Free,,,0,YGRKKRRQRRRGTALDWSWLQTE
CGNVVRQGCGYGRKKRRQRRRGTALDWSWLQTE,33,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Free,,,0,CGNVVRQGCGYGRKKRRQRRRGTALDWSWLQTE
SRRRRRRRRR,10,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Free,,,0,SRRRRRRRRR
CHHHHHRRRRRRRRRHHHHHC,21,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Free,,,0,CHHHHHRRRRRRRRRHHHHHC
FFLIPKGRRRRRRRRR,16,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Free,,,0,FFLIPKGRRRRRRRRR
CGGGYGRKKRRQRRR,15,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Free,,,0,CGGGYGRKKRRQRRR
GLWWKAWWKAWWKSLWWRKRKRKA,24,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Free,,,0,GLWWKAWWKAWWKSLWWRKRKRKA
YGRKKRPQRRR,11,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Free,,,0,YGRKKRPQRRR
DSLKSYWYLQKFSWR,15,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Free,,,0,DSLKSYWYLQKFSWR
KLWMRWWSPTTRRYG,15,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Free,,,0,KLWMRWWSPTTRRYG
RLWMRWYSPWTRRWG,15,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Free,,,0,RLWMRWYSPWTRRWG
RLIMRIYAPTTRRYG,15,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Free,,,0,RLIMRIYAPTTRRYG
RLYMRYYSPTTRRYG,15,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Free,,,0,RLYMRYYSPTTRRYG
RLWMRWYSPRTRAYG,15,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Free,,,0,RLWMRWYSPRTRAYG
KRPTMRFRYTWNPMK,15,Synthetic,Synthetic peptide,,,Chymotrypsin hydrolysis,,Resisting chymotrypsin hydrolysis,Anticancer,Cancer targeted peptides##Stapled Peptides,,Linear,,Free,Free,,,0,KRPTMRFRYTWNPMK
WKCRRQAFRVLHHWN,15,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Free,,,0,WKCRRQAFRVLHHWN
WKARRQCFRVLHHWN,15,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Free,,,0,WKARRQCFRVLHHWN
rRRRRRRR,8,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Free,,,0,RRRRRRRR
rRrRRRRR,8,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Free,,,0,RRRRRRRR
rRrRrRRR,8,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Free,,,0,RRRRRRRR
rRrRrRrR,8,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Free,,,0,RRRRRRRR
rrrRrRrR,8,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Free,,,0,RRRRRRRR
rrrrrrrr,8,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Free,,,0,RRRRRRRR
XXXXXXXX,8,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,5(6)-Carboxyfluorescein,Amidation,X=Nbtg,,0,XXXXXXXX
ZBBZBBZBB,9,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,5(6)-Carboxyfluorescein,Amidation,"Z=NLys from N-tert-butoxycarbonyl-1,4-butanediamine; B=Nspe was derived from (S)-N-(1-phenylethyl)amine",,0,ZBBZBBZBB
ZBBZBBZBBZBB,12,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,5(6)-Carboxyfluorescein,Amidation,"Z=NLys from N-tert-butoxycarbonyl-1,4-butanediamine; B=Nspe was derived from (S)-N-(1-phenylethyl)amine",,0,ZBBZBBZBBZBB
ZXXZXXZXXZXX,12,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,5(6)-Carboxyfluorescein,Amidation,"Z=NLys from N-tert-butoxycarbonyl-1,4-butanediamine; X=Npm from benzylamine (1-phenylethylamine)",,0,ZXXZXXZXXZXX
ZZBZZBZZBZZB,12,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,5(6)-Carboxyfluorescein,Amidation,"Z=NLys from N-tert-butoxycarbonyl-1,4-butanediamine; B=Nspe was derived from (S)-N-(1-phenylethyl)amine",,0,ZZBZZBZZBZZB
ZZZZZZZZBBBB,12,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,5(6)-Carboxyfluorescein,Amidation,"Z=NLys from N-tert-butoxycarbonyl-1,4-butanediamine; B=Nspe was derived from (S)-N-(2-phenylethyl)amine",,0,ZZZZZZZZBBBB
ZZZZZZZZXXXXX,13,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,5(6)-Carboxyfluorescein,Amidation,"Z=NLys from N-tert-butoxycarbonyl-1,4-butanediamine; X=NLeu from isobutylamine",,0,ZZZZZZZZXXXXX
XBBXBBXBBXBB,12,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,5(6)-Carboxyfluorescein,Amidation,"Z=NLys from N-tert-butoxycarbonyl-1,4-butanediamine; B=Nspe was derived from (S)-N-(1-phenylethyl)amine",,0,XBBXBBXBBXBB
XXBXXBXXBXXB,12,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,5(6)-Carboxyfluorescein,Amidation,"Z=NLys from N-tert-butoxycarbonyl-1,4-butanediamine; B=Nspe was derived from (S)-N-(2-phenylethyl)amine",,0,XXBXXBXXBXXB
RRRRRHHH,8,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Free,,,0,RRRRRHHH
RRRRRRHHH,9,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Free,,,0,RRRRRRHHH
RRRRRRRHHH,10,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Free,,,0,RRRRRRRHHH
RRRRRRRRHHH,11,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Free,,,0,RRRRRRRRHHH
RRRRRRRRRHHH,12,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Free,,,0,RRRRRRRRRHHH
RRRRRRRRRR,10,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Amidation,,,0,RRRRRRRRRR
YGRKKRRQRRRX,12,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Free,"X=acp, Epsilon-aminocaproic acid",,0,YGRKKRRQRRRX
YGRKKRRQRRRENAEYLR,18,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Amidation,"X=acp, Epsilon-aminocaproic acid",,0,YGRKKRRQRRRENAEYLR
YGRKKRRQRRRQNAQYLR,18,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Amidation,"X=acp, Epsilon-aminocaproic acid",,0,YGRKKRRQRRRQNAQYLR
YGRKKRRQRRRDYQQD,16,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Amidation,"X=acp, Epsilon-aminocaproic acid",,0,YGRKKRRQRRRDYQQD
YGRKKRRQRRRNYQQN,16,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Amidation,"X=acp, Epsilon-aminocaproic acid",,0,YGRKKRRQRRRNYQQN
CALNNYGRKKRRQRRR,16,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Free,,,0,CALNNYGRKKRRQRRR
GIGKFLHSAKKFGKAFVGEIMNSGGKKWKMRRNQFWVKVQRG,42,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Free,,,0,GIGKFLHSAKKFGKAFVGEIMNSGGKKWKMRRNQFWVKVQRG
RLLRLLRRLLRLLRRLLRC,19,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Free,,,0,RLLRLLRRLLRLLRRLLRC
RGDRGDRRDLRLDRGDLRC,19,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Free,,,0,RGDRGDRRDLRLDRGDLRC
RGDRLDRRDLRLDRRDLRC,19,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Free,,,0,RGDRLDRRDLRLDRRDLRC
RGERGERRELRLERGELRC,19,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Free,,,0,RGERGERRELRLERGELRC
RGERLERRELRLERRELRC,19,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Free,,,0,RGERLERRELRLERRELRC
GLKKLAELFHKLLKLG,16,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,"TAMRA, 5-(and-6)-carboxytetramethylrhodamine",Amidation,,,0,GLKKLAELFHKLLKLG
LKKLAELAHKLLKLG,15,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,TAMRA,Amidation,,,0,LKKLAELAHKLLKLG
GLKKLAELAHKLLKLG,16,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Conjugated to nanoparticles,Amidation,,,0,GLKKLAELAHKLLKLG
BRRRRRRR,8,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Amidation,B=Beta-Alanine,,0,BRRRRRRR
BRRRRRRRRR,10,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Lauroylation,Amidation,B=Beta-Alanine,,0,BRRRRRRRRR
Brrrrrrr,8,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Lauroylation,Amidation,B=Beta-Alanine,,0,BRRRRRRR
BrrrrrRRRR,10,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Lauroylation,Amidation,B=Beta-Alanine,,0,BRRRRRRRRR
BRRRRrrrrr,10,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Lauroylation,Amidation,B=Beta-Alanine,,0,BRRRRRRRRR
BRRRRRRRRRRR,12,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Myrsitoylation,Amidation,B=Beta-Alanine,,0,BRRRRRRRRRRR
Brrrrrrrrrrr,12,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Myrsitoylation,Amidation,B=Beta-Alanine,,0,BRRRRRRRRRRR
AYLLGKINLKALAALAKKIL,20,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,5(6)-Carboxyfluorescein,Amidation,,,0,AYLLGKINLKALAALAKKIL
AXLYLLGKINLKALAALAKKIL,22,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,5(6)-Carboxyfluorescein,Amidation,"X=L-CF3-Bpg, Trifluoromethyl- bicyclopent-[1.1.1]-1-ylglycine",,0,AXLYLLGKINLKALAALAKKIL
AGYXLGKINLKALAALAKKIL,21,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,5(6)-Carboxyfluorescein,Amidation,"X=L-CF3-Bpg, Trifluoromethyl- bicyclopent-[1.1.1]-1-ylglycine",,0,AGYXLGKINLKALAALAKKIL
axlyllgkinlkalaalakkil,22,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,5(6)-Carboxyfluorescein,Amidation,"x=D-CF3-Bpg, Trifluoromethyl- bicyclopent-[1.1.1]-1-ylglycine",,0,AXLYLLGKINLKALAALAKKIL
agyxlgkinlkalaalakkil,21,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,5(6)-Carboxyfluorescein,Amidation,"x=D-CF3-Bpg, Trifluoromethyl- bicyclopent-[1.1.1]-1-ylglycine",,0,AGYXLGKINLKALAALAKKIL
VGAlAvVvWlWlWlWbAGSGPKKKRKVC,28,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Free,,,0,VGALAVVVWLWLWLWBAGSGPKKKRKVC
TPWWRLWTKWHHKRRDLPRKPEGC,24,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Free,,,0,TPWWRLWTKWHHKRRDLPRKPEGC
KLALKLALKALKAALKLA,18,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Acetylation,Amidation,,,0,KLALKLALKALKAALKLA
KLULKLULKULKAULKLU,18,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Acetylation,Amidation,U=α-amino isobutyric acid (Aib),,0,KLULKLULKULKAULKLU
KKALLAHALHLLALLALHLAHALKKA,26,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Free,,,0,KKALLAHALHLLALLALHLAHALKKA
RRRRRRRR,8,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Free,,,0,RRRRRRRR
XNIIXPLLXPIC,12,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Acetylation,Amidation,"X=Aib, α-amino isobutyric acid",,0,XNIIXPLLXPIC
XNIIXPLLAPIC,12,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Acetylation,Amidation,"X=Aib, α-amino isobutyric acid",,0,XNIIXPLLAPIC
ANIIXPLLXPIC,12,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Acetylation,Amidation,"X=Aib, α-amino isobutyric acid",,0,ANIIXPLLXPIC
XNIIAPLLXPIC,12,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Acetylation,Amidation,"X=Aib, α-amino isobutyric acid",,0,XNIIAPLLXPIC
XNIIXXLLXXIC,12,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Acetylation,Amidation,"X=Aib, α-amino isobutyric acid",,0,XNIIXXLLXXIC
XNIIXPLLXXIC,12,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Acetylation,Amidation,"X=Aib, α-amino isobutyric acid",,0,XNIIXPLLXXIC
XNIIXXLLXPIC,12,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Acetylation,Amidation,"X=Aib, α-amino isobutyric acid",,0,XNIIXXLLXPIC
KKKKKKNKKLQQRGD,15,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,"Ahx, 6-aminohexamoic acid",Free,,,0,KKKKKKNKKLQQRGD
RGDGPRRRPRKRRGR,15,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,"Ahx, 6-aminohexamoic acid",Free,,,0,RGDGPRRRPRKRRGR
RRRQKRIVVRRRLIR,15,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,"Ahx, 6-aminohexamoic acid",Free,,,0,RRRQKRIVVRRRLIR
RRVWRRYRRQRWCRR,15,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,"Ahx, 6-aminohexamoic acid",Free,,,0,RRVWRRYRRQRWCRR
RRARRPRRLRPAPGR,15,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,"Ahx, 6-aminohexamoic acid",Free,,,0,RRARRPRRLRPAPGR
LLRARWRRRRSRRFR,15,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,"Ahx, 6-aminohexamoic acid",Free,,,0,LLRARWRRRRSRRFR
RGPRRQPRRHRRPRR,15,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,"Ahx, 6-aminohexamoic acid",Free,,,0,RGPRRQPRRHRRPRR
RRWRRWNRFNRRRCR,15,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,"Ahx, 6-aminohexamoic acid",Free,,,0,RRWRRWNRFNRRRCR
MAARLCCQLDPARDVLCLRP,20,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Free,,,0,MAARLCCQLDPARDVLCLRP
MAARLCCQLDPARDV,15,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Free,,,0,MAARLCCQLDPARDV
MAARLCCQ,8,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Free,,,0,MAARLCCQ
MAARL,5,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Free,Free,,,0,MAARL
XRRRRRR,7,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,FITC,Amidation,X=Beta-Alanine,,0,XRRRRRR
XRRRRRRR,8,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,FITC,Amidation,X=Beta-Alanine,,0,XRRRRRRR
XRRRRRRRR,9,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,FITC,Amidation,X=Beta-Alanine,,0,XRRRRRRRR
XRRRRRRRRR,10,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,FITC,Amidation,"X=Ahx, 6-aminohexanoic acid",,0,XRRRRRRRRR
XKRRRRE,7,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Cyclic,Lys2<--->Glu7,FITC,Amidation,X=Beta-Alanine,,0,XKRRRRE
XKRRRRRRE,9,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Cyclic,Lys2<--->Glu9,FITC,Amidation,X=Beta-Alanine,,0,XKRRRRRRE
XKRRRRRRRE,10,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Cyclic,Lys2<--->Glu10,FITC,Amidation,X=Beta-Alanine,,0,XKRRRRRRRE
XKRRRRRRRRE,11,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Cyclic,Lys2<--->Glu11,FITC,Amidation,X=Beta-Alanine,,0,XKRRRRRRRRE
XKRRRRRRRRRE,12,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Cyclic,Lys2<--->Glu12,FITC,Amidation,X=Beta-Alanine,,0,XKRRRRRRRRRE
XKrrrrrrrE,10,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Cyclic,Lys2<--->Glu10,FITC,Amidation,X=Beta-Alanine,,0,XKRRRRRRRE
XKrrrrrrrrE,11,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Cyclic,Lys2<--->Glu11,FITC,Amidation,X=Beta-Alanine,,0,XKRRRRRRRRE
XKrrrrrrrrrE,12,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Cyclic,Lys2<--->Glu12,FITC,Amidation,X=Beta-Alanine,,0,XKRRRRRRRRRE
XKRrRrRrE,9,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Cyclic,Lys2<--->Glu9,FITC,Amidation,X=Beta-Alanine,,0,XKRRRRRRE
XKrRrRrRrE,10,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Cyclic,Lys2<--->Glu10,FITC,Amidation,X=Beta-Alanine,,0,XKRRRRRRRE
XKRrRrRrRrE,11,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Cyclic,Lys2<--->Glu11,FITC,Amidation,X=Beta-Alanine,,0,XKRRRRRRRRE
XERRRKKRRRE,11,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Cyclic,Glu2<--->Lys6; Lys7<--->Glu11,FITC,Amidation,X=Beta-Alanine,,0,XERRRKKRRRE
XERRRKXKRRRE,12,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Cyclic,Glu2<--->Lys6; Lys8<--->Glu12,FITC,Amidation,X=Beta-Alanine,,0,XERRRKXKRRRE
XERRRKXXKRRRE,13,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Cyclic,Glu2<--->Lys6; Lys9<--->Glu13,FITC,Amidation,X=Beta-Alanine,,0,XERRRKXXKRRRE
XERRRKXXXKRRRE,14,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Cyclic,Glu2<--->Lys6; Lys10<--->Glu14,FITC,Amidation,X=Beta-Alanine,,0,XERRRKXXXKRRRE
XRRRRKRRRE,10,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Cyclic,Lys6<--->Glu10,FITC,Amidation,X=Beta-Alanine,,0,XRRRRKRRRE
XRRRKRRRRE,10,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Cyclic,Lys5<--->Glu10,FITC,Amidation,X=Beta-Alanine,,0,XRRRKRRRRE
XRRKRRRRRE,10,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Cyclic,Lys4<--->Glu11,FITC,Amidation,X=Beta-Alanine,,0,XRRKRRRRRE
XRKRRRRRRE,10,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Cyclic,Lys3<--->Glu11,FITC,Amidation,X=Beta-Alanine,,0,XRKRRRRRRE
YKQCHKKGGXKKGSG,15,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Rhodamine B,Free,"X=Ahx, 6-aminohexanoic acid",,0,YKQCHKKGGXKKGSG
ykqchkkGGkkGsG,14,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Rhodamine B,Free,,,0,YKQCHKKGGKKGSG
YKQSHKKGGKKGSG,14,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Rhodamine B,Free,,,0,YKQSHKKGGKKGSG
YRQSHRRGGRRGSG,14,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Rhodamine B,Free,,,0,YRQSHRRGGRRGSG
WKQSHKKGGKKGSG,14,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Rhodamine B,Free,,,0,WKQSHKKGGKKGSG
AGYXLLGKTNLKALAALAKKIL,22,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Stearylation,Amidation,X=Phosphorylation,,0,AGYXLLGKTNLKALAALAKKIL
AGYLLGKTXNLKALAALAKKIL,22,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Stearylation,Amidation,X=Phosphorylation,,0,AGYLLGKTXNLKALAALAKKIL
AGYXLLGKTXNLKALAALAKKIL,23,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Stearylation,Amidation,X=Phosphorylation,,0,AGYXLLGKTXNLKALAALAKKIL
AGYXLLGKINLKALAALAKKIL,22,Protein derived,Native peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Stearylation,Amidation,X=Phosphorylation,,0,AGYXLLGKINLKALAALAKKIL
RKKRKKKRXRHXRHXRHXR,19,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Cell-penetrating peptides,,Linear,,Stearylation,Amidation,X=4-amino-butanoic acid,,0,RKKRKKKRXRHXRHXRHXR
RQIKIWFQNRRMKWKKAKLNAEKLKDFKIRLQYFARGLQVYIRQLRLALQGKT,53,Synthetic,Synthetic peptide,Mice red blood cells: 8% Hemolysis=20 μM,,,,,Anticancer,Cancer targeted peptides##Induce necrosis,,Linear,,Free,Free,,,0,RQIKIWFQNRRMKWKKAKLNAEKLKDFKIRLQYFARGLQVYIRQLRLALQGKT
RQIKIWFQNRRMKWKKAKLNAEKLKDFKIRLQYFARGGQVYIRQGRLALQGKT,53,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Induce necrosis,,Linear,,Free,Free,,,0,RQIKIWFQNRRMKWKKAKLNAEKLKDFKIRLQYFARGGQVYIRQGRLALQGKT
RADfK,5,Synthetic,Synthetic peptide,,HUVEC: IC50>10 μM,αvβ3,,,Anticancer,Cancer targeted peptides##Antiangiogenic##αvβ3 Inhibitor,,Cyclic,NCB: Arg1<--->Lys5,Free,Free,,,0,RADFK
XRADfK,6,Synthetic,Synthetic peptide,,HUVEC: IC50=50 nM,αvβ3,,,Anticancer,Targeted peptide conjugates##Antiangiogenic##αvβ3 Inhibitor,,Cyclic,NCB: Arg1<--->Lys5,"PEG, Poly ethylene glycol",Free,"X=DOX, Doxorubicin",,0,XRADFK
TSFAEYWALLSXLAXYXP,18,Synthetic,Synthetic peptide,,,"MDM2, MDMX",MDM2: Ki=0.45 μM; MDMX: Ki=0.62 μM,,Anticancer,Cancer targeted peptides##Stapled Peptides##Induce apoptosis##MDM3/MDMX Inhibitor,17.0,Linear,,Acetylation,Amidation,"X(12)=Peg, polyethylene glycol; X(15)=Hyp, hydroxyproline; X(17)=Hle, homoleucine",,0,TSFAEYWALLSXLAXYXP
TEFQTNLVP,9,Synthetic,Synthetic peptide,,,Tubulin,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Tubulin Inhibitors,,Linear,,"FITC, 5(6)-carboxy fluorescence",Free,,,0,TEFQTNLVP
FRRKAFLHWYTG,12,Synthetic,Synthetic peptide,,,Tubulin,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Tubulin Inhibitors,,Linear,,"FITC, 5(6)-carboxy fluorescence",Free,,,0,FRRKAFLHWYTG
VPKDVNAAIA,10,Synthetic,Synthetic peptide,,,Tubulin,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Tubulin Inhibitors,,Linear,,"FITC, 5(6)-carboxy fluorescence",Free,,,0,VPKDVNAAIA
VPELTQQMF,9,Synthetic,Synthetic peptide,,,Tubulin,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Tubulin Inhibitors,,Linear,,"FITC, 5(6)-carboxy fluorescence",Free,,,0,VPELTQQMF
NEALYDICFR,10,Synthetic,Synthetic peptide,,,Tubulin,,,Anticancer,Cancer targeted peptides##Induce apoptosis##Tubulin Inhibitors,,Linear,,"FITC, 5(6)-carboxy fluorescence",Free,,,0,NEALYDICFR
TEXQTNXVP,9,Synthetic,Synthetic peptide,,,Tubulin,,,Anticancer,Cancer targeted peptides##Stapled Peptides##Induce apoptosis##Tubulin Inhibitors,,Cyclic (Stapled),Stapled: Ⓧ(3) and Ⓧ (7) are cross-linked by hydrocarbon stapling,"FITC, 5(6)-carboxy fluorescence",Free,Ⓧ=(S)-2-(4-pentenyl) Ala,,0,TEXQTNXVP
BENPESILDEHVQRVM,16,Synthetic,Synthetic peptide,,,β-catenin,Kd=~5 μM,Inhibit wnt/β-catenin signaling pathway,Anticancer,Cancer targeted peptides##β-catenin inhibitor,15.0,Linear,,FITC,Amidation,B=β-Ala,,0,BENPESILDEHVQRVM
DDEKEQFLYHLLSFNAV,17,Synthetic,Synthetic peptide,,,Rab8a GTPase,rel.Kd=8.7 (rel.Kd=[Kd(peptide)/ Kd(StRIP3)])*,Binds Rab8a(GppNHp) and is able to inhibit a Rab8a PPI.,Anticancer,Cancer targeted peptides##Cell-penetrating peptides##Rab8a GTPase inhibitor,,Linear,,Fluorescein-O2OC-,Free,,,0,DDEKEQFLYHLLSFNAV
LSQETFSDLWKLLPEN,16,Synthetic,Synthetic peptide,,,Mdm2,Kd=410 nM,,Anticancer,Cancer targeted peptides##Mdm2 inhibitor,,Linear,,Free,Free,,,0,LSQETFSDLWKLLPEN
CFETLRGEERILSILRHQNLLKELQD,26,Synthetic (Derived from chromogranin A),Synthetic peptide,,,"αvβ6, αvβ8",αvβ6: Ki>50000 nM; αvβ8: Ki>50000 nM,,Anticancer,Cancer targeted peptides##αvβ6/αvβ8 inhibitor,,Linear,,Free,Amidation,,,0,CFETLRGEERILSILRHQNLLKELQD
CIRLDLELINFQSDLQHELLKTRLRG,26,Synthetic (Derived from chromogranin A),Synthetic peptide,,,"αvβ6, αvβ8",αvβ6: Ki>>200 nM,,Anticancer,Cancer targeted peptides##αvβ6/αvβ8 inhibitor,,Linear,,Free,Free,,,0,CIRLDLELINFQSDLQHELLKTRLRG
NAVPNLRGDLQVLAQKVART,20,Synthetic,Synthetic peptide,,,"αvβ6, αvβ8",αvβ6: Ki=0.9 ± 0.2 nM; αvβ8: Ki=69 ± 0.2 nM,,Anticancer,Cancer targeted peptides##αvβ6/αvβ8 inhibitor,,Linear,,Free,Free,,,0,NAVPNLRGDLQVLAQKVART
KALKALKKALKALKDGR,17,Synthetic,Synthetic peptide,Low hemolysis,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Lipopeptides,,Linear,,C8H15O,Free,,,0,KALKALKKALKALKDGR
KLLKFIWRI,9,Synthetic,Synthetic peptide,,Human epithelial cells: 97±7.1% Survival=100 μM,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,KLLKFIWRI
FLWSRILFRLRK,12,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,FLWSRILFRLRK
LLRHVVKILKYLHGVSGHGQHGVHG,25,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,LLRHVVKILKYLHGVSGHGQHGVHG
HFEYWEERHK,10,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,HFEYWEERHK
ELQSTGRKVA,10,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,ELQSTGRKVA
DASTKKLSECLRRIGDELDS,20,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide##Pro-apoptosis,,Linear,,Free,Free,,,0,DASTKKLSECLRRIGDELDS
QRDMHSHRDFQPVLVALNSPLSGGMRDRG,29,Synthetic,Synthetic peptide,,,α6β1,,,Anticancer,Cancer targeted peptides##α6β1 inhibitor,,Linear,,Free,Free,,,0,QRDMHSHRDFQPVLVALNSPLSGGMRDRG
DSDVWWGGRRLLRRLRRL,18,Synthetic,Synthetic peptide,Low hemolysis,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Lipopeptides,,Linear,,C8H15O,Free,,,0,DSDVWWGGRRLLRRLRRL
XGFFYKD,7,Synthetic,Synthetic peptide,,,,,,Anticancer,Targeted peptide conjugates,,Linear,,Free,Free,X=Lonidamine,,0,XGFFYKD
FSLNWRPPCLFYGRKKRRQRRR,22,Synthetic,Synthetic peptide,,,,,,Anticancer,Targeted peptide conjugates,,Linear,,Free,Free,,,0,FSLNWRPPCLFYGRKKRRQRRR
RAGLQFPVGKLLKKLLKKLLK,21,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,RAGLQFPVGKLLKKLLKKLLK
YGRKKRRQRRRLPDWHIPV,19,Synthetic,Synthetic peptide,,,MDM2,,,Anticancer,Cancer targeted peptides##MDM2 antagonistic ,,Linear,,Free,Free,,,0,YGRKKRRQRRRLPDWHIPV
MSL,3,Chilli seeds,Native peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,MSL
MEDEI,5,Chilli seeds,Native peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,MEDEI
GLWKSLFKNVGKAAGKAALNAVTDMVNQ,28,South America frog Phy l lomeduasauvagi,Native peptide,,,,,Inducing PC-3 cell apoptosis,Anticancer,Cancer targeted peptides##Induce apoptosis,,Linear,,Free,Amidation,,,0,GLWKSLFKNVGKAAGKAALNAVTDMVNQ
FTLE,4,Chilli seeds,Native peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,FTLE
XGFLGGIGAVLKVLTTGLPALISWIKRKRQQ,31,Synthetic,Synthetic peptide,,,,,,Anticancer,Targeted peptide conjugates,,Linear,,Free,Amidation,X=Methotrexate,,0,XGFLGGIGAVLKVLTTGLPALISWIKRKRQQ
KKCGIQDTNDKKQSD,15,Synthetic,Synthetic peptide,,,IGFBP3,,The compound can be used as an agonist to competitively inhibit protein level interaction of PD-L1 and IGFBP3.,Antucancer,Cancer targeted peptides##Agonist,,Linear,,Free,Free,,,0,KKCGIQDTNDKKQSD
WAVLL,5,Frog fecal mildew,Native peptide,,,α-Glucosidase,,,Anticancer,Cancer targeted peptides##α-Glucosidase inhibitor,,Cyclic,NCB: Trp1<--->Leu5,Free,Free,,,0,WAVLL
WVVAIF,6,Frog fecal mildew,Native peptide,,,α-Glucosidase,,,Anticancer,Cancer targeted peptides##α-Glucosidase inhibitor,,Cyclic,NCB: Trp1<--->Phe6,Free,Free,,,0,WVVAIF
WTYIF,5,Frog fecal mildew,Native peptide,,,α-Glucosidase,,,Anticancer,Cancer targeted peptides##α-Glucosidase inhibitor,,Cyclic,NCB: Trp1<--->Phe5,Free,Free,,,0,WTYIF
WTVLL,5,Frog fecal mildew,Native peptide,,,α-Glucosidase,,,Anticancer,Cancer targeted peptides##α-Glucosidase inhibitor,,Cyclic,NCB: Trp1<--->Leu5,Free,Free,,,0,WTVLL
WAVIL,5,Frog fecal mildew,Native peptide,,,α-Glucosidase,,,Anticancer,Cancer targeted peptides##α-Glucosidase inhibitor,,Cyclic,NCB: Trp1<--->Leu5,Free,Free,,,0,WAVIL
MQDAITAV,8,Phycocyanin ,Native peptide,,,,,,Anticancer,Cancer targeted peptides,,Linear,,Free,Free,,,0,MQDAITAV
DLMAQMQGPYNFIQSMLDFENQTL,24,Synthetic (Derived from Caprin1),Synthetic peptide,,,G3BP1,,"The compound can be competitively combined with the G3BP1 protein to specifically block the interaction between the Caprin1 and the G3BP1 protein and inhibit generation of stress particles so as to treat diseases related to the generation of SGs, such as tumors or neurodegenerative diseases.",Anticancer,Cancer targeted peptides,,Linear,,Free,Free,,,0,DLMAQMQGPYNFIQSMLDFENQTL
DPLVRRQRVQDLMAQMQGPYNFIQDSMLDFENQTL,35,Synthetic (Derived from Caprin1),Synthetic peptide,,,G3BP1,,"The compound can be competitively combined with the G3BP1 protein to specifically block the interaction between the Caprin1 and the G3BP1 protein and inhibit generation of stress particles so as to treat diseases related to the generation of SGs, such as tumors or neurodegenerative diseases.",Anticancer,Cancer targeted peptides,,Linear,,Free,Free,,,0,DPLVRRQRVQDLMAQMQGPYNFIQDSMLDFENQTL
DPLVRRQRVQDLMAQMQGPYNFIQDSMLDFENQTLDPAIV,40,Synthetic (Derived from Caprin1),Synthetic peptide,,,G3BP1,,"The compound can be competitively combined with the G3BP1 protein to specifically block the interaction between the Caprin1 and the G3BP1 protein and inhibit generation of stress particles so as to treat diseases related to the generation of SGs, such as tumors or neurodegenerative diseases.",Anticancer,Cancer targeted peptides,,Linear,,Free,Free,,,0,DPLVRRQRVQDLMAQMQGPYNFIQDSMLDFENQTLDPAIV
DLMAQMQGPYNPIQDSMLDPENQTLDPAIV,30,Synthetic (Derived from Caprin1),Synthetic peptide,,,G3BP1,,"The compound can be competitively combined with the G3BP1 protein to specifically block the interaction between the Caprin1 and the G3BP1 protein and inhibit generation of stress particles so as to treat diseases related to the generation of SGs, such as tumors or neurodegenerative diseases.",Anticancer,Cancer targeted peptides,,Linear,,Free,Free,,,0,DLMAQMQGPYNPIQDSMLDPENQTLDPAIV
CIELLQAR,8,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides,,Linear,,Free,Free,,,0,CIELLQAR
CIELLQARX,9,Synthetic,Synthetic peptide,,,,,,Anticancer,Targeted peptide conjugates,,Linear,,"HA, Hyaluronic acid",Free,"X=DTX, Docetaxel",,0,CIELLQARX
IELLQARC,8,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides,,Linear,,Free,Free,,,0,IELLQARC
CRAQLLEI,8,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides,,Linear,,Free,Free,,,0,CRAQLLEI
RAQLLEIC,8,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides,,Linear,,Free,Free,,,0,RAQLLEIC
ciellqar,8,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides,,Linear,,Free,Free,,,0,CIELLQAR
iellqarc,8,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides,,Linear,,Free,Free,,,0,IELLQARC
craqllei,8,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides,,Linear,,Free,Free,,,0,CRAQLLEI
raqlleic,8,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides,,Linear,,Free,Free,,,0,RAQLLEIC
LKKLLKLLKKLLKL,14,Synthetic,Synthetic peptide,Mouse red blood cells:Hemolysis rate=48%=50μM,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted,,Linear,,Free,Amidation,,,0,LKKLLKLLKKLLKL
CLHELLEHLHELLEHCLKKLLKLLKKLLKL,30,Synthetic,Synthetic peptide,Mouse red blood cells:Hemolysis rate=10%=50μM,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Targeted peptide conjugates,,Cyclic,Cys1<--->Cys16,Free,Free,,,0,CLHELLEHLHELLEHCLKKLLKLLKKLLKL
CLKKLLKLLKKLLKLCLEHLLEHLEHLLEH,30,Synthetic,Synthetic peptide,Mouse red blood cells:Hemolysis rate=5%=50μM,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Targeted peptide conjugates,,Cyclic,Cys1<--->Cys16,Free,Free,,,0,CLKKLLKLLKKLLKLCLEHLLEHLEHLLEH
CLKKLLKLLKKLLKLCLEELLHHLEELLHH,30,Synthetic,Synthetic peptide,Mouse red blood cells:Hemolysis rate=5%=50μM,,,,,Anticancer,Cancer targeted peptides##Membrane-targeted##Targeted peptide conjugates,,Cyclic,Cys1<--->Cys16,Free,Free,,,0,CLKKLLKLLKKLLKLCLEELLHHLEELLHH
nAVPNLRGDLQVLAQKVART,20,Synthetic,Synthetic peptide,,,αvβ6,,,Anticancer,Cancer targeted peptides,,Linear,,Free,Free,,,0,NAVPNLRGDLQVLAQKVART
nKVPNLRGDLQVLAQKVART,20,Synthetic,Synthetic peptide,,,αvβ6,,,Anticancer,Cancer targeted peptides,,Linear,,Free,Free,,,0,NKVPNLRGDLQVLAQKVART
nXVPNLRGDLQVLAQKVART,20,Synthetic,Synthetic peptide,,,αvβ6,,,Anticancer,Cancer targeted peptides,,Linear,,Free,Free,X=Lys-biotin,,0,NXVPNLRGDLQVLAQKVART
nKVPNLRGDLQVLAQKVAR,19,Synthetic,Synthetic peptide,,,αvβ6,,,Anticancer,Cancer targeted peptides,,Linear,,Free,Free,,,0,NKVPNLRGDLQVLAQKVAR
nXVPNLRGDLQVLAQKVARt,20,Synthetic,Synthetic peptide,,,αvβ6,,,Anticancer,Cancer targeted peptides,,Linear,,Free,Free,X=Lys-biotin,,0,NXVPNLRGDLQVLAQKVART
nAVPNLRGDLQVLAQKVARt,20,Synthetic,Synthetic peptide,,,αvβ6,,,Anticancer,Cancer targeted peptides,,Linear,,Free,Free,,,0,NAVPNLRGDLQVLAQKVART
FHIVELLA,8,Synthetic (Derived from SLIT2 protein),Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,FHIVELLA
FHAVELLA,8,Synthetic (Derived from SLIT2 protein),Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,FHAVELLA
ASAIYSVETINDGNFHIVELLA,22,Synthetic (Derived from SLIT2 protein),Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,ASAIYSVETINDGNFHIVELLA
FHIVELLALDQSLSLSVDGGNPKIIT,26,Synthetic (Derived from SLIT2 protein),Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,FHIVELLALDQSLSLSVDGGNPKIIT
KIITNLSKQSTLNFDSPLYVGG,22,Synthetic (Derived from SLIT2 protein),Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,KIITNLSKQSTLNFDSPLYVGG
GGMPGKSNVASLRQAPGQNGTSF,23,Synthetic (Derived from SLIT2 protein),Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,GGMPGKSNVASLRQAPGQNGTSF
LRQAPGQNGTSFHGCIRNLYINSE,24,Synthetic (Derived from SLIT2 protein),Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,LRQAPGQNGTSFHGCIRNLYINSE
FKAVELLA,8,Synthetic (Derived from SLIT2 protein),Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,FKAVELLA
FRAVELLA,8,Synthetic (Derived from SLIT2 protein),Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,FRAVELLA
FHAVDLLA,8,Synthetic (Derived from SLIT2 protein),Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,FHAVDLLA
FHAVHLLA,8,Synthetic (Derived from SLIT2 protein),Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,FHAVHLLA
AHAVELLA,8,Synthetic (Derived from SLIT2 protein),Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,AHAVELLA
FHAAELLA,8,Synthetic (Derived from SLIT2 protein),Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,FHAAELLA
FHAVEALA,8,Synthetic (Derived from SLIT2 protein),Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,FHAVEALA
FHAAEALA,8,Synthetic (Derived from SLIT2 protein),Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,FHAAEALA
FAIVALLA,8,Synthetic (Derived from SLIT2 protein),Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,FAIVALLA
FEAVHLLA,8,Synthetic (Derived from SLIT2 protein),Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,FEAVHLLA
YHAVELLA,8,Synthetic (Derived from SLIT2 protein),Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,YHAVELLA
WHAVELLA,8,Synthetic (Derived from SLIT2 protein),Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,WHAVELLA
FHAVELSA,8,Synthetic (Derived from SLIT2 protein),Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,FHAVELSA
FHAVELLS,8,Synthetic (Derived from SLIT2 protein),Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,FHAVELLS
DGNFHIVELLA,11,Synthetic (Derived from SLIT2 protein),Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,DGNFHIVELLA
AHIVELLA,8,Synthetic (Derived from SLIT2 protein),Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,AHIVELLA
FAIVELLA,8,Synthetic (Derived from SLIT2 protein),Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,FAIVELLA
FHIAELLA,8,Synthetic (Derived from SLIT2 protein),Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,FHIAELLA
FHIVALLA,8,Synthetic (Derived from SLIT2 protein),Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,FHIVALLA
FHIVEALA,8,Synthetic (Derived from SLIT2 protein),Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,FHIVEALA
FHIVELAA,8,Synthetic (Derived from SLIT2 protein),Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,FHIVELAA
TLPNSNHIKQGL,12,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides,,,,Free,Free,,,0,TLPNSNHIKQGL
LNKQTHGLIPNS,12,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides,,,,Free,Free,,,0,LNKQTHGLIPNS
NQHSKNTLLIGP,12,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides,,,,Free,Free,,,0,NQHSKNTLLIGP
LKQGNHINLPS,11,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides,,,,Free,Free,,,0,LKQGNHINLPS
YSPLNIHNGQKL,12,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides,,,,Free,Free,,,0,YSPLNIHNGQKL
LPNSNHIKQGL,11,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides,,,,Free,Free,,,0,LPNSNHIKQGL
YLPNSNHIKQGL,12,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides,,,,Free,Free,,,0,YLPNSNHIKQGL
FLPNSNHIKQGL,12,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides,,,,Free,Free,,,0,FLPNSNHIKQGL
CAYHRLRRC,9,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Tumor-homing peptides##Arsenic- containing anti-cancer agent,,Cyclic,Bridging: Cys1<---As--->Cys9,Free,Free,,,0,CAYHRLRRC
CDCRGDCFC,9,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Tumor-homing peptides##Arsenic- containing anti-cancer agent,,Cyclic,Bridging: Cys1<---As--->Cys9,Free,Free,,,0,CDCRGDCFC
CPIEDRPMC,9,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Tumor-homing peptides##Arsenic- containing anti-cancer agent,,Cyclic,Bridging: Cys1<---As--->Cys9,Free,Free,,,0,CPIEDRPMC
CNRRTKAGC,9,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Tumor-homing peptides##Arsenic- containing anti-cancer agent,,Cyclic,Bridging: Cys1<---As--->Cys9,Free,Free,,,0,CNRRTKAGC
CGTKRKC,7,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Tumor-homing peptides##Arsenic- containing anti-cancer agent,,Cyclic,Bridging: Cys1<---As--->Cys7,Free,Free,,,0,CGTKRKC
CRGDGWC,7,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Tumor-homing peptides##Arsenic- containing anti-cancer agent,,Cyclic,Bridging: Cys1<---As--->Cys7,Free,Free,,,0,CRGDGWC
CVSNPRWKC,9,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Tumor-homing peptides##Arsenic- containing anti-cancer agent,,Cyclic,Bridging: Cys1<---As--->Cys9,Free,Free,,,0,CVSNPRWKC
CHVLWSTRC,9,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Tumor-homing peptides##Arsenic- containing anti-cancer agent,,Cyclic,Bridging: Cys1<---As--->Cys9,Free,Free,,,0,CHVLWSTRC
CLDGGRPKC,9,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Tumor-homing peptides##Arsenic- containing anti-cancer agent,,Cyclic,Bridging: Cys1<---As--->Cys9,Free,Free,,,0,CLDGGRPKC
GCSVSSVGALCTHV,14,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Tumor-homing peptides##Arsenic- containing anti-cancer agent,,Cyclic,Bridging: Cys1<---As--->Cys14,Free,Free,,,0,GCSVSSVGALCTHV
CVNHPAFAC,9,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Tumor-homing peptides##Arsenic- containing anti-cancer agent,,Cyclic,Bridging: Cys1<---As--->Cys9,Free,Free,,,0,CVNHPAFAC
CRGDRGPDC,9,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Tumor-homing peptides##Arsenic- containing anti-cancer agent,,Cyclic,Bridging: Cys1<---As--->Cys9,Free,Free,,,0,CRGDRGPDC
CRGDKTTNC,9,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Tumor-homing peptides##Arsenic- containing anti-cancer agent,,Cyclic,Bridging: Cys1<---As--->Cys9,Free,Free,,,0,CRGDKTTNC
CRGDHAGDC,9,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Tumor-homing peptides##Arsenic- containing anti-cancer agent,,Cyclic,Bridging: Cys1<---As--->Cys9,Free,Free,,,0,CRGDHAGDC
CLSYYPSYC,9,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Tumor-homing peptides##Arsenic- containing anti-cancer agent,,Cyclic,Bridging: Cys1<---As--->Cys9,Free,Free,,,0,CLSYYPSYC
CTPSPPFSHC,10,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Tumor-homing peptides##Arsenic- containing anti-cancer agent,,Cyclic,Bridging: Cys1<---As--->Cys10,Free,Free,,,0,CTPSPPFSHC
CPHSKPCLC,9,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Tumor-homing peptides##Arsenic- containing anti-cancer agent,,Cyclic,Bridging: Cys1<---As--->Cys9,Free,Free,,,0,CPHSKPCLC
CSDSWHYWC,9,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Tumor-homing peptides##Arsenic- containing anti-cancer agent,,Cyclic,Bridging: Cys1<---As--->Cys9,Free,Free,,,0,CSDSWHYWC
CSDWQHPWC,9,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Tumor-homing peptides##Arsenic- containing anti-cancer agent,,Cyclic,Bridging: Cys1<---As--->Cys9,Free,Free,,,0,CSDWQHPWC
CSDYNHHWC,9,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Tumor-homing peptides##Arsenic- containing anti-cancer agent,,Cyclic,Bridging: Cys1<---As--->Cys9,Free,Free,,,0,CSDYNHHWC
CSDGQHYWC,9,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Tumor-homing peptides##Arsenic- containing anti-cancer agent,,Cyclic,Bridging: Cys1<---As--->Cys9,Free,Free,,,0,CSDGQHYWC
CYDSWHYWC,9,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Tumor-homing peptides##Arsenic- containing anti-cancer agent,,Cyclic,Bridging: Cys1<---As--->Cys9,Free,Free,,,0,CYDSWHYWC
CFDGNHIWC,9,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Tumor-homing peptides##Arsenic- containing anti-cancer agent,,Cyclic,Bridging: Cys1<---As--->Cys9,Free,Free,,,0,CFDGNHIWC
CTDFPRSFC,9,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Tumor-homing peptides##Arsenic- containing anti-cancer agent,,Cyclic,Bridging: Cys1<---As--->Cys9,Free,Free,,,0,CTDFPRSFC
CTQDRQHPC,9,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Tumor-homing peptides##Arsenic- containing anti-cancer agent,,Cyclic,Bridging: Cys1<---As--->Cys9,Free,Free,,,0,CTQDRQHPC
CLSRYLDQC,9,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Tumor-homing peptides##Arsenic- containing anti-cancer agent,,Cyclic,Bridging: Cys1<---As--->Cys9,Free,Free,,,0,CLSRYLDQC
CRGDCF,6,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Tumor-homing peptides##Arsenic- containing anti-cancer agent,,Cyclic,Bridging: Cys1<---As--->Cys6,Free,Free,,,0,CRGDCF
CGNSNPKSC,9,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Tumor-homing peptides##Arsenic- containing anti-cancer agent,,Cyclic,Bridging: Cys1<---As--->Cys9,Free,Free,,,0,CGNSNPKSC
CPHNLTKLC,9,Synthetic,Synthetic peptide,,,,,,Anticancer,Cancer targeted peptides##Tumor-homing peptides##Arsenic- containing anti-cancer agent,,Cyclic,Bridging: Cys1<---As--->Cys9,Free,Free,,,0,CPHNLTKLC
TCRSSGRYCRSPYDRRRRYCRRITDACV,28,Alpha O-conotoxin,Native peptide,,,α9α10nAChR,IC50=12 nM (Blocking α9α10nAChR),Specifically block the α9α10nAChR,Anticancer,Cancer targeted peptides##α9α10nAChR inhibitor,,Cyclic,Cys2<--->Cys9; Cys20<--->Cys27,Free,Free,,,0,TCRSSGRYCRSPYDRRRRYCRRITDACV
ACRSSGRYCRSPYDRRRRYCRRITDACV,28,Synthetic,Synthetic peptide,,,α9α10nAChR,IC50=8.1 nM (Blocking α9α10nAChR),Specifically block the α9α10nAChR,Anticancer,Cancer targeted peptides##α9α10nAChR inhibitor,,Cyclic,Cys2<--->Cys9; Cys20<--->Cys27,Free,Free,,,0,ACRSSGRYCRSPYDRRRRYCRRITDACV
TCASSGRYCRSPYDRRRRYCRRITDACV,28,Synthetic,Synthetic peptide,,,α9α10nAChR,IC50=74 nM (Blocking α9α10nAChR),Specifically block the α9α10nAChR,Anticancer,Cancer targeted peptides##α9α10nAChR inhibitor,,Cyclic,Cys2<--->Cys9; Cys20<--->Cys27,Free,Free,,,0,TCASSGRYCRSPYDRRRRYCRRITDACV
TCRASGRYCRSPYDRRRRYCRRITDACV,28,Synthetic,Synthetic peptide,,,α9α10nAChR,IC50=14 nM (Blocking α9α10nAChR),Specifically block the α9α10nAChR,Anticancer,Cancer targeted peptides##α9α10nAChR inhibitor,,Cyclic,Cys2<--->Cys9; Cys20<--->Cys27,Free,Free,,,0,TCRASGRYCRSPYDRRRRYCRRITDACV
TCRSAGRYCRSPYDRRRRYCRRITDACV,28,Synthetic,Synthetic peptide,,,α9α10nAChR,IC50=27 nM (Blocking α9α10nAChR),Specifically block the α9α10nAChR,Anticancer,Cancer targeted peptides##α9α10nAChR inhibitor,,Cyclic,Cys2<--->Cys9; Cys20<--->Cys27,Free,Free,,,0,TCRSAGRYCRSPYDRRRRYCRRITDACV
TCRSSARYCRSPYDRRRRYCRRITDACV,28,Synthetic,Synthetic peptide,,,α9α10nAChR,IC50=4.5 nM (Blocking α9α10nAChR),Specifically block the α9α10nAChR,Anticancer,Cancer targeted peptides##α9α10nAChR inhibitor,,Cyclic,Cys2<--->Cys9; Cys20<--->Cys27,Free,Free,,,0,TCRSSARYCRSPYDRRRRYCRRITDACV
TCRSSGAYCRSPYDRRRRYCRRITDACV,28,Synthetic,Synthetic peptide,,,α9α10nAChR,IC50=44 nM (Blocking α9α10nAChR),Specifically block the α9α10nAChR,Anticancer,Cancer targeted peptides##α9α10nAChR inhibitor,,Cyclic,Cys2<--->Cys9; Cys20<--->Cys27,Free,Free,,,0,TCRSSGAYCRSPYDRRRRYCRRITDACV
TCRSSGRACRSPYDRRRRYCRRITDACV,28,Synthetic,Synthetic peptide,,,α9α10nAChR,IC50=10 nM (Blocking α9α10nAChR),Specifically block the α9α10nAChR,Anticancer,Cancer targeted peptides##α9α10nAChR inhibitor,,Cyclic,Cys2<--->Cys9; Cys20<--->Cys27,Free,Free,,,0,TCRSSGRACRSPYDRRRRYCRRITDACV
TCRSSGRYCASPYDRRRRYCRRITDACV,28,Synthetic,Synthetic peptide,,,α9α10nAChR,IC50=71 nM (Blocking α9α10nAChR),Specifically block the α9α10nAChR,Anticancer,Cancer targeted peptides##α9α10nAChR inhibitor,,Cyclic,Cys2<--->Cys9; Cys20<--->Cys27,Free,Free,,,0,TCRSSGRYCASPYDRRRRYCRRITDACV
TCRSSGRYCRAPYDRRRRYCRRITDACV,28,Synthetic,Synthetic peptide,,,α9α10nAChR,IC50=26 nM (Blocking α9α10nAChR),Specifically block the α9α10nAChR,Anticancer,Cancer targeted peptides##α9α10nAChR inhibitor,,Cyclic,Cys2<--->Cys9; Cys20<--->Cys27,Free,Free,,,0,TCRSSGRYCRAPYDRRRRYCRRITDACV
TCRSSGRYCRSAYDRRRRYCRRITDACV,28,Synthetic,Synthetic peptide,,,α9α10nAChR,IC50=16 nM (Blocking α9α10nAChR),Specifically block the α9α10nAChR,Anticancer,Cancer targeted peptides##α9α10nAChR inhibitor,,Cyclic,Cys2<--->Cys9; Cys20<--->Cys27,Free,Free,,,0,TCRSSGRYCRSAYDRRRRYCRRITDACV
TCRSSGRYCRSPADRRRRYCRRITDACV,28,Synthetic,Synthetic peptide,,,α9α10nAChR,IC50=11 nM (Blocking α9α10nAChR),Specifically block the α9α10nAChR,Anticancer,Cancer targeted peptides##α9α10nAChR inhibitor,,Cyclic,Cys2<--->Cys9; Cys20<--->Cys27,Free,Free,,,0,TCRSSGRYCRSPADRRRRYCRRITDACV
TCRSSGRYCRSPYARRRRYCRRITDACV,28,Synthetic,Synthetic peptide,,,α9α10nAChR,IC50=15 nM (Blocking α9α10nAChR),Specifically block the α9α10nAChR,Anticancer,Cancer targeted peptides##α9α10nAChR inhibitor,,Cyclic,Cys2<--->Cys9; Cys20<--->Cys27,Free,Free,,,0,TCRSSGRYCRSPYARRRRYCRRITDACV
TCRSSGRYCRSPYDARRRYCRRITDACV,28,Synthetic,Synthetic peptide,,,α9α10nAChR,IC50=32 nM (Blocking α9α10nAChR),Specifically block the α9α10nAChR,Anticancer,Cancer targeted peptides##α9α10nAChR inhibitor,,Cyclic,Cys2<--->Cys9; Cys20<--->Cys27,Free,Free,,,0,TCRSSGRYCRSPYDARRRYCRRITDACV
TCRSSGRYCRSPYDRARRYCRRITDACV,28,Synthetic,Synthetic peptide,,,α9α10nAChR,IC50=18 nM (Blocking α9α10nAChR),Specifically block the α9α10nAChR,Anticancer,Cancer targeted peptides##α9α10nAChR inhibitor,,Cyclic,Cys2<--->Cys9; Cys20<--->Cys27,Free,Free,,,0,TCRSSGRYCRSPYDRARRYCRRITDACV
TCRSSGRYCRSPYDRRARYCRRITDACV,28,Synthetic,Synthetic peptide,,,α9α10nAChR,IC50=27 nM (Blocking α9α10nAChR),Specifically block the α9α10nAChR,Anticancer,Cancer targeted peptides##α9α10nAChR inhibitor,,Cyclic,Cys2<--->Cys9; Cys20<--->Cys27,Free,Free,,,0,TCRSSGRYCRSPYDRRARYCRRITDACV
TCRSSGRYCRSPYDRRRAYCRRITDACV,28,Synthetic,Synthetic peptide,,,α9α10nAChR,IC50=54 nM (Blocking α9α10nAChR),Specifically block the α9α10nAChR,Anticancer,Cancer targeted peptides##α9α10nAChR inhibitor,,Cyclic,Cys2<--->Cys9; Cys20<--->Cys27,Free,Free,,,0,TCRSSGRYCRSPYDRRRAYCRRITDACV
TCRSSGRYCRSPYDRRRRACRRITDACV,28,Synthetic,Synthetic peptide,,,α9α10nAChR,IC50=16 nM (Blocking α9α10nAChR),Specifically block the α9α10nAChR,Anticancer,Cancer targeted peptides##α9α10nAChR inhibitor,,Cyclic,Cys2<--->Cys9; Cys20<--->Cys27,Free,Free,,,0,TCRSSGRYCRSPYDRRRRACRRITDACV
TCRSSGRYCRSPYDRRRRYCARITDACV,28,Synthetic,Synthetic peptide,,,α9α10nAChR,IC50=14 nM (Blocking α9α10nAChR),Specifically block the α9α10nAChR,Anticancer,Cancer targeted peptides##α9α10nAChR inhibitor,,Cyclic,Cys2<--->Cys9; Cys20<--->Cys27,Free,Free,,,0,TCRSSGRYCRSPYDRRRRYCARITDACV
TCRSSGRYCRSPYDRRRRYCRAITDACV,28,Synthetic,Synthetic peptide,,,α9α10nAChR,IC50=54 nM (Blocking α9α10nAChR),Specifically block the α9α10nAChR,Anticancer,Cancer targeted peptides##α9α10nAChR inhibitor,,Cyclic,Cys2<--->Cys9; Cys20<--->Cys27,Free,Free,,,0,TCRSSGRYCRSPYDRRRRYCRAITDACV
TCRSSGRYCRSPYDRRRRYCRRATDACV,28,Synthetic,Synthetic peptide,,,α9α10nAChR,IC50=16 nM (Blocking α9α10nAChR),Specifically block the α9α10nAChR,Anticancer,Cancer targeted peptides##α9α10nAChR inhibitor,,Cyclic,Cys2<--->Cys9; Cys20<--->Cys27,Free,Free,,,0,TCRSSGRYCRSPYDRRRRYCRRATDACV
TCRSSGRYCRSPYDRRRRYCRRIADACV,28,Synthetic,Synthetic peptide,,,α9α10nAChR,IC50=21 nM (Blocking α9α10nAChR),Specifically block the α9α10nAChR,Anticancer,Cancer targeted peptides##α9α10nAChR inhibitor,,Cyclic,Cys2<--->Cys9; Cys20<--->Cys27,Free,Free,,,0,TCRSSGRYCRSPYDRRRRYCRRIADACV
TCRSSGRYCRSPYDRRRRYCRRITAACV,28,Synthetic,Synthetic peptide,,,α9α10nAChR,IC50=13 nM (Blocking α9α10nAChR),Specifically block the α9α10nAChR,Anticancer,Cancer targeted peptides##α9α10nAChR inhibitor,,Cyclic,Cys2<--->Cys9; Cys20<--->Cys27,Free,Free,,,0,TCRSSGRYCRSPYDRRRRYCRRITAACV
TCRSSGRYCRSPYDRRRRYCRRITDACA,28,Synthetic,Synthetic peptide,,,α9α10nAChR,IC50=15 nM (Blocking α9α10nAChR),Specifically block the α9α10nAChR,Anticancer,Cancer targeted peptides##α9α10nAChR inhibitor,,Cyclic,Cys2<--->Cys9; Cys20<--->Cys27,Free,Free,,,0,TCRSSGRYCRSPYDRRRRYCRRITDACA
TCASSGAYCASPYDAAAAYCAAITDACV,28,Synthetic,Synthetic peptide,,,α9α10nAChR,IC50>10000 nM (Blocking α9α10nAChR),Specifically block the α9α10nAChR,Anticancer,Cancer targeted peptides##α9α10nAChR inhibitor,,Cyclic,Cys2<--->Cys9; Cys20<--->Cys27,Free,Free,,,0,TCASSGAYCASPYDAAAAYCAAITDACV
TCRSSGRYCRSPYDAAAAYCRRITDACV,28,Synthetic,Synthetic peptide,,,α9α10nAChR,IC50>10000 nM (Blocking α9α10nAChR),Specifically block the α9α10nAChR,Anticancer,Cancer targeted peptides##α9α10nAChR inhibitor,,Cyclic,Cys2<--->Cys9; Cys20<--->Cys27,Free,Free,,,0,TCRSSGRYCRSPYDAAAAYCRRITDACV
TCASSGAYCASPYDRRRRYCRRITDACV,28,Synthetic,Synthetic peptide,,,α9α10nAChR,IC50>10000 nM (Blocking α9α10nAChR),Specifically block the α9α10nAChR,Anticancer,Cancer targeted peptides##α9α10nAChR inhibitor,,Cyclic,Cys2<--->Cys9; Cys20<--->Cys27,Free,Free,,,0,TCASSGAYCASPYDRRRRYCRRITDACV
TCASSGAYCRSPYDRRRRYCRRITDACV,28,Synthetic,Synthetic peptide,,,α9α10nAChR,IC50=370 nM (Blocking α9α10nAChR),Specifically block the α9α10nAChR,Anticancer,Cancer targeted peptides##α9α10nAChR inhibitor,,Cyclic,Cys2<--->Cys9; Cys20<--->Cys27,Free,Free,,,0,TCASSGAYCRSPYDRRRRYCRRITDACV
TCASSGRYCASPYDRRRRYCRRITDACV,28,Synthetic,Synthetic peptide,,,α9α10nAChR,IC50=590 nM (Blocking α9α10nAChR),Specifically block the α9α10nAChR,Anticancer,Cancer targeted peptides##α9α10nAChR inhibitor,,Cyclic,Cys2<--->Cys9; Cys20<--->Cys27,Free,Free,,,0,TCASSGRYCASPYDRRRRYCRRITDACV
TCRSSGAYCASPYDRRRRYCRRITDACV,28,Synthetic,Synthetic peptide,,,α9α10nAChR,IC50=440 nM (Blocking α9α10nAChR),Specifically block the α9α10nAChR,Anticancer,Cancer targeted peptides##α9α10nAChR inhibitor,,Cyclic,Cys2<--->Cys9; Cys20<--->Cys27,Free,Free,,,0,TCRSSGAYCASPYDRRRRYCRRITDACV
TCRSSGRYCRSPYDAARRYCRRITDACV,28,Synthetic,Synthetic peptide,,,α9α10nAChR,IC50=260 nM (Blocking α9α10nAChR),Specifically block the α9α10nAChR,Anticancer,Cancer targeted peptides##α9α10nAChR inhibitor,,Cyclic,Cys2<--->Cys9; Cys20<--->Cys27,Free,Free,,,0,TCRSSGRYCRSPYDAARRYCRRITDACV
TCRSSGRYCRSPYDARARYCRRITDACV,28,Synthetic,Synthetic peptide,,,α9α10nAChR,IC50=230 nM (Blocking α9α10nAChR),Specifically block the α9α10nAChR,Anticancer,Cancer targeted peptides##α9α10nAChR inhibitor,,Cyclic,Cys2<--->Cys9; Cys20<--->Cys27,Free,Free,,,0,TCRSSGRYCRSPYDARARYCRRITDACV
TCRSSGRYCRSPYDARRAYCRRITDACV,28,Synthetic,Synthetic peptide,,,α9α10nAChR,IC50=350 nM (Blocking α9α10nAChR),Specifically block the α9α10nAChR,Anticancer,Cancer targeted peptides##α9α10nAChR inhibitor,,Cyclic,Cys2<--->Cys9; Cys20<--->Cys27,Free,Free,,,0,TCRSSGRYCRSPYDARRAYCRRITDACV
TCRSSGRYCRSPYDRAARYCRRITDACV,28,Synthetic,Synthetic peptide,,,α9α10nAChR,IC50=130 nM (Blocking α9α10nAChR),Specifically block the α9α10nAChR,Anticancer,Cancer targeted peptides##α9α10nAChR inhibitor,,Cyclic,Cys2<--->Cys9; Cys20<--->Cys27,Free,Free,,,0,TCRSSGRYCRSPYDRAARYCRRITDACV
TCRSSGRYCRSPYDRARAYCRRITDACV,28,Synthetic,Synthetic peptide,,,α9α10nAChR,IC50=410 nM (Blocking α9α10nAChR),Specifically block the α9α10nAChR,Anticancer,Cancer targeted peptides##α9α10nAChR inhibitor,,Cyclic,Cys2<--->Cys9; Cys20<--->Cys27,Free,Free,,,0,TCRSSGRYCRSPYDRARAYCRRITDACV
TCRSSGRYCRSPYDRRAAYCRRITDACV,28,Synthetic,Synthetic peptide,,,α9α10nAChR,IC50=230 nM (Blocking α9α10nAChR),Specifically block the α9α10nAChR,Anticancer,Cancer targeted peptides##α9α10nAChR inhibitor,,Cyclic,Cys2<--->Cys9; Cys20<--->Cys27,Free,Free,,,0,TCRSSGRYCRSPYDRRAAYCRRITDACV
TCRSSGRYCRSPYDRRRRYCAAITDACV,28,Synthetic,Synthetic peptide,,,α9α10nAChR,IC50=180 nM (Blocking α9α10nAChR),Specifically block the α9α10nAChR,Anticancer,Cancer targeted peptides##α9α10nAChR inhibitor,,Cyclic,Cys2<--->Cys9; Cys20<--->Cys27,Free,Free,,,0,TCRSSGRYCRSPYDRRRRYCAAITDACV
GRYCRSPYDRRRRYCRR,17,Synthetic,Synthetic peptide,,,α9α10nAChR,IC50=14 nM (Blocking α9α10nAChR),Specifically block the α9α10nAChR,Anticancer,Cancer targeted peptides##α9α10nAChR inhibitor,,Cyclic,Cys4<--->Cys15,Free,Free,,,0,GRYCRSPYDRRRRYCRR
RSPYDRRRRY,10,Synthetic,Synthetic peptide,,,α9α10nAChR,IC50=1110 nM (Blocking α9α10nAChR),Specifically block the α9α10nAChR,Anticancer,Cancer targeted peptides##α9α10nAChR inhibitor,,Linear,,Free,Free,,,0,RSPYDRRRRY
ASPYDRRRRY,10,Synthetic,Synthetic peptide,,,α9α10nAChR,,Specifically block the α9α10nAChR,Anticancer,Cancer targeted peptides##α9α10nAChR inhibitor,,Linear,,Free,Free,,,0,ASPYDRRRRY
RAPYDRRRRY,10,Synthetic,Synthetic peptide,,,α9α10nAChR,,Specifically block the α9α10nAChR,Anticancer,Cancer targeted peptides##α9α10nAChR inhibitor,,Linear,,Free,Free,,,0,RAPYDRRRRY
RSAYDRRRRY,10,Synthetic,Synthetic peptide,,,α9α10nAChR,,Specifically block the α9α10nAChR,Anticancer,Cancer targeted peptides##α9α10nAChR inhibitor,,Linear,,Free,Free,,,0,RSAYDRRRRY
RSPADRRRRY,10,Synthetic,Synthetic peptide,,,α9α10nAChR,,Specifically block the α9α10nAChR,Anticancer,Cancer targeted peptides##α9α10nAChR inhibitor,,Linear,,Free,Free,,,0,RSPADRRRRY
RSPYARRRRY,10,Synthetic,Synthetic peptide,,,α9α10nAChR,IC50=120 nM (Blocking α9α10nAChR),Specifically block the α9α10nAChR,Anticancer,Cancer targeted peptides##α9α10nAChR inhibitor,,Linear,,Free,Free,,,0,RSPYARRRRY
RSPYDARRRY,10,Synthetic,Synthetic peptide,,,α9α10nAChR,,Specifically block the α9α10nAChR,Anticancer,Cancer targeted peptides##α9α10nAChR inhibitor,,Linear,,Free,Free,,,0,RSPYDARRRY
RSPYDRARRY,10,Synthetic,Synthetic peptide,,,α9α10nAChR,,Specifically block the α9α10nAChR,Anticancer,Cancer targeted peptides##α9α10nAChR inhibitor,,Linear,,Free,Free,,,0,RSPYDRARRY
RSPYDRRARY,10,Synthetic,Synthetic peptide,,,α9α10nAChR,,Specifically block the α9α10nAChR,Anticancer,Cancer targeted peptides##α9α10nAChR inhibitor,,Linear,,Free,Free,,,0,RSPYDRRARY
RSPYDRRRAY,10,Synthetic,Synthetic peptide,,,α9α10nAChR,,Specifically block the α9α10nAChR,Anticancer,Cancer targeted peptides##α9α10nAChR inhibitor,,Linear,,Free,Free,,,0,RSPYDRRRAY
RSPYDRRRRA,10,Synthetic,Synthetic peptide,,,α9α10nAChR,,Specifically block the α9α10nAChR,Anticancer,Cancer targeted peptides##α9α10nAChR inhibitor,,Linear,,Free,Free,,,0,RSPYDRRRRA
RYCRSPYDRRRRYCRR,16,Synthetic,Synthetic peptide,,,α9α10nAChR,,Specifically block the α9α10nAChR,Anticancer,Cancer targeted peptides##α9α10nAChR inhibitor,,Cyclic,Cys3<--->Cys14,Free,Free,,,0,RYCRSPYDRRRRYCRR
TARSSGRYARSPYDRRRRYCRRITDACV,28,Synthetic,Synthetic peptide,,,α9α10nAChR,IC50=16 nM (Blocking α9α10nAChR),Specifically block the α9α10nAChR,Anticancer,Cancer targeted peptides##α9α10nAChR inhibitor,,Cyclic,Cys20<--->Cys27,Free,Free,,,0,TARSSGRYARSPYDRRRRYCRRITDACV
TSRSSGRYSRSPYDRRRRYCRRITDACV,28,Synthetic,Synthetic peptide,,,α9α10nAChR,IC50=12 nM (Blocking α9α10nAChR),Specifically block the α9α10nAChR,Anticancer,Cancer targeted peptides##α9α10nAChR inhibitor,,Cyclic,Cys20<--->Cys27,Free,Free,,,0,TSRSSGRYSRSPYDRRRRYCRRITDACV
TCRSSGRYCRSPYDRRRRYARRITDAAV,28,Synthetic,Synthetic peptide,,,α9α10nAChR,IC50=14 nM (Blocking α9α10nAChR),Specifically block the α9α10nAChR,Anticancer,Cancer targeted peptides##α9α10nAChR inhibitor,,Cyclic,Cys2<--->Cys9,Free,Free,,,0,TCRSSGRYCRSPYDRRRRYARRITDAAV
TCRSSGRYCRSPYDRRRRYSRRITDASV,28,Synthetic,Synthetic peptide,,,α9α10nAChR,IC50=11 nM (Blocking α9α10nAChR),Specifically block the α9α10nAChR,Anticancer,Cancer targeted peptides##α9α10nAChR inhibitor,,Cyclic,Cys2<--->Cys9,Free,Free,,,0,TCRSSGRYCRSPYDRRRRYSRRITDASV
TARSSGRYCRSPYDRRRRYCRRITDAAV,28,Synthetic,Synthetic peptide,,,α9α10nAChR,IC50=17 nM (Blocking α9α10nAChR),Specifically block the α9α10nAChR,Anticancer,Cancer targeted peptides##α9α10nAChR inhibitor,,Cyclic,Cys9<--->Cys20,Free,Free,,,0,TARSSGRYCRSPYDRRRRYCRRITDAAV
TSRSSGRYCRSPYDRRRRYCRRITDASV,28,Synthetic,Synthetic peptide,,,α9α10nAChR,IC50=21 nM (Blocking α9α10nAChR),Specifically block the α9α10nAChR,Anticancer,Cancer targeted peptides##α9α10nAChR inhibitor,,Cyclic,Cys9<--->Cys20,Free,Free,,,0,TSRSSGRYCRSPYDRRRRYCRRITDASV
TCRSSGRYARSPYDRRRRYARRITDACV,28,Synthetic,Synthetic peptide,,,α9α10nAChR,IC50=36 nM (Blocking α9α10nAChR),Specifically block the α9α10nAChR,Anticancer,Cancer targeted peptides##α9α10nAChR inhibitor,,Cyclic,Cys2<--->Cys27,Free,Free,,,0,TCRSSGRYARSPYDRRRRYARRITDACV
TCRSSGRYSRSPYDRRRRYSRRITDACV,28,Synthetic,Synthetic peptide,,,α9α10nAChR,IC50=13 nM (Blocking α9α10nAChR),Specifically block the α9α10nAChR,Anticancer,Cancer targeted peptides##α9α10nAChR inhibitor,,Cyclic,Cys2<--->Cys27,Free,Free,,,0,TCRSSGRYSRSPYDRRRRYSRRITDACV
TARSSGRYARSPYDRRRRYARRITDAAV,28,Synthetic,Synthetic peptide,,,α9α10nAChR,IC50=14 nM (Blocking α9α10nAChR),Specifically block the α9α10nAChR,Anticancer,Cancer targeted peptides##α9α10nAChR inhibitor,,Linear,,Free,Free,,,0,TARSSGRYARSPYDRRRRYARRITDAAV
TSRSSGRYSRSPYDRRRRYSRRITDASV,28,Synthetic,Synthetic peptide,,,α9α10nAChR,IC50=16 nM (Blocking α9α10nAChR),Specifically block the α9α10nAChR,Anticancer,Cancer targeted peptides##α9α10nAChR inhibitor,,Linear,,Free,Free,,,0,TSRSSGRYSRSPYDRRRRYSRRITDASV
TARSSGRYARSPYDRRRRYSRRITDASV,28,Synthetic,Synthetic peptide,,,α9α10nAChR,IC50=6.1 nM (Blocking α9α10nAChR),Specifically block the α9α10nAChR,Anticancer,Cancer targeted peptides##α9α10nAChR inhibitor,,Linear,,Free,Free,,,0,TARSSGRYARSPYDRRRRYSRRITDASV
TSRSSGRYSRSPYDRRRRYARRITDAAV,28,Synthetic,Synthetic peptide,,,α9α10nAChR,IC50=13 nM (Blocking α9α10nAChR),Specifically block the α9α10nAChR,Anticancer,Cancer targeted peptides##α9α10nAChR inhibitor,,Linear,,Free,Free,,,0,TSRSSGRYSRSPYDRRRRYARRITDAAV
tCRSSGRYCRSPYDRRRRYCRRITDACV,28,Synthetic,Synthetic peptide,,,α9α10nAChR,IC50=24.7 nM (Blocking α9α10nAChR),Specifically block the α9α10nAChR,Anticancer,Cancer targeted peptides##α9α10nAChR inhibitor,,Cyclic,Cys2<--->Cys9; Cys20<--->Cys27,Free,Free,,,0,TCRSSGRYCRSPYDRRRRYCRRITDACV
TCRSSGRYCRSPYDRRRRYCRRITDACv,28,Synthetic,Synthetic peptide,,,α9α10nAChR,IC50=31.29 nM (Blocking α9α10nAChR),Specifically block the α9α10nAChR,Anticancer,Cancer targeted peptides##α9α10nAChR inhibitor,,Cyclic,Cys2<--->Cys9; Cys20<--->Cys27,Free,Free,,,0,TCRSSGRYCRSPYDRRRRYCRRITDACV
tCRSSGRYCRSPYDRRRRYCRRITDACv,28,Synthetic,Synthetic peptide,,,α9α10nAChR,IC50=31.94 nM (Blocking α9α10nAChR),Specifically block the α9α10nAChR,Anticancer,Cancer targeted peptides##α9α10nAChR inhibitor,,Cyclic,Cys2<--->Cys9; Cys20<--->Cys27,Free,Free,,,0,TCRSSGRYCRSPYDRRRRYCRRITDACV
TCRSSGRYCRSPYDrrRRYCRRITDACV,28,Synthetic,Synthetic peptide,,,α9α10nAChR,IC50=17.37 nM (Blocking α9α10nAChR),Specifically block the α9α10nAChR,Anticancer,Cancer targeted peptides##α9α10nAChR inhibitor,,Cyclic,Cys2<--->Cys9; Cys20<--->Cys27,Free,Free,,,0,TCRSSGRYCRSPYDRRRRYCRRITDACV
TCRSSGRYCRSPYDrrrrYCRRITDACV,28,Synthetic,Synthetic peptide,,,α9α10nAChR,IC50=11.02 nM (Blocking α9α10nAChR),Specifically block the α9α10nAChR,Anticancer,Cancer targeted peptides##α9α10nAChR inhibitor,,Cyclic,Cys2<--->Cys9; Cys20<--->Cys27,Free,Free,,,0,TCRSSGRYCRSPYDRRRRYCRRITDACV
TCrSSGrYCrSPYDrrrrYCrrITDACV,28,Synthetic,Synthetic peptide,,,α9α10nAChR,IC50=21.67 nM (Blocking α9α10nAChR),Specifically block the α9α10nAChR,Anticancer,Cancer targeted peptides##α9α10nAChR inhibitor,,Cyclic,Cys2<--->Cys9; Cys20<--->Cys27,Free,Free,,,0,TCRSSGRYCRSPYDRRRRYCRRITDACV
tCrSSGrYCrSPYDrrrrYCrrITDACv,28,Synthetic,Synthetic peptide,,,α9α10nAChR,IC50=24.53 nM (Blocking α9α10nAChR),Specifically block the α9α10nAChR,Anticancer,Cancer targeted peptides##α9α10nAChR inhibitor,,Cyclic,Cys2<--->Cys9; Cys20<--->Cys27,Free,Free,,,0,TCRSSGRYCRSPYDRRRRYCRRITDACV
DCRSSGRYCRSPYDRRRRYCRRITDACV,28,Synthetic,Synthetic peptide,,,α9α10nAChR,IC50=27 nM (Blocking α9α10nAChR),Specifically block the α9α10nAChR,Anticancer,Cancer targeted peptides##α9α10nAChR inhibitor,,Cyclic,Cys2<--->Cys27; Cys9<--->Cys20,Free,Free,,,0,DCRSSGRYCRSPYDRRRRYCRRITDACV
TCDSSGRYCRSPYDRRRRYCRRITDACV,28,Synthetic,Synthetic peptide,,,α9α10nAChR,,Specifically block the α9α10nAChR,Anticancer,Cancer targeted peptides##α9α10nAChR inhibitor,,Cyclic,Cys2<--->Cys27; Cys9<--->Cys20,Free,Free,,,0,TCDSSGRYCRSPYDRRRRYCRRITDACV
TCRDSGRYCRSPYDRRRRYCRRITDACV,28,Synthetic,Synthetic peptide,,,α9α10nAChR,,Specifically block the α9α10nAChR,Anticancer,Cancer targeted peptides##α9α10nAChR inhibitor,,Cyclic,Cys2<--->Cys27; Cys9<--->Cys20,Free,Free,,,0,TCRDSGRYCRSPYDRRRRYCRRITDACV
TCRSDGRYCRSPYDRRRRYCRRITDACV,28,Synthetic,Synthetic peptide,,,α9α10nAChR,,Specifically block the α9α10nAChR,Anticancer,Cancer targeted peptides##α9α10nAChR inhibitor,,Cyclic,Cys2<--->Cys27; Cys9<--->Cys20,Free,Free,,,0,TCRSDGRYCRSPYDRRRRYCRRITDACV
TCRSSDRYCRSPYDRRRRYCRRITDACV,28,Synthetic,Synthetic peptide,,,α9α10nAChR,,Specifically block the α9α10nAChR,Anticancer,Cancer targeted peptides##α9α10nAChR inhibitor,,Cyclic,Cys2<--->Cys27; Cys9<--->Cys20,Free,Free,,,0,TCRSSDRYCRSPYDRRRRYCRRITDACV
TCRSSGDYCRSPYDRRRRYCRRITDACV,28,Synthetic,Synthetic peptide,,,α9α10nAChR,IC50=590 nM (Blocking α9α10nAChR),Specifically block the α9α10nAChR,Anticancer,Cancer targeted peptides##α9α10nAChR inhibitor,,Cyclic,Cys2<--->Cys27; Cys9<--->Cys20,Free,Free,,,0,TCRSSGDYCRSPYDRRRRYCRRITDACV
TCRSSGRDCRSPYDRRRRYCRRITDACV,28,Synthetic,Synthetic peptide,,,α9α10nAChR,,Specifically block the α9α10nAChR,Anticancer,Cancer targeted peptides##α9α10nAChR inhibitor,,Cyclic,Cys2<--->Cys27; Cys9<--->Cys20,Free,Free,,,0,TCRSSGRDCRSPYDRRRRYCRRITDACV
TCRSSGRYCDSPYDRRRRYCRRITDACV,28,Synthetic,Synthetic peptide,,,α9α10nAChR,,Specifically block the α9α10nAChR,Anticancer,Cancer targeted peptides##α9α10nAChR inhibitor,,Cyclic,Cys2<--->Cys27; Cys9<--->Cys20,Free,Free,,,0,TCRSSGRYCDSPYDRRRRYCRRITDACV
TCRSSGRYCRDPYDRRRRYCRRITDACV,28,Synthetic,Synthetic peptide,,,α9α10nAChR,,Specifically block the α9α10nAChR,Anticancer,Cancer targeted peptides##α9α10nAChR inhibitor,,Cyclic,Cys2<--->Cys27; Cys9<--->Cys20,Free,Free,,,0,TCRSSGRYCRDPYDRRRRYCRRITDACV
TCRSSGRYCRSDYDRRRRYCRRITDACV,28,Synthetic,Synthetic peptide,,,α9α10nAChR,,Specifically block the α9α10nAChR,Anticancer,Cancer targeted peptides##α9α10nAChR inhibitor,,Cyclic,Cys2<--->Cys27; Cys9<--->Cys20,Free,Free,,,0,TCRSSGRYCRSDYDRRRRYCRRITDACV
TCRSSGRYCRSPDDRRRRYCRRITDACV,28,Synthetic,Synthetic peptide,,,α9α10nAChR,,Specifically block the α9α10nAChR,Anticancer,Cancer targeted peptides##α9α10nAChR inhibitor,,Cyclic,Cys2<--->Cys27; Cys9<--->Cys20,Free,Free,,,0,TCRSSGRYCRSPDDRRRRYCRRITDACV
TCRSSGRYCRSPYDDRRRYCRRITDACV,28,Synthetic,Synthetic peptide,,,α9α10nAChR,,Specifically block the α9α10nAChR,Anticancer,Cancer targeted peptides##α9α10nAChR inhibitor,,Cyclic,Cys2<--->Cys27; Cys9<--->Cys20,Free,Free,,,0,TCRSSGRYCRSPYDDRRRYCRRITDACV
TCRSSGRYCRSPYDRDRRYCRRITDACV,28,Synthetic,Synthetic peptide,,,α9α10nAChR,,Specifically block the α9α10nAChR,Anticancer,Cancer targeted peptides##α9α10nAChR inhibitor,,Cyclic,Cys2<--->Cys27; Cys9<--->Cys20,Free,Free,,,0,TCRSSGRYCRSPYDRDRRYCRRITDACV
TCRSSGRYCRSPYDRRDRYCRRITDACV,28,Synthetic,Synthetic peptide,,,α9α10nAChR,,Specifically block the α9α10nAChR,Anticancer,Cancer targeted peptides##α9α10nAChR inhibitor,,Cyclic,Cys2<--->Cys27; Cys9<--->Cys20,Free,Free,,,0,TCRSSGRYCRSPYDRRDRYCRRITDACV
TCRSSGRYCRSPYDRRRDYCRRITDACV,28,Synthetic,Synthetic peptide,,,α9α10nAChR,,Specifically block the α9α10nAChR,Anticancer,Cancer targeted peptides##α9α10nAChR inhibitor,,Cyclic,Cys2<--->Cys27; Cys9<--->Cys20,Free,Free,,,0,TCRSSGRYCRSPYDRRRDYCRRITDACV
TCRSSGRYCRSPYDRRRRDCRRITDACV,28,Synthetic,Synthetic peptide,,,α9α10nAChR,IC50=125 nM (Blocking α9α10nAChR),Specifically block the α9α10nAChR,Anticancer,Cancer targeted peptides##α9α10nAChR inhibitor,,Cyclic,Cys2<--->Cys27; Cys9<--->Cys20,Free,Free,,,0,TCRSSGRYCRSPYDRRRRDCRRITDACV
TCRSSGRYCRSPYDRRRRYCDRITDACV,28,Synthetic,Synthetic peptide,,,α9α10nAChR,IC50=550 nM (Blocking α9α10nAChR),Specifically block the α9α10nAChR,Anticancer,Cancer targeted peptides##α9α10nAChR inhibitor,,Cyclic,Cys2<--->Cys27; Cys9<--->Cys20,Free,Free,,,0,TCRSSGRYCRSPYDRRRRYCDRITDACV
TCRSSGRYCRSPYDRRRRYCRDITDACV,28,Synthetic,Synthetic peptide,,,α9α10nAChR,IC50=553 nM (Blocking α9α10nAChR),Specifically block the α9α10nAChR,Anticancer,Cancer targeted peptides##α9α10nAChR inhibitor,,Cyclic,Cys2<--->Cys27; Cys9<--->Cys20,Free,Free,,,0,TCRSSGRYCRSPYDRRRRYCRDITDACV
TCRSSGRYCRSPYDRRRRYCRRDTDACV,28,Synthetic,Synthetic peptide,,,α9α10nAChR,IC50=107 nM (Blocking α9α10nAChR),Specifically block the α9α10nAChR,Anticancer,Cancer targeted peptides##α9α10nAChR inhibitor,,Cyclic,Cys2<--->Cys27; Cys9<--->Cys20,Free,Free,,,0,TCRSSGRYCRSPYDRRRRYCRRDTDACV
TCRSSGRYCRSPYDRRRRYCRRIDDACV,28,Synthetic,Synthetic peptide,,,α9α10nAChR,IC50=129 nM (Blocking α9α10nAChR),Specifically block the α9α10nAChR,Anticancer,Cancer targeted peptides##α9α10nAChR inhibitor,,Cyclic,Cys2<--->Cys27; Cys9<--->Cys20,Free,Free,,,0,TCRSSGRYCRSPYDRRRRYCRRIDDACV
TCRSSGRYCRSPYDRRRRYCRRITDDCV,28,Synthetic,Synthetic peptide,,,α9α10nAChR,IC50=41 nM (Blocking α9α10nAChR),Specifically block the α9α10nAChR,Anticancer,Cancer targeted peptides##α9α10nAChR inhibitor,,Cyclic,Cys2<--->Cys27; Cys9<--->Cys20,Free,Free,,,0,TCRSSGRYCRSPYDRRRRYCRRITDDCV
TCRSSGRYCRSPYDRRRRYCRRITDACD,28,Synthetic,Synthetic peptide,,,α9α10nAChR,,Specifically block the α9α10nAChR,Anticancer,Cancer targeted peptides##α9α10nAChR inhibitor,,Cyclic,Cys2<--->Cys27; Cys9<--->Cys20,Free,Free,,,0,TCRSSGRYCRSPYDRRRRYCRRITDACD
QYDPTPLTW,9,Synthetic,Synthetic peptide,,,HLA-A*24,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,QYDPTPLTW
VWSNVTPLKF,10,Synthetic,Synthetic peptide,,,HLA-A*24,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,VWSNVTPLKF
YLEKFYGL,8,Synthetic,Synthetic peptide,,,HLA-A*24,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,YLEKFYGL
SYEKVINYL,9,Synthetic,Synthetic peptide,,,HLA-A*24,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,SYEKVINYL
RYMKKDYLI,9,Synthetic,Synthetic peptide,,,HLA-A*24,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,RYMKKDYLI
KYKDYFPVI,9,Synthetic,Synthetic peptide,,,HLA-A*24,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,KYKDYFPVI
VQQWSVAVF,9,Synthetic,Synthetic peptide,,,HLA-A*24/B*15,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,VQQWSVAVF
PFLPPAACFF,10,Synthetic,Synthetic peptide,,,HLA-A*24,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,PFLPPAACFF
RILRFPWQL,9,Synthetic,Synthetic peptide,,,HLA-A*24/A*32,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,RILRFPWQL
VWSDVTPLNF,10,Synthetic,Synthetic peptide,,,HLA-A*24,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,VWSDVTPLNF
YYSKSVGFMQW,11,Synthetic,Synthetic peptide,,,HLA-A*24,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,YYSKSVGFMQW
STIRGELFFF,10,Synthetic,Synthetic peptide,,,HLA-A*24/B*57,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,STIRGELFFF
HYTYILEVF,9,Synthetic,Synthetic peptide,,,HLA-A*24,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,HYTYILEVF
SYSSCYSF,8,Synthetic,Synthetic peptide,,,HLA-A*24,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,SYSSCYSF
KYALLLQDL,9,Synthetic,Synthetic peptide,,,HLA-A*24,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,KYALLLQDL
TYNPDFSSL,9,Synthetic,Synthetic peptide,,,HLA-A*24,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,TYNPDFSSL
YYADKKTFIVL,11,Synthetic,Synthetic peptide,,,HLA-A*24,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,YYADKKTFIVL
DYIGSVEKW,9,Synthetic,Synthetic peptide,,,HLA-A*24,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,DYIGSVEKW
ILKEDPFLF,9,Synthetic,Synthetic peptide,,,HLA-A*24,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,ILKEDPFLF
EFTTVLYNF,9,Synthetic,Synthetic peptide,,,HLA-A*24,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,EFTTVLYNF
SYEVRSTF,8,Synthetic,Synthetic peptide,,,HLA-A*24,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,SYEVRSTF
TQPGDWTLF,9,Synthetic,Synthetic peptide,,,HLA-A*24/B*15,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,TQPGDWTLF
KFIISDWRF,9,Synthetic,Synthetic peptide,,,HLA-A*24,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,KFIISDWRF
MYPDLSELLM,10,Synthetic,Synthetic peptide,,,HLA-A*24,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,MYPDLSELLM
SYNGYVFYL,9,Synthetic,Synthetic peptide,,,HLA-A*24,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,SYNGYVFYL
KTPTNYYLF,9,Synthetic,Synthetic peptide,,,HLA-A*24/B*35,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,KTPTNYYLF
NYTLYPITF,9,Synthetic,Synthetic peptide,,,HLA-A*24,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,NYTLYPITF
YYSIISHTL,9,Synthetic,Synthetic peptide,,,HLA-A*24,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,YYSIISHTL
VYPLLSRLYW,10,Synthetic,Synthetic peptide,,,HLA-A*24,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,VYPLLSRLYW
QYLPGWTVLF,10,Synthetic,Synthetic peptide,,,HLA-A*24,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,QYLPGWTVLF
QYQNVLTLW,9,Synthetic,Synthetic peptide,,,HLA-A*24,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,QYQNVLTLW
SLPDLTPTF,9,Synthetic,Synthetic peptide,,,HLA-A*24,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,SLPDLTPTF
KSSVIASLLF,10,Synthetic,Synthetic peptide,,,HLA-A*24/B*57,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,KSSVIASLLF
MQPRMFFLF,9,Synthetic,Synthetic peptide,,,HLA-A*24,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,MQPRMFFLF
KYLEESVWL,9,Synthetic,Synthetic peptide,,,HLA-A*24,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,KYLEESVWL
KQMEDGHTLF,10,Synthetic,Synthetic peptide,,,HLA-A*24/B*15,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,KQMEDGHTLF
QWPWQASLQF,10,Synthetic,Synthetic peptide,,,HLA-A*24,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,QWPWQASLQF
KYTNWKAFL,9,Synthetic,Synthetic peptide,,,HLA-A*24,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,KYTNWKAFL
LIFMLANVF,9,Synthetic,Synthetic peptide,,,HLA-A*24/A*32,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,LIFMLANVF
QYEPPSAPSTTF,12,Synthetic,Synthetic peptide,,,HLA-A*24,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,QYEPPSAPSTTF
VIYFMGAIF,9,Synthetic,Synthetic peptide,,,HLA-A*24/B*15,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,VIYFMGAIF
TLPNTIYRF,9,Synthetic,Synthetic peptide,,,HLA-A*24,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,TLPNTIYRF
IQMDEPMAF,9,Synthetic,Synthetic peptide,,,HLA-A*24/B*15,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,IQMDEPMAF
AYLSAVGTF,9,Synthetic,Synthetic peptide,,,HLA-A*24,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,AYLSAVGTF
KYFVPPQLF,9,Synthetic,Synthetic peptide,,,HLA-A*24,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,KYFVPPQLF
AFPVTSIFHTF,11,Synthetic,Synthetic peptide,,,HLA-A*24,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,AFPVTSIFHTF
KYADYFLEV,9,Synthetic,Synthetic peptide,,,HLA-A*24,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,KYADYFLEV
VFIDHPVHLKF,11,Synthetic,Synthetic peptide,,,HLA-A*24,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,VFIDHPVHLKF
LYISEVRNI,9,Synthetic,Synthetic peptide,,,HLA-A*24,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,LYISEVRNI
SYPELVKMVW,10,Synthetic,Synthetic peptide,,,HLA-A*24,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,SYPELVKMVW
KYALLLQEL,9,Synthetic,Synthetic peptide,,,HLA-A*24,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,KYALLLQEL
KYMKIFHKF,9,Synthetic,Synthetic peptide,,,HLA-A*24,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,KYMKIFHKF
KYITNLEDL,9,Synthetic,Synthetic peptide,,,HLA-A*24,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,KYITNLEDL
LLIKLLQTF,9,Synthetic,Synthetic peptide,,,HLA-A*24/B*15,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,LLIKLLQTF
RWMDQRLVF,9,Synthetic,Synthetic peptide,,,HLA-A*24,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,RWMDQRLVF
VYMIEPLEL,9,Synthetic,Synthetic peptide,,,HLA-A*24,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,VYMIEPLEL
YPSIIQEF,8,Synthetic,Synthetic peptide,,,HLA-A*24,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,YPSIIQEF
QFAAPLRGIYF,11,Synthetic,Synthetic peptide,,,HLA-A*24,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,QFAAPLRGIYF
KYSTTFFMV,9,Synthetic,Synthetic peptide,,,HLA-A*24,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,KYSTTFFMV
TYLSIFDQL,9,Synthetic,Synthetic peptide,,,HLA-A*24,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,TYLSIFDQL
NYAENILTI,9,Synthetic,Synthetic peptide,,,HLA-A*24,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,NYAENILTI
LYQEILAQL,9,Synthetic,Synthetic peptide,,,HLA-A*24,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,LYQEILAQL
VMPSDSFFF,9,Synthetic,Synthetic peptide,,,HLA-A*24,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,VMPSDSFFF
NYAIFDEGHML,11,Synthetic,Synthetic peptide,,,HLA-A*24,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,NYAIFDEGHML
VYPASKMFPFI,11,Synthetic,Synthetic peptide,,,HLA-A*24,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,VYPASKMFPFI
IYFRDSSFL,9,Synthetic,Synthetic peptide,,,HLA-A*24,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,IYFRDSSFL
RYPGKFYRV,9,Synthetic,Synthetic peptide,,,HLA-A*24,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,RYPGKFYRV
IYQQIIQTY,9,Synthetic,Synthetic peptide,,,HLA-A*24,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,IYQQIIQTY
IMPEKFEFW,9,Synthetic,Synthetic peptide,,,HLA-A*24,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,IMPEKFEFW
PYTNYTFDF,9,Synthetic,Synthetic peptide,,,HLA-A*24,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,PYTNYTFDF
SYMVLAPVF,9,Synthetic,Synthetic peptide,,,HLA-A*24,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,SYMVLAPVF
RYEGILYTI,9,Synthetic,Synthetic peptide,,,HLA-A*24,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,RYEGILYTI
SYIGLPLTL,9,Synthetic,Synthetic peptide,,,HLA-A*24,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,SYIGLPLTL
VYDQYFITL,9,Synthetic,Synthetic peptide,,,HLA-A*24,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,VYDQYFITL
NYIYSISVF,9,Synthetic,Synthetic peptide,,,HLA-A*24,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,NYIYSISVF
WYGWHFPEL,9,Synthetic,Synthetic peptide,,,HLA-A*24,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,WYGWHFPEL
AYTLLGHEFV,10,Synthetic,Synthetic peptide,,,HLA-A*24,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,AYTLLGHEFV
TWFPKTPMLF,10,Synthetic,Synthetic peptide,,,HLA-A*24,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,TWFPKTPMLF
RYLADLPTL,9,Synthetic,Synthetic peptide,,,HLA-A*24,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,RYLADLPTL
YYSPLRDLL,9,Synthetic,Synthetic peptide,,,HLA-A*24,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,YYSPLRDLL
LYPEGLRLL,9,Synthetic,Synthetic peptide,,,HLA-A*24,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,LYPEGLRLL
RFLPSPVVI,9,Synthetic,Synthetic peptide,,,HLA-A*24,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,RFLPSPVVI
TYCQNIKEF,9,Synthetic,Synthetic peptide,,,HLA-A*24,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,TYCQNIKEF
YVDINTFRL,9,Synthetic,Synthetic peptide,,,HLA-A*02,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,YVDINTFRL
YIDEFQSLV,9,Synthetic,Synthetic peptide,,,HLA-A*02,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,YIDEFQSLV
FVIDGFDEL,9,Synthetic,Synthetic peptide,,,HLA-A*02,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,FVIDGFDEL
TLYPYQISQL,10,Synthetic,Synthetic peptide,,,HLA-A*02,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,TLYPYQISQL
VQMVITEAQKV,11,Synthetic,Synthetic peptide,,,HLA-A*02,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,VQMVITEAQKV
ILSTTMVTV,9,Synthetic,Synthetic peptide,,,HLA-A*02,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,ILSTTMVTV
FLLMHPSI,8,Synthetic,Synthetic peptide,,,HLA-A*02,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,FLLMHPSI
FALPGLLHA,9,Synthetic,Synthetic peptide,,,HLA-A*02,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,FALPGLLHA
NLRDLLSEV,9,Synthetic,Synthetic peptide,,,HLA-A*02,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,NLRDLLSEV
TLQEKILQV,9,Synthetic,Synthetic peptide,,,HLA-A*02,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,TLQEKILQV
VLPDIETLIGV,11,Synthetic,Synthetic peptide,,,HLA-A*02,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,VLPDIETLIGV
ITIGVLARV,9,Synthetic,Synthetic peptide,,,HLA-A*02,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,ITIGVLARV
HLVGGLHTV,9,Synthetic,Synthetic peptide,,,HLA-A*02,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,HLVGGLHTV
VLALVNSTV,9,Synthetic,Synthetic peptide,,,HLA-A*02,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,VLALVNSTV
LQSSGLTLLL,10,Synthetic,Synthetic peptide,,,HLA-A*02/B*13,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,LQSSGLTLLL
FLKEKVPGI,9,Synthetic,Synthetic peptide,,,HLA-A*02,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,FLKEKVPGI
RQYPTPFQL,9,Synthetic,Synthetic peptide,,,HLA-A*02/B*48,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,RQYPTPFQL
FIISDWRFVL,10,Synthetic,Synthetic peptide,,,HLA-A*02,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,FIISDWRFVL
SLLEQAIAL,9,Synthetic,Synthetic peptide,,,HLA-A*02,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,SLLEQAIAL
FLYYPDPVL,9,Synthetic,Synthetic peptide,,,HLA-A*02,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,FLYYPDPVL
GMLDIFWGV,9,Synthetic,Synthetic peptide,,,HLA-A*02,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,GMLDIFWGV
SLLTHIPTA,9,Synthetic,Synthetic peptide,,,HLA-A*02,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,SLLTHIPTA
FIIDTTYPAYV,11,Synthetic,Synthetic peptide,,,HLA-A*02,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,FIIDTTYPAYV
LLQGAIESV,9,Synthetic,Synthetic peptide,,,HLA-A*02,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,LLQGAIESV
MIIALSLYI,9,Synthetic,Synthetic peptide,,,HLA-A*02,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,MIIALSLYI
LLLGSIGLLGV,11,Synthetic,Synthetic peptide,,,HLA-A*02,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,LLLGSIGLLGV
LLADFQALL,9,Synthetic,Synthetic peptide,,,HLA-A*02,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,LLADFQALL
ALCLLLHLL,9,Synthetic,Synthetic peptide,,,HLA-A*02,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,ALCLLLHLL
SVSDGIHSV,9,Synthetic,Synthetic peptide,,,HLA-A*02,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,SVSDGIHSV
AVLTGLVEV,9,Synthetic,Synthetic peptide,,,HLA-A*02,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,AVLTGLVEV
ILDERQVLL,9,Synthetic,Synthetic peptide,,,HLA-A*02,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,ILDERQVLL
MLLETQDALYV,11,Synthetic,Synthetic peptide,,,HLA-A*02,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,MLLETQDALYV
VLMEENSKL,9,Synthetic,Synthetic peptide,,,HLA-A*02,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,VLMEENSKL
FLDPNARPLV,10,Synthetic,Synthetic peptide,,,HLA-A*02,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,FLDPNARPLV
ALSSVLHSI,9,Synthetic,Synthetic peptide,,,HLA-A*02,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,ALSSVLHSI
RTADITVTV,9,Synthetic,Synthetic peptide,,,HLA-A*02,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,RTADITVTV
ALLANLPAV,9,Synthetic,Synthetic peptide,,,HLA-A*02,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,ALLANLPAV
ALVDTLTGI,9,Synthetic,Synthetic peptide,,,HLA-A*02,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,ALVDTLTGI
ALLEMFPEITV,11,Synthetic,Synthetic peptide,,,HLA-A*02,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,ALLEMFPEITV
LMAFFLAVV,9,Synthetic,Synthetic peptide,,,HLA-A*02,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,LMAFFLAVV
SVASVLLYL,9,Synthetic,Synthetic peptide,,,HLA-A*02,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,SVASVLLYL
VLQPFLPSI,9,Synthetic,Synthetic peptide,,,HLA-A*02,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,VLQPFLPSI
FLSTVTSV,8,Synthetic,Synthetic peptide,,,HLA-A*02,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,FLSTVTSV
GLDGSLVFL,9,Synthetic,Synthetic peptide,,,HLA-A*02,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,GLDGSLVFL
FLGTTPTL,8,Synthetic,Synthetic peptide,,,HLA-A*02,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,FLGTTPTL
VLYDKDAVYV,10,Synthetic,Synthetic peptide,,,HLA-A*02,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,VLYDKDAVYV
NLWGGQGLLGV,11,Synthetic,Synthetic peptide,,,HLA-A*02,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,NLWGGQGLLGV
LLKEFVQRV,9,Synthetic,Synthetic peptide,,,HLA-A*02,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,LLKEFVQRV
ALWLVDPLTV,10,Synthetic,Synthetic peptide,,,HLA-A*02,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,ALWLVDPLTV
MTLPVDAVISV,11,Synthetic,Synthetic peptide,,,HLA-A*02,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,MTLPVDAVISV
AAEIGDKSWLY,11,Synthetic,Synthetic peptide,,,HLA-A*01,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,AAEIGDKSWLY
ASEDSVLLY,9,Synthetic,Synthetic peptide,,,HLA-A*01,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,ASEDSVLLY
ATDLVVLDRY,10,Synthetic,Synthetic peptide,,,HLA-A*01,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,ATDLVVLDRY
ATSKFMEFY,9,Synthetic,Synthetic peptide,,,HLA-A*01,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,ATSKFMEFY
DSDSCHFNY,9,Synthetic,Synthetic peptide,,,HLA-A*01,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,DSDSCHFNY
ECDMAFHIY,9,Synthetic,Synthetic peptide,,,HLA-A*01,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,ECDMAFHIY
ESDREELNY,9,Synthetic,Synthetic peptide,,,HLA-A*01,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,ESDREELNY
ESDVGVVVY,9,Synthetic,Synthetic peptide,,,HLA-A*01,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,ESDVGVVVY
EVAEPSVLFDLY,12,Synthetic,Synthetic peptide,,,HLA-A*01,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,EVAEPSVLFDLY
FIDYPKKEDY,10,Synthetic,Synthetic peptide,,,HLA-A*01,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,FIDYPKKEDY
FLDSQNLSAY,10,Synthetic,Synthetic peptide,,,HLA-A*01,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,FLDSQNLSAY
FVDKPVAY,8,Synthetic,Synthetic peptide,,,HLA-A*01,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,FVDKPVAY
GLNTGSALSY,10,Synthetic,Synthetic peptide,,,HLA-A*01/B*15,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,GLNTGSALSY
GSSDSSTLPKL,11,Synthetic,Synthetic peptide,,,HLA-A*01,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,GSSDSSTLPKL
GTEFTTILY,9,Synthetic,Synthetic peptide,,,HLA-A*01,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,GTEFTTILY
GTEFTTVLY,9,Synthetic,Synthetic peptide,,,HLA-A*01,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,GTEFTTVLY
GTELLSLVY,9,Synthetic,Synthetic peptide,,,HLA-A*01,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,GTELLSLVY
HSDLKVGEY,9,Synthetic,Synthetic peptide,,,HLA-A*01,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,HSDLKVGEY
HTDSLHLLI,9,Synthetic,Synthetic peptide,,,HLA-A*01,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,HTDSLHLLI
KLDRSVFTAY,10,Synthetic,Synthetic peptide,,,HLA-A*01,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,KLDRSVFTAY
LLDISQKNLY,10,Synthetic,Synthetic peptide,,,HLA-A*01,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,LLDISQKNLY
LLDPNPHMY,9,Synthetic,Synthetic peptide,,,HLA-A*01,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,LLDPNPHMY
LLDSLREQY,9,Synthetic,Synthetic peptide,,,HLA-A*01,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,LLDSLREQY
LMDRPIFY,8,Synthetic,Synthetic peptide,,,HLA-A*01,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,LMDRPIFY
LSDLLKQGY,9,Synthetic,Synthetic peptide,,,HLA-A*01,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,LSDLLKQGY
LSDTSVIQFY,10,Synthetic,Synthetic peptide,,,HLA-A*01,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,LSDTSVIQFY
LTEAVLNRY,9,Synthetic,Synthetic peptide,,,HLA-A*01,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,LTEAVLNRY
LVDDGTHGQY,10,Synthetic,Synthetic peptide,,,HLA-A*01,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,LVDDGTHGQY
LVDNSIRELQY,11,Synthetic,Synthetic peptide,,,HLA-A*01,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,LVDNSIRELQY
NSDSSLTLREFY,12,Synthetic,Synthetic peptide,,,HLA-A*01,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,NSDSSLTLREFY
NTDNNLAVY,9,Synthetic,Synthetic peptide,,,HLA-A*01,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,NTDNNLAVY
NTDPTAPPY,9,Synthetic,Synthetic peptide,,,HLA-A*01,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,NTDPTAPPY
NTQITDIGRY,10,Synthetic,Synthetic peptide,,,HLA-A*01,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,NTQITDIGRY
QSDPGTSVLGY,11,Synthetic,Synthetic peptide,,,HLA-A*01,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,QSDPGTSVLGY
QTDHPQPILDRY,12,Synthetic,Synthetic peptide,,,HLA-A*01,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,QTDHPQPILDRY
RLDTPLYFSY,10,Synthetic,Synthetic peptide,,,HLA-A*01,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,RLDTPLYFSY
RSDDTAVYY,9,Synthetic,Synthetic peptide,,,HLA-A*01,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,RSDDTAVYY
RSDPVTLNVLY,11,Synthetic,Synthetic peptide,,,HLA-A*01,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,RSDPVTLNVLY
RTDSCSSAQAQY,12,Synthetic,Synthetic peptide,,,HLA-A*01,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,RTDSCSSAQAQY
RTEFNLNQY,9,Synthetic,Synthetic peptide,,,HLA-A*01,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,RTEFNLNQY
SADDIRGIQSLY,12,Synthetic,Synthetic peptide,,,HLA-A*01,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,SADDIRGIQSLY
SDVTPLTF,8,Synthetic,Synthetic peptide,,,HLA-A*01,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,SDVTPLTF
SRTINVSNLY,10,Synthetic,Synthetic peptide,,,HLA-A*01,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,SRTINVSNLY
SSDEVNFLVY,10,Synthetic,Synthetic peptide,,,HLA-A*01,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,SSDEVNFLVY
SSDSSTLPKL,10,Synthetic,Synthetic peptide,,,HLA-A*01/C*12,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,SSDSSTLPKL
STAKSATWTY,10,Synthetic,Synthetic peptide,,,HLA-A*01,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,STAKSATWTY
STDPWIQMAY,10,Synthetic,Synthetic peptide,,,HLA-A*01,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,STDPWIQMAY
TADGKTYYY,9,Synthetic,Synthetic peptide,,,HLA-A*01,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,TADGKTYYY
TDYHVRVY,8,Synthetic,Synthetic peptide,,,HLA-A*01,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,TDYHVRVY
TLEDIATSHLY,11,Synthetic,Synthetic peptide,,,HLA-A*01,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,TLEDIATSHLY
TSAHPEDSSFY,11,Synthetic,Synthetic peptide,,,HLA-A*01,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,TSAHPEDSSFY
TSDSNLNKY,9,Synthetic,Synthetic peptide,,,HLA-A*01,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,TSDSNLNKY
TTDIIEKY,8,Synthetic,Synthetic peptide,,,HLA-A*01,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,TTDIIEKY
VADLHLYLY,9,Synthetic,Synthetic peptide,,,HLA-A*01,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,VADLHLYLY
VSDAKLDKY,9,Synthetic,Synthetic peptide,,,HLA-A*01,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,VSDAKLDKY
VSDSECLSRY,10,Synthetic,Synthetic peptide,,,HLA-A*01,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,VSDSECLSRY
VTDGINPLIDRY,12,Synthetic,Synthetic peptide,,,HLA-A*01,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,VTDGINPLIDRY
VTDGSLYEGVAY,12,Synthetic,Synthetic peptide,,,HLA-A*01,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,VTDGSLYEGVAY
VTEESFDSKFY,11,Synthetic,Synthetic peptide,,,HLA-A*01,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,VTEESFDSKFY
VTEFSLNTY,9,Synthetic,Synthetic peptide,,,HLA-A*01,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,VTEFSLNTY
VVADTKMIEY,10,Synthetic,Synthetic peptide,,,HLA-A*01,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,VVADTKMIEY
VVDSVGGYLY,10,Synthetic,Synthetic peptide,,,HLA-A*01,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,VVDSVGGYLY
WMFFVINY,8,Synthetic,Synthetic peptide,,,HLA-A*01,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,WMFFVINY
YADTVRPEFY,10,Synthetic,Synthetic peptide,,,HLA-A*01,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,YADTVRPEFY
YLDPVQRDLY,10,Synthetic,Synthetic peptide,,,HLA-A*01,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,YLDPVQRDLY
YLPQHTIETY,10,Synthetic,Synthetic peptide,,,HLA-A*01/B*15,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,YLPQHTIETY
YSDEDVTKY,9,Synthetic,Synthetic peptide,,,HLA-A*01,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,YSDEDVTKY
YVGKEHMFY,9,Synthetic,Synthetic peptide,,,HLA-A*01,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,YVGKEHMFY
KLAELEGALQK,11,Synthetic,Synthetic peptide,,,HLA-A*03,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,KLAELEGALQK
KVKDTPGLGK,10,Synthetic,Synthetic peptide,,,HLA-A*03,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,KVKDTPGLGK
AVFDKFIRY,9,Synthetic,Synthetic peptide,,,HLA-A*03,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,AVFDKFIRY
SLDGAARPK,9,Synthetic,Synthetic peptide,,,HLA-A*03,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,SLDGAARPK
KLIDLSQVMY,10,Synthetic,Synthetic peptide,,,HLA-A*03/B*15,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,KLIDLSQVMY
RSFNGLLTMY,10,Synthetic,Synthetic peptide,,,HLA-A*03/B*15,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,RSFNGLLTMY
GLASRILDAK,10,Synthetic,Synthetic peptide,,,HLA-A*03,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,GLASRILDAK
RTQIPMSEK,9,Synthetic,Synthetic peptide,,,HLA-A*03,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,RTQIPMSEK
ATSGVPVYK,9,Synthetic,Synthetic peptide,,,HLA-A*03,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,ATSGVPVYK
TVNPVAIHK,9,Synthetic,Synthetic peptide,,,HLA-A*03,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,TVNPVAIHK
KAYEQVMHY,9,Synthetic,Synthetic peptide,,,HLA-A*03,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,KAYEQVMHY
LNINMTSPMGTK,12,Synthetic,Synthetic peptide,,,HLA-A*03,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,LNINMTSPMGTK
RTMSEAALVRK,11,Synthetic,Synthetic peptide,,,HLA-A*03,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,RTMSEAALVRK
MMFSGPQILKL,11,Synthetic,Synthetic peptide,,,HLA-A*03/A*32,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,MMFSGPQILKL
KLYAWELAF,9,Synthetic,Synthetic peptide,,,HLA-A*03/A*32,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,KLYAWELAF
RILNQILYY,9,Synthetic,Synthetic peptide,,,HLA-A*03,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,RILNQILYY
KTLVAELLILK,11,Synthetic,Synthetic peptide,,,HLA-A*03,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,KTLVAELLILK
RLRSSLVFK,9,Synthetic,Synthetic peptide,,,HLA-A*03,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,RLRSSLVFK
SPSVSQLSVL,10,Synthetic,Synthetic peptide,,,HLA-B*07,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,SPSVSQLSVL
VPDVAQFVL,9,Synthetic,Synthetic peptide,,,HLA-B*07,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,VPDVAQFVL
NPFYPEVEL,9,Synthetic,Synthetic peptide,,,HLA-B*07,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,NPFYPEVEL
YPKDIYSSF,9,Synthetic,Synthetic peptide,,,HLA-B*07,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,YPKDIYSSF
GPQPWHAAL,9,Synthetic,Synthetic peptide,,,HLA-B*07,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,GPQPWHAAL
LPFDGPGGIL,10,Synthetic,Synthetic peptide,,,HLA-B*07,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,LPFDGPGGIL
SPRMSGLLSQT,11,Synthetic,Synthetic peptide,,,HLA-B*07,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,SPRMSGLLSQT
YPRGNHWAVGH,11,Synthetic,Synthetic peptide,,,HLA-B*07,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,YPRGNHWAVGH
YPRGNHWAVGHL,12,Synthetic,Synthetic peptide,,,HLA-B*07,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,YPRGNHWAVGHL
VPLPAGGGTV,10,Synthetic,Synthetic peptide,,,HLA-B*07,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,VPLPAGGGTV
VPLPAGGGTVL,11,Synthetic,Synthetic peptide,,,HLA-B*07,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,VPLPAGGGTVL
RPRALRDLQL,10,Synthetic,Synthetic peptide,,,HLA-B*07,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,RPRALRDLQL
RPRALRDLQLL,11,Synthetic,Synthetic peptide,,,HLA-B*07,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,RPRALRDLQLL
KPYQGNPTF,9,Synthetic,Synthetic peptide,,,HLA-B*07,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,KPYQGNPTF
RAKNAGVTI,9,Synthetic,Synthetic peptide,,,HLA-B*07,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,RAKNAGVTI
MPLKHYLLL,9,Synthetic,Synthetic peptide,,,HLA-B*07,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,MPLKHYLLL
RVRGGEDGDRAL,12,Synthetic,Synthetic peptide,,,HLA-B*07,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,RVRGGEDGDRAL
RPAATAVISL,10,Synthetic,Synthetic peptide,,,HLA-B*07,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,RPAATAVISL
KPGPPWAAF,9,Synthetic,Synthetic peptide,,,HLA-B*07,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,KPGPPWAAF
YVPSASLFM,9,Synthetic,Synthetic peptide,,,HLA-B*07,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,YVPSASLFM
LSPREVTTVL,10,Synthetic,Synthetic peptide,,,HLA-B*07,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,LSPREVTTVL
SARLATDAL,9,Synthetic,Synthetic peptide,,,HLA-B*07,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,SARLATDAL
SPRWLPVSL,9,Synthetic,Synthetic peptide,,,HLA-B*07,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,SPRWLPVSL
RPIENRILIL,10,Synthetic,Synthetic peptide,,,HLA-B*07,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,RPIENRILIL
FPYVRDFVM,9,Synthetic,Synthetic peptide,,,HLA-B*07/B*35,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,FPYVRDFVM
RIREHVPQL,9,Synthetic,Synthetic peptide,,,HLA-B*07,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,RIREHVPQL
TPLPAVIVL,9,Synthetic,Synthetic peptide,,,HLA-B*07,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,TPLPAVIVL
RALLARLLL,9,Synthetic,Synthetic peptide,,,HLA-B*07,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,RALLARLLL
IPNWARQDL,9,Synthetic,Synthetic peptide,,,HLA-B*07,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,IPNWARQDL
VPSSRILQL,9,Synthetic,Synthetic peptide,,,HLA-B*07,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,VPSSRILQL
SPRDFLSGL,9,Synthetic,Synthetic peptide,,,HLA-B*07,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,SPRDFLSGL
VPRSSGQTV,9,Synthetic,Synthetic peptide,,,HLA-B*07,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,VPRSSGQTV
SPDIRNTTV,9,Synthetic,Synthetic peptide,,,HLA-B*07,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,SPDIRNTTV
RVIDAVRFTL,10,Synthetic,Synthetic peptide,,,HLA-B*07,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,RVIDAVRFTL
NPFPHLITL,9,Synthetic,Synthetic peptide,,,HLA-B*07,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,NPFPHLITL
MPLLENLYL,9,Synthetic,Synthetic peptide,,,HLA-B*07,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,MPLLENLYL
SPRVPSIEL,9,Synthetic,Synthetic peptide,,,HLA-B*07,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,SPRVPSIEL
LPRIPFADV,9,Synthetic,Synthetic peptide,,,HLA-B*07,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,LPRIPFADV
LPRGPLASL,9,Synthetic,Synthetic peptide,,,HLA-B*07,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,LPRGPLASL
RPPAAGLRGISL,12,Synthetic,Synthetic peptide,,,HLA-B*07,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,RPPAAGLRGISL
YPQHPGLNA,9,Synthetic,Synthetic peptide,,,HLA-B*07,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,YPQHPGLNA
APSARVGVC,9,Synthetic,Synthetic peptide,,,HLA-B*07,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,APSARVGVC
SAYPQRLEI,9,Synthetic,Synthetic peptide,,,HLA-B*07/B*51,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,SAYPQRLEI
HPAPYGDLL,9,Synthetic,Synthetic peptide,,,HLA-B*07,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,HPAPYGDLL
RPILIIITL,9,Synthetic,Synthetic peptide,,,HLA-B*07,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,RPILIIITL
SPRQPPRLV,9,Synthetic,Synthetic peptide,,,HLA-B*07,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,SPRQPPRLV
HAYPPGPGL,9,Synthetic,Synthetic peptide,,,HLA-B*07/C*03,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,HAYPPGPGL
HPELVNHIVF,10,Synthetic,Synthetic peptide,,,HLA-B*07/B*35,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,HPELVNHIVF
YPLFRGINL,9,Synthetic,Synthetic peptide,,,HLA-B*07,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,YPLFRGINL
APRAPRLML,9,Synthetic,Synthetic peptide,,,HLA-B*07,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,APRAPRLML
APGPRFLVT,9,Synthetic,Synthetic peptide,,,HLA-B*07,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,APGPRFLVT
MPLPWSLALP,10,Synthetic,Synthetic peptide,,,HLA-B*07/B*35,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,MPLPWSLALP
MPLPWSLALPL,11,Synthetic,Synthetic peptide,,,HLA-B*07,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,MPLPWSLALPL
MPLLWLRGF,9,Synthetic,Synthetic peptide,,,HLA-B*07/B*35,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,MPLLWLRGF
TPYQEHVAL,9,Synthetic,Synthetic peptide,,,HLA-B*07/B*35,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,TPYQEHVAL
APHPPLSVV,9,Synthetic,Synthetic peptide,,,HLA-B*07,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,APHPPLSVV
LPRAGGAFL,9,Synthetic,Synthetic peptide,,,HLA-B*07,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,LPRAGGAFL
MPLFEPRVF,9,Synthetic,Synthetic peptide,,,HLA-B*07/B*35,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,MPLFEPRVF
HPMIDINGIIVF,12,Synthetic,Synthetic peptide,,,HLA-B*07/B*35,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,HPMIDINGIIVF
SPARASPAL,9,Synthetic,Synthetic peptide,,,HLA-B*07,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,SPARASPAL
VPISEEGTPVL,11,Synthetic,Synthetic peptide,,,HLA-B*07,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,VPISEEGTPVL
RPRAPVTPA,9,Synthetic,Synthetic peptide,,,HLA-B*07,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,RPRAPVTPA
MPQIETRVIL,10,Synthetic,Synthetic peptide,,,HLA-B*07,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,MPQIETRVIL
RPHSLSSEL,9,Synthetic,Synthetic peptide,,,HLA-B*07,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,RPHSLSSEL
FPVTSIFHTF,10,Synthetic,Synthetic peptide,,,HLA-B*07/B*35,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,FPVTSIFHTF
FPSFLTNSL,9,Synthetic,Synthetic peptide,,,HLA-B*07/B*35,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,FPSFLTNSL
VPTLRSEL,8,Synthetic,Synthetic peptide,,,HLA-B*07,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,VPTLRSEL
APREEQQRSL,10,Synthetic,Synthetic peptide,,,HLA-B*07,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,APREEQQRSL
FPQKFIDLL,9,Synthetic,Synthetic peptide,,,HLA-B*07,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,FPQKFIDLL
VPENHSVAL,9,Synthetic,Synthetic peptide,,,HLA-B*07,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,VPENHSVAL
APYRPPDISL,10,Synthetic,Synthetic peptide,,,HLA-B*07,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,APYRPPDISL
SPQRLRGLL,9,Synthetic,Synthetic peptide,,,HLA-B*07,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,SPQRLRGLL
SPQRLRGLLL,10,Synthetic,Synthetic peptide,,,HLA-B*07,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,SPQRLRGLLL
RPRSALPRLLLP,12,Synthetic,Synthetic peptide,,,HLA-B*07,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,RPRSALPRLLLP
GPTPNTGAAL,10,Synthetic,Synthetic peptide,,,HLA-B*07,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,GPTPNTGAAL
KPEGTRIAV,9,Synthetic,Synthetic peptide,,,HLA-B*07,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,KPEGTRIAV
MPMQDIKM,8,Synthetic,Synthetic peptide,,,HLA-B*08,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,MPMQDIKM
RAQLKLVAL,9,Synthetic,Synthetic peptide,,,HLA-B*08,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,RAQLKLVAL
FNKRKPLSL,9,Synthetic,Synthetic peptide,,,HLA-B*08,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,FNKRKPLSL
MAQFKEISL,9,Synthetic,Synthetic peptide,,,HLA-B*08,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,MAQFKEISL
VASPKHCVL,9,Synthetic,Synthetic peptide,,,HLA-B*08,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,VASPKHCVL
YMHKLLVL,8,Synthetic,Synthetic peptide,,,HLA-B*08/B*35,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,YMHKLLVL
HLLQKQTSI,9,Synthetic,Synthetic peptide,,,HLA-B*08,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,HLLQKQTSI
LPFPKFTV,8,Synthetic,Synthetic peptide,,,HLA-B*08,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,LPFPKFTV
ELKKLYCQI,9,Synthetic,Synthetic peptide,,,HLA-B*08,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,ELKKLYCQI
ALKLRVAVL,9,Synthetic,Synthetic peptide,,,HLA-B*08,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,ALKLRVAVL
ILKVKVGL,8,Synthetic,Synthetic peptide,,,HLA-B*08,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,ILKVKVGL
ILLPRTVSL,9,Synthetic,Synthetic peptide,,,HLA-B*08,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,ILLPRTVSL
MLKQKVEEL,9,Synthetic,Synthetic peptide,,,HLA-B*08,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,MLKQKVEEL
DAIQRKYSC,9,Synthetic,Synthetic peptide,,,HLA-B*08,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,DAIQRKYSC
LPPKKFVL,8,Synthetic,Synthetic peptide,,,HLA-B*08,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,LPPKKFVL
EIRIRVVQM,9,Synthetic,Synthetic peptide,,,HLA-B*08,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,EIRIRVVQM
EAMLRNKEL,9,Synthetic,Synthetic peptide,,,HLA-B*08,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,EAMLRNKEL
ELKKKEYEEL,10,Synthetic,Synthetic peptide,,,HLA-B*08,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,ELKKKEYEEL
AIISRLVAL,9,Synthetic,Synthetic peptide,,,HLA-B*08,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,AIISRLVAL
DIYQRALNL,9,Synthetic,Synthetic peptide,,,HLA-B*08,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,DIYQRALNL
VIKEKALTL,9,Synthetic,Synthetic peptide,,,HLA-B*08,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,VIKEKALTL
LVKVKVLL,8,Synthetic,Synthetic peptide,,,HLA-B*08,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,LVKVKVLL
EAAIRSVEL,9,Synthetic,Synthetic peptide,,,HLA-B*08,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,EAAIRSVEL
AEMLERVIKNY,11,Synthetic,Synthetic peptide,,,HLA-B*44,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,AEMLERVIKNY
MEVDPIGHVYIF,12,Synthetic,Synthetic peptide,,,HLA-B*44,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,MEVDPIGHVYIF
AEMLESVIKNY,11,Synthetic,Synthetic peptide,,,HLA-B*44,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,AEMLESVIKNY
KEVDPAGHSY,10,Synthetic,Synthetic peptide,,,HLA-B*44,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,KEVDPAGHSY
SEFMQVIF,8,Synthetic,Synthetic peptide,,,HLA-B*44,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,SEFMQVIF
TDSIHAWTF,9,Synthetic,Synthetic peptide,,,HLA-B*44/B*18,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,TDSIHAWTF
QEQDVDLVQKY,11,Synthetic,Synthetic peptide,,,HLA-B*44,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,QEQDVDLVQKY
QEMQHFLGL,9,Synthetic,Synthetic peptide,,,HLA-B*44,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,QEMQHFLGL
YEIEARNQVF,10,Synthetic,Synthetic peptide,,,HLA-B*44/B*18,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,YEIEARNQVF
FEYDFLLQRI,10,Synthetic,Synthetic peptide,,,HLA-B*44,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,FEYDFLLQRI
NEHPSNNW,8,Synthetic,Synthetic peptide,,,HLA-B*44,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,NEHPSNNW
KEGDLGGKQW,10,Synthetic,Synthetic peptide,,,HLA-B*44,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,KEGDLGGKQW
EDAQGHIW,8,Synthetic,Synthetic peptide,,,HLA-B*44,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,EDAQGHIW
MEVPVIKI,8,Synthetic,Synthetic peptide,,,HLA-B*44,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,MEVPVIKI
AETLSTIQI,9,Synthetic,Synthetic peptide,,,HLA-B*44,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,AETLSTIQI
AEDEPAAAHL,10,Synthetic,Synthetic peptide,,,HLA-B*44,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,AEDEPAAAHL
KELEATKQY,9,Synthetic,Synthetic peptide,,,HLA-B*44,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,KELEATKQY
ASSSGPMRWW,10,Synthetic,Synthetic peptide,,,HLA-B*44/B*57,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,ASSSGPMRWW
TENRYCVQL,9,Synthetic,Synthetic peptide,,,HLA-B*44,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,TENRYCVQL
SEGSEPALLHSW,12,Synthetic,Synthetic peptide,,,HLA-B*44,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,SEGSEPALLHSW
SEPALLHSW,9,Synthetic,Synthetic peptide,,,HLA-B*44,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,SEPALLHSW
TEFSLNTY,8,Synthetic,Synthetic peptide,,,HLA-B*44,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,TEFSLNTY
EEIEGKGSFTYF,12,Synthetic,Synthetic peptide,,,HLA-B*44,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,EEIEGKGSFTYF
HEFSSPSHL,9,Synthetic,Synthetic peptide,,,HLA-B*44,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,HEFSSPSHL
TEFTTVLY,8,Synthetic,Synthetic peptide,,,HLA-B*44,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,TEFTTVLY
EEATGQFHVY,10,Synthetic,Synthetic peptide,,,HLA-B*44,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,EEATGQFHVY
IEFIHPQAF,9,Synthetic,Synthetic peptide,,,HLA-B*44,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,IEFIHPQAF
VEAPGPVHVYW,11,Synthetic,Synthetic peptide,,,HLA-B*44,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,VEAPGPVHVYW
ALNPYQYQY,9,Synthetic,Synthetic peptide,,,HLA-B*44/A*29,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,ALNPYQYQY
AEIQGNINHV,10,Synthetic,Synthetic peptide,,,HLA-B*44,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,AEIQGNINHV
AEQDMRELTY,10,Synthetic,Synthetic peptide,,,HLA-B*44,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,AEQDMRELTY
GECDVFKEIL,10,Synthetic,Synthetic peptide,,,HLA-B*44,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,GECDVFKEIL
EEVNYINTF,9,Synthetic,Synthetic peptide,,,HLA-B*44,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,EEVNYINTF
NEVLTYIKF,9,Synthetic,Synthetic peptide,,,HLA-B*44,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,NEVLTYIKF
GEIIMQNNW,9,Synthetic,Synthetic peptide,,,HLA-B*44,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,GEIIMQNNW
TEDPTILRI,9,Synthetic,Synthetic peptide,,,HLA-B*44,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,TEDPTILRI
SDMVRFHLF,9,Synthetic,Synthetic peptide,,,HLA-B*44,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,SDMVRFHLF
EEGRVYLF,8,Synthetic,Synthetic peptide,,,HLA-B*44,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,EEGRVYLF
RELENCFQIQ,10,Synthetic,Synthetic peptide,,,HLA-B*44,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,RELENCFQIQ
KEADIHFLI,9,Synthetic,Synthetic peptide,,,HLA-B*44,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,KEADIHFLI
DELFSIALY,9,Synthetic,Synthetic peptide,,,HLA-B*44,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,DELFSIALY
AEVPTGVII,9,Synthetic,Synthetic peptide,,,HLA-B*44,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,AEVPTGVII
SENLFFASF,9,Synthetic,Synthetic peptide,,,HLA-B*44,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,SENLFFASF
SEKGVIQVY,9,Synthetic,Synthetic peptide,,,HLA-B*44,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,SEKGVIQVY
AELDKLTSV,9,Synthetic,Synthetic peptide,,,HLA-B*44,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,AELDKLTSV
AETPIQNVI,9,Synthetic,Synthetic peptide,,,HLA-B*44,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,AETPIQNVI
SEMNVNMKY,9,Synthetic,Synthetic peptide,,,HLA-B*44,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,SEMNVNMKY
AENLFRAF,8,Synthetic,Synthetic peptide,,,HLA-B*44,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,AENLFRAF
GEVHPSEMI,9,Synthetic,Synthetic peptide,,,HLA-B*44,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,GEVHPSEMI
GEFPVRVQV,9,Synthetic,Synthetic peptide,,,HLA-B*44,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,GEFPVRVQV
EEIERFFKL,9,Synthetic,Synthetic peptide,,,HLA-B*44,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,EEIERFFKL
YEDLSQKY,8,Synthetic,Synthetic peptide,,,HLA-B*44,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,YEDLSQKY
GELALKKKI,9,Synthetic,Synthetic peptide,,,HLA-B*44,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,GELALKKKI
TEGIIMKDF,9,Synthetic,Synthetic peptide,,,HLA-B*44,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,TEGIIMKDF
MEMQKSPVF,9,Synthetic,Synthetic peptide,,,HLA-B*44,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,MEMQKSPVF
DEVNFLVY,8,Synthetic,Synthetic peptide,,,HLA-B*44/B*18,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,DEVNFLVY
VYSDLHAFYY,10,Synthetic,Synthetic peptide,,,HLA-A*24,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,VYSDLHAFYY
KYVKDFHKF,9,Synthetic,Synthetic peptide,,,HLA-A*24,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,KYVKDFHKF
VYVGAVNRI,9,Synthetic,Synthetic peptide,,,HLA-A*24,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,VYVGAVNRI
KFLGPAEHLTF,11,Synthetic,Synthetic peptide,,,HLA-A*24,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,KFLGPAEHLTF
NYIVPDKQIF,10,Synthetic,Synthetic peptide,,,HLA-A*24,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,NYIVPDKQIF
VFQEKHHVI,9,Synthetic,Synthetic peptide,,,HLA-A*24,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,VFQEKHHVI
TYSKKHFRI,9,Synthetic,Synthetic peptide,,,HLA-A*24,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,TYSKKHFRI
IYHSHHPTL,9,Synthetic,Synthetic peptide,,,HLA-A*24,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,IYHSHHPTL
RYKQDVERF,9,Synthetic,Synthetic peptide,,,HLA-A*24,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,RYKQDVERF
KYVKVFDKF,9,Synthetic,Synthetic peptide,,,HLA-A*24,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,KYVKVFDKF
MYINEVERL,9,Synthetic,Synthetic peptide,,,HLA-A*24,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,MYINEVERL
VYNDHSIYVW,10,Synthetic,Synthetic peptide,,,HLA-A*24,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,VYNDHSIYVW
RWLPQKNAAQF,11,Synthetic,Synthetic peptide,,,HLA-A*24,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,RWLPQKNAAQF
FSIPEGALVAV,11,Synthetic,Synthetic peptide,,,HLA-A*02,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,FSIPEGALVAV
TLMEQPLTTL,10,Synthetic,Synthetic peptide,,,HLA-A*02,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,TLMEQPLTTL
HIMPTVHTV,9,Synthetic,Synthetic peptide,,,HLA-A*02,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,HIMPTVHTV
SLIDMRGIETV,11,Synthetic,Synthetic peptide,,,HLA-A*02,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,SLIDMRGIETV
SLFKDQMEL,9,Synthetic,Synthetic peptide,,,HLA-A*02,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,SLFKDQMEL
ILLPYLQTL,9,Synthetic,Synthetic peptide,,,HLA-A*02,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,ILLPYLQTL
ASEAEMRLFY,10,Synthetic,Synthetic peptide,,,HLA-A*01,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,ASEAEMRLFY
ASEASRLAHY,10,Synthetic,Synthetic peptide,,,HLA-A*01,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,ASEASRLAHY
ASEFGNHYLY,10,Synthetic,Synthetic peptide,,,HLA-A*01,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,ASEFGNHYLY
ASEITSKGASLY,12,Synthetic,Synthetic peptide,,,HLA-A*01,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,ASEITSKGASLY
ASEQQALHTVQY,12,Synthetic,Synthetic peptide,,,HLA-A*01,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,ASEQQALHTVQY
ATDIPCLLY,9,Synthetic,Synthetic peptide,,,HLA-A*01,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,ATDIPCLLY
ATDISRQNEY,10,Synthetic,Synthetic peptide,,,HLA-A*01,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,ATDISRQNEY
DSDESYMEKSLY,12,Synthetic,Synthetic peptide,,,HLA-A*01,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,DSDESYMEKSLY
DTDSQRLAY,9,Synthetic,Synthetic peptide,,,HLA-A*01,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,DTDSQRLAY
ELDSKVEVLTY,11,Synthetic,Synthetic peptide,,,HLA-A*01,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,ELDSKVEVLTY
ETARKFLYY,9,Synthetic,Synthetic peptide,,,HLA-A*01,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,ETARKFLYY
ETEEGIYWRY,10,Synthetic,Synthetic peptide,,,HLA-A*01,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,ETEEGIYWRY
ETEQTKFWDY,10,Synthetic,Synthetic peptide,,,HLA-A*01,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,ETEQTKFWDY
FSDNDKLYLY,10,Synthetic,Synthetic peptide,,,HLA-A*01,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,FSDNDKLYLY
FTEQWTDGY,9,Synthetic,Synthetic peptide,,,HLA-A*01,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,FTEQWTDGY
FVDPLVTNY,9,Synthetic,Synthetic peptide,,,HLA-A*01,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,FVDPLVTNY
GSDHQSPSSSSY,12,Synthetic,Synthetic peptide,,,HLA-A*01,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,GSDHQSPSSSSY
GTVYEDLRY,9,Synthetic,Synthetic peptide,,,HLA-A*01,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,GTVYEDLRY
ILDEVIMGY,9,Synthetic,Synthetic peptide,,,HLA-A*01,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,ILDEVIMGY
ISDRYYTALY,10,Synthetic,Synthetic peptide,,,HLA-A*01,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,ISDRYYTALY
KTDESLTKY,9,Synthetic,Synthetic peptide,,,HLA-A*01,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,KTDESLTKY
LLDPRSYHTY,10,Synthetic,Synthetic peptide,,,HLA-A*01,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,LLDPRSYHTY
LLDTAQKNLY,10,Synthetic,Synthetic peptide,,,HLA-A*01,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,LLDTAQKNLY
LLEDKHFQSY,10,Synthetic,Synthetic peptide,,,HLA-A*01,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,LLEDKHFQSY
LSDPSGPKSY,10,Synthetic,Synthetic peptide,,,HLA-A*01,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,LSDPSGPKSY
LSELKPMSY,9,Synthetic,Synthetic peptide,,,HLA-A*01,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,LSELKPMSY
LTEDKETLQY,10,Synthetic,Synthetic peptide,,,HLA-A*01,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,LTEDKETLQY
LTELLERAAFY,11,Synthetic,Synthetic peptide,,,HLA-A*01,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,LTELLERAAFY
MIDVTKSYY,9,Synthetic,Synthetic peptide,,,HLA-A*01,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,MIDVTKSYY
NLDAVHDITVAY,12,Synthetic,Synthetic peptide,,,HLA-A*01,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,NLDAVHDITVAY
NLDEEKQLLY,10,Synthetic,Synthetic peptide,,,HLA-A*01,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,NLDEEKQLLY
NLDIIQQEY,9,Synthetic,Synthetic peptide,,,HLA-A*01,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,NLDIIQQEY
NLDQATRVAY,10,Synthetic,Synthetic peptide,,,HLA-A*01,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,NLDQATRVAY
NSDEQKITEMVY,12,Synthetic,Synthetic peptide,,,HLA-A*01,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,NSDEQKITEMVY
NSELSCQLY,9,Synthetic,Synthetic peptide,,,HLA-A*01,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,NSELSCQLY
NTEDSSMSGYLY,12,Synthetic,Synthetic peptide,,,HLA-A*01,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,NTEDSSMSGYLY
NTEGLHHLY,9,Synthetic,Synthetic peptide,,,HLA-A*01,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,NTEGLHHLY
NTSDMMGRMSY,11,Synthetic,Synthetic peptide,,,HLA-A*01,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,NTSDMMGRMSY
NVDPVQHTY,9,Synthetic,Synthetic peptide,,,HLA-A*01,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,NVDPVQHTY
QIDTGENLY,9,Synthetic,Synthetic peptide,,,HLA-A*01,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,QIDTGENLY
QTDCAPNNGY,10,Synthetic,Synthetic peptide,,,HLA-A*01,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,QTDCAPNNGY
QTDDTWRTEY,10,Synthetic,Synthetic peptide,,,HLA-A*01,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,QTDDTWRTEY
QTETGTPYMLY,11,Synthetic,Synthetic peptide,,,HLA-A*01,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,QTETGTPYMLY
STDGKHWWEY,10,Synthetic,Synthetic peptide,,,HLA-A*01,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,STDGKHWWEY
STDNFNCKY,9,Synthetic,Synthetic peptide,,,HLA-A*01,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,STDNFNCKY
TLDAGKFQIY,10,Synthetic,Synthetic peptide,,,HLA-A*01,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,TLDAGKFQIY
TLDENPGVRY,10,Synthetic,Synthetic peptide,,,HLA-A*01,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,TLDENPGVRY
TLDSALNAASYY,12,Synthetic,Synthetic peptide,,,HLA-A*01,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,TLDSALNAASYY
TSDFSRFTNY,10,Synthetic,Synthetic peptide,,,HLA-A*01,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,TSDFSRFTNY
TTDFPSESSFEY,12,Synthetic,Synthetic peptide,,,HLA-A*01,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,TTDFPSESSFEY
TTDTVIRSY,9,Synthetic,Synthetic peptide,,,HLA-A*01,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,TTDTVIRSY
VLDQGKITEY,10,Synthetic,Synthetic peptide,,,HLA-A*01,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,VLDQGKITEY
VTAQVVGTERY,11,Synthetic,Synthetic peptide,,,HLA-A*01,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,VTAQVVGTERY
VVDEDHELIY,10,Synthetic,Synthetic peptide,,,HLA-A*01,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,VVDEDHELIY
YLDIPNPRY,9,Synthetic,Synthetic peptide,,,HLA-A*01,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,YLDIPNPRY
YLDRGTGNVSFY,12,Synthetic,Synthetic peptide,,,HLA-A*01,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,YLDRGTGNVSFY
YSDDGQKWTVY,11,Synthetic,Synthetic peptide,,,HLA-A*01,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,YSDDGQKWTVY
YSDSLVQKGY,10,Synthetic,Synthetic peptide,,,HLA-A*01,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,YSDSLVQKGY
YVDAVLGKGHQY,12,Synthetic,Synthetic peptide,,,HLA-A*01,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,YVDAVLGKGHQY
AINTSIKNK,9,Synthetic,Synthetic peptide,,,HLA-A*03,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,AINTSIKNK
KVYTPSISK,9,Synthetic,Synthetic peptide,,,HLA-A*03,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,KVYTPSISK
RIADIFVKK,9,Synthetic,Synthetic peptide,,,HLA-A*03,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,RIADIFVKK
SMFTAILKK,9,Synthetic,Synthetic peptide,,,HLA-A*03,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,SMFTAILKK
SINKPTSER,9,Synthetic,Synthetic peptide,,,HLA-A*03,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,SINKPTSER
GIADFVLKY,9,Synthetic,Synthetic peptide,,,HLA-A*03,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,GIADFVLKY
RPMQQARAQL,10,Synthetic,Synthetic peptide,,,HLA-B*07,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,RPMQQARAQL
MPMAGDMNGL,10,Synthetic,Synthetic peptide,,,HLA-B*07,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,MPMAGDMNGL
RPILIIVTL,9,Synthetic,Synthetic peptide,,,HLA-B*07,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,RPILIIVTL
RPFHTRATV,9,Synthetic,Synthetic peptide,,,HLA-B*07,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,RPFHTRATV
TPKAGPTL,8,Synthetic,Synthetic peptide,,,HLA-B*07,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,TPKAGPTL
YPRPGTPAA,9,Synthetic,Synthetic peptide,,,HLA-B*07,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,YPRPGTPAA
VPRPIFSQL,9,Synthetic,Synthetic peptide,,,HLA-B*07,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,VPRPIFSQL
APYKSVTSL,9,Synthetic,Synthetic peptide,,,HLA-B*07,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,APYKSVTSL
KPFSSFTSM,9,Synthetic,Synthetic peptide,,,HLA-B*07,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,KPFSSFTSM
SPMYGQAGL,9,Synthetic,Synthetic peptide,,,HLA-B*07,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,SPMYGQAGL
YPENGVVQM,9,Synthetic,Synthetic peptide,,,HLA-B*07,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,YPENGVVQM
SPNSYFRVL,9,Synthetic,Synthetic peptide,,,HLA-B*07,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,SPNSYFRVL
KPRPDVTNEL,10,Synthetic,Synthetic peptide,,,HLA-B*07,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,KPRPDVTNEL
NPRATDAQL,9,Synthetic,Synthetic peptide,,,HLA-B*07,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,NPRATDAQL
LPRALLSSL,9,Synthetic,Synthetic peptide,,,HLA-B*07,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,LPRALLSSL
LPRLLPAL,8,Synthetic,Synthetic peptide,,,HLA-B*07,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,LPRLLPAL
RPHKPGLYL,9,Synthetic,Synthetic peptide,,,HLA-B*07,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,RPHKPGLYL
AEEEIMKKI,9,Synthetic,Synthetic peptide,,,HLA-B*44,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,AEEEIMKKI
QENSYQSRL,9,Synthetic,Synthetic peptide,,,HLA-B*44,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,QENSYQSRL
SEIEQEIGSL,10,Synthetic,Synthetic peptide,,,HLA-B*44,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,SEIEQEIGSL
AEIQPQTQV,9,Synthetic,Synthetic peptide,,,HLA-B*44,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,AEIQPQTQV
GEVSGLTKDF,10,Synthetic,Synthetic peptide,,,HLA-B*44,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,GEVSGLTKDF
RELQHEHSL,9,Synthetic,Synthetic peptide,,,HLA-B*44,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,RELQHEHSL
TEREWADEW,9,Synthetic,Synthetic peptide,,,HLA-B*44,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,TEREWADEW
EENDQSTHKW,10,Synthetic,Synthetic peptide,,,HLA-B*44,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,EENDQSTHKW
AEVGFVRFF,9,Synthetic,Synthetic peptide,,,HLA-B*44,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,AEVGFVRFF
SEIEDSTKQVF,11,Synthetic,Synthetic peptide,,,HLA-B*44,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,SEIEDSTKQVF
SEDDPILQI,9,Synthetic,Synthetic peptide,,,HLA-B*44,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,SEDDPILQI
AEDQLHHSF,9,Synthetic,Synthetic peptide,,,HLA-B*44,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,AEDQLHHSF
TEFPIIKMY,9,Synthetic,Synthetic peptide,,,HLA-B*44,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,TEFPIIKMY
SEIGKAVGF,9,Synthetic,Synthetic peptide,,,HLA-B*44,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,SEIGKAVGF
SYVKVLHHL,9,Synthetic,Synthetic peptide,,,HLA-B*24,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,SYVKVLHHL
KYLEKYYNL,9,Synthetic,Synthetic peptide,,,HLA-B*24,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,KYLEKYYNL
NYEDHFPLL,9,Synthetic,Synthetic peptide,,,HLA-B*24,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,NYEDHFPLL
TYKYVDINTF,10,Synthetic,Synthetic peptide,,,HLA-B*24,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,TYKYVDINTF
RYLEKFYGL,9,Synthetic,Synthetic peptide,,,HLA-B*24,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,RYLEKFYGL
SYNDALLTF,9,Synthetic,Synthetic peptide,,,HLA-B*24,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,SYNDALLTF
VFMKDGFFYF,10,Synthetic,Synthetic peptide,,,HLA-B*24,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,VFMKDGFFYF
NYPKSIHSF,9,Synthetic,Synthetic peptide,,,HLA-B*24,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,NYPKSIHSF
EYIRALQQL,9,Synthetic,Synthetic peptide,,,HLA-B*24,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,EYIRALQQL
VYFVAPAKF,9,Synthetic,Synthetic peptide,,,HLA-B*24,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,VYFVAPAKF
VWSDVTPLTF,10,Synthetic,Synthetic peptide,,,HLA-B*24,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,VWSDVTPLTF
GYIDNVTLI,9,Synthetic,Synthetic peptide,,,HLA-B*24,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,GYIDNVTLI
SVHKITSTF,9,Synthetic,Synthetic peptide,,,HLA-B*24,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,SVHKITSTF
VHFEDTGKTLLF,12,Synthetic,Synthetic peptide,,,HLA-B*24,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,VHFEDTGKTLLF
VYEKNGYIYF,10,Synthetic,Synthetic peptide,,,HLA-B*24,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,VYEKNGYIYF
AYISGLDVF,9,Synthetic,Synthetic peptide,,,HLA-B*24,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,AYISGLDVF
RYVFPLPYL,9,Synthetic,Synthetic peptide,,,HLA-B*24,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,RYVFPLPYL
VYIAELEKI,9,Synthetic,Synthetic peptide,,,HLA-B*24,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,VYIAELEKI
IYVTGGHLF,9,Synthetic,Synthetic peptide,,,HLA-B*24,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,IYVTGGHLF
ALLEEEEGV,9,Synthetic,Synthetic peptide,,,HLA-A*02,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,ALLEEEEGV
KVLEHVVRV,9,Synthetic,Synthetic peptide,,,HLA-A*02,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,KVLEHVVRV
KIWEELSVLEV,11,Synthetic,Synthetic peptide,,,HLA-A*02,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,KIWEELSVLEV
VLGEEQEGV,9,Synthetic,Synthetic peptide,,,HLA-A*02,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,VLGEEQEGV
KLVELEHTL,9,Synthetic,Synthetic peptide,,,HLA-A*02,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,KLVELEHTL
VQLDSIEDLEV,11,Synthetic,Synthetic peptide,,,HLA-A*02,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,VQLDSIEDLEV
KIFEMLEGV,9,Synthetic,Synthetic peptide,,,HLA-A*02,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,KIFEMLEGV
YTFSGDVQL,9,Synthetic,Synthetic peptide,,,HLA-A*02,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,YTFSGDVQL
TLYNPERTITV,11,Synthetic,Synthetic peptide,,,HLA-A*02,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,TLYNPERTITV
GLLEDERALQL,11,Synthetic,Synthetic peptide,,,HLA-A*02,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,GLLEDERALQL
KIQEILTQV,9,Synthetic,Synthetic peptide,,,HLA-A*02,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,KIQEILTQV
KIQEMQHFL,9,Synthetic,Synthetic peptide,,,HLA-A*02,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,KIQEMQHFL
FVYGEPREL,9,Synthetic,Synthetic peptide,,,HLA-A*02,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,FVYGEPREL
TLDEKVAEL,9,Synthetic,Synthetic peptide,,,HLA-A*02,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,TLDEKVAEL
HLIAEIHTA,9,Synthetic,Synthetic peptide,,,HLA-A*02,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,HLIAEIHTA
KVWSDVTPL,9,Synthetic,Synthetic peptide,,,HLA-A*02,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,KVWSDVTPL
RLDDLKMTV,9,Synthetic,Synthetic peptide,,,HLA-A*02,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,RLDDLKMTV
VLSPFILTL,9,Synthetic,Synthetic peptide,,,HLA-A*02,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,VLSPFILTL
LLDSVSRL,8,Synthetic,Synthetic peptide,,,HLA-A*02,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,LLDSVSRL
RLLDSVSRL,9,Synthetic,Synthetic peptide,,,HLA-A*02,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,RLLDSVSRL
HPSAHDVIL,9,Synthetic,Synthetic peptide,,,HLA-A*07,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,HPSAHDVIL
APAAWLRSAA,10,Synthetic,Synthetic peptide,,,HLA-A*07,,,Anticancer,Cancer targeted peptides##Immunotherapeutic peptides,,Linear,,Free,Free,,,0,APAAWLRSAA
KSGIACFL,8,TRAIL (Tumor necrosis factor-related apoptosis-inducing ligand),Synthetic peptide,,,,,Induce cell death,Anticancer,Tumor active peptide##Cell death inducible peptide,,Linear,,Free,Free,,,0,KSGIACFL
GIACFLKE,8,TRAIL (Tumor necrosis factor-related apoptosis-inducing ligand),Synthetic peptide,,,,,Induce cell death,Anticancer,Tumor active peptide##Cell death inducible peptide,,Linear,,Free,Free,,,0,GIACFLKE
CWQVKWQL,8,TRAIL (Tumor necrosis factor-related apoptosis-inducing ligand),Synthetic peptide,,,,,Induce cell death,Anticancer,Tumor active peptide##Cell death inducible peptide,,Linear,,Free,Free,,,0,CWQVKWQL
NTKNDKQM,8,TRAIL (Tumor necrosis factor-related apoptosis-inducing ligand),Synthetic peptide,,,,,Induce cell death,Anticancer,Tumor active peptide##Cell death inducible peptide,,Linear,,Free,Free,,,0,NTKNDKQM
SARNSCWS,8,TRAIL (Tumor necrosis factor-related apoptosis-inducing ligand),Synthetic peptide,,,,,Induce cell death,Anticancer,Tumor active peptide##Cell death inducible peptide,,Linear,,Free,Free,,,0,SARNSCWS
RNSCWSKD,8,TRAIL (Tumor necrosis factor-related apoptosis-inducing ligand),Synthetic peptide,,,,,Induce cell death,Anticancer,Tumor active peptide##Cell death inducible peptide,,Linear,,Free,Free,,,0,RNSCWSKD
CNSCWSDK,8,TRAIL227–234,Synthetic peptide,,,,,Induce cell death,Anticancer,Tumor active peptide##Cell death inducible peptide,,Linear,,Free,Free,,,0,CNSCWSDK
RCSCWSDK,8,TRAIL227–234,Synthetic peptide,,,,,Induce cell death,Anticancer,Tumor active peptide##Cell death inducible peptide,,Linear,,Free,Free,,,0,RCSCWSDK
RKSCWSKD,8,TRAIL227–234,Synthetic peptide,,,,,Induce cell death,Anticancer,Tumor active peptide##Cell death inducible peptide,,Linear,,Free,Free,,,0,RKSCWSKD
RNDCWSKD,8,TRAIL227–234,Synthetic peptide,,,,,Induce cell death,Anticancer,Tumor active peptide##Cell death inducible peptide,,Linear,,Free,Free,,,0,RNDCWSKD
RNLCWSKD,8,TRAIL227–234,Synthetic peptide,,,,,Induce cell death,Anticancer,Tumor active peptide##Cell death inducible peptide,,Linear,,Free,Free,,,0,RNLCWSKD
RNNCWSKD,8,TRAIL227–234,Synthetic peptide,,,,,Induce cell death,Anticancer,Tumor active peptide##Cell death inducible peptide,,Linear,,Free,Free,,,0,RNNCWSKD
RNSCRSKD,8,TRAIL227–234,Synthetic peptide,,,,,Induce cell death,Anticancer,Tumor active peptide##Cell death inducible peptide,,Linear,,Free,Free,,,0,RNSCRSKD
RNSCWSKN,8,TRAIL227–234,Synthetic peptide,,,,,Induce cell death,Anticancer,Tumor active peptide##Cell death inducible peptide,,Linear,,Free,Free,,,0,RNSCWSKN
ECKFTVKPYLKRFQVYYKGRMWCP,24,Penaeus monodon,Synthetic peptide,,,,,"SALF can induce apoptotic gene expressions, enhance antitumor activity of cisplatin in vitro, and inhibit tumor growth in nude mice.",Anticancer; Antimicrobial,Tumor active peptide##Membrane lysis##Induce apoptosis,,Cyclic,Cys2<--->Cys23,Acetylation,Amidation,,,0,ECKFTVKPYLKRFQVYYKGRMWCP
GAGIVVASIDTGVRVSHE,18,Virulence factor of aquatic pathogenic fungus Aphanomyces invadans,Native peptide,,Rat skeletal myoblast cell line (L6): 91.73 ± 2% viability = 10 µM; 90.65 ± 2.9% viability = 20 µM; 87.91 ± 3.05% viability = 30 µM; 87.29 ± 1.9% viability = 40 µM; 84.44 ± 3.8% viability = 50 µM,,,"GE18 affects the cellular morphology, which triggers the cells to undergo apoptosis for biological cellular elimination",Anticancer; Antimicrobial,Tumor active peptide##Induce apoptosis,,Linear,,Amidation,Acetylation,,,0,GAGIVVASIDTGVRVSHE
RSHRLRLH,8,EWI-2 protein,Synthetic peptide,,,CD9,,"CD9-BP impaired CD9-related functions by adversely affecting the formation of tetraspanin webs—networks composed of CD9 and its partner proteins. The anti-cancer metastasis effect of CD9-BP was evidenced by the in vitro inhibition of cancer cell migration and invasion as well as exosome secretion and uptake, which are essential processes during metastasis. ",Anticancer,Cancer targeted peptides,,Linear,,Free,Free,,,0,RSHRLRLH
ANGRGD,6,Synthetic,Synthetic peptide,,Vero: IC50=71.37µg/mL,,,The perceived cancer cell-selective killing of both peptides P1 and P2 seems to stalk from cationic peptides and the electrostatic interactions between the anionic lipids of cancer cells on account of specific binding between integrins proteins and N (APN/CD13) ligand-receptor on the cancer cell membrane and the presence of binding RGD and NGR motifs in peptides.,Anticancer,Tumor active peptide##Membrane lysis##Induce apoptosis,,Linear,,"1-oxo-1H-phenalene-2,3-carbonitrile (Ar)",Amidation,,,0,ANGRGD
KRGDKA,6,Synthetic,Synthetic peptide,,Vero: IC50=65.03µg/mL,,,The perceived cancer cell-selective killing of both peptides P1 and P2 seems to stalk from cationic peptides and the electrostatic interactions between the anionic lipids of cancer cells on account of specific binding between integrins proteins and N (APN/CD13) ligand-receptor on the cancer cell membrane and the presence of binding RGD and NGR motifs in peptides.,Anticancer,Tumor active peptide##Membrane lysis##Induce apoptosis,,Linear,,"α-(2,5,7-tri-tert-butyl) tryptophan (W*)",Amidation,,,0,KRGDKA
NynQPnS,7,Bacillus subtilis ,Native peptide,,,,,"Iturin A significantly inhibited the growth of tumor cells, induce apoptosis, autophagy and paraptosis.",Anticancer,Tumor active peptide##Induce apoptosis##Lipopeptide##Amphiphilic,,Linear,,Free,β-amino fatty acid with a-(CH2)10CH3 group,,,0,NYNQPNS
LLLLLLLLLLLLLL,14,Synthetic,Synthetic peptide,,HUVEC: IC50=108µg/mL,,,,Anticancer,Tumor active peptide##Lipopeptide,,Linear,,C6,Free,,,0,LLLLLLLLLLLLLL
LLLLLLLLLLLLLLLLLLLLLLLLL,25,Synthetic,Synthetic peptide,,HUVEC: IC50=77µg/mL,,,,Anticancer,Tumor active peptide##Lipopeptide,,Linear,,C6,Free,,,0,LLLLLLLLLLLLLLLLLLLLLLLLL
LLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLL,40,Synthetic,Synthetic peptide,,HUVEC: IC50=50µg/mL,,,,Anticancer,Tumor active peptide##Lipopeptide,,Linear,,C6,Free,,,0,LLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLL
LLLLLLLLLLLLL,13,Synthetic,Synthetic peptide,,HUVEC: IC50=82µg/mL,,,,Anticancer,Tumor active peptide##Lipopeptide,,Linear,,C12,Free,,,0,LLLLLLLLLLLLL
LLLLLLLLLLLLLLLLLLLLLLLLLL,26,Synthetic,Synthetic peptide,,HUVEC: IC50=44µg/mL,,,,Anticancer,Tumor active peptide##Lipopeptide,,Linear,,C12,Free,,,0,LLLLLLLLLLLLLLLLLLLLLLLLLL
LLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLL,37,Synthetic,Synthetic peptide,,HUVEC: IC50=105µg/mL,,,,Anticancer,Tumor active peptide##Lipopeptide,,Linear,,C12,Free,,,0,LLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLL
LLLLLLLLLLLLLLLLLLLLLLLL,24,Synthetic,Synthetic peptide,,HUVEC: IC50=18µg/mL,,,,Anticancer,Tumor active peptide##Lipopeptide,,Linear,,C16,Free,,,0,LLLLLLLLLLLLLLLLLLLLLLLL
LLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLL,38,Synthetic,Synthetic peptide,,HUVEC: IC50=126µg/mL,,,,Anticancer,Tumor active peptide##Lipopeptide,,Linear,,C16,Free,,,0,LLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLLL
LLLLLLLLLLL,11,Synthetic,Synthetic peptide,,HUVEC: IC50=28µg/mL,,,,Anticancer,Tumor active peptide##Lipopeptide,,Linear,,C18,Free,,,0,LLLLLLLLLLL
LLLLLLLLLLLLLLLLLLLLLLL,23,Synthetic,Synthetic peptide,,HUVEC: IC50=91µg/mL,,,,Anticancer,Tumor active peptide##Lipopeptide,,Linear,,C18,Free,,,0,LLLLLLLLLLLLLLLLLLLLLLL
GXVXXPI,7,marine cyanobacterium Lyngbya majuscula,Native peptide,,,,,,Anticancer; Antimicrobial,Tumor active peptide,,Cyclic,Amide bond: Gly1<--->Ile7,Free,Free,"X(2)=2,2-dimethyl-3-hydroxy-7-octynoic (Dhoya); X(4)=N-Me-Phe; X(5)=2-Hydroxy 3-methyl pentanoic acid (Hmpa)",,0,GXVXXPI
XGLXGGLXGIL,11,Ascomycetes (Tric),Native peptide,,,,,,Anticancer; Antimicrobial,Tumor active peptide##Membrane lysis,,Linear,,Oct (Fatty acid 1-Octanoyl),Free,X=Aib,,0,XGLXGGLXGIL
XKLXGGLXGIX,11,Ascomycetes (Tric),Synthetic peptide,,,,,,Anticancer; Antimicrobial,Tumor active peptide##Membrane lysis,,Linear,,Oct (Fatty acid 1-Octanoyl),Free,X(1/4/8)=Aib; X(11)=Lol (Amino alcohol leucinol),,0,XKLXGGLXGIX
XKLXGGLXGIL,11,Ascomycetes (Tric),Synthetic peptide,,,,,,Anticancer; Antimicrobial,Tumor active peptide##Membrane lysis,,Linear,,Oct (Fatty acid 1-Octanoyl),OMe,X=Aib,,0,XKLXGGLXGIL
XGLXGKLXGIL,11,Ascomycetes (Tric),Synthetic peptide,,,,,,Anticancer; Antimicrobial,Tumor active peptide##Membrane lysis,,Linear,,Oct (Fatty acid 1-Octanoyl),OMe,X=Aib,,0,XGLXGKLXGIL
XGLXGGLXKIX,11,Ascomycetes (Tric),Synthetic peptide,,,,,,Anticancer; Antimicrobial,Tumor active peptide##Membrane lysis,,Linear,,Oct (Fatty acid 1-Octanoyl),Free,X(1/4/8)=Aib; X(11)=Lol (Amino alcohol leucinol),,0,XGLXGGLXKIX
XGLXGGLXKIL,11,Ascomycetes (Tric),Synthetic peptide,,,,,,Anticancer; Antimicrobial,Tumor active peptide##Membrane lysis,,Linear,,Oct (Fatty acid 1-Octanoyl),OMe,X=Aib,,0,XGLXGGLXKIL
GLLSVLGSVAKHVLGHVVGVIAEHL,25,Synthetic,Synthetic peptide,,,,,,,,,Linear,,Free,Amidation,,,0,GLLSVLGSVAKHVLGHVVGVIAEHL
RRRRRRRRGGDRDYKKFWAGLQGLTIYFYN,30,Synthetic (STAP-2 PH domain–derived peptide),Synthetic peptide,,,EGFR ,,STAP-2 PH domain–derived peptide inhibited STAP-2–EGFR interaction and suppressed EGFR-mediated proliferation in several cancer cell lines.,Anticancer,Cancer targeted peptides##Tumor active peptide##Coupling peptide,,Linear,,Free,Free,,,0,RRRRRRRRGGDRDYKKFWAGLQGLTIYFYN
RRRRRRRRGGMWKGFILTVVELRVPTDLTL,30,Synthetic (STAP-2 PH domain–derived peptide),Synthetic peptide,,,EGFR ,,STAP-2 PH domain–derived peptide inhibited STAP-2–EGFR interaction and suppressed EGFR-mediated proliferation in several cancer cell lines.,Anticancer,Cancer targeted peptides##Tumor active peptide##Coupling peptide,,Linear,,Free,Free,,,0,RRRRRRRRGGMWKGFILTVVELRVPTDLTL
RRRRRRRRGGFWAGLQGLTIYFYNSNRDFQ,30,Synthetic (STAP-2 PH domain–derived peptide),Synthetic peptide,,,EGFR ,,STAP-2 PH domain–derived peptide inhibited STAP-2–EGFR interaction and suppressed EGFR-mediated proliferation in several cancer cell lines.,Anticancer,Cancer targeted peptides##Tumor active peptide##Coupling peptide,,Linear,,Free,Free,,,0,RRRRRRRRGGFWAGLQGLTIYFYNSNRDFQ
RRRRRRRRGGQGLTIYFYNSNRDFQ,25,Synthetic (STAP-2 PH domain–derived peptide),Synthetic peptide,,,EGFR ,,STAP-2 PH domain–derived peptide inhibited STAP-2–EGFR interaction and suppressed EGFR-mediated proliferation in several cancer cell lines.,Anticancer,Cancer targeted peptides##Tumor active peptide##Coupling peptide,,Linear,,Free,Free,,,0,RRRRRRRRGGQGLTIYFYNSNRDFQ
RRRRRRRRGGQGLTIYFYNSNR,22,Synthetic (STAP-2 PH domain–derived peptide),Synthetic peptide,,,EGFR ,,STAP-2 PH domain–derived peptide inhibited STAP-2–EGFR interaction and suppressed EGFR-mediated proliferation in several cancer cell lines.,Anticancer,Cancer targeted peptides##Tumor active peptide##Coupling peptide,,Linear,,Free,Free,,,0,RRRRRRRRGGQGLTIYFYNSNR
RRRRRRRRGGQGLTIYFY,18,Synthetic (STAP-2 PH domain–derived peptide),Synthetic peptide,,,EGFR ,,STAP-2 PH domain–derived peptide inhibited STAP-2–EGFR interaction and suppressed EGFR-mediated proliferation in several cancer cell lines.,Anticancer,Cancer targeted peptides##Tumor active peptide##Coupling peptide,,Linear,,Free,Free,,,0,RRRRRRRRGGQGLTIYFY
RRRRRRRRGGGLTIYFYN,18,Synthetic (STAP-2 PH domain–derived peptide),Synthetic peptide,,,EGFR ,,STAP-2 PH domain–derived peptide inhibited STAP-2–EGFR interaction and suppressed EGFR-mediated proliferation in several cancer cell lines.,Anticancer,Cancer targeted peptides##Tumor active peptide##Coupling peptide,,Linear,,Free,Free,,,0,RRRRRRRRGGGLTIYFYN
RRRRRRRRGGGLTIYFY,17,Synthetic (STAP-2 PH domain–derived peptide),Synthetic peptide,,,EGFR ,,STAP-2 PH domain–derived peptide inhibited STAP-2–EGFR interaction and suppressed EGFR-mediated proliferation in several cancer cell lines.,Anticancer,Cancer targeted peptides##Tumor active peptide##Coupling peptide,,Linear,,Free,Free,,,0,RRRRRRRRGGGLTIYFY
RRRRRRRRGGVVELRVPTDLTLLPGHLYMM,30,Synthetic (STAP-2 PH domain–derived peptide),Synthetic peptide,,,EGFR ,,STAP-2 PH domain–derived peptide inhibited STAP-2–EGFR interaction and suppressed EGFR-mediated proliferation in several cancer cell lines.,Anticancer,Cancer targeted peptides##Tumor active peptide##Coupling peptide,,Linear,,Free,Free,,,0,RRRRRRRRGGVVELRVPTDLTLLPGHLYMM
RRRRRRRRGGILTVVELRVP,20,Synthetic (STAP-2 PH domain–derived peptide),Synthetic peptide,,,EGFR ,,STAP-2 PH domain–derived peptide inhibited STAP-2–EGFR interaction and suppressed EGFR-mediated proliferation in several cancer cell lines.,Anticancer,Cancer targeted peptides##Tumor active peptide##Coupling peptide,,Linear,,Free,Free,,,0,RRRRRRRRGGILTVVELRVP
IWDTIEK,7,Snake venom of N. kaouthia,Native peptide,,,EGFR,,,Anticancer,Cancer targeted peptides##Tumor active peptide,,Linear,,Free,Free,,,0,IWDTIEK
WWSDHR,6,Snake venom of N. kaouthia,Native peptide,,,EGFR ,,,Anticancer,Cancer targeted peptides##Tumor active peptide,,Linear,,Free,Free,,,0,WWSDHR
FLPLLAGLAANFLPQIICKIARKC,24,"Skin secretions of the Wuyi torrent frog, Amolops wuyiensis (A. wuyiensisi)",Native peptide,,HMEC-1: IC50=32.96μM; HaCaT: IC50=44.09μM,,,,Anticancer; Antimicrobial,Tumor active peptide##Membrane-targeted,,Linear,,Free,Free,,,0,FLPLLAGLAANFLPQIICKIARKC
FLPLLAGLAANFLPKIICKIARKC,24,Synthetic (derived from B1AW),Synthetic peptide,,HMEC-1: IC50=26.45μM; HaCaT: IC50=20.53μM,,,,Anticancer; Antimicrobial,Tumor active peptide##Membrane-targeted,,Linear,,Free,Free,,,0,FLPLLAGLAANFLPKIICKIARKC
FHAVPQSFYT,10,Synthetic (derived from MGS4),Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Acetylization,Free,,,0,FHAVPQSFYT
KLWCKSSQVPQSR,13,Synthetic,Synthetic peptide,,,,,,Anticancer,Tumor active peptide,,Linear,,Free,Free,,,0,KLWCKSSQVPQSR
TKEQKEQIAKATGLTTKQVRNWYVQLNASIKVCMCSC,37,Synthetic,Synthetic peptide,,,,,,Anticancer; Antimicrobial,Tumor active peptide,,Linear,,Free,Free,,,0,TKEQKEQIAKATGLTTKQVRNWYVQLNASIKVCMCSC
